nct_id,title,official_title,overall_status,phase,study_type,enrollment_count,enrollment_type,start_date,completion_date,lead_sponsor,sponsor_class,allocation,intervention_model,masking,intervention_types,intervention_names,conditions,primary_outcome_measures,min_age,max_age,sex,has_results,trial_duration_days,is_completed,is_recruiting,phase_numeric,is_randomized,is_blinded,is_industry_sponsored,intervention_count,completed,enrollment_bucket,tests_approved_drug,enrollment_count_clean,enrollment_log,trial_complexity,is_large_trial,phase_risk_score,Actual_Completed,LR_Prediction,LR_Probability,LR_Correct,RF_Prediction,RF_Probability,RF_Correct,XGB_Prediction,XGB_Probability,XGB_Correct
NCT05322135,A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma,A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma,TERMINATED,EARLY_PHASE1,INTERVENTIONAL,3.0,ACTUAL,2022-09-14,2025-03-07,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","18F-FSPG, 11C-Glutamine","Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer",,,,,False,905.0,True,False,0.5,False,False,False,2,False,Small (<30),0,3.0,1.3862943611198906,1,0,0.57,False,False,0.12083903705095983,1,False,0.10752443479981817,1,0,0.10376415,1
NCT04513223,A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors,"Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of SHR-A1811, in Patients With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: a Phase 1 Study",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,101.0,ACTUAL,2021-03-30,2024-12-01,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SHR-A1811,"Gastric Cancer, Colorectal Cancer",,,,,False,1342.0,False,False,1.0,False,False,True,1,True,Large (100-300),0,101.0,4.624972813284271,0,1,0.56,True,True,0.710374483960807,1,True,0.7734458000901054,1,1,0.7531315,1
NCT01486043,Metformin and Transient Hyperglycemia,Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy,TERMINATED,,INTERVENTIONAL,4.0,ACTUAL,2011-12-01,2013-05-01,Children's Hospital Los Angeles,OTHER,,SINGLE_GROUP,NONE,DRUG,Metformin,"Acute Lymphoblastic Leukemia, Hyperglycemia, Insulin Resistance, Diabetes Mellitus",,,,,False,517.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,4.0,1.6094379124341005,0,0,0.6,False,False,0.1884136547154226,1,False,0.21190099084689729,1,0,0.19037007,1
NCT05064514,Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease,"Single Centre, Prospective, Single Arm Open Label Series of a Transcatheter Tricuspid Valved Stent Graft System for the Reduction of Tricuspid Regurgitation and Improved Patient Reported Outcomes in Patients With Carcinoid Heart Disease",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,15.0,ESTIMATED,2022-04-06,2028-03-01,Queen Mary University of London,OTHER,,SINGLE_GROUP,NONE,DEVICE,Transcatheter Tricuspid Valved Stent Graft,"Tricuspid Regurgitation, Tricuspid Valve Disease, Carcinoid Syndrome, Carcinoid Heart Disease",,,,,False,2156.0,False,False,-1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.6,True,True,0.5367527415603633,1,True,0.6708195929593692,1,1,0.83952713,1
NCT02399592,Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer,Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2015-03-01,2019-07-01,Vejle Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Bevacizumab, Tocotrinol",Ovarian Cancer,,,,,False,1583.0,True,False,2.0,False,False,False,2,True,Small (<30),1,23.0,3.1780538303479458,1,0,0.58,True,False,0.46882273076743236,0,False,0.4932856012406126,0,1,0.5039432,1
NCT04669704,"Effectiveness of a Tele-Rehabilitation Evidence-based Tablet App for Rehabilitation in Traumatic Bone and Soft Injuries of the Hand, Wrist and Fingers.","Clinical and Economic Effectiveness of a Tele-rehabilitation Evidence-based Tablet Application for Rehabilitation in Traumatic Bone and Soft Injuries of the Hand, Wrist and Fingers.",COMPLETED,,INTERVENTIONAL,663.0,ACTUAL,2021-01-20,2022-01-05,University of Seville,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","Experimental: Tablet application, Comparator: Conventional treatment","Soft Tissue Injuries, Distal Radius Fracture, Metacarpal Fracture, Carpal Fracture, Carpal Tunnel Syndrome, Thumb Osteoarthritis, Dupuytren's Disease",,,,,False,350.0,True,False,-1.0,False,False,False,2,True,Very Large (300+),0,663.0,6.498282149476434,1,1,0.6,True,True,0.917595406772682,1,True,0.9621954371117826,1,1,0.97492945,1
NCT04473378,Glucose Monitoring During Chemotherapy,Pilot Study of Glucose Monitoring to Determine Rates of Hyperglycemia During Chemotherapy for Early Stage Breast Cancer,COMPLETED,,OBSERVATIONAL,22.0,ACTUAL,2019-10-31,2022-08-17,Columbia University,OTHER,,,,DEVICE,FreeStyle Libre Pro,"Breast Cancer, Hyperglycemia",,,,,False,1021.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.6,True,True,0.5754554449328407,1,True,0.629709597682038,1,1,0.65967405,1
NCT03664778,Abbreviated Breast MRI After Cancer Treatment,Cancer Detection Rate of Abbreviated (Fast) Breast MRI (AB-MR) After Negative Digital Breast Tomosynthesis in Women Status Post Conservation Therapy (BCT),COMPLETED,,OBSERVATIONAL,184.0,ACTUAL,2018-09-07,2025-09-30,University of Pennsylvania,OTHER,,,,,,"Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating",,,,,False,2580.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,184.0,5.220355825078324,0,1,0.6,True,True,0.8789807688751298,1,True,0.8438416268031209,1,1,0.80015194,1
NCT03693300,A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer,"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)",COMPLETED,PHASE2,INTERVENTIONAL,117.0,ACTUAL,2019-04-16,2023-04-21,AstraZeneca,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Durvalumab,Non-small Cell Lung Cancer (NSCLC),,,,,False,1466.0,True,False,2.0,False,False,True,1,True,Large (100-300),1,117.0,4.770684624465665,0,1,0.58,True,True,0.7096151644342945,1,True,0.8421467644166825,1,1,0.8536491,1
NCT02159872,Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,2015-05-18,2020-04-14,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Omacetaxine,Leukemia,,,,,False,1793.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,48.0,3.8918202981106265,0,0,0.58,True,True,0.7154284959669484,1,True,0.8281813321120598,1,1,0.8904329,1
NCT05892653,A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors,"A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients With BRAF V600-Mutant Relapsed &Drug Resistant Primary Malignant Brain Tumors",TERMINATED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2023-06-30,2024-08-27,ABM Therapeutics Shanghai Company Limited,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,ABM-1310,Primary Malignant Brain Tumor,,,,,False,424.0,True,False,1.0,False,False,True,1,False,Small (<30),0,15.0,2.772588722239781,0,0,0.56,False,False,0.3971639990443269,1,True,0.7301884315262014,0,1,0.79089826,0
NCT01470924,Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007,High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007,COMPLETED,,OBSERVATIONAL,76.0,ACTUAL,2003-01-01,2011-06-01,Region Örebro County,OTHER,,,,,,Acute Lymphoblastic Leukemia,,,,,False,3073.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,76.0,4.343805421853684,0,0,0.6,True,True,0.8852054797420092,1,True,0.863787321245751,1,1,0.81136924,1
NCT01992042,Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer,Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer,COMPLETED,PHASE2,INTERVENTIONAL,33.0,ACTUAL,2014-02-01,2016-12-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Fluvastatin, Pimonidazole",Prostate Cancer,,,,,False,1034.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,33.0,3.5263605246161616,1,0,0.58,True,True,0.5410325306429513,1,True,0.5407617098712345,1,0,0.4998614,0
NCT02627963,A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC),"A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma",COMPLETED,PHASE3,INTERVENTIONAL,350.0,ACTUAL,2016-05-24,2021-06-21,"AVEO Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Tivozanib hydrochloride, Sorafenib","Carcinoma, Renal Cell",,,,,False,1854.0,True,False,3.0,True,False,True,2,True,Very Large (300+),1,350.0,5.860786223465865,2,1,0.77,True,True,0.7526084000281211,1,True,0.9444943172948789,1,1,0.9619171,1
NCT05160545,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer","An Open-Label, Multi-Center, Phase I Study I Study to Evaluate the Safety, Tolerability, Pharmacokinetic/Phamacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2021-11-26,2025-12-01,"Sichuan Baili Pharmaceutical Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,GNC-035,Breast Cancer,,,,,False,1466.0,False,False,1.0,False,False,True,1,True,Medium (30-100),0,36.0,3.610917912644224,0,0,0.56,True,True,0.6692508618415124,1,True,0.7176366403849399,1,1,0.6817322,1
NCT00028834,Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer,A Phase II Trial Of Bevacizumab (NSC#704865) Plus Gemcitabine In Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2002-02-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, OTHER","gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis","Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer",,,,,False,1303.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.58,True,True,0.6469243168813641,1,True,0.6887866258066074,1,1,0.7135133,1
NCT04768894,Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates,"Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates in Patient With High-risk Non-muscle-invasive Bladder Cancer: A Prospective, Randomized, Controlled Study",COMPLETED,,INTERVENTIONAL,109.0,ACTUAL,2016-08-01,2020-12-10,Saglik Bilimleri Universitesi,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,PROCEDURE,Second transurehral resection of bladder tumour,Bladder Cancer,,,,,False,1592.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,109.0,4.700480365792417,1,1,0.6,True,True,0.7071041924674699,1,True,0.7819008843702335,1,1,0.75848585,1
NCT04136756,NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma,"A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,30.0,ACTUAL,2019-10-07,2023-04-24,Nektar Therapeutics,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG","NKTR-255, NKTR-255 Q21, Rituximab, Daratumumab","Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma",,,,,False,1295.0,True,False,1.0,False,False,True,4,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.56,True,True,0.5502203432777173,1,True,0.5967807713981166,1,1,0.57097197,1
NCT00004026,CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy,A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer,TERMINATED,PHASE2,INTERVENTIONAL,80.0,ESTIMATED,1998-12-01,2005-01-01,CTI BioPharma,INDUSTRY,RANDOMIZED,,,"DRUG, DRUG","CT-2584, chemotherapy",Prostate Cancer,,,,,False,2223.0,True,False,2.0,True,False,True,2,False,Medium (30-100),0,80.0,4.394449154672439,2,0,0.58,False,True,0.7280356883262521,0,True,0.6665254720379362,0,1,0.5759814,0
NCT01130753,"Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer","A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,43.0,ESTIMATED,2007-01-01,2012-12-01,Samsung Medical Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Erlotinib,"Lung Neoplasms, Erlotinib, Neoadjuvant Therapy",,,,,False,2161.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,43.0,3.784189633918261,0,0,0.58,True,True,0.701685771434273,1,True,0.9264859111140566,1,1,0.8855382,1
NCT04481048,Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1,Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,58.0,ESTIMATED,2020-12-15,2025-12-01,"Children's Hospital Medical Center, Cincinnati",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, OTHER","N-Acetyl cysteine, Placebo",Neurofibromatosis 1,,,,,False,1812.0,False,False,2.0,True,True,False,2,True,Medium (30-100),0,58.0,4.07753744390572,3,0,0.58,True,True,0.666225305559507,1,True,0.6129642814638951,1,1,0.6761644,1
NCT01744626,Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.",COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2012-12-01,2015-12-01,Celgene Corporation,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","CC-292, Rituximab",Leukemia Lymphocytic Chronic B-Cell,,,,,False,1095.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.56,True,True,0.622725447326356,1,True,0.5725150430516281,1,1,0.61696273,1
NCT01484847,A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma,Pharmacokinetic Assessment of PF-00299804 in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Following Administration Through a Gastrojejunostomy Feeding Tube,COMPLETED,,INTERVENTIONAL,6.0,ACTUAL,2011-12-01,2015-07-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,DRUG,PF-00299804,Head and Neck Squamous Cell Carcinoma,,,,,False,1308.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,6.0,1.9459101490553128,0,0,0.6,True,False,0.2831951985962012,0,False,0.34971534987320346,0,0,0.36619347,0
NCT00983047,Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer,Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer,TERMINATED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2009-08-01,2015-08-01,"Biotech Pharmaceutical Co., Ltd.",OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Nimotuzumab and Docetaxel,Advanced Non-Small Cell Lung Cancer,,,,,False,2191.0,True,False,2.0,True,False,False,1,False,Small (<30),1,30.0,3.4339872044851463,1,0,0.58,False,True,0.5339281495101525,0,True,0.6770712930898856,0,1,0.8023412,0
NCT00991952,Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery,A Multicenter Random Assignment Phase II Study of Irinotecan and Alvocidib (Flavopiridol) Versus Irinotecan Alone for Patients With p53 Wild Type Gastric Adenocarcinoma,COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2009-09-01,2014-04-01,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, OTHER","alvocidib, irinotecan hydrochloride, laboratory biomarker analysis","Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer",,,,,False,1673.0,True,False,2.0,True,True,False,3,True,Small (<30),1,19.0,2.995732273553991,3,0,0.58,True,False,0.3663803914521536,0,False,0.44394893915567557,0,1,0.6253126,1
NCT03895918,Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients,A Novel Parenting Skills Intervention to Improve Medication Adherence in Pediatric Cancer,COMPLETED,,INTERVENTIONAL,9.0,ACTUAL,2019-01-03,2020-11-25,Roswell Park Cancer Institute,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, PROCEDURE, OTHER","Educational Activity, Patient Monitoring, Questionnaire Administration","Guardian, Hematologic and Lymphocytic Disorder, Malignant Neoplasm, Parent",,,,,False,692.0,True,False,-1.0,True,False,False,3,True,Small (<30),0,9.0,2.302585092994046,2,0,0.6,True,False,0.2232251367730031,0,False,0.09389305174881646,0,0,0.0747235,0
NCT00949117,Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer,"An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss",TERMINATED,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2009-09-01,2011-11-01,University of South Florida,OTHER,RANDOMIZED,PARALLEL,NONE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DRUG","Ensure, PediaSure, cyproheptadine hydrochloride","Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific, Weight Changes",,,,,False,791.0,True,False,2.0,True,False,False,3,False,Small (<30),0,9.0,2.302585092994046,2,0,0.58,False,False,0.17053097699047248,1,False,0.06404749811451815,1,0,0.03420867,1
NCT03181035,Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer,Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen,SUSPENDED,PHASE1,INTERVENTIONAL,10.0,ESTIMATED,2018-01-25,2024-12-01,Sunnybrook Health Sciences Centre,OTHER,,SINGLE_GROUP,NONE,"RADIATION, DRUG","(18)F-Fluoroazomycin arabinoside, Pimonidazole",Tongue Cancer,,,,,False,2502.0,False,False,1.0,False,False,False,2,False,Small (<30),0,10.0,2.3978952727983707,1,0,0.56,False,False,0.35430341566970713,1,False,0.45855785939321586,1,0,0.4682395,1
NCT03464942,Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer,A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2018-08-01,2023-06-22,"Peter MacCallum Cancer Centre, Australia",OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG","SABR, Atezolizumab",Breast Cancer,,,,,False,1786.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,54.0,4.007333185232471,2,0,0.58,True,True,0.612285650517834,1,True,0.6897462827752138,1,1,0.6341575,1
NCT03569111,Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter,Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter Kit With Thermosphere™ Technology,COMPLETED,,OBSERVATIONAL,30.0,ACTUAL,2019-02-27,2020-10-28,Medtronic - MITG,INDUSTRY,,,,DEVICE,Bronchoscopic ablation catheter,"Cancer, Lung, Cancer, Metastatic to Lung",,,,,False,609.0,True,False,-1.0,False,False,True,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6319080418182182,1,True,0.7655540523646374,1,1,0.73293775,1
NCT00322218,Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.,"Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.",TERMINATED,PHASE3,INTERVENTIONAL,68.0,ACTUAL,2006-05-01,2008-12-01,"Spectrum Pharmaceuticals, Inc",INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,Zevalin,"Lymphoma, Large Cell, Diffuse",,,,,False,945.0,True,False,3.0,True,False,True,1,False,Medium (30-100),0,68.0,4.23410650459726,1,0,0.77,False,True,0.5980465841061365,0,True,0.7032955924850687,0,0,0.38215202,1
NCT00136487,Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer,"A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib Versus Placebo in Men With Prostate Cancer With Rising PSA Following Prostatectomy or Radiation Therapy",COMPLETED,PHASE2,INTERVENTIONAL,85.0,,2002-10-01,2006-09-01,Dana-Farber Cancer Institute,OTHER,RANDOMIZED,CROSSOVER,DOUBLE,DRUG,Celecoxib,Prostate Cancer,,,,,False,1431.0,True,False,2.0,True,True,False,1,True,Medium (30-100),0,85.0,4.454347296253507,2,0,0.58,True,True,0.771491095062259,1,True,0.6938051183762443,1,1,0.74789006,1
NCT02076230,A Phase 1 TH-302 Mass Balance Trial,"A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2014-02-01,2016-03-01,"Merck KGaA, Darmstadt, Germany",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","[14C] TH-302 (Label 1), [14C] TH-302 (Label 2), Unlabeled TH-302",Solid Tumor,,,,,False,759.0,True,False,1.0,False,False,True,3,True,Small (<30),0,10.0,2.3978952727983707,1,0,0.56,True,False,0.27220836111932023,0,False,0.3206716162878426,0,0,0.27025685,0
NCT03800134,A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer,"A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,825.0,ACTUAL,2018-12-06,2028-09-11,AstraZeneca,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, OTHER, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery",Non-Small Cell Lung Cancer,,,,,False,3567.0,False,False,3.0,True,True,True,8,True,Very Large (300+),1,825.0,6.716594773520978,3,1,0.77,True,True,0.8940240220858688,1,True,0.9006323514004982,1,1,0.9421019,1
NCT00121420,Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases,Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases,TERMINATED,PHASE2,INTERVENTIONAL,45.0,,,,Pharmacyclics LLC.,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Motexafin gadolinium,"Neoplasm Metastasis, Brain Neoplasms",,,,,False,1303.0,True,False,2.0,False,False,True,1,False,Medium (30-100),0,45.0,3.828641396489095,0,0,0.58,False,True,0.6797278602443082,0,True,0.6701396543611203,0,1,0.62579143,0
NCT00866957,Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC),Human Liver Explants for HIF-1 Alpha- Analysis/Comparison,COMPLETED,,OBSERVATIONAL,180.0,ACTUAL,2006-02-01,2019-07-01,Northwestern University,OTHER,,,,PROCEDURE,Blood draw,Liver Cancer,,,,,False,4898.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,180.0,5.198497031265826,0,1,0.6,True,True,0.9185732115531976,1,True,0.8460497275707478,1,1,0.7162354,1
NCT02803281,Assessment of Patient Frailty Prior to Thoracic Surgery,Assessment of Patient Frailty Prior to Thoracic Surgery: A Feasibility Study,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2015-07-29,2018-11-21,"University Health Network, Toronto",OTHER,,,,OTHER,Frailty Assessment,"Lung Cancer, Esophageal Cancer",,,,,False,1211.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7242925913248326,1,True,0.7977017070495084,1,1,0.8016682,1
NCT04047589,Assessing Exercise Behavior and Preferences Among Patients and Oncologists,Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer Center,COMPLETED,,OBSERVATIONAL,60.0,ACTUAL,2019-04-08,2020-02-28,Indiana University,OTHER,,,,"BEHAVIORAL, BEHAVIORAL","Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center., Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations","Solid Tumor, Exercise",,,,,False,326.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,1,0,0.6,True,True,0.7303963790314091,1,True,0.9122630053144245,1,1,0.93334883,1
NCT05012124,"Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE",Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers (AKA: SUPPORTING COLLABORATIVE CARE TO OPTIMIZE PSYCHOSOCIAL ENGAGEMENT IN THE CANCER SETTING [SCOPE]),ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,297.0,ACTUAL,2022-04-15,2026-03-31,University of Washington,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER, OTHER, OTHER","Collaborative care, Interview or Focus Group, Media/technology Intervention with collaborative care, Survey Administration","Depression, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",,,,,False,1446.0,False,False,-1.0,True,False,False,4,True,Large (100-300),0,297.0,5.697093486505405,2,1,0.6,True,True,0.8296471653120042,1,True,0.8973818027685057,1,1,0.921804,1
NCT00933517,"Assessment of the Efficacy of the Neoadjuvant Combination: ""Chemotherapy-Targeted Therapy"" in Breast Cancer.","Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study",COMPLETED,PHASE2,INTERVENTIONAL,62.0,ACTUAL,2009-09-01,2011-10-01,Centre Jean Perrin,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","vectibix, fluorouracile, Epirubicine, cyclophosphamide, docetaxel",Pathological Response Rate,,,,,False,760.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,62.0,4.143134726391533,1,0,0.58,True,True,0.6627950214845538,1,True,0.7446727335912933,1,1,0.7292858,1
NCT01304667,Chemo- and Radiotherapy in Epithelial Vulvar Cancer,Chemo- and Radiotherapy in Epithelial Vulvar Cancer,COMPLETED,,OBSERVATIONAL,1618.0,ACTUAL,2011-02-01,2012-06-01,AGO Study Group,OTHER,,,,,,Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer,,,,,False,486.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1618.0,7.389563953677635,0,1,0.6,True,True,0.9563742443006532,1,True,0.9583639427051815,1,1,0.9469039,1
NCT03656172,Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor,Investigating the Value of Reticulocyte Haemoglobin Content (RET-he) in the Management of Functional Martial Deficiency Anaemia in Patients With Solid Tumours,COMPLETED,,OBSERVATIONAL,54.0,ACTUAL,2017-05-04,2020-05-11,Institut Cancerologie de l'Ouest,OTHER,,,,BIOLOGICAL,Haemoglobin measure,"Solid Tumor, Adult, Anemia Deficiency",,,,,False,1103.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,54.0,4.007333185232471,0,0,0.6,True,True,0.7784616768946614,1,True,0.7148411233960674,1,1,0.71398896,1
NCT00778102,A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.,A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA),COMPLETED,PHASE2,INTERVENTIONAL,80.0,ACTUAL,2008-10-01,2013-10-01,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","5-FU, 5-FU, 5-FU, Irinotecan, Leucovorin, Leucovorin, Oxaliplatin, bevacizumab [Avastin]",Colorectal Cancer,,,,,False,1826.0,True,False,2.0,True,False,True,8,True,Medium (30-100),1,80.0,4.394449154672439,2,0,0.58,True,True,0.6793256004336955,1,True,0.7955505861287431,1,1,0.8262251,1
NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML),COMPLETED,PHASE3,INTERVENTIONAL,637.0,ACTUAL,2004-07-01,2014-08-01,SWOG Cancer Research Network,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER, DRUG, DRUG","gemtuzumab ozogamicin, observation, Cytosine arabinoside, Daunomycin",Leukemia,,,,,False,3683.0,True,False,3.0,True,False,False,4,True,Very Large (300+),0,637.0,6.45833828334479,2,1,0.77,True,True,0.8773519591000022,1,True,0.9575653320236475,1,1,0.9750885,1
NCT00003688,Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia,Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia,COMPLETED,PHASE2,INTERVENTIONAL,,,1999-10-01,,Gynecologic Oncology Group,NETWORK,,,,BIOLOGICAL,dactinomycin,Gestational Trophoblastic Tumor,,,,,False,1303.0,True,False,2.0,False,False,False,1,True,,0,,,0,0,0.58,True,True,0.6987698312676027,1,True,0.7427144973975056,1,1,0.7404288,1
NCT04040244,Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis,A Pilot Study of Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis After Chemoradiotherapy For Stage III Non-Small Cell Lung Cancer,TERMINATED,,INTERVENTIONAL,16.0,ACTUAL,2019-12-09,2022-03-10,Wake Forest University Health Sciences,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER","Exhaled Breath Collection, Blood sample","Pneumonitis, Nonsmall Cell Lung Cancer Stage III",,,,,False,822.0,True,False,-1.0,False,False,False,2,False,Small (<30),0,16.0,2.833213344056216,1,0,0.6,False,False,0.4322209820096797,1,True,0.5479734006018216,0,1,0.61712444,0
NCT01887288,Capecitabine With Digoxin for Metastatic Breast Cancer,Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment,TERMINATED,PHASE2,INTERVENTIONAL,16.0,ACTUAL,2013-04-01,2015-11-01,Western Regional Medical Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Capecitabine, Digoxin",Metastatic Breast Cancer,,,,,False,944.0,True,False,2.0,False,False,False,2,False,Small (<30),1,16.0,2.833213344056216,1,0,0.58,False,False,0.34724465951801486,1,False,0.2958116242289627,1,0,0.31577438,1
NCT02208401,Randomised Comparison of 2 Cold Snare Polypectomy Techniques,A Prospective Randomised Comparison of Cold Snare Polypectomy Versus Cold Snare Pseudosuction Technique,COMPLETED,,INTERVENTIONAL,112.0,ACTUAL,2014-01-01,2014-08-01,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","conventional cold snare polypectomy, Cold snare polypectomy with suction",Bowel Cancer,,,,,False,212.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,112.0,4.727387818712341,2,1,0.6,True,True,0.6019638103216769,1,True,0.9536908058332534,1,1,0.9828986,1
NCT02187276,The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia,The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer Disease and Mixed Dementia: a Naturalistic Study,COMPLETED,,OBSERVATIONAL,129.0,ACTUAL,2009-06-01,2013-03-01,Federal University of Minas Gerais,OTHER,,,,DRUG,cholinesterase inhibitors,"Alzheimer Disease, Late Onset",,,,,False,1369.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,129.0,4.867534450455582,0,1,0.6,True,True,0.795126938521505,1,True,0.8439100060508135,1,1,0.83907014,1
NCT01470417,Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma,GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma,COMPLETED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2011-10-01,2019-10-01,University of Florida,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Chemotherapy, Chemotherapy + ChemoRadiotherapy",Pancreatic Cancer,,,,,False,2922.0,True,False,2.0,False,False,False,2,True,Small (<30),0,10.0,2.3978952727983707,1,0,0.58,True,False,0.3398060517914733,0,False,0.40484020840994595,0,0,0.3867884,0
NCT00924326,CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma,An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2009-02-17,2021-11-17,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, BIOLOGICAL, DRUG, DRUG, DRUG","Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL, Aldesleukin, Fludarabine, Cyclophosphamide","Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell",,,,,False,4656.0,True,False,1.0,False,False,False,6,True,Medium (30-100),1,43.0,3.784189633918261,1,0,0.56,True,True,0.7748154780247664,1,True,0.8484687222130667,1,1,0.6997338,1
NCT03532880,A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer,A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer,COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2018-07-12,2025-02-04,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION","Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg, Olaparib Pill 200 mg, Olaparib Pill 250 mg, Olaparib Pill 300 mg, Radiotherapy","Small-cell Lung Cancer, Small Cell Lung Carcinoma",,,,,False,2399.0,True,False,1.0,False,False,False,7,True,Small (<30),0,26.0,3.295836866004329,1,0,0.56,True,True,0.5619719336616261,1,True,0.7630378343913868,1,1,0.8498652,1
NCT03177057,SMART Project in Preventing Skin Cancer,Self-Monitoring and Readiness Texting Project (SMART),COMPLETED,,INTERVENTIONAL,114.0,ACTUAL,2013-04-23,2014-12-31,Fox Chase Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, OTHER, OTHER","Compliance Monitoring, Health Telemonitoring, Questionnaire Administration",Skin Carcinoma,,,,,False,617.0,True,False,-1.0,True,False,False,3,True,Large (100-300),0,114.0,4.74493212836325,2,1,0.6,True,True,0.6213919932543492,1,True,0.8666297911477022,1,1,0.9091625,1
NCT00490880,Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer,The Evaluation of Efficacy and Toxicity of Combined Treatment: Neoadjuvant Chemotherapy (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer Stage T2b-T3 NO/Nx M0,COMPLETED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2003-11-01,2004-08-01,Eli Lilly and Company,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, PROCEDURE, PROCEDURE","gemcitabine, cisplatin, radical cystectomy, radiotherapy",Bladder Cancer,,,,,False,274.0,True,False,2.0,True,False,True,4,True,Small (<30),1,2.0,1.0986122886681098,2,0,0.58,True,False,0.045141106012489045,0,False,0.04766590302108069,0,0,0.020085469,0
NCT02182063,A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer,An Open Label Randomized Phase II Study of Oral Treatment With BIBF 1120 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen,COMPLETED,PHASE2,INTERVENTIONAL,81.0,ACTUAL,2005-11-01,,Boehringer Ingelheim,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","BIBF 1120 low dose, BIBF 1120 high dose",Prostatic Neoplasms,,,,,False,1303.0,True,False,2.0,True,False,True,2,True,Medium (30-100),0,81.0,4.406719247264253,2,0,0.58,True,True,0.6912685293387573,1,True,0.6652483316790833,1,1,0.5629606,1
NCT01661829,An RCT for the Effect of Biofeedback Therapy the Prevention of AR Syndrome in Rectal Cancer Patients,A Randomised Controlled Trial for the Effect of Biofeedback Therapy for the Preveintion of Anterior Resection Syndrome in Rectal Cancer Patients Who Have Undergone Low Anterior Resection With Total Mesorectal Excision Following Neoadjuvant Chemoradiation Therapy,COMPLETED,,OBSERVATIONAL,56.0,ACTUAL,2012-03-01,2015-02-01,The Catholic University of Korea,OTHER,,,,,,Rectal Cancer,,,,,False,1067.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,56.0,4.04305126783455,0,0,0.6,True,True,0.7871242781856259,1,True,0.7892651254786035,1,1,0.7928307,1
NCT02257567,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,"A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,331.0,ACTUAL,2014-10-15,2021-10-21,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized)",Lymphoma,,,,,False,2563.0,True,False,1.0,True,False,True,5,True,Very Large (300+),1,331.0,5.805134968916488,2,1,0.56,True,True,0.840396279072024,1,True,0.9342555053545663,1,1,0.9371797,1
NCT01717261,Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer,,COMPLETED,PHASE1,INTERVENTIONAL,10.0,ESTIMATED,2012-08-01,2023-10-01,Maisonneuve-Rosemont Hospital,OTHER,,SINGLE_GROUP,NONE,RADIATION,Single Pre-Operative Radiation Therapy,Breast Cancer,,,,,False,4078.0,True,False,1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.48401171019711187,0,True,0.5209300745773495,1,1,0.5116417,1
NCT00566553,The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women,The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women: A Pilot Study,COMPLETED,,INTERVENTIONAL,39.0,ACTUAL,2008-02-01,2011-09-01,Mayo Clinic,OTHER,RANDOMIZED,PARALLEL,NONE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Grape Seed Extract, Grape Seed Extract, Grape Seed Extract, Grape Seed Extract",Breast Cancer,,,,,False,1308.0,True,False,-1.0,True,False,False,4,True,Medium (30-100),0,39.0,3.688879454113936,2,0,0.6,True,True,0.5891350701822433,1,True,0.6770541563168797,1,1,0.7602646,1
NCT00062296,Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia,Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL,COMPLETED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2003-03-01,2005-08-01,Fox Chase Cancer Center,OTHER,,,NONE,"BIOLOGICAL, DRUG","rituximab, epirubicin hydrochloride","Leukemia, Lymphoma",,,,,False,884.0,True,False,2.0,False,False,False,2,True,Small (<30),1,5.0,1.791759469228055,1,0,0.58,True,False,0.14467405773604466,0,False,0.08087973522240603,0,0,0.05554595,0
NCT02454855,Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients,Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (> = 70 Years) - PHRC-K13-170,TERMINATED,PHASE3,INTERVENTIONAL,123.0,ACTUAL,2015-07-01,2022-02-01,Centre Jean Perrin,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","melatonin, placebo",Cancer,,,,,False,2407.0,True,False,3.0,True,True,False,2,False,Large (100-300),0,123.0,4.820281565605037,3,1,0.77,False,True,0.5927182422288394,0,True,0.6966911620018509,0,1,0.5845576,0
NCT04150692,Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma,ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2021-01-08,2026-03-31,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, PROCEDURE, PROCEDURE","Dara-SC, Blood for research assessments, Bone marrow for research assessments",Multiple Myeloma,,,,,False,1908.0,True,False,2.0,True,False,False,3,False,,0,0.0,0.0,2,0,0.58,False,False,0.02055178660192378,1,False,0.015412772818576195,1,0,0.0030942205,1
NCT01446809,Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging,COMPLETED,,INTERVENTIONAL,23.0,ACTUAL,2012-04-01,2019-01-01,University of Washington,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, RADIATION, DRUG, OTHER, DRUG, OTHER, OTHER, PROCEDURE","Doxorubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study, Placebo, Therapeutic Conventional Surgery","Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma",,,,,False,2466.0,True,False,-1.0,True,True,False,8,True,Small (<30),1,23.0,3.1780538303479458,3,0,0.6,True,True,0.5168359757234634,1,True,0.5448027354797369,1,1,0.71015096,1
NCT03219047,Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma,A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE Trial,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,1.0,ACTUAL,2018-12-20,2023-07-03,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, DRUG, OTHER, OTHER","Best Practice, Ibrutinib, Patient Derived Xenograft, Personalized Medicine","Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",,,,,False,1656.0,True,False,0.5,False,False,False,4,True,Small (<30),0,1.0,0.6931471805599453,1,0,0.57,True,False,0.06744316566851045,0,False,0.17925805119567834,0,0,0.21089579,0
NCT02910596,Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA,,COMPLETED,PHASE4,INTERVENTIONAL,56.0,ACTUAL,2016-10-01,2017-05-31,Department of Medical Services Ministry of Public Health of Thailand,OTHER_GOV,RANDOMIZED,PARALLEL,NONE,"DRUG, DEVICE, OTHER, OTHER","bethanechol chloride, early bladder training, early bladder training and bethanechol chloride, no early bladder training and no bethanechol chloride",Bladder Dysfunction,,,,,False,242.0,True,False,4.0,True,False,False,4,True,Medium (30-100),0,56.0,4.04305126783455,2,0,0.7,True,False,0.44011060793870876,0,True,0.6915634210291518,1,1,0.8272722,1
NCT00712556,PET Study in Patients With Non-Hodgkin Lymphoma,Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma,COMPLETED,,OBSERVATIONAL,55.0,ACTUAL,2008-05-01,2009-03-01,Vanderbilt-Ingram Cancer Center,OTHER,,,,RADIATION,fluorine 18-fludeoxyglucose positron emission tomography,Lymphoma,,,,,False,304.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,55.0,4.02535169073515,0,0,0.6,True,True,0.752049816892099,1,True,0.8165549220561482,1,1,0.77419937,1
NCT01809600,Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults,"Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL",COMPLETED,,OBSERVATIONAL,43.0,ACTUAL,2013-02-01,2014-03-01,Gachon University Gil Medical Center,OTHER,,,,OTHER,No intervention (observational study),"Burkitt's Lymphoma, High-grade B-cell Lymphoma",,,,,False,393.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,43.0,3.784189633918261,0,0,0.6,True,True,0.7049853118187674,1,True,0.7236960132473625,1,1,0.6876906,1
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,Induction of Specific Immune Responses Against Melanoma-Associated Antigens in Vivo by Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial,COMPLETED,PHASE1,INTERVENTIONAL,20.0,,2004-07-01,2007-01-01,University Hospital Tuebingen,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","mRNA, GM-CSF s.c.",Malignant Melanoma,,,,,False,914.0,True,False,1.0,False,False,False,2,True,Small (<30),0,20.0,3.044522437723423,1,0,0.56,True,False,0.44303990251200964,0,False,0.48382091216493356,0,1,0.5370685,1
NCT04250922,LAM561 With RT and TMZ for Adults With Glioblastoma,"A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,144.0,ACTUAL,2019-12-01,2026-11-30,Laminar Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, RADIATION","LAM561, TMZ, RT","Primary Glioblastoma, Glioblastoma Multiforme",,,,,False,2556.0,False,False,2.0,True,True,True,3,True,Large (100-300),0,144.0,4.976733742420574,3,1,0.58,True,True,0.7121383137688669,1,True,0.8154186088092393,1,1,0.9088587,1
NCT04606147,Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy,"Comparison of Effectiveness of Ultrasound Guided Erector Spinae Plane Block With Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy, Randomized Single Blinded Comparative Study.",COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2020-01-10,2020-05-20,"National Cancer Institute, Egypt",OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Serratus Anterior Plane Block, Erector spinae plane block","Breast Cancer, Postoperative Pain",,,,,False,131.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.6,True,True,0.6470473129245009,1,True,0.8854848506230724,1,1,0.9692542,1
NCT00634452,Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma,"A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2008-02-01,2010-01-01,Bristol-Myers Squibb,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,MDX-1401,Hodgkin's Lymphomas,,,,,False,700.0,True,False,1.0,False,False,True,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.56,True,True,0.5083063193471793,1,True,0.5073532776950896,1,0,0.48455206,0
NCT02532868,A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002),"A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer",TERMINATED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2005-05-01,2008-01-01,Merck Sharp & Dohme LLC,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,MK-0457,Cancer,,,,,False,975.0,True,False,1.0,False,False,True,1,False,Small (<30),0,27.0,3.332204510175204,0,0,0.56,False,True,0.5751337803539167,0,True,0.5516635341298798,0,1,0.5449302,0
NCT05067556,Decreasing Long-term Opioid Use in Cancer Survivors,Creating a Pathway for Disease-Free Cancer Survivors to Decrease Long-term Opioid Use,SUSPENDED,,INTERVENTIONAL,18.0,ESTIMATED,2021-12-20,2028-03-30,Virginia Commonwealth University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Acceptance and Commitment Therapy for chronic pain (ACT-CP),"Pain, Chronic Pain, Cancer Pain, Survivorship",,,,,False,2292.0,False,False,-1.0,False,False,False,1,False,Small (<30),0,18.0,2.9444389791664403,0,0,0.6,False,True,0.5895013627987268,0,True,0.5118135497145465,0,1,0.5959516,0
NCT01175499,Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract,Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2010-07-01,,"University of California, San Francisco",OTHER,,SINGLE_GROUP,SINGLE,"DEVICE, DEVICE","Direct Rigid Endoscopy, Transnasal Flexible Endoscopy with Narrowband Imaging","Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal, Oropharyngeal Cancer, Neoplasms, Hypopharyngeal, Hypopharyngeal Cancer, Head and Neck Neoplasms, UADT Neoplasms, Carcinoma, Squamous Cell, Papilloma",,,,,False,1303.0,True,False,-1.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.6,False,False,0.036828294731531354,1,False,0.011781381625548431,1,0,0.0031735622,1
NCT00496132,A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,"An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Have Been Treated With a Purine Nucleoside Analogue-Containing Regimen",TERMINATED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2007-08-27,2009-06-17,"Genentech, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,PRO131921,Chronic Lymphocytic Leukemia,,,,,False,660.0,True,False,1.0,False,False,True,1,False,Small (<30),0,16.0,2.833213344056216,0,0,0.56,False,False,0.4249671198048937,1,True,0.754278654886376,0,1,0.6491111,0
NCT06263699,Goniometry and Goniometric Measurement on Standardised Images in Dupuytren's Disease,Comparing the Accuracy of Clinical Goniometry and Goniometric Measurement on Standardised Images in Dupuytren's Disease,COMPLETED,,OBSERVATIONAL,59.0,ACTUAL,2024-01-29,2025-03-03,Universitaire Ziekenhuizen KU Leuven,OTHER,,,,PROCEDURE,ROM measurement of the MCP and PIP joints in digits 4 and 5,Dupuytren's Disease,,,,,False,399.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,59.0,4.0943445622221,0,0,0.6,True,True,0.7689736237700008,1,True,0.9189156095239128,1,1,0.92341965,1
NCT04305249,Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies,"A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies",TERMINATED,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2020-08-15,2024-05-24,Antengene Therapeutics Limited,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","ATG-017, ATG-017+Nivolumab","Solid Tumor, Hematological Malignancy",,,,,False,1378.0,True,False,1.0,False,False,True,2,False,Medium (30-100),1,36.0,3.610917912644224,1,0,0.56,False,True,0.6106424908514405,0,True,0.688684982962692,0,1,0.6503506,0
NCT02671435,A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors,A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,383.0,ACTUAL,2016-02-22,2025-09-01,MedImmune LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab",Advanced Solid Tumors,,,,,False,3479.0,False,False,1.0,True,False,True,5,True,Very Large (300+),1,383.0,5.950642552587727,2,1,0.56,True,True,0.8787699970088596,1,True,0.9290953321551966,1,1,0.94506013,1
NCT04722055,A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China,A Multicenter Clinical Trial of Human Multigene Methylation Detection Kit (Fluorescent PCR),COMPLETED,,OBSERVATIONAL,1273.0,ACTUAL,2021-01-26,2022-08-08,"Creative Biosciences (Guangzhou) Co., Ltd.",INDUSTRY,,,,DIAGNOSTIC_TEST,Multigene Methylation Detection Kit,"Colorectal Cancer, Advanced Adenocarcinoma, Hyperplastic Polyp, Colorectal Neoplasms, Digestive System Neoplasm, Neoplasms",,,,,False,559.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,1273.0,7.149916836132109,0,1,0.6,True,True,0.9534882429920698,1,True,0.9877788856078011,1,1,0.99137986,1
NCT03052127,Study in Subjects With Small Primary Choroidal Melanoma,"A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma",COMPLETED,PHASE1,INTERVENTIONAL,57.0,ACTUAL,2017-02-27,2021-01-26,Aura Biosciences,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DEVICE","Light-activated AU-011, Laser Activation","Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma",,,,,False,1429.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,57.0,4.060443010546419,1,0,0.56,True,True,0.7248469999792887,1,True,0.7737836740494951,1,1,0.61610043,1
NCT03999658,A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies,"An Open-label, Multicenter, Global Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Malignancies.",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2023-03-01,2024-07-01,"Sorrento Therapeutics, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,STI-3031,"Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal",,,,,False,488.0,True,False,2.0,False,False,True,1,False,,0,0.0,0.0,0,0,0.58,False,False,0.0270965163691254,1,False,0.005076926569060525,1,0,0.002099824,1
NCT04831567,Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors,Phase II Study of MIBG-I131 (Metaiodobenzylguanidine) in Patients With Well Differentiated Neuroendocrine Tumors and MIBG Positive Scan,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2021-02-04,2022-05-13,AC Camargo Cancer Center,OTHER,,SINGLE_GROUP,NONE,RADIATION,MIBG-I131,Neuroendocrine Tumors,,,,,False,463.0,True,False,2.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.58,False,False,0.02695969094062403,1,False,0.005076926569060525,1,0,0.0020323184,1
NCT07363746,Scool of Pain (SchooP): A Way to Create Value in Healthcare?,Implementation and Evaluation of a Novel Pain School Intervention Targeting Patients With Chronic Non-cancer Pain as a Tool to Achieve Value in Healthcare.,COMPLETED,,INTERVENTIONAL,82.0,ACTUAL,2023-09-12,2025-12-11,"Rigshospitalet, Denmark",OTHER,,SINGLE_GROUP,NONE,OTHER,Pain school intervention,"Chronic Non-cancer Pain, Patient Education as Topic",,,,,False,821.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,82.0,4.418840607796598,0,0,0.6,True,True,0.8364573077980768,1,True,0.8196420409676526,1,1,0.8234827,1
NCT04270123,An EORTC Study Updating the QLQ-BR23 to BR45,"An International Phase 4 Field Study to Analyse the Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer (EORTC QLQ-BR23, Update EORTC QLQ-BR45)",COMPLETED,,OBSERVATIONAL,38.0,ACTUAL,2020-11-02,2022-01-31,University of Leeds,OTHER,,,,OTHER,EORTC QLQ-BR45 questionnaire,"Cancer, Breast Cancer",,,,,False,455.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.6,True,True,0.6802562960470451,1,True,0.6699224661850783,1,1,0.58298486,1
NCT04509648,Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer,"One-week Hypofractionated Radiotherapy in Breast Cancer Patients With an Indication for Regional Nodal Irradiation: Prospective, Single-arm Trial",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,197.0,ESTIMATED,2021-01-21,2030-12-30,Ruijin Hospital,OTHER,,SINGLE_GROUP,NONE,RADIATION,External Beam radiotherapy using IMRT technique,Breast Cancer,,,,,False,3630.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,197.0,5.288267030694535,0,1,0.6,True,True,0.9044418871331089,1,True,0.8254828118080658,1,1,0.7443237,1
NCT00411450,Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment,"Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,116.0,ACTUAL,2006-11-01,2010-10-01,Amgen,INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","Panitumumab, FOLFIRI","Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Oncology",,,,,False,1430.0,True,False,2.0,False,False,True,2,True,Large (100-300),1,116.0,4.762173934797756,1,1,0.58,True,True,0.6612983261249266,1,True,0.78745048049739,1,1,0.7841679,1
NCT03297346,Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer,Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project,COMPLETED,,INTERVENTIONAL,250.0,ACTUAL,2017-09-01,2021-05-31,Institut de Radioprotection et de Surete Nucleaire,OTHER_GOV,,SINGLE_GROUP,NONE,OTHER,Cardiac imaging and circulating biomarkers,Breast Cancer Female,,,,,False,1368.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,250.0,5.525452939131784,0,1,0.6,True,True,0.8813820866434311,1,True,0.8778516939584244,1,1,0.86409897,1
NCT03822234,A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit,A Prospective Multicenter Randomized Controlled Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit,COMPLETED,,INTERVENTIONAL,104.0,ACTUAL,2019-01-15,2020-03-11,Sun Yat-sen University,OTHER,RANDOMIZED,PARALLEL,SINGLE,PROCEDURE,Modified ileal conduit,Bladder Cancer,,,,,False,421.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,104.0,4.653960350157523,1,1,0.6,True,True,0.6432847552242528,1,True,0.8444398668485156,1,1,0.93625754,1
NCT04491643,Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma,Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,2020-09-01,2025-04-11,Fudan University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Megestrol Acetate, Rosuvastatin",Endometrial Carcinoma Stage I,,,,,False,1683.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,48.0,3.8918202981106265,1,0,0.58,True,True,0.6661445438979048,1,True,0.7830158953750056,1,1,0.73835146,1
NCT03585062,Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer,Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer,TERMINATED,PHASE2,INTERVENTIONAL,40.0,ACTUAL,2017-11-20,2019-07-01,Zhejiang Provincial People's Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","S1,, Paclitaxel-albumin","Pancreatic Cancer, Neoadjuvant Chemotherapy",,,,,False,588.0,True,False,2.0,False,False,False,2,False,Medium (30-100),1,40.0,3.713572066704308,1,0,0.58,False,True,0.5607542277436103,0,False,0.44212188083920867,1,0,0.429421,1
NCT02049281,A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011),A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor,TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2014-02-01,2014-05-01,Endocyte,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Vintafolide,Solid Tumor,,,,,False,89.0,True,False,1.0,False,False,True,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.56,False,False,0.119501860715492,1,False,0.17304831815567606,1,0,0.29458657,1
NCT06316531,A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,A Randomized Controlled Phase III Clinical Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,274.0,ACTUAL,2024-05-08,2026-05-01,"Sichuan Baili Pharmaceutical Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","BL-M07D1, T-DM1",HER2-positive Breast Cancer,,,,,False,723.0,False,False,3.0,True,False,True,2,True,Large (100-300),0,274.0,5.616771097666572,2,1,0.77,True,True,0.664314971650316,1,True,0.7383128644584417,1,1,0.59409225,1
NCT01418326,Cancer Mortality Affected by the Choice of Anesthetic Drugs?,Cancer Mortality Affected by the Choice of Anesthetic Drugs?,COMPLETED,,OBSERVATIONAL,3284.0,ACTUAL,2010-11-01,2011-10-01,Enlund,OTHER,,,,,,"Breast Cancer, Colo-rectal Cancer, Skin Cancer",,,,,False,334.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,3284.0,8.09712193091871,0,1,0.6,True,True,0.9459326401212215,1,True,0.9895574633248674,1,1,0.98590994,1
NCT01173913,Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir,Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir,COMPLETED,PHASE1,INTERVENTIONAL,57.0,ACTUAL,2010-09-01,2017-01-26,The Netherlands Cancer Institute,OTHER,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG, DRUG","ModraDoc001 10mg capsules, ModraDoc003 10mg tablets and ModraDoc004 10/50 mg, ModraDoc006 10 mg tablet",Cancer,,,,,False,2339.0,True,False,1.0,True,False,False,3,True,Medium (30-100),0,57.0,4.060443010546419,2,0,0.56,True,True,0.687302072673403,1,True,0.8218314852594311,1,1,0.78154975,1
NCT04458740,The Life and Care of Colorectal Cancer Patients After 65 Years and Their Family,The Life and Care of Colorectal Cancer Patients After 65 Years and Their Family,COMPLETED,,OBSERVATIONAL,18.0,ACTUAL,2018-10-29,2019-05-17,Poitiers University Hospital,OTHER,,,,OTHER,biographical interviews,Colorectal Cancer,,,,,False,200.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.6,True,False,0.48163810274604196,0,True,0.7070454610703972,1,1,0.72872627,1
NCT02094105,Endoscopic Screening on Esophageal Cancer,"Effect of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: 10-year Follow up of a Community-based, Controlled Study Among High Risk Population in China",COMPLETED,,INTERVENTIONAL,45386.0,ACTUAL,1999-11-01,2013-12-01,Chinese Academy of Medical Sciences,OTHER,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,Endoscopy examination with iodine staining,Esophageal Squamous Cell Carcinoma,,,,,False,5144.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.953441976245296,1,True,0.9730774325444128,1,1,0.9853098,1
NCT00826982,Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer,Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer,COMPLETED,,OBSERVATIONAL,90.0,ACTUAL,2008-01-01,,Mayo Clinic,OTHER,,,,,,Pancreatic Cancer,,,,,False,1303.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,90.0,4.51085950651685,0,0,0.6,True,True,0.8640081391903519,1,True,0.6883602743422997,1,1,0.7083599,1
NCT02258529,Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma,"A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma",TERMINATED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2015-09-14,2016-05-03,Gilead Sciences,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL","Idelalisib, Rituximab","Follicular Lymphoma, Small Lymphocytic Lymphoma",,,,,False,232.0,True,False,2.0,False,False,True,2,False,Small (<30),1,10.0,2.3978952727983707,1,0,0.58,False,False,0.22230847221762176,1,False,0.21256295849583065,1,0,0.12747921,1
NCT01721148,A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours,A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours,COMPLETED,PHASE1,INTERVENTIONAL,39.0,ACTUAL,2012-10-01,2016-12-01,ASLAN Pharmaceuticals,OTHER,,SINGLE_GROUP,NONE,DRUG,ASLAN002( BMS 777607),Malignant Solid Tumour,,,,,False,1522.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,39.0,3.688879454113936,0,0,0.56,True,True,0.6899805550595508,1,True,0.7362771943912507,1,1,0.66836095,1
NCT04895410,Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma,"A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma",TERMINATED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2022-01-17,2022-06-24,AbbVie,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL","Lemzoparlimab, Dexamethasone, Carfilzomib, Pomalidomide, Daratumumab",Multiple Myeloma,,,,,False,158.0,True,False,1.0,False,False,True,5,False,Small (<30),1,8.0,2.19722457733622,1,0,0.56,False,False,0.19840780265195582,1,False,0.20270853054820503,1,0,0.0664742,1
NCT02559024,Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer,TERMINATED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2016-03-14,2018-10-01,Providence Health & Services,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,MEDI6469,Colorectal Neoplasms,,,,,False,931.0,True,False,1.0,False,False,False,1,False,Small (<30),0,4.0,1.6094379124341005,0,0,0.56,False,False,0.17103638457351647,1,False,0.15841252246145981,1,0,0.14949405,1
NCT02567851,"A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity","BREVITY: A Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity",COMPLETED,PHASE2,INTERVENTIONAL,38.0,ACTUAL,2014-02-01,2017-10-02,University of Birmingham,OTHER,,SINGLE_GROUP,NONE,DRUG,Brentuximab Vedotin,Hodgkin Disease,,,,,False,1339.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.58,True,True,0.6418549451943462,1,True,0.7071335938504077,1,1,0.6734155,1
NCT03111732,"Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)","A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)",COMPLETED,PHASE2,INTERVENTIONAL,11.0,ACTUAL,2017-06-14,2021-11-08,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG","Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine","Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer",,,,,False,1608.0,True,False,2.0,False,False,False,3,True,Small (<30),1,11.0,2.4849066497880004,1,0,0.58,True,False,0.29074460055109314,0,False,0.3614791726733486,0,1,0.5367537,1
NCT04223141,Single-stapled Double Purse-string Technique for Colorectal Anastomosis,Single-stapled Double Purse-string Anastomotic (SIA) Technique in Robotic Malignant Sigmoid Resections,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,39.0,ACTUAL,2020-03-17,2025-12-31,Vejle Hospital,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,SIA,Colo-rectal Cancer,,,,,False,2115.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,39.0,3.688879454113936,0,0,0.6,True,True,0.7553870846426045,1,True,0.6983975663678045,1,1,0.5774469,1
NCT04760184,Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden,Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden - a Retrospective Cohort Study,COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2021-04-01,2021-12-31,Uppsala University,OTHER,,,,OTHER,Autologous stem cell transplantation,"Covid19, Myeloma Multiple, Malignant Lymphoma, Hematologic Neoplasms, Stem Cell Transplant Complications",,,,,False,274.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5125688027931549,1,True,0.7575891850288287,1,1,0.6816996,1
NCT03532451,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2019-03-22,2022-10-05,"PrECOG, LLC.",OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","Nivolumab, Nivolumab/Lirilumab",Bladder Cancer,,,,,False,1293.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,43.0,3.784189633918261,1,0,0.56,True,True,0.6497357962269817,1,True,0.5767970653778471,1,1,0.6013284,1
NCT01712893,"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer","A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for ≤ 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer",COMPLETED,PHASE3,INTERVENTIONAL,216.0,ACTUAL,2009-06-01,2017-08-01,Fudan University,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Zoladex,Breast Cancer,,,,,False,2983.0,True,False,3.0,True,False,False,1,True,Large (100-300),0,216.0,5.37989735354046,1,1,0.77,True,True,0.7568744895760215,1,True,0.699807861602183,1,1,0.77997077,1
NCT03128060,Expanding Access to Home-Based Palliative Care,Expanding Access to Home-Based Palliative Care Through Primary Care Medical Groups,TERMINATED,,INTERVENTIONAL,35.0,ACTUAL,2017-08-19,2019-03-01,University of Southern California,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","Home-based palliative care, Enhanced usual care","Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease",,,,,False,559.0,True,False,-1.0,True,False,False,2,False,Medium (30-100),0,35.0,3.58351893845611,2,0,0.6,False,True,0.5330941313133936,0,True,0.6884644904142924,0,1,0.64095914,0
NCT03172559,Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI),"A Multi-Center Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy as a ""Bridge"" Prior to Liver Transplant for Hepatocellular Carcinoma Versus no Intervention in Patients Not Eligible to Transarterial Chemoembolization or Ablation",WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2020-09-01,2029-09-01,"University Health Network, Toronto",OTHER,RANDOMIZED,PARALLEL,SINGLE,RADIATION,Stereotactic body radiotherapy,Hepatocellular Carcinoma,,,,,False,3287.0,True,False,-1.0,True,False,False,1,False,,0,0.0,0.0,1,0,0.6,False,False,0.047751408837950496,1,False,0.07179002154659866,1,0,0.0030066364,1
NCT00673114,"Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies","A Prospective, Phase I/II Trial Determining the Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Banked Unrelated Umbilical Cord Blood Supplemented With Related, Haplo-Identical T-Cell Depleted Stem Cells in Subjects With High Risk Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2007-08-01,2012-04-01,"Joanne Kurtzberg, MD",OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,haplo/cord transplant,"Hematologic Malignancy, Myelodysplastic Syndrome (MDS), Aplastic Anemia",,,,,False,1705.0,True,False,1.0,False,False,False,1,True,Small (<30),0,3.0,1.3862943611198906,0,0,0.56,True,False,0.1596498749350847,0,False,0.17199341857619324,0,0,0.13385066,0
NCT00084513,Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer,"Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer",COMPLETED,PHASE1,INTERVENTIONAL,18.0,ESTIMATED,2004-08-01,2007-03-01,Fox Chase Cancer Center,OTHER,,,,"BIOLOGICAL, DRUG","trastuzumab, imatinib mesylate","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,942.0,True,False,1.0,False,False,False,2,True,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,True,False,0.41104739449083594,0,True,0.514446412516817,1,0,0.4598172,0
NCT05519774,Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning,Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning,COMPLETED,,OBSERVATIONAL,54.0,ACTUAL,2022-08-01,2024-10-18,Inova Health Care Services,OTHER,,,,,,Brain Fog,,,,,False,809.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,54.0,4.007333185232471,0,0,0.6,True,True,0.7713688392807674,1,True,0.717551383064256,1,1,0.70816815,1
NCT01693445,"S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer","Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2012-06-01,2014-08-01,Hallym University Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,"OIS (Oxaliplatin, Irinotecan, S-1)",Gastrointestinal Neoplasms,,,,,False,791.0,True,False,1.0,False,False,False,1,True,Small (<30),1,22.0,3.1354942159291497,0,0,0.56,True,True,0.5059752234509572,1,True,0.5848304150557714,1,1,0.6344793,1
NCT01809210,Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer,"A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE1,INTERVENTIONAL,55.0,ACTUAL,2013-04-04,2016-01-04,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","selumetinib, gemcitabine, cisplatin, carboplatin, pemetrexed",Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV,,,,,False,1005.0,True,False,1.0,False,False,True,5,True,Medium (30-100),1,55.0,4.02535169073515,1,0,0.56,True,True,0.6799032033873738,1,True,0.6427161478992531,1,1,0.6752428,1
NCT04398927,Systemic Chemotherapy Plus PD-1 for Metastasis ICC,Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil Plus PD-1 for Metastasis ICC-single Arm Prospective Study,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2020-05-01,2021-02-01,Sun Yat-sen University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Folfirinox, Sintilimab","ICC, Metastatic Cancer",,,,,False,276.0,True,False,2.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.021181741789001868,1,False,0.0058116987155848445,1,0,0.001725787,1
NCT01409226,3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women,A Study to Evaluate 3.0 Tesla Magnetic Resonance Imaging of the Breasts in High Risk Women,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2009-08-01,2012-01-01,NYU Langone Health,OTHER,,SINGLE_GROUP,NONE,"DEVICE, PROCEDURE","3.0-T MRI, biopsy","Breast Cancer, BRCA1 Mutation, BRCA2 Mutation",,,,,False,883.0,True,False,-1.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.6,False,False,0.03385015797667489,1,False,0.005643493623353496,1,0,0.0023668713,1
NCT00025454,R115777 in Treating Patients With Advanced Solid Tumors,Phase I Trial of R115777 (NSA 702818) in Advanced Malignant Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,,,2001-08-01,2008-07-01,City of Hope Medical Center,OTHER,,,,DRUG,tipifarnib,"Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2526.0,True,False,1.0,False,False,False,1,True,,0,,,0,0,0.56,True,True,0.7768440782943336,1,True,0.8052648056876017,1,1,0.8984692,1
NCT00165061,Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer - Early Results From the Chinese University Research Group for Esophageal Cancer (CURE),Phase 3 Multicenter Randomized Study Comparing Esophagectomy Against Definitive Chemoradiation for Treatment of Squamous Esophageal Cancer,COMPLETED,PHASE3,INTERVENTIONAL,80.0,,2000-07-01,,Chinese University of Hong Kong,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Esophagectomy, Chemoradiation",Esophageal Cancer,,,,,False,1303.0,True,False,3.0,True,False,False,2,True,Medium (30-100),0,80.0,4.394449154672439,2,0,0.77,True,True,0.606382902141718,1,True,0.6208093531295815,1,0,0.4526254,0
NCT01766557,Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.,Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.,COMPLETED,,INTERVENTIONAL,9.0,ACTUAL,2010-08-01,2013-12-01,Laval University,OTHER,RANDOMIZED,CROSSOVER,NONE,"OTHER, OTHER","Semi-controlled nutritional intervention with fish protein diet, Semi-controlled intervention with other animal proteins","Insulin Sensitivity, Polycystic Ovarian Syndrome",,,,,False,1218.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,9.0,2.302585092994046,2,0,0.6,True,False,0.24657195416512356,0,False,0.13027900693539135,0,0,0.09824932,0
NCT02401906,MRI and Orbital Tumours (MEDORT),MRI for the Etiological Diagnosis of Orbital Tumours,COMPLETED,,OBSERVATIONAL,200.0,ACTUAL,2015-05-27,2020-05-25,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,,OTHER,MRI,"Orbital Tumor, Orbital Pseudotumor",,,,,False,1825.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8683721777391578,1,True,0.8864282752493057,1,1,0.8624164,1
NCT01736605,The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction,The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction - A Pilot Study,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2013-01-01,2014-10-01,Mayo Clinic,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","Massage, Massage combined with meditation",Breast Cancer,,,,,False,638.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.5716121264324477,1,True,0.7924415041028411,1,1,0.7360033,1
NCT05720195,ALBI and PALBI Scores and HCC Prognosis,Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities,COMPLETED,,OBSERVATIONAL,645.0,ACTUAL,2019-01-01,2022-12-31,Sohag University,OTHER,,,,DIAGNOSTIC_TEST,ALBI,Hepatocellular Carcinoma (HCC) Prognosis,,,,,False,1460.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,645.0,6.470799503782602,0,1,0.6,True,True,0.9442607739646028,1,True,0.9072778980571263,1,1,0.8980986,1
NCT05310565,The Effects of Chiropractic in Adults With Colon Cancer,The Effects of Chiropractic Care on the Quality of Life and Autonomic Nervous System in Adults With Colon Cancer: a Single-arm Pilot Trial,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2025-01-01,2025-03-01,Life University,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,HVLA cervical chiropractic adjustments,"Colon Cancer Stage III, Colon Cancer Stage IV",,,,,False,59.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.03507167805580221,1,False,0.018759682197816346,1,0,0.0038109496,1
NCT04832854,"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2021-04-23,2025-03-05,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel",Non-Small Cell Lung Cancer (NSCLC),,,,,False,1412.0,True,False,2.0,False,False,True,7,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.58,True,True,0.6332428656272097,1,True,0.8211132868247191,1,1,0.82482785,1
NCT01112449,Influence of Selenium on Prostate Cancer Related Biomarkers,Influence of Selenium on Prostate Cancer Related Biomarkers,COMPLETED,,INTERVENTIONAL,130.0,ACTUAL,2008-05-01,2014-05-01,Milton S. Hershey Medical Center,OTHER,RANDOMIZED,FACTORIAL,DOUBLE,"OTHER, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Placebo, selenomethionine, low dose selenized-yeast, high dose selenized-yeast",Effect of Selenium on Oxidative Stress in Healthy Men,,,,,False,2191.0,True,False,-1.0,True,True,False,4,True,Large (100-300),0,130.0,4.875197323201151,3,1,0.6,True,True,0.7430402127624772,1,True,0.8321809378149513,1,1,0.85434085,1
NCT01236716,Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung,A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung,COMPLETED,PHASE2,INTERVENTIONAL,126.0,ACTUAL,2010-11-01,2014-06-01,Chinese Society of Lung Cancer,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Albumin paclitaxel plus carboplatin, Gemcitabine plus carboplatin","Carcinoma, Non-Small-Cell Lung",,,,,False,1308.0,True,False,2.0,True,False,False,2,True,Large (100-300),1,126.0,4.844187086458591,2,1,0.58,True,True,0.5933108912692651,1,True,0.7479228450704185,1,1,0.6720904,1
NCT02429570,Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary,Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,30.0,ACTUAL,2015-04-22,2026-04-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Meclofenamate,"Recurrent Brain Metastases, Progressive Brain Metastases",,,,,False,3997.0,False,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.7765231167545931,1,True,0.6429310951570726,1,1,0.5746047,1
NCT02856100,Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer,Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer,COMPLETED,,OBSERVATIONAL,18.0,ACTUAL,2016-08-03,2020-01-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,,,DRUG,18F DCFPyL- Radiopharmaceutical,Prostate Cancer,,,,,False,1246.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.6,True,True,0.5359906202688961,1,False,0.4867008075104775,0,0,0.45587695,0
NCT04588038,NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery,A Window of Opportunity Trial of NT-I7 in Patients With Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery,TERMINATED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2021-03-12,2025-02-03,"Hyunseok Kang, MD",OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,Efineptakin alfa,"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Resectable Oropharyngeal Squamous Cell Carcinoma",,,,,False,1424.0,True,False,1.0,False,False,False,1,False,Small (<30),0,4.0,1.6094379124341005,0,0,0.56,False,False,0.186078202180793,1,False,0.15078842641144086,1,0,0.08732306,1
NCT02656563,Radium 223 Following Intermittent ADT,"Phase II, Randomized, Open Label to Evaluate Efficacy,Safety of Radium 223 in Prolonging the Off Treatment Interval in Men With Rising PSA Post-rad, or Post-prostatectomy Without Bone Mets on Intermittent Androgen Ablation Therapy",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2015-10-01,2020-10-01,Canadian Urology Research Consortium,OTHER,RANDOMIZED,PARALLEL,NONE,RADIATION,Radium 223 Dichloride (Xofigo®),Prostate Cancer,,,,,False,1827.0,True,False,2.0,True,False,False,1,False,,0,0.0,0.0,1,0,0.58,False,False,0.025279074400512695,1,False,0.013718151567162003,1,0,0.0025203163,1
NCT02944032,Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1,Multimodal Intervention Trial for Cognitive Deficits in Neurofibromatosis Type 1: Efficacy of Computerized Cognitive Training and Stimulant Medication,COMPLETED,,INTERVENTIONAL,103.0,ACTUAL,2016-05-01,2021-09-27,Kristina Hardy,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","CogmedRM, Mobymax",Neurofibromatosis Type 1,,,,,False,1975.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,103.0,4.6443908991413725,2,1,0.6,True,True,0.6670715907178713,1,True,0.7745919379952844,1,1,0.8285138,1
NCT02675842,Investigation of Cannabis for Pain and Inflammation in Lung Cancer,Investigation of Cannabis for Pain and Inflammation in Lung Cancer,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,,2021-10-28,New York State Psychiatric Institute,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Smoked Cannabis High CBD/low THC, Smoked Placebo Cannabis Low CBD/low THC",Lung Cancer,,,,,False,1303.0,True,False,1.0,True,True,False,2,False,,0,0.0,0.0,3,0,0.56,False,False,0.02431632353774487,1,False,0.02445619176283749,1,0,0.0035652404,1
NCT06703437,Long Acting Neuraxial Peri-prostatic Block in Cancer,A Phase I Open Label Peri-prostatic Neuraxial Block With Lidocaine and Ethanol in High-risk Localized Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2022-12-13,2026-06-01,Icahn School of Medicine at Mount Sinai,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Dehydrated alcohol, Lidocaine IV",Prostate Cancer,,,,,False,1266.0,False,False,1.0,False,False,False,2,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.56,True,False,0.3372093651255127,0,False,0.4520767061929138,0,1,0.55735594,1
NCT04462419,18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain,18F-Fluciclovine PET Discrimination of Radiation Injury to the Brain,TERMINATED,,OBSERVATIONAL,19.0,ACTUAL,2020-08-18,2024-11-13,Mayo Clinic,OTHER,,,,"RADIATION, OTHER","Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography, Fluciclovine F18","Metastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm",,,,,False,1548.0,True,False,-1.0,False,False,False,2,False,Small (<30),0,19.0,2.995732273553991,1,0,0.6,False,True,0.513599363062023,0,False,0.4596729546126106,1,0,0.44504297,1
NCT02040480,Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib,"A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers",COMPLETED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2014-02-05,2014-04-04,GlaxoSmithKline,INDUSTRY,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG","GSK2110183 Gelatin Capsule, GSK2110183 IR Tablet",Cancer,,,,,False,58.0,True,False,1.0,True,False,True,2,True,Small (<30),0,18.0,2.9444389791664403,2,0,0.56,True,False,0.29623003676565673,0,True,0.6462592743232743,1,1,0.79829156,1
NCT01211990,An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States,An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States,COMPLETED,,OBSERVATIONAL,22.0,ACTUAL,2010-08-31,2013-05-13,National Institute of Mental Health (NIMH),NIH,,,,,,"Cancer, Allogeneic Peripheral Blood Stem Cell Transplant, Bone Marrow Transplantation",,,,,False,986.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.6,True,True,0.5786856313118638,1,True,0.6139290916097876,1,1,0.65867597,1
NCT05235022,After Cancer in the Military: What Happens After Long-term Sick Leave,After Cancer in the Military: What Happens After Long-term Sick Leave,COMPLETED,,OBSERVATIONAL,17.0,ACTUAL,2022-03-03,2022-07-29,Direction Centrale du Service de Santé des Armées,OTHER,,,,OTHER,Questionnaires,Cancer,,,,,False,148.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,True,False,0.4643379071624436,0,True,0.6915438849644916,1,1,0.643707,1
NCT02988843,Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2017-03-29,2019-12-15,"Masonic Cancer Center, University of Minnesota",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Brentuximab Vedotin, Bevacizumab",Germ Cell Tumor,,,,,False,991.0,True,False,2.0,False,False,False,2,False,Small (<30),1,1.0,0.6931471805599453,1,0,0.58,False,False,0.04951529530755285,1,False,0.1222579981550953,1,0,0.17480247,1
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2013-12-01,2015-07-01,University of Arizona,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Acitretin, Vemurafenib",Malignant Melanoma,,,,,False,577.0,True,False,2.0,False,False,False,2,False,Small (<30),1,2.0,1.0986122886681098,1,0,0.58,False,False,0.06928624088844186,1,False,0.07105533272810834,1,0,0.06754459,1
NCT02200172,The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study,The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2014-12-01,2016-04-01,Bruyère Health Research Institute.,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"OTHER, OTHER","Melatonin, Placebo",Cancer,,,,,False,487.0,True,False,2.0,True,True,False,2,True,Medium (30-100),0,60.0,4.110873864173311,3,0,0.58,True,True,0.6108113254193874,1,True,0.6661491546999655,1,1,0.8041053,1
NCT00532623,Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer,A Phase II Study of Gemcitabine in Combination With Vinorelbine vs. Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,82.0,ACTUAL,2004-05-01,2006-10-01,"National Cancer Center, Korea",OTHER_GOV,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Gemcitabine plus Vinorelbine, Sequential",Metastatic Breast Cancer,,,,,False,883.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,82.0,4.418840607796598,2,0,0.58,True,True,0.6688670545639466,1,True,0.5298346098203887,1,1,0.6341304,1
NCT00966667,"Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer",Health Behaviors Among Individuals Diagnosed With Colorectal Cancer,COMPLETED,,OBSERVATIONAL,222.0,ESTIMATED,2009-11-01,2019-08-07,"Rutgers, The State University of New Jersey",OTHER,,,,,,Colorectal Cancer,,,,,False,3566.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,222.0,5.407171771460119,0,1,0.6,True,True,0.9145404893276923,1,True,0.7742427320664298,1,1,0.75872684,1
NCT04197492,Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas,A Phase II Study of Hypofractionated Stereotactic Radiotherapy Combined With Anlotinib in Patients With Recurrent High-Grade Glioma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,22.0,ESTIMATED,2019-12-16,2024-12-31,Huashan Hospital,OTHER,,SINGLE_GROUP,NONE,"RADIATION, DRUG","Hypofractionated Stereotactic Radiotherapy, Anlotinib",Malignant Glioma,,,,,False,1842.0,False,False,2.0,False,False,False,2,True,Small (<30),0,22.0,3.1354942159291497,1,0,0.58,True,False,0.4778400892456398,0,True,0.6449947738325652,1,1,0.66782594,1
NCT02908165,Randomized Phase II Trial of Chemoembolization and Sorafenib,Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2016-06-01,2020-06-01,Yale University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule",Hepatocellular Carcinoma,,,,,False,1461.0,True,False,2.0,True,False,False,2,False,,1,0.0,0.0,2,0,0.58,False,False,0.018618301690424274,1,False,0.00951327859909673,1,0,0.0031411753,1
NCT01945879,Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer,Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.,COMPLETED,PHASE1,INTERVENTIONAL,19.0,ACTUAL,2003-01-01,2004-04-01,CONKO-Studiengruppe,OTHER,,SINGLE_GROUP,NONE,DRUG,Enoxaparine,Pancreatic Cancer,,,,,False,456.0,True,False,1.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.56,True,False,0.4579098545022333,0,True,0.6012166833459137,1,1,0.7145315,1
NCT03148886,Advanced Breast Cancer and Lifestyle Exercise Study,Advanced Breast Cancer and Lifestyle Exercise Study,COMPLETED,,INTERVENTIONAL,51.0,ACTUAL,2016-10-01,2018-01-01,Centre Leon Berard,OTHER,,SINGLE_GROUP,NONE,OTHER,PA intervention,Metastatic Breastcancer,,,,,False,457.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,51.0,3.951243718581428,0,0,0.6,True,True,0.7431948017366209,1,True,0.7738587084650187,1,1,0.6805603,1
NCT00096499,SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel,"A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer",COMPLETED,PHASE2,INTERVENTIONAL,40.0,ACTUAL,2005-04-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, OTHER, OTHER","ispinesib, pharmacological study, laboratory biomarker analysis","Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer",,,,,False,1303.0,True,False,2.0,False,False,False,3,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.58,True,True,0.5988737142884857,1,True,0.7211105540574333,1,1,0.7877776,1
NCT02871999,Clinical Trial on Acupuncture Adjuvant Treatment in the Pain After the Surgery of Gastrointestinal Carcinoma,,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2016-08-01,2019-01-01,Xiaonan Cui,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, PROCEDURE","Acupuncture therapy, Laparoscopic Surgery","Gastrointestinal Carcinoma, Pain",,,,,False,883.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.6,True,True,0.6819159878965669,1,True,0.7083852363890276,1,1,0.79981005,1
NCT00821652,"Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination","Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1",COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2009-02-01,2014-12-01,Nina Bhardwaj,OTHER,RANDOMIZED,FACTORIAL,TRIPLE,"DRUG, DRUG","NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo",Tumors,,,,,False,2129.0,True,False,1.0,True,True,False,2,True,Small (<30),0,26.0,3.295836866004329,3,0,0.56,True,True,0.5179070667967922,1,True,0.6926183235164598,1,1,0.84101135,1
NCT05141721,A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer,"A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,700.0,ESTIMATED,2022-02-12,2027-03-01,Seattle Project Corporation,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab",Colorectal Neoplasms,,,,,False,1843.0,False,False,2.0,True,False,True,6,True,Very Large (300+),1,700.0,6.55250788703459,2,1,0.58,True,True,0.8746664961248648,1,True,0.9126959723634165,1,1,0.9788719,1
NCT05303090,Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer,"A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer",COMPLETED,PHASE1,INTERVENTIONAL,56.0,ACTUAL,2022-03-31,2024-04-23,Fudan University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","H101, Tislelizumab, lenvatinib",Pancreatic Ductal Adenocarcinoma,,,,,False,754.0,True,False,1.0,False,False,False,3,True,Medium (30-100),1,56.0,4.04305126783455,1,0,0.56,True,True,0.6815527069589814,1,True,0.5806923702717869,1,0,0.36034748,0
NCT05317078,"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications","Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications",TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2023-02-28,2024-04-01,Amgen,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,AMG 794,"Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors",,,,,False,398.0,True,False,1.0,False,False,True,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.56,False,False,0.12643578556143822,1,False,0.11874687217170483,1,0,0.08276993,1
NCT05150938,A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE),Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE),COMPLETED,,OBSERVATIONAL,5737.0,ACTUAL,2022-03-18,2023-02-28,Bayer,INDUSTRY,,,,"DRUG, DRUG, DRUG, DRUG","Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), vitamin K antagonist (VKA), other NOACs",Treatment of Venous Thromboembolism in Cancer Patients,,,,,False,347.0,True,False,-1.0,False,False,True,4,True,Very Large (300+),0,5737.0,8.65486599654131,1,1,0.6,True,True,0.8556488892309665,1,True,0.9728610982968938,1,1,0.984059,1
NCT01706939,The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer,The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,23.0,ACTUAL,2012-09-01,2035-05-01,Icahn School of Medicine at Mount Sinai,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION, DRUG","Reduced Dose Radiation, Standard Dose Radiation, Carboplatin",Squamous Cell Carcinomas,,,,,False,8277.0,False,False,3.0,True,False,False,3,True,Small (<30),1,23.0,3.1780538303479458,2,0,0.77,True,True,0.6310481044958263,1,True,0.5055256968423584,1,1,0.6381689,1
NCT03778606,Oligosaccharide for Cdiff(+) Heme-onc Patients,Oligosaccharide Supplementation Among Hematology-Oncology Clostridium Difficile Colonized Patients,COMPLETED,,INTERVENTIONAL,8.0,ACTUAL,2019-06-01,2021-08-01,Medical College of Wisconsin,OTHER,,SINGLE_GROUP,NONE,DIETARY_SUPPLEMENT,Potato starch,"Clostridium Difficile, Hematologic Diseases",,,,,False,792.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,8.0,2.19722457733622,0,0,0.6,True,False,0.31817123744758447,0,False,0.3840977713954542,0,0,0.40423042,0
NCT01743989,A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.,"A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.",COMPLETED,PHASE3,INTERVENTIONAL,620.0,ACTUAL,2013-04-15,2020-07-08,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,Nilotinib,Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP),,,,,False,2641.0,True,False,3.0,True,False,True,1,True,Very Large (300+),1,620.0,6.431331081933479,1,1,0.77,True,True,0.8756681429363486,1,True,0.9270682868703992,1,1,0.8653143,1
NCT05767515,The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS,"The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS",COMPLETED,,INTERVENTIONAL,120.0,ACTUAL,2023-07-15,2024-03-10,Khyber Medical University Peshawar,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DRUG,metformin,"Infertility, Female, PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries",,,,,False,239.0,True,False,-1.0,True,True,False,1,True,Large (100-300),0,120.0,4.795790545596741,2,1,0.6,True,True,0.6950292815850184,1,True,0.9429696334709513,1,1,0.98489743,1
NCT05642780,SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors,"A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,240.0,ESTIMATED,2023-01-17,2027-12-31,Klus Pharma Inc.,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","SKB264, Pembrolizumab",Solid Tumor,,,,,False,1809.0,False,False,2.0,False,False,True,2,True,Large (100-300),1,240.0,5.484796933490655,1,1,0.58,True,True,0.8125568099565423,1,True,0.7702193351671798,1,1,0.8744223,1
NCT00281632,"A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer","This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.",COMPLETED,PHASE2,INTERVENTIONAL,35.0,ACTUAL,2006-03-01,2010-10-01,GlaxoSmithKline,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,GW786034,"Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer",,,,,False,1675.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.58,True,True,0.6381860528330012,1,True,0.8058359692407033,1,1,0.77720666,1
NCT02452268,A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers,TERMINATED,PHASE1,INTERVENTIONAL,83.0,ACTUAL,2017-05-08,2022-03-07,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","NIZ985, PDR001",Metastatic and Advanced Solid Tumors,,,,,False,1764.0,True,False,1.0,False,False,True,2,False,Medium (30-100),0,83.0,4.430816798843313,1,0,0.56,False,True,0.8066779518543583,0,True,0.5823047550939444,0,1,0.60711515,0
NCT02650193,A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.,"A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single-dose And Multiple-dose Administration By Subcutaneous Injection",COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2015-12-01,2017-10-01,Pfizer,INDUSTRY,,PARALLEL,NONE,DRUG,HSP-130,Non-metastatic Breast Cancer,,,,,False,670.0,True,False,2.0,False,False,True,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.58,True,True,0.5020051195744905,1,False,0.48240280890198534,0,1,0.5373421,1
NCT02097225,"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors,TERMINATED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2014-05-29,2022-10-26,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, OTHER, DRUG, OTHER, DRUG","Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib","BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm",,,,,False,3072.0,True,False,1.0,False,False,False,5,False,Small (<30),1,22.0,3.1354942159291497,1,0,0.56,False,True,0.5569660420588429,0,True,0.7933572404501813,0,1,0.8341915,0
NCT04527900,The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach,"The ""Upproach"" Approach: A Phase 2 Study Of Upfront Intensity Modulated Proton Beam Therapy (Impt) And Concurrent Chemotherapy For Post-Operative Treatment In Loco-Regionally Advanced Endometrial Cancer",TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2021-02-23,2024-07-02,"University of Maryland, Baltimore",OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","carboplatin and paclitaxel, pelvic IMPT (Intensity Modulated Proton Therapy)",Endometrial Cancer,,,,,False,1225.0,True,False,2.0,False,False,False,2,False,Small (<30),1,2.0,1.0986122886681098,1,0,0.58,False,False,0.07850433064818498,1,False,0.16423057757425938,1,0,0.19868304,1
NCT03770117,Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease,A Pilot Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease,COMPLETED,,OBSERVATIONAL,113.0,ACTUAL,2018-10-04,2019-07-01,Manchester University NHS Foundation Trust,OTHER_GOV,,,,"PROCEDURE, PROCEDURE","Prehabilitation, Standard Procedure",Pancreatic Ductal Adenocarcinoma,,,,,False,270.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,113.0,4.736198448394496,1,1,0.6,True,True,0.6867034002139876,1,True,0.9624465652443892,1,1,0.9642708,1
NCT00918229,Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects,"One-arm, Multi-center, International Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy",COMPLETED,,INTERVENTIONAL,24.0,ACTUAL,2009-06-01,2011-05-01,BioProtect,INDUSTRY,,SINGLE_GROUP,NONE,"DEVICE, PROCEDURE","balloon implant, Balloon implantation",Prostate Cancer,,,,,False,699.0,True,False,-1.0,False,False,True,2,True,Small (<30),0,24.0,3.218875824868201,1,0,0.6,True,True,0.5297181138062018,1,True,0.6874120426978564,1,1,0.6379133,1
NCT00857103,Effect of Interactive Tailored Assessment on Patient-provider Communication,Improving Patient-Provider Communication in Cancer Care,COMPLETED,,INTERVENTIONAL,200.0,ACTUAL,2006-08-01,2009-06-01,Oslo University Hospital,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,BEHAVIORAL,CHOICE,Lymphoma,,,,,False,1035.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8484155860508684,1,True,0.8658670036440348,1,1,0.8980298,1
NCT03261128,Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG),Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment. Feasibility and Acceptability Study.,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2017-11-21,2018-12-05,Poitiers University Hospital,OTHER,,,,OTHER,Self-questionnaire,"75 Years Old and More, Cancer, Chemotherapy",,,,,False,379.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.7360887401520982,1,True,0.7952849584341632,1,1,0.7099344,1
NCT05078398,Postoperative Opt-In Narcotics Treatment in Breast,Postoperative Opt-In Narcotics Treatment in Breast,COMPLETED,,INTERVENTIONAL,109.0,ACTUAL,2022-06-01,2025-01-01,"University of California, Los Angeles",OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","POINT Protocol, Usual care","Breast Cancer, Breast Surgery, Opioid Use",,,,,False,945.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,109.0,4.700480365792417,2,1,0.6,True,True,0.6314640155142845,1,True,0.7972602634226827,1,1,0.70431304,1
NCT00744159,Prospective Comparison of Immunological Benefit of Laparoscopic Colectomy,Prospective Comparative Study of Immunological Benefit Between Laparoscopic Colectomy and Open Colectomy,COMPLETED,,OBSERVATIONAL,84.0,ACTUAL,2006-01-01,2007-11-01,Samsung Medical Center,OTHER,,,,,,Immunity,,,,,False,669.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,84.0,4.442651256490317,0,0,0.6,True,True,0.8383337072898548,1,True,0.8705076809916191,1,1,0.9143385,1
NCT01152645,Study of ARQ 197 Monotherapy,Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer,COMPLETED,PHASE2,INTERVENTIONAL,31.0,ACTUAL,2010-06-01,2011-08-01,"Kyowa Kirin Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,ARQ 197,Gastric Cancer,,,,,False,426.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,31.0,3.4657359027997265,0,0,0.58,True,True,0.5451233849942637,1,True,0.5386697432191605,1,1,0.5157338,1
NCT05746156,Lymphatic Mapping for Image Guided Radiotherapy in Patients With LACC - a Feasibility Study,"Lymphatic Mapping for Image Guided Radiotherapy in Patients With Locally Advanced Cervical Cancer, a Feasibility Study",COMPLETED,,INTERVENTIONAL,17.0,ACTUAL,2020-07-20,2022-07-19,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),OTHER,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,lymphatic mapping,Locally Advanced Cervical Cancer,,,,,False,729.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,True,False,0.49450676254700165,0,True,0.6274202524898091,1,1,0.6286878,1
NCT04897568,Shared Decision Making in Rural Primary Care Lung Cancer Screening and Smoking Cessation,Shared Decision Making in Rural Primary Care Lung Cancer Screening and Smoking Cessation,COMPLETED,,INTERVENTIONAL,120.0,ACTUAL,2020-07-15,2023-11-29,"University of Colorado, Denver",OTHER,RANDOMIZED,CROSSOVER,NONE,OTHER,Patient decision aid,"Lung Cancer, Smoking Cessation",,,,,False,1232.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,120.0,4.795790545596741,1,1,0.6,True,True,0.7118424999399658,1,True,0.7891199605965018,1,1,0.83404195,1
NCT04711733,"Supportive Care Needs of Former Child, AYA Cancer Patients, and of Their Parents: Evaluation During Long-term Follow-up","Supportive Care Needs of Former Child, Adolescent and Young Adult Cancer Patients, and of Their Parents: Evaluation During Long-term Follow-up",COMPLETED,,OBSERVATIONAL,99.0,ACTUAL,2021-02-11,2023-02-15,Centre Leon Berard,OTHER,,,,"OTHER, OTHER, OTHER","Interview, Self-report questionnaire, Medical consultation",Solid Tumor or Lymphoma,,,,,False,734.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,99.0,4.605170185988092,1,0,0.6,True,True,0.829105768084814,1,True,0.8240474120384792,1,1,0.8315504,1
NCT00338182,AZD1152 in Patients With Advanced Solid Malignancies,"A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2006-05-23,2017-03-01,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","AZD1152 part A, AZD1152 part B",Tumors,,,,,False,3935.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,43.0,3.784189633918261,1,0,0.56,True,True,0.7678113267553637,1,True,0.8418891252217948,1,1,0.79589045,1
NCT01048684,Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy,Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy,COMPLETED,,INTERVENTIONAL,80.0,ACTUAL,2010-04-01,2011-05-01,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Mannitol, Mannitol","Brain Tumor, Intracranial Pressure",,,,,False,395.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,80.0,4.394449154672439,3,0,0.6,True,True,0.7475883907126474,1,True,0.9543007090792092,1,1,0.9651492,1
NCT06649006,Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL),"A Phase 1b Open-label Study to Investigate Safety, Tolerability and Pharmacokinetics of Intravenous Blinatumomab in Japanese Adult Subjects With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)",COMPLETED,PHASE1,INTERVENTIONAL,6.0,ACTUAL,2025-01-08,2025-12-04,Amgen,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Blinatumomab,B-precursor Acute Lymphoblastic Leukemia,,,,,False,330.0,True,False,1.0,False,False,True,1,True,Small (<30),0,6.0,1.9459101490553128,0,0,0.56,True,False,0.2081162337742986,0,True,0.5306021977433218,1,0,0.4585695,0
NCT02786797,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,COMPLETED,,INTERVENTIONAL,214.0,ACTUAL,2016-03-07,2020-07-01,University of South Florida,OTHER,RANDOMIZED,FACTORIAL,SINGLE,"BEHAVIORAL, BEHAVIORAL","MBSR(BC) 6 Week Program, BCES 6 Week Program",Breast Cancer,,,,,False,1577.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,214.0,5.3706380281276624,2,1,0.6,True,True,0.7928855886973883,1,True,0.8896729345560158,1,1,0.8008156,1
NCT01513083,A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,"A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function",COMPLETED,PHASE1,INTERVENTIONAL,28.0,ACTUAL,2012-02-01,2014-09-01,Hoffmann-La Roche,INDUSTRY,,PARALLEL,NONE,DRUG,trastuzumab emtansine,Breast Cancer,,,,,False,943.0,True,False,1.0,False,False,True,1,True,Small (<30),1,28.0,3.367295829986474,0,0,0.56,True,True,0.575841433768045,1,True,0.5942527808577506,1,1,0.56981903,1
NCT00268710,Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC],Multicenter Phase II Study of Taxotere (Docetaxel) Administered Weekly or Every Three Weeks in Combination With Prednisone as Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer (HRPC),COMPLETED,PHASE2,INTERVENTIONAL,,,2004-02-01,2006-03-01,Sanofi,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,docetaxel,Prostatic Neoplasms,,,,,False,759.0,True,False,2.0,False,False,True,1,True,,1,,,0,0,0.58,True,True,0.6681799793079558,1,True,0.7785286798302531,1,1,0.688866,1
NCT06713941,Management of Bone Metastases,Study of the Management of Bone Metastases Compared to National Recommendations,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,900.0,ESTIMATED,2024-03-15,2025-07-01,Hospices Civils de Lyon,OTHER,,,,OTHER,Study of the treatment,"Cancer, Bone Metastases",,,,,False,473.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,900.0,6.803505257608338,0,1,0.6,True,True,0.9448101300835509,1,True,0.9850694596506346,1,1,0.98475885,1
NCT03153982,Ruxolitinib in Operable Head and Neck Cancer,Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial,TERMINATED,PHASE2,INTERVENTIONAL,16.0,ACTUAL,2018-06-08,2023-10-18,"University of California, San Francisco",OTHER,,SINGLE_GROUP,NONE,DRUG,Ruxolitinib,Head and Neck Squamous Cell Carcinoma,,,,,False,1958.0,True,False,2.0,False,False,False,1,False,Small (<30),0,16.0,2.833213344056216,0,0,0.58,False,False,0.4542112816349909,1,True,0.643736547409496,0,1,0.69899637,0
NCT00101816,Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,COMPLETED,PHASE2,INTERVENTIONAL,124.0,ACTUAL,2004-12-01,2008-03-01,Bristol-Myers Squibb,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Dasatinib,"Chronic Myeloid Leukemia, Blast Crisis",,,,,False,1186.0,True,False,2.0,False,False,True,1,True,Large (100-300),1,124.0,4.8283137373023015,0,1,0.58,True,True,0.7097646903336715,1,True,0.8367477432967206,1,1,0.83833945,1
NCT00813150,Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma,Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma,COMPLETED,PHASE3,INTERVENTIONAL,96.0,ACTUAL,2009-01-01,2013-01-01,Janssen-Cilag G.m.b.H,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Dexamethasone, Bortezomib, Cyclophosphamide",Multiple Myeloma,,,,,False,1461.0,True,False,3.0,True,False,True,3,True,Medium (30-100),1,96.0,4.574710978503383,2,0,0.77,True,True,0.6466177185846134,1,True,0.6154651873098138,1,1,0.6853281,1
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma,TERMINATED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2012-11-01,2015-07-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Doxycycline, Ipilimumab, Temozolomide",Melanoma,,,,,False,972.0,True,False,1.0,False,False,False,3,False,Small (<30),1,12.0,2.5649493574615367,1,0,0.56,False,False,0.3130869611415914,1,False,0.42422984944050357,1,0,0.43563634,1
NCT07326969,MOVEMENT ANALYSIS IN PATIENTS UNDERGOING VERTEBRECTOMIES FOR SPINE ONCOLOGY: A PILOT STUDY,MOVEMENT ANALYSIS IN PATIENTS UNDERGOING VERTEBRECTOMIES FOR THE TREATMENT OF SPINE ONCOLOGY: A PILOT STUDY,COMPLETED,,OBSERVATIONAL,10.0,ACTUAL,2023-03-03,2025-12-21,Istituto Ortopedico Rizzoli,OTHER,,,,OTHER,vertebrectomy,"Spine Tumor, Vertebral Metastasis, Vertebral Column Mass",,,,,False,1024.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.3786081165582914,0,True,0.5905409187116555,1,1,0.7659766,1
NCT02567929,Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer,Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer,COMPLETED,,INTERVENTIONAL,218.0,ACTUAL,2016-03-01,2016-12-01,Konkuk University Medical Center,OTHER,RANDOMIZED,FACTORIAL,QUADRUPLE,"DRUG, DRUG","propofol group, sevoflurane group",Breast Cancer,,,,,False,275.0,True,False,-1.0,True,True,False,2,True,Large (100-300),0,218.0,5.389071729816501,3,1,0.6,True,True,0.7712417341373127,1,True,0.8905258184237621,1,1,0.8654049,1
NCT00961090,Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery,A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.,COMPLETED,PHASE2,INTERVENTIONAL,72.0,ACTUAL,2009-09-01,2015-04-23,Matthew R Quigley,OTHER,,SINGLE_GROUP,NONE,DRUG,Aminolevulinic Acid,Glioblastoma,,,,,False,2060.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,72.0,4.290459441148391,0,0,0.58,True,True,0.8021479960219476,1,True,0.8132447069059406,1,1,0.75394577,1
NCT01192204,Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention,Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention,COMPLETED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2010-10-01,2014-02-01,Ohio State University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","10% FBR containing bioadhesive gel, placebo gel","Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia",,,,,False,1219.0,True,False,1.0,True,True,False,2,True,Medium (30-100),0,41.0,3.737669618283368,3,0,0.56,True,True,0.5883333595162856,1,True,0.7488793007972938,1,1,0.83565825,1
NCT06993987,Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU (InterOncoRea),Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,139.0,ESTIMATED,2025-03-01,2025-10-31,"University Hospital, Brest",OTHER,,,,OTHER,Descriptive analysis,"Intensive Care Unit (ICU) Patients, Metastatic Cancer",,,,,False,244.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,139.0,4.941642422609304,0,1,0.6,True,True,0.7680381886932341,1,True,0.9277131492732161,1,1,0.9198622,1
NCT04728321,A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma,An Open-Label Multi-Center Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 Alone or in Combination With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2021-01-27,2023-08-02,Akeso,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","AK104 lenvatinib, AK104",Hepatocellular Carcinoma,,,,,False,917.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,32.0,3.49650756146648,1,0,0.58,True,True,0.5199384477721445,1,True,0.5297841978161684,1,0,0.46831813,0
NCT01973868,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,"A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment",COMPLETED,PHASE1,INTERVENTIONAL,42.0,ACTUAL,2013-11-21,2018-04-03,Bayer,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)",Neoplasms,,,,,False,1594.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.56,True,True,0.6583487065741342,1,True,0.766953909358016,1,1,0.7978296,1
NCT06979921,"PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST",Breast Cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Retrospective and Prospective Study,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,496.0,ACTUAL,2021-07-10,2026-12-30,The First Affiliated Hospital with Nanjing Medical University,OTHER,,,,DEVICE,Blood test,Cancer,,,,,False,1999.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,496.0,6.208590026096629,0,1,0.6,True,True,0.9394336481243205,1,True,0.9706464017990531,1,1,0.96577907,1
NCT04158583,A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors,"An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor",TERMINATED,PHASE1,INTERVENTIONAL,76.0,ACTUAL,2019-12-09,2022-07-21,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,RO7296682,Solid Tumors,,,,,False,955.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,76.0,4.343805421853684,0,0,0.56,False,True,0.7985490032002454,0,True,0.676512102218027,0,1,0.58623004,0
NCT03837353,A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1,A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1,TERMINATED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2019-04-01,2022-09-20,NYU Langone Health,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","DKN-01, Docetaxel",Prostate Cancer,,,,,False,1268.0,True,False,1.0,False,False,False,2,False,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,False,False,0.4275656088726654,1,True,0.5683083341788995,0,1,0.57737136,0
NCT06351306,DEC-C and Thioguanine for R/R AML,"A Phase II Open-Label, Single Center Trial of Oral Decitabine-Cedazuridine (DEC-C) (Inqovi®) in Combination With Thioguanine (Tabloid®) in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2024-04-01,2024-04-01,Columbia University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Thioguanine (Tabloid ®), DecitabineCedazuridine (Inqovi ®)",Acute Myeloid Leukemia,,,,,False,0.0,True,False,2.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.02002300431767826,1,False,0.006378822848750425,1,0,0.0026900608,1
NCT00470834,Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy,A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase,COMPLETED,PHASE4,INTERVENTIONAL,127.0,ACTUAL,2007-05-01,2013-02-01,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG","dutasteride, placebo, bicalutamide","Neoplasms, Prostate",,,,,False,2103.0,True,False,4.0,True,True,True,3,True,Large (100-300),1,127.0,4.852030263919617,3,1,0.7,True,True,0.5634554360958441,1,True,0.7865822608151731,1,1,0.84376156,1
NCT02897934,CWI and Discharge After Breast Cancer Surgery,Continuous Wound Infiltration and 23 Hour Discharge Following Major Breast Cancer Surgery,COMPLETED,,OBSERVATIONAL,10.0,ACTUAL,2016-08-01,2018-07-31,University College Cork,OTHER,,,,DRUG,Bupivacaine continuous infusion,"Breast Cancer, Pain",,,,,False,729.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.364275376185589,0,True,0.542372815766432,1,1,0.5224283,1
NCT04496089,"Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC","Open-label Phase I of 89Zr-girentuximab (89Zr-TLX250) to Assess the Safety, Biodistribution, Pharmacokinetics and Sensitivity/Specificity of PET/CT Images in Patients With Suspected Renal Cell Carcinoma Including Clear Cell Renal Cell Carcinoma (ZIRDAC-JP Study)",COMPLETED,PHASE1,INTERVENTIONAL,6.0,ACTUAL,2020-08-01,2021-04-06,Telix Pharmaceuticals (Innovations) Pty Limited,INDUSTRY,,SEQUENTIAL,NONE,DIAGNOSTIC_TEST,89Zr-girentuximab,"Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma",,,,,False,248.0,True,False,1.0,False,False,True,1,True,Small (<30),0,6.0,1.9459101490553128,0,0,0.56,True,False,0.20531773800070208,0,True,0.5534357995735713,1,1,0.5749235,1
NCT00973882,Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers,Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2005-04-01,2010-01-01,Centre Leon Berard,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Carboplatin, Etoposide",Prostate Cancer,,,,,False,1736.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,60.0,4.110873864173311,1,0,0.58,True,True,0.7122453862187726,1,True,0.8076063570613695,1,1,0.88432485,1
NCT03171090,Efficacy of Bilateral Ultrasonic Guided Sphenopalatine Ganglion Block in Maxilofacial Cancer Surgeries,Efficacy of Bilaterally Ultrasonic Guided Sphenopalatine Ganglion Block for Perioperative Pain Management in Maxilofacial Cancer Surgeries,COMPLETED,,INTERVENTIONAL,48.0,ACTUAL,2017-06-05,2018-03-15,Assiut University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"OTHER, OTHER","sphenopalatine block with local anesthetic, sphenopalatine block with saline",Maxillofacial Tumors,,,,,False,283.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,48.0,3.8918202981106265,3,0,0.6,True,True,0.6297209229755408,1,True,0.8451096440938435,1,1,0.7610522,1
NCT05825625,NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing,"Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing: a Non-randomized, Open-label, Single-arm Phase II Study",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,35.0,ESTIMATED,2023-05-26,2027-06-01,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Atezolizumab, Tiragolumab",Non-small Cell Lung Cancer,,,,,False,1467.0,False,False,2.0,False,False,False,2,True,Medium (30-100),1,35.0,3.58351893845611,1,0,0.58,True,True,0.571442850113216,1,True,0.7160102700992573,1,1,0.725735,1
NCT03237013,Strategies to Promote Skin Health,Strategies to Promote Skin Health,COMPLETED,,INTERVENTIONAL,219.0,ACTUAL,2016-02-18,2017-01-14,San Diego State University,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Facial Morphing Intervention, Mindfulness Intervention","Skin Cancer, Skin Cancer Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma",,,,,False,331.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,219.0,5.393627546352362,2,1,0.6,True,True,0.7512601227427774,1,True,0.9446445914002826,1,1,0.95411634,1
NCT01625520,SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer,"Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression",COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2012-02-01,,Federico II University,OTHER,,SINGLE_GROUP,NONE,DRUG,SOM230 alone or in combination with RAD001.,Medullary Thyroid Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.58,True,False,0.46409299174287266,0,True,0.5629332696071997,1,1,0.50774837,1
NCT00061945,Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia,"A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)",COMPLETED,PHASE1,INTERVENTIONAL,302.0,ACTUAL,2003-06-01,2012-10-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG, OTHER, OTHER","allopurinol, cyclophosphamide, daunorubicin hydrochloride, vincristine sulfate, dexamethasone, asparaginase, filgrastim, imatinib mesylate, methotrexate, cytarabine, trimethoprim-sulfamethoxazole, mercaptopurine, leucovorin calcium, alemtuzumab, acyclovir, laboratory biomarker analysis, pharmacological study","Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Adult Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia",,,,,False,3410.0,True,False,1.0,False,False,False,17,True,Very Large (300+),1,302.0,5.713732805509369,1,1,0.56,True,True,0.8650655420454548,1,True,0.8303091203970301,1,1,0.87699664,1
NCT05032092,Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer,Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,235.0,ESTIMATED,2021-11-24,2027-12-01,Medical University of Graz,OTHER,,SINGLE_GROUP,NONE,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, GENETIC","Next Generation Sequencing, Next Generation Sequencing, Biomarker Monitoring","Locally Advanced Carcinoma, Metastatic Cancer",,,,,False,2198.0,False,False,-1.0,False,False,False,3,True,Large (100-300),0,235.0,5.4638318050256105,1,1,0.6,True,True,0.8688557557490546,1,True,0.8074232244278621,1,1,0.7918317,1
NCT00388700,"A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer","Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2006-10-01,2009-06-01,Galectin Therapeutics Inc.,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab",Colorectal Cancer,,,,,False,974.0,True,False,2.0,False,False,True,2,False,,1,0.0,0.0,1,0,0.58,False,False,0.023748416953378232,1,False,0.010884862880485423,1,0,0.003177432,1
NCT01325883,The Effect of Chemotherapy and Surgery for Cancer on Exercise Capacity,The Effect of Neoadjuvant Chemotherapy on Exercise Capacity and Outcome Following Upper Gastrointestinal Cancer Surgery.,COMPLETED,,OBSERVATIONAL,253.0,ACTUAL,2011-04-01,2016-01-01,Liverpool University Hospitals NHS Foundation Trust,OTHER_GOV,,,,,,"Tumor of Esophagus, Stomach and Duodenum",,,,,False,1736.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,253.0,5.537334267018537,0,1,0.6,True,True,0.8922516622154688,1,True,0.8761455399864918,1,1,0.9100577,1
NCT06298123,Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling,Risk Factor Analysis and Prognostic Modelling of Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma,COMPLETED,,OBSERVATIONAL,304.0,ACTUAL,2019-02-01,2023-02-01,Chen Xiaoping,OTHER,,,,DRUG,Anti-PD-1 monoclonal antibody,"Hepatocellular Carcinoma, Adjuvant Immunotherapy, Checkpoint Inhibitor",,,,,False,1461.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,304.0,5.720311776607412,0,1,0.6,True,True,0.9008586534726755,1,True,0.9036215337240165,1,1,0.9004923,1
NCT00746161,Evaluation of Double Tract Reconstruction After Total Gastrectomy in Patients With Gastric Cancer,A Prospective Randomized Controlled Trial Comparing Double Tract Method With Roux-en-Y Method After Total Gastrectomy in Patients With Gastric Cancer,COMPLETED,PHASE3,INTERVENTIONAL,44.0,ACTUAL,2002-04-01,2008-04-01,Wakayama Medical University,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","Reconstruction after total gastrectomy, Reconstruction after total gastrectomy",Gastric Cancer,,,,,False,2192.0,True,False,3.0,True,False,False,2,True,Medium (30-100),0,44.0,3.80666248977032,2,0,0.77,True,False,0.49870485730928493,0,True,0.6825139409089226,1,1,0.5493152,1
NCT02083653,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,"Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies",COMPLETED,PHASE2,INTERVENTIONAL,254.0,ACTUAL,2014-03-06,2017-04-26,Symphogen A/S,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, OTHER, DRUG, DRUG","Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC), Fluorouracil (5-FU), Capecitabine",Metastatic Colorectal Cancer,,,,,False,1147.0,True,False,2.0,True,False,True,5,True,Large (100-300),1,254.0,5.541263545158426,2,1,0.58,True,True,0.725332633830637,1,True,0.7315473404279493,1,1,0.70825964,1
NCT00003511,Antineoplaston Therapy in Treating Patients With Multiple Myeloma,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Multiple Myeloma,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,1996-04-04,1999-10-21,Burzynski Research Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,Antineoplaston therapy (Atengenal + Astugenal),Multiple Myeloma,,,,,False,1295.0,True,False,2.0,False,False,False,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.58,False,False,0.18923451900037996,1,False,0.10875737408937283,1,0,0.06299177,1
NCT01673269,Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD,Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2012-07-01,2013-10-01,"Texas Tech University Health Sciences Center, El Paso",OTHER,,SINGLE_GROUP,NONE,OTHER,Blood culture ( aerobic and anaerobic),"Choledocholithiasis, Cholangiocarcinoma, Benign Stricture of Common Bile Duct",,,,,False,457.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,0,0,0.6,True,True,0.7741865447494314,1,True,0.9109130109461325,1,1,0.9081611,1
NCT05275530,The Impact of Choice on Colorectal Cancer Screening,The Impact of Choice on Colorectal Cancer (CRC) Screening Uptake Among Average-risk Individuals 45-49 Years of Age,COMPLETED,,INTERVENTIONAL,20509.0,ACTUAL,2022-02-21,2022-11-21,"University of California, Los Angeles",OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Active FIT Choice, Active Colonoscopy Choice, Active Dual Choice","Colorectal Cancer, Colorectal Neoplasms, Health Screening",,,,,False,273.0,True,False,-1.0,True,False,False,3,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.6,True,True,0.8064241591625485,1,True,0.9457142539867647,1,1,0.9813783,1
NCT01054924,Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening,Clinical Study to Assess the Performance of the Invendo C20 Colonoscope System in Persons Undergoing Colorectal Cancer Screening at Average Risk for CRC,COMPLETED,,OBSERVATIONAL,,,2009-11-01,2009-12-01,Invendo Medical GmbH,INDUSTRY,,,,,,Colorectal Cancer Screening,,,,,False,30.0,True,False,-1.0,False,False,True,0,True,,0,,,0,0,0.6,True,True,0.7216243996981517,1,True,0.8486294137867767,1,1,0.93311346,1
NCT06462014,Description of Relugolix Use in Patients With Prostate Cancer Within the VHA,Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data,COMPLETED,,OBSERVATIONAL,507.0,ACTUAL,2024-06-19,2024-12-13,Pfizer,INDUSTRY,,,,DRUG,Relugolix,Prostate Cancer,,,,,False,177.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,507.0,6.230481447578482,0,1,0.6,True,True,0.9152823778363802,1,True,0.9832996004694229,1,1,0.988492,1
NCT02948855,Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases,Study on Regulation of LncRNA to Regulatory B Cells(Bregs) Through Notch Pathway in Patients With Thymoma and Autoimmune Diseases,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2016-10-01,2018-05-01,Tianjin Medical University Cancer Institute and Hospital,OTHER,,,,,,"Thymoma, Autoimmune Disease",,,,,False,577.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.03968321871616028,1,False,0.008594528453366349,1,0,0.0028460962,1
NCT01253837,L19TNFα in Patients With Advanced Solid Tumors,Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,34.0,ESTIMATED,2007-09-01,2011-09-01,Philogen S.p.A.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,L19TNFa,"Solid Tumors, Colorectal Cancer",,,,,False,1461.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,34.0,3.555348061489413,0,0,0.56,True,True,0.6556812075614068,1,True,0.6468575274106922,1,1,0.6016388,1
NCT01277276,Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain,Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2008-11-01,2013-02-01,"University of California, Irvine",OTHER,,,,DEVICE,Diffuse optical spectroscopy and Near infrared spectroscopy,Signs and Symptoms,,,,,False,1553.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.04725764636222247,1,False,0.011310846330309259,1,0,0.0031533784,1
NCT00923871,Automating Breast Radiation Therapy (RT),Automating the Breast Radiation Therapy Process to Improve Efficiency,COMPLETED,,INTERVENTIONAL,160.0,ESTIMATED,2009-06-01,2016-04-29,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Cone Beam CT,Breast Cancer,,,,,False,2524.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,160.0,5.081404364984463,0,1,0.6,True,True,0.8596666532900128,1,True,0.9006757434861055,1,1,0.94690174,1
NCT04171609,Expressive Writing for Cancer Survivors,Expressive Writing for Resilience in Adult Cancer Survivors.,COMPLETED,,INTERVENTIONAL,14.0,ACTUAL,2019-07-19,2020-05-14,Duke University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Expressive writing,Cancer Survivors,,,,,False,300.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,14.0,2.70805020110221,0,0,0.6,True,False,0.42334908544914446,0,True,0.5966887675824042,1,1,0.5562651,1
NCT00900120,Collecting and Storing Blood Samples From Patients With Cancer,Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2004-03-01,2011-05-01,University of Medicine and Dentistry of New Jersey,OTHER,,,,,,"Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific",,,,,False,2617.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.05942524751990478,1,False,0.05921491241745419,1,0,0.0026310922,1
NCT00583726,The Women's Healthy Lifestyle Study,Motivational Interviewing for Weight Maintenance,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2007-12-01,2011-11-01,University of Michigan,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","motivational interviewing, written materials only",Breast Cancer,,,,,False,1431.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.6114639488885544,1,True,0.7490430522538414,1,1,0.74416876,1
NCT01796821,Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs),"A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)",COMPLETED,PHASE2,INTERVENTIONAL,138.0,ACTUAL,2014-08-01,2018-10-01,"G&E Herbal Biotechnology Co., LTD",INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG","Vehicle gel, SR-T100 gel with 1.0 % SM, SR-T100 gel with 2.3% SM","Condyloma Acuminata, Genital Warts, Condylomata Acuminata, Venereal Warts",,,,,False,1522.0,True,False,2.0,True,True,True,3,True,Large (100-300),0,138.0,4.934473933130692,3,1,0.58,True,True,0.6565227192799337,1,True,0.7259792563788047,1,1,0.7765302,1
NCT01662505,Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML),"An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia",COMPLETED,PHASE1,INTERVENTIONAL,19.0,ACTUAL,2012-08-01,2015-05-01,Boehringer Ingelheim,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Volasertib,"Leukemia, Myeloid, Acute",,,,,False,1003.0,True,False,1.0,False,False,True,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.56,True,False,0.48627373832790294,0,True,0.6192275587065679,1,1,0.6621669,1
NCT00630110,Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer,Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE1,INTERVENTIONAL,172.0,ACTUAL,2008-02-01,2011-06-01,"Nereus Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","docetaxel, NPI-2358 + docetaxel",Cancer,,,,,False,1216.0,True,False,1.0,True,False,True,2,True,Large (100-300),1,172.0,5.153291594497779,2,1,0.56,True,True,0.6945449530178454,1,True,0.7245902484141981,1,1,0.72217065,1
NCT04801966,Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study,Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study,TERMINATED,,INTERVENTIONAL,3.0,ACTUAL,2021-09-23,2022-12-30,"Peter MacCallum Cancer Centre, Australia",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab",Cancer,,,,,False,463.0,True,False,-1.0,False,False,False,15,False,Small (<30),1,3.0,1.3862943611198906,1,0,0.6,False,False,0.0981074411902327,1,False,0.10020256318396094,1,0,0.05052379,1
NCT02758249,Anesthetic Effect on Immune Cell in Patients With Cancer,Anesthetic Effect on Immune Cell in Patients With Cancer,COMPLETED,,INTERVENTIONAL,47.0,ACTUAL,2016-01-01,2016-01-01,Konkuk University Medical Center,OTHER,RANDOMIZED,FACTORIAL,SINGLE,"DRUG, DRUG","Sevoflurane, propofol",Breast Cancer,,,,,False,0.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,47.0,3.871201010907891,2,0,0.6,True,True,0.5803200187891815,1,True,0.858894223665228,1,1,0.89640135,1
NCT05108623,A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors,"A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,34.0,ACTUAL,2022-01-28,2024-01-02,MiNK Therapeutics,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","agenT-797, Approved ICIs","Tumor, Solid",,,,,False,704.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,34.0,3.555348061489413,1,0,0.56,True,True,0.5691429265173039,1,True,0.5165773644917955,1,0,0.40765235,0
NCT00277290,Study of XL999 in Patients With Previously Treated Ovarian Cancer,A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer,TERMINATED,PHASE2,INTERVENTIONAL,24.0,ACTUAL,2006-01-01,2006-11-01,"Symphony Evolution, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,XL999,Ovarian Cancer,,,,,False,304.0,True,False,2.0,False,False,True,1,False,Small (<30),0,24.0,3.218875824868201,0,0,0.58,False,False,0.4724051416907244,1,False,0.4537478935201613,1,0,0.35799795,1
NCT03561454,A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients,A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx™ System Patients,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,100.0,ESTIMATED,2019-01-11,2029-08-01,MedStar Franklin Square Medical Center,OTHER,,,,DEVICE,IORT,Early Stage Breast Cancer,,,,,False,3855.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.8339820747224203,1,True,0.7375042894151309,1,1,0.70637196,1
NCT01235468,Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB),Allogenic Transplantation of Ex-vivo Expanded CB Progenitors for Haematological Disorders,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2012-06-01,2015-11-01,Dr. Avichai Shimoni MD,OTHER_GOV,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,ex vivo expansion,"Umbilical Cord Blood, Stem Cell Transplantation, Hematological Malignancies",,,,,False,1248.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.03656841275787606,1,False,0.008324861631089793,1,0,0.002728114,1
NCT04048447,Endoscopic Characterization of Colorectal Neoplasia With the Different Published Classifications,Endoscopic Characterization of Colorectal Neoplasia With the Different Published Classifications: a Prospective Comparative Study Involving Gastroenterologists From Trainees to Experts.,COMPLETED,,OBSERVATIONAL,206.0,ACTUAL,2018-08-01,2019-08-01,Hôpital Edouard Herriot,OTHER,,,,,,Colorectal Neoplasia,,,,,False,365.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,206.0,5.332718793265369,0,1,0.6,True,True,0.8364448108500373,1,True,0.8693923486634777,1,1,0.8732422,1
NCT03891654,Dynamic Contrast Enhanced Computed Tomography to Assess Radiation Therapy in Liver Cancer Patients,Pilot Study of Dynamic Contrast Enhanced Computed Tomography (DCE-CT) Imaging for the Assessment of Radiation Therapy Outcome for Liver Cancer Patients,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,3.0,ACTUAL,2019-08-01,2022-04-28,"University of Colorado, Denver",OTHER,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,Dynamic Contrast Enhanced Computed Tomography,Liver Cancer,,,,,False,1001.0,True,False,0.5,False,False,False,1,True,Small (<30),0,3.0,1.3862943611198906,0,0,0.57,True,False,0.14725136561818145,0,False,0.2074571131967249,0,0,0.45685655,0
NCT06902441,Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database,Impact of Androgen Receptor Signaling Inhibitors on Cardiovascular Events in Prostate Cancer: a Pharmacoepidemiology Study Using the French Health Care Claims Database,COMPLETED,,OBSERVATIONAL,52000.0,ACTUAL,2025-01-07,2025-06-30,"University Hospital, Caen",OTHER,,,,,,Prostate Cancer,,,,,False,174.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.8813782430949779,1,True,0.988726066962782,1,1,0.98435944,1
NCT01130025,Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer,Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT,COMPLETED,PHASE3,INTERVENTIONAL,900.0,ACTUAL,2010-08-01,2014-05-01,LEO Pharma,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Warfarin, Innohep®",Venous Thromboembolism,,,,,False,1369.0,True,False,3.0,True,False,True,2,True,Very Large (300+),0,900.0,6.803505257608338,2,1,0.77,True,True,0.8521958517587616,1,True,0.8468383389137888,1,1,0.8916835,1
NCT00306241,A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years,"A Phase III, Double-blind, Randomized, Controlled Study to Evaluate Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly (0, 1, 6 Month Schedule) in Healthy Females Aged 18 - 35 Years",COMPLETED,PHASE3,INTERVENTIONAL,300.0,ACTUAL,2006-03-01,2007-06-01,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,BIOLOGICAL,HPV-16/18 L1 VLP AS04,"Infections, Papillomavirus",,,,,False,457.0,True,False,3.0,True,True,True,1,True,Large (100-300),0,300.0,5.707110264748875,2,1,0.77,True,True,0.739858490863569,1,True,0.8245707916957487,1,1,0.8619865,1
NCT04167631,Can VI-RADS/ADC Accurately Stage Bladder Cancer??,Can Vesical Imaging-Reporting And Data System and Apparent Diffusion Coefficient Values (the VI-RADS/ADC) Accurately Predict Non-Muscle Invasive Bladder Cancer,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,150.0,ESTIMATED,2019-01-01,2024-12-01,Mansoura University,OTHER,,SINGLE_GROUP,NONE,RADIATION,Multi-parametric MRI,"MRI Contrast Media Adverse Reaction, Bladder Cancer, Bladder Disease, Bladder Neoplasm, Bladder Urothelial Carcinoma, Bladder Cancer Stage, Diagnoses Disease",,,,,False,2161.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,150.0,5.017279836814924,0,1,0.6,True,True,0.8419238847846559,1,True,0.8337899727301052,1,1,0.80629206,1
NCT03892720,Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer,A Phase II Study of Non-Coplanar SBRT Re-Irradiation Using HyperArc in Patients With Recurrent Head and Neck Cancer,COMPLETED,,INTERVENTIONAL,33.0,ACTUAL,2019-03-27,2024-08-21,Jonsson Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER, RADIATION","Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy",Recurrent Head and Neck Carcinoma,,,,,False,1974.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,33.0,3.5263605246161616,1,0,0.6,True,True,0.6671039119879083,1,True,0.720167269641857,1,1,0.6734598,1
NCT01435525,Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation,Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication,COMPLETED,,OBSERVATIONAL,369.0,ACTUAL,2011-09-01,2014-03-01,AstraZeneca,INDUSTRY,,,,,,"Gastric Ulcer, Duodenal Ulcer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Lymphoma Idiopathic Thrombocytopenic Purpura, Early Gastric Cancer",,,,,False,912.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,369.0,5.91350300563827,0,1,0.6,True,True,0.9077702737212795,1,True,0.8786564823307497,1,1,0.9203536,1
NCT04111510,Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer,A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,6.0,ACTUAL,2019-12-23,2023-05-11,Yale University,OTHER,,SINGLE_GROUP,NONE,DRUG,Tumor infiltrating lymphocytes (TIL) LN-145,Metastatic Triple Negative Breast Cancer,,,,,False,1235.0,True,False,2.0,False,False,False,1,True,Small (<30),0,6.0,1.9459101490553128,0,0,0.58,True,False,0.21427229005425744,0,False,0.10724234327904872,0,0,0.0803107,0
NCT02342353,Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI,TERMINATED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2015-05-18,2018-02-06,Washington University School of Medicine,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Pacritinib, Erlotinib","Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung",,,,,False,995.0,True,False,1.0,False,False,False,2,False,Small (<30),1,8.0,2.19722457733622,1,0,0.56,False,False,0.23857252949248042,1,False,0.34401309657292173,1,1,0.5331357,0
NCT04618081,Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL),Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma),COMPLETED,,OBSERVATIONAL,151.0,ACTUAL,2020-12-17,2025-03-27,Celgene,INDUSTRY,,,,,,Lymphoma Nonhodgkin,,,,,False,1561.0,True,False,-1.0,False,False,True,0,True,Large (100-300),0,151.0,5.0238805208462765,0,1,0.6,True,True,0.8284814937778802,1,True,0.8649857273400614,1,1,0.9011745,1
NCT02073916,T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients,COMPLETED,PHASE1,INTERVENTIONAL,24.0,ACTUAL,2013-10-01,2018-12-01,"Jenny C. Chang, MD",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","T-DM1, Lapatinib, Abraxane",Metastatic Breast Cancer,,,,,False,1887.0,True,False,1.0,False,False,False,3,True,Small (<30),0,24.0,3.218875824868201,1,0,0.56,True,True,0.5353480445185385,1,True,0.6290308153550076,1,1,0.582966,1
NCT01344967,Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect,,COMPLETED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2009-02-01,2011-12-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,DRUG,Zoledronic acid,Metastatic Breast Cancer With Bone Involvement,,,,,False,1033.0,True,False,2.0,False,False,False,1,True,Small (<30),0,21.0,3.091042453358316,0,0,0.58,True,False,0.47578746747585277,0,True,0.5203627518201879,1,1,0.57891834,1
NCT00681044,HD Melphalan and SCT in Patients With IGDD or LCDD,High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD),TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2006-10-01,2016-01-01,Boston Medical Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, PROCEDURE","filgrastim, melphalan, Stem Cell Infusion",Multiple Myeloma,,,,,False,3379.0,True,False,2.0,False,False,False,3,False,Small (<30),0,5.0,1.791759469228055,1,0,0.58,False,False,0.22270073853451172,1,False,0.33125327980657937,1,1,0.61933655,0
NCT04466137,Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy,"A Multi-centers, Randomized, Open-labeled, Positive-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF, Once-per-cycle, in Patients With Malignancies Receiving Myelosuppressive Chemotherapy.",COMPLETED,PHASE3,INTERVENTIONAL,398.0,ACTUAL,2020-10-16,2021-09-01,"Xiamen Amoytop Biotech Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","YPEG-rhG-CSF, YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF",Non-Myeloid Malignancy,,,,,False,320.0,True,False,3.0,True,False,True,3,True,Very Large (300+),0,398.0,5.988961416889864,2,1,0.77,True,True,0.7137030421823063,1,True,0.9079995030988617,1,1,0.9084987,1
NCT05649046,"Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE","Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,160.0,ACTUAL,2023-01-23,2024-06-01,Assistance Publique Hopitaux De Marseille,OTHER,,SINGLE_GROUP,NONE,"DEVICE, BIOLOGICAL, BIOLOGICAL","thoracic scan Low dose, BLOOD SAMPLE, FECES SAMPLE","Smoking-related Pathology, Atheroma, Chronic Bronchitis, Non-progressive Cancer > 5 Years, Lung Cancer",,,,,False,495.0,False,False,-1.0,False,False,False,3,True,Large (100-300),0,160.0,5.081404364984463,1,1,0.6,True,True,0.761609817035792,1,True,0.9510930526816462,1,1,0.96636367,1
NCT02718755,"Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies","Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2018-05-01,2022-05-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Fludarabine, Cytarabine, Erwinase",Hematologic Malignancy,,,,,False,1461.0,True,False,2.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.58,False,False,0.025696454046399596,1,False,0.013086606164201686,1,0,0.0035789981,1
NCT04818983,The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2),"The Exploratory Study to Evaluate Biomarkers in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer (J-TAIL-2)",COMPLETED,,OBSERVATIONAL,470.0,ACTUAL,2021-04-07,2023-02-03,Chugai Pharmaceutical,INDUSTRY,,,,,,"Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer",,,,,False,667.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,470.0,6.154858094016418,0,1,0.6,True,True,0.9199119226715523,1,True,0.9610034388566956,1,1,0.95671356,1
NCT04266301,"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)",TERMINATED,PHASE3,INTERVENTIONAL,530.0,ACTUAL,2020-06-08,2024-10-02,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG","Sabatolimab, Azacitidine, Placebo","Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic",,,,,False,1577.0,True,False,3.0,True,True,True,3,False,Very Large (300+),0,530.0,6.274762021241939,3,1,0.77,False,True,0.8230497718817954,0,True,0.8471077047452296,0,1,0.81154287,0
NCT04919811,Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC,"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,217.0,ACTUAL,2021-09-01,2027-12-01,Nuvation Bio Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Taletrectinib,Non Small Cell Lung Cancer,,,,,False,2282.0,False,False,2.0,False,False,True,1,True,Large (100-300),0,217.0,5.384495062789089,0,1,0.58,True,True,0.846215419798435,1,True,0.7982557666236856,1,1,0.7825638,1
NCT04729855,"Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population","Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population",COMPLETED,,OBSERVATIONAL,60.0,ACTUAL,2022-04-15,2024-09-20,"Esraa Hassan,MD",OTHER,,,,DIAGNOSTIC_TEST,"PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168",Colo-rectal Cancer,,,,,False,889.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,0,0,0.6,True,True,0.789516098199475,1,True,0.8779276499120455,1,1,0.922852,1
NCT02190721,"A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement","A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement",COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2015-05-12,2017-04-04,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,tbo-filgrastim,Neutropenia,,,,,False,693.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.58,True,True,0.6760295062486396,1,True,0.6880947236658579,1,1,0.677322,1
NCT02067416,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,"Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2012-07-01,2014-06-01,"Jenny C. Chang, MD",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Anthracycline based chemotherapy, taxane-based chemotherapy",Breast Cancer,,,,,False,700.0,True,False,2.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.02309069866074202,1,False,0.006886520432973826,1,0,0.0023038602,1
NCT02935790,Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma,COMPLETED,PHASE1,INTERVENTIONAL,1.0,ACTUAL,2016-09-30,2017-04-07,Celgene,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","ACY-241, nivolumab, ipilimumab",Malignant Melanoma,,,,,False,189.0,True,False,1.0,False,False,True,3,True,Small (<30),1,1.0,0.6931471805599453,1,0,0.56,True,False,0.04784647778772008,0,False,0.072221546396431,0,0,0.057104237,0
NCT00039130,"Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia","Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia",COMPLETED,PHASE2,INTERVENTIONAL,105.0,ACTUAL,2002-05-01,2014-10-01,Alliance for Clinical Trials in Oncology,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol","Leukemia, Lymphoma",,,,,False,4536.0,True,False,2.0,False,False,False,13,True,Large (100-300),1,105.0,4.663439094112067,1,1,0.58,True,True,0.7287184785379204,1,True,0.8216628126017644,1,1,0.8275422,1
NCT01260714,"Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia",A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML),TERMINATED,PHASE1,INTERVENTIONAL,13.0,ACTUAL,2010-12-01,2015-06-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, DRUG","Azacitidine, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia",,,,,False,1643.0,True,False,1.0,False,False,False,4,False,Small (<30),1,13.0,2.6390573296152584,1,0,0.56,False,False,0.35753521298327195,1,False,0.433299290861414,1,0,0.34158325,1
NCT00049582,Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia,"Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients With High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary)",TERMINATED,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2002-09-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, OTHER, OTHER","decitabine, laboratory biomarker analysis, pharmacological study","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia",,,,,False,1303.0,True,False,1.0,False,False,False,3,False,Medium (30-100),0,36.0,3.610917912644224,1,0,0.56,False,True,0.6087713276886455,0,True,0.6364204551427084,0,1,0.64311516,0
NCT04914286,A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors,"A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,148.0,ACTUAL,2021-10-20,2023-12-31,Genfleet Therapeutics (Shanghai) Inc.,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","GFH018, Toripalimab",Advanced Solid Tumor,,,,,False,802.0,True,False,1.0,False,False,True,2,True,Large (100-300),0,148.0,5.003946305945459,1,1,0.56,True,True,0.7239287523131018,1,True,0.717314907500527,1,1,0.53773504,1
NCT00582764,Quantitative Dynamic Contrast Enhanced Breast MRI,Quantitative Dynamic Contrast Enhanced Breast MRI,COMPLETED,,OBSERVATIONAL,116.0,ACTUAL,2005-09-01,2015-07-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,OTHER,perform dynamic contrast enhanced (DCE) MRI,Breast Cancer,,,,,False,3590.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,116.0,4.762173934797756,0,1,0.6,True,True,0.8469135703979277,1,True,0.7487979235722618,1,1,0.7159661,1
NCT01615640,Diffusion Study on Patients With Osteosarcoma,Monitoring the Response of Osteosarcoma Under Neoadjuvant Chemotherapy: The Value of Dynamic Contrast Enhancement and Diffusion-weighted MRI,COMPLETED,,OBSERVATIONAL,30.0,ESTIMATED,2010-09-01,2019-06-07,Klinikum Stuttgart,OTHER,,,,,,Osteosarcoma,,,,,False,3201.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.7503303804767825,1,True,0.5083055375384798,1,0,0.39784968,0
NCT01179074,Role of Radiotherapy Following Oesophageal Stenting in Cancer,Palliative Stenting With or Without Radiotherapy for Inoperable Oesophageal Carcinoma: a Randomised Trial,COMPLETED,,INTERVENTIONAL,84.0,ACTUAL,2007-04-01,2009-03-01,All India Institute of Medical Sciences,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","oesophageal stenting with self expandable metal stent, Oesophageal stent followed by external beam radiotherapy",Oesophageal Cancer,,,,,False,700.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,84.0,4.442651256490317,2,0,0.6,True,True,0.7452890598754941,1,True,0.8722435891966256,1,1,0.88504994,1
NCT03859349,The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial,Routine Systematic Sampling vs. Targeted Sampling of Mediastinal Lymph Nodes Prior to Lung Cancer Treatment: A Feasibility Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,38.0,ACTUAL,2019-05-06,2020-06-08,St. Joseph's Healthcare Hamilton,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Selective Targeted Sampling, Systematic Sampling",Non Small Cell Lung Cancer,,,,,False,399.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,38.0,3.6635616461296463,2,0,0.6,True,True,0.5461492299305004,1,True,0.769702429388044,1,1,0.6882412,1
NCT04549207,Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer,A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA),ACTIVE_NOT_RECRUITING,PHASE4,INTERVENTIONAL,240.0,ACTUAL,2020-10-09,2026-06-01,Ottawa Hospital Research Institute,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Bone modifying agent,"Breast Cancer, Castration-resistant Prostate Cancer",,,,,False,2061.0,False,False,4.0,True,False,False,1,True,Large (100-300),0,240.0,5.484796933490655,1,1,0.7,True,True,0.7318836755341367,1,True,0.7845076512307488,1,1,0.8322451,1
NCT03487549,Cantharidin and Occlusion in Verruca Epithelium,"A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)",COMPLETED,PHASE2,INTERVENTIONAL,56.0,ACTUAL,2018-03-27,2019-07-15,Verrica Pharmaceuticals Inc.,INDUSTRY,,SEQUENTIAL,NONE,"COMBINATION_PRODUCT, COMBINATION_PRODUCT","VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution","Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca",,,,,False,475.0,True,False,2.0,False,False,True,2,True,Medium (30-100),0,56.0,4.04305126783455,1,0,0.58,True,True,0.6457119856815751,1,True,0.6904000239822621,1,1,0.6268804,1
NCT00550004,Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine,"Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma",TERMINATED,PHASE2,INTERVENTIONAL,153.0,ESTIMATED,2007-09-01,2009-10-01,SciClone Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG","RP101, Gemcitabine (1000 mg/m2)",Pancreatic Cancer,,,,,False,761.0,True,False,2.0,True,True,True,2,False,Large (100-300),1,153.0,5.0369526024136295,3,1,0.58,False,True,0.6422500604133112,0,True,0.6300664933381569,0,1,0.5900038,0
NCT00614965,Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV,A Multicenter Randomized Phase II Study of the Combination of Irinotecan/Cisplatin Versus Pemetrexed/Cisplatin as Second-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,INTERVENTIONAL,124.0,ESTIMATED,2006-11-01,2010-03-01,Hellenic Oncology Research Group,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Irinotecan, Cisplatin, Pemetrexed",Non Small Cell Lung Cancer,,,,,False,1216.0,True,False,2.0,True,False,False,3,True,Large (100-300),1,124.0,4.8283137373023015,2,1,0.58,True,True,0.5797614563076169,1,True,0.7125931222809657,1,1,0.7522499,1
NCT00796978,Trastuzumab in Treating Older Women With Early-Stage Breast Cancer,Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin®) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial,COMPLETED,PHASE2,INTERVENTIONAL,56.0,ACTUAL,2009-02-05,2020-02-26,"Cynthia Owusu, MD",OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER, PROCEDURE, PROCEDURE","trastuzumab, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment",Breast Cancer,,,,,False,4038.0,True,False,2.0,False,False,False,4,True,Medium (30-100),1,56.0,4.04305126783455,1,0,0.58,True,True,0.7811648632326554,1,True,0.9061441440231683,1,1,0.92011577,1
NCT01484275,A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma,"A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma",COMPLETED,PHASE2,INTERVENTIONAL,85.0,ACTUAL,2012-03-01,2019-08-21,"Janssen Research & Development, LLC",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Siltuximab, Placebo",High-risk Smoldering Multiple Myeloma,,,,,False,2729.0,True,False,2.0,True,True,True,2,True,Medium (30-100),0,85.0,4.454347296253507,3,0,0.58,True,True,0.7822255132719291,1,True,0.6792403760263853,1,1,0.77346367,1
NCT06345482,A Study of MHB039A for Advanced Solid Tumor,A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,196.0,ESTIMATED,2024-04-16,2029-06-01,Minghui Pharmaceutical (Hangzhou) Ltd,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,MHB039A,Advanced Solid Tumor,,,,,False,1872.0,False,False,1.0,False,False,True,1,True,Large (100-300),0,196.0,5.2832037287379885,0,1,0.56,True,True,0.8419274799907709,1,True,0.6362536334363604,1,1,0.52568316,1
NCT02658708,Bright Light on Fatigue in Women Being Treated for Breast Cancer,Bright Light on Fatigue in Women Being Treated for Breast Cancer: A Pilot Study,COMPLETED,PHASE1,INTERVENTIONAL,19.0,ACTUAL,2015-10-12,2017-05-09,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER, OTHER, OTHER, OTHER, OTHER, OTHER, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, OTHER, OTHER","Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Digital foot candle datalogging light meter (Extech Instrument, Model SDL400), Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA), Horne-Ostberg Morningness-Eveningness Questionnaire, Daily Fatigue and Sleep Log","Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast",,,,,False,575.0,True,False,1.0,True,False,False,11,True,Small (<30),0,19.0,2.995732273553991,2,0,0.56,True,False,0.2917623629899472,0,False,0.4511829919200715,0,1,0.60297894,1
NCT02597478,Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea,A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea,COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2016-01-04,2021-01-27,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, PROCEDURE, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call",Advanced Cancers,,,,,False,1850.0,True,False,2.0,True,True,False,5,True,Medium (30-100),0,50.0,3.9318256327243257,3,0,0.58,True,True,0.6183850710137583,1,True,0.6987891790960044,1,1,0.6572276,1
NCT06839872,A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,BOSS: BTK Inhibitor Optimal Sequencing Study Phase II Open-label Single Arm Trial of Pirtobrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma After First-line Acalabrutinib Progression,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2025-06-30,2030-07-29,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Pirtobrutinib, Acalabrutinib","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",,,,,False,1855.0,True,False,2.0,False,False,True,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.029182014344705888,1,False,0.01756927323950636,1,0,0.0028480347,1
NCT05492617,Early Detection of de Novo Cancer in Liver Transplant Recipients,Early Detection of de Novo Cancer in Liver Transplant Recipients - a ScandiaTransplant Collaboration,COMPLETED,,OBSERVATIONAL,3628.0,ACTUAL,2010-01-01,2020-12-31,"Rigshospitalet, Denmark",OTHER,,,,,,"De Novo Cancer, Liver Transplant Disorder",,,,,False,4017.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,3628.0,8.19671240721307,0,1,0.6,True,True,0.9717362379318638,1,True,0.9682642235939158,1,1,0.95619947,1
NCT02440425,Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2015-10-20,2021-05-27,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Pembrolizumab, Paclitaxel",Ovarian Cancer,,,,,False,2046.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.58,True,True,0.6453408332509285,1,True,0.8148101033476486,1,1,0.76713395,1
NCT04560725,PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer,PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,50.0,ESTIMATED,2020-10-22,2024-12-01,Peking University Cancer Hospital & Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,11C-Choline,Prostate Cancer,,,,,False,1501.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.7788965158627013,1,True,0.6372955511887954,1,1,0.5775035,1
NCT00261313,ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer,An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,80.0,ACTUAL,2005-12-01,2007-12-01,Amgen,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Neulasta, Aranesp",Breast Cancer,,,,,False,730.0,True,False,2.0,False,False,True,2,True,Medium (30-100),0,80.0,4.394449154672439,1,0,0.58,True,True,0.7357361291897119,1,True,0.6866431758336934,1,1,0.56506944,1
NCT01600196,Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus,Surgical Resection Versus Best Supportive Care for Resectable Hepatocellular Carcinoma Invading the First Branch of Portal Vein,TERMINATED,PHASE4,INTERVENTIONAL,126.0,ACTUAL,2006-01-01,2011-07-01,Sun Yat-sen University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,Liver resection plus Thrombectomy,Hepatocellular Carcinoma With Portal Vein Tumor Thrombus,,,,,False,2007.0,True,False,4.0,False,False,False,1,False,Large (100-300),0,126.0,4.844187086458591,0,1,0.7,False,True,0.6699858898772366,0,True,0.8907942517615506,0,1,0.896648,0
NCT03595345,A Worldwide Score for Hepatocellular Cancer and Liver Transplantation,A Worldwide Usable Scoring System for Patients With Hepatocellular Cancer Waiting for Liver Transplantation,COMPLETED,,OBSERVATIONAL,3100.0,ACTUAL,2016-12-15,2018-10-15,European Hepatocellular Cancer Liver Transplant Group,OTHER,,,,PROCEDURE,Liver transplantation,"Liver Cancer, Dropout, Patient, Recurrence",,,,,False,669.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,3100.0,8.03947991910045,0,1,0.6,True,True,0.9504991647360803,1,True,0.987431044714031,1,1,0.9922472,1
NCT02287519,Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention,Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention,COMPLETED,,INTERVENTIONAL,53.0,ACTUAL,2014-11-01,2019-12-01,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Group Session, Telephone Coaching Session, Webinar",Ovarian Cancer,,,,,False,1856.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,53.0,3.9889840465642745,1,0,0.6,True,True,0.7622787314281204,1,True,0.7578178402681588,1,1,0.66138667,1
NCT06396845,Assessing the Benefits of Robotic and Laparoscopic Surgery for Mid and Low Rectal Cancer in Patients: The Charlson Comorbidity Index (CCI),Assessing the Benefits of Robotic and Laparoscopic Surgery for Mid and Low Rectal Cancer in Patients: The Charlson Comorbidity Index (CCI),COMPLETED,,OBSERVATIONAL,505.0,ACTUAL,2019-01-01,2024-01-03,Daorong Wang,OTHER,,,,"PROCEDURE, PROCEDURE","robotic surgery, laparoscopic surgery","Robotic, Laparoscopic, Anterior Resection for Rectal Cancer",,,,,False,1828.0,True,False,-1.0,False,False,False,2,True,Very Large (300+),0,505.0,6.226536669287466,1,1,0.6,True,True,0.9249894403937043,1,True,0.9284273191956427,1,1,0.954358,1
NCT01634763,Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK),"A Phase I, Multicenter, Open-label Dose Escalation Study of LDK378, Administered Orally in Japanese Patients With Tumors Characterized by Genetic Alterations in ALK",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2012-06-01,2016-01-01,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,LDK378,Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK),,,,,False,1309.0,True,False,1.0,False,False,True,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.56,True,True,0.539908137072094,1,True,0.5945346571160262,1,1,0.57015496,1
NCT01931865,IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation,IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation,TERMINATED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2012-09-01,2015-07-01,Yale University,OTHER,,SINGLE_GROUP,NONE,DRUG,IncobotulinumtoxinA,Pain,,,,,False,1033.0,True,False,2.0,False,False,False,1,False,Small (<30),0,12.0,2.5649493574615367,0,0,0.58,False,False,0.33907164617035124,1,False,0.3107716062543466,1,0,0.34591466,1
NCT00003397,Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma,"Autologous Stem Cell Transplantation for Poor Prognosis, Relapsed, or Refractory Intermediate-High Grade B-Cell Lymphoma Using Gemcitabine Plus High Dose BCNU and Melphalan Followed by Anti-CD20 Moab (IDEC C2B8, Rituximab, Rituxan) and Consolidative Chemotherapy",COMPLETED,PHASE2,INTERVENTIONAL,25.0,ESTIMATED,1998-09-01,2002-12-01,"University of Maryland, Baltimore",OTHER,,,,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation",Lymphoma,,,,,False,1552.0,True,False,2.0,False,False,False,13,True,Small (<30),1,25.0,3.258096538021482,1,0,0.58,True,False,0.4327591256701766,0,False,0.49192567219065325,0,0,0.48142323,0
NCT03774654,CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR),Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,13.0,ACTUAL,2020-06-22,2035-02-28,Baylor College of Medicine,OTHER,NON_RANDOMIZED,PARALLEL,NONE,GENETIC,CD19.CAR-aNKT cells,"Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma",,,,,False,5364.0,False,False,1.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.56,True,True,0.6143992106522639,1,True,0.5736089146440312,1,1,0.78179425,1
NCT04507568,The Person-centered Evolution of Radiotherapy Services in Ontario Study,The Person-centered Evolution of Radiotherapy Services in Ontario (PERSON) Study,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,109.0,ACTUAL,2020-08-13,2027-08-01,"University Health Network, Toronto",OTHER,RANDOMIZED,PARALLEL,SINGLE,OTHER,Quality of Life Questionnaires,"Breast Cancer, Quality of Life",,,,,False,2544.0,False,False,-1.0,True,False,False,1,True,Large (100-300),0,109.0,4.700480365792417,1,1,0.6,True,True,0.7463975388877061,1,True,0.7796977783393616,1,1,0.8146769,1
NCT05501886,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),"Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,701.0,ESTIMATED,2022-12-08,2026-12-31,Celcuity Inc,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Gedatolisib, Palbociclib, Fulvestrant, Alpelisib",Breast Cancer,,,,,False,1484.0,False,False,3.0,True,False,True,4,True,Very Large (300+),1,701.0,6.553933404025811,2,1,0.77,True,True,0.824782370359844,1,True,0.8424737022570088,1,1,0.94079745,1
NCT02912247,Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers,"A Open, Randomized, Single-dose, Comparative Bioequivalency and Safety Study of Human Recombinant Anti-tumor Necrosis Factor Alpha Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers",COMPLETED,PHASE1,INTERVENTIONAL,183.0,ACTUAL,2016-10-27,2017-09-22,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab",Healthy,,,,,False,330.0,True,False,1.0,True,False,True,2,True,Large (100-300),0,183.0,5.214935757608986,2,1,0.56,True,True,0.6740135063744489,1,True,0.8236781682181765,1,1,0.9475929,1
NCT06697899,TGRX-678 Phase I Oral Pharmacokinetic Study,Food Effect on Pharmacokinetic Profile for TGRX-678 Tablet in Chinese Healthy Subject With Single Oral Administration,COMPLETED,PHASE1,INTERVENTIONAL,76.0,ACTUAL,2024-11-24,2025-02-20,"Shenzhen TargetRx, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,TGRX-678,Chronic Myeloid Leukemia,,,,,False,88.0,True,False,1.0,True,False,True,1,True,Medium (30-100),0,76.0,4.343805421853684,1,0,0.56,True,True,0.6999048931759358,1,True,0.8003583891039204,1,1,0.9606627,1
NCT01839955,Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2013-09-01,2016-10-01,Neelesh Sharma MD PhD,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, OTHER, OTHER, DRUG","erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose","Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer",,,,,False,1126.0,True,False,1.0,True,False,False,5,True,Small (<30),1,12.0,2.5649493574615367,2,0,0.56,True,False,0.2414619272674306,0,False,0.36652942199626876,0,0,0.32139987,0
NCT01253070,Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia,A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients &gt;/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2011-04-01,2021-04-15,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DRUG, DRUG, OTHER, OTHER, OTHER, DRUG","Biopsy, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate","Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Acute Promyelocytic Leukemia With PML-RARA, FLT3 Gene Mutation, Therapy-Related Acute Myeloid Leukemia",,,,,False,3667.0,True,False,2.0,False,False,False,8,True,Medium (30-100),1,54.0,4.007333185232471,1,0,0.58,True,True,0.7455943026079569,1,True,0.8870936016393821,1,1,0.93824536,1
NCT06802809,Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota,"Evaluation of the Efficacy of Lactobacillus Crispatus M247 Administration in Promoting Clearance of Genital HR-HPV Infection and Modulating the Vaginal Microbiota: A Multicenter, Randomized, Placebo-Controlled, Single-Blind, Longitudinal, Prospective Clinical Trial",COMPLETED,,INTERVENTIONAL,66.0,ACTUAL,2022-01-05,2024-12-30,Liaquat University of Medical & Health Sciences,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DIETARY_SUPPLEMENT, OTHER","Lactobacillus crispatus M247 (Crispact®), Placebo",Human Papillomavirus Infection,,,,,False,1090.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,66.0,4.204692619390966,2,0,0.6,True,True,0.7119465074010595,1,True,0.7387962087330063,1,1,0.6771247,1
NCT00003443,Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,A Phase II Trial of Bryostatin-1 In Patients With Metastatic or Recurrent Squamos Cell Carcinoma of the Head and Neck,COMPLETED,PHASE2,INTERVENTIONAL,,,1998-07-01,2001-05-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,DRUG,bryostatin 1,Head and Neck Cancer,,,,,False,1035.0,True,False,2.0,False,False,False,1,True,,0,,,0,0,0.58,True,True,0.6869010223555095,1,True,0.789861457402887,1,1,0.8015244,1
NCT00389974,"Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery","A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma",COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2007-01-01,2009-03-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,DRUG,sunitinib malate,"Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer, Stage IVB Cervical Cancer",,,,,False,790.0,True,False,2.0,False,False,False,1,True,Small (<30),1,19.0,2.995732273553991,0,0,0.58,True,False,0.4307220250714752,0,True,0.5044979095539633,1,1,0.5236243,1
NCT02749331,Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy,Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,35.0,ESTIMATED,2016-03-01,2025-12-01,Uppsala University,OTHER,,SINGLE_GROUP,NONE,DRUG,AdVince,Neuroendocrine Tumors,,,,,False,3562.0,False,False,1.0,False,False,False,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.56,True,True,0.7524296960974833,1,True,0.8300052512531386,1,1,0.8331465,1
NCT05043649,Camsirubicin + Pegfilgrastim to Determine MTD in ASTS,"A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue Sarcomas",TERMINATED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2021-09-22,2024-05-13,Monopar Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Camsirubicin,Advanced Soft-tissue Sarcoma,,,,,False,964.0,True,False,1.0,False,False,True,1,False,Small (<30),0,14.0,2.70805020110221,0,0,0.56,False,False,0.4073432428331735,1,False,0.49130629101693535,1,1,0.5774213,0
NCT02402036,A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study,TERMINATED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2015-02-01,2017-11-01,Georgetown University,OTHER,,SINGLE_GROUP,NONE,DRUG,Regorafenib,Colon Cancer,,,,,False,1004.0,True,False,2.0,False,False,False,1,False,Small (<30),1,10.0,2.3978952727983707,0,0,0.58,False,False,0.2924756459286227,1,False,0.2636883715571116,1,0,0.3505096,1
NCT02725528,Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's,"A Multi-Center, Randomized Controlled Trial Comparing The Clinical Effectiveness and Cost-Effectiveness of Collagenase Injection (Xiaflex) and Palmar Fasciectomy in the Management of Dupuytren's Disease",COMPLETED,PHASE3,INTERVENTIONAL,22.0,ACTUAL,2017-07-08,2021-12-17,McMaster University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, PROCEDURE","collagenase injection, limited palmar fasciectomy",Dupuytren's Disease,,,,,False,1623.0,True,False,3.0,True,False,False,2,True,Small (<30),0,22.0,3.1354942159291497,2,0,0.77,True,False,0.3004158464117621,0,False,0.3578604999606562,0,0,0.23811288,0
NCT03588039,Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors,"Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies",TERMINATED,PHASE1,INTERVENTIONAL,34.0,ACTUAL,2018-10-25,2023-05-12,"Athenex, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, BIOLOGICAL","Oraxol, Pembrolizumab",Solid Tumor,,,,,False,1660.0,True,False,1.0,False,False,True,2,False,Medium (30-100),1,34.0,3.555348061489413,1,0,0.56,False,True,0.6104137790749785,0,True,0.6372741641060433,0,1,0.5093715,0
NCT00310167,Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma,A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma,COMPLETED,PHASE3,INTERVENTIONAL,614.0,ACTUAL,2005-10-01,2017-01-01,"University College, London",OTHER,RANDOMIZED,PARALLEL,NONE,RADIATION,radiation therapy,Lymphoma,,,,,False,4110.0,True,False,3.0,True,False,False,1,True,Very Large (300+),0,614.0,6.421622267806518,1,1,0.77,True,True,0.9071133146304693,1,True,0.9543061509303429,1,1,0.95899016,1
NCT02040376,Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,COMPLETED,PHASE3,INTERVENTIONAL,24.0,ACTUAL,2014-06-13,2017-12-15,The Hospital for Sick Children,OTHER,RANDOMIZED,CROSSOVER,QUADRUPLE,"DRUG, DRUG","Metformin, Placebo",Brain Tumor Treated With Cranial or Cranial-Spinal Radiation,,,,,False,1281.0,True,False,3.0,True,True,False,2,True,Small (<30),0,24.0,3.218875824868201,3,0,0.77,True,False,0.3317331915267837,0,False,0.4252961244131291,0,1,0.50937074,1
NCT02521389,"Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143","Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects",COMPLETED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2015-06-29,2017-02-24,"MEI Pharma, Inc.",INDUSTRY,RANDOMIZED,CROSSOVER,NONE,DRUG,PWT-143,Malignancies,,,,,False,606.0,True,False,1.0,True,False,True,1,True,Medium (30-100),0,35.0,3.58351893845611,1,0,0.56,True,True,0.5365464825308179,1,True,0.6070154927353566,1,1,0.53069246,1
NCT00121251,"Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer",A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2005-06-03,2017-03-14,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Capecitabine, Gemcitabine Hydrochloride, Sorafenib Tosylate","Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7",,,,,False,4302.0,True,False,1.0,False,False,False,3,True,Small (<30),1,17.0,2.8903717578961645,1,0,0.56,True,True,0.5647678558513497,1,True,0.591229636842189,1,1,0.58458704,1
NCT00912743,"Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status","A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status",COMPLETED,PHASE2,INTERVENTIONAL,33.0,ACTUAL,2009-05-01,2012-03-01,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,olaparib,Colorectal Cancer,,,,,False,1035.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,33.0,3.5263605246161616,0,0,0.58,True,True,0.5921628317862494,1,True,0.6286346149925727,1,1,0.60231537,1
NCT00631371,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,"Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma",COMPLETED,PHASE3,INTERVENTIONAL,791.0,ACTUAL,2008-04-01,2015-04-01,Pfizer,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Bevacizumab, Temsirolimus, Bevacizumab, Interferon-Alfa 9MU",Renal Cell Carcinoma,,,,,False,2556.0,True,False,3.0,True,False,True,4,True,Very Large (300+),1,791.0,6.674561391814426,2,1,0.77,True,True,0.8643499078550717,1,True,0.9509971016985809,1,1,0.98415226,1
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,Intravital Microscopy (IVM) During Sentinel Lymph Node (SLN) Biopsy for Melanoma,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2016-11-03,2022-06-13,Roswell Park Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, DRUG, OTHER, PROCEDURE","Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Sentinel Lymph Node Biopsy","Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma",,,,,False,2048.0,True,False,-1.0,False,False,False,4,True,Small (<30),0,20.0,3.044522437723423,1,0,0.6,True,True,0.5424586728180621,1,True,0.517279698003998,1,0,0.41421032,0
NCT00848016,"Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery",A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC),COMPLETED,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2009-02-01,2012-06-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,DRUG,R-(-)-gossypol acetic acid,"Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma",,,,,False,1216.0,True,False,2.0,False,False,False,1,True,Small (<30),0,29.0,3.4011973816621555,0,0,0.58,True,True,0.5685490046579852,1,True,0.6389449517997184,1,1,0.61342466,1
NCT00573885,Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum,Phase II Trial of Polyphenon E in Former Smokers With Abnormal Sputa,COMPLETED,PHASE2,INTERVENTIONAL,53.0,ACTUAL,2008-01-01,2008-12-01,British Columbia Cancer Agency,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER","defined green tea catechin extract, placebo","Lung Cancer, Tobacco Use Disorder",,,,,False,335.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,53.0,3.9889840465642745,2,0,0.58,True,True,0.5408375677668261,1,False,0.44784223811932933,0,0,0.24368836,0
NCT05059756,PTNS and PFR in the Treatment of Childhood Constipation,Percutaneous Tibial Nerve Stimulation and Pelvic Floor Rehabilitation in the Treatment of Childhood Constipation,COMPLETED,,INTERVENTIONAL,84.0,ACTUAL,2019-05-08,2021-12-08,Shengjing Hospital,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DEVICE, DEVICE","PTNS, Sham PTNS","Constipation, Childhood ALL, Pelvic Floor Disorders",,,,,False,945.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,84.0,4.442651256490317,3,0,0.6,True,True,0.7774180575268398,1,True,0.9194358455543439,1,1,0.83969957,1
NCT00448240,Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer,Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck,TERMINATED,PHASE2,INTERVENTIONAL,6.0,ACTUAL,2007-02-01,2012-01-01,Henry Ford Health System,OTHER,,SINGLE_GROUP,NONE,DRUG,Erlotinib,"Head and Neck Cancer, Carcinoma, Squamous Cell",,,,,False,1795.0,True,False,2.0,False,False,False,1,False,Small (<30),1,6.0,1.9459101490553128,0,0,0.58,False,False,0.22950980361278367,1,False,0.33184049809925914,1,0,0.41065258,1
NCT00217633,Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer,Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer,COMPLETED,PHASE2,INTERVENTIONAL,38.0,ACTUAL,2006-01-01,,Gynecologic Oncology Group,NETWORK,,SINGLE_GROUP,NONE,PROCEDURE,Conventional Surgery,"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma",,,,,False,1303.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.58,True,True,0.6401308153176701,1,True,0.696005032290165,1,1,0.63620186,1
NCT01139138,"Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer","A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT",COMPLETED,PHASE1,INTERVENTIONAL,49.0,ACTUAL,2010-06-01,2017-06-01,The Queen Elizabeth Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Panitumumab, Irinotecan, Everolimus","Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal",,,,,False,2557.0,True,False,1.0,False,False,False,3,True,Medium (30-100),1,49.0,3.912023005428146,1,0,0.56,True,True,0.7304349802690271,1,True,0.8920025303225759,1,1,0.92999643,1
NCT04225572,Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT),Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT),COMPLETED,,INTERVENTIONAL,135.0,ACTUAL,2017-12-27,2025-12-12,"Masonic Cancer Center, University of Minnesota",OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Physical Therapy: Dependent on Patient's Needs,Breast Cancer,,,,,False,2907.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,135.0,4.912654885736052,1,1,0.6,True,True,0.7977230271322576,1,True,0.7512412593346718,1,1,0.74248755,1
NCT00375661,Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC,Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma,COMPLETED,PHASE4,INTERVENTIONAL,100.0,ACTUAL,2006-09-01,2013-03-01,Kyoto University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,interferon-alfa-2b and ribavirin,"Hepatitis C, Chronic",,,,,False,2373.0,True,False,4.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.7,True,True,0.633838759750139,1,True,0.8122067283193001,1,1,0.8073552,1
NCT00006025,Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma,Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma,COMPLETED,PHASE1,INTERVENTIONAL,,,2001-01-05,2007-12-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,,"DRUG, DRUG","irinotecan hydrochloride, temozolomide",Brain and Central Nervous System Tumors,,,,,False,2521.0,True,False,1.0,False,False,False,2,True,,1,,,1,0,0.56,True,True,0.7329923074040324,1,True,0.8994514808478137,1,1,0.9429509,1
NCT00861419,"To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.","An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,88.0,ESTIMATED,2005-12-01,,Amgen,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Sorafenib, AMG 706, AMG 706, AMG 386, Sunitinib, Bevacizumab, AMG 386",Advanced Solid Tumors,,,,,False,1303.0,True,False,1.0,False,False,True,7,True,Medium (30-100),1,88.0,4.48863636973214,1,0,0.56,True,True,0.7793928695928628,1,True,0.599254416866505,1,1,0.5444895,1
NCT01287520,A Study of LY2090314 in Patients With Advanced or Metastatic Cancer,Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin,COMPLETED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2007-11-01,2011-04-01,Eli Lilly and Company,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, OTHER","LY2090314, pemetrexed, Carboplatin, ranitidine",Advanced Cancer,,,,,False,1247.0,True,False,1.0,False,False,True,4,True,Medium (30-100),1,41.0,3.737669618283368,1,0,0.56,True,True,0.6265672472880912,1,True,0.6332829166326034,1,1,0.65887374,1
NCT00496353,MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED),A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2007-06-01,2008-11-01,Merck Sharp & Dohme LLC,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,MK2461,Neoplasm,,,,,False,519.0,True,False,1.0,False,False,True,1,True,Small (<30),0,26.0,3.295836866004329,0,0,0.56,True,True,0.5420771697310192,1,True,0.5949964606547105,1,0,0.4963201,0
NCT03435952,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2018-07-10,2026-10-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, DRUG","Pembrolizumab, Clostridium Novyi-NT, Doxycycline","Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract",,,,,False,3005.0,False,False,1.0,False,False,False,3,True,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,True,True,0.5122957672436462,1,True,0.6141318974328935,1,1,0.6996611,1
NCT00402714,"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies","A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies",COMPLETED,PHASE2,INTERVENTIONAL,14.0,ACTUAL,2006-07-01,2009-08-01,Yale University,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG, RADIATION, DRUG, RADIATION","extracorporeal photopheresis, Pentostatin, Total Body Irradiation, Pentostatin, Total Body Irradiation",Hematologic Malignancies,,,,,False,1127.0,True,False,2.0,True,False,False,5,True,Small (<30),0,14.0,2.70805020110221,2,0,0.58,True,False,0.2474687737389768,0,False,0.2203119890453413,0,0,0.20064627,0
NCT00194714,Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab,Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo,COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2016-05-01,2023-05-22,University of Washington,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER","HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis","HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer",,,,,False,2577.0,True,False,1.0,False,False,False,2,True,Small (<30),0,22.0,3.1354942159291497,1,0,0.56,True,True,0.5537075817712329,1,True,0.7216237492406377,1,1,0.6025043,1
NCT00600587,Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC),Phase Ⅱ Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy,COMPLETED,PHASE2,INTERVENTIONAL,24.0,ACTUAL,2007-09-01,2013-06-01,Guangdong Provincial People's Hospital,OTHER,NON_RANDOMIZED,FACTORIAL,NONE,"DRUG, DRUG","neoadjuvant erlotinib therapy, neoadjuvant gemcitabine/carboplatin therapy","Carcinoma, Non-Small-Cell Lung",,,,,False,2100.0,True,False,2.0,False,False,False,2,True,Small (<30),1,24.0,3.218875824868201,1,0,0.58,True,True,0.5067044762076042,1,True,0.6030143584553312,1,1,0.6370232,1
NCT05239663,GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer,The Effects of Ganglioside-Monosialic Acid in Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer: A Randomized Trial,TERMINATED,PHASE3,INTERVENTIONAL,76.0,ACTUAL,2022-02-08,2024-07-31,Sun Yat-sen University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Ganglioside-Monosialic Acid, 250ml normal saline (NS)","Chemotherapy-Related Cognitive Impairment, Breast Cancer",,,,,False,904.0,True,False,3.0,True,True,False,2,False,Medium (30-100),0,76.0,4.343805421853684,3,0,0.77,False,True,0.6039728355149991,0,True,0.7307682163815773,0,1,0.70940727,0
NCT02933307,Continuous Monitoring on the General Ward,Continuous Monitoring of Vital Signs in Hospitalized Patients,COMPLETED,,INTERVENTIONAL,90.0,ACTUAL,2015-04-01,2016-09-01,Radboud University Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, DEVICE","HealthPatch, ViSi Mobile","Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Arthritis, Hypertension, Sepsis",,,,,False,519.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,90.0,4.51085950651685,2,0,0.6,True,True,0.7515938511642947,1,True,0.8533496507929983,1,1,0.82385606,1
NCT01252290,Breast Cancer Risk Biomarkers in Postmenopausal Women,Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids,COMPLETED,PHASE2,INTERVENTIONAL,35.0,ACTUAL,2010-11-01,2013-05-01,"Carol Fabian, MD",OTHER,,SINGLE_GROUP,NONE,DRUG,Lovaza™,Breast Cancer,,,,,False,912.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.58,True,True,0.600777297907278,1,True,0.6325438624556682,1,1,0.66188705,1
NCT00261846,Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias,A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias,COMPLETED,PHASE2,INTERVENTIONAL,571.0,ACTUAL,2006-01-18,2015-08-06,Pfizer,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Bosutinib,Chronic Myeloid Leukemia,,,,,False,3487.0,True,False,2.0,False,False,True,1,True,Very Large (300+),1,571.0,6.349138991379798,0,1,0.58,True,True,0.9414573801282312,1,True,0.8886117205500846,1,1,0.88540626,1
NCT01004172,Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases,Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases,COMPLETED,PHASE2,INTERVENTIONAL,38.0,ACTUAL,2009-11-01,2017-02-01,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","carboplatin, bevacizumab, herceptin","Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer",,,,,False,2649.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,38.0,3.6635616461296463,1,0,0.58,True,True,0.645443550437105,1,True,0.9450192523106327,1,1,0.9345066,1
NCT02911155,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,COMPLETED,,OBSERVATIONAL,229.0,ACTUAL,2016-09-21,2020-05-01,National Cancer Institute (NCI),NIH,,,,,,"Brain Cancer, Thyroid Cancer, Circulatory Disease, Breast Cancer",,,,,False,1318.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,229.0,5.438079308923196,0,1,0.6,True,True,0.8735019302244402,1,True,0.7771473570662099,1,1,0.8066225,1
NCT02068794,"MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,34.0,ACTUAL,2014-04-25,2026-09-01,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"OTHER, PROCEDURE, BIOLOGICAL, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE","Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging","Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma",,,,,False,4512.0,False,False,1.0,False,False,False,10,True,Medium (30-100),0,34.0,3.555348061489413,1,0,0.56,True,True,0.7123279139317165,1,True,0.823690130935223,1,1,0.78295004,1
NCT00060333,Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma,Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2003-07-01,2016-04-01,Alliance for Clinical Trials in Oncology,OTHER,,SINGLE_GROUP,NONE,RADIATION,radiation therapy,Recurrent Melanoma,,,,,False,4658.0,True,False,2.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.58,True,True,0.6472965355999497,1,True,0.7087385190620548,1,1,0.78216416,1
NCT01294280,Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy,Participation in the Lung Adjuvant Cisplatin Evaluation Biological Program (LACE-BIO). A Study of Prognostic and Predictive Markers in Early Stage Non-Small Cell Lung Cancer,COMPLETED,,OBSERVATIONAL,241.0,ACTUAL,2008-07-01,2016-02-02,Alliance for Clinical Trials in Oncology,OTHER,,,,OTHER,Laboratory Biomarker Analysis,Lung Cancer,,,,,False,2772.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,241.0,5.488937726156687,0,1,0.6,True,True,0.9057704856221075,1,True,0.8005221880835331,1,1,0.8856408,1
NCT03706742,STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention,STOP-HCC Evidence-Based Hepatocellular Cancer Prevention Through Treatment of Hepatitis C Virus Infection,COMPLETED,,INTERVENTIONAL,12386.0,ACTUAL,2018-09-10,2021-03-31,University of Texas Southwestern Medical Center,OTHER,RANDOMIZED,PARALLEL,DOUBLE,BEHAVIORAL,Mailed outreach,"Hepatitis C, HepatoCellular Carcinoma",,,,,False,933.0,True,False,-1.0,True,True,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.6,True,True,0.8720352368931654,1,True,0.9177941755423782,1,1,0.96500975,1
NCT03843853,Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer,"A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2019-05-01,2022-05-01,The First Affiliated Hospital with Nanjing Medical University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Pemetrexed, S-1, Bevacizumab",Colorectal Neoplasms,,,,,False,1096.0,True,False,2.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.58,False,False,0.023861612975263034,1,False,0.008044675675556162,1,0,0.00323927,1
NCT02867332,PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.,A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-11-01,2020-11-01,Peking University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG","PD-1 Knockout T Cells, Cyclophosphamide, IL-2",Metastatic Renal Cell Carcinoma,,,,,False,1461.0,True,False,1.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.56,False,False,0.029771578933022007,1,False,0.015192763528042304,1,0,0.00281993,1
NCT02347683,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2015-01-01,2016-02-01,University of Nebraska,OTHER,,,,,,Thyroid Cancer,,,,,False,396.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.7407355742658585,1,True,0.8155510066724092,1,1,0.6628635,1
NCT02984995,Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation,"Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia",COMPLETED,PHASE2,INTERVENTIONAL,37.0,ACTUAL,2016-12-08,2018-09-14,"Daiichi Sankyo Co., Ltd.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Quizartinib,"Leukemia, Myeloid, Acute",,,,,False,645.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.58,True,True,0.6013621827186916,1,True,0.5889230164714778,1,0,0.35237345,0
NCT05520138,Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC),A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in the 100% Medicare Fee-For-Service (FFS) Data (2009-2020),COMPLETED,,OBSERVATIONAL,5506.0,ACTUAL,2022-08-29,2023-06-30,Pfizer,INDUSTRY,,,,"DRUG, DRUG","Enzalutamide, Abiraterone acetate","Prostatic Neoplasms, Castration-Resistant",,,,,False,305.0,True,False,-1.0,False,False,True,2,True,Very Large (300+),1,5506.0,8.613775289262481,1,1,0.6,True,True,0.8667969077049466,1,True,0.9515904118434135,1,1,0.9716959,1
NCT05510635,"The Effectiveness of Bibliotherapy on Emotional Distress, Coping Strategies and Resilience of Adolescents With Cancer",The Effectiveness of Bibliotherapy on Improving Emotional Distress and Coping Strategies and Enhancing Resilience of Adolescents With Cancer: A Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,27.0,ACTUAL,2022-11-30,2023-07-26,National Yang Ming Chiao Tung University,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","interactive bibliotherapy, reading bibliotherapy","Emotional Distress, Pediatric Cancer",,,,,False,238.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,27.0,3.332204510175204,2,0,0.6,True,False,0.44902360262662905,0,True,0.7029462798791795,1,1,0.8658849,1
NCT03478397,Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project),Mixed-Methods Approach to Evaluate a mHealth Intervention to Increase Adherence to Triage of HPV+ Women Who Have Performed Self-collection,COMPLETED,,INTERVENTIONAL,5389.0,ACTUAL,2018-12-05,2020-08-31,Centro de Estudio de Estado y Sociedad,OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,Multicomponent mHealth Intervention,Patient Adherence,,,,,False,635.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,5389.0,8.592300663903043,1,1,0.6,True,True,0.8667601297862474,1,True,0.954553993978683,1,1,0.98450905,1
NCT01947868,Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor,"A Prospective, Non-interventional Evaluation of Symptoms Improvement of First-Line Therapy of EGFR Tyrosine Kinase Inhibitor in Advanced NSCLC Patients With Positive EGFR Mutation - the SMILE Study",COMPLETED,,OBSERVATIONAL,346.0,ACTUAL,2013-11-01,2015-09-01,AstraZeneca,INDUSTRY,,,,,,Non-Small-Cell Lung Cancer,,,,,False,669.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,346.0,5.849324779946859,0,1,0.6,True,True,0.898372322090703,1,True,0.8791007029274985,1,1,0.88848376,1
NCT00003569,Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel,Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol,COMPLETED,,OBSERVATIONAL,2.0,ACTUAL,1998-03-01,,Roswell Park Cancer Institute,OTHER,,,,"DRUG, DRUG, DRUG","cisplatin, dimesna, paclitaxel","Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer",,,,,False,1303.0,True,False,-1.0,False,False,False,3,True,Small (<30),1,2.0,1.0986122886681098,1,0,0.6,True,False,0.10797181085310477,0,False,0.18728983855994524,0,0,0.41414884,0
NCT02748135,A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma",COMPLETED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2016-05-01,2020-10-06,Oncurious NV,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg, TB-403 175mg/kg","Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)",,,,,False,1619.0,True,False,1.0,False,False,True,4,True,Small (<30),0,18.0,2.9444389791664403,1,0,0.56,True,False,0.44237856369642364,0,False,0.4765728609087336,0,0,0.4295425,0
NCT01441115,ECI301 and Radiation for Advanced or Metastatic Cancer,Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer,TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2011-09-06,2013-04-24,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"PROCEDURE, DRUG","Radiation Therapy, ECI301","Cancer, Neoplasm Metastasis, Radiation Oncology, Neoplasm, Metastasis",,,,,False,596.0,True,False,1.0,False,False,False,2,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.56,False,False,0.0821042940992552,1,False,0.053277315434347244,1,0,0.046080988,1
NCT00565708,Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers,"Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,1587.0,ACTUAL,2008-12-01,2024-06-01,"National Cancer Centre, Singapore",OTHER,RANDOMIZED,PARALLEL,TRIPLE,"OTHER, DRUG","placebo, Acetylsalicylic acid",Colorectal Cancer,,,,,False,5661.0,False,False,3.0,True,True,False,2,True,Very Large (300+),0,1587.0,7.370230641807081,3,1,0.77,True,True,0.9522185595596275,1,True,0.7612249404196885,1,1,0.8726697,1
NCT02627560,The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy,The Effect of Topical Administration of Tranexamic Acid on Postoperative Bleeding and Seroma Formation in Patients Undergoing Mastectomy: A Prospective Placebo-controlled Double Blinded Randomized Study,COMPLETED,PHASE4,INTERVENTIONAL,202.0,ACTUAL,2016-01-01,2018-10-01,St. Olavs Hospital,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Tranexamic Acid, saline","Postoperative Hemorrhage, Breast Neoplasms, Seroma",,,,,False,1004.0,True,False,4.0,True,True,False,2,True,Large (100-300),0,202.0,5.313205979041787,3,1,0.7,True,True,0.6309666370081932,1,True,0.7299284573744248,1,1,0.9133475,1
NCT03276429,Lung Cancer Registry for Lung Cancer Patients,"Development of an Electronic Data Base for Lung Cancer Registry Which Will Include All the Epidemiological, Clinical, Pathological, Molecular and Treatment Parameters in Lung Cancer Patients Who Are Referred to a Tertiary Oncology Unit",COMPLETED,,OBSERVATIONAL,650.0,ACTUAL,2017-08-08,2018-12-27,Oncology Center of Biochemical Education And Research,OTHER,,,,,,Lung Cancer,,,,,False,506.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,650.0,6.478509642208569,0,1,0.6,True,True,0.9344548367715061,1,True,0.8862838207778614,1,1,0.8737557,1
NCT00212394,Tourniquet Complications in Orthopaedic Surgery,"A Prospective, Epidemiological Study of the Incidence and Nature of Tourniquet Complications in Norway",COMPLETED,,OBSERVATIONAL,10.0,,2005-01-01,2005-09-01,Norwegian University of Science and Technology,OTHER,,,,,,"Tourniquet Complications, Paresis, Palsy, Nerve Compression",,,,,False,243.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.345816000810378,0,True,0.5670048783126308,1,1,0.5984548,1
NCT04962919,Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.,Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,584.0,ACTUAL,2020-01-14,2025-05-07,Latin American Cooperative Oncology Group,OTHER,,,,,,"Prostatic Neoplasms, Castration-Resistant",,,,,False,1940.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,584.0,6.371611847231857,0,1,0.6,True,True,0.946699673120328,1,True,0.8650788602331732,1,1,0.9176615,1
NCT01639885,"Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer","Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum Resistant Ovarian Cancer CHIP Trial",COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2011-08-01,,Leiden University Medical Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, BIOLOGICAL","Interferon Alfa-2b, Interferon Alfa-2b, p53 SLP",Recurrent Ovarian Cancer,,,,,False,1303.0,True,False,1.0,False,False,False,3,True,Small (<30),0,15.0,2.772588722239781,1,0,0.56,True,False,0.38625443630003703,0,True,0.5018975599956436,1,1,0.6153752,1
NCT00490698,Zoledronate With Atorvastatin in Renal Cell Carcinoma,Bone-Targeted Therapy Combining Zoledronate With Atorvastatin in Renal Cell Carcinoma: A Phase II Study,COMPLETED,PHASE2,INTERVENTIONAL,11.0,ACTUAL,2006-10-01,2012-01-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Zoledronate, Atorvastatin","Kidney Cancer, Renal Cell Carcinoma",,,,,False,1918.0,True,False,2.0,False,False,False,2,True,Small (<30),0,11.0,2.4849066497880004,1,0,0.58,True,False,0.3146499458125396,0,False,0.4145405498940599,0,1,0.5121683,1
NCT00740116,Tranexamic Acid in Surgery of Advanced Ovarian Cancer,Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study,COMPLETED,PHASE4,INTERVENTIONAL,100.0,ACTUAL,2008-03-01,2012-06-01,"Preben Kjolhede, MD, professor",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Tranexamic acid, 0.9% NaCl solution",Ovarian Cancer,,,,,False,1553.0,True,False,4.0,True,True,False,2,True,Medium (30-100),0,100.0,4.61512051684126,3,1,0.7,True,False,0.48648897548771897,0,True,0.7693599016240857,1,1,0.78577936,1
NCT04022876,A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection),"A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression",TERMINATED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2019-09-03,2022-08-30,"Aileron Therapeutics, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","ALRN-6924, Carboplatin, Pemetrexed, Placebo, ALRN-6924, Topotecan","Non Small Cell Lung Cancer, Small-cell Lung Cancer",,,,,False,1092.0,True,False,1.0,True,True,True,6,False,Medium (30-100),1,35.0,3.58351893845611,3,0,0.56,False,True,0.5137704214214243,0,True,0.6455543442306023,0,1,0.7379754,0
NCT03185325,Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma,Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma,COMPLETED,,OBSERVATIONAL,62.0,ACTUAL,2018-03-10,2019-12-24,Assiut University,OTHER,,,,"OTHER, OTHER","bone marrow puncture and venous blood samples, venous blood samples",Non Hodgkin Lymphoma,,,,,False,654.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,62.0,4.143134726391533,1,0,0.6,True,True,0.7500802720517156,1,True,0.8454095778580857,1,1,0.8436408,1
NCT01188707,A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer,A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer,TERMINATED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2010-10-01,2011-06-30,Herlev Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Belinostat and Erlotinib,Non Small Cell Lung Cancer,,,,,False,272.0,True,False,1.0,False,False,False,1,False,Small (<30),1,5.0,1.791759469228055,0,0,0.56,False,False,0.17584291210932118,1,False,0.23514438804589413,1,0,0.14847256,1
NCT00343044,Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers,"Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers",COMPLETED,PHASE2,INTERVENTIONAL,40.0,ACTUAL,2006-06-01,2011-08-01,Benaroya Research Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Topotecan, Bevacizumab","Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",,,,,False,1887.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.58,True,True,0.6258772372650783,1,True,0.8467541926334862,1,1,0.86085576,1
NCT00005644,Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function,Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency,COMPLETED,PHASE2,INTERVENTIONAL,,,2001-01-02,2007-06-15,Eastern Cooperative Oncology Group,NETWORK,,,,"DRUG, DRUG","gemcitabine hydrochloride, paclitaxel","Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer",,,,,False,2355.0,True,False,2.0,False,False,False,2,True,,1,,,1,0,0.58,True,True,0.6950672614548229,1,True,0.9136424754834911,1,1,0.93474853,1
NCT00982449,124I-FIAU Imaging in EBV and KSHV Associated Cancers,Study of Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2010-12-01,2013-07-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"OTHER, OTHER","FIAU-PET-CT-2, FIAU-PET-CT-4","Hodgkin Lymphoma, Non Hodgkin Lymphoma, Kaposi's Sarcoma, Gastric Cancer, Nasopharyngeal Cancer",,,,,False,943.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.6,True,False,0.36845111311234496,0,True,0.5207621881330996,1,1,0.5571545,1
NCT00003899,Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors,High-Dose Consolidation With Escalating Doses of Melphalan and Thiotepa for Stage IV Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,,,1999-01-01,2001-11-01,Fred Hutchinson Cancer Center,OTHER,,,,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","filgrastim, cyclophosphamide, melphalan, paclitaxel, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1035.0,True,False,1.0,False,False,False,7,True,,1,,,1,0,0.56,True,True,0.6451976199583258,1,True,0.6904721157648003,1,1,0.7452749,1
NCT03389347,High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia,Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,40.0,ACTUAL,2018-02-14,2026-12-19,University of Washington,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, DEVICE, OTHER","Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis","Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma",,,,,False,3230.0,False,False,-1.0,False,False,False,3,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.6,True,True,0.7608459008180427,1,True,0.8445787330662462,1,1,0.9328046,1
NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),"A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,122.0,ACTUAL,2004-07-01,2006-11-01,"Genentech, Inc.",INDUSTRY,,,,"DRUG, DRUG","Avastin (bevacizumab), Tarceva (erlotinib HCl)","Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local",,,,,False,853.0,True,False,2.0,False,False,True,2,True,Large (100-300),1,122.0,4.812184355372417,1,1,0.58,True,True,0.6457119659677953,1,True,0.7225686964234531,1,1,0.7108418,1
NCT06486441,Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26),"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,640.0,ESTIMATED,2024-08-28,2029-06-01,Gilead Sciences,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel",Endometrial Cancer,,,,,False,1738.0,False,False,3.0,True,False,True,3,True,Very Large (300+),1,640.0,6.46302945692067,2,1,0.77,True,True,0.8261297450121925,1,True,0.9517524287493427,1,1,0.9678454,1
NCT02824185,Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma,Potential Interest of Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) for the Selection of Patients Proposed for Curative Treatment of a Hepatocellular Carcinoma,COMPLETED,,INTERVENTIONAL,61.0,ACTUAL,2017-06-14,2023-01-02,Hospices Civils de Lyon,OTHER,,SINGLE_GROUP,NONE,DEVICE,"PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)",Patients Eligible to a Curative Treatment for Primary HCC,,,,,False,2028.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,61.0,4.127134385045092,0,0,0.6,True,True,0.8286759560498974,1,True,0.8844849346286549,1,1,0.8831002,1
NCT00511043,PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma,Phase II Open Label Study of PTK787/ZK222584 in Adults Patients With Refractory or Relapsed Diffuse Large Cell Lymphoma,TERMINATED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2005-11-01,2010-06-01,"David Rizzieri, MD",OTHER,,SINGLE_GROUP,NONE,DRUG,PTK787,"Lymphoma, Large-Cell, Diffuse",,,,,False,1673.0,True,False,2.0,False,False,False,1,False,Small (<30),0,20.0,3.044522437723423,0,0,0.58,False,False,0.4964854288583255,1,True,0.5986044031311571,0,1,0.580029,0
NCT02335827,Irreversible Electroporation(IRE) For Unresectable Renal Tumors,Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial,COMPLETED,,INTERVENTIONAL,15.0,ESTIMATED,2015-01-01,2021-01-01,"Fuda Cancer Hospital, Guangzhou",OTHER,RANDOMIZED,PARALLEL,SINGLE,PROCEDURE,irreversible electroporation,Renal Tumor,,,,,False,2192.0,True,False,-1.0,True,False,False,1,True,Small (<30),0,15.0,2.772588722239781,1,0,0.6,True,False,0.4513550917427558,0,True,0.5714543845180795,1,1,0.6365169,1
NCT02085564,Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer,Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer,COMPLETED,,OBSERVATIONAL,87.0,ACTUAL,2014-03-01,2015-06-01,"Rigshospitalet, Denmark",OTHER,,,,PROCEDURE,Peritoneal washing cytology,Gastroesophageal-junction Cancer,,,,,False,457.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,87.0,4.477336814478207,0,0,0.6,True,True,0.8344440441603453,1,True,0.6954947892545045,1,1,0.6635572,1
NCT03317990,Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.,"A Single Blinded, IDEAL Stage 3, Multi-Centre, Randomised Controlled Trial to Assess NeuroSAFE Robotic Assisted Radical Prostatectomy (RARP) vs Standard Robotic Assisted Radical Prostatectomy (RARP) in Men With Prostate Cancer",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,407.0,ACTUAL,2018-04-09,2027-12-01,"University College, London",OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","NeuroSAFE procedure, Standard RARP",Prostate Cancer,,,,,False,3523.0,False,False,-1.0,True,False,False,2,True,Very Large (300+),0,407.0,6.0112671744041615,2,1,0.6,True,True,0.9118408425652935,1,True,0.8758771901306501,1,1,0.81828636,1
NCT00524277,Vaccine Therapy in Treating Patients With Breast Cancer,Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients,COMPLETED,PHASE2,INTERVENTIONAL,456.0,ACTUAL,2007-01-01,2017-03-31,San Antonio Military Medical Center,FED,RANDOMIZED,PARALLEL,SINGLE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","GP2 peptide + GM-CSF vaccine, GM-CSF (sargramostim), AE37 + GM-CSF vaccine, GM-CSF (sargramostim)",Breast Cancer,,,,,False,3742.0,True,False,2.0,True,False,False,4,True,Very Large (300+),0,456.0,6.124683390894205,2,1,0.58,True,True,0.8890426054746416,1,True,0.9124320171840408,1,1,0.93927324,1
NCT00651443,Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma,"A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma",TERMINATED,PHASE1,INTERVENTIONAL,20.0,ESTIMATED,2008-08-01,2010-12-01,Biogen,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Galiximab,"Lymphoma, Non-Hodgkin's",,,,,False,852.0,True,False,1.0,False,False,True,1,False,Small (<30),0,20.0,3.044522437723423,0,0,0.56,False,False,0.4916178655256905,1,True,0.604301281318946,0,1,0.77240777,0
NCT03504488,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),"A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)",COMPLETED,PHASE1,INTERVENTIONAL,132.0,ACTUAL,2018-06-27,2024-12-30,"BioAtla, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL","CAB-ROR2-ADC, PD-1 inhibitor","Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer",,,,,False,2378.0,True,False,1.0,True,False,True,2,True,Large (100-300),0,132.0,4.890349128221754,2,1,0.56,True,True,0.6957298933013322,1,True,0.7791204594242438,1,1,0.7411978,1
NCT03576612,"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas",Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas,COMPLETED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2018-02-27,2023-06-30,"Candel Therapeutics, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, RADIATION, DRUG, BIOLOGICAL, OTHER","AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis","Glioma, Malignant",,,,,False,1949.0,True,False,1.0,False,False,True,6,True,Medium (30-100),1,41.0,3.737669618283368,1,0,0.56,True,True,0.6508048488794034,1,True,0.827314734173603,1,1,0.8342959,1
NCT05488626,Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer,Daily Adaptive vs Non-Adaptive External Beam Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung),ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,244.0,ESTIMATED,2022-10-20,2028-12-01,"Varian, a Siemens Healthineers Company",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DEVICE, DEVICE, DRUG, DRUG","Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy, Immunotherapy",Stage III Non-small Cell Lung Cancer,,,,,False,2234.0,False,False,-1.0,True,False,True,4,True,Large (100-300),0,244.0,5.501258210544727,2,1,0.6,True,True,0.8268712928377431,1,True,0.8876269365125906,1,1,0.889647,1
NCT00190528,A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer,Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102),TERMINATED,PHASE3,INTERVENTIONAL,200.0,ACTUAL,2002-02-01,2009-02-01,Haruhiko Fukuda,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE","neoadjuvant chemotherapy + radical hysterectomy, radical hysterectomy",Cervical Neoplasms,,,,,False,2557.0,True,False,3.0,True,False,False,2,False,Large (100-300),0,200.0,5.303304908059076,2,1,0.77,False,True,0.6822723165867509,0,True,0.6661450964438361,0,0,0.49724355,1
NCT01626222,"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research",COMPLETED,PHASE3,INTERVENTIONAL,301.0,ACTUAL,2012-06-01,2013-11-01,Novartis Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Exemestane, Everolimus (RAD001)",Metastatic Breast Cancer,,,,,False,518.0,True,False,3.0,False,False,True,2,True,Very Large (300+),1,301.0,5.71042701737487,1,1,0.77,True,True,0.7404716500631069,1,True,0.8117156550879351,1,1,0.8658416,1
NCT00569036,Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors,A Phase I Multiple Ascending Dose Study of BMS-754807 in Subjects With Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,63.0,ACTUAL,2008-04-01,2013-04-01,Bristol-Myers Squibb,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,BMS-754807,"Neoplasms, Solid Tumors, Metastases",,,,,False,1826.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,63.0,4.158883083359672,0,0,0.56,True,True,0.7963611062923768,1,True,0.6608917312226714,1,1,0.6159391,1
NCT00228683,Hepatoblastoma Biology Study and Tissue Bank,Hepatoblastoma Biology Study and Tissue Bank,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2005-09-01,2015-01-01,Emory University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,PROCEDURE,Biology Study and Tissue Banking,Hepatoblastoma,,,,,False,3409.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.06802307403021944,1,False,0.061953476526161025,1,0,0.0030572773,1
NCT00656760,PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer,The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of Neck Nodes With an Unknown Primary Malignancy.,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2007-07-01,2011-03-01,University of Calgary,OTHER,,SINGLE_GROUP,SINGLE,OTHER,PET/CT,Head and Neck Cancer,,,,,False,1339.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.567567292577665,1,False,0.4979308379199825,0,0,0.48089603,0
NCT00494026,Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC),"Phase II Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage of Small Cell Lung Cancer",TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2007-09-01,2008-10-01,Eli Lilly and Company,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, PROCEDURE","pemetrexed, carboplatin, radiotherapy",Small Cell Lung Cancer,,,,,False,396.0,True,False,2.0,False,False,True,3,False,Small (<30),1,4.0,1.6094379124341005,1,0,0.58,False,False,0.10928880731290369,1,False,0.05549012093541287,1,0,0.025330856,1
NCT02970513,Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery,Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2017-03-27,2017-10-27,"University Hospital, Clermont-Ferrand",OTHER,,SINGLE_GROUP,NONE,OTHER,Psychiatric evaluation,Colorectal Cancer,,,,,False,214.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.6,True,False,0.38169012916037515,0,True,0.6418416813103724,1,1,0.76278645,1
NCT00664677,Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia,"Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia",TERMINATED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2007-08-01,2009-06-01,Erimos Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Terameprocol (EM-1421),"Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL), Chronic Myeloid Leukemia (CML-BP), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)",,,,,False,670.0,True,False,1.0,False,False,True,1,False,Small (<30),0,16.0,2.833213344056216,0,0,0.56,False,False,0.42547577971875555,1,True,0.7592806166536059,0,1,0.7258864,0
NCT01635296,A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia,"A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)",COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2012-07-01,2013-10-01,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","RO5045377, RO5045377, cytarabine, cytarabine","Myelogenous Leukemia, Acute",,,,,False,457.0,True,False,1.0,False,False,True,4,True,Medium (30-100),1,43.0,3.784189633918261,1,0,0.56,True,True,0.5993726176609646,1,False,0.483974752665272,0,0,0.39211413,0
NCT00600977,Liposomal Anthracyclin in the Treatment of Elderly ALL,A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2002-03-01,2006-10-01,French Innovative Leukemia Organisation,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Doxorubicine, Doxorubicine pegylated",Acute Lymphoblastic Leukemia,,,,,False,1675.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,60.0,4.110873864173311,2,0,0.58,True,True,0.6326618367315163,1,True,0.7774797731519726,1,1,0.8119249,1
NCT00951496,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",COMPLETED,PHASE3,INTERVENTIONAL,1560.0,ACTUAL,2009-08-11,2016-01-11,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, OTHER, DRUG, DRUG, OTHER","Bevacizumab, Carboplatin, Carboplatin, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Paclitaxel, Quality-of-Life Assessment","Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7",,,,,False,2344.0,True,False,3.0,True,False,False,8,True,Very Large (300+),1,1560.0,7.353081920515432,2,1,0.77,True,True,0.8830173041939574,1,True,0.8936013813984454,1,1,0.9382311,1
NCT02668913,LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer,LCC-CARIS-01: A Pilot Feasibility Study to Assess the Use of Molecular Profiling to Determine Choice of Treatment for Patients With Gynecological Cancer,COMPLETED,,INTERVENTIONAL,72.0,ACTUAL,2016-02-01,2020-10-01,Geoff Hall,OTHER,,SINGLE_GROUP,NONE,OTHER,Diagnostic analysis,"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Gynaecological Malignancy",,,,,False,1704.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,72.0,4.290459441148391,0,0,0.6,True,True,0.8430615555424845,1,True,0.7399717453472124,1,1,0.7086877,1
NCT02575391,The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer,The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy,TERMINATED,PHASE1,INTERVENTIONAL,7.0,ACTUAL,2009-10-01,2012-09-01,Providence Health & Services,OTHER,,SINGLE_GROUP,NONE,DIETARY_SUPPLEMENT,Whole Food Intervention,Esophagitis,,,,,False,1066.0,True,False,1.0,False,False,False,1,False,Small (<30),0,7.0,2.079441541679836,0,0,0.56,False,False,0.26161505212509345,1,False,0.4235698757944617,1,1,0.62729186,0
NCT00178373,Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer,Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer,COMPLETED,PHASE2,INTERVENTIONAL,96.0,ESTIMATED,2004-05-01,2006-03-01,University of Rochester,OTHER,RANDOMIZED,SINGLE_GROUP,QUADRUPLE,"DRUG, DRUG","Modafinil, sugar pill","Cancer, Fatigue, Chemotherapy",,,,,False,669.0,True,False,2.0,True,True,False,2,True,Medium (30-100),0,96.0,4.574710978503383,3,0,0.58,True,True,0.7261720003727332,1,True,0.6481219665001315,1,1,0.70701855,1
NCT00135187,"Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma","A Pilot Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma",COMPLETED,,INTERVENTIONAL,30.0,ACTUAL,2004-07-01,2007-12-01,University of Michigan Rogel Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","VELCADE, Doxil, Dexamethasone",Multiple Myeloma,,,,,False,1248.0,True,False,-1.0,False,False,False,3,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.6,True,True,0.609372251271446,1,True,0.7591682104604119,1,1,0.77742755,1
NCT05375708,Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites,A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer,SUSPENDED,PHASE2,INTERVENTIONAL,93.0,ESTIMATED,2025-12-01,2034-06-01,UMC Utrecht,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG","Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)","Metastatic Colorectal Cancer, Oligometastatic Disease",,,,,False,3104.0,False,False,2.0,True,False,False,2,False,Medium (30-100),1,93.0,4.543294782270004,2,0,0.58,False,True,0.7850097144917573,0,True,0.8710346424656508,0,1,0.7915603,0
NCT02509052,Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma,A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2015-12-02,2022-06-09,City of Hope Medical Center,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"OTHER, DRUG, OTHER","Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study","Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma",,,,,False,2381.0,True,False,1.0,False,False,False,3,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.56,True,False,0.3859847652733728,0,False,0.4550173763365305,0,0,0.2925536,0
NCT01598597,"An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)","An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin",COMPLETED,,OBSERVATIONAL,276.0,ACTUAL,2012-03-01,2014-11-01,"Genentech, Inc.",INDUSTRY,,,,,,"Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer",,,,,False,975.0,True,False,-1.0,False,False,True,0,True,Large (100-300),0,276.0,5.6240175061873385,0,1,0.6,True,True,0.8846343053970784,1,True,0.9024047861300073,1,1,0.92902625,1
NCT02853422,Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours,A Study Evaluating The Clinical Utility Of The Health-Related Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours QUALINETS Study,COMPLETED,,OBSERVATIONAL,199.0,ACTUAL,2016-04-01,2017-01-01,Ipsen,INDUSTRY,,,,,,Gastrointestinal Neuroendocrine Tumours,,,,,False,275.0,True,False,-1.0,False,False,True,0,True,Large (100-300),0,199.0,5.298317366548036,0,1,0.6,True,True,0.8291620078273421,1,True,0.8776790184974801,1,1,0.82912177,1
NCT02669771,Long-Term Specified Drug Use-Results Survey for Xtandi Capsule,Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey,COMPLETED,,OBSERVATIONAL,1018.0,ACTUAL,2014-11-30,2018-11-30,Astellas Pharma Inc,INDUSTRY,,,,DRUG,enzalutamide,Castration-resistant Prostate Cancer,,,,,False,1461.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),1,1018.0,6.926577033222725,0,1,0.6,True,True,0.9562139678216165,1,True,0.9614886644082883,1,1,0.9728581,1
NCT04092179,Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers,Phase Ib/II Study of IDH2 Inhibitor Enasidenib in Combination With BCL2 Inhibitor Venetoclax in Patients With IDH2-Mutated Myeloid Malignancies (ENAVEN-AML),TERMINATED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2020-11-05,2023-10-26,"University Health Network, Toronto",OTHER,,SEQUENTIAL,NONE,"DRUG, DRUG","Enasidenib, Venetoclax","Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer, IDH2 Gene Mutation",,,,,False,1085.0,True,False,1.0,False,False,False,2,False,Small (<30),0,27.0,3.332204510175204,1,0,0.56,False,True,0.5293452281254099,0,False,0.394226091233182,1,0,0.36083066,1
NCT06425276,Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation,"A Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan Hydrochloride for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation",COMPLETED,PHASE4,INTERVENTIONAL,67.0,ACTUAL,2020-07-24,2021-09-18,"CASI Pharmaceuticals (China) Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Melphalan Hydrochloride for Injection,Multiple Myeloma,,,,,False,421.0,True,False,4.0,False,False,True,1,True,Medium (30-100),0,67.0,4.219507705176107,0,0,0.7,True,True,0.6416344967793455,1,True,0.8165637144311152,1,1,0.8989405,1
NCT05680454,A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine,A Phase I Trial in Healthy Chinese Women Ages 18-45 to Evaluate the Safety and Tolerability Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli),COMPLETED,PHASE1,INTERVENTIONAL,160.0,ACTUAL,2019-09-01,2022-05-10,"Beijing Health Guard Biotechnology, Inc",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"BIOLOGICAL, BIOLOGICAL","Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine",Human Papillomavirus Infection,,,,,False,982.0,True,False,1.0,True,True,True,2,True,Large (100-300),0,160.0,5.081404364984463,3,1,0.56,True,True,0.701693189726116,1,True,0.7007573879475728,1,1,0.9023016,1
NCT00461877,High-Risk HPV Infections in Women Aged 25 to 65,High-Risk HPV Infections in Women Aged 25 to 65,COMPLETED,,OBSERVATIONAL,303.0,ACTUAL,2007-03-01,2008-12-01,University of Washington,OTHER,,,,,,Papillomavirus Infections,,,,,False,641.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,303.0,5.717027701406222,0,1,0.6,True,True,0.8863159922201753,1,True,0.9237207676778506,1,1,0.9224801,1
NCT04634071,Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment,Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,126.0,ACTUAL,2021-01-12,2026-01-01,"Joseph Valentino, MD",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, BEHAVIORAL, BEHAVIORAL, OTHER, DRUG","Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products","Smoking Cessation, Cancer, Treatment-Related",,,,,False,1815.0,False,False,2.0,False,False,False,7,True,Large (100-300),0,126.0,4.844187086458591,1,1,0.58,True,True,0.6810974470185776,1,True,0.7673497836710869,1,1,0.8662098,1
NCT04640870,The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib,An Observational Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib in Real-world Clinical Set-tings in Greece,COMPLETED,,OBSERVATIONAL,59.0,ACTUAL,2015-03-15,2020-05-01,Hellenic Cooperative Oncology Group,OTHER,,,,DRUG,Afatinib,"Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Gene Mutation",,,,,False,1874.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),1,59.0,4.0943445622221,0,0,0.6,True,True,0.814759085094871,1,True,0.8601716356960164,1,1,0.8972337,1
NCT03187223,Bendamustine and Melphalan in Myeloma,A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients,COMPLETED,PHASE2,INTERVENTIONAL,120.0,ACTUAL,2017-07-20,2020-05-28,"Insel Gruppe AG, University Hospital Bern",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Melphalan, Bendamustine",Multiple Myeloma,,,,,False,1043.0,True,False,2.0,True,False,False,2,True,Large (100-300),0,120.0,4.795790545596741,2,1,0.58,True,True,0.5747619037979677,1,True,0.7022645525336499,1,1,0.6747516,1
NCT04339478,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy with Central Lymph Node Compartment Dissection,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy with Central Lymph Node Compartment Dissection,COMPLETED,,OBSERVATIONAL,180.0,ACTUAL,2020-04-06,2022-08-30,Aristotle University Of Thessaloniki,OTHER,,,,,,"Thyroid Cancer, Thyroidectomy with Central Lymph Node Dissection",,,,,False,876.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,180.0,5.198497031265826,0,1,0.6,True,True,0.8329362862297834,1,True,0.8833814081177127,1,1,0.9246263,1
NCT02309437,Early Use of Opioid in Radiation Mucositis,Influences on the Nutrition Statuses and Clinical Outcomes of Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients,COMPLETED,PHASE2,INTERVENTIONAL,200.0,ACTUAL,2015-01-01,2017-12-31,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Oxycodone, Oxycodone","Nutrition Disorders, Quality of Life",,,,,False,1095.0,True,False,2.0,True,False,False,2,True,Large (100-300),0,200.0,5.303304908059076,2,1,0.58,True,True,0.6944572279152638,1,True,0.6856522678223684,1,1,0.6745446,1
NCT04213794,Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients,A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy),TERMINATED,EARLY_PHASE1,INTERVENTIONAL,2.0,ACTUAL,2019-11-08,2024-10-03,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"DRUG, PROCEDURE, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE","Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection","Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma",,,,,False,1791.0,True,False,0.5,False,False,False,9,False,Small (<30),1,2.0,1.0986122886681098,1,0,0.57,False,False,0.09226691662057407,1,False,0.27824260929568234,1,0,0.37580627,1
NCT00821249,A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma,,COMPLETED,PHASE1,INTERVENTIONAL,55.0,ACTUAL,2009-01-01,2016-03-16,Pfizer,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral","Multiple Myeloma, Plasma Cell Leukemia",,,,,False,2631.0,True,False,1.0,False,False,True,3,True,Medium (30-100),0,55.0,4.02535169073515,1,0,0.56,True,True,0.7615202869428827,1,True,0.8243227442737883,1,1,0.76582694,1
NCT00055887,Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer,"A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer",WITHDRAWN,PHASE3,INTERVENTIONAL,0.0,ACTUAL,2002-11-01,,"Spectrum Pharmaceuticals, Inc",INDUSTRY,RANDOMIZED,,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","carboplatin, cisplatin, efaproxiral, gemcitabine hydrochloride, paclitaxel, vinorelbine ditartrate, radiation therapy",Lung Cancer,,,,,False,1303.0,True,False,3.0,True,False,True,7,False,,1,0.0,0.0,2,0,0.77,False,False,0.01141469911704592,1,False,0.01061769652636394,1,0,0.0026556512,1
NCT04543916,Venetoclax and Irinotecan in Relapsed/Refractory SCLC,A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2021-06-30,2028-06-30,Virginia Commonwealth University,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Venetoclax 50 MG, Venetoclax 100 MG, Venetoclax 200 MG, Venetoclax 400, Venetoclax 600, Irinotecan 60 mg/m2, Venetoclax (RP2D)","Relapsed Small Cell Lung Cancer, Refractory Small Cell Lung Carcinoma",,,,,False,2557.0,True,False,1.0,False,False,False,7,False,,1,0.0,0.0,1,0,0.56,False,False,0.03429176423657562,1,False,0.06018093945849766,1,0,0.0048786807,1
NCT01660997,MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma,MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2012-07-30,2014-03-11,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","MLN9708, Dexamethasone",Multiple Myeloma,,,,,False,589.0,True,False,2.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.022575293817226633,1,False,0.004827128198205673,1,0,0.0023171592,1
NCT01503541,S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin,The Development of Predictive Biomarker Models for Patients Receiving Standard Induction Chemotherapy With and Without Gemtuzumab Ozogamicin,COMPLETED,,OBSERVATIONAL,365.0,ACTUAL,2011-12-01,2012-06-01,SWOG Cancer Research Network,NETWORK,,,,"GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, OTHER","DNA analysis, RNA analysis, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis",Leukemia,,,,,False,183.0,True,False,-1.0,False,False,False,6,True,Very Large (300+),0,365.0,5.902633333401366,1,1,0.6,True,True,0.8599189323705141,1,True,0.9237997534047758,1,1,0.98026365,1
NCT01613768,Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer,Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers,COMPLETED,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2012-05-08,2017-08-23,University of Washington,OTHER,,SINGLE_GROUP,NONE,DRUG,eribulin mesylate,"Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer",,,,,False,1933.0,True,False,2.0,False,False,False,1,True,Small (<30),0,29.0,3.4011973816621555,0,0,0.58,True,True,0.6047161198144319,1,True,0.7674402784336172,1,1,0.82292527,1
NCT04862104,The Effect of Discharge Training on Surgical Recovery in Oncology Patients,The Effect of Discharge Training on Surgical Recovery in Oncology Patients: A Randomized Control Trial,COMPLETED,,INTERVENTIONAL,78.0,ACTUAL,2018-08-01,2019-12-27,Aydin Adnan Menderes University,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Intervention group,"Surgery--Complications, Nursing Caries",,,,,False,513.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,78.0,4.3694478524670215,1,0,0.6,True,True,0.7624766146327682,1,True,0.859109776582835,1,1,0.86220175,1
NCT05183776,Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT,Clinical Validation of a Fractional Administration Device for Holmium-166 Microspheres During Selective Internal Radiation Therapy in Patients With Liver Tumours,COMPLETED,,INTERVENTIONAL,5.0,ACTUAL,2022-07-12,2023-08-08,Radboud University Medical Center,OTHER,,SINGLE_GROUP,NONE,DEVICE,Fractional administration device,"Liver Cancer, Liver Metastasis Colon Cancer, Primary Liver Cancer",,,,,False,392.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.6,True,False,0.2162897579863489,0,False,0.2738181096896106,0,0,0.25276643,0
NCT01062490,Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS),Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS),COMPLETED,PHASE2,INTERVENTIONAL,45.0,ACTUAL,2004-11-01,2009-10-01,medac GmbH,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Treosulfan,Myelodysplastic Syndrome,,,,,False,1795.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.58,True,True,0.7015973709299497,1,True,0.8072338543952159,1,1,0.82329357,1
NCT00136552,Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden,FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden,COMPLETED,PHASE3,INTERVENTIONAL,360.0,,2000-05-01,2004-12-01,Lymphoma Study Association,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,rituximab,Lymphoma,,,,,False,1675.0,True,False,3.0,True,False,False,1,True,Very Large (300+),1,360.0,5.8888779583328805,1,1,0.77,True,True,0.7872545886239125,1,True,0.8599022664228463,1,1,0.8901977,1
NCT00002348,A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma,Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome,COMPLETED,PHASE2,INTERVENTIONAL,,,,,"Genzyme, a Sanofi Company",INDUSTRY,,,,DRUG,Mitoguazone,"Lymphoma, Non-Hodgkin, HIV Infections",,,,,False,1303.0,True,False,2.0,False,False,True,1,True,,0,,,0,0,0.58,True,True,0.6987698312676027,1,True,0.7427144973975056,1,1,0.7404288,1
NCT03716531,Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement,PACER (Pancreatic AdenoCarcinoma With Electron Intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,199.0,ACTUAL,2019-03-19,2027-12-31,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,RADIATION,IORT,Pancreas Cancer,,,,,False,3209.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,199.0,5.298317366548036,0,1,0.6,True,True,0.8975047301533201,1,True,0.8743094797935683,1,1,0.8588688,1
NCT01602666,Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors,Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT),COMPLETED,PHASE2,INTERVENTIONAL,262.0,ACTUAL,2012-06-27,2024-09-30,Children's Oncology Group,NETWORK,,SINGLE_GROUP,NONE,"RADIATION, DRUG, DRUG, DRUG, RADIATION","3-Dimensional Conformal Radiation Therapy, Carboplatin, Etoposide, Ifosfamide, Intensity-Modulated Radiation Therapy","Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma",,,,,False,4478.0,True,False,2.0,False,False,False,5,True,Large (100-300),1,262.0,5.572154032177765,1,1,0.58,True,True,0.8852826921483534,1,True,0.8540081702323582,1,1,0.8871629,1
NCT04239573,Comparing Two Methods to Follow Patients With Pancreatic Cysts,Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,4606.0,ESTIMATED,2020-06-16,2037-06-03,ECOG-ACRIN Cancer Research Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, OTHER, OTHER","Computed Tomography, Endoscopic Ultrasound, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration",Pancreatic Carcinoma,,,,,False,6196.0,False,False,-1.0,True,False,False,5,True,Very Large (300+),0,4606.0,8.435332164935916,2,1,0.6,True,True,0.9545003998314991,1,True,0.8907922632393721,1,1,0.9809935,1
NCT03397160,Pioneering Advances in Care and Education (PACE),"Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer",COMPLETED,,INTERVENTIONAL,119.0,ACTUAL,2018-07-19,2020-09-30,"University of California, San Francisco",OTHER,RANDOMIZED,CROSSOVER,NONE,BEHAVIORAL,Decision Support Intervention (DSI),"Decision Support Systems, Clinical, Prostate Cancer",,,,,False,804.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,119.0,4.787491742782046,1,1,0.6,True,True,0.6914215887266181,1,True,0.7409184052036424,1,1,0.78707045,1
NCT01768897,"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)",COMPLETED,PHASE1,INTERVENTIONAL,67.0,ACTUAL,2013-01-01,2016-01-01,Wake Forest University Health Sciences,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, OTHER, OTHER","CPI-613, cytarabine, mitoxantrone hydrochloride, laboratory biomarker analysis, pharmacological study","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia",,,,,False,1095.0,True,False,1.0,False,False,False,5,True,Medium (30-100),1,67.0,4.219507705176107,1,0,0.56,True,True,0.7266240688019585,1,True,0.6688897371962291,1,1,0.627552,1
NCT01636882,CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext),"A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total (VLA-008 CALM Ext)",COMPLETED,PHASE2,INTERVENTIONAL,16.0,ACTUAL,2012-07-03,2016-04-06,Viralytics,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,CVA21,Melanoma,,,,,False,1373.0,True,False,2.0,False,False,True,1,True,Small (<30),0,16.0,2.833213344056216,0,0,0.58,True,False,0.4242332727654685,0,False,0.46595413405557246,0,0,0.36605498,0
NCT07153783,Interventional AI-Human Collaboration for Liver Tumor Diagnosis,AI-human Collaborative Diagnosis of Liver Tumors Using CE-CT,COMPLETED,,INTERVENTIONAL,10333.0,ACTUAL,2025-09-01,2025-11-07,Shengjing Hospital,OTHER,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,AI-human collaboration for CE-CTs diagnosis,"Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma, Cyst, Focal Nodular Hyperplasia",,,,,False,67.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.876831206343313,1,True,0.9952925105513954,1,1,0.99718297,1
NCT03575611,Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma,Definitive Radiation-Based Treatment Strategy for Oligometastatic and Low Metastatic Burden Renal Cell Carcinoma in Lieu of Systemic Therapy,SUSPENDED,PHASE2,INTERVENTIONAL,123.0,ACTUAL,2018-06-14,2030-09-30,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, RADIATION","Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy","Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8",,,,,False,4491.0,False,False,2.0,False,False,False,6,False,Large (100-300),0,123.0,4.820281565605037,1,1,0.58,False,True,0.7878222237971388,0,True,0.8941166121622395,0,1,0.8933629,0
NCT02961374,Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis,COMPLETED,PHASE2,INTERVENTIONAL,46.0,ACTUAL,2017-10-27,2021-09-27,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG","Erlotinib, Erlotinib Hydrochloride","Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis",,,,,False,1431.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,46.0,3.8501476017100575,1,0,0.58,True,True,0.6377575763760271,1,True,0.775409002219815,1,1,0.73082644,1
NCT01689792,A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate),"A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)",COMPLETED,PHASE4,INTERVENTIONAL,398.0,ACTUAL,2011-11-01,2013-12-01,Norgine,INDUSTRY,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG","MOVIPREP, CitraFleet",Colorectal Cancer,,,,,False,761.0,True,False,4.0,True,False,True,2,True,Very Large (300+),0,398.0,5.988961416889864,2,1,0.7,True,True,0.7281692642557136,1,True,0.8303174065445519,1,1,0.79602116,1
NCT00148135,"Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site","A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site",TERMINATED,PHASE2,INTERVENTIONAL,,,2001-05-01,2007-10-01,University of Michigan Rogel Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Carboplatin, Gemcitabine, Capecitabine",Carcinoma of Unknown Primary,,,,,False,2344.0,True,False,2.0,False,False,False,3,False,,1,,,1,0,0.58,False,True,0.6902115846866436,0,True,0.9556702315749284,0,1,0.96120226,0
NCT01673243,Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting,"Tobacco Trials at St. Jude: Parent Willingness to Participate Among Families of Children With Cancer, Sickle Cell Disease, or Survivors of Childhood Cancer",COMPLETED,,OBSERVATIONAL,88.0,ACTUAL,2012-09-01,2014-07-01,St. Jude Children's Research Hospital,OTHER,,,,OTHER,Questionnaire,"Smoking, Cancer, Sickle Cell Disease",,,,,False,668.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,88.0,4.48863636973214,0,0,0.6,True,True,0.8419959101893174,1,True,0.6473336330680879,1,1,0.7232426,1
NCT00558051,Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2008-01-01,2014-04-01,Pawel Kalinski,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","DC-based vaccine, DC-based vaccine, DC-based vaccine",Metastatic Colorectal Cancer,,,,,False,2282.0,True,False,1.0,False,False,False,3,True,Small (<30),0,15.0,2.772588722239781,1,0,0.56,True,False,0.435527043032618,0,False,0.46051576027941843,0,0,0.4296989,0
NCT06929065,Randomized Trial of HIFU vs. Cryo for Prostate Cancer,Randomized Prospective Trial of Focal Therapy (HIFU vs Cryo) for Early Stage Unifocal Prostate Cancer,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2023-04-01,2025-02-01,Kaiser Permanente,OTHER,RANDOMIZED,PARALLEL,NONE,PROCEDURE,HIFU vs Cryoablation,"Prostate Cancer, Prostate Cancer Stage I, Prostate Cancer Stage II, High Intensity Focused Ultrasound, HIFU, Cryoablation",,,,,False,672.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.6,True,True,0.6762849176196761,1,True,0.752494341603438,1,1,0.73823,1
NCT03974971,Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.,Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population: A Multicenter Study,COMPLETED,,OBSERVATIONAL,36.0,ACTUAL,2019-04-30,2020-02-29,Samsung Medical Center,OTHER,,,,,,Blastic Plasmacytoid Dendritic Cell Neoplasm,,,,,False,305.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,36.0,3.610917912644224,0,0,0.6,True,True,0.6654778537907013,1,True,0.7235308005545262,1,1,0.7015468,1
NCT00478283,Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer,Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Hormonal Therapy in Older and/or Frail Women: A Survey of Oncologists and Geriatricians,COMPLETED,,INTERVENTIONAL,300.0,ESTIMATED,2006-12-01,2007-10-01,City of Hope Medical Center,OTHER,,,,OTHER,survey administration,Breast Cancer,,,,,False,304.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,300.0,5.707110264748875,0,1,0.6,True,True,0.8758696980287154,1,True,0.9530925037894589,1,1,0.97723573,1
NCT00515853,The Role of Biofeedback in Improving Continence After Anterior Resection,The Role of Biofeedback in Improving Continence After Anterior Resection,COMPLETED,,INTERVENTIONAL,121.0,ACTUAL,2006-11-27,2010-05-13,University of Southampton,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Biofeedback,"Rectal Neoplasms, Fecal Incontinence, Aged",,,,,False,1263.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,121.0,4.804021044733257,1,1,0.6,True,True,0.7148846085121303,1,True,0.7982633911756261,1,1,0.81913066,1
NCT03955640,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,A Pilot Trial of Hyperthermia in Combination With Olaparib in Breast Cancer Patients With Chest Wall Recurrences,TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2019-05-20,2021-08-26,Thomas Jefferson University,OTHER,,SINGLE_GROUP,NONE,"DRUG, PROCEDURE, OTHER, OTHER","Olaparib, Hyperthermia Treatment, Questionnaire Administration, Quality-of-Life Assessment","Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma",,,,,False,829.0,True,False,1.0,False,False,False,4,False,Small (<30),0,3.0,1.3862943611198906,1,0,0.56,False,False,0.10983847211989027,1,False,0.0638888400274874,1,0,0.05276029,1
NCT01759303,Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,TERMINATED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2013-04-01,2017-05-01,Emerald Clinical Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,pazopanib,"Osteosarcoma, Metastatic Osteosarcoma",,,,,False,1491.0,True,False,2.0,False,False,True,1,False,Small (<30),1,12.0,2.5649493574615367,0,0,0.58,False,False,0.3542566179709985,1,False,0.36313196709659523,1,0,0.3770815,1
NCT02061007,Biomarker Correlates of Hypoxia in Metastatic Melanoma,Biomarker Correlates of Hypoxia in Metastatic Melanoma,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2014-10-01,2016-02-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, PROCEDURE","Pimonidazole hydrochloride (Hypoxyprobe™-1), Optional 18F-FMISO PET scan (18F-fluoromisonidazole), Surgical Resection of Melanoma Metastases","Melanoma, Skin Cancer",,,,,False,488.0,True,False,2.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.58,False,False,0.021676649943712583,1,False,0.005147703121674788,1,0,0.0022056922,1
NCT00919022,Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate,"Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire)",TERMINATED,,OBSERVATIONAL,194.0,ACTUAL,2009-08-01,2011-08-01,Bayer,INDUSTRY,,,,DRUG,"Cyproterone Acetate (Androcur, BAY94-8367)",Prostate Cancer,,,,,False,730.0,True,False,-1.0,False,False,True,1,False,Large (100-300),0,194.0,5.272999558563747,0,1,0.6,False,True,0.8360426880503214,0,True,0.8598955863883784,0,1,0.84646434,0
NCT04169841,Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment,Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,270.0,ESTIMATED,2020-02-10,2027-08-10,Centre Georges Francois Leclerc,OTHER,,SINGLE_GROUP,NONE,DRUG,"olaparib, durvalumab, tremelimumab",Immunotherapy,,,,,False,2738.0,False,False,2.0,False,False,False,1,True,Large (100-300),1,270.0,5.602118820879701,0,1,0.58,True,True,0.8785975285217622,1,True,0.890109257564911,1,1,0.9608362,1
NCT02787707,Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting,ٍEffect of Iranian Traditional Medicine Remedy Compared With Placebo on Chemotherapy Induced Nausea and Vomiting in Breast Cancer; a Double-blind Randomized Controlled Cross-over Clinical Trial,COMPLETED,PHASE2,INTERVENTIONAL,69.0,ACTUAL,2015-10-01,2016-05-01,Mashhad University of Medical Sciences,OTHER,RANDOMIZED,CROSSOVER,TRIPLE,"DRUG, DRUG","Persumac, lactose","Nausea, Vomiting",,,,,False,213.0,True,False,2.0,True,True,False,2,True,Medium (30-100),0,69.0,4.248495242049359,3,0,0.58,True,True,0.6315976371434631,1,True,0.7713892178158958,1,1,0.93404454,1
NCT00897325,Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma,A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens,COMPLETED,,OBSERVATIONAL,811.0,ACTUAL,2006-09-25,2019-12-31,Children's Oncology Group,NETWORK,,,,"OTHER, OTHER","Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis","Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma",,,,,False,4845.0,True,False,-1.0,False,False,False,2,True,Very Large (300+),0,811.0,6.699500340161678,1,1,0.6,True,True,0.9701075666649611,1,True,0.9120774181796014,1,1,0.897749,1
NCT03113487,"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2018-02-01,2026-05-04,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab","Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",,,,,False,3014.0,False,False,2.0,False,False,False,2,True,Small (<30),1,29.0,3.4011973816621555,1,0,0.58,True,True,0.60196539961406,1,True,0.7305404961694267,1,1,0.84201795,1
NCT06139406,A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer,"A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,70.0,ACTUAL,2023-12-06,2026-08-31,"Janssen Research & Development, LLC",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG","JNJ-87801493, JNJ-80948543, JNJ-75348780","Lymphoma, Non-Hodgkin",,,,,False,999.0,False,False,1.0,False,False,True,3,True,Medium (30-100),0,70.0,4.262679877041316,1,0,0.56,True,True,0.74505088600558,1,True,0.7122697926810898,1,1,0.6897438,1
NCT00717002,Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study,Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study,COMPLETED,,OBSERVATIONAL,,,2008-02-01,2013-04-01,"National University Hospital, Singapore",OTHER,,,,,,Non Small Cell Lung Cancer,,,,,False,1886.0,True,False,-1.0,False,False,False,0,True,,0,,,0,0,0.6,True,True,0.7922929374067592,1,True,0.646142556076835,1,1,0.5984973,1
NCT01949883,A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,"A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,64.0,ACTUAL,2013-09-05,2017-12-20,Constellation Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,CPI-0610,Lymphoma,,,,,False,1567.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,64.0,4.174387269895637,0,0,0.56,True,True,0.7902093335885784,1,True,0.7610436392345915,1,1,0.7040655,1
NCT03955393,FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS,THE ROLE OF 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS,COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2016-09-01,2019-09-30,IRCCS San Raffaele,OTHER,,,,OTHER,18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS,Renal Cell Carcinoma (RCC),,,,,False,1124.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5565537120960091,1,True,0.648872037520724,1,1,0.64342153,1
NCT01593410,Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma,"A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma",COMPLETED,PHASE2,INTERVENTIONAL,194.0,ACTUAL,2010-08-01,2013-01-03,Celgene,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Lenalidomide, Dexamethasone",Multiple Myeloma,,,,,False,886.0,True,False,2.0,False,False,True,2,True,Large (100-300),0,194.0,5.272999558563747,1,1,0.58,True,True,0.7498536315357213,1,True,0.6829301857489627,1,1,0.568126,1
NCT00630188,Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial,Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,128.0,ACTUAL,2005-03-01,2006-04-01,University of North Carolina,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","You Decide, Reducing Your Risks in the Crash",Prostatic Neoplasms,,,,,False,396.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,128.0,4.859812404361672,2,1,0.6,True,True,0.6428074861730083,1,True,0.9422682337097537,1,1,0.9320748,1
NCT01980771,Barbershop Talk: HIV Prevention for African American Heterosexual Men,Barbershop Talk: HIV Prevention for African American Heterosexual Men,COMPLETED,,INTERVENTIONAL,860.0,ACTUAL,2012-11-01,2017-02-01,State University of New York - Downstate Medical Center,OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","BTWB intervention, Cancer prevention and screening",HIV,,,,,False,1553.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,860.0,6.7580945044277305,2,1,0.6,True,True,0.922752972893991,1,True,0.883772878379436,1,1,0.922849,1
NCT04935255,Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe,Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe; an Observational Pharmacokinetic Study,COMPLETED,,OBSERVATIONAL,17.0,ACTUAL,2021-08-11,2022-06-23,Radboud University Medical Center,OTHER,,,,OTHER,Blood sampling - Pharmacokinetic assessment,Testicular Cancer,,,,,False,316.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,True,False,0.4730444097572411,0,True,0.7019003466485194,1,1,0.6581535,1
NCT00012896,Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines,Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines,COMPLETED,,INTERVENTIONAL,320.0,ESTIMATED,,2004-09-01,US Department of Veterans Affairs,FED,RANDOMIZED,FACTORIAL,SINGLE,BEHAVIORAL,Telephone Care + Educational (AV Materials),"Cancers, Pain",,,,,False,1303.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,320.0,5.771441123130016,1,1,0.6,True,True,0.8665286500526174,1,True,0.9101166373292788,1,1,0.7289132,1
NCT00976456,Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer,Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer,COMPLETED,PHASE3,INTERVENTIONAL,271.0,ACTUAL,2009-09-01,2014-10-01,PD Dr. med. Wolfgang Schuette,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Bevacizumab + Pemetrexed, Bevacizumab + Pemetrexed + Carboplatin",Non-squamous Non-small Cell Lung Cancer,,,,,False,1856.0,True,False,3.0,True,False,False,2,True,Large (100-300),1,271.0,5.605802066295998,2,1,0.77,True,True,0.7067924317331041,1,True,0.8934698810042981,1,1,0.9521328,1
NCT06532344,"An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer","An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,32.0,ACTUAL,2021-07-30,2026-12-31,Ono Pharmaceutical Co. Ltd,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","ONO-7913, ONO-4538, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil",Metastatic Pancreatic Cancer,,,,,False,1980.0,False,False,1.0,False,False,True,6,True,Medium (30-100),1,32.0,3.49650756146648,1,0,0.56,True,True,0.5915415023836633,1,True,0.7054429371561238,1,1,0.7901704,1
NCT00176462,CINJALL: Treatment for Children With Acute Lymphocytic Leukemia,CINJALL: Treatment for Children With Acute Lymphocytic Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2001-02-01,2008-09-01,"Rutgers, The State University of New Jersey",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","aminopterin, L-asparaginase, cyclophosphamide, cytarabine, daunomycin, dexamethasone, 6-mercaptopurine, methotrexate, 6-thioguanine, vincristine, Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone), Leucovorin",Acute Lymphocytic Leukemia,,,,,False,2769.0,True,False,2.0,False,False,False,12,True,Medium (30-100),1,60.0,4.110873864173311,1,0,0.58,True,True,0.7142482448259482,1,True,0.8942293178156553,1,1,0.93593997,1
NCT03038672,Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2018-12-21,2026-10-24,National Cancer Institute (NCI),NIH,RANDOMIZED,CROSSOVER,NONE,"BIOLOGICAL, DRUG","Nivolumab, Varlilumab","ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",,,,,False,2864.0,False,False,2.0,True,False,False,2,True,Medium (30-100),1,54.0,4.007333185232471,2,0,0.58,True,True,0.6640248567746353,1,True,0.8169101887897208,1,1,0.79853773,1
NCT04136340,Supportive Care Delivered by Telemedicine to Cancer Patients at Home,Virtual Visits by Supportive Care Specialists to Cancer Patients at Home: A Randomized Controlled Pilot Noninferiority Trial of Video Telemedicine,COMPLETED,,INTERVENTIONAL,33.0,ACTUAL,2019-10-24,2025-07-03,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","In-person in clinic follow-up visit, Telemedicine follow-up visit","Cancer, Supportive Care",,,,,False,2079.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,33.0,3.5263605246161616,2,0,0.6,True,True,0.5956858874041919,1,True,0.6748571288483092,1,1,0.65989375,1
NCT07065422,AI Models for Predicting Occult Pleural Dissemination in NSCLC,"Comparing Radiomics, Deep Learning, and Fusion Models for Predicting Occult Pleural Dissemination in Patients With Non-small Cell Lung Cancer",COMPLETED,,OBSERVATIONAL,326.0,ACTUAL,2023-12-13,2025-01-01,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,OTHER,,,,,,Non-Small Cell Lung Cancer,,,,,False,385.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,326.0,5.7899601708972535,0,1,0.6,True,True,0.8876361770749572,1,True,0.8813447951208512,1,1,0.776544,1
NCT01661023,The Ghana Breast Health Study,A Multidisciplinary Study of Breast Cancer in Ghana,COMPLETED,,OBSERVATIONAL,4241.0,ACTUAL,2012-07-19,2020-04-16,National Cancer Institute (NCI),NIH,,,,,,Breast Neoplasms,,,,,False,2828.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,4241.0,8.352790135124629,0,1,0.6,True,True,0.9570816834703637,1,True,0.9654788555772426,1,1,0.9706541,1
NCT03661437,Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy,Light Therapy to Prevent Frailty in Older Men With Prostate Cancer on Hormonal Therapy: A Pilot RCT,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,33.0,ACTUAL,2018-09-24,2025-03-24,City of Hope Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, OTHER, PROCEDURE, PROCEDURE","Actigraph, Questionnaire Administration, Systematic Light Exposure, Systematic Light Exposure",Prostate Carcinoma,,,,,False,2373.0,True,False,0.5,True,False,False,4,True,Medium (30-100),0,33.0,3.5263605246161616,2,0,0.57,True,True,0.5633051544833593,1,True,0.7590979611330699,1,1,0.84757954,1
NCT05936853,The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA),"The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA) - A Randomised, Feasibility Trial",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,16.0,ACTUAL,2023-08-03,2026-09-30,University Hospital Southampton NHS Foundation Trust,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"OTHER, OTHER","Intravenous approach to anaesthetic maintenance, Inhalational approach to anaesthetic maintenance","Hypospadias, Anesthesia; Adverse Effect, Perioperative Complication, Pediatric ALL",,,,,False,1154.0,False,False,-1.0,True,True,False,2,True,Small (<30),0,16.0,2.833213344056216,3,0,0.6,True,False,0.39469604717139545,0,True,0.5101169349129706,1,1,0.6707885,1
NCT02210858,"Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders","Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders",COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2000-05-01,2017-03-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"OTHER, DRUG","Laboratory Biomarker Analysis, Tipifarnib","Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase of Disease, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Recurrent Disease",,,,,False,6148.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,31.0,3.4657359027997265,1,0,0.56,True,True,0.7883536878006283,1,True,0.7912553482038682,1,1,0.8966494,1
NCT01613469,Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer,Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2011-08-01,2017-03-16,"Marks, John, M.D.",INDIV,,SINGLE_GROUP,NONE,DRUG,5FU/Leucovorin,Rectal Neoplasms,,,,,False,2054.0,True,False,2.0,False,False,False,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.58,False,False,0.21466538989143902,1,False,0.22125800413955074,1,0,0.17040344,1
NCT04500925,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,COMPLETED,,OBSERVATIONAL,301.0,ACTUAL,2006-01-01,2020-01-01,Tel-Aviv Sourasky Medical Center,OTHER_GOV,,,,PROCEDURE,UNILATERAL THYROIDECTOMY,"Well Differentiated Thyroid Carcinoma, Papillary Thyroid Cancer",,,,,False,5113.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,301.0,5.71042701737487,0,1,0.6,True,True,0.9506298406800657,1,True,0.8017609216374177,1,1,0.8555356,1
NCT00052676,Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer,French Randomized Sentinel Node Multicentric Study,COMPLETED,,INTERVENTIONAL,,,2002-10-01,2007-05-01,Centre Paul Strauss,OTHER,RANDOMIZED,,,"DRUG, PROCEDURE, PROCEDURE, RADIATION","patent blue V dye, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid",Breast Cancer,,,,,False,1673.0,True,False,-1.0,True,False,False,4,True,,0,,,2,0,0.6,True,True,0.6625644748146947,1,True,0.6487194648277291,1,1,0.6755748,1
NCT00561912,Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma,Phase II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Interferon Alfa-2b in Advanced Renal Cell Carcinoma,TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2007-10-01,2009-11-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Decitabine, Interferon Alfa-2b",Renal Cell Carcinoma,,,,,False,762.0,True,False,2.0,False,False,False,2,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.58,False,False,0.07371755272969646,1,False,0.07258147162902766,1,0,0.04397235,1
NCT06490055,Predicting the Efficacy in Advanced Gastric Cancer.,Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer.,COMPLETED,,OBSERVATIONAL,162.0,ACTUAL,2018-10-01,2025-07-01,City of Hope Medical Center,OTHER,,,,DRUG,Paclitaxel,"Gastric Cancer, Chemotherapy Effect, Paclitaxel, Ramucirumab",,,,,False,2465.0,True,False,-1.0,False,False,False,1,True,Large (100-300),1,162.0,5.093750200806762,0,1,0.6,True,True,0.8562305133352982,1,True,0.9171276469351232,1,1,0.9656792,1
NCT01287871,Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer,Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,336.0,ACTUAL,2011-01-01,2025-12-31,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,OTHER,supportive care,Cervical Cancer Screening,,,,,False,5478.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,336.0,5.820082930352362,0,1,0.6,True,True,0.9582498026149603,1,True,0.7968022437803068,1,1,0.7026095,1
NCT04915404,Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV),"A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy",TERMINATED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2022-12-07,2023-12-30,WPD Pharmaceuticals Sp. z o.o.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Berubicin Hydrochloride,Recurrent Glioblastoma Multiforme,,,,,False,388.0,True,False,1.0,False,False,True,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.56,False,False,0.183567295802449,1,False,0.24024341170390287,1,0,0.17417893,1
NCT00854789,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer,Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients,COMPLETED,PHASE1,INTERVENTIONAL,95.0,ACTUAL,2002-12-01,2013-03-01,"COL George Peoples, MD, FACS",FED,RANDOMIZED,PARALLEL,NONE,BIOLOGICAL,E75 + GM-CSF vaccine,Breast Cancer,,,,,False,3743.0,True,False,1.0,True,False,False,1,True,Medium (30-100),0,95.0,4.564348191467836,1,0,0.56,True,True,0.8626921330295708,1,True,0.7082084046233474,1,1,0.6961672,1
NCT05868850,Application of Auricular Point Sticking in Patients With Taste Alteration,Study On The Application of Auricular Point Sticking Based On Holographic Theory In Chemotherapy-related Taste Alterations In Cancer Patients,COMPLETED,,INTERVENTIONAL,120.0,ACTUAL,2023-06-03,2023-12-30,Affiliated Hospital of Jiangnan University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,BEHAVIORAL,auricular point sticking,"Dysgeusia, Acupressure, Chemotherapy Effect",,,,,False,210.0,True,False,-1.0,True,True,False,1,True,Large (100-300),0,120.0,4.795790545596741,2,1,0.6,True,True,0.6937484817406124,1,True,0.9447251532756777,1,1,0.9838689,1
NCT02794493,Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer,"A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of Traditional Chinese Medicine Formula LC09 for Treatment of Capecitabine-Induced Hand and Foot Syndrome",COMPLETED,PHASE3,INTERVENTIONAL,156.0,ACTUAL,2015-04-01,2018-04-25,China-Japan Friendship Hospital,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, OTHER","Traditional Chinese Medicine Formula LC09, Placebo",Hand Foot Syndrome,,,,,False,1120.0,True,False,3.0,True,True,False,2,True,Large (100-300),0,156.0,5.056245805348308,3,1,0.77,True,True,0.5857484375366456,1,True,0.5976552019446901,1,1,0.62532663,1
NCT02041065,Waterjet Versus Ultrasound Dissection During Hepatic Transection,Waterjet Versus Ultrasound Dissection During Hepatic Transection,COMPLETED,PHASE2,INTERVENTIONAL,84.0,ACTUAL,2011-02-01,2015-03-01,Karolinska University Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DEVICE, DEVICE","Waterjet induced dissection, CUSA induced dissection",Liver Tumour,,,,,False,1489.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,84.0,4.442651256490317,2,0,0.58,True,True,0.7073081062730157,1,True,0.6843598363699155,1,1,0.6641143,1
NCT07008560,Spatiotemporal Associations Between the COVID-19 Pandemic and Cancer Diagnoses in Bavaria,"Evaluation of Spatiotemporal Associations Between the COVID-19 Pandemic and the Incidence of Cancer Diagnoses in Bavaria, Germany: A Registry-based Study (PanSCan)",ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,438000.0,ESTIMATED,2025-09-03,2026-02-28,Bavarian Cancer Registry,OTHER_GOV,,,,,,Cancer,,,,,False,178.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.8814652513825346,1,True,0.988726066962782,1,1,0.98435944,1
NCT04610671,Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC,A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,21.0,ACTUAL,2020-10-26,2026-01-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","CG0070, Nivolumab","Muscle-Invasive Bladder Carcinoma, Bladder Cancer",,,,,False,1893.0,False,False,1.0,False,False,False,2,True,Small (<30),1,21.0,3.091042453358316,1,0,0.56,True,False,0.4992446065913937,0,True,0.60399646962026,1,1,0.51895887,1
NCT06681831,Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer,"Feasibility, Safety, and Efficacy of Robotic Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer: a Pilot Study",COMPLETED,,INTERVENTIONAL,15.0,ACTUAL,2024-06-26,2024-10-15,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,SINGLE_GROUP,NONE,DEVICE,DaVinci SP,Endometrial Cancer,,,,,False,111.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.6,True,False,0.4308640153576024,0,True,0.7121795942175839,1,1,0.89176965,1
NCT00002935,Photodynamic Therapy in Treating Patients With Early Esophageal Cancer,A Phase II Study of the Safety and Efficacy of Photodynamic Therapy in Carcinoma in Situ of the Esophagus,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,1995-10-01,2007-09-01,Roswell Park Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,porfimer sodium,Esophageal Cancer,,,,,False,4353.0,True,False,2.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.58,True,True,0.7239431296342851,1,True,0.7104238470344032,1,1,0.7298939,1
NCT02522988,The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors,The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors,COMPLETED,,INTERVENTIONAL,74.0,ACTUAL,2015-06-01,2021-08-01,University of Alabama at Birmingham,OTHER,RANDOMIZED,CROSSOVER,SINGLE,BEHAVIORAL,Open-label placebo intervention,Fatigue,,,,,False,2253.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,74.0,4.31748811353631,1,0,0.6,True,True,0.813648630694876,1,True,0.7809590548501795,1,1,0.72180694,1
NCT06024343,"Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction","Long-term Outcome in Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction: A Prospective Cohort Study",COMPLETED,,INTERVENTIONAL,230.0,ACTUAL,2019-07-01,2024-08-31,Fudan University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,"MPD Exposure, Repair or Reconstruction","Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas",,,,,False,1888.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,230.0,5.442417710521793,0,1,0.6,True,True,0.8843780017578284,1,True,0.7958122458198013,1,1,0.795936,1
NCT01871480,CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer,"An Open-label, Randomized, Controlled Study of Gefitinib Plus Autologous Cytokine-Induced Killer Cell Immunotherapy（CIK）Versus Gefitinib Alone As Second Or Third-Line Treatment in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer",TERMINATED,PHASE2,INTERVENTIONAL,50.0,ESTIMATED,2013-05-01,2016-05-01,Kunming Medical University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib",Non-Small Cell Lung Cancer,,,,,False,1096.0,True,False,2.0,True,False,False,2,False,Medium (30-100),1,50.0,3.9318256327243257,2,0,0.58,False,True,0.5579927574445014,0,False,0.43177022081115884,1,0,0.39937636,1
NCT00005947,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,"A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge) for Asymptomatic Metastatic Hormome-Refractory Prostate Cancer",COMPLETED,PHASE3,INTERVENTIONAL,127.0,ACTUAL,1999-11-01,2004-09-01,Dendreon,INDUSTRY,RANDOMIZED,,QUADRUPLE,"BIOLOGICAL, BIOLOGICAL","sipuleucel-T, Placebo",Prostate Cancer,,,,,False,1766.0,True,False,3.0,True,True,True,2,True,Large (100-300),0,127.0,4.852030263919617,3,1,0.77,True,True,0.5681309656244827,1,True,0.7276241605392513,1,1,0.7557669,1
NCT05069935,FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,"A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2021-10-15,2023-08-11,Fate Therapeutics,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, COMBINATION_PRODUCT, COMBINATION_PRODUCT","FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion","Solid Tumor, Adult",,,,,False,665.0,True,False,1.0,False,False,True,5,False,Small (<30),1,16.0,2.833213344056216,1,0,0.56,False,False,0.3544801294669746,1,False,0.4593248880319157,1,0,0.3924619,1
NCT01611090,A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",COMPLETED,PHASE3,INTERVENTIONAL,578.0,ACTUAL,2012-09-19,2019-01-23,"Janssen Research & Development, LLC",INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG","Ibrutinib, Bendamustine hydrochloride, Rituximab, Placebo","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",,,,,False,2317.0,True,False,3.0,True,True,True,4,True,Very Large (300+),1,578.0,6.361302477572996,3,1,0.77,True,True,0.8467301313016281,1,True,0.9280777727058692,1,1,0.93904096,1
NCT01320787,18-F-Fluoroacetate as PET Imaging Agent,A Phase I Study of 18-F-Fluoroacetate Sodium as a PET Imaging Agent for Tumor Detection,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2014-10-01,,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,18F-fluoroacetate,"Brain Cancer, Breast Cancer, Prostate Cancer",,,,,False,1303.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.036973834170945886,1,False,0.008324861631089793,1,0,0.0023865518,1
NCT00480064,Lomustine and Intermediate Dose Cytarabine in Older Patients With AML,Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia,COMPLETED,PHASE3,INTERVENTIONAL,360.0,ACTUAL,1995-07-01,2007-05-01,French Innovative Leukemia Organisation,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,"Lomustine, intermediate dose cytarabine",Acute Myeloid Leukemia,,,,,False,4322.0,True,False,3.0,True,False,False,1,True,Very Large (300+),1,360.0,5.8888779583328805,1,1,0.77,True,True,0.8652207730996646,1,True,0.9419336034290552,1,1,0.9638226,1
NCT00703170,Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies,Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,28.0,ACTUAL,2008-03-01,2011-07-01,Washington University School of Medicine,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Temsirolimus, Pegylated liposomal doxorubicin",Resistant Solid Malignancies,,,,,False,1217.0,True,False,1.0,False,False,False,2,True,Small (<30),1,28.0,3.367295829986474,1,0,0.56,True,True,0.5385593176422862,1,False,0.4539453329582478,0,1,0.52462745,1
NCT04603183,"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL","A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria",COMPLETED,PHASE2,INTERVENTIONAL,162.0,ACTUAL,2021-06-02,2025-06-30,MedSIR,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Abemaciclib, Paclitaxel, Letrozole, Fulvestrant",Breast Cancer Metastatic,,,,,False,1489.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,162.0,5.093750200806762,2,1,0.58,True,True,0.6516933987491016,1,True,0.9011800652451923,1,1,0.93699646,1
NCT02992171,Primary Palliative Care for Patients With Advanced Hematologic Malignancies,SHARE - Supportive Care Management for Patients With Hematologic Cancers by Registered Nurses,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2017-05-02,2020-03-19,University of Pittsburgh,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,care management by oncology nurses,Advanced Cancer,,,,,False,1052.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,0,0,0.6,True,True,0.7950981455965923,1,True,0.8859023558255446,1,1,0.88330483,1
NCT01263704,A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia,"A Phase II, Multicenter, Single Arm Study to Determine the Efficacy and Safety of Low Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab as Primary Therapy in Elderly Untreated Patients (>/=65 Years Old) With Chronic Lymphocytic Leukemia",COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2011-07-17,2017-04-03,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Cyclophosphamide, Fludarabine, Rituximab","Lymphocytic Leukemia, Chronic",,,,,False,2087.0,True,False,2.0,False,False,True,3,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.58,True,True,0.6425926455848879,1,True,0.9051612133217257,1,1,0.87549144,1
NCT02890758,Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803,Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803,COMPLETED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2018-05-22,2023-02-17,"Brenda Cooper, MD",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","Natural Killer (NK) Cells, ALT803","Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma",,,,,False,1732.0,True,False,1.0,False,False,False,2,True,Small (<30),0,14.0,2.70805020110221,1,0,0.56,True,False,0.39572036298086155,0,False,0.4602457682965465,0,0,0.49459493,0
NCT01516736,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®,COMPLETED,PHASE3,INTERVENTIONAL,308.0,ACTUAL,2012-03-01,2013-12-01,Sandoz,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","LA-EP2006, Neulasta®","Chemotherapy-induced Neutropenia, Breast Cancer",,,,,False,640.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,308.0,5.733341276897746,3,1,0.77,True,True,0.7107789852407692,1,True,0.6772250257933099,1,1,0.65132165,1
NCT00996125,Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects,COMPLETED,PHASE3,INTERVENTIONAL,750.0,ACTUAL,2009-10-24,2010-12-08,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"BIOLOGICAL, OTHER","CervarixTM, Control","Infections, Papillomavirus",,,,,False,410.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,750.0,6.621405651764134,3,1,0.77,True,True,0.8272536662223277,1,True,0.8383401701288828,1,1,0.91458505,1
NCT05512377,"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours",COMPLETED,PHASE2,INTERVENTIONAL,99.0,ACTUAL,2022-12-13,2025-09-25,Boehringer Ingelheim,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,brigimadlin,"Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer",,,,,False,1017.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,99.0,4.605170185988092,0,0,0.58,True,True,0.819271940130176,1,True,0.717567635748669,1,1,0.7700343,1
NCT00244946,"Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas,COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2004-03-01,2013-03-01,Barbara Ann Karmanos Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE","therapeutic autologous lymphocytes, carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation (PBSCT)",Lymphoma,,,,,False,3287.0,True,False,1.0,False,False,False,6,True,Small (<30),1,15.0,2.772588722239781,1,0,0.56,True,False,0.4650572161807108,0,True,0.6249284309162707,1,1,0.85235095,1
NCT00085332,Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer),A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,,,2004-07-01,,Gynecologic Oncology Group,NETWORK,,,NONE,DRUG,docetaxel,Endometrial Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,1,True,,1,,,0,0,0.58,True,True,0.6927870726708768,1,True,0.783000460998721,1,1,0.74436486,1
NCT02546375,A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands,A RETROSPECTIVE OBSERVATIONAL RESEARCH STUDY TO DESCRIBE THE REAL WORLD USE OF BOSUTINIB IN THE UK AND NETHERLANDS,COMPLETED,,OBSERVATIONAL,87.0,ACTUAL,2015-07-15,2017-01-16,Pfizer,INDUSTRY,,,,DRUG,Bosutinib,Chronic Myeloid Leukaemia,,,,,False,551.0,True,False,-1.0,False,False,True,1,True,Medium (30-100),1,87.0,4.477336814478207,0,0,0.6,True,True,0.8332383936970889,1,True,0.7055982824948467,1,1,0.64814776,1
NCT02825940,"A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors","A Phase I, Open-Label Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously as a Single Agent or in Combination With Chemotherapy in Chinese Patients With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,120.0,ACTUAL,2016-08-04,2022-11-04,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Atezolizumab, Gemcitabine, Cisplatin",Neoplasms,,,,,False,2283.0,True,False,1.0,False,False,True,3,True,Large (100-300),1,120.0,4.795790545596741,1,1,0.56,True,True,0.7334012463397525,1,True,0.8736440585731606,1,1,0.880208,1
NCT02505750,Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma,European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,148.0,ACTUAL,2015-06-24,2030-06-01,Centre Antoine Lacassagne,OTHER,RANDOMIZED,PARALLEL,,"RADIATION, DEVICE, DRUG","3D conformal EBRT, Contact X-ray brachytherapy 50 kV, Capecitabine",Rectal Neoplasms,,,,,False,5456.0,False,False,3.0,True,False,False,3,True,Large (100-300),1,148.0,5.003946305945459,2,1,0.77,True,True,0.7352452766098668,1,True,0.7736005866105122,1,1,0.9261175,1
NCT02332863,Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer.,Comparison of Traditional Back-loaded Fiducial Needles With Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement for Image-guided Radiation Therapy in Patients With Pancreatic Cancer: A Multicenter Randomized Controlled Trial.,COMPLETED,,INTERVENTIONAL,44.0,ACTUAL,2016-08-03,2020-05-01,"University of Colorado, Denver",OTHER,RANDOMIZED,PARALLEL,SINGLE,"DEVICE, DEVICE","Back-loaded Needle (Device), Preloaded Needle (Device)",Pancreatic Cancer,,,,,False,1367.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,44.0,3.80666248977032,2,0,0.6,True,True,0.6317427974159923,1,True,0.6869642557168851,1,1,0.691024,1
NCT01744262,A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy,,COMPLETED,,INTERVENTIONAL,66.0,ACTUAL,2011-05-01,2012-03-01,Yonsei University,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Total intravenous anesthesia, Inhalation Anesthesia",Prostate Cancer,,,,,False,305.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,66.0,4.204692619390966,3,0,0.6,True,True,0.7042323317351271,1,True,0.9320023257861629,1,1,0.9686003,1
NCT04495959,Dynamic Whole Body PET/ MRI,Dynamic Whole Body Positron Emission Tomography/ Magnetic Resonance Imaging,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2025-08-01,2028-09-01,British Columbia Cancer Agency,OTHER,,,,DRUG,68Ga-HTK03149,Prostatic Cancer,,,,,False,1127.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.04342230513328005,1,False,0.003848046794741144,1,0,0.0035773776,1
NCT05011409,Prevalence of Depression and Anxiety Among Breast Cancer Patients,"Prevalence of Depression and Anxiety Symptoms Among Newly Diagnosed Breast Cancer Patients in Almaty, Kazakhstan",COMPLETED,,OBSERVATIONAL,162.0,ACTUAL,2021-05-17,2022-03-10,Kazakh Medical University of Continuing Education,OTHER,,,,,,"Depression, Anxiety, Breast Cancer",,,,,False,297.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,162.0,5.093750200806762,0,1,0.6,True,True,0.7992977172196767,1,True,0.9024565823184146,1,1,0.96312124,1
NCT03217747,"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,173.0,ACTUAL,2017-08-02,2026-04-30,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, BIOLOGICAL, RADIATION, BIOLOGICAL","Avelumab, Ivuxolimab, Radiation Therapy, Utomilumab","Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8",,,,,False,3193.0,False,False,1.0,False,False,False,4,True,Large (100-300),1,173.0,5.159055299214529,1,1,0.56,True,True,0.8245609170396633,1,True,0.8116753046119871,1,1,0.79591095,1
NCT01812369,Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer,"Randomized Phase III Study of Gemcitabine/Cisplatine (GC) Versus High-dose Intensity Methotrexate, Vinblastine, Doxorubicine and Cisplatin (HD-MVAC) in the Perioperative Setting for Patients With Locally Advanced Transitional Cell Cancer of the Bladder",COMPLETED,PHASE3,INTERVENTIONAL,500.0,ACTUAL,2013-02-01,2023-09-25,"University Hospital, Rouen",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","GEMCITABINE CISPLATINE, METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF",Bladder Cancer,,,,,False,3888.0,True,False,3.0,True,False,False,2,True,Very Large (300+),1,500.0,6.2166061010848646,2,1,0.77,True,True,0.8627245889942181,1,True,0.9522655703379685,1,1,0.9520686,1
NCT02715596,Changes in Body Composition After EPA Supplementation in Head and Neck Patients,Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb),COMPLETED,PHASE3,INTERVENTIONAL,54.0,ACTUAL,2015-12-23,2019-09-02,Institut Català d'Oncologia,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DIETARY_SUPPLEMENT, OTHER","EPA supplementation, Placebo",Squamous Cell Carcinoma of Head and Neck,,,,,False,1349.0,True,False,3.0,True,True,False,2,True,Medium (30-100),0,54.0,4.007333185232471,3,0,0.77,True,True,0.5397214879157007,1,True,0.5909426374684674,1,1,0.5830619,1
NCT04592224,Cancer Information Your Way: Get What You Need to Make Your Decisions,Cancer Information Your Way: Get What You Need to Make Your Decisions - a Qualitative Study of Decision Making by Patients With Lower Health Literacy Receiving Care for Incurable Cancer,COMPLETED,,OBSERVATIONAL,21.0,ACTUAL,2020-11-12,2021-11-30,University of Southampton,OTHER,,,,,,Cancer,,,,,False,383.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,21.0,3.091042453358316,0,0,0.6,True,True,0.5358928981033113,1,True,0.7051647519588125,1,1,0.73680097,1
NCT00058448,"S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)",Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2004-10-01,2005-11-01,SWOG Cancer Research Network,NETWORK,,SINGLE_GROUP,NONE,DRUG,docetaxel,Penile Cancer,,,,,False,396.0,True,False,2.0,False,False,False,1,False,Small (<30),1,1.0,0.6931471805599453,0,0,0.58,False,False,0.053640617360766314,1,False,0.07164259069546607,1,0,0.051899873,1
NCT04542837,The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma,A Phase II Study Evaluating the Safety and Efficacy of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,55.0,ACTUAL,2020-09-11,2024-03-15,Peking University Cancer Hospital & Institute,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","KN046, Lenvatinib",HCC,,,,,False,1281.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,55.0,4.02535169073515,1,0,0.58,True,True,0.6728125596386852,1,True,0.6620525110373551,1,1,0.52481955,1
NCT00423917,Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer,Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor,COMPLETED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2007-08-01,2017-01-15,Alliance for Clinical Trials in Oncology,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","bevacizumab, fulvestrant",Breast Cancer,,,,,False,3455.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,36.0,3.610917912644224,1,0,0.58,True,True,0.6749993160444873,1,True,0.9273937583978263,1,1,0.9238543,1
NCT06199297,Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma,Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study,COMPLETED,,OBSERVATIONAL,188.0,ACTUAL,2021-03-02,2023-07-25,Sun Yat-sen University,OTHER,,,,"DRUG, DRUG, PROCEDURE","Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy",Hepatocellular Carcinoma,,,,,False,875.0,True,False,-1.0,False,False,False,3,True,Large (100-300),1,188.0,5.241747015059643,1,1,0.6,True,True,0.797629847727581,1,True,0.8804296279207426,1,1,0.8568112,1
NCT04659421,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,"A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine in the Treatment of Low-grade Gliomas in Children",COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2020-11-03,2023-07-20,Beijing Sanbo Brain Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,combined therapy with rh-ES and CV,"Low-grade Glioma, Pediatric Brain Tumor",,,,,False,989.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,0,0,0.58,True,True,0.7285582631812211,1,True,0.780112034741919,1,1,0.80791396,1
NCT05954780,Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma,A Non-interventional Study of Selinexor (Nexpovio®) in Combination With Bortezomib and Dexamethasone (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (R/RMM),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,75.0,ACTUAL,2023-06-28,2026-10-30,iOMEDICO AG,INDUSTRY,,,,DRUG,Selinexor,Multiple Myeloma,,,,,False,1220.0,False,False,-1.0,False,False,True,1,True,Medium (30-100),0,75.0,4.330733340286331,0,0,0.6,True,True,0.8351792090409812,1,True,0.7806047209546779,1,1,0.8282332,1
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma,TERMINATED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2014-03-01,2019-06-21,University of Washington,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER, OTHER, RADIATION","Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy","Recurrent Melanoma, Stage IV Skin Melanoma",,,,,False,1938.0,True,False,2.0,False,False,False,4,False,Small (<30),1,23.0,3.1780538303479458,1,0,0.58,False,False,0.47700930620532167,1,True,0.5491622549740771,0,1,0.56716865,0
NCT05845476,Sexual Orientation and Gender Identity (SOGI) Data Collection Program Implementation and Evaluation,Sexual Orientation and Gender Identity (SOGI) Data Collection Program Implementation and Evaluation,COMPLETED,,OBSERVATIONAL,54.0,ACTUAL,2023-03-14,2024-03-14,Ohio State University Comprehensive Cancer Center,OTHER,,,,"OTHER, OTHER, OTHER","Patient SOGI Self-Report, SOGI Resource for Clinical Care Education (SORCE), Cancer Center Care Environment",Cancer Surveillance,,,,,False,366.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,54.0,4.007333185232471,1,0,0.6,True,True,0.7057051882697358,1,True,0.7351373274846528,1,1,0.69099593,1
NCT06917560,Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study,"The Role of Serological Autoantibody Profiles in the Early Diagnosis and Prognosis of Renal Carcinoma: A Multicenter, Retrospective Clinical Study",ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,400.0,ESTIMATED,2025-04-01,2027-08-01,First Affiliated Hospital of Fujian Medical University,OTHER,,,,,,"Renal Carcinoma, Serology, Autoantibody",,,,,False,852.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,400.0,5.993961427306569,0,1,0.6,True,True,0.9124765781379184,1,True,0.9215398159333239,1,1,0.94803756,1
NCT04331067,Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2020-11-19,2026-05-31,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, BIOLOGICAL, BIOLOGICAL, PROCEDURE, PROCEDURE, PROCEDURE","Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw",Triple Negative Breast Cancer,,,,,False,2019.0,False,False,1.0,True,False,False,7,True,Small (<30),1,15.0,2.772588722239781,2,0,0.56,True,False,0.3155324558791545,0,False,0.4813746062009519,0,1,0.6123234,1
NCT02980731,A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).,"Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) (VENICE II)",COMPLETED,PHASE3,INTERVENTIONAL,210.0,ACTUAL,2016-12-13,2021-12-29,AbbVie,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Venetoclax,Chronic Lymphocytic Leukemia (CLL),,,,,False,1842.0,True,False,3.0,False,False,True,1,True,Large (100-300),0,210.0,5.351858133476067,0,1,0.77,True,True,0.7722260551584339,1,True,0.788520354211883,1,1,0.9164394,1
NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,"A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,46.0,ACTUAL,2017-02-28,2022-04-24,Celgene,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide","Lymphoma, Large B-Cell, Diffuse",,,,,False,1881.0,True,False,2.0,False,False,True,7,True,Medium (30-100),1,46.0,3.8501476017100575,1,0,0.58,True,True,0.6356888759536389,1,True,0.9027843157100157,1,1,0.90718764,1
NCT00293540,Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer,Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer,COMPLETED,PHASE3,INTERVENTIONAL,249.0,ACTUAL,2006-02-01,2015-03-01,International Breast Cancer Research Foundation,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG","oophorectomy, Tamoxifen",Breast Cancer,,,,,False,3315.0,True,False,3.0,True,False,False,2,True,Large (100-300),1,249.0,5.521460917862246,2,1,0.77,True,True,0.75100656877789,1,True,0.8064393194594445,1,1,0.83628005,1
NCT06428279,Survey of Sexual Health in Cancer Patients,Sexual Health in Cancer Patients: a Survey and Pilot Study of Psychosexual Therapy as a Non-pharmacological Supportive Care,COMPLETED,,OBSERVATIONAL,200.0,ACTUAL,2024-04-19,2024-05-19,Institut Rafael,OTHER,,,,BEHAVIORAL,Survey,Integrative Oncology,,,,,False,30.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8195154820238415,1,True,0.9494563610371343,1,1,0.9797289,1
NCT05924282,PET on Surgery for Loco-regionally Recurrent Colorectal Cancer,Impact of Positron-Emission-Tomography on the Surgical Treatment for Loco-regionally Recurrent Colorectal Cancer,COMPLETED,,OBSERVATIONAL,193.0,ACTUAL,2010-07-01,2023-06-20,National Taiwan University Hospital,OTHER,,,,PROCEDURE,Curative intent surgery,"PET-driven Surgery, Loco-regional Recurrent Colorectal Cancer",,,,,False,4737.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,193.0,5.267858159063328,0,1,0.6,True,True,0.9211416938401024,1,True,0.8390060779946849,1,1,0.6413203,1
NCT03113981,Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®),Randomized Controlled Non-inferiority Trial Assessing the Osseointegration of THA Grafted by Sodium Polystyrene Sulfonate -PolyNASS- (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®),ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,340.0,ACTUAL,2017-05-08,2039-12-01,Societe ACTIVBIOMAT,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,DEVICE,Total Hip Arthroplasty,"Osteoarthritis, Hip, Coxarthrosis; Primary, Coxarthrosis; Secondary, Osteonecrosis; Aseptic, Idiopathic, Hip Arthroplasty Replacement, Hip Arthroplasty, Total, Hip Arthroplasty",,,,,False,8242.0,False,False,-1.0,True,True,True,1,True,Very Large (300+),0,340.0,5.831882477283517,2,1,0.6,True,True,0.9705542775799954,1,True,0.9227330179748431,1,1,0.91194963,1
NCT01808573,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA),COMPLETED,PHASE3,INTERVENTIONAL,621.0,ACTUAL,2013-03-29,2019-12-09,"Puma Biotechnology, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","neratinib, capecitabine, lapatinib",HER2+ Metastatic Breast Cancer (MBC),,,,,False,2446.0,True,False,3.0,True,False,True,3,True,Very Large (300+),1,621.0,6.432940092739179,2,1,0.77,True,True,0.8434208579577094,1,True,0.9733118280942928,1,1,0.9757581,1
NCT01423695,Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer,Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,121.0,ACTUAL,2001-02-01,2009-12-01,WiSP Wissenschaftlicher Service Pharma GmbH,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,paclitaxel plus trastuzumab,Metastatic Breast Cancer,,,,,False,3225.0,True,False,2.0,False,False,False,1,True,Large (100-300),1,121.0,4.804021044733257,0,1,0.58,True,True,0.7847820290757844,1,True,0.8084071102228986,1,1,0.8406975,1
NCT00369707,Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL,A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2006-08-09,2014-10-10,Northwestern University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Rituximab, bortezomib",Non-Hodgkin's Lymphoma,,,,,False,2984.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.58,True,True,0.6886546224432009,1,True,0.9637377731915358,1,1,0.9650463,1
NCT02705859,Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study),Phase Ib/II Clinical Trial of Copanlisib in Combination With Trastuzumab in Pretreated Recurrent or Metastatic HER2-positive Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2016-04-01,2022-07-01,Cancer Trials Ireland,NETWORK,,SINGLE_GROUP,NONE,"DRUG, DRUG","Copanlisib, Trastuzumab",HER2 Positive Breast Cancer,,,,,False,2282.0,True,False,1.0,False,False,False,2,True,Small (<30),1,26.0,3.295836866004329,1,0,0.56,True,True,0.5742349547646006,1,True,0.7354658704978383,1,1,0.78421813,1
NCT04953130,Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania,Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania,ACTIVE_NOT_RECRUITING,PHASE4,INTERVENTIONAL,10400.0,ESTIMATED,2022-08-01,2026-10-01,London School of Hygiene and Tropical Medicine,OTHER,RANDOMIZED,PARALLEL,SINGLE,BIOLOGICAL,Gardasil® HPV vaccine,"HPV Infection, Vaccine Preventable Disease",,,,,False,1522.0,False,False,4.0,True,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,1,1,0.7,True,True,0.7610860842616479,1,True,0.8993871220119525,1,1,0.9803359,1
NCT00336076,Molecular Mechanisms and Diagnosis of Mastocytosis,Investigation of Cellular and Molecular Pathologic Mechanisms in Mast Cell Disorders.,COMPLETED,,OBSERVATIONAL,136.0,ACTUAL,2004-07-01,2009-07-01,University of Michigan,OTHER,,,,OTHER,Collection of blood and bone marrow,Mastocytosis,,,,,False,1826.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,136.0,4.919980925828125,0,1,0.6,True,True,0.8182519607278296,1,True,0.7201860768211124,1,1,0.67508364,1
NCT00726986,"Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer",Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer,TERMINATED,PHASE2,INTERVENTIONAL,18.0,ACTUAL,2008-07-01,2012-07-01,"Afshin Dowlati, MD",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","cisplatin, etoposide, sorafenib tosylate",Lung Cancer,,,,,False,1461.0,True,False,2.0,False,False,False,3,False,Small (<30),1,18.0,2.9444389791664403,1,0,0.58,False,False,0.395671068459594,1,False,0.4162940297979485,1,0,0.38151318,1
NCT03568526,Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer,The Effects of a Sensorimotor Rehabilitation Program on the Upper and Lower Limbs of Persons With Cancer Following Taxane-Based Chemotherapy for Early Stage Breast Cancer,COMPLETED,,INTERVENTIONAL,36.0,ACTUAL,2015-07-02,2022-09-14,Ohio State University Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"OTHER, BEHAVIORAL, OTHER, OTHER, OTHER","Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration","Peripheral Neuropathy, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7",,,,,False,2631.0,True,False,-1.0,False,False,False,5,True,Medium (30-100),0,36.0,3.610917912644224,1,0,0.6,True,True,0.707154504421989,1,True,0.7311859565749966,1,1,0.7246363,1
NCT02352389,A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents,A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents,COMPLETED,,OBSERVATIONAL,16.0,ACTUAL,2015-03-30,2022-12-08,St. Jude Children's Research Hospital,OTHER,,,,"OTHER, OTHER, OTHER, OTHER, OTHER","Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist","Influenza, Human",,,,,False,2810.0,True,False,-1.0,False,False,False,5,True,Small (<30),0,16.0,2.833213344056216,1,0,0.6,True,True,0.5198363576959121,1,False,0.4652317689360186,0,0,0.37404338,0
NCT02924675,Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.,Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.,TERMINATED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2015-06-05,2018-12-12,"University Hospital, Lille",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Pregabalin, Placebo",Earache,,,,,False,1286.0,True,False,2.0,True,True,False,2,False,Medium (30-100),0,42.0,3.7612001156935615,3,0,0.58,False,True,0.5608964469978307,0,True,0.6440000201970265,0,1,0.7091408,0
NCT04122911,Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas,A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy,COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2017-01-29,2019-12-16,"National Cancer Institute, Naples",OTHER,,SINGLE_GROUP,NONE,DRUG,Temozolomide,Neuroendocrine Carcinomas,,,,,False,1051.0,True,False,2.0,False,False,False,1,True,Small (<30),1,25.0,3.258096538021482,0,0,0.58,True,True,0.5147578980601533,1,True,0.583398254992948,1,1,0.65876704,1
NCT00081965,Acupuncture in Treating Hot Flashes in Women With Breast Cancer,Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients: A Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,80.0,ESTIMATED,,2007-05-01,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,,,"PROCEDURE, PROCEDURE, PROCEDURE","acupuncture therapy, hot flashes attenuation, management of therapy complications","Breast Cancer, Hot Flashes",,,,,False,1303.0,True,False,-1.0,True,False,False,3,True,Medium (30-100),0,80.0,4.394449154672439,2,0,0.6,True,True,0.7555052953572505,1,True,0.7720244906750157,1,1,0.83238095,1
NCT00193557,Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,COMPLETED,PHASE2,INTERVENTIONAL,40.0,,2004-05-01,2009-01-01,"SCRI Development Innovations, LLC",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Bortezomib,Multiple Myeloma,,,,,False,1706.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.58,True,True,0.6711456673837681,1,True,0.8268748611419116,1,1,0.78471595,1
NCT04803201,Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma,A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas,SUSPENDED,PHASE2,INTERVENTIONAL,170.0,ESTIMATED,2021-10-08,2026-06-30,Alliance for Clinical Trials in Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine","Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified",,,,,False,1726.0,False,False,2.0,True,False,False,7,False,Large (100-300),1,170.0,5.14166355650266,2,1,0.58,False,True,0.6597190154883228,0,True,0.7355931255875723,0,1,0.79745495,0
NCT00568997,10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus,A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,8000.0,ESTIMATED,2005-06-27,2028-06-01,"Bausch Health Americas, Inc.",INDUSTRY,,,,DRUG,Pimecrolimus,Atopic Dermatitis,,,,,False,8375.0,False,False,-1.0,False,False,True,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9756794367322486,1,True,0.9530292768236825,1,1,0.98131096,1
NCT01550510,Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA,Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer,TERMINATED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2011-12-01,2015-02-01,Thomas Jefferson University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Ascorbic Acid, Irinotecan",Stage IV Colorectal Cancer,,,,,False,1158.0,True,False,1.0,True,False,False,2,False,Small (<30),1,4.0,1.6094379124341005,2,0,0.56,False,False,0.10740813887217159,1,False,0.07375771066355787,1,0,0.05046397,1
NCT00891761,A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy,A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Cisplatin-Induced Nausea and Vomiting,WITHDRAWN,PHASE3,INTERVENTIONAL,0.0,ACTUAL,2009-09-01,2010-07-01,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG, DRUG","Dexamethasone, Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron","Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer",,,,,False,303.0,True,False,3.0,True,True,True,5,False,,0,0.0,0.0,3,0,0.77,False,False,0.011271558375055444,1,False,0.011283122907698536,1,0,0.0014977325,1
NCT00096083,Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer,A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver,COMPLETED,PHASE2,INTERVENTIONAL,56.0,ACTUAL,2004-09-01,2012-08-01,Delcath Systems Inc.,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","isolated perfusion, melphalan",Cancer,,,,,False,2891.0,True,False,2.0,False,False,True,2,True,Medium (30-100),0,56.0,4.04305126783455,1,0,0.58,True,True,0.7508328328459015,1,True,0.9135162727299836,1,1,0.87268287,1
NCT02603003,"the""Fuzheng"" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs","A Study on the""Fuzheng""Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation",COMPLETED,PHASE1,INTERVENTIONAL,218.0,ACTUAL,2015-06-01,2019-09-01,Shanghai University of Traditional Chinese Medicine,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG, DRUG","JinFuKang, Cisplatin, Pemetrexed",Non-small Cell Lung Cancer(NSCLC),,,,,False,1553.0,True,False,1.0,True,False,False,3,True,Large (100-300),1,218.0,5.389071729816501,2,1,0.56,True,True,0.7507032264908935,1,True,0.7620120497530098,1,1,0.82005095,1
NCT00537056,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,COMPLETED,,INTERVENTIONAL,17.0,ACTUAL,2007-10-01,2012-04-01,Stanford University,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DRUG, DRUG, DRUG","FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib","Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer",,,,,False,1644.0,True,False,-1.0,False,False,False,5,True,Small (<30),1,17.0,2.8903717578961645,1,0,0.6,True,False,0.46765180208456975,0,False,0.4476364260823068,0,0,0.26289397,0
NCT04960709,"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,712.0,ACTUAL,2021-08-05,2028-09-08,AstraZeneca,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, PROCEDURE","Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy",Muscle Invasive Bladder Cancer,,,,,False,2591.0,False,False,3.0,True,False,True,4,True,Very Large (300+),1,712.0,6.569481420414296,2,1,0.77,True,True,0.8569396273128959,1,True,0.9569233462607813,1,1,0.9546197,1
NCT00314353,Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon,Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer,TERMINATED,PHASE2,INTERVENTIONAL,7.0,ACTUAL,2006-03-01,2010-06-01,NSABP Foundation Inc,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan",Colorectal Neoplasms,,,,,False,1553.0,True,False,2.0,True,False,False,4,False,Small (<30),1,7.0,2.079441541679836,2,0,0.58,False,False,0.15250272797716327,1,False,0.1586602817292458,1,0,0.13583125,1
NCT03469271,Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients,"Resistance Training and 1,25 (OH)2D3 Administration to Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients",COMPLETED,PHASE4,INTERVENTIONAL,63.0,ACTUAL,2018-05-25,2020-05-21,Mayo Clinic,OTHER,RANDOMIZED,FACTORIAL,TRIPLE,"DRUG, OTHER, DRUG, OTHER, DEVICE","1,25 (OH)2 D3, Inspiratory isometric resistance training, Oral Placebo, Sham Inspiratory Isometric Resistance Training, Threshold Inspiratory Muscle Trainer (IMT)",Cancer,,,,,False,727.0,True,False,4.0,True,True,False,5,True,Medium (30-100),0,63.0,4.158883083359672,3,0,0.7,True,True,0.5220981637902871,1,True,0.7054390819469822,1,1,0.7259815,1
NCT01984359,HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer,"A Pilot, Single-Center Study Of Quantitative HPV Serum Or Plasma DNA As A Prognostic Marker In P16+/HPV+ Squamous Carcinomas Of The Oropharynx And Unknown Primary Head And Neck Cancers",COMPLETED,,INTERVENTIONAL,80.0,ACTUAL,2013-05-01,2018-05-24,Abramson Cancer Center at Penn Medicine,OTHER,,SINGLE_GROUP,NONE,OTHER,Obtaining Human tissue,Subjects With p16 Positive/HPV Positive Squamous Cell Carcinomas of the Oropharynx,,,,,False,1849.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,80.0,4.394449154672439,0,0,0.6,True,True,0.8606281483525708,1,True,0.8426183752308184,1,1,0.7749297,1
NCT01061788,"A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007",A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial),COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2010-04-01,2018-12-19,Jeffrey Clarke,OTHER,,SINGLE_GROUP,NONE,DRUG,"AMG 479, Everolimus, Panitumumab","Advanced Solid Tumors, Non-small Cell Lung Cancer",,,,,False,3184.0,True,False,1.0,False,False,False,1,True,Medium (30-100),1,43.0,3.784189633918261,0,0,0.56,True,True,0.7719996027073104,1,True,0.8329835774172757,1,1,0.90763,1
NCT03042897,Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer,Endometrial Cancer and Obesity: An Exercise and Diet Intervention for Weight Loss,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2017-09-08,2019-07-31,University of Southern California,OTHER,,SINGLE_GROUP,NONE,"DIETARY_SUPPLEMENT, BEHAVIORAL, OTHER, OTHER","Dietary Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment","Estrogen Receptor Positive, Obesity, Progesterone Receptor Positive, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer",,,,,False,691.0,True,False,-1.0,False,False,False,4,False,,0,0.0,0.0,1,0,0.6,False,False,0.03129890508812412,1,False,0.013230237863241588,1,0,0.0022738813,1
NCT00118638,A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy,"A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",COMPLETED,PHASE3,INTERVENTIONAL,705.0,ACTUAL,2004-03-01,2005-01-01,Amgen,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Darbepoetin alfa - 2.25 mcg/kg, Darbepoetin alfa - 500mcg","Anemia, Non-Myeloid Malignancies",,,,,False,306.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,705.0,6.559615237493242,3,1,0.77,True,True,0.8180474980528061,1,True,0.8519641982182765,1,1,0.9479235,1
NCT03057314,"Improving Function,Welfare of Late-stage Cancer Subjects by ACC","Exploratory, Open Label Study to Improve Function and Welfare of Late-stage Cancer Subjects by Amorphous Calcium Carbonate (ACC) Treatment, Administered Orally and Concomitantly With Inhalation",TERMINATED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2017-06-25,2019-12-31,Amorphical Ltd.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Amorphous Calcium Carbonate,"Solid Malignancies, With or Without Lung Metastases",,,,,False,919.0,True,False,1.0,False,False,True,1,False,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,False,False,0.3270796935503626,1,False,0.46740633510649343,1,1,0.5380005,0
NCT01141309,Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2010-06-01,2026-06-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,sorafenib with everolimus,Thyroid Cancer,,,,,False,5844.0,False,False,2.0,False,False,False,1,True,Medium (30-100),1,41.0,3.737669618283368,0,0,0.58,True,True,0.8280818029881976,1,True,0.9257667648433778,1,1,0.93446136,1
NCT03430635,Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma,What is the Prognostic Value of ¹¹C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma?,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2010-01-01,2016-01-31,Humanitas Clinical and Research Center,OTHER,,,,PROCEDURE,Hepatectomy,Hepatocellular Carcinoma,,,,,False,2221.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.764237830186075,1,True,0.7849067325084705,1,1,0.7146341,1
NCT00193154,OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma,A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,63.0,ACTUAL,2003-02-01,2014-03-01,"SCRI Development Innovations, LLC",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","OSI-774, Bevacizumab",Kidney Cancer,,,,,False,4046.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,63.0,4.158883083359672,1,0,0.58,True,True,0.808123903011963,1,True,0.8995354131371107,1,1,0.94579196,1
NCT02503774,MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.,"A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,192.0,ACTUAL,2015-07-24,2023-03-07,MedImmune LLC,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Oleclumab, Durvalumab",Solid Tumors,,,,,False,2783.0,True,False,1.0,False,False,True,2,True,Large (100-300),1,192.0,5.262690188904886,1,1,0.56,True,True,0.8328053491348905,1,True,0.7725305925745876,1,1,0.77421165,1
NCT04906343,Endoscopic Surveillance in Serrated Polyposis Syndrome and Low-risk of Advanced Neoplasia,Endoscopic Surveillance in Patients With Serrated Polyposis Syndrome and Low-risk of Advanced Neoplasia.,COMPLETED,,INTERVENTIONAL,144.0,ACTUAL,2021-06-05,2024-11-22,Hospital Universitario de Móstoles,OTHER,RANDOMIZED,PARALLEL,NONE,PROCEDURE,Colonoscopy,"Colonic Polyp, Colonic Neoplasms, Colonic Cancer, Serrated Polyposis, Serrated Polyp of Colon",,,,,False,1266.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,144.0,4.976733742420574,1,1,0.6,True,True,0.7494151045359984,1,True,0.7779302793130491,1,1,0.8040945,1
NCT05754944,Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery,Impact and Prevalence of PAD on Cancer Patients at High-risk for PAD Going to Surgery,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,114.0,ACTUAL,2023-02-22,2026-02-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,"DIAGNOSTIC_TEST, OTHER","ABI/TBI, Questionnaires",Peripheral Arterial Disease (PAD) in Cancer Patients,,,,,False,1075.0,False,False,-1.0,False,False,False,2,True,Large (100-300),0,114.0,4.74493212836325,1,1,0.6,True,True,0.7233749320053013,1,True,0.8693249668665747,1,1,0.82247776,1
NCT01844817,Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer,"A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel Combined With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial)",COMPLETED,PHASE2,INTERVENTIONAL,132.0,ACTUAL,2013-09-01,2016-03-01,"SCRI Development Innovations, LLC",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","OGX-427, Placebo",Pancreatic Cancer,,,,,False,912.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,132.0,4.890349128221754,3,1,0.58,True,True,0.6216603467527156,1,True,0.6467095062456814,1,1,0.70491934,1
NCT02053376,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,COMPLETED,PHASE2,INTERVENTIONAL,43.0,ACTUAL,2014-01-01,2018-05-14,"Nathan Bahary, MD",OTHER,,SINGLE_GROUP,NONE,DRUG,Regorafenib,Metastatic Biliary Tract Carcinoma,,,,,False,1594.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,43.0,3.784189633918261,0,0,0.58,True,True,0.6764127741650643,1,True,0.8717522726941688,1,1,0.85651195,1
NCT02393209,Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer,A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,TERMINATED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2015-06-03,2017-01-20,"Millennium Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Docetaxel, TAK-117",Non-small Cell Lung Cancer,,,,,False,597.0,True,False,1.0,True,False,True,2,False,Small (<30),1,14.0,2.70805020110221,2,0,0.56,False,False,0.26157944765525876,1,False,0.39941439493438,1,0,0.49391395,1
NCT06181058,Escape Room Game in Oncology Nursing,The Effect of the Escape Room Game on Students' Academic Self-Efficacy and Critical Thinking: An Oncology Nursing Course Example,COMPLETED,,INTERVENTIONAL,42.0,ACTUAL,2023-12-25,2023-12-26,Ankara Yildirim Beyazıt University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,escape room game,"Oncology, Education",,,,,False,1.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.6,True,True,0.6824364335822783,1,True,0.8540771289004898,1,1,0.95445615,1
NCT05447949,Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy,"Comparison of Dexmedetomidine Versus Dexamethasone as Adjuncts to Levobupivacaine in Ultrasound Guided Erector Spinae Plane Block for Patients Undergoing Modified Radical Mastectomy, Randomized Double-Blinded Comparative Study.",COMPLETED,,INTERVENTIONAL,90.0,ACTUAL,2020-12-15,2022-03-15,"National Cancer Institute, Egypt",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,PROCEDURE,Adjuncts to levobupivacaine in Erector Spinae Plane Block,"Breast Cancer, Post Operative Pain",,,,,False,455.0,True,False,-1.0,True,True,False,1,True,Medium (30-100),0,90.0,4.51085950651685,2,0,0.6,True,True,0.8066000750090024,1,True,0.8260959577502048,1,1,0.8387707,1
NCT01668784,Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025),"A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy",COMPLETED,PHASE3,INTERVENTIONAL,821.0,ACTUAL,2012-10-09,2021-07-19,Bristol-Myers Squibb,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG","Nivolumab, Everolimus",Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma,,,,,False,3205.0,True,False,3.0,True,False,True,2,True,Very Large (300+),1,821.0,6.71174039505618,2,1,0.77,True,True,0.8860747691534645,1,True,0.929302866141605,1,1,0.9165437,1
NCT00634582,Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases,"Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer",TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2009-01-01,2015-06-01,Wake Forest University Health Sciences,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, OTHER, OTHER, PROCEDURE, PROCEDURE","paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment","Metastatic Cancer, Prostate Cancer",,,,,False,2342.0,True,False,2.0,False,False,False,5,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.58,False,False,0.09417695616165585,1,False,0.25673294155406756,1,0,0.46713528,1
NCT02359058,A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer,Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma,COMPLETED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2015-02-01,2016-11-01,Eli Lilly and Company,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Ramucirumab, Capecitabine, Cisplatin, S-1, Oxaliplatin",Stomach Neoplasms,,,,,False,639.0,True,False,1.0,False,False,True,5,True,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,True,False,0.38124774598634087,0,False,0.3782898724485999,0,0,0.37440798,0
NCT02608684,A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2016-02-08,2022-03-07,Cedars-Sinai Medical Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Pembrolizumab, Gemcitabine, Cisplatin",Ovarian Cancer,,,,,False,2219.0,True,False,2.0,False,False,False,3,True,Small (<30),1,21.0,3.091042453358316,1,0,0.58,True,False,0.4732538623306469,0,True,0.6268058620405943,1,1,0.66198254,1
NCT01764360,Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe,Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe (SIKO),COMPLETED,,INTERVENTIONAL,1024.0,ACTUAL,2013-02-01,2017-06-01,"University of Colorado, Denver",OTHER,,SINGLE_GROUP,NONE,OTHER,KS structured clinical care training,"Kaposi Sarcoma (KS), HIV",,,,,False,1581.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1024.0,6.932447891572509,0,1,0.6,True,True,0.9585066775561122,1,True,0.9765096135694603,1,1,0.9769661,1
NCT01747239,Cabazitaxel in Platinum Refractory Ovarian Cancer,Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial,TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2013-01-01,2014-07-01,Vejle Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Cabazitaxel,Ovarian Cancer,,,,,False,546.0,True,False,2.0,False,False,False,1,False,Small (<30),1,4.0,1.6094379124341005,0,0,0.58,False,False,0.1372781107585482,1,False,0.09287153776389553,1,0,0.08336495,1
NCT01969448,Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction,A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction,COMPLETED,,INTERVENTIONAL,79.0,ACTUAL,2013-03-28,2017-04-17,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, DEVICE, DRUG","Inframammary Fold Incision or Lateral Radial Incision, Lateral Radial Incision, Inframammary Fold Incision, Laser-assisted fluorescence angiography, Indocyanine Green","Ductal Carcinoma in Situ - Category, Breast Cancer, Prophylactic Mastectomy",,,,,False,1481.0,True,False,-1.0,True,False,False,5,True,Medium (30-100),0,79.0,4.382026634673881,2,0,0.6,True,True,0.7523501288450611,1,True,0.6356333600295413,1,1,0.58475304,1
NCT00310362,Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates,Use of Telehealth In-Home Messaging to Improve GI Endoscopy Completion Rates,COMPLETED,,INTERVENTIONAL,3610.0,ACTUAL,2007-07-01,2009-02-01,VA Office of Research and Development,FED,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures,Colorectal Cancer,,,,,False,581.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,3610.0,8.191740021277457,1,1,0.6,True,True,0.9210675681575811,1,True,0.9596236650229097,1,1,0.98704565,1
NCT01474356,Hyperthermia Combined Brachytherapy in CCU,HDR Brachytherapy Combined With Interstitial Hyperthermia 500 kHz in Locally Advanced Cervical Cancer Patients. A Prospective Clinical Trial,COMPLETED,PHASE3,INTERVENTIONAL,224.0,ACTUAL,2006-11-01,2009-03-01,Maria Sklodowska-Curie National Research Institute of Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,hyperthermia,Cervical Cancer,,,,,False,851.0,True,False,3.0,True,False,False,1,True,Large (100-300),0,224.0,5.41610040220442,1,1,0.77,True,True,0.6741201786541181,1,True,0.7120612285778358,1,1,0.7372429,1
NCT00473005,Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast,A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer,TERMINATED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2007-08-01,2011-12-01,Stanford University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Capecitabine, RAD001",Breast Cancer,,,,,False,1583.0,True,False,1.0,False,False,False,2,False,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,False,False,0.44368177893309807,1,True,0.513004000947636,0,0,0.48084044,1
NCT00161174,Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity,Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157),COMPLETED,,OBSERVATIONAL,173.0,ACTUAL,2005-07-01,2011-01-01,University Medical Center Groningen,OTHER,,,,,,Non-seminomatous Testicular Cancer,,,,,False,2010.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,173.0,5.159055299214529,0,1,0.6,True,True,0.8585736620831264,1,True,0.8610654754514779,1,1,0.77566504,1
NCT05347485,A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma,A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma,COMPLETED,PHASE2,INTERVENTIONAL,86.0,ACTUAL,2022-05-13,2023-12-15,"Janssen Scientific Affairs, LLC",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)",Multiple Myeloma,,,,,False,581.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,86.0,4.465908118654584,1,0,0.58,True,True,0.7387272206248852,1,True,0.6106534764187588,1,1,0.54635686,1
NCT02115828,A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy,A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,9.0,ACTUAL,2014-04-01,2016-04-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,NONE,DRUG,Vismodegib,Prostate Cancer,,,,,False,731.0,True,False,0.5,False,False,False,1,True,Small (<30),0,9.0,2.302585092994046,0,0,0.57,True,False,0.3071994458822795,0,False,0.2852008343385797,0,0,0.3320838,0
NCT02372994,My Team of Care: a Pilot Randomized Controlled Trial of an Online Communication Tool for Collaborative Care,My Team of Care (MyTOC) Trial: a Pilot Randomized Controlled Trial of an Online Communication Tool (Loop) for Collaborative Care in Complex Patients,COMPLETED,,INTERVENTIONAL,49.0,ACTUAL,2015-01-01,2016-04-01,"Mount Sinai Hospital, Canada",OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,Loop,"Neoplasms, Communication",,,,,False,456.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.6,True,True,0.6616614154685496,1,True,0.743375747093266,1,1,0.7504206,1
NCT03061708,Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy,Phase II Trial of Single Agent AZD2014 in RICTOR Amplified or Over-expressed GC Patients as Second-line Therapy,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2017-02-01,2018-11-16,Samsung Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,AZD2014,Stomach Neoplasms,,,,,False,653.0,True,False,2.0,False,False,False,1,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.58,False,False,0.0579452882739444,1,False,0.06909838830857967,1,0,0.041435264,1
NCT01398462,Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,"A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis",COMPLETED,PHASE1,INTERVENTIONAL,69.0,ACTUAL,2011-07-01,2015-12-01,JW Pharmaceutical,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,CWP232291,"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis",,,,,False,1614.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,69.0,4.248495242049359,0,0,0.56,True,True,0.8044219865809248,1,True,0.6694339908543835,1,1,0.58525866,1
NCT04051827,Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC),"A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer",COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2019-12-23,2021-12-07,"Millennium Pharmaceuticals, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","Midazolam, TAK-788","Carcinoma, Non-Small-Cell Lung, Lung Neoplasms",,,,,False,715.0,True,False,1.0,False,False,True,2,True,Small (<30),0,26.0,3.295836866004329,1,0,0.56,True,True,0.5003233915667997,1,False,0.3837905871708702,0,0,0.392558,0
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,A Phase I/II Trial For Neutron Capture Therapy In Glioblastoma Multiforme And Intracranial Melanoma,COMPLETED,PHASE1,INTERVENTIONAL,,,2002-05-01,2005-01-01,Beth Israel Deaconess Medical Center,OTHER,,,,DRUG,boronophenylalanine-fructose complex,"Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer",,,,,False,976.0,True,False,1.0,False,False,False,1,True,,0,,,0,0,0.56,True,True,0.7160159565346501,1,True,0.7069978955141135,1,1,0.74910986,1
NCT05339022,"Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial",Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Phase II Randomized Supportive Care Intervention Clinical Trial,COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2022-04-14,2025-10-01,Ohio State University Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER, PROCEDURE, OTHER, OTHER, PROCEDURE","Best Practice, Exercise Intervention, Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration, Relaxation Therapy","Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Small Cell Carcinoma",,,,,False,1266.0,True,False,-1.0,True,False,False,6,True,Medium (30-100),0,100.0,4.61512051684126,2,1,0.6,True,True,0.6070781535002535,1,True,0.8475006540045531,1,1,0.8241333,1
NCT01554059,Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients,Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma,COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2012-03-01,2014-08-01,"Sixth Affiliated Hospital, Sun Yat-sen University",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, RADIATION","Bevacizumab, Oxaliplatin, 5-FU, Radiotherapy",Rectal Adenocarcinoma,,,,,False,883.0,True,False,2.0,False,False,False,4,True,Small (<30),1,25.0,3.258096538021482,1,0,0.58,True,False,0.44394671800949853,0,False,0.3023339438205954,0,0,0.25037855,0
NCT00670397,"Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer","Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and Stage I Carcinoma of the Oral Cavity",TERMINATED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2010-06-01,2015-07-01,Roswell Park Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,HPPH,Head and Neck Cancer,,,,,False,1856.0,True,False,1.0,False,False,False,1,False,Small (<30),0,11.0,2.4849066497880004,0,0,0.56,False,False,0.3937027154072759,1,False,0.4898972342599937,1,1,0.55014104,0
NCT01412515,A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma,A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma,TERMINATED,PHASE2,INTERVENTIONAL,11.0,ACTUAL,2008-06-01,2011-05-01,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,everolimus,Kaposi Sarcoma,,,,,False,1064.0,True,False,2.0,False,False,False,1,False,Small (<30),0,11.0,2.4849066497880004,0,0,0.58,False,False,0.3212578559643079,1,False,0.30127276539475584,1,0,0.32921702,1
NCT00898066,S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease,Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma,COMPLETED,,OBSERVATIONAL,37.0,ACTUAL,2005-09-01,2007-06-01,SWOG Cancer Research Network,NETWORK,,,,"GENETIC, GENETIC","cytogenetic analysis, fluorescence in situ hybridization","Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition",,,,,False,638.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,37.0,3.6375861597263857,1,0,0.6,True,True,0.635754568512237,1,True,0.5312718166457174,1,0,0.31159362,0
NCT05248685,Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia,"Single-center, Open-Label, Non-randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Tolerability of Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2022-02-16,2023-12-31,Beijing Boren Hospital,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,Dual CD33/CLL1 CAR T,Acute Myeloid Leukemia,,,,,False,683.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.03264405015141286,1,False,0.005198883139730329,1,0,0.0020670285,1
NCT00066690,Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer,COMPLETED,PHASE3,INTERVENTIONAL,3066.0,ACTUAL,2003-12-17,2024-11-06,ETOP IBCSG Partners Foundation,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER, PROCEDURE, OTHER, RADIATION, DRUG, DRUG","Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin","Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer",,,,,False,7630.0,True,False,3.0,True,False,False,7,True,Very Large (300+),1,3066.0,8.028455164114252,2,1,0.77,True,True,0.9528353044007469,1,True,0.9157638471678069,1,1,0.98779154,1
NCT01980888,Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia",TERMINATED,PHASE3,INTERVENTIONAL,311.0,ACTUAL,2014-02-05,2016-06-16,Gilead Sciences,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG","Idelalisib, Bendamustine, Rituximab, Placebo",Chronic Lymphocytic Leukemia,,,,,False,862.0,True,False,3.0,True,True,True,4,False,Very Large (300+),1,311.0,5.7430031878094825,3,1,0.77,False,True,0.7078363716800398,0,True,0.5993045607336167,0,1,0.78614956,0
NCT03736746,Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals,Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals,COMPLETED,,INTERVENTIONAL,54.0,ACTUAL,2018-11-16,2019-08-02,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Motivational Interviewing,Other Cancer,,,,,False,259.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,54.0,4.007333185232471,0,0,0.6,True,True,0.7466967376375572,1,True,0.7902777169265246,1,1,0.76828563,1
NCT02106416,Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development,Development of a Novel Technique for PET/MRI Tracer Kinetic Analysis for Urologic Pelvic Malignancy,COMPLETED,,INTERVENTIONAL,21.0,ACTUAL,2013-08-01,2016-04-01,NYU Langone Health,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,PET/MRI,"Prostate Cancer, Bladder Cancer",,,,,False,974.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,21.0,3.091042453358316,0,0,0.6,True,True,0.5612650814968305,1,True,0.6637514394613133,1,1,0.72869605,1
NCT01268280,Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis,"A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy",TERMINATED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2010-12-01,2012-10-01,Cytokinetics,INDUSTRY,RANDOMIZED,CROSSOVER,QUADRUPLE,"DRUG, DRUG, DRUG","Placebo, 250 mg CK-2017357, 500 mg CK-2017357",Myasthenia Gravis,,,,,False,670.0,True,False,2.0,True,True,True,3,False,Medium (30-100),0,32.0,3.49650756146648,3,0,0.58,False,False,0.4531928124889496,1,False,0.454583355149791,1,0,0.44172552,1
NCT02831192,Microtransplantation in Older Patients With Acute Myeloid Leukemia,International Multi-center Clinical Study on Microtransplantation for Treatment of Newly Diagnosed Elderly Acute Myeloid Leukemia (EAML),COMPLETED,PHASE2,INTERVENTIONAL,150.0,ACTUAL,2006-05-01,2015-07-01,The Affiliated Hospital of the Chinese Academy of Military Medical Sciences,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,microtransplantation,Acute Myeloid Leukemia,,,,,False,3348.0,True,False,2.0,False,False,False,1,True,Large (100-300),0,150.0,5.017279836814924,0,1,0.58,True,True,0.8269476716334618,1,True,0.8958347670934553,1,1,0.87767816,1
NCT00020943,Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma,A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,79.0,ACTUAL,2001-06-01,2009-09-01,Alliance for Clinical Trials in Oncology,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","filgrastim, rituximab, carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation",Lymphoma,,,,,False,3014.0,True,False,2.0,False,False,False,12,True,Medium (30-100),1,79.0,4.382026634673881,1,0,0.58,True,True,0.7777831991818456,1,True,0.895343617714955,1,1,0.9185539,1
NCT02122380,The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome,The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome,COMPLETED,PHASE4,INTERVENTIONAL,23.0,ACTUAL,2016-02-01,2019-08-01,Vanderbilt University,OTHER,RANDOMIZED,CROSSOVER,TRIPLE,"DRUG, DRUG","Sitagliptin, Placebo",Polycystic Ovary Syndrome,,,,,False,1277.0,True,False,4.0,True,True,False,2,True,Small (<30),0,23.0,3.1780538303479458,3,0,0.7,True,False,0.313100152782664,0,False,0.47001373016247494,0,1,0.59469986,1
NCT00611650,Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia,Phase II Trial of Polyphenon E in Current and Former Smokers With Bronchial Dysplasia,TERMINATED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2006-10-01,2011-07-01,British Columbia Cancer Agency,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, OTHER","defined green tea catechin extract, placebo","Lung Cancer, Precancerous Condition, Tobacco Use Disorder",,,,,False,1734.0,True,False,2.0,True,True,False,2,False,Small (<30),0,23.0,3.1780538303479458,3,0,0.58,False,False,0.4282254505811681,1,False,0.4817845666043038,1,0,0.46015483,1
NCT06140836,A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3),"Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,190.0,ESTIMATED,2023-12-21,2027-03-15,Bristol-Myers Squibb,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Repotrectinib, Crizotinib","Carcinoma, Non-Small-Cell Lung",,,,,False,1180.0,False,False,3.0,True,False,True,2,True,Large (100-300),1,190.0,5.25227342804663,2,1,0.77,True,True,0.598532400195134,1,True,0.5975044402300886,1,0,0.4163273,0
NCT00188526,Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration,CT Guided Lung Biopsy: Core or Fine Needle Aspiration,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2005-09-01,2006-09-01,"University Health Network, Toronto",OTHER,RANDOMIZED,SINGLE_GROUP,NONE,DEVICE,lung biopsy,Lung Cancer,,,,,False,365.0,True,False,-1.0,True,False,False,1,False,,0,0.0,0.0,1,0,0.6,False,False,0.026572631338221544,1,False,0.005038167862829057,1,0,0.002435838,1
NCT03931356,Follow-up of Pulmonary Radiotoxicity for Bronchopulmonary Cancer.,Follow-up of Pulmonary Toxicity by Respiratory Functional Tests of Patients Treated With Dynamic Cancer ARCtherapy for Bronchopulmonary Cancer.,COMPLETED,,OBSERVATIONAL,39.0,ACTUAL,2019-01-14,2022-10-15,"University Hospital, Brest",OTHER,,,,OTHER,Pulmonary function tests,"Cancer, Lung, Radiotherapy; Complications",,,,,False,1370.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,39.0,3.688879454113936,0,0,0.6,True,True,0.7256184351806654,1,True,0.7053987258206091,1,1,0.6176718,1
NCT01525550,A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,"A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS",COMPLETED,PHASE4,INTERVENTIONAL,106.0,ACTUAL,2012-06-06,2018-07-26,Pfizer,INDUSTRY,,,NONE,DRUG,sunitinib,Well-differentiated Pancreatic Neuroendocrine Tumor,,,,,False,2241.0,True,False,4.0,False,False,True,1,True,Large (100-300),1,106.0,4.672828834461906,0,1,0.7,True,True,0.6347504038200965,1,True,0.8458368372706444,1,1,0.90731007,1
NCT06111872,Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.,Combination Use of Intravenous Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography ; A Randomized Control Trial,COMPLETED,PHASE2,INTERVENTIONAL,90.0,ACTUAL,2023-07-18,2024-10-25,National University of Malaysia,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG, DRUG","Ketamine, Midazolam, Pethidin","Cholangitis, Pancreatic Cancer, Choledocholithiasis, Choledochal Cyst",,,,,False,465.0,True,False,2.0,True,False,False,3,True,Medium (30-100),0,90.0,4.51085950651685,2,0,0.58,True,True,0.6725784454943703,1,True,0.6679930569519205,1,1,0.70199436,1
NCT02080078,A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,"A Phase I, Single-center, Non-randomized, Open-label Study to Determine the Lowest Effective Theophylline Dose That Decreased Erlotinib's Diarrhea at the Standard Dose of 150 mg/Day and to Determine the Highest Erlotinib Dose in Combination With Theophylline That Can be Administered to Patients",TERMINATED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2014-09-01,2019-04-30,AHS Cancer Control Alberta,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Theophylline, Erlotinib","Non-small Cell Lung Cancer, Advanced Solid Malignancies",,,,,False,1702.0,True,False,1.0,False,False,False,2,False,Small (<30),1,15.0,2.772588722239781,1,0,0.56,False,False,0.4042493428201124,1,True,0.5052416631020684,0,1,0.5144524,0
NCT04108208,A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",ACTIVE_NOT_RECRUITING,PHASE4,INTERVENTIONAL,75.0,ACTUAL,2019-12-17,2026-06-05,"Janssen Research & Development, LLC",INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","Apalutamide, Placebo, Androgen-deprivation Therapy (ADT)",Prostatic Neoplasms,,,,,False,2362.0,False,False,4.0,True,True,True,3,True,Medium (30-100),1,75.0,4.330733340286331,3,0,0.7,True,True,0.6508077394130422,1,True,0.7824864527460135,1,1,0.93470573,1
NCT03941665,Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,Double Blind Study - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,136.0,ACTUAL,2019-03-25,2020-05-03,Sheba Medical Center,OTHER_GOV,RANDOMIZED,PARALLEL,DOUBLE,"DEVICE, OTHER","Gelronate, Aloevera",Radiation Dermatitis,,,,,False,405.0,True,False,-1.0,True,True,False,2,True,Large (100-300),0,136.0,4.919980925828125,3,1,0.6,True,True,0.6849665878594093,1,True,0.909458792104539,1,1,0.93472767,1
NCT06069778,"Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma","A Phase I/Randomized Phase II, Open-label Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma",TERMINATED,PHASE1,INTERVENTIONAL,1.0,ACTUAL,2024-03-27,2024-09-18,BioNTech SE,INDUSTRY,RANDOMIZED,SEQUENTIAL,SINGLE,"DRUG, DRUG, DRUG, DRUG","BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX, BNT321 RP2D",Pancreatic Cancer,,,,,False,175.0,True,False,1.0,True,False,True,4,False,Small (<30),0,1.0,0.6931471805599453,2,0,0.56,False,False,0.03436117180594781,1,False,0.05588565551479112,1,0,0.0441647,1
NCT00004052,Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia,"Phase II, Multicenter Vaccination of Patients With Chronic Myelogenous Leukemia With a Multivalent Tumor Specific Breakpoint Peptide Vaccine",COMPLETED,PHASE2,INTERVENTIONAL,24.0,ESTIMATED,1999-03-01,2005-08-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,"BIOLOGICAL, BIOLOGICAL","QS21, bcr-abl peptide vaccine",Leukemia,,,,,False,2345.0,True,False,2.0,False,False,False,2,True,Small (<30),0,24.0,3.218875824868201,1,0,0.58,True,True,0.5264936173454106,1,True,0.6273392778439753,1,1,0.6641585,1
NCT05399160,Effect of Nurse-led Supportive Care on Quality of Life,"Effect of Nurse-led Supportive Care on Quality of Life in Women With Breast Cancer: An Assessor-blinded, Parallel Group, Randomized Controlled Trial",COMPLETED,,INTERVENTIONAL,42.0,ACTUAL,2022-01-03,2022-06-10,Izmir Bakircay University,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Nurse-led Supportive Care,Quality of Life,,,,,False,158.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,1,0,0.6,True,True,0.6100922787514808,1,True,0.9014362061909176,1,1,0.9116688,1
NCT03346135,Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma,"A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,31.0,ACTUAL,2019-07-17,2026-07-01,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, BIOLOGICAL, OTHER, DRUG","Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis, Melphalan","Plasma Cell Myeloma, Secondary Amyloidosis",,,,,False,2541.0,False,False,2.0,False,False,False,4,True,Medium (30-100),1,31.0,3.4657359027997265,1,0,0.58,True,True,0.5850764661805504,1,True,0.7748094054760659,1,1,0.8322101,1
NCT00379197,Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer,"Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer",TERMINATED,PHASE2,INTERVENTIONAL,13.0,ACTUAL,2006-07-01,2013-05-01,"Masonic Cancer Center, University of Minnesota",OTHER,,SINGLE_GROUP,NONE,"DRUG, PROCEDURE","naltrexone, PET scan",Breast Cancer,,,,,False,2496.0,True,False,2.0,False,False,False,2,False,Small (<30),0,13.0,2.6390573296152584,1,0,0.58,False,False,0.37974253052305107,1,False,0.39320832032873504,1,0,0.42100123,1
NCT02206360,Pancreatic Cancer Early Detection Program,Observational Study to Analyze the Outcomes of Subjects Who - Based Upon Their Sufficiently Elevated Risk for the Development of Pancreatic Adenocarcinoma- Elect to Undergo Early Detection Testing,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,100.0,ESTIMATED,2014-04-01,2024-06-01,White Plains Hospital,OTHER,,,,"PROCEDURE, PROCEDURE","Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)","Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer, BRCA 1/2, HNPCC, Lynch Syndrome, Hereditary Pancreatitis, FAMMM, Familial Atypical Multiple Mole Melanoma, Peutz Jeghers Syndrome",,,,,False,3714.0,False,False,-1.0,False,False,False,2,True,Medium (30-100),0,100.0,4.61512051684126,1,1,0.6,True,True,0.7984389016051499,1,True,0.7901049564871115,1,1,0.79947454,1
NCT05118724,Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin,Perioperative/Adjuvant Atezolizumab in Patients With MSI-high or MMR-deficient Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin-based Chemotherapy - a Phase II Study,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,80.0,ESTIMATED,2021-12-10,2027-04-01,AIO-Studien-gGmbH,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Atezolizumab, IMM-101",Colorectal Cancer,,,,,False,1938.0,False,False,2.0,True,False,False,2,True,Medium (30-100),1,80.0,4.394449154672439,2,0,0.58,True,True,0.7103532187515784,1,True,0.7741374219866707,1,1,0.82962006,1
NCT02068677,Evaluation of Injection Techniques in Celiac Plexus Neurolysis,Evaluation of Injection Techniques in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN),COMPLETED,,INTERVENTIONAL,51.0,ACTUAL,2013-08-01,2014-11-01,AdventHealth,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"OTHER, OTHER","Sympathetic response, no sympathetic response","Pancreatic Cancer, Pain",,,,,False,457.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,51.0,3.951243718581428,1,0,0.6,True,True,0.7014966393047214,1,True,0.768816236884468,1,1,0.7586382,1
NCT02973672,"Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas","A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer",COMPLETED,PHASE1,INTERVENTIONAL,75.0,ACTUAL,2016-01-01,2019-05-01,Surgimab,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SGM-101,"Colon Cancer, Rectum Cancer, Pancreas Cancer, Metastatic Colorectal Cancer, Recurrent Colorectal Carcinoma",,,,,False,1216.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,75.0,4.330733340286331,0,0,0.56,True,True,0.8050003239852328,1,True,0.6653673719394811,1,1,0.74948686,1
NCT02617485,MabionCD20 Compared to MabThera in Lymphoma Patients,"Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma",COMPLETED,PHASE3,INTERVENTIONAL,143.0,ACTUAL,2015-12-01,2018-01-01,Mabion SA,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG, DRUG","Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, prednisone",Diffuse Large B-Cell Lymphoma,,,,,False,762.0,True,False,3.0,True,True,True,5,True,Large (100-300),1,143.0,4.969813299576001,3,1,0.77,True,True,0.5237455001745251,1,False,0.45124618618672796,0,0,0.34412098,0
NCT00602420,Prevention of Pegfilgrastim-Induced Bone Pain (PIBP),Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial,COMPLETED,PHASE3,INTERVENTIONAL,510.0,ACTUAL,2008-06-01,2012-03-01,Gary Morrow,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, OTHER","naproxen, placebo","Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1369.0,True,False,3.0,True,True,False,2,True,Very Large (300+),0,510.0,6.236369590203704,3,1,0.77,True,True,0.8151740611424005,1,True,0.8234191583161369,1,1,0.84502554,1
NCT00414336,Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria,"Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults",COMPLETED,PHASE1,INTERVENTIONAL,150.0,,2006-12-15,2006-12-15,National Institute of Allergy and Infectious Diseases (NIAID),NIH,RANDOMIZED,PARALLEL,DOUBLE,DRUG,AMA1-C1/Alhydrogel + CPG 7909 Vaccine,Malaria,,,,,False,0.0,True,False,1.0,True,True,False,1,True,Large (100-300),0,150.0,5.017279836814924,2,1,0.56,True,True,0.6888701399211,1,True,0.880511040886342,1,1,0.9789013,1
NCT04855448,Evaluation of the Learning Curve in Low Anterior Resection for Rectal Resection With the Two Surgical Robots,"Accelerated Learning Curve in Low Anterior Resection for Rectal Resection, a New Surgical Robot Micro Hand S Versus da Vinci, Can be Attained Simultaneously: a Single Center Experience",COMPLETED,,INTERVENTIONAL,112.0,ACTUAL,2017-05-01,2019-10-31,The Third Xiangya Hospital of Central South University,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,"DEVICE, DEVICE","Micro Hand S robot and da Vinci robot, da Vinci robot",Rectal Cancer,,,,,False,913.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,112.0,4.727387818712341,1,1,0.6,True,True,0.7129002512343144,1,True,0.8632799395628584,1,1,0.87827164,1
NCT00704912,Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women,Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women,COMPLETED,PHASE2,INTERVENTIONAL,217.0,ACTUAL,2008-09-01,2014-03-01,Milton S. Hershey Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments",Polycystic Ovary Syndrome,,,,,False,2007.0,True,False,2.0,True,False,False,3,True,Large (100-300),0,217.0,5.384495062789089,2,1,0.58,True,True,0.7444633149626947,1,True,0.876415980914707,1,1,0.8859133,1
NCT01164150,Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06,Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer,TERMINATED,PHASE2,INTERVENTIONAL,92.0,ACTUAL,2010-03-01,2020-03-13,Cancer Trials Ireland,NETWORK,RANDOMIZED,PARALLEL,NONE,RADIATION,45 Gy/25 fractions,"Endometrial Cancer, Gastrointestinal Complications, Radiation Toxicity, Urinary Complications",,,,,False,3665.0,True,False,2.0,True,False,False,1,False,Medium (30-100),0,92.0,4.532599493153256,1,0,0.58,False,True,0.8371542969193294,0,True,0.7867007745104891,0,1,0.7610216,0
NCT01340755,Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer,A Pilot Study of Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer,COMPLETED,,INTERVENTIONAL,5.0,ACTUAL,2011-03-01,2017-05-01,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Transanal endoscopic surgery,Adenocarcinoma of the Rectum,,,,,False,2253.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.6,True,False,0.28902772305939406,0,False,0.3205318502730447,0,0,0.3200545,0
NCT02647398,Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue,Randomized Study Comparing Two Strategies of Physical Activity in Long-term Breast and Colon Cancer Survivors and Their Impact on Fatigue,COMPLETED,,INTERVENTIONAL,32.0,ACTUAL,2016-01-01,2017-09-01,Puerta de Hierro University Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Vigorous aerobic training,"Neoplasms, Fatigue",,,,,False,609.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,32.0,3.49650756146648,1,0,0.6,True,True,0.5640715460120227,1,True,0.8428424568299839,1,1,0.75191647,1
NCT03778658,Utilizing Novel Information Technology to Promote Exercise and Well-Being in Adolescents and Young Adults With Cancer,AYA-UNITE (Utilizing Novel Information Technology to Promote Exercise and Well-Being),COMPLETED,,INTERVENTIONAL,7.0,ACTUAL,2020-12-15,2022-09-01,Milton S. Hershey Medical Center,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Physical Activity Intervention,"Adolescent, Young Adult, Cancer, Physical Activity, Psychological Distress, Social Isolation",,,,,False,625.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,7.0,2.079441541679836,0,0,0.6,True,False,0.28388707254014706,0,False,0.3551840952266307,0,0,0.32129353,0
NCT01633541,Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer,COMPLETED,PHASE2,INTERVENTIONAL,55.0,ACTUAL,2012-03-01,2021-11-06,University of Michigan Rogel Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","AT-101, Docetaxel, Cisplatin, Carboplatin",Laryngeal Cancer,,,,,False,3537.0,True,False,2.0,True,False,False,4,True,Medium (30-100),1,55.0,4.02535169073515,2,0,0.58,True,True,0.6898558218826868,1,True,0.8636169890476794,1,1,0.89426917,1
NCT03349957,TACE for HCC by TANDEM and Idarubicin,Retrospective Study on TACE for HCC by TANDEM and Idarubicin,COMPLETED,,OBSERVATIONAL,98.0,ACTUAL,2017-12-01,2018-03-30,"University Hospital, Montpellier",OTHER,,,,DRUG,Transarterial chemoembolization using TANDEM and idarubicin,Hepatocellular Carcinoma (HCC),,,,,False,119.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),1,98.0,4.59511985013459,0,0,0.6,True,True,0.8377188013795577,1,True,0.838845835097232,1,1,0.8861283,1
NCT03355079,Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy,"Efficacy of Long-term Parenteral Nutrition With SmofKabiven® E Concomitant to Chemo- and/or Immunotherapy: A Prospective, Randomised, Controlled, Open, Multicentre, Two-stage, Adaptive Clinical Trial in Metastatic Non-small Cell Lung Cancer",TERMINATED,PHASE4,INTERVENTIONAL,2.0,ACTUAL,2018-02-28,2019-04-05,Fresenius Kabi,INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,SmofKabiven® E,Cancer-related Malnutrition,,,,,False,401.0,True,False,4.0,True,False,True,1,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.7,False,False,0.04111927315346226,1,False,0.040089776251380584,1,0,0.027814744,1
NCT06293508,mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public,mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public,TERMINATED,,INTERVENTIONAL,1180.0,ACTUAL,2024-04-30,2024-10-04,"Clinical Research Centre, Malaysia",OTHER,RANDOMIZED,PARALLEL,DOUBLE,"BEHAVIORAL, BEHAVIORAL","Standard Health Communication Intervention, Behavioural Change Health Communication Intervention",Breast Neoplasm Female,,,,,False,157.0,True,False,-1.0,True,True,False,2,False,Very Large (300+),0,1180.0,7.074116816197362,3,1,0.6,False,True,0.922423140911986,0,True,0.9217502337704911,0,1,0.97207445,0
NCT02215733,The Use of Angiotensin Receptor Blockers and the Risk of Cancer,The Use of Angiotensin Receptor Blockers and the Risk of Cancer,COMPLETED,,OBSERVATIONAL,1165781.0,ACTUAL,2011-02-01,,Boehringer Ingelheim,INDUSTRY,,,,"DRUG, DRUG, DRUG, DRUG, DRUG","ARB, ACEI, Beta-blockers, Diuretics, Telmisartan",Neoplasm,,,,,False,1303.0,True,False,-1.0,False,False,True,5,True,Very Large (300+),0,5757.019999999997,8.658348944594362,1,1,0.6,True,True,0.8754717401456337,1,True,0.8992699934502469,1,1,0.9565718,1
NCT05521594,Accuracy of FNAC in Thyroid Nodules Compared to to Surgical Specimen : QOC Experience,Accuracy of FNAC in Thyroid Nodules Compared to to Surgical Specimen : QOC Experience,COMPLETED,,INTERVENTIONAL,86.0,ACTUAL,2021-01-01,2022-07-31,Qena Oncology Center,OTHER_GOV,RANDOMIZED,SINGLE_GROUP,NONE,PROCEDURE,Fine Needle Aspiration Cytology,"Fine Needle Aspiration Cytology, Thyroid Diseases",,,,,False,576.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,86.0,4.465908118654584,1,0,0.6,True,True,0.7825060588266348,1,True,0.7892107018412696,1,1,0.8444812,1
NCT06959849,"Robot-assisted Surgery for Colorectal Cancer Resection: A Population-based Analysis of Prevalence, Trends and Outcomes","Robot-assisted Surgery for Colorectal Cancer Resection: A Population-based Analysis to Ascertain the Prevalence, Trends and Quality of Short- and Long-term Outcomes in Comparison With Laparoscopic Surgery.",ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,128000.0,ESTIMATED,2016-01-01,2026-02-28,Medizinische Hochschule Brandenburg Theodor Fontane,OTHER,,,,DEVICE,Use of robot surgical system,"Colorectal Cancer (CRC), Robotic Surgical Procedures, Laparoscopic Abdominal Surgery, Outcome Assessment",,,,,False,3711.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9382628693511905,1,True,0.9570994652775572,1,1,0.9721887,1
NCT01254929,F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases,"18F-Fluoride PET Bone Scans Versus Traditional 99mTc-MDP Gamma Camera Bone Scans for the Diagnosis of Bone Metastases: a Blinded, Prospective Trial",COMPLETED,,OBSERVATIONAL,299.0,ACTUAL,2010-12-01,2020-03-01,Seattle Nuclear Medicine,OTHER,,,,"DEVICE, DEVICE","F-18 PET bone scan, Tc-99m bone scan","Cancer, Bone Metastases",,,,,False,3378.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,299.0,5.703782474656201,1,1,0.6,True,True,0.91547358053232,1,True,0.8489862842033622,1,1,0.8469012,1
NCT02674555,"A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors","A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors Harboring Epidermal Growth Factor Receptor (EGFR) Mutations",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-11-15,2016-11-15,"Astellas Pharma Global Development, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","radio-labeled naquotinib, naquotinib","Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors",,,,,False,0.0,True,False,1.0,False,False,True,2,False,,0,0.0,0.0,1,0,0.56,False,False,0.023219836255405402,1,False,0.002752105356193762,1,0,0.0025589422,1
NCT01453205,"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL,COMPLETED,PHASE2,INTERVENTIONAL,187.0,ACTUAL,2012-02-27,2016-07-11,MedImmune LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, PROCEDURE, DRUG","MEDI-551 2 mg/kg, Rituximab, ICE, DHAP, Autologous Stem Cell Transplant (ASCT), MEDI-551 4 mg/kg",Diffuse Large B-Cell Lymphoma,,,,,False,1596.0,True,False,2.0,True,False,True,6,True,Large (100-300),1,187.0,5.236441962829949,2,1,0.58,True,True,0.6790367098828479,1,True,0.7778677513863869,1,1,0.87092745,1
NCT00208546,"Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer","Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study",COMPLETED,PHASE3,INTERVENTIONAL,750.0,ACTUAL,2005-06-01,2009-12-01,Dutch Colorectal Cancer Group,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab",Colorectal Cancer,,,,,False,1644.0,True,False,3.0,True,False,False,2,True,Very Large (300+),1,750.0,6.621405651764134,2,1,0.77,True,True,0.8414144243827253,1,True,0.8386144270944361,1,1,0.858958,1
NCT00589212,GliaSite 1-3 Mets Study,A Phase II Study Utilizing Focal Radiation in Patients With 1-3 Brain Metastases,COMPLETED,PHASE2,INTERVENTIONAL,50.0,ESTIMATED,2003-10-01,2008-03-01,"Hologic, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DEVICE,GliaSite Radiation Therapy System,Brain Metastases,,,,,False,1613.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.58,True,True,0.7164771849569103,1,True,0.8035489171940623,1,1,0.77636844,1
NCT00080626,Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer,A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer,TERMINATED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2003-08-11,2006-05-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, PROCEDURE, PROCEDURE","pegfilgrastim, docetaxel, conventional surgery, neoadjuvant therapy",Breast Cancer,,,,,False,994.0,True,False,2.0,False,False,False,4,False,Small (<30),1,19.0,2.995732273553991,1,0,0.58,False,False,0.38090848755801127,1,False,0.3386757216258773,1,0,0.3199175,1
NCT06386653,Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1,SPECT Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 in Lung and Ovarian Cancers Patients,COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2024-04-14,2024-12-31,Tomsk National Research Medical Center of the Russian Academy of Sciences,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,"DRUG, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Diagnostic injection of [123I]I-DARPIN-Ec1, Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1, Whole-body SPECT with [123I]I-DARPIN-Ec1","Lung Cancer, Ovarian Cancer",,,,,False,261.0,True,False,1.0,False,False,False,3,True,Small (<30),0,10.0,2.3978952727983707,1,0,0.56,True,False,0.25216659387880586,0,False,0.3111109511122732,0,0,0.18589121,0
NCT00361049,Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant,Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial,COMPLETED,PHASE1,INTERVENTIONAL,49.0,ACTUAL,2004-09-01,2010-11-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, GENETIC, OTHER, OTHER, OTHER, PROCEDURE, PROCEDURE","graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications",Cancer,,,,,False,2252.0,True,False,1.0,False,False,False,7,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.56,True,True,0.7067272455146418,1,True,0.8456698933380471,1,1,0.84777147,1
NCT05791097,Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.,"AdvanTIG-306: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118/BGB-A1217) Combined With Tislelizumab (VDT482/BGB-A317) Plus Platinum-based Doublet Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Platinum-based Doublet Chemotherapy as First-line Therapy for Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",WITHDRAWN,PHASE3,INTERVENTIONAL,0.0,ACTUAL,2023-07-28,2027-12-26,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Ociperlimab, Placebo, Tislelizumab, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel",Non-small Cell Lung Cancer (NSCLC),,,,,False,1612.0,True,False,3.0,True,True,True,9,False,,1,0.0,0.0,3,0,0.77,False,False,0.013228666952743245,1,False,0.024718591314160383,1,0,0.002577993,1
NCT06307470,Nurse-led Mind-body Intervention on Sexual Health for Breast Cancer Survivors,Impact of a Nurse-led Mind-body Intervention on Sexual Health for Young Women,COMPLETED,,INTERVENTIONAL,43.0,ACTUAL,2024-10-15,2025-11-30,University of Arkansas,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience),"Women's Health: Neoplasm of Breast, Menopause, Premature, Body Image, Sexual Dysfunction, Cancer, Breast",,,,,False,411.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,43.0,3.784189633918261,1,0,0.6,True,True,0.6283003125285618,1,True,0.8281226231866954,1,1,0.788412,1
NCT02494388,Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions,Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions,TERMINATED,,OBSERVATIONAL,10.0,ACTUAL,2015-06-01,2017-06-01,University of Medicine and Pharmacy Craiova,OTHER,,,,PROCEDURE,Endoscopic ultrasound guided needle based confocal endomicroscopy,"Pancreatic Cysts, Pancreatic Mucinous-Cystic Neoplasm, Intraductal Papillary Mucinous Neoplasm, Solid Pseudopapillary Tumour of the Pancreas, Cystadenocarcinoma, Serous Cystadenoma",,,,,False,731.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,False,False,0.3643717735616566,1,True,0.5436004806383931,0,1,0.53538936,0
NCT00991263,Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741,Intrinsic Breast Cancer Subtypes and Benefit of Paclitaxel in CALGB 9344 and Dose Dense Therapy in CALGB 9741,COMPLETED,,OBSERVATIONAL,3677.0,ESTIMATED,2009-04-01,2012-02-01,Alliance for Clinical Trials in Oncology,OTHER,,,,"GENETIC, GENETIC, OTHER","gene expression analysis, polymerase chain reaction, laboratory biomarker analysis",Breast Cancer,,,,,False,1036.0,True,False,-1.0,False,False,False,3,True,Very Large (300+),0,3677.0,8.210124405164267,1,1,0.6,True,True,0.9342605570657436,1,True,0.9171794070772864,1,1,0.955503,1
NCT04855136,Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma,"An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)",TERMINATED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,2021-06-01,2025-04-25,Celgene,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG","BB2121, CC-220, BMS-986405",Multiple Myeloma,,,,,False,1424.0,True,False,1.0,False,False,True,3,False,Small (<30),0,21.0,3.091042453358316,1,0,0.56,False,False,0.47679575514963746,1,False,0.3803746113426638,1,0,0.34126756,1
NCT05067777,Massage for Prostate Cancer-Related Fatigue (mPROSTATE),Massage for Prostate Cancer-Related Fatigue (mPROSTATE),TERMINATED,PHASE2,INTERVENTIONAL,28.0,ACTUAL,2022-06-17,2025-08-02,University of Utah,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, PROCEDURE, OTHER","Swedish Massage Therapy (SMT), Light Touch (LT) Control, Waitlist Control (WLC)",Prostate Carcinoma,,,,,False,1142.0,True,False,2.0,True,True,False,3,False,Small (<30),0,28.0,3.367295829986474,3,0,0.58,False,False,0.44309100708170857,1,False,0.4675925300839214,1,0,0.48019037,1
NCT06575361,Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis,Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis: a Real-World Prospective Diagnostic Study,COMPLETED,,INTERVENTIONAL,365.0,ACTUAL,2024-01-01,2025-08-31,Peking University First Hospital,OTHER,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,Combination of targeted biopsy and systematic biopsy,Prostate Cancer,,,,,False,608.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,365.0,5.902633333401366,0,1,0.6,True,True,0.8996507987966832,1,True,0.8688541090542345,1,1,0.92045724,1
NCT01477489,Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer,A Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,33.0,ACTUAL,2012-01-01,2017-10-01,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","Veliparib, Standard radiation treatment",Breast Cancer,,,,,False,2100.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,33.0,3.5263605246161616,1,0,0.56,True,True,0.6312882875197537,1,True,0.778410537621282,1,1,0.7595786,1
NCT01581944,Gonadotropin-releasing Hormone Agonist Prior to Myomectomy,Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.,COMPLETED,PHASE3,INTERVENTIONAL,68.0,ACTUAL,2008-01-01,2011-12-01,Mt. Hope Maternity Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG","2 Doses Goserelin, 3 Doses Goserelin",Fibroids,,,,,False,1430.0,True,False,3.0,True,False,False,2,True,Medium (30-100),0,68.0,4.23410650459726,2,0,0.77,True,True,0.5720119794246012,1,True,0.6393071650495681,1,1,0.5858011,1
NCT04481113,Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer,A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2021-06-07,2025-06-20,OHSU Knight Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Abemaciclib, Niraparib Tosylate Monohydrate","Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma",,,,,False,1474.0,True,False,1.0,False,False,False,2,True,Small (<30),1,8.0,2.19722457733622,1,0,0.56,True,False,0.25715039015803404,0,False,0.41486175430324257,0,0,0.49110445,0
NCT00003912,Chemotherapy in Treating Children With Liver Cancer,Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma,COMPLETED,PHASE3,INTERVENTIONAL,260.0,ESTIMATED,1998-06-01,2009-10-01,Societe Internationale d'Oncologie Pediatrique,OTHER,RANDOMIZED,,,"DRUG, DRUG, DRUG, PROCEDURE","carboplatin, cisplatin, doxorubicin hydrochloride, conventional surgery",Liver Cancer,,,,,False,4140.0,True,False,3.0,True,False,False,4,True,Large (100-300),1,260.0,5.564520407322694,2,1,0.77,True,True,0.7816618258348836,1,True,0.8855809605913062,1,1,0.9420488,1
NCT00112112,Safety Study to Evaluate FluMist in Immunocompromised Children,"A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age",COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2005-08-01,2008-05-01,MedImmune LLC,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"BIOLOGICAL, BIOLOGICAL","FluMist, Placebo",Cancer,,,,,False,1004.0,True,False,1.0,True,True,True,2,True,Small (<30),0,20.0,3.044522437723423,3,0,0.56,True,False,0.39316727110370225,0,True,0.5570487132094852,1,1,0.7102451,1
NCT01827813,Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies,Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies,COMPLETED,,INTERVENTIONAL,74.0,ACTUAL,2007-06-01,2013-02-01,TC Erciyes University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE, PROCEDURE","Transrectal prostate biopsy with ultrasonography., Periprostatic block, Sedoanalgesia",Prostate Cancer,,,,,False,2072.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,74.0,4.31748811353631,1,0,0.6,True,True,0.8259894614400697,1,True,0.8243632811701467,1,1,0.74422777,1
NCT00337259,Gemcitabine for Marginal Zone Lymphoma,Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma,TERMINATED,PHASE2,INTERVENTIONAL,43.0,ACTUAL,2006-06-01,2009-03-01,Asan Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,gemcitabine,"Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma",,,,,False,1004.0,True,False,2.0,False,False,False,1,False,Medium (30-100),1,43.0,3.784189633918261,0,0,0.58,False,True,0.6489767776538488,0,True,0.8046370081175332,0,1,0.78584987,0
NCT03927027,Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection,ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,534.0,ACTUAL,2019-07-29,2027-01-01,Alliance for Clinical Trials in Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE, PROCEDURE, OTHER, OTHER","Isosulfan Blue, Axillary Lymph Node Dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration","Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III",,,,,False,2713.0,False,False,3.0,True,False,False,5,True,Very Large (300+),0,534.0,6.282266746896006,2,1,0.77,True,True,0.8337401415378348,1,True,0.9330844086007322,1,1,0.946698,1
NCT01184027,Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment,Impact of Nutrition and Swallowing Function in a Randomized Controlled Trial of Head and Neck Cancer Patients During the Course of Treatment,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2010-10-01,2011-10-01,University of Alberta,OTHER,,,,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","nutrition /swallowing counseling, G-tube/swallowing intervention, nutrition /swallowing intervention","Head and Neck Cancer, Surgery, Nutrition, Swallowing",,,,,False,365.0,True,False,-1.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.6,False,False,0.02989536844666939,1,False,0.005267446372269683,1,0,0.0021270106,1
NCT05941585,Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia,"A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection Combined With Chemotherapy in Previously Untreated de Novo Acute Myeloid Leukemia",COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2023-08-08,2025-01-17,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Mitoxantrone hydrochloride liposome injection30mg/m2, HomoharringtonineD1-D7(2mg/m2/day), Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day), Cytarabine(standard-dose:d1-d7100mg/m2/day), Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2), Mitoxantrone hydrochloride liposome injection24mg/m2",Acute Myeloid Leukemia,,,,,False,528.0,True,False,-1.0,True,False,False,6,True,Medium (30-100),1,60.0,4.110873864173311,2,0,0.6,True,True,0.6406912963492385,1,True,0.6032676887278913,1,1,0.59451044,1
NCT00008008,Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma,"CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy",COMPLETED,PHASE2,INTERVENTIONAL,40.0,ESTIMATED,1997-09-01,2008-05-01,Herbert Irving Comprehensive Cancer Center,OTHER,,,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, PROCEDURE, PROCEDURE, PROCEDURE","filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation",Brain and Central Nervous System Tumors,,,,,False,3895.0,True,False,2.0,False,False,False,7,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.58,True,True,0.6963287496397801,1,True,0.9205295903253164,1,1,0.94344264,1
NCT04134468,MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma,UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2020-01-01,2022-11-11,Abramson Cancer Center at Penn Medicine,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Pegvorhyaluronidase alfa, Abraxane, Gemcitabine",Pancreatic Ductal Adenocarcinoma,,,,,False,1045.0,True,False,2.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.58,False,False,0.023615632944364223,1,False,0.008044675675556162,1,0,0.0033940696,1
NCT01682811,Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1),"Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light",COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2012-03-12,2016-07-07,"Harry T Whelan, MD",OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3",Neurofibromatoses,,,,,False,1578.0,True,False,1.0,False,False,False,7,True,Small (<30),0,20.0,3.044522437723423,1,0,0.56,True,False,0.45183981250760774,0,False,0.49574421710650995,0,1,0.68866557,1
NCT04135521,Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer,Far Eastern Memorial Hospital,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2019-10-28,2020-03-31,Far Eastern Memorial Hospital,OTHER,,,,DRUG,Intraperitoneal chemotherapy,Advanced Ovarian Cancer,,,,,False,155.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.726933392554523,1,True,0.9031888162996359,1,1,0.8754736,1
NCT00872014,A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer,Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2009-08-01,2015-06-01,Amgen,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","AMG 386, AMG 386, Sorafenib","Advanced Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma",,,,,False,2130.0,True,False,2.0,False,False,True,3,True,Medium (30-100),1,60.0,4.110873864173311,1,0,0.58,True,True,0.7246795559506709,1,True,0.9220266750280502,1,1,0.93554235,1
NCT01727011,Single Fraction Elderly Breast Irradiation (SiFEBI),A Phase I-II Trial Evaluating the Toxicity of Early Breast Partial Irradiation in Patients Aged at Least of 70 Years With Breast Cancer at Low Risk of Local Recurrence,COMPLETED,,INTERVENTIONAL,37.0,ACTUAL,2012-11-01,2015-11-01,Centre Antoine Lacassagne,OTHER,,SINGLE_GROUP,NONE,RADIATION,IPAS,Breast Cancer,,,,,False,1095.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.6,True,True,0.7027234452399871,1,True,0.6797456797552622,1,1,0.6166387,1
NCT01338753,Study to Evaluate Markers of Response in Locally Advanced Breast Cancer,"A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy",COMPLETED,PHASE2,INTERVENTIONAL,74.0,ACTUAL,2009-10-01,2011-05-01,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,,SINGLE_GROUP,NONE,OTHER,"Bevacizumab, docetaxel and doxorubicin followed by surgery",Breast Neoplasms,,,,,False,577.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,74.0,4.31748811353631,0,0,0.58,True,True,0.7486236266644144,1,True,0.7108212316840148,1,1,0.7465621,1
NCT01005043,Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma,Phase I/II Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma,COMPLETED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2010-12-01,2019-10-01,University Hospital Heidelberg,OTHER,,SINGLE_GROUP,NONE,RADIATION,heavy ion radiotherapy (C12),Osteosarcoma,,,,,False,3226.0,True,False,1.0,False,False,False,1,True,Small (<30),0,23.0,3.1780538303479458,0,0,0.56,True,True,0.6467837885522515,1,True,0.7357063249146313,1,1,0.8285019,1
NCT00952081,A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients,A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients,COMPLETED,PHASE4,INTERVENTIONAL,22.0,ACTUAL,2009-07-01,2010-02-01,NYU Langone Health,OTHER,,SINGLE_GROUP,NONE,DRUG,Clevidipine,"Hypertension, Brain Tumor, Epilepsy",,,,,False,215.0,True,False,4.0,False,False,False,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.7,True,False,0.34965364383336234,0,True,0.560237948191977,1,1,0.8038665,1
NCT01915524,Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC),"An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor",TERMINATED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2013-04-01,2016-07-01,CureVac,INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, RADIATION","CV9202, local radiation",Non-Small Cell Lung Carcinoma,,,,,False,1187.0,True,False,1.0,False,False,True,2,False,Small (<30),0,26.0,3.295836866004329,1,0,0.56,False,True,0.5248609217212409,0,False,0.4453136978446101,1,0,0.4668724,1
NCT05970250,Effect Of Whole Body Vibration Versus Weight Bearing Exercises On Osteoporosis In Breast Cancer Patients After Chemotherapy,Effect Of Whole Body Vibration Versus Weight Bearing Exercises On Osteoporosis In Breast Cancer Patients After Chemotherapy,COMPLETED,,INTERVENTIONAL,45.0,ACTUAL,2022-01-20,2022-07-20,Cairo University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"OTHER, OTHER, DRUG","Whole body vibration group, Weight bearing exercises, vitamin D supplements and calcium","Osteoporosis, Breast Cancer",,,,,False,181.0,True,False,-1.0,True,True,False,3,True,Medium (30-100),0,45.0,3.828641396489095,3,0,0.6,True,True,0.6039318007794241,1,True,0.9000538895834985,1,1,0.9259166,1
NCT01156454,Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling,Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS),COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2009-11-01,2012-01-01,University of Arkansas,OTHER,,,,PROCEDURE,X-ray,Breast Cancer,,,,,False,791.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5393890512200464,1,True,0.6873291255603386,1,1,0.697174,1
NCT02717962,"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting",Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting,COMPLETED,PHASE2,INTERVENTIONAL,118.0,ACTUAL,2017-01-20,2024-12-30,"Kintara Therapeutics, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,"VAL-083, Dianhydrogalactitol","Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer",,,,,False,2901.0,True,False,2.0,False,False,True,1,True,Large (100-300),0,118.0,4.77912349311153,0,1,0.58,True,True,0.7736585183299737,1,True,0.7335873678815054,1,1,0.8339529,1
NCT06382194,Decision Making Tool for Firearm Storage,Shared Decision Making for Firearm Safety Among Older Adults With Early Changes Associated With Alzheimer's Disease/Alzheimer's Disease-Related Dementias (AD/ADRD),COMPLETED,,INTERVENTIONAL,5.0,ACTUAL,2024-02-14,2024-10-09,University of Washington,OTHER,,SINGLE_GROUP,NONE,OTHER,Decision aid,"Dementia, Mild, Depression",,,,,False,238.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.6,True,False,0.21090636604020166,0,False,0.3036589769823131,0,0,0.40859178,0
NCT04350398,Rehabilitation Through Hippotherapy for the Management of Women After Primary Treatment of Breast Cancer,Effect of Multidisciplinary Management by Hippotherapy on the Quality of Life of Women With a Diagnosis of Breast Cancer: Randomized Controlled Clinical Trial on the Effectiveness of the Therapeutic Intervention,COMPLETED,,INTERVENTIONAL,83.0,ACTUAL,2017-04-20,2022-08-30,Alliance Equiphoria,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","Hippotherapy, Conventional therapy","Breast Cancer Female, Side Effects, Psychological Distress, Physical Disability",,,,,False,1958.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,83.0,4.430816798843313,2,0,0.6,True,True,0.7896947656155351,1,True,0.7022772287933337,1,1,0.7087302,1
NCT04557956,"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2021-08-19,2027-01-23,National Cancer Institute (NCI),NIH,RANDOMIZED,SEQUENTIAL,NONE,"PROCEDURE, PROCEDURE, DRUG, PROCEDURE, PROCEDURE, PROCEDURE, DRUG, DRUG","Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide","Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma",,,,,False,1983.0,False,False,1.0,True,False,False,8,True,Small (<30),1,16.0,2.833213344056216,2,0,0.56,True,False,0.32374216313309195,0,True,0.546278303738882,1,1,0.69987994,1
NCT02144649,Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery,A Comparison of Tangerine and Red Tomato Juice in Men With Prostate Cancer: A Pilot Study,COMPLETED,,INTERVENTIONAL,45.0,ACTUAL,2015-06-01,2016-09-22,Ohio State University Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER, OTHER","dietary intervention (tangerine tomato juice), dietary intervention (red tomato juice), questionnaire administration, Correlative studies","Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer",,,,,False,479.0,True,False,-1.0,True,False,False,4,True,Medium (30-100),0,45.0,3.828641396489095,2,0,0.6,True,True,0.5835403345051413,1,True,0.7335216998177905,1,1,0.7276111,1
NCT01856283,Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells,"An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment",COMPLETED,PHASE2,INTERVENTIONAL,87.0,ACTUAL,2013-03-01,2021-01-01,Niguarda Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Nilotinib 300mg BID,"Leukemia, Myeloid, Chronic-Phase",,,,,False,2863.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,87.0,4.477336814478207,0,0,0.58,True,True,0.8499772807356734,1,True,0.9340964252869769,1,1,0.87977093,1
NCT05691517,Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers,Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,35.0,ESTIMATED,2024-06-12,2026-10-15,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, DRUG","Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12","Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm",,,,,False,855.0,False,False,1.0,False,False,False,4,True,Medium (30-100),0,35.0,3.58351893845611,1,0,0.56,True,True,0.574195688553983,1,True,0.555005034103777,1,1,0.5960057,1
NCT00272558,Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma,Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma,COMPLETED,PHASE2,INTERVENTIONAL,40.0,ESTIMATED,2004-09-01,2009-09-01,"Rigshospitalet, Denmark",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Carboplatin and Vinorelbine,Malignant Pleural Mesothelioma,,,,,False,1826.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,40.0,3.713572066704308,0,0,0.58,True,True,0.6704189379491438,1,True,0.8681246037977697,1,1,0.87298816,1
NCT05116202,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma),"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)",COMPLETED,PHASE1,INTERVENTIONAL,110.0,ACTUAL,2022-02-02,2024-05-28,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tiragolumab, RO7247669 600 mg",Melanoma,,,,,False,846.0,True,False,1.0,True,False,True,6,True,Large (100-300),1,110.0,4.709530201312334,2,1,0.56,True,True,0.5529923183669795,1,True,0.6523787204216172,1,1,0.71754825,1
NCT01987232,"Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer","Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer",COMPLETED,PHASE1,INTERVENTIONAL,32.0,ACTUAL,2013-11-05,2017-05-04,Amgen,INDUSTRY,,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG","Carfilzomib, Carboplatin, Etoposide",Extensive-Stage Small-Cell Lung Cancer,,,,,False,1276.0,True,False,1.0,False,False,True,3,True,Medium (30-100),1,32.0,3.49650756146648,1,0,0.56,True,True,0.5708656854753211,1,True,0.6286673129162403,1,1,0.6611272,1
NCT04156659,Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL,"A Phase II, Single Arm, Multi-center Trial to Evaluate the Efficacy and Safety of Tisagenlecleucel in Chinese Pediatric and Young Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2021-11-30,2027-11-30,Novartis Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,Tisagenlecleucel,B-cell Acute Lymphoblastic Leukemia,,,,,False,2191.0,True,False,2.0,False,False,True,1,False,,0,0.0,0.0,0,0,0.58,False,False,0.03818229666869276,1,False,0.03205448923537517,1,0,0.00402377,1
NCT04697927,A Study of Risk Factors for the COVID-19 Virus Infection,Ascertainment of Epidemiologic Risk Information to Assess Susceptibility to and Severity of SARS-CoV-2 Infection,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,389.0,ACTUAL,2020-12-30,2026-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,OTHER,Questionnaires,COVID-19 Infections in Cancer Patients,,,,,False,2162.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,389.0,5.966146739123692,0,1,0.6,True,True,0.9290591571489776,1,True,0.9141967704109618,1,1,0.9207485,1
NCT02719977,A Phase I Study of CX5461,A Phase I Study of CX5461,COMPLETED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2016-06-13,2023-01-18,Canadian Cancer Trials Group,NETWORK,,SINGLE_GROUP,NONE,DRUG,CX5461,Cancer,,,,,False,2410.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,41.0,3.737669618283368,0,0,0.56,True,True,0.7382842788196795,1,True,0.8195475742763954,1,1,0.8542435,1
NCT02376413,Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients,Prospective Non-randomized Evaluation of Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2015-03-01,2022-12-01,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,,,,"PROCEDURE, DRUG, RADIATION","Breast surgery, Chemotherapy or endocrine therapy or Trastuzumab therapy, Radiation therapy",Local Recurrence of Malignant Tumor of Breast,,,,,False,2832.0,True,False,-1.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.6,False,False,0.047673338757938576,1,False,0.08719444034338593,1,0,0.0039886413,1
NCT00734851,Multimodality Phase II Study in Prostate Cancer,Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study,TERMINATED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2008-12-01,2014-11-01,Duke University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, RADIATION","Docetaxel, Sunitinib, EBXRT",Prostate Cancer,,,,,False,2161.0,True,False,2.0,False,False,False,3,False,Medium (30-100),1,36.0,3.610917912644224,1,0,0.58,False,True,0.608511319350077,0,True,0.9133076630846262,0,1,0.9481524,0
NCT01546142,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area",COMPLETED,PHASE3,INTERVENTIONAL,516.0,ACTUAL,2012-03-01,2013-08-01,Kythera Biopharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Deoxycholic acid injection, Placebo",Moderate or Severe Submental Fullness,,,,,False,518.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,516.0,6.248042874508429,3,1,0.77,True,True,0.7885430514839603,1,True,0.8529046127037706,1,1,0.84299135,1
NCT02798406,Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects,"A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)",COMPLETED,PHASE2,INTERVENTIONAL,49.0,ACTUAL,2016-10-06,2021-06-30,"DNAtrix, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","DNX-2401, pembrolizumab","Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases",,,,,False,1728.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,49.0,3.912023005428146,1,0,0.58,True,True,0.6667287906466789,1,True,0.8512476008032777,1,1,0.8851511,1
NCT00610844,Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors,Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors,COMPLETED,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2004-04-01,,University Hospital Tuebingen,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,pulmonary radiofrequency ablation,"Lung Cancer, Lung Metastasis",,,,,False,1303.0,True,False,2.0,False,False,False,1,True,Small (<30),0,9.0,2.302585092994046,0,0,0.58,True,False,0.2897453746287429,0,False,0.15711239293367898,0,0,0.12282219,0
NCT00627614,Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer,Identification and Differentiation of Breast Masses by Vibro-Acoustography,COMPLETED,,INTERVENTIONAL,147.0,ACTUAL,2006-03-01,2014-04-01,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,OTHER,breast imaging study,Breast Cancer,,,,,False,2953.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,147.0,4.997212273764115,0,1,0.6,True,True,0.860232879040189,1,True,0.8582917291185322,1,1,0.87915343,1
NCT00686166,"S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer","A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,83.0,ACTUAL,2009-02-01,2018-03-01,SWOG Cancer Research Network,NETWORK,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, PROCEDURE, RADIATION","cetuximab, capecitabine, oxaliplatin, therapeutic surgical procedure, radiation therapy",Colorectal Cancer,,,,,False,3315.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,83.0,4.430816798843313,1,0,0.58,True,True,0.8190825076432804,1,True,0.9131624371765865,1,1,0.9253894,1
NCT01408160,Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia,A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia,TERMINATED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2013-04-01,2018-06-26,Albert Einstein College of Medicine,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, OTHER, OTHER","Cytarabine, Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins, Laboratory Biomarker Analysis, Pharmacological Study","Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia",,,,,False,1912.0,True,False,1.0,False,False,False,4,False,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,False,False,0.4504629010951732,1,False,0.4980146608063302,1,0,0.3829774,1
NCT01069094,A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata,"A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata",COMPLETED,PHASE1,INTERVENTIONAL,29.0,ACTUAL,2004-07-01,2005-01-01,Repros Therapeutics Inc.,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG, DRUG, DRUG","Progenta, Progenta, Progenta, Lucron Depot, Placebo",Uterine Leiomyomata,,,,,False,184.0,True,False,1.0,True,True,True,5,True,Small (<30),0,29.0,3.4011973816621555,3,0,0.56,True,False,0.43017641071771257,0,True,0.6334292295208913,1,1,0.8355042,1
NCT03078452,Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy,Comparison of Quality of Bone Marrow Biopsy and Patient Convenience and Pain Control by a Battery Powered Drill Versus Conventional Methods in Patients With Plasma Cell Disorders,COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2017-02-14,2023-12-01,Emory University,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, DEVICE","Power drill, Jamshidi needle",Plasma Cell Myeloma,,,,,False,2481.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,100.0,4.61512051684126,2,1,0.6,True,True,0.6835185485367266,1,True,0.8167731334095687,1,1,0.8661349,1
NCT01131247,PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab,PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB,WITHDRAWN,PHASE2,INTERVENTIONAL,37.0,ESTIMATED,,,Nevada Cancer Institute,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,ofatumumab + bendamustine,Chronic Lymphocytic Leukemia (CLL),,,,,False,1303.0,True,False,2.0,False,False,False,1,False,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.58,False,True,0.6336915175669023,0,True,0.665643402172689,0,1,0.5827173,0
NCT04638049,Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT),Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT): A Prospective Biomarker Study,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2020-08-25,2022-08-08,"University Hospital, Ghent",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Collection of human biofluids, Patient reported outcome measures","Prostate Cancer, Prostate Adenocarcinoma, Prostatic Neoplasms",,,,,False,713.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.6,True,True,0.7082797968471339,1,True,0.7286804603105135,1,1,0.7082737,1
NCT00002890,Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia,PHASE I DOSE-ESCALATION TRIAL OF YTTRIUM-90-LABELED HuM195 (HUMANIZED ANTI-CD33) IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES,COMPLETED,PHASE1,INTERVENTIONAL,24.0,ESTIMATED,1996-10-01,2001-01-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,BIOLOGICAL,lintuzumab,"Leukemia, Myelodysplastic Syndromes",,,,,False,1553.0,True,False,1.0,False,False,False,1,True,Small (<30),0,24.0,3.218875824868201,0,0,0.56,True,True,0.5746482320090325,1,True,0.5919053908849355,1,1,0.5722964,1
NCT02494869,Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer,Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,75.0,ACTUAL,2015-07-01,2026-07-01,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, OTHER, OTHER, OTHER","Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test",High Risk for Developing Breast Cancer,,,,,False,4018.0,False,False,-1.0,True,False,False,4,True,Medium (30-100),0,75.0,4.330733340286331,2,0,0.6,True,True,0.8328405979295983,1,True,0.8422344066296552,1,1,0.89130455,1
NCT01270698,Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer,A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.,COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2011-05-01,2014-12-01,Gilead Sciences,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,IMMU-130,Metastatic Colorectal Cancer,,,,,False,1310.0,True,False,1.0,False,False,True,1,True,Small (<30),0,26.0,3.295836866004329,0,0,0.56,True,True,0.5825693627490072,1,True,0.6666198794039941,1,1,0.68195,1
NCT03810625,Food Effect Study of D-0502 Tablet in Healthy Volunteers,"A Phase I, Randomized, Open Label, Two-Sequence, Two-Period Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of D-0502 Tablet in Postmenopausal Female Healthy Subjects",COMPLETED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2018-10-23,2019-04-17,"InventisBio Co., Ltd",INDUSTRY,RANDOMIZED,CROSSOVER,NONE,DRUG,D-0502,Breast Cancer,,,,,False,176.0,True,False,1.0,True,False,True,1,True,Small (<30),0,14.0,2.70805020110221,1,0,0.56,True,False,0.2913321351437895,0,True,0.5052373216060166,1,0,0.39167082,0
NCT01582061,"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.","An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).",COMPLETED,PHASE3,INTERVENTIONAL,104.0,ACTUAL,2011-08-16,2017-01-26,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Pasireotide sub-cutaneous,Cushing's Disease,,,,,False,1990.0,True,False,3.0,False,False,True,1,True,Large (100-300),0,104.0,4.653960350157523,0,1,0.77,True,True,0.6340369489730907,1,True,0.8327440974448405,1,1,0.884984,1
NCT01913652,Ph II Cabazitaxel DD Liposarcoma,Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma,COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2014-10-01,2020-12-01,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,,SINGLE_GROUP,NONE,DRUG,Cabazitaxel,Dedifferentiated Liposarcoma,,,,,False,2253.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,42.0,3.7612001156935615,0,0,0.58,True,True,0.7005477321566702,1,True,0.9373583375951217,1,1,0.8857693,1
NCT03934567,A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma,"An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,87.0,ACTUAL,2020-04-22,2025-10-30,"Xynomic Pharmaceuticals, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Abexinostat,"Lymphoma, Follicular",,,,,False,2017.0,False,False,2.0,False,False,True,1,True,Medium (30-100),0,87.0,4.477336814478207,0,0,0.58,True,True,0.8301399297522959,1,True,0.8206978835197254,1,1,0.7340142,1
NCT03448146,A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction,A Phase III Single Arm Trial of PTS (Para Toluenesulfonamide Injection) Via Bronchoscopy Intervention Intratumoral Injection in Patients With Central Air Way NSCLC Tumor Severe Obstruction,COMPLETED,PHASE3,INTERVENTIONAL,90.0,ACTUAL,2009-08-01,2011-12-01,PTS International Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Para-Toluenesulfonamide,Nsclc,,,,,False,852.0,True,False,3.0,False,False,True,1,True,Medium (30-100),0,90.0,4.51085950651685,0,0,0.77,True,True,0.7345880079417073,1,True,0.7486491834164076,1,1,0.86382127,1
NCT04196530,BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab,Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Atezolizumab in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2019-11-21,2024-08-15,Eikon Therapeutics,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","BDB001 (EIK1001), Atezolizumab","Tumor, Solid",,,,,False,1729.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.56,True,True,0.6531875206030806,1,True,0.7314513927121153,1,1,0.75782996,1
NCT00180089,Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation,Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation,COMPLETED,PHASE3,INTERVENTIONAL,242.0,ESTIMATED,2004-01-01,2010-01-01,Technische Universität Dresden,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DRUG,Budesonide,"Leukemia, Graft-Versus-Host Disease",,,,,False,2192.0,True,False,3.0,True,True,False,1,True,Large (100-300),0,242.0,5.493061443340548,2,1,0.77,True,True,0.7695515234734963,1,True,0.6907926336543783,1,1,0.65253556,1
NCT05215951,Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC,"The Efficacy and Safety of Osimertinib With Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncommon Epidermal Growth Factor Receptor Mutations: A phase2, Open Label, Single Arm, Multicenter, Exploratory Study",TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2022-01-19,2023-03-09,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,osimertinib,Lung Cancer,,,,,False,414.0,True,False,2.0,False,False,True,1,False,Small (<30),1,4.0,1.6094379124341005,0,0,0.58,False,False,0.13405685884298008,1,False,0.08889586755932546,1,0,0.06163542,1
NCT00877110,Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma,Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma,COMPLETED,PHASE1,INTERVENTIONAL,71.0,ACTUAL,2009-04-02,2019-01-07,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,"cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8","Neuroblastoma, Bone Marrow, Sympathetic Nervous System",,,,,False,3567.0,True,False,1.0,False,False,False,1,True,Medium (30-100),1,71.0,4.276666119016055,0,0,0.56,True,True,0.8608086837402221,1,True,0.8490943080920398,1,1,0.8417444,1
NCT01217203,"Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse","Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse",COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2010-09-01,2014-02-01,Innate Pharma,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,IPH2101 combined to lenalidomide,"Patients With Multiple Myeloma Experiencing a, First or Second Relapse",,,,,False,1249.0,True,False,1.0,False,False,True,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.56,True,False,0.43890735531898917,0,True,0.8052414577530058,1,1,0.81608135,1
NCT05882890,Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?,Does Manuel Treatment With Craniosacral Therapy Change the Experience of Dry Mouth in People Who Suffers With Dry Mouth After Cancer in Throat Ore Mouth - a Pilot Study,COMPLETED,,INTERVENTIONAL,11.0,ACTUAL,2022-03-18,2023-11-27,Cathrine Rahbek,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER","Craniosacral Therapy, Exercices Targeting Upper Posture and Respiration","Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery, Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head",,,,,False,619.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,11.0,2.4849066497880004,1,0,0.6,True,False,0.3332965362784429,0,False,0.490879193549876,0,1,0.5214713,1
NCT00743678,Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis,A Phase II Study of Neoadjuvant FOLFOX6 Plus Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis,COMPLETED,PHASE2,INTERVENTIONAL,73.0,ACTUAL,2008-06-01,2012-06-01,Samsung Medical Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,FOLFOX6/cetuximab,"Colorectal Cancer, Unresectable Liver Metastasis",,,,,False,1461.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,73.0,4.30406509320417,0,0,0.58,True,True,0.7792246582420295,1,True,0.8365800977119975,1,1,0.80084616,1
NCT03231475,Phase I Study of SPH1188-11 in NSCLC,"Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2017-07-21,2022-03-31,"Shanghai Pharmaceuticals Holding Co., Ltd",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SPH1188-11,"NSCLC Stage IIIB, NSCLC Stage IV",,,,,False,1714.0,True,False,1.0,False,False,True,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.04014311797125579,1,False,0.02324437119378341,1,0,0.0026771289,1
NCT04804709,Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG),A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat Administration in Children With Progressive Diffuse Midline Glioma (DMG),TERMINATED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2021-07-28,2022-03-31,Columbia University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DEVICE","Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication","Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant",,,,,False,246.0,True,False,1.0,False,False,False,2,False,Small (<30),0,5.0,1.791759469228055,1,0,0.56,False,False,0.15057203651208342,1,False,0.1477243142207494,1,0,0.0981163,1
NCT01085331,MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC),"A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects",TERMINATED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2010-03-01,2012-04-01,EMD Serono,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG","Pimasertib, Placebo, FOLFIRI",Metastatic Colorectal Cancer,,,,,False,762.0,True,False,1.0,True,True,True,3,False,Small (<30),0,16.0,2.833213344056216,3,0,0.56,False,False,0.3243554469935556,1,True,0.5280133892592379,0,1,0.6737773,0
NCT02665143,A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2016-07-21,2021-03-30,Yale University,OTHER,,SINGLE_GROUP,NONE,DRUG,Nintedanib and AML induction,Relapsed/Refractory Acute Myeloid Leukemia,,,,,False,1713.0,True,False,2.0,False,False,False,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.58,True,True,0.5560357852595056,1,True,0.6249263828942617,1,1,0.631247,1
NCT01091831,"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects","A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects",COMPLETED,PHASE3,INTERVENTIONAL,389.0,ACTUAL,2009-07-01,2024-07-01,Fondazione EMN Italy Onlus,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Cyclophosphamide, Lenalidomide, Dexamethasone, Melphalan",Multiple Myeloma,,,,,False,5479.0,True,False,3.0,True,False,False,4,True,Very Large (300+),1,389.0,5.966146739123692,2,1,0.77,True,True,0.8719824634278937,1,True,0.9634464267586961,1,1,0.9826072,1
NCT00987922,Mild Hypothermia in Acute Ischemic Stroke,"Mild Hypothermia in Acute Ischemic Stroke After Thrombolytic Therapy: a Prospective,Open,Randomized,Single-center,Safety and Feasibility Study",COMPLETED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2007-07-01,2011-09-01,University of Helsinki,OTHER,RANDOMIZED,PARALLEL,NONE,DEVICE,Hypothermia,Brain Ischemia,,,,,False,1523.0,True,False,2.0,True,False,False,1,True,Medium (30-100),0,36.0,3.610917912644224,1,0,0.58,True,True,0.5536187919469778,1,True,0.5975952808076248,1,1,0.6322314,1
NCT03636750,A Study of Injection HB002.1T in Subjects With Solid Tumor,"A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravenous Injections of HB002.1T (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Solid Tumor",COMPLETED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2018-06-28,2020-03-21,"Huabo Biopharm Co., Ltd.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,HB002.1T,Solid Tumor,,,,,False,632.0,True,False,1.0,False,False,True,1,True,Small (<30),0,27.0,3.332204510175204,0,0,0.56,True,True,0.5576039688963976,1,True,0.5620943869189141,1,0,0.34265935,0
NCT03655002,"IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer",A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2019-02-21,2026-03-30,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, BIOLOGICAL","Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab","Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8",,,,,False,2594.0,False,False,1.0,False,False,False,3,True,Small (<30),1,8.0,2.19722457733622,1,0,0.56,True,False,0.29979828074837733,0,False,0.45744933899438345,0,1,0.58031684,1
NCT01522300,Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study- Contribution of Tomosynthesis In Locoregional Pretherapeutic Staging of a Breast Tumor: Multicentricity Search,Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité,TERMINATED,PHASE2,INTERVENTIONAL,81.0,ACTUAL,2012-01-01,2013-08-01,Centre Jean Perrin,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER","Evaluation of the Tomosynthesis, Avaluation of a medical device: the tomosynthesis",Mammary Tumor,,,,,False,578.0,True,False,2.0,False,False,False,2,False,Medium (30-100),0,81.0,4.406719247264253,1,0,0.58,False,True,0.7320672016580732,0,True,0.7291307628778106,0,1,0.778339,0
NCT00305448,"A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg","Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy",COMPLETED,PHASE2,INTERVENTIONAL,143.0,ACTUAL,2006-03-01,2012-02-01,AstraZeneca,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Fulvestrant, Fulvestrant","Advanced Breast Cancer, Metastatic Breast Cancer",,,,,False,2163.0,True,False,2.0,True,True,True,2,True,Large (100-300),1,143.0,4.969813299576001,3,1,0.58,True,True,0.6919524808679955,1,True,0.7719544558358392,1,1,0.8509932,1
NCT00900328,Study of Tumor Samples From Patients With Lung Cancer,A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens,COMPLETED,,OBSERVATIONAL,280.0,ACTUAL,2008-09-01,2012-09-01,Alliance for Clinical Trials in Oncology,OTHER,,,,OTHER,laboratory biomarker analysis,Lung Cancer,,,,,False,1461.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,280.0,5.638354669333745,0,1,0.6,True,True,0.8938855117535868,1,True,0.887113960825873,1,1,0.8495613,1
NCT04321135,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2019-11-01,2022-07-30,Medical College of Wisconsin,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Guided Lifestyle Program Intervention, Self-Guided Lifestyle Program (Control Arm)","Breast Cancer, Gynecologic Cancer",,,,,False,1002.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.5900536007207758,1,True,0.7501606365325303,1,1,0.79697376,1
NCT05879978,A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3,"A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,45.0,ACTUAL,2023-06-27,2026-06-30,Boehringer Ingelheim,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Obrixtamig, Ezabenlimab","Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms",,,,,False,1099.0,False,False,1.0,False,False,True,2,True,Medium (30-100),0,45.0,3.828641396489095,1,0,0.56,True,True,0.657742979949615,1,True,0.5218443494092943,1,1,0.5373239,1
NCT03595540,Fasting-mimicking Diet in Patients Undergoing Active Cancer Treatment,Phase II Clinical Study of a Fasting-mimicking Diet in Patients Undergoing Oncologic Treatment,COMPLETED,,INTERVENTIONAL,90.0,ACTUAL,2017-11-22,2021-04-15,University of Genova,OTHER,,SINGLE_GROUP,NONE,OTHER,Prolon,"Cancer, Breast Cancer, Colorectal Cancer",,,,,False,1240.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,90.0,4.51085950651685,0,0,0.6,True,True,0.8600079774723521,1,True,0.6048273987474354,1,1,0.5992493,1
NCT00251368,Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia,Multicenter Study of 9-AC in Refractory Leukemia,COMPLETED,PHASE1,INTERVENTIONAL,52.0,ESTIMATED,1995-01-01,2007-09-01,Dana-Farber Cancer Institute,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,9-Aminocamptothecin (9-AC),"Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia",,,,,False,4626.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,52.0,3.970291913552122,0,0,0.56,True,True,0.8515035901024286,1,True,0.7974095113759719,1,1,0.6805914,1
NCT00893035,Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients,Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.,COMPLETED,,OBSERVATIONAL,885.0,ACTUAL,2006-06-01,2019-10-29,Institut du Cancer de Montpellier - Val d'Aurelle,OTHER,,,,,,"Breast Cancer, Prostate Cancer",,,,,False,4898.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,885.0,6.786716950605081,0,1,0.6,True,True,0.9775112806833666,1,True,0.9030398471534078,1,1,0.87473935,1
NCT03137615,The Cardiovascular Changes Associated With Septal Local Anaesthesia,An Observational Study of the Cardiovascular Response to Infiltration of Local Anaesthetic Into the Nasal Septum in Patients Undergoing Trans-sphenoidal Resection of a Pituitary Lesion,COMPLETED,,OBSERVATIONAL,15.0,ACTUAL,2014-11-01,2015-06-01,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,,,,"PROCEDURE, DRUG","Pituitary surgery, local anaesthetic injection","Hypothalamic Neoplasms, Pituitary Diseases, Anesthesia, Local",,,,,False,212.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,15.0,2.772588722239781,1,0,0.6,True,False,0.3856789702811617,0,True,0.5529371734059069,1,1,0.740273,1
NCT00153881,"Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer","Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction",COMPLETED,PHASE1,INTERVENTIONAL,44.0,ACTUAL,2000-02-01,2013-09-01,Dartmouth-Hitchcock Medical Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Capecitabine (Xeloda),Esophageal Neoplasms,,,,,False,4961.0,True,False,1.0,False,False,False,1,True,Medium (30-100),1,44.0,3.80666248977032,0,0,0.56,True,True,0.8338935042079333,1,True,0.7820417438546837,1,1,0.5662547,1
NCT03130439,"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer","A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",TERMINATED,PHASE2,INTERVENTIONAL,27.0,ACTUAL,2017-05-26,2022-01-30,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,Abemaciclib,Breast Cancer,,,,,False,1710.0,True,False,2.0,False,False,False,1,False,Small (<30),1,27.0,3.332204510175204,0,0,0.58,False,True,0.5685991798054482,0,True,0.7269607422531311,0,1,0.7628812,0
NCT04552418,Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors,Pilot Study of Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,12.0,ACTUAL,2021-06-02,2023-01-24,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Potato starch,Solid Tumor,,,,,False,601.0,True,False,0.5,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.57,True,False,0.36472338743064886,0,False,0.43802423435566956,0,0,0.48851332,0
NCT05184153,Medullary Colonic Carcinoma,Medullary Colonic Carcinoma,COMPLETED,,OBSERVATIONAL,10.0,ACTUAL,2020-03-03,2021-09-01,"University Hospital, Limoges",OTHER,,,,,,"Medullary Carcinoma of Colon, Prognostic Factors, Survival Analysis",,,,,False,547.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.36026512352064916,0,False,0.4421518446595008,0,0,0.3837663,0
NCT04190446,"A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer","A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic and/or Para-Aortic Lymph Nodes Following Primary Localized Treatment",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,84.0,ACTUAL,2020-01-06,2028-11-22,Mayo Clinic,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION, OTHER, OTHER, PROCEDURE, PROCEDURE, PROCEDURE","Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection","Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8",,,,,False,3243.0,False,False,2.0,True,False,False,7,True,Medium (30-100),0,84.0,4.442651256490317,2,0,0.58,True,True,0.7585579215019267,1,True,0.7884267153456795,1,1,0.81331956,1
NCT03180502,Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma,"A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,120.0,ESTIMATED,2018-01-23,2027-06-01,NRG Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, RADIATION, OTHER, PROCEDURE, RADIATION, OTHER, OTHER, DRUG","Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide","Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma",,,,,False,3416.0,False,False,2.0,True,False,False,8,True,Large (100-300),1,120.0,4.795790545596741,2,1,0.58,True,True,0.6556100208941502,1,True,0.7790147557477293,1,1,0.8321876,1
NCT03473652,Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer,Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer,COMPLETED,,INTERVENTIONAL,45.0,ACTUAL,2018-05-29,2018-12-11,Centre Francois Baclesse,OTHER,,SINGLE_GROUP,NONE,OTHER,Adapted walking platform,"Oncology, Adapted Physical Activity",,,,,False,196.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.6,True,True,0.7063322118111277,1,True,0.8076922988087024,1,1,0.88039273,1
NCT02148549,Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study,The Pilot Study of Neoadjuvant Chemotherapy of FIRINOX for Patients With Borderline Resectable Pancreatic Cancer,COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2014-04-01,2017-02-01,Wakayama Medical University,OTHER,,SINGLE_GROUP,NONE,DRUG,FIRINOX,Patients With Borderline Resectable Pancreatic Cancer,,,,,False,1037.0,True,False,1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.3325076623003589,0,False,0.47067338312565554,0,1,0.5530077,1
NCT01766219,CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery,A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2013-05-01,2018-05-18,Wake Forest University Health Sciences,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,"6,8-bis(benzylthio)octanoic acid","Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer",,,,,False,1843.0,True,False,1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.56,True,True,0.5014401194345194,1,True,0.7882943381011333,1,1,0.6827627,1
NCT04390542,Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy,"A Pilot Study Evaluating Feasibility, Acceptability, Usability, Satisfaction and Preliminary Efficacy of an Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy",WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2021-06-01,2021-09-01,Case Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Psychoeducation,Blood Cancer,,,,,False,92.0,True,False,-1.0,True,False,False,1,False,,0,0.0,0.0,1,0,0.6,False,False,0.02514185635274011,1,False,0.01075939080918979,1,0,0.0030789904,1
NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,COMPLETED,PHASE1,INTERVENTIONAL,24.0,ACTUAL,2004-03-01,2016-10-01,Ohio State University Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, PROCEDURE","CHOP, Alemtuzumab, Plasma Samples",Non-Hodgkin's Lymphoma,,,,,False,4597.0,True,False,1.0,False,False,False,3,True,Small (<30),0,24.0,3.218875824868201,1,0,0.56,True,True,0.6694350691762565,1,True,0.8069651687310656,1,1,0.80062747,1
NCT02394795,"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer",COMPLETED,PHASE3,INTERVENTIONAL,823.0,ACTUAL,2015-05-29,2022-01-14,Takeda,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab",Colorectal Cancer,,,,,False,2422.0,True,False,3.0,True,False,True,2,True,Very Large (300+),1,823.0,6.714170529909472,2,1,0.77,True,True,0.8687325931272729,1,True,0.9384379159475864,1,1,0.9449858,1
NCT05617352,The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study,The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: A Single Center Retrospective Analysis,COMPLETED,,OBSERVATIONAL,1659.0,ACTUAL,2022-05-01,2022-10-10,Yongtao Han,OTHER,,,,DIAGNOSTIC_TEST,"Since the data were collected retrospectively, there were no interventions",Esophageal Cancer,,,,,False,162.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1659.0,7.414572881350589,0,1,0.6,True,True,0.9527136152224769,1,True,0.9792904436293927,1,1,0.99104017,1
NCT00979173,Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma,A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants,COMPLETED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2009-11-01,2012-06-01,Annick Desjardins,OTHER,,SINGLE_GROUP,NONE,DRUG,AC480,Glioma,,,,,False,943.0,True,False,1.0,False,False,False,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.56,True,False,0.2015142407560798,0,False,0.25371448764723914,0,0,0.26821172,0
NCT00493636,1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy,"A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy",COMPLETED,PHASE2,INTERVENTIONAL,160.0,ACTUAL,2007-06-01,2012-11-01,Accelerated Community Oncology Research Network,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG","Gemcitabine, Sorafenib, Placebo, Capecitabine",Breast Cancer,,,,,False,1980.0,True,False,2.0,True,True,False,4,True,Large (100-300),1,160.0,5.081404364984463,3,1,0.58,True,True,0.6989662310659198,1,True,0.8487917878962054,1,1,0.9256497,1
NCT04417465,First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors,"A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors",COMPLETED,PHASE1,INTERVENTIONAL,101.0,ACTUAL,2020-06-03,2025-08-21,AbbVie,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG","ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI",Advanced Solid Tumors Cancer,,,,,False,1905.0,True,False,1.0,False,False,True,3,True,Large (100-300),0,101.0,4.624972813284271,1,1,0.56,True,True,0.6868964631591545,1,True,0.6953646964662856,1,1,0.6881682,1
NCT01829113,Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer,Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial),COMPLETED,PHASE2,INTERVENTIONAL,155.0,ACTUAL,2013-07-01,2017-04-19,"SCRI Development Innovations, LLC",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","OGX-427, Placebo",Non Squamous Non Small Cell Lung Cancer,,,,,False,1388.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,155.0,5.049856007249537,3,1,0.58,True,True,0.6806711718764376,1,True,0.7084866745565281,1,1,0.87097657,1
NCT01316549,Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation,Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation,COMPLETED,,OBSERVATIONAL,67.0,ACTUAL,2011-01-01,2016-04-30,"University of California, San Francisco",OTHER,,,,DRUG,Fludarabine,"Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease",,,,,False,1946.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,67.0,4.219507705176107,0,0,0.6,True,True,0.8398092975188066,1,True,0.863801358911251,1,1,0.817948,1
NCT01587703,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",COMPLETED,PHASE1,INTERVENTIONAL,196.0,ACTUAL,2012-03-28,2019-07-29,GlaxoSmithKline,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,GSK525762,"Carcinoma, Midline",,,,,False,2679.0,True,False,1.0,False,False,True,1,True,Large (100-300),0,196.0,5.2832037287379885,0,1,0.56,True,True,0.8630187121424846,1,True,0.7220749057159322,1,1,0.74933296,1
NCT02788578,A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours,Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours,TERMINATED,,OBSERVATIONAL,40.0,ACTUAL,2016-06-01,2017-07-01,Ipsen,INDUSTRY,,,,,,Neuroendocrine Tumours,,,,,False,395.0,True,False,-1.0,False,False,True,0,False,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,False,True,0.6935034109871302,0,True,0.7828311738987048,0,1,0.696908,0
NCT02913196,"Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC","A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2016-12-30,2026-10-01,Weill Medical College of Cornell University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Apalutamide, Abiraterone acetate, Docetaxel, Prednisone",Prostate Cancer Metastatic,,,,,False,3562.0,False,False,1.0,False,False,False,4,True,Small (<30),1,16.0,2.833213344056216,1,0,0.56,True,True,0.5060088652060122,1,True,0.5993107068877938,1,1,0.7586111,1
NCT00416533,"Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy",A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer,COMPLETED,PHASE2,INTERVENTIONAL,47.0,ESTIMATED,2004-08-01,,Wake Forest University Health Sciences,OTHER,,,NONE,"DRUG, DRUG, DRUG","docetaxel, doxorubicin hydrochloride, prednisone",Prostate Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,47.0,3.871201010907891,1,0,0.58,True,True,0.6320321911883618,1,True,0.7556669265027276,1,1,0.7123888,1
NCT03918278,A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001),"A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.",COMPLETED,PHASE1,INTERVENTIONAL,222.0,ACTUAL,2019-06-19,2025-06-09,Merck Sharp & Dohme LLC,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG","MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed",Neoplasms,,,,,False,2182.0,True,False,1.0,False,False,True,7,True,Large (100-300),1,222.0,5.407171771460119,1,1,0.56,True,True,0.8203388370129749,1,True,0.6249007219931965,1,1,0.55471075,1
NCT04955522,Multimodal Imaging Analysis of Spinal Tumors,Multimodal Imaging Analysis of Spinal Tumors,COMPLETED,,OBSERVATIONAL,242.0,ACTUAL,2019-12-01,2020-12-30,Peking University Third Hospital,OTHER,,,,DIAGNOSTIC_TEST,radiomics,Bone Tumor,,,,,False,395.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,242.0,5.493061443340548,0,1,0.6,True,True,0.8547416260131014,1,True,0.9317915655579092,1,1,0.93033445,1
NCT02436707,Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,129.0,ACTUAL,2015-10-27,2026-12-31,Canadian Cancer Trials Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor",Lymphoma,,,,,False,4083.0,False,False,2.0,True,False,False,10,True,Large (100-300),1,129.0,4.867534450455582,2,1,0.58,True,True,0.6931423610743255,1,True,0.7773878467274661,1,1,0.729016,1
NCT06119633,Implant-based Breast Reconstruction and Mastectomy With Fat Grafting After Breast Conserving Surgery and Radiotherapy,Immediate Tissue Expander and Lipofilling After Mastectomy for Breast Cancer Recurrence Following Lumpectomy and Irradiation: Retrospective Multicentric Clinical Trial,COMPLETED,,INTERVENTIONAL,163.0,ACTUAL,2007-06-01,2023-12-01,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Immediate tissue expander and lipofilling after mastectomy,Breast Cancer,,,,,False,6027.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,163.0,5.099866427824199,0,1,0.6,True,True,0.9282441768863077,1,True,0.8982719543198538,1,1,0.965331,1
NCT00139204,Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients,"An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine (C11 MET) in Prostate Cancer, as Assessed by Positron Emission Tomography (PET)",COMPLETED,,INTERVENTIONAL,20.0,,2005-04-01,2006-07-01,Dana-Farber Cancer Institute,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,PROCEDURE,C11 Methionine PET scan,Prostate Cancer,,,,,False,456.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5220266025506344,1,True,0.7689830221443629,1,1,0.8159461,1
NCT00456261,First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC,A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer,COMPLETED,PHASE2,INTERVENTIONAL,110.0,ACTUAL,2007-03-01,2012-09-01,"SCRI Development Innovations, LLC",OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin",Lung Cancer,,,,,False,2011.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,110.0,4.709530201312334,2,1,0.58,True,True,0.5853738178383119,1,True,0.8767943591304522,1,1,0.8244137,1
NCT00972686,Dose-Escalation Study of GSK2126458,"A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,79.0,ACTUAL,2009-08-31,2015-03-31,GlaxoSmithKline,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,GSK2126458,Solid Tumours,,,,,False,2038.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,79.0,4.382026634673881,0,0,0.56,True,True,0.8379057371370973,1,True,0.6041162731963008,1,1,0.51373047,1
NCT05577702,"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,121.0,ACTUAL,2023-03-15,2025-01-23,BeiGene,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Tislelizumab, Ociperlimab, LBL-007, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel",Non Small Cell Lung Cancer,,,,,False,680.0,True,False,2.0,True,False,True,7,True,Large (100-300),1,121.0,4.804021044733257,2,1,0.58,True,True,0.5258078330459034,1,True,0.5075038270257474,1,0,0.3461049,0
NCT02682485,Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing,"A Multicenter, Phase II, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of Serial Endoscopic Surveillance (SES) and Direct Topical Antibiotics (DTA) to Define the Role of Microbes in Anastomotic Healing",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2017-03-03,2017-03-03,University of Chicago,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, PROCEDURE, DRUG","Cipro, metronidazole, neomycin combo, Serial Endoscopic Surveillance, Saline","Anastomotic Leak, Rectal Cancer",,,,,False,0.0,True,False,2.0,True,True,False,3,False,,0,0.0,0.0,3,0,0.58,False,False,0.015749347063860435,1,False,0.009247558224251894,1,0,0.0025763346,1
NCT03996096,Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.,Etude Observationnelle Biologique Sur le Syndrome de Sevrage Des Inhibiteurs de Tyrosine Kinase Dans la Leucémie Myéloïde Chronique.,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2019-04-23,2023-03-16,"University Hospital, Caen",OTHER,,,,,,"Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, Withdrawal Syndrome",,,,,False,1423.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.779633778370912,1,True,0.6639172558148622,1,0,0.45065716,0
NCT07023822,"WISH, Feasibility of a Factorial Design","Women's Interventions for Sexual Health: WISH, Feasibility of a Factorial Design",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,18.0,ESTIMATED,2025-06-16,2025-09-30,"The University of Tennessee, Knoxville",OTHER,RANDOMIZED,FACTORIAL,NONE,"DEVICE, DEVICE, BEHAVIORAL, BEHAVIORAL","Hyaluronic acid (HLA) Vaginal Moisturizer, Polycarbophil Vaginal Moisturizer, Hypnotic Relaxation, Progressive Muscle Relaxation (PMR)","Breast Cancer, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder, Body Image",,,,,False,106.0,False,False,-1.0,True,False,False,4,True,Small (<30),0,18.0,2.9444389791664403,2,0,0.6,True,False,0.33353182903982437,0,False,0.44923379447947404,0,0,0.38238096,0
NCT04926168,6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM),Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2023-03-01,2026-12-31,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,,,"OTHER, OTHER","Delay of TMZ, Standard of Care (SOC) Adjuvant TMZ (no intervention",MGMT-Methylated Glioblastoma,,,,,False,1401.0,True,False,-1.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.6,False,False,0.03755864331523488,1,False,0.015044937241591203,1,0,0.002900353,1
NCT03743064,A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,INTERVENTIONAL,318.0,ACTUAL,2019-05-06,2022-12-27,Helsinn Healthcare SA,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","anamorelin HCl, Placebo Oral Tablet","Cachexia; Cancer, Non Small Cell Lung Cancer",,,,,False,1331.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,318.0,5.765191102784844,3,1,0.77,True,True,0.7449816677860126,1,True,0.6696289773898906,1,1,0.78911364,1
NCT06397651,A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life,"A Decentralized, Double-blinded, Randomized, 18 Month, Parallel-group, Superiority Study to Evaluate the Impact of Complement Theory's Live Coactive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,146.0,ESTIMATED,2024-05-12,2026-02-28,Complement Theory Inc.,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"BEHAVIORAL, BEHAVIORAL","Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification","Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer",,,,,False,657.0,False,False,-1.0,True,True,True,2,True,Large (100-300),0,146.0,4.990432586778736,3,1,0.6,True,True,0.711036925554138,1,True,0.8743697100820961,1,1,0.89509237,1
NCT01336933,Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma,"A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,34.0,ACTUAL,2011-07-06,2016-12-28,University of Nebraska,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, OTHER, GENETIC, GENETIC, GENETIC, GENETIC, OTHER, GENETIC, GENETIC","prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis","Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma",,,,,False,2002.0,True,False,2.0,False,False,False,13,True,Medium (30-100),1,34.0,3.555348061489413,1,0,0.58,True,True,0.5357196238002951,1,True,0.8088784725501706,1,1,0.82955927,1
NCT01746056,A Comparative Study of Occlusive Heat Patch in the Treatment of Warts,A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca,COMPLETED,,INTERVENTIONAL,73.0,ACTUAL,2012-12-01,2019-10-31,Yale University,OTHER,RANDOMIZED,PARALLEL,NONE,DEVICE,Occlusive Heat Patch,Verruca (Warts),,,,,False,2525.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,73.0,4.30406509320417,1,0,0.6,True,True,0.8200069390851453,1,True,0.8304174670547948,1,1,0.86356646,1
NCT04431076,Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes,The PRO-PANC1 Project: Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,560.0,ACTUAL,2020-05-07,2024-06-30,Massimo Falconi,OTHER,,,,,,"Pancreatic Cancer, Patient Reported Outcome Measures, Quality of Life, Pancreatectomy, Nutritional Status, Recovery of Function",,,,,False,1515.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,560.0,6.329720905522696,0,1,0.6,True,True,0.940290247943291,1,True,0.8507834628944133,1,1,0.77268225,1
NCT05740501,Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer,Pharmacokinetic Profiling of Pembrolizumab (Keytruda&Amp;Reg;) and Nivolumab (Opdiva&Amp;Reg;) in Patients With Melanoma and/or Non-Small Cell Lung Cancer: Clinical Validation of a Mass Spectrometry-based Assay,COMPLETED,,OBSERVATIONAL,13.0,ACTUAL,2017-04-26,2020-01-03,Mayo Clinic,OTHER,,,,"PROCEDURE, OTHER, OTHER","Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration","Lung Non-Small Cell Carcinoma, Melanoma",,,,,False,982.0,True,False,-1.0,False,False,False,3,True,Small (<30),0,13.0,2.6390573296152584,1,0,0.6,True,False,0.3844387466371502,0,True,0.5159917440779682,1,1,0.56793696,1
NCT02100891,Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors,Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial,TERMINATED,PHASE2,INTERVENTIONAL,15.0,ACTUAL,2013-03-20,2020-07-15,Monica Thakar,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, DRUG","Allogeneic HCT, Donor NK Cell Infusion","Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors",,,,,False,2674.0,True,False,2.0,False,False,False,2,False,Small (<30),0,15.0,2.772588722239781,1,0,0.58,False,False,0.4234501350288689,1,False,0.48884549467735133,1,0,0.4066133,1
NCT04147780,Sentinel Node Extended in Squamous Cell Vulvar Cancer,Can the Investigators Extend the Indication for Sentinel Node Biopsy in Vulvar Cancer? A Nationwide Feasibility Study From Sweden,COMPLETED,,OBSERVATIONAL,64.0,ACTUAL,2019-12-14,2023-02-15,Diana Zach,OTHER,,,,PROCEDURE,Sentinel node biopsy,"Vulva Cancer, Sentinel Lymph Node",,,,,False,1159.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,64.0,4.174387269895637,0,0,0.6,True,True,0.8092872273045449,1,True,0.8346637199723637,1,1,0.78580624,1
NCT02305810,A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus,An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus,COMPLETED,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2013-09-01,2018-06-01,European Institute of Oncology,OTHER,,SINGLE_GROUP,NONE,DRUG,Everolimus 10 mg daily,Pancreatic Neuroendocrine Tumour Metastatic,,,,,False,1734.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,54.0,4.007333185232471,0,0,0.58,True,True,0.7374088872068756,1,True,0.7856868331181575,1,1,0.78501827,1
NCT04699721,Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC,Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,60.0,ESTIMATED,2020-07-01,2027-12-01,Xiangya Hospital of Central South University,OTHER,,SINGLE_GROUP,NONE,DRUG,nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5,"Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB",,,,,False,2709.0,False,False,2.0,False,False,False,1,True,Medium (30-100),1,60.0,4.110873864173311,0,0,0.58,True,True,0.788685437117344,1,True,0.9353870373160408,1,1,0.9541888,1
NCT05396859,Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia,A Phase I Study of Entrectinib in Combination With ASTX727 (35 mg Decitabine and 100 mg Cedazuridine) in Patients With Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (AML),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,13.0,ACTUAL,2022-10-28,2026-06-30,OHSU Knight Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER","Decitabine and Cedazuridine, Entrectinib, Laboratory Biomarker Analysis","Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia",,,,,False,1341.0,False,False,1.0,False,False,False,3,True,Small (<30),0,13.0,2.6390573296152584,1,0,0.56,True,False,0.3543103959475218,0,False,0.4091054207792928,0,0,0.31126538,0
NCT00103376,Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer,VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer,TERMINATED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2004-10-01,2011-06-01,Medical University of South Carolina,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Velcade, LH-RH Agonist, Androgen Receptor Antagonists",Prostate Cancer,,,,,False,2434.0,True,False,2.0,False,False,False,3,False,Small (<30),0,23.0,3.1780538303479458,1,0,0.58,False,True,0.5149914908059552,0,True,0.6326451927167901,0,1,0.68630016,0
NCT06900686,Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival,A Retrospective Study of the Effect of PD-1 Inhibitors in Improving Clinical Outcome for Colorectal Cancer.,COMPLETED,,OBSERVATIONAL,458.0,ACTUAL,2013-03-20,2025-03-23,Yanhong Deng,OTHER,,,,DRUG,PD1 Inhibitor,"Rectal Cancer, Colon Cancer",,,,,False,4386.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,458.0,6.129050210060545,0,1,0.6,True,True,0.9598192591577411,1,True,0.9392250267061009,1,1,0.9338118,1
NCT00915096,Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma,High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response,COMPLETED,,OBSERVATIONAL,121.0,ACTUAL,2007-09-18,2013-02-08,Lymphoma Study Association,OTHER,,,,,,"Lymphoma, Follicular",,,,,False,1970.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,121.0,4.804021044733257,0,1,0.6,True,True,0.8079668012474496,1,True,0.7416098635241345,1,1,0.7957476,1
NCT01265381,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,TERMINATED,,OBSERVATIONAL,673.0,ACTUAL,2010-12-22,2020-02-26,National Cancer Institute (NCI),NIH,,,,,,Thyroid Cancer,,,,,False,3353.0,True,False,-1.0,False,False,False,0,False,Very Large (300+),0,673.0,6.513230110912307,0,1,0.6,False,True,0.963538954718112,0,True,0.822289699627499,0,1,0.79147476,0
NCT04863924,Accelerating Lung Cancer Diagnosis Through Liquid Biopsy,Accelerating Lung Cancer Diagnosis Through Liquid Biopsy,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,170.0,ACTUAL,2021-01-14,2026-12-01,"University Health Network, Toronto",OTHER,,,,DIAGNOSTIC_TEST,Liquid Biopsy,Non-small Cell Lung Cancer,,,,,False,2147.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,170.0,5.14166355650266,0,1,0.6,True,True,0.8574410675569833,1,True,0.8928886345687981,1,1,0.9060278,1
NCT02394015,"Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC","Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet",COMPLETED,,OBSERVATIONAL,90.0,ACTUAL,2013-05-06,2017-12-01,Grupo Español de Investigación en Cáncer de Ovario,OTHER,,,,DRUG,Trabectedin and Pegylated Liposomal Doxorubicin,Ovarian Epithelial Cancer Recurrent,,,,,False,1670.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),1,90.0,4.51085950651685,0,0,0.6,True,True,0.867218066895087,1,True,0.6558586925042488,1,1,0.5049528,1
NCT06098248,Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis,"A Prospective, Multi-centered, Assessor-blinded Clinical Performance Study to Evaluate the Sensitivity and Specificity of the cCeLL-Ex Vivo Device for Intraoperative Brain Tumor Diagnosis.",TERMINATED,,INTERVENTIONAL,285.0,ACTUAL,2023-01-01,2024-11-27,VPIX Medical,INDUSTRY,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,cCeLL - Ex vivo,"Benign Brain Tumor, Malignant Brain Tumor",,,,,False,696.0,True,False,-1.0,False,False,True,1,False,Large (100-300),0,285.0,5.655991810819852,0,1,0.6,False,True,0.8795571963780558,0,True,0.9240093164995135,0,1,0.9237266,0
NCT02220985,Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD,A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD,COMPLETED,PHASE2,INTERVENTIONAL,84.0,ACTUAL,2015-02-03,2025-05-01,Fred Hutchinson Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG, DRUG, OTHER, DRUG, DRUG, PROCEDURE, PROCEDURE, DRUG, DRUG, RADIATION","Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission",,,,,False,3740.0,True,False,2.0,False,False,False,11,True,Medium (30-100),1,84.0,4.442651256490317,1,0,0.58,True,True,0.8157550239789798,1,True,0.8903048316332074,1,1,0.9163248,1
NCT01034514,4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy,4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy,TERMINATED,EARLY_PHASE1,INTERVENTIONAL,35.0,ACTUAL,2009-12-01,2014-06-24,Billy W. Loo Jr.,OTHER,,SINGLE_GROUP,NONE,"DEVICE, DEVICE, DEVICE, DEVICE, DEVICE, DRUG, DRUG","Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA",Lung Cancer,,,,,False,1666.0,True,False,0.5,False,False,False,7,False,Medium (30-100),0,35.0,3.58351893845611,1,0,0.57,False,True,0.6123602275113698,0,True,0.6758825877973196,0,1,0.68197656,0
NCT02189226,Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection,,COMPLETED,,INTERVENTIONAL,101.0,ACTUAL,2013-11-01,2015-01-20,Yonsei University,OTHER,RANDOMIZED,PARALLEL,NONE,DEVICE,Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE),Early Gastric Cancer,,,,,False,445.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,101.0,4.624972813284271,1,1,0.6,True,True,0.6375312588338051,1,True,0.8326662475191874,1,1,0.9040564,1
NCT02296918,Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL,A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL,COMPLETED,PHASE1,INTERVENTIONAL,69.0,ACTUAL,2014-12-22,2025-10-22,Acerta Pharma BV,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","acalabrutinib, Obinutuzumab, Venetoclax, Rituximab","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia",,,,,False,3957.0,True,False,1.0,False,False,True,4,True,Medium (30-100),1,69.0,4.248495242049359,1,0,0.56,True,True,0.8353842920649698,1,True,0.8526373396250523,1,1,0.7941833,1
NCT04285996,IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types,IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types,COMPLETED,,INTERVENTIONAL,19.0,ACTUAL,2016-03-17,2022-07-15,Queen Mary University of London,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,PET Scan,Cancer,,,,,False,2311.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.6,True,True,0.6038208811423765,1,True,0.5173140346825131,1,1,0.5936155,1
NCT01594723,A Study of LY2784544 in Participants With Myeloproliferative Neoplasms,A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,110.0,ESTIMATED,2012-05-22,2026-12-01,Eli Lilly and Company,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,120 mg LY2784544,"Neoplasms, Hematologic",,,,,False,5306.0,False,False,2.0,False,False,True,1,True,Large (100-300),0,110.0,4.709530201312334,0,1,0.58,True,True,0.8399829161413062,1,True,0.8008853314236414,1,1,0.95123696,1
NCT05526482,Preoperative Treatment of Respiratory Physiotherapy in Lung Cancer,Applicability of Respiratory Tele-physiotherapy in the Preoperative Context of Thoracic Surgery at the Hospital de la Santa Creu y Sant Pau (HSCSP).,COMPLETED,,OBSERVATIONAL,8.0,ACTUAL,2022-03-02,2022-08-23,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,OTHER,,,,DEVICE,mobile app,"Lung Cancer, Physical Therapy, Thoracic Surgery, Preoperative",,,,,False,174.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,8.0,2.19722457733622,0,0,0.6,True,False,0.2909434430890058,0,False,0.4609394979442884,0,0,0.42667785,0
NCT02579863,Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).,TERMINATED,PHASE3,INTERVENTIONAL,310.0,ACTUAL,2015-10-19,2020-07-13,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG","Pembrolizumab, Lenalidomide, Dexamethasone",Multiple Myeloma,,,,,False,1729.0,True,False,3.0,True,False,True,3,False,Very Large (300+),1,310.0,5.739792912179234,2,1,0.77,False,True,0.7224956103055077,0,True,0.9391949439951278,0,1,0.97470134,0
NCT02315157,Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma,Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2014-06-01,2018-11-01,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Bendamustine,"Multiple Myeloma, Plasma Cell Leukemia",,,,,False,1614.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.039348831352906,1,False,0.019851460673130646,1,0,0.0026194768,1
NCT04690231,Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma,Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China,COMPLETED,,INTERVENTIONAL,79.0,ACTUAL,2020-12-01,2021-06-01,Peking University People's Hospital,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Apatinib Mesylate, ifosfamide and etoposide","Effect of Drug, Toxicity, Drug, Secondary Resistance",,,,,False,182.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),1,79.0,4.382026634673881,1,0,0.6,True,True,0.7727839717610944,1,True,0.8572036024195324,1,1,0.79770464,1
NCT00003216,"Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas",A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma,COMPLETED,PHASE3,INTERVENTIONAL,518.0,ESTIMATED,1998-07-01,,Radiation Therapy Oncology Group,NETWORK,RANDOMIZED,,,"DRUG, DRUG, RADIATION","fluorouracil, gemcitabine hydrochloride, radiation therapy",Pancreatic Cancer,,,,,False,1303.0,True,False,3.0,True,False,False,3,True,Very Large (300+),1,518.0,6.251903883165888,2,1,0.77,True,True,0.7871391716266652,1,True,0.6808819481185236,1,1,0.6416084,1
NCT04159025,EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer,EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer: A Feasibility Study,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2020-01-08,2022-02-25,Washington University School of Medicine,OTHER,,SINGLE_GROUP,NONE,DEVICE,CoreDx Pulmonary Mini-Forceps,"Non Small Cell Lung Cancer, NSCLC",,,,,False,779.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5387685080971857,1,True,0.6873291255603386,1,1,0.6821707,1
NCT02401100,Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow,Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow,COMPLETED,,OBSERVATIONAL,36.0,ACTUAL,2015-05-01,2018-09-01,Umeå University,OTHER,,,,,,Anastomotic Leak,,,,,False,1219.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,36.0,3.610917912644224,0,0,0.6,True,True,0.7064123891026952,1,True,0.6783102574043655,1,1,0.64234155,1
NCT00051116,A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma,A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma,COMPLETED,PHASE2,INTERVENTIONAL,100.0,ACTUAL,2002-05-01,2006-10-01,Celgene Corporation,INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,CC-5013,Multiple Myeloma,,,,,False,1614.0,True,False,2.0,True,False,True,1,True,Medium (30-100),0,100.0,4.61512051684126,1,1,0.58,True,True,0.6087956319382518,1,True,0.7364826007491092,1,1,0.6848926,1
NCT03081689,Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients,Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study,COMPLETED,PHASE2,INTERVENTIONAL,46.0,ACTUAL,2017-04-15,2023-10-18,Spanish Lung Cancer Group,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Nivolumab 360 mg, Paclitaxel 200mg/m2, Carboplatin AUC 6",Non Small Cell Lung Cancer,,,,,False,2377.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,46.0,3.8501476017100575,1,0,0.58,True,True,0.6774343066886847,1,True,0.9398522148603853,1,1,0.9307528,1
NCT01553357,Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia,A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2009-03-01,2011-09-01,IRCCS Centro di Riferimento Oncologico della Basilicata,OTHER,,SINGLE_GROUP,NONE,DRUG,"Lenalidomide, dexamethasone",Primary Plasma Cell Leukemia,,,,,False,914.0,True,False,2.0,False,False,False,1,True,Small (<30),0,23.0,3.1780538303479458,0,0,0.58,True,False,0.49309240715882874,0,True,0.5255580206715816,1,1,0.5679317,1
NCT00895349,Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial),The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer,COMPLETED,,INTERVENTIONAL,171.0,ACTUAL,2010-04-01,2019-08-01,Ontario Clinical Oncology Group (OCOG),OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","CT Abdomen and Pelvis scan + whole body PET-CT scan, CT Abdomen and Pelvis scan","Cervical Cancer, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma",,,,,False,3409.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,171.0,5.147494476813453,2,1,0.6,True,True,0.8182404811246058,1,True,0.906058923369708,1,1,0.8806165,1
NCT01496118,Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma,Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma,COMPLETED,PHASE1,INTERVENTIONAL,80.0,ACTUAL,2011-12-01,2020-12-01,"SCRI Development Innovations, LLC",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","panobinostat, carfilzomib",Multiple Myeloma,,,,,False,3288.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,80.0,4.394449154672439,1,0,0.56,True,True,0.8465357162493677,1,True,0.7308127889620109,1,1,0.7750939,1
NCT00085540,FR901228 in Treating Patients With Recurrent High-Grade Gliomas,A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas,COMPLETED,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2005-01-01,2009-03-01,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,depsipeptide,"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor",,,,,False,1520.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.56,True,True,0.7425168560559248,1,True,0.7444780255521528,1,1,0.7238396,1
NCT01475955,Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK),"A Phase II Study of Photodynamic Therapy With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp",COMPLETED,PHASE2,INTERVENTIONAL,235.0,ACTUAL,2011-12-01,2012-11-01,"DUSA Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DEVICE","Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment",Actinic Keratosis,,,,,False,336.0,True,False,2.0,True,True,True,6,True,Large (100-300),0,235.0,5.4638318050256105,3,1,0.58,True,True,0.7031588100692412,1,True,0.8034534812462918,1,1,0.91258556,1
NCT00755261,Phase II Study of Doxorubicin and Avastin® in Sarcoma.,Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.,TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2008-09-01,2010-11-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Avastin, Doxorubicin","Sarcoma, Soft Tissue Sarcoma",,,,,False,791.0,True,False,2.0,False,False,False,2,False,Small (<30),1,4.0,1.6094379124341005,1,0,0.58,False,False,0.11969729692560037,1,False,0.06929088082422946,1,0,0.05669255,1
NCT00358566,GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer,"""Primovax"" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.",TERMINATED,PHASE3,INTERVENTIONAL,360.0,ACTUAL,2006-06-01,2008-08-01,Pharmexa A/S,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG","GV1001, Gemcitabine (Chemotherapy)",Advanced Unresectable Pancreatic Cancer,,,,,False,792.0,True,False,3.0,True,False,True,2,False,Very Large (300+),1,360.0,5.8888779583328805,2,1,0.77,False,True,0.714324523588908,0,True,0.6527386758909757,0,1,0.6014727,0
NCT01183832,Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects,Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects,COMPLETED,,OBSERVATIONAL,490.0,ACTUAL,2005-08-01,2016-01-01,Centre Oscar Lambret,OTHER,,,,,,Breast Cancer,,,,,False,3805.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,490.0,6.19644412779452,0,1,0.6,True,True,0.9580376858264125,1,True,0.9197908974302658,1,1,0.89321804,1
NCT03796702,Early Versus Late Closure of Preventive Ileostomy,,TERMINATED,,INTERVENTIONAL,86.0,ACTUAL,2011-11-01,2018-12-30,Vilnius University,OTHER,RANDOMIZED,PARALLEL,SINGLE,PROCEDURE,Deileostomy,"Ileostomy, Rectal Cancer",,,,,False,2616.0,True,False,-1.0,True,False,False,1,False,Medium (30-100),0,86.0,4.465908118654584,1,0,0.6,False,True,0.846172778924405,0,True,0.7972087762026796,0,1,0.65013397,0
NCT02004782,Barretts oEsophageal Resection With Steroid Therapy Trial,"Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.",WITHDRAWN,PHASE4,INTERVENTIONAL,0.0,ACTUAL,2020-03-09,2020-03-09,Professor Michael Bourke,OTHER,RANDOMIZED,SINGLE_GROUP,DOUBLE,"DRUG, DRUG","Prednisolone, Placebo Oral Tablet","Barrett Esophagus, Esophageal Stenosis",,,,,False,0.0,True,False,4.0,True,True,False,2,False,,0,0.0,0.0,3,0,0.7,False,False,0.010814198060065033,1,False,0.012193465534454006,1,0,0.0038589896,1
NCT01252069,PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study),"A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding",COMPLETED,PHASE3,INTERVENTIONAL,132.0,ACTUAL,2011-01-01,2014-01-01,PregLem SA,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","PGL4001, placebo, drug free period, PGL4001, progestin, drug free period",Uterine Fibroids,,,,,False,1096.0,True,False,3.0,True,True,True,2,True,Large (100-300),0,132.0,4.890349128221754,3,1,0.77,True,True,0.5433456166895235,1,True,0.5871736861837237,1,0,0.45593476,0
NCT00527735,Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC),"A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,334.0,ACTUAL,2008-02-01,2011-12-01,Bristol-Myers Squibb,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG","Ipilimumab, Placebo, Paclitaxel, Carboplatin","Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung",,,,,False,1399.0,True,False,2.0,True,True,True,4,True,Very Large (300+),1,334.0,5.814130531825066,3,1,0.58,True,True,0.8056842740565661,1,True,0.7255852588170277,1,1,0.7695883,1
NCT04629651,Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms,Phase I/II Prospective Trial Investigating the Safety and Efficacy of Captopril Use on the Degree of Marrow Fibrosis in Patients With Primary or Secondary Bone Marrow Fibrosis/Myeloproliferative Neoplasms,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2024-04-01,2024-10-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Captopril,"Bone Marrow Fibrosis, Myeloproliferative Neoplasm",,,,,False,183.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.029513106557703457,1,False,0.008819373048148256,1,0,0.0030340133,1
NCT01894243,Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,"An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment",COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2014-03-13,2017-03-30,AstraZeneca,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Olaparib tablet dosing,Solid Tumours,,,,,False,1113.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,31.0,3.4657359027997265,0,0,0.56,True,True,0.6166507404073417,1,True,0.5582571769474458,1,1,0.5205427,1
NCT00002733,Biological Therapy in Treating Patients With Metastatic Cancer,"ALPHA INTERFERON, TUMOR INFILTRATING LYMPHOCYTES, AND INTERLEUKIN-2 IN THE TREATMENT OF CANCER",COMPLETED,PHASE2,INTERVENTIONAL,30.0,ESTIMATED,1996-01-01,2000-01-01,Hoag Memorial Hospital Presbyterian,OTHER,,,,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG","aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes, cimetidine","Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1461.0,True,False,2.0,False,False,False,4,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.58,True,True,0.5282153257820437,1,True,0.6999292001770994,1,1,0.6971615,1
NCT00544193,Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer,Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,1997-12-01,2012-08-01,City of Hope Medical Center,OTHER,,,,"DRUG, GENETIC, OTHER, PROCEDURE, RADIATION, RADIATION","gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method, conventional surgery, intraoperative radiation therapy, radiation therapy","Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer",,,,,False,5357.0,True,False,1.0,False,False,False,6,True,Small (<30),1,16.0,2.833213344056216,1,0,0.56,True,True,0.5882102297777086,1,True,0.6353927097873094,1,1,0.8352265,1
NCT00132028,Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma,A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,27.0,ACTUAL,2005-09-01,2009-05-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, OTHER","vorinostat, laboratory biomarker analysis","Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Adult Unfavorable Prognosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma",,,,,False,1338.0,True,False,2.0,False,False,False,2,True,Small (<30),0,27.0,3.332204510175204,1,0,0.58,True,True,0.5046942393514561,1,True,0.5994229598426416,1,1,0.6622433,1
NCT02250157,"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies","A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2014-09-05,2020-03-04,"Athenex, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Oratecan,Solid Tumor,,,,,False,2007.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.56,True,True,0.6873991179547528,1,True,0.7747285191520372,1,1,0.67588305,1
NCT00925743,A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer,"A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,76.0,ACTUAL,2009-06-01,2013-03-01,Sanofi,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,cabazitaxel (XRP6258),Solid Cancer,,,,,False,1369.0,True,False,1.0,False,False,True,1,True,Medium (30-100),1,76.0,4.343805421853684,0,0,0.56,True,True,0.807701906754194,1,True,0.6846314524163359,1,1,0.5718625,1
NCT00008190,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia,High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,,,1999-03-01,2008-05-01,Herbert Irving Comprehensive Cancer Center,OTHER,,,,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE","aldesleukin, filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, peripheral blood stem cell transplantation",Leukemia,,,,,False,3349.0,True,False,2.0,False,False,False,7,True,,1,,,1,0,0.58,True,True,0.7167080546608476,1,True,0.9287128456380493,1,1,0.9731898,1
NCT04857138,"A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors","An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-α (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,80.0,ACTUAL,2021-05-18,2024-01-18,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","RO7300490, Atezolizumab",Solid Tumors,,,,,False,975.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,80.0,4.394449154672439,1,0,0.56,True,True,0.768175932119388,1,True,0.6192826329693851,1,1,0.7748622,1
NCT02737553,Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal,Enclosed Electromechanical Morcellation and Vaginal Removal During Laparoscopic Myomectomy,COMPLETED,,INTERVENTIONAL,118.0,ACTUAL,2016-10-01,2020-02-01,Ege University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Enclosed morcellation, vaginal morcellation",Myoma,,,,,False,1218.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,118.0,4.77912349311153,2,1,0.6,True,True,0.6628795129986657,1,True,0.8340946826021529,1,1,0.8409641,1
NCT00610883,LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma,LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,17.0,ACTUAL,1990-05-01,2008-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,"LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU",Non-Hodgkin's Lymphoma,,,,,False,6789.0,True,False,2.0,False,False,False,1,True,Small (<30),1,17.0,2.8903717578961645,0,0,0.58,True,True,0.7017111646004124,1,True,0.6492113974044667,1,1,0.65565276,1
NCT00948090,PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients,"A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,207.0,ACTUAL,2010-01-01,2013-06-01,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,"IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)",Lymphoma,,,,,False,1247.0,True,False,2.0,False,False,True,1,True,Large (100-300),1,207.0,5.337538079701318,0,1,0.58,True,True,0.8047068848895378,1,True,0.7950001835483106,1,1,0.8427927,1
NCT02533765,Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor,Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor,COMPLETED,PHASE2,INTERVENTIONAL,18.0,ACTUAL,2015-09-11,2023-02-13,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,OTHER,,SINGLE_GROUP,NONE,DRUG,Olaparib,"Neoplasms, Germ Cell and Embryonal",,,,,False,2712.0,True,False,2.0,False,False,False,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.58,True,True,0.5234357026572276,1,True,0.6472624315130586,1,0,0.49516973,0
NCT00898755,Collecting and Storing Tissue From Young Patients With Cancer,Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies,COMPLETED,,OBSERVATIONAL,213.0,ESTIMATED,2007-03-05,2025-03-31,Children's Oncology Group,NETWORK,,,,"OTHER, OTHER","Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis","Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma",,,,,False,6601.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,213.0,5.365976015021851,1,1,0.6,True,True,0.9389714265916138,1,True,0.8191663059597082,1,1,0.9176,1
NCT00006247,SU5416 in Treating Children With Recurrent or Progressive Brain Tumors,A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors,TERMINATED,PHASE1,INTERVENTIONAL,33.0,ACTUAL,2000-08-01,2006-03-01,Pediatric Brain Tumor Consortium,NETWORK,,,,DRUG,semaxanib,Brain and Central Nervous System Tumors,,,,,False,2038.0,True,False,1.0,False,False,False,1,False,Medium (30-100),0,33.0,3.5263605246161616,0,0,0.56,False,True,0.6754741381949291,0,True,0.7568709383378672,0,1,0.6383743,0
NCT03194399,Development of Personalized Health Care Service in Patients With Breast Cancer,Development of Personalized Health Care Service in Patients With Breast Cancer,COMPLETED,,INTERVENTIONAL,11.0,ACTUAL,2015-11-27,2016-02-22,Seoul National University Bundang Hospital,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Personalized health care service,"Breast Cancer, Lymphedema, Cancer-related Problem/Condition",,,,,False,87.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,11.0,2.4849066497880004,0,0,0.6,True,False,0.35529907077885853,0,True,0.7091918545060862,1,1,0.92423886,1
NCT00161265,Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer,UMCC 2004.064: Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer,COMPLETED,,OBSERVATIONAL,68.0,ACTUAL,2005-05-01,2016-06-01,University of Michigan Rogel Cancer Center,OTHER,,,,PROCEDURE,tissue procurement,Breast Cancer,,,,,False,4049.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,68.0,4.23410650459726,0,0,0.6,True,True,0.8918597085129514,1,True,0.8557750059290917,1,1,0.84651667,1
NCT00969722,A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients,"A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients",TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2009-08-01,,United Therapeutics,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid",Primary Refractory Neuroblastoma,,,,,False,1303.0,True,False,2.0,True,False,True,3,False,Small (<30),0,1.0,0.6931471805599453,2,0,0.58,False,False,0.03797992666068489,1,False,0.08179903200142641,1,0,0.08665228,1
NCT05589558,Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection,Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection,COMPLETED,,INTERVENTIONAL,102.0,ACTUAL,2020-10-01,2022-02-25,I.M. Sechenov First Moscow State Medical University,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,"consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)","Prostate Cancer, Prostate Adenocarcinoma",,,,,False,512.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,102.0,4.634728988229636,0,1,0.6,True,True,0.7188310545010409,1,True,0.9400898934459271,1,1,0.89798504,1
NCT04592861,Carbon Ion RT for Locally Advanced Pancreatic Cancer,"A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer",TERMINATED,PHASE3,INTERVENTIONAL,5.0,ACTUAL,2020-11-01,2022-08-24,Albert Einstein College of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG","carbon ion RT, Chemotherapy drug",Pancreatic Cancer,,,,,False,661.0,True,False,3.0,True,False,False,2,False,Small (<30),0,5.0,1.791759469228055,2,0,0.77,False,False,0.07542556432998032,1,False,0.04224488669811057,1,0,0.040802155,1
NCT00799188,CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial,CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial,COMPLETED,PHASE3,INTERVENTIONAL,175.0,ACTUAL,2008-10-01,,Hospices Civils de Lyon,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Everolimus,"Cardiac Transplantation, Skin Cancer",,,,,False,1303.0,True,False,3.0,True,False,False,1,True,Large (100-300),0,175.0,5.170483995038151,1,1,0.77,True,True,0.6412130971368615,1,True,0.5771841372976487,1,0,0.439779,0
NCT02505698,A Data Collection Study for the Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment,A Data Collection Study for the Evaluation of Real Imaging's Real Imager 8 (RI-8) Developed for Risk Assessment of Breast Cancer,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2015-10-01,2015-10-01,Real Imaging Ltd.,INDUSTRY,,,,,,Breast Cancer,,,,,False,0.0,True,False,-1.0,False,False,True,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.035351617805414785,1,False,0.02805763913109882,1,0,0.0041424357,1
NCT05071703,"Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study","Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study",COMPLETED,PHASE4,INTERVENTIONAL,30.0,ACTUAL,2021-08-11,2022-11-30,"Jiangsu Simcere Pharmaceutical Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Trilaciclib,Extensive-stage Small-cell Lung Cancer,,,,,False,476.0,True,False,4.0,False,False,True,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.7,True,False,0.43924379489836557,0,True,0.6450866955026389,1,1,0.7334753,1
NCT03066310,Urine-DNA Biomarkers in Detecting Bladder Cancer,Detection of Bladder Cancer Using Urinary Cell-free DNA and Cellular DNA,COMPLETED,,OBSERVATIONAL,125.0,ACTUAL,2017-01-17,2020-01-10,Xiangya Hospital of Central South University,OTHER,,,,DIAGNOSTIC_TEST,Next generation sequencing,"Bladder Cancer, Biomarker, Diagnosis, Urine",,,,,False,1088.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,125.0,4.836281906951478,0,1,0.6,True,True,0.7800148208704942,1,True,0.8456825130390871,1,1,0.8137502,1
NCT01260168,Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies,Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies,COMPLETED,,OBSERVATIONAL,435.0,ACTUAL,2010-10-01,2013-11-01,Exact Sciences Corporation,INDUSTRY,,,,,,"Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer",,,,,False,1127.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,435.0,6.077642243349034,0,1,0.6,True,True,0.9222074643685488,1,True,0.969728179371119,1,1,0.96226186,1
NCT05022641,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,COMPLETED,,INTERVENTIONAL,160.0,ACTUAL,2021-12-01,2024-05-31,University of Michigan,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DEVICE, OTHER","PTeye, Standard of Care","Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism",,,,,False,912.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,160.0,5.081404364984463,2,1,0.6,True,True,0.7148107327594994,1,True,0.8901306604783373,1,1,0.93028927,1
NCT05604378,Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis,Does Epstein-Barr Virus-positive Gastric Cancer Establish a Significant Relationship With the Multiple Genes Related to Gastric Carcinogenesis?,COMPLETED,,OBSERVATIONAL,460.0,ACTUAL,2022-08-03,2022-10-28,"Saint Vincent's Hospital, Korea",OTHER,,,,PROCEDURE,Gastrectomy,"Gastric Cancer, EBV Infection, MSI",,,,,False,86.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,460.0,6.133398042996649,0,1,0.6,True,True,0.9073787227721071,1,True,0.9842992858334066,1,1,0.99432856,1
NCT01468636,A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts,A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts,TERMINATED,PHASE4,INTERVENTIONAL,50.0,ACTUAL,2011-11-01,2012-01-01,University of British Columbia,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Oral Zinc, Placebo","Genital Warts, HPV",,,,,False,61.0,True,False,4.0,True,True,False,2,False,Medium (30-100),0,50.0,3.9318256327243257,3,0,0.7,False,False,0.44286874246420915,1,True,0.6746933439334404,0,1,0.91528976,0
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction",COMPLETED,PHASE1,INTERVENTIONAL,37.0,ACTUAL,2012-08-03,2020-09-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"OTHER, DRUG","Pharmacological Study, Romidepsin","Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm",,,,,False,2951.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,37.0,3.6375861597263857,1,0,0.56,True,True,0.6972536126830138,1,True,0.8281553279526973,1,1,0.8276316,1
NCT05644808,MYLUNG Consortium Study Protocol 2,Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,1002.0,ACTUAL,2020-12-29,2027-12-01,US Oncology Research,INDUSTRY,,,,,,"Carcinoma, Non-Small-Cell Lung",,,,,False,2528.0,False,False,-1.0,False,False,True,0,True,Very Large (300+),0,1002.0,6.910750787961936,0,1,0.6,True,True,0.9659898289610088,1,True,0.9177527124302115,1,1,0.9550793,1
NCT00635778,A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002),"An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers",COMPLETED,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2006-08-07,2008-11-05,Merck Sharp & Dohme LLC,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,dalotuzumab,Advanced Solid Tumors,,,,,False,821.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.56,True,True,0.7137395578118351,1,True,0.6301758090617843,1,1,0.5789516,1
NCT03181334,The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation,The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation,COMPLETED,,INTERVENTIONAL,7711.0,ACTUAL,2017-09-05,2020-12-31,University of Texas Southwestern Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Branch I, Branch II, Branch III, Branch IV, Branch V",Colorectal Cancer,,,,,False,1213.0,True,False,-1.0,True,False,False,5,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.6,True,True,0.829421594399123,1,True,0.8347457701640525,1,1,0.94659793,1
NCT02776813,Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma,"Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,34.0,ACTUAL,2016-08-01,2020-02-12,"Cogent Biosciences, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","ACTR087, rituximab",Lymphoma,,,,,False,1290.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,34.0,3.555348061489413,1,0,0.56,True,True,0.5919537063887101,1,True,0.5998604748858241,1,0,0.46802956,0
NCT03388346,68Ga PSMA in Preprostatectomy Patients,68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients,COMPLETED,PHASE2,INTERVENTIONAL,22.0,ACTUAL,2018-02-16,2021-07-22,"Michael Graham PhD, MD",OTHER,,SINGLE_GROUP,NONE,DRUG,Ga-68 PSMA-HBED-CC PET,"Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasm of Uncertain Behavior",,,,,False,1252.0,True,False,2.0,False,False,False,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.58,True,False,0.49917936891710213,0,False,0.4526820926191998,0,0,0.45432866,0
NCT01667289,Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma,A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma,TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2012-06-01,2017-06-01,Fudan University,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG","Radiotherapy alone, Concurrent chemoradiation","Extranodal NK/T-cell Lymphoma, Nasal Type",,,,,False,1826.0,True,False,2.0,True,False,False,2,False,Small (<30),0,4.0,1.6094379124341005,2,0,0.58,False,False,0.10894166035442987,1,False,0.12262819958874585,1,0,0.08259623,1
NCT02890979,"Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease",Next Generation Sequencing of Esophageal Cytology for the Early Detection of Esophageal Cancer,COMPLETED,,INTERVENTIONAL,11.0,ACTUAL,2016-08-03,2017-10-10,OHSU Knight Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER, OTHER, DEVICE","Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Swallowable Sponge Cell Sampling Device","Barrett Esophagus, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Reflux Disease, Metaplasia",,,,,False,433.0,True,False,-1.0,False,False,False,4,True,Small (<30),0,11.0,2.4849066497880004,1,0,0.6,True,False,0.3158171571014099,0,False,0.4765276685473494,0,0,0.4595584,0
NCT02035358,Immunotherapy Study for Metastatic Renal Cell Cancer,A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer,COMPLETED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2015-05-01,2021-01-12,NewLink Genetics Corporation,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,HyperAcute®-Renal (HAR) Immunotherapy,"Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Metastatic Kidney Cancer",,,,,False,2083.0,True,False,1.0,False,False,True,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.56,True,True,0.5285432441919267,1,True,0.7989631268960696,1,1,0.7724645,1
NCT03628144,Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer,The Use of Immunonutrition to Reduce Toxicities From Concurrent Chemotherapy and Radiotherapy for Treatment of Unresectable Stage IIIA-B Non-Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2020-07-01,2023-09-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, RADIATION, DRUG, OTHER, OTHER, OTHER","Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)","Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA",,,,,False,1157.0,True,False,2.0,True,False,False,7,False,,0,0.0,0.0,2,0,0.58,False,False,0.016263790289390675,1,False,0.008612124983983898,1,0,0.0026117184,1
NCT02068157,Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer,Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II,TERMINATED,PHASE2,INTERVENTIONAL,3.0,ACTUAL,2014-04-01,2016-11-04,Roswell Park Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"OTHER, DRUG, DRUG","Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium","Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma",,,,,False,948.0,True,False,2.0,False,False,False,3,False,Small (<30),0,3.0,1.3862943611198906,1,0,0.58,False,False,0.09988535389816837,1,False,0.09107580447869462,1,0,0.07926164,1
NCT06273852,A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors,A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,8.0,ACTUAL,2024-04-29,2025-03-31,Pure Biologics S.A.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,PBA-0405,"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer",,,,,False,336.0,True,False,0.5,False,False,True,1,True,Small (<30),0,8.0,2.19722457733622,0,0,0.57,True,False,0.2669458324627741,0,False,0.34274385180593275,0,0,0.3037762,0
NCT00828386,Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers,"A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)",TERMINATED,PHASE3,INTERVENTIONAL,83.0,ACTUAL,2009-01-01,2017-04-19,Groupe Oncologie Radiotherapie Tete et Cou,OTHER,RANDOMIZED,PARALLEL,NONE,PROCEDURE,Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy,Nasopharyngeal Cancers,,,,,False,3030.0,True,False,3.0,True,False,False,1,False,Medium (30-100),0,83.0,4.430816798843313,1,0,0.77,False,True,0.7384283974130833,0,True,0.6738181773504407,0,1,0.6931168,0
NCT02942121,Application-based Perioperative Management of the Radical Cystectomy Patient,Application-based Perioperative Management of the Radical Cystectomy Patient,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2016-09-01,2018-09-30,University of Kansas Medical Center,OTHER,,SINGLE_GROUP,NONE,OTHER,LifeScience Technologies application,Bladder Cancer,,,,,False,759.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5377340034412212,1,True,0.6786252025385879,1,1,0.62428236,1
NCT01580410,Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,"A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors",COMPLETED,PHASE2,INTERVENTIONAL,136.0,ACTUAL,2009-05-01,2016-11-01,Wake Forest University Health Sciences,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, PROCEDURE, OTHER, DRUG","mitomycin C, oxaliplatin, therapeutic conventional surgery, quality-of-life assessment, hyperthermic intraperitoneal chemotherapy","Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer",,,,,False,2741.0,True,False,2.0,True,False,False,5,True,Large (100-300),1,136.0,4.919980925828125,2,1,0.58,True,True,0.6662961279414166,1,True,0.7184492147563197,1,1,0.80044794,1
NCT00312819,Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer,Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine,COMPLETED,PHASE2,INTERVENTIONAL,60.0,ESTIMATED,2006-03-01,2009-12-01,Hadassah Medical Organization,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,DRUG,chemotherapy +/- disulfiram,Non-small Cell Lung Cancer,,,,,False,1371.0,True,False,2.0,True,True,False,1,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.58,True,True,0.6990770194380701,1,True,0.7208968525203835,1,1,0.7936522,1
NCT01613677,"Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer","Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2015-11-01,2017-09-01,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,SINGLE_GROUP,NONE,DRUG,BKM120,Treatment for Metastatic or Locally Advanced Cervical Cancer,,,,,False,670.0,True,False,2.0,True,False,True,1,False,,0,0.0,0.0,1,0,0.58,False,False,0.0199775176621919,1,False,0.0013565971769726364,1,0,0.002589586,1
NCT04559854,Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer,"Mindful After Cancer Study: Fostering Positive Body Image, Sexual Health, and Well-being",COMPLETED,,INTERVENTIONAL,22.0,ACTUAL,2019-07-01,2020-10-05,Oregon State University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Mindful After Cancer,"Breast Cancer, Gynecologic Cancer",,,,,False,462.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.6,True,True,0.5468140558659569,1,True,0.7152552282431556,1,1,0.7587448,1
NCT03612596,Narrative Visualization for Breast Cancer Survivors' Physical Activity,Narrative Visualization for Breast Cancer Survivors' Physical Activity,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2018-09-01,2022-03-31,"The University of Texas Medical Branch, Galveston",OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","Narrative visualization, Standard self-regulation",Breast Cancer,,,,,False,1307.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.6053155421550204,1,True,0.7522001502274104,1,1,0.75571233,1
NCT03074110,Isocapnic Hyperventilation - an Alternative Method,Isocapnic Hyperventilation for Enhancing Recovery After Inhalation Anaesthesia - an Alternative Method,COMPLETED,,INTERVENTIONAL,31.0,ACTUAL,2016-11-11,2017-08-15,Sahlgrenska University Hospital,OTHER,RANDOMIZED,SEQUENTIAL,NONE,DEVICE,Isocapnic hyperventilation,Oropharyngeal Neoplasms,,,,,False,277.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,31.0,3.4657359027997265,1,0,0.6,True,True,0.5388001221196386,1,True,0.8846155904359191,1,1,0.8086072,1
NCT03918668,Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women,Observational Study to Understand the Risk Factors Associated With Breast Cancer in Women With a Recent Diagnosis at the Community of Madrid,COMPLETED,,OBSERVATIONAL,66.0,ACTUAL,2018-07-01,2019-12-31,Instituto de Investigación Hospital Universitario La Paz,OTHER,,,,BEHAVIORAL,Women with recent diagnosis of breast cancer,"Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast",,,,,False,548.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,66.0,4.204692619390966,0,0,0.6,True,True,0.7941668123488985,1,True,0.9076537768887338,1,1,0.9106469,1
NCT01924351,HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2015-02-01,2016-06-01,"University of Maryland, Baltimore",OTHER,,SINGLE_GROUP,NONE,RADIATION,Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis,Breast Cancer With Brain Metastasis,,,,,False,486.0,True,False,2.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.58,False,False,0.027085545537035075,1,False,0.005076926569060525,1,0,0.0020323184,1
NCT00006379,Non-Ablative Allo HSCT For Hematologic Malignancies or SAA,Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia,COMPLETED,PHASE2,INTERVENTIONAL,58.0,ACTUAL,2000-06-01,2011-10-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, PROCEDURE","anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation","Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer",,,,,False,4139.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,58.0,4.07753744390572,1,0,0.58,True,True,0.7874372293912648,1,True,0.911002970057493,1,1,0.9616897,1
NCT00661102,A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).,"A Randomized, Open Label Study Comparing the Efficacy of Topical Corticosteroids or Bepantol in the Prophylaxis of Hand-foot Syndrome in Patients Receiving Oral Xeloda for Treatment of Metastatic Breast Cancer or Colorectal Cancer.",COMPLETED,PHASE3,INTERVENTIONAL,598.0,ACTUAL,2008-12-01,2011-04-01,Hoffmann-La Roche,INDUSTRY,,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Corticosteroids, Placebo, capecitabine [Xeloda], dexpantenol [Bepantol]",Breast Cancer,,,,,False,851.0,True,False,3.0,False,False,True,4,True,Very Large (300+),1,598.0,6.395261598115449,1,1,0.77,True,True,0.8393681485673745,1,True,0.743164320206153,1,1,0.844985,1
NCT03166631,A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,"An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies",TERMINATED,PHASE1,INTERVENTIONAL,62.0,ACTUAL,2017-09-08,2020-10-28,Boehringer Ingelheim,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","BI 891065, BI 754091","Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung",,,,,False,1146.0,True,False,1.0,False,False,True,2,False,Medium (30-100),0,62.0,4.143134726391533,1,0,0.56,False,True,0.730532263490139,0,True,0.8284705083821057,0,1,0.7408774,0
NCT01210482,Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan),"SAFETY AND EFFECTIVENESS OF TEMSIROLIMUS IN JAPANESE PATIENTS WITH UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA: A POST-MARKETING, ALL-CASE SURVEILLANCE STUDY INCLUDING B1771016 STUDY - SURVEY ON LONG-TERM USE -",COMPLETED,,OBSERVATIONAL,1050.0,ACTUAL,2010-08-24,2018-05-31,Pfizer,INDUSTRY,,,,DRUG,Temsirolimus,Renal Cell Carcinoma,,,,,False,2837.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,1050.0,6.957497370876951,0,1,0.6,True,True,0.9681251493207976,1,True,0.9689015190251818,1,1,0.9795791,1
NCT01448759,Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel,Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion,COMPLETED,,INTERVENTIONAL,30.0,ACTUAL,2011-10-01,2012-02-01,Institut Curie,OTHER,,SINGLE_GROUP,NONE,OTHER,blood sampling,Tumors,,,,,False,123.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.608083935266692,1,True,0.8916375350844545,1,1,0.93085515,1
NCT00077961,"Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL","Phase I/II Study of Rituximab Plus CAMPATH in Patients With Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma",TERMINATED,PHASE1,INTERVENTIONAL,49.0,,2003-12-01,,"Genzyme, a Sanofi Company",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,CAMPATH (alemtuzumab),Non-Hodgkin's Lymphoma,,,,,False,1303.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,49.0,3.912023005428146,0,0,0.56,False,True,0.7296483784045452,0,True,0.6913701402288024,0,1,0.711271,0
NCT04200287,Study to Improve Survivorship Care Related to Fertility and Family-building After Cancer,Pilot Study to Improve Survivorship Care Related to Fertility and Family-building After Cancer,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2020-01-06,2021-09-11,Stanford University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Online decision aid tool,Cancer,,,,,False,614.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5302246747838714,1,True,0.6898206187413973,1,1,0.73099095,1
NCT00025389,"Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer",A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer,COMPLETED,PHASE2,INTERVENTIONAL,8.0,ACTUAL,2001-11-01,2007-08-01,University of Chicago,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, PROCEDURE, PROCEDURE","bevacizumab, carboplatin, paclitaxel, conventional surgery, neoadjuvant therapy",Lung Cancer,,,,,False,2099.0,True,False,2.0,False,False,False,5,True,Small (<30),1,8.0,2.19722457733622,1,0,0.58,True,False,0.2416400400535924,0,False,0.343940820520567,0,0,0.36382222,0
NCT00931567,Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing,Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing,COMPLETED,PHASE2,INTERVENTIONAL,80.0,ACTUAL,2007-08-01,2010-02-01,Centre Hospitalier Universitaire de Nice,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DEVICE","Autologous platelets gel, Vaselitulle",Dupuytren's Contracture,,,,,False,915.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,80.0,4.394449154672439,2,0,0.58,True,True,0.6709443912277318,1,True,0.6561997474176163,1,1,0.57489854,1
NCT00925600,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,"A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy",COMPLETED,PHASE3,INTERVENTIONAL,769.0,ACTUAL,2009-11-30,2016-05-12,Amgen,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"BIOLOGICAL, BIOLOGICAL","Denosumab, Placebo","Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer",,,,,False,2355.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,769.0,6.646390514847729,3,1,0.77,True,True,0.8794655485382772,1,True,0.7910004182266825,1,1,0.8279205,1
NCT00296023,Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer,Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies,COMPLETED,,INTERVENTIONAL,25.0,ACTUAL,1999-01-01,2008-06-01,"University of California, San Francisco",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation","Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes",,,,,False,3439.0,True,False,-1.0,False,False,False,9,True,Small (<30),1,25.0,3.258096538021482,1,0,0.6,True,True,0.636382769947336,1,True,0.7627081111007605,1,1,0.89788294,1
NCT02645864,Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma,Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2016-01-01,2018-12-01,Peking University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Apatinib, Irinotecan",Esophageal Squamous Cell Carcinoma,,,,,False,1065.0,True,False,1.0,False,False,False,2,True,Small (<30),1,12.0,2.5649493574615367,1,0,0.56,True,False,0.3217257516144047,0,False,0.48118828479340886,0,1,0.5573666,1
NCT04105465,Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer,"Randomised,Crossover, Feasibility Study to Evaluate the PlasmaJet in the Management of Lymphedema and Lymphocyst Formation in Patients Undergoing Bilateral Groin Node Dissection (BGND) for Vulval Cancer",TERMINATED,,INTERVENTIONAL,21.0,ACTUAL,2013-07-01,2016-12-01,Royal Surrey County Hospital NHS Foundation Trust,OTHER,RANDOMIZED,CROSSOVER,DOUBLE,DEVICE,PlasmaJet,"Vulvar Cancer, Groin Node",,,,,False,1249.0,True,False,-1.0,True,True,False,1,False,Small (<30),0,21.0,3.091042453358316,2,0,0.6,False,True,0.5198934076194629,0,False,0.4827220223337151,1,1,0.5715302,0
NCT04539678,"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications",Retrospective and Prospective Multicenter Study Evaluating the Impact of Treatment With Cytoreducing Agents on the Recurrence of Thrombosis in Thrombotic Patients With a Diagnosis of Myeloproliferative Neoplasia and Normal Blood Counts - a FIM Study,COMPLETED,,OBSERVATIONAL,253.0,ACTUAL,2019-05-21,2023-12-31,Nantes University Hospital,OTHER,,,,,,"Thrombotic Patients, Diagnosis of Myeloproliferative Neoplasia, Impact of Treatment With Cytoreducing Agent",,,,,False,1685.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,253.0,5.537334267018537,0,1,0.6,True,True,0.8912269833566684,1,True,0.8599292998655378,1,1,0.84623057,1
NCT00339495,Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial,Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,154900.0,ACTUAL,1998-05-01,2026-12-31,National Cancer Institute (NCI),NIH,,,,,,"Cancer, Death",,,,,False,10471.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9844580555127875,1,True,0.9403859858824475,1,1,0.95945007,1
NCT04827745,Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL,A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL),COMPLETED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2021-06-11,2025-05-22,"University of Maryland, Baltimore",OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,BLINCYTO (Blinatumomab),"Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)",,,,,False,1441.0,True,False,2.0,False,False,False,1,True,Small (<30),0,2.0,1.0986122886681098,0,0,0.58,True,False,0.10143143383890872,0,False,0.15629205797036785,0,0,0.1733917,0
NCT03480659,"Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC","Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA.",TERMINATED,,OBSERVATIONAL,165.0,ACTUAL,2018-06-01,2021-09-01,HKGepitherapeutics,INDUSTRY,,,,,,"Breast Cancer, Breast Cancer Female",,,,,False,1188.0,True,False,-1.0,False,False,True,0,False,Large (100-300),0,165.0,5.111987788356544,0,1,0.6,False,True,0.8299905068745412,0,True,0.9393562947868044,0,1,0.95932466,0
NCT03694262,"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)","An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2019-07-19,2026-01-05,Medical College of Wisconsin,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Rucaparib, Bevacizumab, Atezolizumab","Endometrial Cancer, Uterine Carcinosarcoma",,,,,False,2362.0,False,False,2.0,False,False,False,3,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.58,True,True,0.5726694617530829,1,True,0.7824751673905613,1,1,0.8619311,1
NCT00739206,Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.,"A Multicenter, Open Label, Efficacy and Safety Study of Parenteral SAR97276A in the Treatment of Symptomatic Uncomplicated and Severe Malaria in Adults and Children",TERMINATED,PHASE2,INTERVENTIONAL,113.0,ACTUAL,2008-08-01,2009-06-01,Sanofi,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,SAR97276A,Malaria,,,,,False,304.0,True,False,2.0,False,False,True,1,False,Large (100-300),0,113.0,4.736198448394496,0,1,0.58,False,True,0.6557769250540447,0,True,0.87598247783481,0,1,0.9384754,0
NCT05357508,Colorectal Cancer Screening Based on Predicted Risk,Protocol Title: Colorectal Cancer Screening Decisions Based on Predicted Risk: the PREcision ScreENing Randomized Controlled Trial (PRESENT),COMPLETED,,INTERVENTIONAL,515.0,ACTUAL,2022-05-01,2023-12-31,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",OTHER,RANDOMIZED,PARALLEL,DOUBLE,"BEHAVIORAL, BEHAVIORAL","Intervention brochure, Control brochure",Colorectal Cancer,,,,,False,609.0,True,False,-1.0,True,True,False,2,True,Very Large (300+),0,515.0,6.246106765481563,3,1,0.6,True,True,0.8859624023610752,1,True,0.8921301955617412,1,1,0.94252527,1
NCT00947856,A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study,Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study,COMPLETED,PHASE2,INTERVENTIONAL,110.0,ACTUAL,2009-07-01,2013-03-01,Seagen Inc.,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,brentuximab vedotin,"Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin",,,,,False,1339.0,True,False,2.0,False,False,True,1,True,Large (100-300),0,110.0,4.709530201312334,0,1,0.58,True,True,0.6968817381596756,1,True,0.8029456512737483,1,1,0.81496876,1
NCT01845454,A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy,"A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy (""DOSE"" Trial)",TERMINATED,,INTERVENTIONAL,36.0,ACTUAL,2013-04-01,2015-01-01,"CSA Medical, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DEVICE,trūFreeze™ Spray Cryotherapy,Barrett's Esophagus,,,,,False,640.0,True,False,-1.0,False,False,True,1,False,Medium (30-100),0,36.0,3.610917912644224,0,0,0.6,False,True,0.6763400889057158,0,True,0.567068712776585,0,0,0.39238173,1
NCT04131881,The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients,The Consistency of Drug Sensitivity in Vitro and Neoadjuvant Chemotherapy Results in Vivo for Early Breast Cancer Patients,COMPLETED,,OBSERVATIONAL,45.0,ACTUAL,2017-04-01,2019-09-01,Peking University People's Hospital,OTHER,,,,,,"Breast Cancer, Drug Effect",,,,,False,883.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.6,True,True,0.7390687026864087,1,True,0.7815155382705379,1,1,0.76780814,1
NCT00965172,Caphosol in Sarcoma Patients With Mucositis,A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2010-04-01,2012-02-01,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"OTHER, OTHER","Caphosol, Baking Soda","Sarcoma, Oral Mucositis",,,,,False,671.0,True,False,2.0,True,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,2,0,0.58,True,False,0.4108724680575091,0,False,0.43496508214639995,0,0,0.48770842,0
NCT01835288,Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2013-05-01,,Stanford University,OTHER,,SINGLE_GROUP,NONE,"DRUG, OTHER","arsenic trioxide, laboratory biomarker analysis","Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia",,,,,False,1303.0,True,False,2.0,False,False,False,2,False,,0,0.0,0.0,1,0,0.58,False,False,0.02609758964672443,1,False,0.006696236716913185,1,0,0.0028281626,1
NCT05987930,Bone Lid Technique Versus Standard Technique for Treatment of Mandibular Lesions,Lecturer of Oral and Maxillofacial Surgery,COMPLETED,,INTERVENTIONAL,24.0,ACTUAL,2023-06-20,2023-12-20,Tanta University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DEVICE, DEVICE","bone lid technique, standard technique","Mandible Cyst, Mandible Tumor, Mandibular Diseases",,,,,False,183.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,24.0,3.218875824868201,2,0,0.6,True,False,0.41621212460050705,0,True,0.7368214947234374,1,1,0.85389113,1
NCT03646123,Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma,Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects,TERMINATED,PHASE2,INTERVENTIONAL,255.0,ACTUAL,2019-01-28,2024-08-23,Seagen Inc.,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab",Hodgkin Lymphoma,,,,,False,2034.0,True,False,2.0,False,False,True,6,False,Large (100-300),1,255.0,5.545177444479562,1,1,0.58,False,True,0.8159010561247224,0,True,0.8098079691781196,0,1,0.89626527,0
NCT03542877,Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer,"An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,44.0,ACTUAL,2018-06-01,2022-03-07,Academic Thoracic Oncology Medical Investigators Consortium,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Oral Tablet: Cabozantinib,Colorectal Cancer,,,,,False,1375.0,True,False,2.0,False,False,True,1,True,Medium (30-100),1,44.0,3.80666248977032,0,0,0.58,True,True,0.6716746600276592,1,True,0.7873098551256397,1,1,0.6886643,1
NCT02632370,5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor,"A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study",COMPLETED,,OBSERVATIONAL,69.0,ACTUAL,2016-05-01,2018-12-31,Constantinos Hadjipanayis,OTHER,,,,"DRUG, PROCEDURE","Gliolan®, Fluorescence-Guided Surgery",Malignant Gliomas,,,,,False,974.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,69.0,4.248495242049359,1,0,0.6,True,True,0.78191707057501,1,True,0.8141190216669638,1,1,0.78943884,1
NCT03732820,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,"A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,895.0,ACTUAL,2018-10-31,2026-04-27,AstraZeneca,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","olaparib, abiraterone acetate",Metastatic Castration-resistant Prostate Cancer,,,,,False,2735.0,False,False,3.0,True,True,True,2,True,Very Large (300+),1,895.0,6.79794041297493,3,1,0.77,True,True,0.8938628938392363,1,True,0.7655320869293974,1,1,0.6513246,1
NCT05073432,Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer,A Study in Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer,COMPLETED,,INTERVENTIONAL,10.0,ACTUAL,2021-07-28,2023-03-15,University of Rochester,OTHER,,SINGLE_GROUP,NONE,OTHER,Experimental,Breast Cancer,,,,,False,595.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.3578418850176566,0,True,0.5273853282921386,1,1,0.5081772,1
NCT00819832,Anderson Circulating Tumor Cell Burden (CTCB) Study,Assessment of Circulating Tumor Cell Burden After Radiofrequency-Based Plasma Ablation (COBLATION®) in Conjunction With Vertebroplasty or Kyphoplasty for Augmenting Painful Vertebral Compression Fractures Secondary to Malignancy,TERMINATED,PHASE4,INTERVENTIONAL,3.0,ACTUAL,2008-12-01,2010-05-01,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DEVICE","Kyphoplasty, Vertebroplasty, Cavity SpineWand","Cancer, Spinal Disease, Vertebral Compression Fractures",,,,,False,516.0,True,False,4.0,True,False,False,3,False,Small (<30),0,3.0,1.3862943611198906,2,0,0.7,False,False,0.04565847034729655,1,False,0.03837004405182182,1,0,0.034240138,1
NCT04877821,The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC,An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,31.0,ESTIMATED,2021-09-15,2025-12-31,Guangdong Provincial People's Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Sintilimab, Anlotinib, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide",Triple Negative Breast Cancer,,,,,False,1568.0,False,False,2.0,False,False,False,6,True,Medium (30-100),1,31.0,3.4657359027997265,1,0,0.58,True,True,0.5250065225185481,1,True,0.7510811916569367,1,1,0.77131677,1
NCT00606216,Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy,Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy,COMPLETED,,OBSERVATIONAL,66.0,ACTUAL,2007-01-01,2015-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,"PROCEDURE, PROCEDURE, PROCEDURE","MRI and cognitive evaluation, MRI and cognitive evaluation, brain MRI study and a brief neuropsychological evaluation","Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Biphenotypic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma",,,,,False,3256.0,True,False,-1.0,False,False,False,3,True,Medium (30-100),0,66.0,4.204692619390966,1,0,0.6,True,True,0.8435772184610205,1,True,0.8978249710856245,1,1,0.9290652,1
NCT01104155,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer","The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,123.0,ACTUAL,2010-02-22,2017-01-18,Eisai Inc.,INDUSTRY,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","eribulin mesylate + erlotinib, eribulin mesylate + erlotinib",Non-small Cell Lung Cancer,,,,,False,2522.0,True,False,2.0,True,False,True,2,True,Large (100-300),1,123.0,4.820281565605037,2,1,0.58,True,True,0.6470068379318097,1,True,0.8427823570829099,1,1,0.9022129,1
NCT04094961,Ixazomib + Pomalidomide + Dexamethasone In MM,Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,52.0,ACTUAL,2019-09-18,2027-01-01,"Omar Nadeem, MD",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Ixazomib, Pomalidomide, Dexamethasone","Multiple Myeloma, Multiple Myeloma in Relapse",,,,,False,2662.0,False,False,1.0,False,False,False,3,True,Medium (30-100),0,52.0,3.970291913552122,1,0,0.56,True,True,0.7519374535244482,1,True,0.8560313470240216,1,1,0.8019593,1
NCT03279991,Neuromed- Integrated Health Life Platform and Biobank,Neuromed- Integrated Health Life Platform and Biobank,COMPLETED,,OBSERVATIONAL,4000.0,ACTUAL,2019-03-04,2023-05-30,Neuromed IRCCS,OTHER,,,,,,"Cardiovascular Diseases, Neuro-Degenerative Disease, Cancer, Pregnancy",,,,,False,1548.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,4000.0,8.294299608857235,0,1,0.6,True,True,0.948546544238629,1,True,0.9785064241142132,1,1,0.9769678,1
NCT00138060,Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants,Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques l'Interet Des Determinants Genotypiques Pour l'Optimisation de l'Efficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile,COMPLETED,PHASE4,INTERVENTIONAL,71.0,ACTUAL,2005-06-01,2008-12-01,Institut de Recherche Clinique sur les Cancers et le Sang,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","irinotecan, 5 fluorouracil",Metastatic Colorectal Cancer,,,,,False,1279.0,True,False,4.0,False,False,False,2,True,Medium (30-100),1,71.0,4.276666119016055,1,0,0.7,True,True,0.6421684866381191,1,True,0.7594672533732304,1,1,0.77621627,1
NCT03371420,PET Imaging of Subjects Using 124I-PU-AD,PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study,TERMINATED,EARLY_PHASE1,INTERVENTIONAL,5.0,ACTUAL,2016-04-01,2019-06-10,"Samus Therapeutics, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DEVICE, OTHER","PU-AD, PET Scan, Blood Draws","Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma",,,,,False,1165.0,True,False,0.5,False,False,True,3,False,Small (<30),0,5.0,1.791759469228055,1,0,0.57,False,False,0.18118316042637347,1,False,0.1934690794039644,1,0,0.16350542,1
NCT02635789,Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC),"A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex",COMPLETED,PHASE3,INTERVENTIONAL,62.0,ACTUAL,2015-12-01,2016-10-01,Nobelpharma,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","NPC-12G gel, Placebo gel","Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque",,,,,False,305.0,True,False,3.0,True,True,True,2,True,Medium (30-100),0,62.0,4.143134726391533,3,0,0.77,True,True,0.5214648943987377,1,True,0.7128305582887684,1,1,0.81367195,1
NCT03096782,Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma,Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment,COMPLETED,PHASE2,INTERVENTIONAL,6.0,ACTUAL,2017-10-13,2022-09-20,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG, RADIATION, PROCEDURE","Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome",,,,,False,1803.0,True,False,2.0,False,False,False,12,True,Small (<30),1,6.0,1.9459101490553128,1,0,0.58,True,False,0.1648168822772116,0,False,0.33205268280704553,0,0,0.31727073,0
NCT00375245,Rapamycin With Grapefruit Juice for Advanced Malignancies,A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2006-09-01,2012-05-01,University of Chicago,OTHER,,SINGLE_GROUP,NONE,"DRUG, OTHER","Rapamycin (sirolimus), Grapefruit Juice","Tumors, Neoplasm Metastasis",,,,,False,2069.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,41.0,3.737669618283368,1,0,0.56,True,True,0.6808967612037244,1,True,0.7136465078682095,1,1,0.59717196,1
NCT00958724,Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors,A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,6.0,ACTUAL,2009-07-01,2010-04-01,"Puma Biotechnology, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Neratinib, Vinorelbine",Advanced Malignant Solid Tumors,,,,,False,274.0,True,False,1.0,False,False,True,2,True,Small (<30),1,6.0,1.9459101490553128,1,0,0.56,True,False,0.1701671442692656,0,False,0.2824393366347083,0,0,0.1725932,0
NCT03986593,Cryoablation of Bone Metastases From Endocrine Tumors,Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors,TERMINATED,,INTERVENTIONAL,17.0,ACTUAL,2019-09-26,2023-05-29,Instituto do Cancer do Estado de São Paulo,OTHER,,SINGLE_GROUP,NONE,DEVICE,cryoablation,"Neoplasm Metastasis, Thyroid Neoplasm, Pheochromocytoma, Adrenal Neoplasm, Neuroendocrine Tumors, Bone Metastases",,,,,False,1341.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,False,True,0.5263243931049545,0,False,0.48403109832950897,1,0,0.4747518,1
NCT03707860,Radiation Oncology Mobile Application,Radiation Oncology Mobile Application: Symptoms Reporting System and Quality Assurance Tool,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2019-02-01,2021-10-20,King Hussein Cancer Center,OTHER,,,,,,"Head and Neck Cancer, Radiation Toxicity",,,,,False,992.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.043108681848130416,1,False,0.012266358776066544,1,0,0.0039522243,1
NCT02150746,Circulating Tumor Cells in Operative Blood,Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence,COMPLETED,,OBSERVATIONAL,3.0,ACTUAL,2015-02-01,2016-02-01,University of Florida,OTHER,,,,"PROCEDURE, PROCEDURE","Peripheral/Central Venous Blood Draw, Peritoneal Wash","Carcinoma, Pancreatic Ductal",,,,,False,365.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,3.0,1.3862943611198906,1,0,0.6,True,False,0.12522986508681996,0,False,0.08421394547873193,0,0,0.06338781,0
NCT02460835,A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma,A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma,COMPLETED,,INTERVENTIONAL,77.0,ACTUAL,2016-01-26,2022-01-20,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,RADIATION,Adaptive Radiation Therapy,Hepatocellular Carcinoma,,,,,False,2186.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,77.0,4.356708826689592,0,0,0.6,True,True,0.8642556049354593,1,True,0.8660632111063019,1,1,0.7425453,1
NCT05848050,Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases,Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases,COMPLETED,,INTERVENTIONAL,21.0,ACTUAL,2023-06-27,2025-07-25,GCS Ramsay Santé pour l'Enseignement et la Recherche,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,biological samples (blood test and lumbar puncture),Brain Metastases,,,,,False,759.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,21.0,3.091042453358316,0,0,0.6,True,True,0.5502181908068892,1,True,0.638597753683266,1,1,0.6080312,1
NCT03927924,High-intensity Focused Ultrasound Study,Evaluation of the Effectiveness of High-intensity Focused Ultrasound for the Treatment of Prostate Cancer,TERMINATED,,INTERVENTIONAL,5.0,ACTUAL,2019-06-25,2021-01-28,Chinese University of Hong Kong,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,High-intensity focused ultrasound,Prostate Cancer,,,,,False,583.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.6,False,False,0.2231037954433687,1,False,0.2658957670698764,1,0,0.28169736,1
NCT03507010,Ledderhose Disease: Radiotherapy or Not?,"Ledderhose Disease: Radiotherapy or Not? A Randomised, Multicentre, Prospective, Double Blind Phase III Trial Investigating the Effect of Radiotherapy on Patients With Ledderhose Disease",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,84.0,ACTUAL,2018-01-23,2029-03-15,University Medical Center Groningen,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"RADIATION, OTHER","Radiotherapy, Sham Radiotherapy",Ledderhose Disease,,,,,False,4069.0,False,False,3.0,True,True,False,2,True,Medium (30-100),0,84.0,4.442651256490317,3,0,0.77,True,True,0.765714211308795,1,True,0.7401647660208255,1,1,0.7788033,1
NCT00301691,Nutrition Education for Low-Income Healthy Participants Who Eat an Unhealthy Diet,Tailoring Nutrition Education for Low-Income Audiences,COMPLETED,,INTERVENTIONAL,2000.0,ESTIMATED,2000-09-01,2006-05-01,Brown University,OTHER,RANDOMIZED,,,"BEHAVIORAL, OTHER, OTHER","behavioral dietary intervention, educational intervention, preventative dietary intervention","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2068.0,True,False,-1.0,True,False,False,3,True,Very Large (300+),0,2000.0,7.601402334583733,2,1,0.6,True,True,0.9441360901687168,1,True,0.8146699409618147,1,1,0.79284215,1
NCT02126319,Facilitating Participation in a Prostate Cancer Risk Assessment Program,Facilitating Participation in a Prostate Cancer Family Risk Assessment Program,COMPLETED,,INTERVENTIONAL,128.0,ACTUAL,1998-10-01,2002-04-01,Fox Chase Cancer Center,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"BEHAVIORAL, BEHAVIORAL","Cognitive Affective preparation, General Health Education",Prostate Cancer,,,,,False,1278.0,True,False,-1.0,True,True,False,2,True,Large (100-300),0,128.0,4.859812404361672,3,1,0.6,True,True,0.7103701302742182,1,True,0.8884915847585988,1,1,0.86054224,1
NCT04870840,Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer,Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES],COMPLETED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2020-10-19,2023-07-11,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"RADIATION, OTHER, OTHER","Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration","Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Malignant Posterior Tongue Neoplasm, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma",,,,,False,995.0,True,False,1.0,False,False,False,3,True,Small (<30),0,3.0,1.3862943611198906,1,0,0.56,True,False,0.11533940854324766,0,False,0.08400109235468763,0,0,0.14329244,0
NCT00028587,PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors,A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,96.0,ACTUAL,2001-12-01,,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, OTHER","bortezomib, paclitaxel, carboplatin, laboratory biomarker analysis","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Medium (30-100),1,96.0,4.574710978503383,1,0,0.56,True,True,0.8042761260583389,1,True,0.6351470916809161,1,1,0.5514432,1
NCT04117438,Tell us Your Food Story,Interviewing Breast Cancer Patients to Understand the Patients Relationship With Food Before and After Cancer Diagnosis.,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2019-10-01,2020-11-20,Medical College of Wisconsin,OTHER,,,,OTHER,no intervention,Breast Neoplasms,,,,,False,416.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.03767478534632709,1,False,0.005757424250524357,1,0,0.003065959,1
NCT00001572,Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype,Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype,COMPLETED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,1997-01-30,2010-11-02,National Cancer Institute (NCI),NIH,,,,"DRUG, DRUG","Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug","B Cell Lymphoma, Follicular Lymphoma, Neoplasm",,,,,False,5024.0,True,False,1.0,False,False,False,2,True,Small (<30),0,21.0,3.091042453358316,1,0,0.56,True,True,0.6630384853777389,1,True,0.7011220952734792,1,1,0.6964106,1
NCT02537743,Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma,"Open-labeled, Multicenter, Non-interventional, Prospective PRO Registry for Patients With First Line Treatment for Advanced RCC Using a Tablet-technology Based Digital Device",COMPLETED,,OBSERVATIONAL,98.0,ACTUAL,2015-08-19,2021-02-19,iOMEDICO AG,INDUSTRY,,,,,,Renal Cell Carcinoma,,,,,False,2011.0,True,False,-1.0,False,False,True,0,True,Medium (30-100),0,98.0,4.59511985013459,0,0,0.6,True,True,0.8893282381077896,1,True,0.7655438932352812,1,1,0.79091555,1
NCT03073785,Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer,A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,46.0,ACTUAL,2016-09-16,2027-12-01,University of Nebraska,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, OTHER, OTHER, RADIATION, DRUG","Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid","Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7",,,,,False,4093.0,False,False,2.0,True,False,False,6,True,Medium (30-100),1,46.0,3.8501476017100575,2,0,0.58,True,True,0.66543590329985,1,True,0.8460185620636222,1,1,0.8683871,1
NCT00256932,Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain",COMPLETED,PHASE3,INTERVENTIONAL,518.0,ACTUAL,2005-08-01,2006-05-01,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","alvimopan, Placebo","Bowel Dysfunction, Constipation",,,,,False,273.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,518.0,6.251903883165888,3,1,0.77,True,True,0.780441213317967,1,True,0.8783375334880609,1,1,0.948858,1
NCT01133743,"Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia","An Open-Label Phase 2 Study of Lenalidomide (Revlimid) in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (CLL)",COMPLETED,PHASE2,INTERVENTIONAL,31.0,ACTUAL,2010-05-01,2016-12-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,DRUG,Lenalidomide and Dexamethasone,Chronic Lymphocytic Leukemia,,,,,False,2406.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,31.0,3.4657359027997265,0,0,0.58,True,True,0.6440673284651577,1,True,0.7715736990266457,1,1,0.7270548,1
NCT04186819,Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.,"A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer",COMPLETED,PHASE3,INTERVENTIONAL,356.0,ACTUAL,2020-03-02,2021-06-21,Blue Earth Diagnostics,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DIAGNOSTIC_TEST","rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan",Prostate Cancer,,,,,False,476.0,True,False,3.0,False,False,True,2,True,Very Large (300+),0,356.0,5.877735781779639,1,1,0.77,True,True,0.7719011625210851,1,True,0.8592329565715532,1,1,0.81407255,1
NCT02057432,Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO),A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO),COMPLETED,,INTERVENTIONAL,15.0,ACTUAL,2012-04-01,2016-08-01,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DEVICE,intra-operative MRI,"Stage I Breast Carcinoma, Stage II Breast Carcinoma",,,,,False,1583.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.6,True,True,0.5070056366760696,1,True,0.5797798784565625,1,1,0.5800374,1
NCT00393224,"Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families","Defining Markers of Susceptibility to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families",TERMINATED,,OBSERVATIONAL,952.0,ACTUAL,2005-07-05,2020-06-02,National Cancer Institute (NCI),NIH,,,,,,Nasopharyngeal Neoplasms,,,,,False,5446.0,True,False,-1.0,False,False,False,0,False,Very Large (300+),0,952.0,6.859614903654202,0,1,0.6,False,True,0.9806757848110618,0,True,0.907641694240663,0,1,0.9370013,0
NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,"An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myeloid Leukaemia Ineligible for Intensive Treatment",COMPLETED,PHASE2,INTERVENTIONAL,68.0,ACTUAL,2008-05-01,2014-03-01,Boehringer Ingelheim,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","BI 811283 (d 1 and 15), Cytarabine, BI 811283 (d1), Cytarabine","Leukemia, Myeloid, Acute",,,,,False,2130.0,True,False,2.0,True,False,True,4,True,Medium (30-100),1,68.0,4.23410650459726,2,0,0.58,True,True,0.6742609790613656,1,True,0.8530261104498374,1,1,0.83137023,1
NCT02315469,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers,COMPLETED,,OBSERVATIONAL,190.0,ACTUAL,2015-02-10,2019-02-09,NRG Oncology,OTHER,,,,"OTHER, OTHER","Comprehensive Geriatric Assessment, Questionnaire Administration","Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7",,,,,False,1460.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,190.0,5.25227342804663,1,1,0.6,True,True,0.8252655433739078,1,True,0.868565624223282,1,1,0.75368315,1
NCT00983944,Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma,A Randomized Phase II Study of Dose-Adjusted EPOCH-R and R-VACOP-B in Primary Mediastinal (Thymic) Large B-Cell Lymphoma,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2009-09-01,2011-04-25,Ohio State University Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","bleomycin sulfate, rituximab, EPOCH regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate",Lymphoma,,,,,False,601.0,True,False,2.0,True,False,False,8,False,,1,0.0,0.0,2,0,0.58,False,False,0.013830999120626169,1,False,0.01093475262967219,1,0,0.0024355263,1
NCT01048918,Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer,Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer,COMPLETED,,OBSERVATIONAL,280.0,ACTUAL,2008-09-04,2022-04-08,City of Hope Medical Center,OTHER,,,,,,"Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer, Stage III-IV Breast Cancer or Inflammatory",,,,,False,4964.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,280.0,5.638354669333745,0,1,0.6,True,True,0.9468800359784932,1,True,0.8305821205339603,1,1,0.5744958,1
NCT04476654,Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video,Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video,COMPLETED,,INTERVENTIONAL,57.0,ACTUAL,2021-11-01,2023-06-12,Virginia Commonwealth University,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,YouTube Video Arm,Breast Cancer,,,,,False,588.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,57.0,4.060443010546419,1,0,0.6,True,True,0.7018148417668858,1,True,0.851630301659565,1,1,0.7491176,1
NCT02960555,Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR),Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR),ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,61.0,ESTIMATED,2017-02-08,2030-04-30,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER","Isatuximab, Laboratory Biomarker Analysis",Smoldering Plasma Cell Myeloma,,,,,False,4829.0,False,False,2.0,False,False,False,2,True,Medium (30-100),0,61.0,4.127134385045092,1,0,0.58,True,True,0.8313892880863963,1,True,0.9255785452667671,1,1,0.92606145,1
NCT03696355,Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas,"Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy",COMPLETED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2018-11-19,2022-09-04,St. Jude Children's Research Hospital,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, RADIATION","GDC-0084, radiation therapy",Brain and Central Nervous System Tumors,,,,,False,1385.0,True,False,1.0,False,False,False,2,True,Small (<30),0,27.0,3.332204510175204,1,0,0.56,True,True,0.5448669103827222,1,False,0.49502710597895844,0,0,0.48049694,0
NCT06719973,Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521),"An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2025-05-14,2025-05-14,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","M9466, Carboplatin, Etoposide, Atezolizumab, M9446, M9446, Carboplatin",Advanced Solid Tumors,,,,,False,0.0,True,False,1.0,False,False,True,7,False,,1,0.0,0.0,1,0,0.56,False,False,0.020429846619439727,1,False,0.004051862233140785,1,0,0.0019982432,1
NCT00611858,"Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer","Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer",TERMINATED,PHASE2,INTERVENTIONAL,13.0,ACTUAL,2008-05-01,2016-09-01,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, RADIATION","Cetuximab, 5-Fluorouracil, Radiation",Rectal Cancer,,,,,False,3045.0,True,False,2.0,False,False,False,3,False,Small (<30),1,13.0,2.6390573296152584,1,0,0.58,False,False,0.39528066225227265,1,False,0.48869642982469885,1,1,0.5718777,0
NCT02599467,EMG at Performing ULTN 1 in Breast Cancer Patients,Evoked EMG Muscle Activity at Performing ULTN 1 in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,124.0,ACTUAL,2015-01-01,2015-06-01,University of Alcala,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,OTHER,ULNT 1 and EMG recording,Physiotherapy,,,,,False,151.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,124.0,4.8283137373023015,0,1,0.6,True,True,0.7431882934245728,1,True,0.9530611658874819,1,1,0.9664937,1
NCT02538926,"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2018-07-01,2021-07-30,University of Washington,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, OTHER, DRUG, BIOLOGICAL, DRUG","Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate","B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma",,,,,False,1125.0,True,False,2.0,False,False,False,9,False,,1,0.0,0.0,1,0,0.58,False,False,0.021281322140462633,1,False,0.010950299211260377,1,0,0.0028632719,1
NCT06808672,Biomarkers of Cancer-Associated Myositis,Plasma Membrane Antigens As Trigger in Cancer-associated Myositis,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,50.0,ACTUAL,2019-06-13,2025-12-31,Azienda USL Reggio Emilia - IRCCS,OTHER_GOV,,,,,,Dermatomyositis,,,,,False,2393.0,False,False,-1.0,False,False,False,0,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.8123585687426913,1,True,0.7156435118762754,1,1,0.74111915,1
NCT02590263,Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma,"A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma",COMPLETED,PHASE1,INTERVENTIONAL,53.0,ACTUAL,2015-08-24,2020-08-27,AbbVie,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"RADIATION, DRUG, DRUG","Whole Brain Radiation, Temozolomide, ABT-414","Malignant Glioma, Glioblastoma Multiforme",,,,,False,1830.0,True,False,1.0,False,False,True,3,True,Medium (30-100),1,53.0,3.9889840465642745,1,0,0.56,True,True,0.7165529684844982,1,True,0.7403905015885428,1,1,0.6532152,1
NCT00455923,SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII),SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII),COMPLETED,PHASE4,INTERVENTIONAL,100.0,ACTUAL,2005-05-03,2007-07-31,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,,"DRUG, DRUG","Seretide, Flixotide",Asthma,,,,,False,819.0,True,False,4.0,True,False,True,2,True,Medium (30-100),0,100.0,4.61512051684126,2,1,0.7,True,False,0.4175430566329922,0,True,0.7851355373209872,1,1,0.78842914,1
NCT02267213,Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma,"An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma",TERMINATED,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2014-04-10,2015-07-09,Taiwan Liposome Company,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Lipotecan,Hepatocellular Carcinoma,,,,,False,455.0,True,False,2.0,False,False,True,1,False,Small (<30),0,29.0,3.4011973816621555,0,0,0.58,False,True,0.5293549464451989,0,False,0.47088243361203214,1,0,0.41230202,1
NCT03925883,Predicting and Addressing Colonoscopy in Safety Net Settings,Predicting and Addressing Colonoscopy in Safety Net Settings,COMPLETED,,INTERVENTIONAL,1200.0,ACTUAL,2019-07-29,2023-06-05,Kaiser Permanente,OTHER,RANDOMIZED,CROSSOVER,NONE,BEHAVIORAL,Patient navigation,Colorectal Cancer,,,,,False,1407.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,1200.0,7.090909822079984,1,1,0.6,True,True,0.9440009371267104,1,True,0.9352879698247791,1,1,0.9671796,1
NCT02950766,NeoVax Plus Ipilimumab in Renal Cell Carcinoma,"A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,19.0,ESTIMATED,2019-03-03,2030-05-30,"Patrick Ott, MD, PhD",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","NeoVax, Ipilimumab",Kidney Cancer,,,,,False,4106.0,False,False,1.0,False,False,False,2,True,Small (<30),1,19.0,2.995732273553991,1,0,0.56,True,True,0.5876851222313803,1,True,0.643047658066964,1,1,0.5332904,1
NCT05408026,"Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM","A Phase II, Multicenter, Open-Label Study of the Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2022-10-01,2026-02-01,"Alliance Foundation Trials, LLC.",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Daratumumab, Pomalidomide",Relapsed or Refractory Multiple Myeloma,,,,,False,1219.0,True,False,1.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.56,False,False,0.02892148155726569,1,False,0.0033526356557098073,1,0,0.0033182446,1
NCT02743390,Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension,"Effects of the TNF-alpha Inhibiton on Blood Pressure, Hemodynamic Parameters and Biomarkers in Resistant Hypertension",COMPLETED,PHASE4,INTERVENTIONAL,10.0,ACTUAL,2015-03-01,2017-07-01,"University of Campinas, Brazil",OTHER,RANDOMIZED,CROSSOVER,DOUBLE,"BIOLOGICAL, OTHER","Infliximab, Saline",Hypertension,,,,,False,853.0,True,False,4.0,True,True,False,2,True,Small (<30),0,10.0,2.3978952727983707,3,0,0.7,True,False,0.1518541672146479,0,False,0.19180762468912654,0,0,0.23405944,0
NCT00061048,Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma,Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2003-05-01,2012-07-01,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,Alemtuzumab,Acute T-Cell Leukemia-Lymphoma,,,,,False,3349.0,True,False,2.0,False,False,False,1,True,Small (<30),0,29.0,3.4011973816621555,0,0,0.58,True,True,0.6725743179704554,1,True,0.7379949717150549,1,1,0.81980366,1
NCT04872556,Evaluation of the Effect of Laser Acupuncture on Taxane Acute Pain Syndrome Patients,Evaluation of the Effect of Laser Acupuncture on Myalgia and Arthralgia During Docetaxel or Paclitaxel Treatment in Cancer Patients,TERMINATED,,INTERVENTIONAL,10.0,ACTUAL,2021-05-13,2022-02-24,Chang Gung Memorial Hospital,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DEVICE, DEVICE","Laser acupuncture device, Pseudo-laser acupuncture","Pain Cancer, Joint Pain",,,,,False,287.0,True,False,-1.0,True,True,False,2,False,Small (<30),0,10.0,2.3978952727983707,3,0,0.6,False,False,0.253323546591841,1,False,0.3446127711961693,1,0,0.23518392,1
NCT02622568,Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study,Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study,COMPLETED,PHASE4,INTERVENTIONAL,28.0,ACTUAL,2015-07-01,2016-06-01,University of Texas Southwestern Medical Center,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, PROCEDURE","Veregen only, Cryotherapy and Veregen","Verruca, Warts",,,,,False,336.0,True,False,4.0,True,False,False,2,True,Small (<30),0,28.0,3.367295829986474,2,0,0.7,True,False,0.28836006312386375,0,False,0.49886866922335044,0,0,0.43481088,0
NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers,COMPLETED,PHASE1,INTERVENTIONAL,49.0,ACTUAL,2016-06-29,2022-03-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","osimertinib, Bevacizumab","Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers",,,,,False,2071.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,49.0,3.912023005428146,1,0,0.56,True,True,0.7142680471685151,1,True,0.8053371616875066,1,1,0.78992957,1
NCT03513211,Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer,A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2018-08-23,2023-10-30,"St Vincent's Hospital, Sydney",OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","SUBA-itraconazole, Hydroxychloroquine",Prostate Cancer,,,,,False,1894.0,True,False,1.0,False,False,False,2,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.56,True,False,0.3670121224919209,0,False,0.4752274036090764,0,0,0.48446006,0
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,"An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of Vemurafenib (RO5185426) in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations",TERMINATED,PHASE1,INTERVENTIONAL,6.0,ACTUAL,2013-01-01,2015-12-01,Hoffmann-La Roche,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,vemurafenib,Malignant Melanoma,,,,,False,1064.0,True,False,1.0,False,False,True,1,False,Small (<30),1,6.0,1.9459101490553128,0,0,0.56,False,False,0.22937853904004352,1,False,0.4401033774806884,1,1,0.68810886,0
NCT02875626,Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer,Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer (FLUO-BREAST),COMPLETED,,INTERVENTIONAL,80.0,ACTUAL,2016-09-01,2019-03-01,Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie,OTHER,,SINGLE_GROUP,NONE,DRUG,Infracyanine,Breast Cancer,,,,,False,911.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,80.0,4.394449154672439,0,0,0.6,True,True,0.8355249474121964,1,True,0.820640586675172,1,1,0.9147661,1
NCT00002931,Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer,Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer,COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,1997-02-01,2014-12-01,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, autologous bone marrow transplantation, bone marrow ablation with stem cell support","Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor",,,,,False,6512.0,True,False,2.0,False,False,False,7,True,Medium (30-100),1,48.0,3.8918202981106265,1,0,0.58,True,True,0.8270615237954919,1,True,0.8993870889291847,1,1,0.9694629,1
NCT02861703,Pilot Feasibility Study of an Online Lifestyle Intervention for Overweight Breast Cancer Survivors,"The Feasibility, Acceptability and Preliminary Effectiveness of an Online Lifestyle Intervention for Healthy Weight Management and Improved Quality of Life in Breast Cancer Survivors",COMPLETED,,INTERVENTIONAL,15.0,ACTUAL,2015-07-01,2018-07-01,Sunnybrook Health Sciences Centre,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Online lifestyle intervention,Obesity,,,,,False,1096.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.6,True,False,0.4816758109816579,0,True,0.6832848641252315,1,1,0.80733895,1
NCT03915717,Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring,Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring,TERMINATED,,OBSERVATIONAL,14.0,ACTUAL,2019-09-19,2022-05-05,"Sonavex, Inc.",INDUSTRY,,,,"DEVICE, DEVICE","EchoMark, EchoSure","Free Flap Transfer, Malignant Neoplasm",,,,,False,959.0,True,False,-1.0,False,False,True,2,False,Small (<30),0,14.0,2.70805020110221,1,0,0.6,False,False,0.40610398703321277,1,True,0.505394186114795,0,1,0.5312638,0
NCT03526562,Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients,Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients: a Phase I Prescription Dose Escalation Trial,COMPLETED,,INTERVENTIONAL,9.0,ACTUAL,2018-01-15,2018-06-15,"University Hospital, Ghent",OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Exercise,"Prostatic Neoplasms, Exercise, Castration-resistant Prostate Cancer, Physical Activity",,,,,False,151.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,9.0,2.302585092994046,0,0,0.6,True,False,0.31413213403965407,0,False,0.47473070951791635,0,1,0.5547734,1
NCT00599989,Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer,Accelerated Partial Breast Irradiation,COMPLETED,,INTERVENTIONAL,28.0,ACTUAL,2005-01-01,2009-05-11,Abramson Cancer Center at Penn Medicine,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, RADIATION, RADIATION, RADIATION, RADIATION","adjuvant therapy, conventional surgery, 3-dimensional conformal radiation therapy, brachytherapy, intracavitary balloon brachytherapy, proton beam radiation therapy","Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Skin Reactions Secondary to Radiation Therapy",,,,,False,1591.0,True,False,-1.0,False,False,False,6,True,Small (<30),0,28.0,3.367295829986474,1,0,0.6,True,True,0.5945189343536549,1,True,0.6898355783515345,1,1,0.6838932,1
NCT04517318,Treatment After Palbociclib-containing Regimens,A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer,COMPLETED,,OBSERVATIONAL,200.0,ACTUAL,2017-08-15,2021-07-15,Fudan University,OTHER,,,,,,Breast Cancer,,,,,False,1430.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.861159552899456,1,True,0.87913650965233,1,1,0.81336427,1
NCT03572582,Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma,"A Phase II Single-arm, Open-label Study of Transarterial Chemoembolization (TACE) in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (HCC)",COMPLETED,PHASE2,INTERVENTIONAL,49.0,ACTUAL,2018-06-14,2021-12-10,AIO-Studien-gGmbH,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Nivolumab, TACE","Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer",,,,,False,1275.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,49.0,3.912023005428146,1,0,0.58,True,True,0.6454615457493758,1,True,0.7433481036876133,1,1,0.78233,1
NCT00306202,Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia,"Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005",COMPLETED,PHASE1,INTERVENTIONAL,63.0,ACTUAL,2006-03-31,2019-05-22,Bristol-Myers Squibb,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Dasatinib, Dasatinib, Dasatinib",Leukemia,,,,,False,4800.0,True,False,1.0,False,False,True,3,True,Medium (30-100),1,63.0,4.158883083359672,1,0,0.56,True,True,0.8488565053113247,1,True,0.8377955714444627,1,1,0.8472109,1
NCT05813145,Fenofibrate Role in Breast Cancer Patients,Fenofibrate Role Against Chemotherapy Induced Peripheral Neurotoxicity in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2023-01-01,2024-08-05,Damanhour University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Placebo, Fenofibrate 160mg",Breast Cancer,,,,,False,582.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,3,0,0.6,True,True,0.6538182515427189,1,True,0.8483586387590087,1,1,0.88923085,1
NCT02299141,Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2015-05-07,2025-04-23,Washington University School of Medicine,OTHER,,SINGLE_GROUP,NONE,DRUG,Nintedanib,"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer",,,,,False,3639.0,True,False,2.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.58,True,True,0.5975106665588895,1,True,0.7138874004141982,1,1,0.79625404,1
NCT00001850,Evaluation of Women With Endocrine and Reproductive-Related Conditions,Evaluation of Women and Men With Endocrine and Reproductive-Related Conditions,TERMINATED,,OBSERVATIONAL,833.0,ACTUAL,1999-05-10,2023-05-23,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,,,,,,"Endocrine Disease, Infertility, Leiomyoma, Endometriosis, Fibroids",,,,,False,8779.0,True,False,-1.0,False,False,False,0,False,Very Large (300+),0,833.0,6.726233402358747,0,1,0.6,False,True,0.9894782840265176,0,True,0.877648407313546,0,1,0.9251304,0
NCT03160482,PACE4 in Thyroid Cancer,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,COMPLETED,,OBSERVATIONAL,39.0,ACTUAL,2017-05-15,2018-01-15,Robert Day,OTHER,,,,DIAGNOSTIC_TEST,Immunohistochemistry,Thyroid Nodule,,,,,False,245.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,39.0,3.688879454113936,0,0,0.6,True,True,0.6766394621632738,1,True,0.7570583784064536,1,1,0.7992749,1
NCT00342888,Case-Control Study of Pesticides and Childhood Leukemia,A Case-Control Study of Pesticides and Childhood Leukemia,COMPLETED,,OBSERVATIONAL,629.0,ACTUAL,2001-10-30,,National Cancer Institute (NCI),NIH,,,,,,Leukemia,,,,,False,1303.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,629.0,6.4457198193855785,0,1,0.6,True,True,0.9426442340876975,1,True,0.8644790092002806,1,1,0.88170266,1
NCT02568787,The Effect of an RBAC Supplement (BRM4) on NAFLD,The Effect of an Enhanced Rice Bran Nutritional Supplement on Non-Alcoholic Fatty Liver Disease (NAFLD),COMPLETED,,INTERVENTIONAL,23.0,ACTUAL,2016-05-01,2017-06-10,University of Miami,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","rice bran arabinoxylan compound (RBAC), Placebo",Non-Alcoholic Fatty Liver Disease,,,,,False,405.0,True,False,-1.0,True,True,False,2,True,Small (<30),0,23.0,3.1780538303479458,3,0,0.6,True,False,0.44764701361863035,0,True,0.6778797489129016,1,1,0.8847829,1
NCT03157947,Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer,Development and Testing of a Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2017-08-01,2019-12-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Decision Aid Tool, baseline survey, follow-up surveys",Prostate Cancer,,,,,False,852.0,True,False,-1.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.6,False,False,0.03297909020667841,1,False,0.007332213704970258,1,0,0.0025337227,1
NCT05649969,STRONG Program for Cancer Patients,STRONG-PD: Support Through Remote Observation And Nutrition Guidance (STRONG) Program For Cancer Patients With Peritoneal Disease,COMPLETED,,INTERVENTIONAL,10.0,ACTUAL,2022-12-01,2025-01-21,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit smartphone application, Questionnaires",Gastrointestinal Cancer,,,,,False,782.0,True,False,-1.0,False,False,False,3,True,Small (<30),0,10.0,2.3978952727983707,1,0,0.6,True,False,0.3154956822881494,0,False,0.44554997318341266,0,0,0.45628577,0
NCT03743662,Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma,A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,39.0,ACTUAL,2018-11-12,2026-11-01,Memorial Sloan Kettering Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG, DRUG, PROCEDURE","Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection",Glioblastoma,,,,,False,2911.0,False,False,2.0,False,False,False,4,True,Medium (30-100),1,39.0,3.688879454113936,1,0,0.58,True,True,0.6593061522128085,1,True,0.975640668490775,1,1,0.9771339,1
NCT03706235,Colvera for Detection of Disease Recurrence,"Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed With Colorectal Cancer- ""NOVA""",COMPLETED,,OBSERVATIONAL,488.0,ACTUAL,2018-02-01,2020-04-29,Clinical Genomics Pathology,INDUSTRY,,,,OTHER,Blood draw (venipuncture),Colorectal Adenocarcinoma,,,,,False,818.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,488.0,6.192362489474872,0,1,0.6,True,True,0.9229158024389678,1,True,0.9793534153170002,1,1,0.95636755,1
NCT02476994,Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion,"A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (Lipid Injectable Emulsion, USP) 20% or Standard-of-Care Soybean Oil-Based Lipid Emulsion",TERMINATED,PHASE4,INTERVENTIONAL,1.0,ACTUAL,2015-05-01,2016-10-01,Baxter Healthcare Corporation,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Clinolipid, Intralipid",Essential Fatty Acid Deficiency (EFAD),,,,,False,519.0,True,False,4.0,True,True,True,2,False,Small (<30),0,1.0,0.6931471805599453,3,0,0.7,False,False,0.0253319004023442,1,False,0.04406246836512187,1,0,0.041802652,1
NCT00360672,Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome,Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities,COMPLETED,PHASE2,INTERVENTIONAL,27.0,ACTUAL,2009-01-01,2012-05-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Revlimid,"Acute Myelogenous Leukemia, Myelodysplastic Syndrome",,,,,False,1216.0,True,False,2.0,False,False,False,1,True,Small (<30),0,27.0,3.332204510175204,0,0,0.58,True,True,0.5502281228131475,1,True,0.5952778608918523,1,1,0.58549595,1
NCT01947140,Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies,Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,57.0,ACTUAL,2013-09-09,2022-09-01,Jennifer Amengual,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Pralatrexate, Romidepsin","Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma",,,,,False,3279.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,57.0,4.060443010546419,1,0,0.56,True,True,0.79472629499884,1,True,0.8134836269200117,1,1,0.7955303,1
NCT01777945,XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer,Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study),COMPLETED,,OBSERVATIONAL,46.0,ACTUAL,2012-12-01,2014-12-01,Hoffmann-La Roche,INDUSTRY,,,,"DRUG, DRUG","capecitabine, docetaxel",Breast Cancer,,,,,False,730.0,True,False,-1.0,False,False,True,2,True,Medium (30-100),1,46.0,3.8501476017100575,1,0,0.6,True,True,0.6846567715979257,1,True,0.6727930326648267,1,1,0.58384126,1
NCT04715061,Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments,Modulation of Immune Response and Side Effects of Cancer Treatments by Aerobic Exercise: Role of Exercise Intensity,COMPLETED,,INTERVENTIONAL,19.0,ACTUAL,2020-11-04,2022-10-04,Université de Sherbrooke,OTHER,RANDOMIZED,CROSSOVER,NONE,"OTHER, OTHER, OTHER","Resting state (Control), Moderate Intensity Continuous Exercise (MICE), High Intensity Interval Exercise (HIIE)",Colorectal Cancer Stage IV,,,,,False,699.0,True,False,-1.0,True,False,False,3,True,Small (<30),0,19.0,2.995732273553991,2,0,0.6,True,False,0.379241815030326,0,False,0.41093001775803806,0,0,0.39629218,0
NCT03731585,Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment,Online Psychosocial Intervention for Women With Lung Cancer Undergoing Treatment,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,70.0,ACTUAL,2018-11-15,2027-09-30,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, OTHER, OTHER, PROCEDURE","Behavioral Intervention, Educational Intervention, Questionnaire Administration, Support Group Therapy","Non-Small Cell Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8",,,,,False,3241.0,False,False,-1.0,True,False,False,4,True,Medium (30-100),0,70.0,4.262679877041316,2,0,0.6,True,True,0.7978025413141133,1,True,0.8425956158462722,1,1,0.8806237,1
NCT01506856,Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial,"A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,655.0,ACTUAL,2010-05-01,2021-02-28,Gynecologic Oncology Trial & Investigation Consortium,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Paclitaxel(intravenous) + Carboplatin(intravenous), Paclitaxel(intravenous) + Carboplatin(intraperitoneal)","Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma",,,,,False,3956.0,True,False,2.0,True,False,False,2,True,Very Large (300+),1,655.0,6.486160788944089,2,1,0.58,True,True,0.9182078866580524,1,True,0.951147534251605,1,1,0.92793435,1
NCT03085381,A Phase I Study of Quadrivalent HPV Recombinant Vaccine,"A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years",COMPLETED,PHASE1,INTERVENTIONAL,90.0,ACTUAL,2016-12-01,2018-08-01,"Shanghai Bovax Biotechnology Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"BIOLOGICAL, BIOLOGICAL","HPV vaccine, Placebo",HPV Infections,,,,,False,608.0,True,False,1.0,True,True,True,2,True,Medium (30-100),0,90.0,4.51085950651685,3,0,0.56,True,True,0.7403126592132658,1,True,0.767694115027423,1,1,0.857037,1
NCT04295174,KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers,KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers,COMPLETED,,OBSERVATIONAL,70.0,ACTUAL,2018-01-01,2020-01-01,Odense University Hospital,OTHER,,,,,,"Carcinoma, Renal Cell",,,,,False,730.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,70.0,4.262679877041316,0,0,0.6,True,True,0.8130207723857511,1,True,0.872996046235786,1,1,0.8252981,1
NCT06173297,Assessing the Agreement Between Endoscopic and Histopathological Diagnosis of Colorectal Sessile Serrated Lesions.,Assessing the Agreement Between Endoscopic and Histopathological Diagnosis of Colorectal Sessile Serrated Lesions.,COMPLETED,,OBSERVATIONAL,772.0,ACTUAL,2020-02-01,2020-09-01,Hospital Sirio-Libanes,OTHER,,,,,,"Sessile Serrated Adenoma, Colorectal Polyp, Adenoma Colon, Colorectal Cancer, Colonoscopy, Adenoma Detection Rate, Quality Indicator",,,,,False,213.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,772.0,6.650279048587422,0,1,0.6,True,True,0.9378080138652067,1,True,0.9697208991983112,1,1,0.954707,1
NCT05867953,Assessment of Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System,A Prospective Investigation to Assess the Accurate Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System With Adjunct Real-time Imaging,COMPLETED,,INTERVENTIONAL,200.0,ACTUAL,2023-04-20,2025-06-04,Intuitive Surgical,INDUSTRY,,SINGLE_GROUP,NONE,DEVICE,Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging,Lung Cancer,,,,,False,776.0,True,False,-1.0,False,False,True,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8413523859492213,1,True,0.8684484195170706,1,1,0.8631899,1
NCT05309733,A Long-term Follow-up Study of Patients Who Received VOR33,A Long-term Follow-up Study of Patients Who Received VOR33,TERMINATED,,OBSERVATIONAL,10.0,ACTUAL,2022-04-15,2025-05-28,Vor Biopharma,INDUSTRY,,,,GENETIC,VOR33,"Leukemia, Myeloid, Acute",,,,,False,1139.0,True,False,-1.0,False,False,True,1,False,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,False,False,0.3842549893072777,1,True,0.5784423389269264,0,1,0.69849473,0
NCT01858740,Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children,A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2014-04-10,2023-07-30,Fred Hutchinson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, DRUG, OTHER, DRUG, PROCEDURE, BIOLOGICAL, DRUG, DRUG, RADIATION","Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Peripheral Blood Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia",,,,,False,3398.0,True,False,2.0,False,False,False,9,True,Small (<30),1,20.0,3.044522437723423,1,0,0.58,True,False,0.49121097320721063,0,True,0.7296165666083253,1,1,0.9110648,1
NCT02843425,The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial,The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,71.0,ACTUAL,2016-07-25,2027-04-01,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,CROSSOVER,NONE,"OTHER, OTHER","Regular Diet, Navy Beans (Canned)",Colorectal Cancer Prevention,,,,,False,3902.0,False,False,-1.0,True,False,False,2,True,Medium (30-100),0,71.0,4.276666119016055,2,0,0.6,True,True,0.8272050279042715,1,True,0.8569783253043322,1,1,0.8558422,1
NCT01317901,A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma,A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2011-05-01,2013-06-01,Aptevo Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","TRU-016, Bendamustine, Rituximab",B-cell Small Lymphocytic Lymphoma Recurrent,,,,,False,762.0,True,False,1.0,False,False,True,3,True,Small (<30),1,12.0,2.5649493574615367,1,0,0.56,True,False,0.30376524318072556,0,False,0.3840067858320857,0,0,0.37165973,0
NCT00293423,GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma,Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma,COMPLETED,PHASE1,INTERVENTIONAL,96.0,ACTUAL,2005-11-18,2013-01-12,"University of California, San Francisco",OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, PROCEDURE","HSPPC-96, Standard Surgical Resection",Brain and Central Nervous System Tumors,,,,,False,2612.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,96.0,4.574710978503383,1,0,0.56,True,True,0.852578520274048,1,True,0.7038025196043586,1,1,0.6089129,1
NCT00006475,STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis,An Open-Label Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Blast Crisis,COMPLETED,PHASE2,INTERVENTIONAL,,,2000-09-01,2002-12-01,Novartis,INDUSTRY,,,,DRUG,imatinib mesylate,Leukemia,,,,,False,821.0,True,False,2.0,False,False,True,1,True,,1,,,0,0,0.58,True,True,0.6710346244105506,1,True,0.7876585476806365,1,1,0.76276416,1
NCT02162173,Dual Focus NBI and pCLE in FAP Related Duodenal Adenoma,Diagnostic Values of Dual Focus Narrow Band Imaging and Probe-based Confocal Laser Endomicroscopy in FAP Related Duodenal Adenoma,COMPLETED,,INTERVENTIONAL,26.0,ACTUAL,2012-12-01,,King Chulalongkorn Memorial Hospital,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Endoscopy,"Complication of Diagnostic Procedure, Adverse Effect of Diagnostic Agents, Subsequent Encounter",,,,,False,1303.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,26.0,3.295836866004329,0,0,0.6,True,True,0.6308775434426159,1,True,0.7925323079429059,1,1,0.82176125,1
NCT04295317,PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery,Eﬀect of PD-1 Antibody (SHR-1210) Combined with Capecitabine Treatment After Resection of Intrahepatic Cholangiocarcinoma with High Risk of Recurrence : a Phase 2 Study.,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,65.0,ESTIMATED,2020-08-01,2025-06-01,Shanghai Zhongshan Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","PD-1 blocking antibody SHR-1210, Capecitabine",Intrahepatic Cholangiocarcinoma,,,,,False,1765.0,False,False,2.0,False,False,False,2,True,Medium (30-100),1,65.0,4.189654742026425,1,0,0.58,True,True,0.7302042514581599,1,True,0.7913164821590364,1,1,0.8276272,1
NCT02093546,Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290,"A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer",COMPLETED,,OBSERVATIONAL,40.0,ESTIMATED,2004-08-13,2020-01-15,M.D. Anderson Cancer Center,OTHER,,,,PROCEDURE,Biospecimen Collection,Recurrent Endometrial Carcinoma,,,,,False,5633.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.8683168129045776,1,True,0.7840947230692307,1,1,0.9214696,1
NCT03731260,"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis","A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,251.0,ACTUAL,2019-04-16,2027-06-23,Blueprint Medicines Corporation,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Avapritinib, Placebo",Indolent Systemic Mastocytosis,,,,,False,2990.0,False,False,2.0,True,True,True,2,True,Large (100-300),0,251.0,5.529429087511423,3,1,0.58,True,True,0.8262528369123964,1,True,0.823002302597612,1,1,0.8310961,1
NCT02271581,Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer,INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer,COMPLETED,,OBSERVATIONAL,38.0,ACTUAL,2014-10-01,2019-04-19,Leo W. Jenkins Cancer Center,OTHER,,,,,,"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung",,,,,False,1661.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.6,True,True,0.7362291896081556,1,True,0.6789854041965296,1,1,0.6057012,1
NCT02174445,"An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years","Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years",TERMINATED,PHASE3,INTERVENTIONAL,14.0,ACTUAL,2014-03-01,2019-10-01,Prof. Dr. Nikolas von Bubnoff,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Imatinib, Nilotinib",Chronic Myeloid Leukemia,,,,,False,2040.0,True,False,3.0,True,False,False,2,False,Small (<30),1,14.0,2.70805020110221,2,0,0.77,False,False,0.22271244558390174,1,False,0.30001785373169504,1,0,0.17436421,1
NCT05610891,Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG,"A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,50.0,ESTIMATED,2023-10-01,2026-09-01,"Cellectar Biosciences, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,CLR 131,High-Grade Glioma,,,,,False,1066.0,False,False,1.0,False,False,True,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.56,True,True,0.7240429078231841,1,True,0.6749699254807459,1,1,0.6400856,1
NCT00440388,Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma,"An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2006-10-01,2008-11-01,Ascenta Therapeutics,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","AT-101, Rituximab",Follicular Lymphoma,,,,,False,762.0,True,False,2.0,False,False,True,2,True,Small (<30),1,23.0,3.1780538303479458,1,0,0.58,True,False,0.4265999814450728,0,False,0.2998339209725616,0,0,0.2657351,0
NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer","Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors",COMPLETED,PHASE2,INTERVENTIONAL,67.0,ACTUAL,2013-11-08,2019-10-28,Washington University School of Medicine,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Irinotecan, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil","Stomach Neoplasms, Esophageal Neoplasms",,,,,False,2180.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,67.0,4.219507705176107,1,0,0.58,True,True,0.7411545393643619,1,True,0.9139012230682836,1,1,0.9118753,1
NCT02935972,"Combined Intravenous Diazepam, Local Periprostatic Nerve Block for Prostate Biopsy","Pain Reduction During Transrectal Ultrasound-guided Biopsy of the Prostate: Intravenous Diazepam, Local Periprostatic Nerve Block or Combination",COMPLETED,PHASE2,INTERVENTIONAL,336.0,ACTUAL,2013-11-01,2015-01-01,Assiut University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Diazepam, Lidocaine 1%, Diazepam and Lidocaine 1%",Pain Relief During Prostate Biopsy,,,,,False,426.0,True,False,2.0,True,False,False,3,True,Very Large (300+),0,336.0,5.820082930352362,2,1,0.58,True,True,0.7591075981797104,1,True,0.8454265701675943,1,1,0.8798648,1
NCT00504218,Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients,Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoitic Stem Cell Transplant Recipients,TERMINATED,,OBSERVATIONAL,62.0,ACTUAL,2007-07-17,2018-06-12,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,,,,,,"Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic",,,,,False,3983.0,True,False,-1.0,False,False,False,0,False,Medium (30-100),0,62.0,4.143134726391533,0,0,0.6,False,True,0.8829423811890939,0,True,0.8389321289107495,0,1,0.8539637,0
NCT03572530,Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma,Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent Posterior Fossa Ependymoma: A Phase I Study,COMPLETED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2019-02-08,2020-11-24,"The University of Texas Health Science Center, Houston",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3",Recurrent Ependymoma,,,,,False,655.0,True,False,1.0,False,False,False,3,True,Small (<30),0,3.0,1.3862943611198906,1,0,0.56,True,False,0.10831344562945228,0,False,0.059626284023316406,0,0,0.05134596,0
NCT00982592,Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer,"A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma",COMPLETED,PHASE2,INTERVENTIONAL,124.0,ACTUAL,2009-09-01,2014-10-01,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, OTHER, DRUG, OTHER","oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis","Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer",,,,,False,1856.0,True,False,2.0,True,True,False,6,True,Large (100-300),1,124.0,4.8283137373023015,3,1,0.58,True,True,0.6270268891476795,1,True,0.7355506699127866,1,1,0.8046019,1
NCT00911092,Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer,Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer,COMPLETED,PHASE4,INTERVENTIONAL,50.0,ACTUAL,2007-10-01,2011-12-01,Centre Oscar Lambret,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, RADIATION, DRUG","Blood sampling, Radiation, Chemotherapy (Fluorouracil and Cisplatin)",Esophageal Cancer,,,,,False,1522.0,True,False,4.0,False,False,False,3,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.7,True,True,0.5620940279512912,1,True,0.862952571909881,1,1,0.9261139,1
NCT01302613,Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma,A Pilot and Phase II Study of Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2011-03-01,2012-11-01,University of Texas Southwestern Medical Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, RADIATION, PROCEDURE","Capecitabine, 5-FU, Leucovorin, Oxaliplatin, radiation, total mesorectal excision","Stage II Rectal Cancer, Stage III Rectal Cancer",,,,,False,611.0,True,False,1.0,False,False,False,6,False,,1,0.0,0.0,1,0,0.56,False,False,0.02360435178218363,1,False,0.006566580424465202,1,0,0.0027764232,1
NCT03714958,Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type,"A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer.",COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2018-12-20,2023-09-12,Centre Leon Berard,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","HDM201, Trametinib","Colorectal Cancer, Advanced Cancer, Metastatic Cancer",,,,,False,1727.0,True,False,1.0,False,False,False,2,True,Small (<30),1,12.0,2.5649493574615367,1,0,0.56,True,False,0.3524978912466386,0,False,0.4777722317069278,0,1,0.5403784,1
NCT05412459,99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy,SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Using 99mTc-DARPinG3 in HER2-positive Breast Cancer Patients in Dynamic of Chemo+Targeted Therapy,COMPLETED,,OBSERVATIONAL,15.0,ACTUAL,2022-05-01,2023-01-31,Tomsk National Research Medical Center of the Russian Academy of Sciences,OTHER,,,,DRUG,99mTc-DARPinG3,"HER2-positive Breast Cancer, Female",,,,,False,275.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.6,True,False,0.4392527357978705,0,True,0.6744420191827889,1,1,0.59039694,1
NCT01905891,Nanocytology Test to Evaluate Skin Cancer in High Risk Patients,Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients,COMPLETED,,INTERVENTIONAL,7.0,ACTUAL,2013-07-01,2014-11-01,Northwestern University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,Superficial shave biopsy,"Actinic Keratosis, Squamous Cell Carcinoma",,,,,False,488.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,7.0,2.079441541679836,0,0,0.6,True,False,0.27812654261542086,0,False,0.3767818738257472,0,0,0.36053696,0
NCT04206891,CDH1 Germline Mutations in Lobular Breast Cancer,Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer,COMPLETED,,OBSERVATIONAL,421.0,ACTUAL,2018-12-01,2025-11-26,European Institute of Oncology,OTHER,,,,,,"Lobular Breast Carcinoma, CDH1 Gene Inactivation",,,,,False,2552.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,421.0,6.045005314036012,0,1,0.6,True,True,0.9394436900642171,1,True,0.9383248020111897,1,1,0.95446295,1
NCT00788476,Childhood Cancer Survivor Survey,Needs Assessment Survey in Childhood Cancer Survivors and Their Parents,COMPLETED,,OBSERVATIONAL,167.0,ACTUAL,2008-10-01,2013-08-01,M.D. Anderson Cancer Center,OTHER,,,,OTHER,Survey,Cancer,,,,,False,1765.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,167.0,5.123963979403259,0,1,0.6,True,True,0.8451515713289476,1,True,0.9183098020890246,1,1,0.95455694,1
NCT00612651,PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas,"A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas",COMPLETED,PHASE1,INTERVENTIONAL,37.0,ACTUAL,2005-10-01,2011-06-01,Duke University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Temodar and SCH 66336,"Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma",,,,,False,2069.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.56,True,True,0.7024304087333209,1,True,0.7685281111746772,1,1,0.6244248,1
NCT01293851,Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage,Characterization of the Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Peripheral Neuropathy Progression,TERMINATED,,OBSERVATIONAL,3.0,ACTUAL,2010-12-22,2012-11-13,National Institute of Nursing Research (NINR),NIH,,,,,,"Peripheral Neuropathic Pain, Neurotoxicity, Cancer",,,,,False,692.0,True,False,-1.0,False,False,False,0,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.6,False,False,0.16151070859078148,1,False,0.16865188098486913,1,0,0.13511875,1
NCT03985215,The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives,The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2020-12-01,2021-11-01,University of Aarhus,OTHER,,,,OTHER,Questionnaires,"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Surveys and Questionnaires",,,,,False,335.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.03706834559727409,1,False,0.003863722274703465,1,0,0.0023567292,1
NCT05631873,Colonoscopy Screening: Setting Epic Follow-up Times,Improving Follow-up Recommendations After a Colonoscopy for Colorectal Cancer Screening,COMPLETED,,INTERVENTIONAL,43.0,ACTUAL,2022-11-18,2024-03-11,Massachusetts General Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,OTHER,Assistance with implementing Epic Smartlist,"Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, Colorectal Cancer",,,,,False,479.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,43.0,3.784189633918261,1,0,0.6,True,True,0.6315993340332082,1,True,0.8218166631800247,1,1,0.7454431,1
NCT01012427,Percutaneous Renal Tumor Cryoablation Followed by Biopsy,Percutaneous Renal Tumor Cryoablation Followed by Biopsy,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2009-11-01,2015-09-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,percutaneous cryoablation,Renal Cancer,,,,,False,2130.0,True,False,1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.56,True,True,0.5163668159980404,1,True,0.786793743907592,1,1,0.79961157,1
NCT02171260,"This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas","A Phase 1 Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent in Children With Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas",COMPLETED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2014-07-31,2016-01-28,Eisai Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Eribulin Mesylate,"Pediatrics, Solid Tumors",,,,,False,546.0,True,False,1.0,False,False,True,1,True,Small (<30),0,23.0,3.1780538303479458,0,0,0.56,True,True,0.5117909730391397,1,True,0.5311113876768228,1,0,0.48964673,0
NCT00897351,Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803,"Evaluation of Polymorphisms, Mutations, and Protein Expression by Automated Quantitative Immunohistochemistry (AQUA) in the LapatinibTargets and Metabolic Pathway in Samples From E5803",COMPLETED,,OBSERVATIONAL,37.0,ACTUAL,2008-07-10,2009-02-10,ECOG-ACRIN Cancer Research Group,NETWORK,,,,"GENETIC, GENETIC, GENETIC, OTHER, OTHER","mutation analysis, polymorphism analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis",Prostate Cancer,,,,,False,215.0,True,False,-1.0,False,False,False,5,True,Medium (30-100),0,37.0,3.6375861597263857,1,0,0.6,True,True,0.6004623772461922,1,True,0.693102444399852,1,1,0.80517334,1
NCT04141566,Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal Adenocarcinoma,"Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal Adenocarcinoma: Comparaison of Out of Pocket Costs, Hospital Bills and Quality of Life",COMPLETED,,OBSERVATIONAL,35.0,ACTUAL,2018-01-01,2020-06-30,Moroccan Society of Surgery,OTHER,,,,"PROCEDURE, PROCEDURE","Perineal pseudocontinent colostomy, Permanent left iliac colostomy","Rectal Neoplasms, Colostomy Stoma, Quality of Life",,,,,False,911.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,35.0,3.58351893845611,1,0,0.6,True,True,0.6354788408890641,1,True,0.5098942316024503,1,1,0.52054405,1
NCT03856463,Coaches Activating Reaching and Engaging Patients,"CAREPlan: Coaches Activating, Reaching, and Engaging Patients in End-of-Life Care Plan",COMPLETED,,INTERVENTIONAL,400.0,ACTUAL,2019-04-03,2023-09-25,Stanford University,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"BEHAVIORAL, OTHER","Lay Navigator Intervention, Usual Care","Cancer, End-of-Life",,,,,False,1636.0,True,False,-1.0,True,True,False,2,True,Very Large (300+),0,400.0,5.993961427306569,3,1,0.6,True,True,0.886429865834517,1,True,0.8566247860059171,1,1,0.78061837,1
NCT03335826,Epidural Anesthesia and Long-term Outcomes in Elderly Patients After Surgery,Impact of Epidural Anesthesia-analgesia on Long-term Outcomes in Elderly Patients After Surgery: 5-year Follow-up of a Multicenter Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,1802.0,ACTUAL,2017-08-01,2019-09-30,Peking University First Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Combined epidural-general anesthesia, General anesthesia","Elderly Patients, Solid Organ Cancer, Surgical Resection, Epidural Anesthesia, Long-term Outcome",,,,,False,790.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,1802.0,7.497207223203318,2,1,0.6,True,True,0.9297556593465437,1,True,0.8113808347470979,1,1,0.802365,1
NCT00195247,Study Evaluating TTI-237 in Advanced Malignant Solid Tumors,A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors,TERMINATED,PHASE1,INTERVENTIONAL,45.0,,2005-05-01,,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,NON_RANDOMIZED,FACTORIAL,NONE,DRUG,TTI-237,Neoplasms,,,,,False,1303.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,45.0,3.828641396489095,0,0,0.56,False,True,0.7117531703024019,0,True,0.5743748247604081,0,1,0.54188585,0
NCT03523195,Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors,Physical Activity After Cancer Treatment (PACT): Pilot Study of Exercise in Stage II-III Breast Cancer Survivors,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2018-04-18,2019-07-15,Fred Hutchinson Cancer Center,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"BEHAVIORAL, OTHER, OTHER, DEVICE, OTHER, OTHER","Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Questionnaire Administration, Physical Performance Testing","Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Cancer Survivor, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sedentary Lifestyle",,,,,False,453.0,True,False,-1.0,True,True,False,6,True,Small (<30),0,20.0,3.044522437723423,3,0,0.6,True,False,0.39492440372037985,0,True,0.5114134215290653,1,1,0.7558375,1
NCT04349111,"An Efficacy Study of the Xoft® Axxent® eBx® IORT System® ""Lite""","An Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer ""Lite""",WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2022-06-30,2034-06-30,"Xoft, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,RADIATION,Intra-operative Radiation Therapy - IORT,"Invasive Ductal Carcinoma, Ductal Carcinoma In Situ",,,,,False,4383.0,True,False,-1.0,False,False,True,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.08205459274460074,1,False,0.12572151967708095,1,0,0.004807238,1
NCT01081405,Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation,Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Hematologic Malignancies,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2007-11-01,2022-11-01,Fondazione EMN Italy Onlus,OTHER,,SINGLE_GROUP,NONE,OTHER,TOTAL LYMPHOID IRRADIATION,HEMATOLOGIC MALIGNANCIES,,,,,False,5479.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.7564926093506561,1,True,0.6004377762466184,1,1,0.7786434,1
NCT05036486,The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer,The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,480.0,ACTUAL,2021-10-25,2030-12-01,"National Health Research Institutes, Taiwan",OTHER,,,,GENETIC,next-generation sequencing,Biliary Tract Cancer (BTC),,,,,False,3324.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,480.0,6.175867270105761,0,1,0.6,True,True,0.9521560250090209,1,True,0.9435632859582008,1,1,0.9374244,1
NCT00783588,A Phase I Extension Trial of Repeated Infusions of ISF35,A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914,COMPLETED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2007-05-01,2008-09-01,"Memgen, LLC",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,ISF35,Chronic Lymphocytic Leukemia,,,,,False,489.0,True,False,1.0,False,False,True,1,True,Small (<30),0,4.0,1.6094379124341005,0,0,0.56,True,False,0.15838570793417797,0,False,0.12884585636364534,0,0,0.106505536,0
NCT02289950,A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer",COMPLETED,PHASE2,INTERVENTIONAL,332.0,ACTUAL,2015-03-19,2020-08-13,Eisai Inc.,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Farletuzumab, Placebo",Platinum-Sensitive Ovarian Cancer in First Relapse,,,,,False,1974.0,True,False,2.0,True,True,True,2,True,Very Large (300+),0,332.0,5.808142489980444,3,1,0.58,True,True,0.8328259729628735,1,True,0.8526479209321249,1,1,0.84947914,1
NCT01445054,111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer,A Phase 0 Trial of (111)Indium CHX-A DTPA Trastuzumab Imaging in Cancer,TERMINATED,EARLY_PHASE1,INTERVENTIONAL,13.0,ACTUAL,2007-03-01,2014-08-20,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,DRUG,111Indium CHX-A,"Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer",,,,,False,2729.0,True,False,0.5,False,False,False,1,False,Small (<30),0,13.0,2.6390573296152584,0,0,0.57,False,False,0.49211969248687787,1,False,0.49094347437338504,1,0,0.45944372,1
NCT01597284,Oral Therapies in Oncology: Cognitive Function and Compliance,Oral Therapies in Oncology: Cognitive Function and Compliance,TERMINATED,,OBSERVATIONAL,129.0,ACTUAL,2012-02-01,2016-03-01,Centre Francois Baclesse,OTHER,,,,,,"Oral Therapies, Cancer, Cognitive Function, Compliance",,,,,False,1490.0,True,False,-1.0,False,False,False,0,False,Large (100-300),0,129.0,4.867534450455582,0,1,0.6,False,True,0.8024714312388912,0,True,0.7478332055324838,0,1,0.63775253,0
NCT04288336,"Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy","A Prospective Pilot Study Evaluating the Feasibility of Daily, Long-Term Intermittent Fasting for Men on PSA Surveillance Following Radical Prostatectomy for Localized, High-Risk Prostate Cancer",WITHDRAWN,EARLY_PHASE1,INTERVENTIONAL,0.0,ACTUAL,2020-01-08,2022-03-25,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER, OTHER","Food Diary, Preventative Dietary Intervention, Questionnaire Administration","Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8",,,,,False,807.0,True,False,0.5,False,False,False,3,False,,0,0.0,0.0,1,0,0.57,False,False,0.028173527468551285,1,False,0.019792835624291148,1,0,0.0029659984,1
NCT00911716,"TC Avastin. ICORG 08-10, V6","Pilot Evaluation of Bevacizumab, in Combination With Docetaxel and Cyclophosphamide in the Adjuvant Treatment of Patients With HER 2 Negative Breast Cancer",COMPLETED,,INTERVENTIONAL,106.0,ACTUAL,2008-10-01,2015-09-01,Cancer Trials Ireland,NETWORK,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, PROCEDURE","bevacizumab, cyclophosphamide, docetaxel, adjuvant therapy",Breast Cancer,,,,,False,2526.0,True,False,-1.0,False,False,False,4,True,Large (100-300),1,106.0,4.672828834461906,1,1,0.6,True,True,0.7539299894524546,1,True,0.875952103316366,1,1,0.93179214,1
NCT05775289,A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer,"A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,182.0,ACTUAL,2023-03-15,2026-06-01,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG, DRUG","Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin",Non-small Cell Lung Cancer,,,,,False,1174.0,False,False,2.0,True,True,True,5,True,Large (100-300),1,182.0,5.209486152841421,3,1,0.58,True,True,0.6860030847844845,1,True,0.575022745208798,1,1,0.66789794,1
NCT00186992,Radiation Therapy to Treat Musculoskeletal Tumors,Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,202.0,ACTUAL,2003-01-10,2029-10-01,St. Jude Children's Research Hospital,OTHER,,SINGLE_GROUP,NONE,RADIATION,image-guided radiotherapy,"Sarcoma, Ewing's, Rhabdomyosarcoma, Soft Tissue Sarcoma, Musculoskeletal Tumors",,,,,False,9761.0,False,False,2.0,False,False,False,1,True,Large (100-300),0,202.0,5.313205979041787,0,1,0.58,True,True,0.9605489749561837,1,True,0.8749755103056842,1,1,0.9532738,1
NCT04688333,iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma,E-Interventions to Treat Fear of Cancer Recurrence for Patients With Localized Renal Cell Carcinoma,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2022-08-20,2023-08-27,City of Hope Medical Center,OTHER,,,,"OTHER, OTHER, OTHER","Internet-Based Intervention - Complete iConquerFear program, Quality-of-Life Assessment, Questionnaire Administration",Renal Cell Carcinoma,,,,,False,372.0,True,False,-1.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.6,False,False,0.029937647944928092,1,False,0.005267446372269683,1,0,0.0021270106,1
NCT00103051,"Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer",Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC,COMPLETED,PHASE2,INTERVENTIONAL,,,2004-12-01,,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,,,NONE,"DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","cisplatin, gefitinib, gemcitabine hydrochloride, conventional surgery, neoadjuvant therapy",Lung Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,5,True,,1,,,1,0,0.58,True,True,0.6326071443753074,1,True,0.8100096138742963,1,1,0.81925863,1
NCT00632489,LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients,A Phase I Study of LBH589 in Combination With Capecitabine ± Lapatinib,COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2008-05-01,2011-07-01,"SCRI Development Innovations, LLC",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","LBH589, Capecitabine, Lapatinib",Breast Cancer,,,,,False,1156.0,True,False,1.0,False,False,False,3,True,Small (<30),1,20.0,3.044522437723423,1,0,0.56,True,False,0.4434298726228842,0,True,0.5044609309432053,1,0,0.45285675,0
NCT04823377,Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.,Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,364.0,ESTIMATED,2021-09-24,2027-09-23,Institut Curie,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"OTHER, OTHER","Usual care, Optimization of the medical decision","Carcinoma, Non-Small-Cell Lung, Advanced Cancer",,,,,False,2190.0,False,False,-1.0,False,False,False,2,True,Very Large (300+),0,364.0,5.899897353582492,1,1,0.6,True,True,0.9098640798294301,1,True,0.881740991493518,1,1,0.91852736,1
NCT01605526,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,"A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma",COMPLETED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2012-05-01,2013-06-01,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","RO5045337, doxorubicin",Sarcoma,,,,,False,396.0,True,False,1.0,False,False,True,2,True,Small (<30),1,23.0,3.1780538303479458,1,0,0.56,True,False,0.44509336185839427,0,False,0.43801283999446844,0,0,0.35453796,0
NCT02449837,Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy,Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy,COMPLETED,,OBSERVATIONAL,162.0,ACTUAL,2014-05-01,2022-02-20,UNC Lineberger Comprehensive Cancer Center,OTHER,,,,OTHER,Blood draw,Circulating Tumor Cells,,,,,False,2852.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,162.0,5.093750200806762,0,1,0.6,True,True,0.8691126376852687,1,True,0.9101912665696706,1,1,0.9527846,1
NCT04719988,Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.,"Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. A Phase II Study",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,55.0,ESTIMATED,2022-01-04,2026-07-05,Centre Hospitalier Universitaire de Besancon,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, PROCEDURE","Blood sample collection, Biopsy",Squamous Cell Carcinoma of the Anus Stage III,,,,,False,1643.0,False,False,2.0,False,False,False,2,True,Medium (30-100),0,55.0,4.02535169073515,1,0,0.58,True,True,0.695198737194746,1,True,0.7242287965324324,1,1,0.67929554,1
NCT00113386,Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer,Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer,TERMINATED,PHASE3,INTERVENTIONAL,19.0,ACTUAL,2005-04-01,,Radiation Therapy Oncology Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, PROCEDURE, PROCEDURE, PROCEDURE, RADIATION","filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy",Lung Cancer,,,,,False,1303.0,True,False,3.0,True,False,False,8,False,Small (<30),1,19.0,2.995732273553991,2,0,0.77,False,False,0.2289048323203493,1,False,0.318394620218122,1,0,0.28006795,1
NCT05181228,"Evaluation of the Impact of a Family-Centered Empowerment Program on Self-Efficacy, Self-Esteem, Depression, Anxiety, Stress Level, and Care Skills in Parents of Children With Oncological Problems",Evaluating The Effectiveness of A Family-Centered Empowerment Program Applied to Parents of Children With Oncological Problems,COMPLETED,,INTERVENTIONAL,76.0,ACTUAL,2022-05-20,2023-05-01,Mersin University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,BEHAVIORAL,Web-Based Education Based on Family-Centered Empowerment Model,Pediatric Cancer,,,,,False,346.0,True,False,-1.0,True,True,False,1,True,Medium (30-100),0,76.0,4.343805421853684,2,0,0.6,True,True,0.7739412383296813,1,True,0.8956526867292881,1,1,0.9300149,1
NCT02924272,Ixazomib Rollover Study,"An Open-Label, Rollover Protocol for Patients Previously Enrolled in Takeda-Sponsored Ixazomib Studies",COMPLETED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2016-12-16,2024-07-03,Takeda,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Ixazomib,"Multiple Myeloma, Lymphoma, Amyloidosis",,,,,False,2756.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,32.0,3.49650756146648,0,0,0.58,True,True,0.6679654985537048,1,True,0.6663655869987971,1,1,0.59201515,1
NCT01688973,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery,Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,55.0,ACTUAL,2012-08-20,2017-04-30,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER, DRUG","Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib","Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma",,,,,False,1714.0,True,False,2.0,True,False,False,3,True,Medium (30-100),1,55.0,4.02535169073515,2,0,0.58,True,True,0.6083933495321472,1,True,0.7832535307322466,1,1,0.72135586,1
NCT00077428,"Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck",Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck,COMPLETED,PHASE2,INTERVENTIONAL,37.0,ACTUAL,2004-06-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER","bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer",,,,,False,1303.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,37.0,3.6375861597263857,1,0,0.58,True,True,0.5722645336134454,1,True,0.6691180871952394,1,1,0.64049757,1
NCT05292898,A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia,"A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia",TERMINATED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2022-03-14,2025-03-31,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,LCAR-AIO Cells,Acute Lymphocytic Leukemia,,,,,False,1113.0,True,False,1.0,False,False,False,1,False,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,False,False,0.33602744919331334,1,False,0.46264397474256286,1,1,0.52120036,0
NCT04230031,Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma,LCI-HEM-MYE-PurD-001: Phase II Study of Daratumumab Pre-Mobilization and Post-Autologous Stem Cell Transplant in Patients With Multiple Myeloma and Sub-Optimal Response to Induction,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2021-07-02,2027-01-01,Wake Forest University Health Sciences,OTHER,,SINGLE_GROUP,NONE,DRUG,Daratumumab,Multiple Myeloma,,,,,False,2009.0,True,False,2.0,False,False,False,1,False,,1,0.0,0.0,0,0,0.58,False,False,0.035826073252687475,1,False,0.03963844932224695,1,0,0.0038204999,1
NCT02564900,Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,"Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors",COMPLETED,PHASE1,INTERVENTIONAL,292.0,ACTUAL,2015-09-01,2023-12-22,"Daiichi Sankyo Co., Ltd.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG","DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)",Advanced Solid Tumors,,,,,False,3034.0,True,False,1.0,False,False,True,3,True,Large (100-300),0,292.0,5.680172609017068,1,1,0.56,True,True,0.8873931064797248,1,True,0.8688227698940052,1,1,0.90894985,1
NCT03411980,Pharmacokinetics and Safety of Vilaprisan in Renal Impairment,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Vilaprisan in Subjects With Decreased Renal Function in Comparison With Matched Subjects With Normal Renal Function",COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2018-02-02,2019-02-06,Bayer,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Vilaprisan (BAY1002670),"Uterine Fibroids, Endometriosis",,,,,False,369.0,True,False,1.0,False,False,True,1,True,Small (<30),0,26.0,3.295836866004329,0,0,0.56,True,True,0.5343184146520725,1,True,0.6467891621234015,1,1,0.64553833,1
NCT03661840,Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors,Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2018-12-04,2021-03-04,"University of Colorado, Denver",OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, OTHER","Acceptance and Commitment Therapy, Treatment as Usual",Chronic Pain,,,,,False,821.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,2,0,0.6,True,True,0.6363495665285969,1,True,0.5735297261487854,1,1,0.5278945,1
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma,COMPLETED,PHASE1,INTERVENTIONAL,9.0,ACTUAL,2013-06-01,2017-03-23,"University Hospital, Grenoble",OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,GeniusVac-Mel4,"Melanoma, Tumor Vaccines, Effects of Immunotherapy",,,,,False,1391.0,True,False,1.0,False,False,False,1,True,Small (<30),0,9.0,2.302585092994046,0,0,0.56,True,False,0.3258723027752965,0,False,0.35209288883769296,0,0,0.3348456,0
NCT01334502,"Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL),COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2012-03-01,2017-08-01,Alliance for Clinical Trials in Oncology,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG","rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate",Lymphoma,,,,,False,1979.0,True,False,1.0,False,False,False,6,True,Small (<30),1,26.0,3.295836866004329,1,0,0.56,True,True,0.5384273739834308,1,True,0.6545278583291635,1,1,0.6819725,1
NCT06570174,Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients,Oral Protein Supplements Might Improve Nutritional Status and Quality of Life in Elderly Patients After Standard Pancreatic Resection,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2021-01-07,2022-07-18,Yonsei University,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DIETARY_SUPPLEMENT, GENETIC","oral protein supplements, placebo","Pancreatic Cancer, Cholangiocarcinoma, Intraductal Papillary Mucinous Neoplasm, Neuroendocrine Tumor, Solid Pseudopapillary Tumor",,,,,False,557.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,60.0,4.110873864173311,3,0,0.6,True,True,0.6944050858816855,1,True,0.8957936045865691,1,1,0.954685,1
NCT00075660,3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma,A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2004-05-11,2008-09-22,NCIC Clinical Trials Group,NETWORK,,SINGLE_GROUP,NONE,DRUG,triapine,Kidney Cancer,,,,,False,1595.0,True,False,2.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.58,True,False,0.47923571286239797,0,True,0.6081610241273907,1,1,0.5577868,1
NCT04180371,Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression,"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,288.0,ESTIMATED,2019-11-07,2027-07-31,BicycleTx Limited,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","BT5528, Nivolumab","Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer",,,,,False,2823.0,False,False,1.0,False,False,True,2,True,Large (100-300),1,288.0,5.666426688112432,1,1,0.56,True,True,0.8807979146122592,1,True,0.9052553081937864,1,1,0.93615645,1
NCT05285306,Surveillance Pelvic Examination Anxiety: Brief Coping Skills Intervention,Developing and Pilot Testing a Brief Intervention to Reduce Anxiety During Pelvic Examinations Among Female Cancer Survivors (Pelvic Examination and Anxiety Coping Skills for Empowerment: PEACE),COMPLETED,,INTERVENTIONAL,16.0,ACTUAL,2022-03-21,2022-09-02,Duke University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,PEACE Program,Anxiety,,,,,False,165.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,16.0,2.833213344056216,0,0,0.6,True,False,0.4498382985952162,0,True,0.662348314335642,1,1,0.6047681,1
NCT01717677,"Evaluation of Four Treatment Modalities in Prostate Cancer With Low or ""Early Intermediate"" Risk","Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or ""Early Intermediate"" Risk",TERMINATED,,INTERVENTIONAL,457.0,ACTUAL,2012-10-01,2018-04-30,Association of Urologic Oncology (AUO),OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, RADIATION, RADIATION, PROCEDURE","radical prostatectomy, percutaneous radiation therapy, permanent seed implantation, Active Surveillance",Prostate Cancer,,,,,False,2037.0,True,False,-1.0,True,False,False,4,False,Very Large (300+),0,457.0,6.126869184114185,2,1,0.6,False,True,0.8892861020074776,0,True,0.9014870722726388,0,1,0.9241234,0
NCT03022539,Repeat CT Scans for Evaluation of Inter- and Intrafraction Motion and it's Effect on Radiotherapy Dose Distribution During Curative Radiotherapy for Pelvic Tumours,,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2016-12-01,2021-08-02,University Medical Center Groningen,OTHER,,,,RADIATION,Repeat CT scan,Pelvic Tumor,,,,,False,1705.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7443431553525736,1,True,0.6878718651683264,1,1,0.67100424,1
NCT05757232,Construction of an Ultrasound Profile and a Mammographic Profile Corresponding to the Different Molecular Subtypes of Brest Cancer. A Retrospective Study,Construction of an Ultrasound Profile and a Mammography Profile Corresponding to the Different Molecular Subtypes of Brest Cancer. A Retrospective Study of 203 Cases Diagnosed During the National Screening Campaign in 2015-2018 (PROFILS),COMPLETED,,OBSERVATIONAL,203.0,ACTUAL,2015-06-01,2018-07-01,Elsan,OTHER,,,,,,Breast Cancer,,,,,False,1126.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,203.0,5.318119993844216,0,1,0.6,True,True,0.8552215326779894,1,True,0.8358319955514811,1,1,0.8808845,1
NCT06320184,AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs,Artificial Intelligence Tools Integrating Blood Biomarkers and Radiomics to Define Lung Cancer Risk in Computed Tomography Screening Programs,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,650.0,ACTUAL,2023-04-30,2026-04-30,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,,,,DIAGNOSTIC_TEST,Artificial Intelligence risk model,"Lung Cancer, Blood Biomarkers",,,,,False,1096.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,650.0,6.478509642208569,0,1,0.6,True,True,0.9404473399704393,1,True,0.9163408326494068,1,1,0.93693787,1
NCT02566408,"Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity","Attitudes, Beliefs and Preferences of Older Breast Cancer Survivors Towards Physical Activity",COMPLETED,,INTERVENTIONAL,61.0,ACTUAL,2015-10-14,2016-10-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER","One-on-one interview, Survey Questions","Cancer Survivor, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",,,,,False,353.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,61.0,4.127134385045092,1,0,0.6,True,True,0.7348688741804045,1,True,0.9206090352186423,1,1,0.9313479,1
NCT03354884,caBozantinib in cOllectiNg ductS Renal Cell cArcInoma,caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI),COMPLETED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2018-01-12,2020-11-19,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,,SINGLE_GROUP,NONE,DRUG,cabozantinib,Collecting Duct Carcinoma (Kidney),,,,,False,1042.0,True,False,2.0,False,False,False,1,True,Small (<30),1,23.0,3.1780538303479458,0,0,0.58,True,False,0.4926860149450386,0,True,0.5761281085601195,1,1,0.662084,1
NCT03131778,The Inflammatory Response to Stress and Angiogenesis in Liver Resection,The Inflammatory Response to Stress and Angiogenesis in Open Versus Laparoscopic Liver Resection for Colorectal Liver Metastases,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2010-04-01,2011-06-30,"University Hospital, Ghent",OTHER,RANDOMIZED,PARALLEL,NONE,PROCEDURE,Liver resection,"Liver Cancer, Colorectal Cancer, Metastatic Cancer, Liver Metastases",,,,,False,455.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.6,True,True,0.6126704489488841,1,True,0.8555869395072783,1,1,0.8211171,1
NCT03972072,MRI - Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer (MARTHA-trial),MARTHA-trial: MRI - Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer Including Longitudinal Evaluation of the Patient's Immune Profile Under Radiotherapy,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,49.0,ACTUAL,2019-10-15,2026-05-21,Panagiotis Balermpas,OTHER,,SINGLE_GROUP,NONE,"OTHER, DIAGNOSTIC_TEST","Pre-defined MR-linac based IGRT and plan adaptation protocol, salivary flow measurements","Head and Neck Cancer, Xerostomia Due to Radiotherapy",,,,,False,2410.0,False,False,-1.0,False,False,False,2,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.6,True,True,0.7719107536977067,1,True,0.8175516148119292,1,1,0.8782486,1
NCT01129037,Goal Directed Fluid Therapy in Free Flap Reconstructive Surgery,"Goal Directed Fluid Management and Patient Outcome in Free Flap Reconstructive Surgery for Head and Neck Oncology: a Feasibility Randomized, Controlled Trial",COMPLETED,,INTERVENTIONAL,78.0,ACTUAL,2010-07-01,2013-02-01,"University Health Network, Toronto",OTHER,RANDOMIZED,PARALLEL,DOUBLE,OTHER,Goal directed fluid management based on continuous monitoring of stroke volume,Head and Neck Cancer,,,,,False,946.0,True,False,-1.0,True,True,False,1,True,Medium (30-100),0,78.0,4.3694478524670215,2,0,0.6,True,True,0.7993877625318995,1,True,0.7692824104133706,1,1,0.6582912,1
NCT00005602,Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas,Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas,COMPLETED,PHASE1,INTERVENTIONAL,13.0,ACTUAL,2001-02-01,2005-09-01,Children's Oncology Group,NETWORK,,,,"DRUG, DRUG, RADIATION","carboplatin, cereport, radiation therapy",Brain and Central Nervous System Tumors,,,,,False,1673.0,True,False,1.0,False,False,False,3,True,Small (<30),1,13.0,2.6390573296152584,1,0,0.56,True,False,0.3637059340293217,0,False,0.4699499465894113,0,0,0.4431985,0
NCT05427812,Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma,"A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma",TERMINATED,PHASE1,INTERVENTIONAL,29.0,ACTUAL,2022-09-27,2024-11-19,Ichnos Sciences SA,INDUSTRY,RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D",Relapsed/Refractory Multiple Myeloma,,,,,False,784.0,True,False,1.0,True,False,True,2,False,Small (<30),0,29.0,3.4011973816621555,2,0,0.56,False,False,0.445034859819556,1,True,0.5581063587552244,0,1,0.5577904,0
NCT06984159,"The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.","An Open-Label, Single-Arm, Multicenter Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer",COMPLETED,PHASE3,INTERVENTIONAL,137.0,ACTUAL,2022-07-12,2024-04-24,"Changchun GeneScience Pharmaceutical Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Leuprolide Injectable Emulsion (CAMCEVI®),Advanced Prostate Cancer,,,,,False,652.0,True,False,3.0,False,False,True,1,True,Large (100-300),0,137.0,4.927253685157205,0,1,0.77,True,True,0.6343711773121419,1,True,0.9082042418595908,1,1,0.879096,1
NCT02424448,"Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer","BIOMETHS Study. A Methodology Study to Determine the Feasibility, Evaluability and Temporal Variability in Candidate Pharmacodynamic Markers of Drug Action in Castration Resistant Prostate Cancer",COMPLETED,,OBSERVATIONAL,6.0,ACTUAL,2014-12-01,2016-07-01,The Christie NHS Foundation Trust,OTHER,,,,PROCEDURE,"Biopsies, blood and urine samples",Metastatic Castration Resistant Prostate Cancer,,,,,False,578.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,6.0,1.9459101490553128,0,0,0.6,True,False,0.2533936127226844,0,False,0.3586904828500671,0,0,0.3870242,0
NCT05470140,A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML),A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML),COMPLETED,PHASE1,INTERVENTIONAL,9.0,ACTUAL,2023-07-01,2024-10-08,"Wugen, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,WU-NK-101,Acute Myeloid Leukemia,,,,,False,465.0,True,False,1.0,False,False,True,1,True,Small (<30),0,9.0,2.302585092994046,0,0,0.56,True,False,0.28503284172281024,0,False,0.2714501597841639,0,0,0.21677482,0
NCT01342679,"A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib","A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib",COMPLETED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2011-04-01,2014-09-01,Kanto CML Study Group,OTHER,,SINGLE_GROUP,NONE,DRUG,dasatinib,Chronic Myeloid Leukemia,,,,,False,1249.0,True,False,2.0,False,False,False,1,True,Small (<30),1,21.0,3.091042453358316,0,0,0.58,True,False,0.47995141444217954,0,False,0.45536245895131044,0,0,0.49740162,0
NCT01204203,Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901),A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma,COMPLETED,PHASE2,INTERVENTIONAL,8.0,ACTUAL,2009-06-01,2016-04-01,University of Alabama at Birmingham,OTHER,,SINGLE_GROUP,NONE,DRUG,Zometa,Mesothelioma,,,,,False,2496.0,True,False,2.0,False,False,False,1,True,Small (<30),0,8.0,2.19722457733622,0,0,0.58,True,False,0.3179829625390573,0,False,0.34634725831701124,0,0,0.43641743,0
NCT02368886,Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC),COMPLETED,PHASE2,INTERVENTIONAL,123.0,ACTUAL,2015-03-27,2023-03-02,Academic and Community Cancer Research United,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER, OTHER, DRUG","Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment, Regorafenib","Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7",,,,,False,2897.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,123.0,4.820281565605037,2,1,0.58,True,True,0.6554118702554715,1,True,0.8358603800413976,1,1,0.87300706,1
NCT00513292,Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery,A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer,COMPLETED,PHASE3,INTERVENTIONAL,280.0,ACTUAL,2007-07-01,2013-02-21,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, OTHER, DRUG, PROCEDURE, BIOLOGICAL","Cyclophosphamide, Epirubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Trastuzumab","HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",,,,,False,2062.0,True,False,3.0,True,False,False,6,True,Large (100-300),1,280.0,5.638354669333745,2,1,0.77,True,True,0.7049630709795724,1,True,0.9157711923192151,1,1,0.9433153,1
NCT06192017,Development of a Molecular Diagnostic Tool for Endometrial Cancer.,Development of a Molecular Diagnostic Tool for Endometrial Cancer.,COMPLETED,,OBSERVATIONAL,1950.0,ACTUAL,2023-10-18,2025-07-31,"MiMARK Diagnostics, S.L.",INDUSTRY,,,,DIAGNOSTIC_TEST,WomEC,Endometrium Cancer,,,,,False,652.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,1950.0,7.576097340623111,0,1,0.6,True,True,0.9574140817903335,1,True,0.9747801099941326,1,1,0.973056,1
NCT00058292,Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,44.0,ACTUAL,2000-04-01,2009-03-01,Northwestern University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE, RADIATION","filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan",Lymphoma,,,,,False,3256.0,True,False,1.0,False,False,False,8,True,Medium (30-100),1,44.0,3.80666248977032,1,0,0.56,True,True,0.7165295450452602,1,True,0.875958121221491,1,1,0.9509292,1
NCT04036461,"A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma","A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma",TERMINATED,PHASE1,INTERVENTIONAL,47.0,ACTUAL,2019-08-26,2024-08-19,Celgene,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","CC-99712, BMS-986405",Multiple Myeloma,,,,,False,1820.0,True,False,1.0,False,False,True,2,False,Medium (30-100),0,47.0,3.871201010907891,1,0,0.56,False,True,0.7002984720321423,0,True,0.6082889582571815,0,0,0.48464143,1
NCT00822718,Obestatin Change in Distal Gastrectomy,,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2005-01-01,2007-07-01,Samsung Medical Center,OTHER,,,,,,Gastric Cancer Patients Treated by Subtotal Gastrectomy,,,,,False,911.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7353489688915171,1,True,0.9032794717694891,1,1,0.9351128,1
NCT02410564,CBT-I Intervention for Insomnia in Newly Diagnosed Cancer Patients,Testing an Accessible Cognitive Behavioral Therapy for Insomnia (CBT-I) Intervention in Newly Diagnosed Cancer Patients,TERMINATED,,INTERVENTIONAL,29.0,ACTUAL,2014-12-01,2016-01-01,Virginia Commonwealth University,OTHER,RANDOMIZED,CROSSOVER,NONE,"BEHAVIORAL, BEHAVIORAL","cognitive behavioral therapy for insomnia (CBTI), Waitlist control condition","Cancer, Chronic Insomnia",,,,,False,396.0,True,False,-1.0,True,False,False,2,False,Small (<30),0,29.0,3.4011973816621555,2,0,0.6,False,False,0.47567108221618315,1,True,0.7130864110754426,0,1,0.7508598,0
NCT04273139,Ibrutinib + Venetoclax in Untreated WM,Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,45.0,ACTUAL,2020-07-09,2028-02-01,Dana-Farber Cancer Institute,OTHER,,SEQUENTIAL,NONE,"DRUG, DRUG","IBRUTINIB, Venetoclax","Waldenstrom Macroglobulinemia, MYD88 Gene Mutation",,,,,False,2763.0,False,False,2.0,False,False,False,2,True,Medium (30-100),0,45.0,3.828641396489095,1,0,0.58,True,True,0.7001830744627976,1,True,0.9152908780106475,1,1,0.8885262,1
NCT05416749,A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors,"Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors",SUSPENDED,PHASE1,INTERVENTIONAL,216.0,ESTIMATED,2022-08-05,2026-03-01,"Mabwell (Shanghai) Bioscience Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,8MW2311,Solid Tumors,,,,,False,1304.0,False,False,1.0,False,False,True,1,False,Large (100-300),0,216.0,5.37989735354046,0,1,0.56,False,True,0.8387048470479197,0,True,0.7314279023524263,0,1,0.6981569,0
NCT00162695,Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood,,TERMINATED,PHASE3,INTERVENTIONAL,400.0,,1995-07-01,,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,"Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide","Rhabdomyosarcoma, Malignant Soft Tissue",,,,,False,1303.0,True,False,3.0,True,False,False,1,False,Very Large (300+),1,400.0,5.993961427306569,1,1,0.77,False,True,0.7896451224902832,0,True,0.6790702367352975,0,1,0.5266215,0
NCT06469255,Short Term Ketogenic Diet in Polycictic Ovary Syndrome,Effects of Short-Term Low-Calorie Ketogenic Diet on Biochemical and Anthropometric Parameters in Women With Polycystic Ovary Syndrome,COMPLETED,,INTERVENTIONAL,13.0,ACTUAL,2019-10-01,2020-03-30,Istanbul Bilgi University,OTHER,,SINGLE_GROUP,NONE,OTHER,Diet Treatment,Polycystic Ovary Syndrome,,,,,False,181.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.6,True,False,0.3992170511644904,0,True,0.631618880419331,1,1,0.58200383,1
NCT02836548,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,COMPLETED,PHASE1,INTERVENTIONAL,33.0,ACTUAL,2016-06-01,2023-11-01,The Netherlands Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,Vorinostat,"Melanoma, Skin Neoplasms",,,,,False,2709.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,33.0,3.5263605246161616,0,0,0.56,True,True,0.7053066865970591,1,True,0.7192368618997113,1,1,0.6088128,1
NCT05565638,PROFAST Intervention in Precursor Multiple Myeloma,PROlonged Nightly FASTing for Obesity Reduction and Prevention of Disease Prevention in Precursor Multiple Myeloma (PROFAST),COMPLETED,,INTERVENTIONAL,23.0,ACTUAL,2023-03-06,2025-08-04,Dana-Farber Cancer Institute,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Prolonged Fasting Intervention, EDUCATION CONTROL","Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma",,,,,False,882.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,23.0,3.1780538303479458,2,0,0.6,True,False,0.4410355301598671,0,True,0.5478665448886247,1,1,0.5990206,1
NCT02455024,An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®,A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (Ponatinib) in Routine Clinical Practice in the United States (OMNI).,TERMINATED,,OBSERVATIONAL,3.0,ACTUAL,2018-03-02,2019-02-19,Ariad Pharmaceuticals,INDUSTRY,,,,,,"Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL",,,,,False,354.0,True,False,-1.0,False,False,True,0,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.6,False,False,0.15220964065182244,1,False,0.16975435090836435,1,0,0.1409402,1
NCT04561817,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,An Open Label Phase II Study to Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2020-10-01,2023-10-01,Icahn School of Medicine at Mount Sinai,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Ipatasertib, Paclitaxel",Ovarian Neoplasms,,,,,False,1095.0,True,False,2.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.58,False,False,0.024339312131283406,1,False,0.008184874051667897,1,0,0.003017393,1
NCT02562118,Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer,Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,40.0,ESTIMATED,2015-10-02,2027-06-01,"National University Hospital, Singapore",OTHER,,SINGLE_GROUP,NONE,DRUG,Lenvatinib + Letrozole,Breast Cancer,,,,,False,4260.0,False,False,1.0,False,False,False,1,True,Medium (30-100),1,40.0,3.713572066704308,0,0,0.56,True,True,0.7970624618502851,1,True,0.8114396427185377,1,1,0.77952164,1
NCT02589366,Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium,"A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection",TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2015-11-01,2018-04-01,"University of California, San Diego",OTHER,,SINGLE_GROUP,NONE,DRUG,Lymphoseek plus Vital Blue Dye,Endometrial Cancer,,,,,False,882.0,True,False,1.0,False,False,False,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.56,False,False,0.10467130040890263,1,False,0.09363380702815922,1,0,0.077064365,1
NCT02729701,Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation,Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation in Peri or Post-menopausal Women at Moderate Risk for Development of Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,28.0,ACTUAL,2016-05-01,2019-06-01,University of Kansas Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Duavee,Breast Cancer,,,,,False,1126.0,True,False,2.0,False,False,False,1,True,Small (<30),0,28.0,3.367295829986474,0,0,0.58,True,True,0.5549480074429958,1,True,0.568311767820408,1,0,0.4636562,0
NCT06090318,Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss,A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4),WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2023-05-19,2023-05-30,Rain Oncology Inc,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Milademetan, Atezolizumab","Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer",,,,,False,11.0,True,False,1.0,False,False,True,2,False,,1,0.0,0.0,1,0,0.56,False,False,0.022637926488481026,1,False,0.0016619074006574655,1,0,0.0019219504,1
NCT01502982,Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04),"CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study",COMPLETED,PHASE2,INTERVENTIONAL,160.0,ACTUAL,2004-11-01,2014-05-01,Nordic Lymphoma Group,NETWORK,,SINGLE_GROUP,NONE,DRUG,R-CHOEP14x6+HD-AraC+HD-Mtx,Diffuse Large B-Cell Lymphoma,,,,,False,3468.0,True,False,2.0,False,False,False,1,True,Large (100-300),0,160.0,5.081404364984463,0,1,0.58,True,True,0.8393615791272868,1,True,0.9206291723594062,1,1,0.95053184,1
NCT01547806,Collection of Transplant Stem Cells for Plasma Cell Myeloma,Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM),COMPLETED,PHASE2,INTERVENTIONAL,49.0,ACTUAL,2012-02-22,2018-01-11,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, PROCEDURE","Filgrastim, Plerixafor, Apheresis","Plasma Cell Myeloma, Multiple Myeloma",,,,,False,2150.0,True,False,2.0,False,False,False,3,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.58,True,True,0.687616292107913,1,True,0.8867881941847948,1,1,0.9072147,1
NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2015-07-09,2021-03-03,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Palbociclib, Bazedoxifene","Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer",,,,,False,2064.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,36.0,3.610917912644224,1,0,0.56,True,True,0.6440035243976122,1,True,0.7719058341359721,1,1,0.76455235,1
NCT03178383,Integration of Cancer Health Activities Into African American Churches,Integration of Cancer Health Activities Into African American Churches,COMPLETED,,INTERVENTIONAL,446.0,ACTUAL,2016-07-01,2022-06-30,"University of Maryland, College Park",OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","Project HEAL, Project HEAL 2.0","Breast Cancer, Prostate Cancer, Colorectal Cancer",,,,,False,2190.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,446.0,6.102558594613569,2,1,0.6,True,True,0.8943664003432975,1,True,0.9220485209510607,1,1,0.93948656,1
NCT01633970,A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors,A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,240.0,ACTUAL,2012-07-11,2020-02-26,"Genentech, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed",Cancer,,,,,False,2786.0,True,False,1.0,True,False,True,9,True,Large (100-300),1,240.0,5.484796933490655,2,1,0.56,True,True,0.7904819593625163,1,True,0.7329604997196515,1,1,0.6841767,1
NCT00005036,Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU,COMPLETED,PHASE3,INTERVENTIONAL,560.0,ACTUAL,1999-11-01,,National Cancer Institute (NCI),NIH,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG, DRUG, DRUG, PROCEDURE","irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, quality-of-life assessment","Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer",,,,,False,1303.0,True,False,3.0,True,False,False,5,True,Very Large (300+),1,560.0,6.329720905522696,2,1,0.77,True,True,0.7904231981813389,1,True,0.688904872997509,1,1,0.69935256,1
NCT01538472,Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma,"Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2003-09-01,2011-11-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, DRUG","Y Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, Stem Cell Infusion, G-CSF",Lymphoma,,,,,False,2983.0,True,False,1.0,False,False,False,9,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.56,True,True,0.6853978128278453,1,True,0.915743849420864,1,1,0.95783865,1
NCT02210104,Adoptive Therapy Using Antigen-Specific CD4 T-Cells,Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-12-01,,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, BIOLOGICAL","Ipilimumab, Cyclophosphamide, CD4+ T cells","Melanoma, Sarcoma",,,,,False,1303.0,True,False,1.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.56,False,False,0.028836297332582375,1,False,0.004485311627809789,1,0,0.0030932717,1
NCT01574274,SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma,Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,240.0,ACTUAL,2012-06-01,2027-07-01,Dana-Farber Cancer Institute,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","SC-PEG, Oncaspar","Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma",,,,,False,5508.0,False,False,2.0,True,False,False,2,True,Large (100-300),0,240.0,5.484796933490655,2,1,0.58,True,True,0.8715620980731422,1,True,0.9080489702024029,1,1,0.957016,1
NCT04080531,Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders,Influenza Vaccination in Plasma Cell Dyscrasias,COMPLETED,PHASE4,INTERVENTIONAL,165.0,ACTUAL,2019-10-18,2022-12-15,Emory University,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL","Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine",Plasma Cell Neoplasm,,,,,False,1154.0,True,False,4.0,True,False,False,2,True,Large (100-300),0,165.0,5.111987788356544,2,1,0.7,True,True,0.5604109926969296,1,True,0.842840577645009,1,1,0.9221781,1
NCT01339273,Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection,Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial,COMPLETED,,INTERVENTIONAL,72.0,ACTUAL,2011-09-01,2015-12-01,Oxford University Hospitals NHS Trust,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, PROCEDURE","Ultrasound guided Transversus Abdominis Plane (TAP) bock, Local anaesthetic infiltration of laparoscopic port sites","Colonic Cancer, Rectal Cancer, Colonic Diverticulum, Ulcerative Colitis",,,,,False,1552.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,72.0,4.290459441148391,3,0,0.6,True,True,0.7716112732839959,1,True,0.7912351093440894,1,1,0.8428505,1
NCT00016874,3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer,"A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer",COMPLETED,PHASE1,INTERVENTIONAL,,,2000-12-01,2008-01-01,Vion Pharmaceuticals,INDUSTRY,,,,"DRUG, DRUG, DRUG","cisplatin, paclitaxel, triapine","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2587.0,True,False,1.0,False,False,True,3,True,,1,,,1,0,0.56,True,True,0.7316625675959639,1,True,0.8920025303225759,1,1,0.919317,1
NCT00654030,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2006-10-01,2009-11-01,Edward Hirschowitz,OTHER,,SINGLE_GROUP,NONE,DRUG,1650-G Vaccine,Non-Small Cell Lung Cancer,,,,,False,1127.0,True,False,2.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.58,True,False,0.34346950303173673,0,False,0.32710541983789343,0,0,0.35212654,0
NCT01406782,DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402,The Influence of KIR and HLA Genotype on the Response to Rituximab Immunotherapy in Patients With Follicular Lymphoma,COMPLETED,,OBSERVATIONAL,200.0,ACTUAL,2011-12-13,2012-01-13,Eastern Cooperative Oncology Group,NETWORK,,,,"BIOLOGICAL, GENETIC, GENETIC, GENETIC, OTHER","rituximab, DNA analysis, gene expression analysis, polymerase chain reaction, laboratory biomarker analysis",Lymphoma,,,,,False,31.0,True,False,-1.0,False,False,False,5,True,Large (100-300),1,200.0,5.303304908059076,1,1,0.6,True,True,0.7712261223546147,1,True,0.9288981106124109,1,1,0.8821173,1
NCT02177812,A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML),"A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",TERMINATED,PHASE1,INTERVENTIONAL,41.0,ACTUAL,2014-08-27,2017-12-08,GlaxoSmithKline,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","GSK2879552, ATRA","Leukaemia, Myelocytic, Acute",,,,,False,1199.0,True,False,1.0,False,False,True,2,False,Medium (30-100),0,41.0,3.737669618283368,1,0,0.56,False,True,0.6403382250701255,0,True,0.6233644328798599,0,1,0.6636637,0
NCT02880111,Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa,Comparison of Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients Colonized Patients Between Chronic and Non-chronic Patients Colonized With Pseudomonas Aeruginosa,TERMINATED,,OBSERVATIONAL,1.0,ACTUAL,2016-03-23,2022-03-01,"University Hospital, Lille",OTHER,,,,,,Malignant Brain Tumor,,,,,False,2169.0,True,False,-1.0,False,False,False,0,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.6,False,False,0.10938550224507008,1,False,0.23025782429548391,1,0,0.39025682,1
NCT00062049,Interleukin-7 in Treating Patients With Refractory Solid Tumors,"A Phase I Study of Subcutaneous ""CYT 99 007"" (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy",COMPLETED,PHASE1,INTERVENTIONAL,30.0,ESTIMATED,2003-04-01,2011-05-01,National Institutes of Health Clinical Center (CC),NIH,,,,BIOLOGICAL,recombinant interleukin-7,"Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2952.0,True,False,1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.56,True,True,0.6950686035410137,1,True,0.7434573562015525,1,1,0.6043845,1
NCT01264952,Treatment of Liver Metastases With Electrochemotherapy,Treatment of Liver Metastases With Electrochemotherapy,COMPLETED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2008-11-01,2013-11-01,Institute of Oncology Ljubljana,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Electrochemotherapy,Liver Metastases,,,,,False,1826.0,True,False,1.0,False,False,False,1,True,Small (<30),0,16.0,2.833213344056216,0,0,0.56,True,False,0.4850672903744421,0,True,0.7781734841264043,1,1,0.6986482,1
NCT00051467,A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer,"A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer",COMPLETED,PHASE3,INTERVENTIONAL,,,,,GenVec,INDUSTRY,RANDOMIZED,,NONE,GENETIC,TNFerade,Pancreatic Cancer,,,,,False,1303.0,True,False,3.0,True,False,True,1,True,,0,,,1,0,0.77,True,True,0.5325549169639541,1,True,0.666768999906706,1,1,0.52239627,1
NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,COMPLETED,PHASE2,INTERVENTIONAL,75.0,ACTUAL,2011-10-01,2015-12-01,Yale University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Folfirinox,"Metastatic Pancreatic Cancer, Pancreatic Cancer",,,,,False,1522.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,75.0,4.330733340286331,0,0,0.58,True,True,0.7908632348118841,1,True,0.7851087970462052,1,1,0.75927657,1
NCT04950452,Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia,Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia in Older Adults by Enhancing Physical and Immunological Reserve,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2018-08-22,2020-01-06,Duke University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Exercise Training,"Aging, Chronic Lymphocytic Leukemia",,,,,False,502.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5244148050288525,1,True,0.7698428479914492,1,1,0.79440516,1
NCT00813592,Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma,A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation,TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2008-11-01,2013-03-01,University of Utah,OTHER,,SINGLE_GROUP,NONE,DRUG,SOM230B,Cancer,,,,,False,1581.0,True,False,2.0,False,False,False,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.58,False,False,0.10411804945640142,1,False,0.16231209856858528,1,0,0.1606476,1
NCT01215721,Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II),Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2010-10-01,2013-05-01,"University of California, Irvine",OTHER,,SINGLE_GROUP,NONE,DRUG,Vesicare,Urinary Incontinence,,,,,False,943.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7130163992471265,1,True,0.7614486943999665,1,1,0.6461233,1
NCT04054908,Gut Microbiome in Colorectal Cancer,Gut Microbiome and Oral Fluoropyrimidine Study in Patients With Colorectal Cancer,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2018-04-13,2022-06-30,"University of California, San Francisco",OTHER,,,,,,"Gastrointestinal Microbiome, Neoplasm, Colorectal",,,,,False,1539.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.7837534494025641,1,True,0.6352315651777745,1,1,0.56393784,1
NCT00706069,Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer,A Phase I Study Of Vinorelbine Oral Plus Capecitabine Combination In Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,40.0,ESTIMATED,2008-06-01,2009-07-01,Hellenic Oncology Research Group,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Vinorelbine oral, Capecitabine",Metastatic Breast Cancer,,,,,False,395.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.56,True,True,0.5879383719553671,1,False,0.4980630029450891,0,0,0.39691058,0
NCT03742349,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer",TERMINATED,PHASE1,INTERVENTIONAL,64.0,ACTUAL,2019-01-31,2023-02-06,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, BIOLOGICAL, BIOLOGICAL","spartalizumab, LAG525, NIR178, capmatinib, MCS110, canakinumab",Triple Negative Breast Cancer (TNBC),,,,,False,1467.0,True,False,1.0,False,False,True,6,False,Medium (30-100),0,64.0,4.174387269895637,1,0,0.56,False,True,0.7340155984702055,0,True,0.807948550836489,0,1,0.7323154,0
NCT01570868,Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase,TERMINATED,PHASE2,INTERVENTIONAL,51.0,ACTUAL,2012-04-01,2016-05-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Ponatinib,Leukemia,,,,,False,1491.0,True,False,2.0,False,False,False,1,False,Medium (30-100),1,51.0,3.951243718581428,0,0,0.58,False,True,0.7097288413770009,0,True,0.8166780777225775,0,1,0.7835523,0
NCT03663647,Advanced Melanoma in Russian Experience,Multicentral Retrospective Chart Review Study of Targeted Therapy Use in Patients With BRAF V600 Advanced (Unresectable or Metastatic) Cutaneous Melanoma in Routine Clinical Practice in Russian Federation,COMPLETED,,OBSERVATIONAL,382.0,ACTUAL,2018-10-08,2019-04-27,"MelanomaPRO, Russia",OTHER,,,,,,"Cutaneous Melanoma, Stage IV, BRAF V600 Mutation",,,,,False,201.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,382.0,5.948034989180646,0,1,0.6,True,True,0.8974283265989417,1,True,0.8889333926988475,1,1,0.9024084,1
NCT00366275,"Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma","Phase II of Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Patients With Relapsed or Refractory Follicular Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,64.0,ACTUAL,2002-01-01,2007-09-01,Fondazione IRCCS Policlinico San Matteo di Pavia,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,PROCEDURE,"Immunochemotherapy, in vivo purging and autrotransplant",Follicular Lymphoma,,,,,False,2069.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,64.0,4.174387269895637,0,0,0.58,True,True,0.782325636528928,1,True,0.7928270481730344,1,1,0.69331217,1
NCT04243499,First-in-Human Study of ICT01 in Patients With Advanced Cancer,"A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,292.0,ACTUAL,2020-03-05,2026-10-01,ImCheck Therapeutics,INDUSTRY,RANDOMIZED,PARALLEL,NONE,BIOLOGICAL,IV ICT01,"Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer",,,,,False,2401.0,False,False,1.0,True,False,True,1,True,Large (100-300),0,292.0,5.680172609017068,1,1,0.56,True,True,0.8595315613927673,1,True,0.908351938401774,1,1,0.86983925,1
NCT00093405,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer,A Phase II Study Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG)In Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,,,2004-08-01,2005-11-01,Memorial Sloan Kettering Cancer Center,OTHER,,,NONE,DRUG,tanespimycin,Kidney Cancer,,,,,False,457.0,True,False,2.0,False,False,False,1,True,,0,,,0,0,0.58,True,True,0.6604674525399331,1,True,0.6618681289466708,1,1,0.6043648,1
NCT04448730,Polycystic Ovary Syndrome and BETATROPHIN,Can the Betatrophin be a Reliable Marker of Insulin Resistance in Normal Weight and Overweight Women With Polycystic Ovary Syndrome?,COMPLETED,,OBSERVATIONAL,73.0,ACTUAL,2018-01-01,2019-12-30,Hatice Akkaya,OTHER_GOV,,,,DIAGNOSTIC_TEST,serum marker levels,"Polycystic Ovary, Obesity",,,,,False,728.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,73.0,4.30406509320417,0,0,0.6,True,True,0.8164338068932894,1,True,0.7111631619406059,1,1,0.6784908,1
NCT02557854,HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors,,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-12-01,2019-03-16,Theodore Laetsch,OTHER,,SINGLE_GROUP,NONE,"DRUG, DEVICE","Doxorubicin HCl liposomal injection, Philips Sonalleve MR-HIFU Hyperthermia","Rhabdomyosarcoma, Neuroblastoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid",,,,,False,835.0,True,False,1.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.56,False,False,0.026759532708136892,1,False,0.0035856929973158607,1,0,0.0023628834,1
NCT02365805,Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer,"Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuvant Chemotherapy Scheme Customized by Levels of BRCA1 in Women With Primary HER2 Negative Breast Cancer (The BERNAQ Clinical Trial)",COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2014-04-01,2016-10-10,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide",Breast Cancer,,,,,False,923.0,True,False,2.0,True,False,False,3,True,Small (<30),1,30.0,3.4339872044851463,2,0,0.58,True,False,0.41175903070978537,0,False,0.43707573186635307,0,0,0.38805637,0
NCT06879353,Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery,Comparison of Efficacy of Single Dose Tranexamic Acid Versus Placebo Before Surgery in Females Undergoing Surgery for Ovarian Cancer,COMPLETED,,INTERVENTIONAL,372.0,ACTUAL,2023-07-12,2024-07-12,Sheikh Zayed Medical College,OTHER_GOV,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Tranexamic Acid (TXA), Placebo","Ovarian Cancer, Perioperative Blood Loss, Blood Transfusion Events",,,,,False,366.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,372.0,5.921578419643816,2,1,0.6,True,True,0.8322249842029958,1,True,0.7979652754354476,1,1,0.9066999,1
NCT01873482,Traditional African Healing Ceremony in a U.S. Population,Traditional African Healing Ceremony in a U.S. Population,COMPLETED,,INTERVENTIONAL,17.0,ACTUAL,2014-05-01,,Duke University,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Movement to rhythm,"Chronic Fatigue Syndrome, Anxiety, Depression, Cancer",,,,,False,1303.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,True,True,0.5243523422338974,1,False,0.4918343460834594,0,1,0.5581797,1
NCT07145320,The Impact of Oral Cryotherapy and Chewing Gum Interventions,"The Impact of Oral Cryotherapy and Chewing Gum Interventions on Chemotherapy-induced Acute and Anticipatory Nausea, Vomiting, and Taste Alterations in Women Receiving Treatment for Breast Cancer: A Randomized Controlled Trial",COMPLETED,,INTERVENTIONAL,135.0,ACTUAL,2021-06-01,2022-05-01,Hacettepe University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","Oral Cryotherapy Group (Group 1), Chewing Gum Group (Group 2)","Breast Cancer, Nausea and Vomiting, Quality of Life, Chewing Gum",,,,,False,334.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,135.0,4.912654885736052,2,1,0.6,True,True,0.6521328762037238,1,True,0.917369375437033,1,1,0.9280098,1
NCT00005578,Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease,Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study,COMPLETED,PHASE3,INTERVENTIONAL,219.0,ACTUAL,1997-03-01,2008-06-01,Children's Oncology Group,NETWORK,RANDOMIZED,SINGLE_GROUP,SINGLE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION","bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy","Cardiac Toxicity, Lymphoma",,,,,False,4110.0,True,False,3.0,True,False,False,9,True,Large (100-300),1,219.0,5.393627546352362,2,1,0.77,True,True,0.7317158410091454,1,True,0.7696618774275565,1,1,0.84233296,1
NCT04237883,Primary Care Clinical Excellence Incentive Study,Effects of Social Comparison Performance Feedback on Primary Care Quality,COMPLETED,,INTERVENTIONAL,225.0,ACTUAL,2019-11-01,2021-01-01,"University of California, Los Angeles",OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Standard communication email, Social comparison Intervention, Leadership Training","Behavioral Economics, Primary Health Care, Health Maintenance, Diabetes, Colorectal Cancer Screening, Cervical Cancer Screening, Chlamydia Screening, HPV Screening",,,,,False,427.0,True,False,-1.0,True,False,False,3,True,Large (100-300),0,225.0,5.420534999272286,2,1,0.6,True,True,0.755979826357003,1,True,0.8753373679103498,1,1,0.8808141,1
NCT01508390,Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate,"Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,35.0,ACTUAL,2011-06-01,2027-12-01,Boston Medical Center,OTHER,,SINGLE_GROUP,NONE,RADIATION,CyberKnife Boost,Prostate Cancer,,,,,False,6027.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.6,True,True,0.8616111662076367,1,True,0.6687056426105324,1,1,0.8185272,1
NCT00665002,Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms,Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms,COMPLETED,,INTERVENTIONAL,16.0,ACTUAL,2008-06-01,2015-02-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG","WT-1, Montanide, Sargramostim (GM-CSF)",Leukemia,,,,,False,2436.0,True,False,-1.0,False,False,False,3,True,Small (<30),0,16.0,2.833213344056216,1,0,0.6,True,True,0.5106457468503806,1,True,0.5444169629712884,1,1,0.5631548,1
NCT07249138,Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study,Impact of Congenital Heart Disease on Quality of Life and Long-Term Outcomes in Childhood Hematological Tumor Survivors,COMPLETED,,OBSERVATIONAL,800.0,ACTUAL,2025-02-15,2025-11-10,Children's Hospital of Fudan University,OTHER,,,,,,"Congenital Heart Disease (CHD), Hematologic Malignancy",,,,,False,268.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,800.0,6.68586094706836,0,1,0.6,True,True,0.939768160768736,1,True,0.9787185602153403,1,1,0.97323596,1
NCT03347994,Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia,"A Phase I Pilot Study of Minnelide, A Novel Heat Shock Protein 70 Inhibitor, in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2018-04-01,2022-04-01,Justin Watts,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Minnelide,Acute Myeloid Leukemia,,,,,False,1461.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.038162678572961066,1,False,0.012625784616325988,1,0,0.0029125686,1
NCT01015911,A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma,"A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma",COMPLETED,PHASE1,INTERVENTIONAL,58.0,ACTUAL,2009-11-01,2012-03-01,Seagen Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SGN-75,"Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin",,,,,False,851.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,58.0,4.07753744390572,0,0,0.56,True,True,0.7454844485370421,1,True,0.7932419753208015,1,1,0.897268,1
NCT03749083,A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer,A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2019-12-31,2024-10-31,Massachusetts General Hospital,OTHER,,,,OTHER,The Functional Assessment of Cancer Therapy- Colorectal,Gastrointestinal Malignancies,,,,,False,1766.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.04929408478726138,1,False,0.019495358433927225,1,0,0.003194944,1
NCT00498875,Depression and Adherence in Head and Neck Cancer,Depression and Adherence in Head and Neck Cancer,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,185.0,ACTUAL,2005-03-15,2026-12-31,M.D. Anderson Cancer Center,OTHER,,,,"BEHAVIORAL, BEHAVIORAL","Questionnaire, Depression Intervention","Oropharyngeal Cancer, Head and Neck Cancer",,,,,False,7961.0,False,False,-1.0,False,False,False,2,True,Large (100-300),0,185.0,5.225746673713202,1,1,0.6,True,True,0.9468134058566423,1,True,0.8633094832604368,1,1,0.92796284,1
NCT05063916,Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix,Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,18.0,ESTIMATED,2022-02-28,2027-08-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,AK104,"Carcinomas, Cervix Cancer, Cervical Cancer",,,,,False,1980.0,False,False,2.0,False,False,False,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.58,True,False,0.4853712772081786,0,True,0.6975934885694184,1,1,0.7374904,1
NCT01246102,AT13387 in Adults With Refractory Solid Tumors,"Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2010-11-19,2017-10-27,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,AT13387,"Solid Tumors, Breast Cancer",,,,,False,2534.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,31.0,3.4657359027997265,0,0,0.56,True,True,0.6837573915772149,1,True,0.7438785925929194,1,1,0.71301913,1
NCT00971139,Implementing Online Patient-Provider Communication Into Clinical Practice,Implementing Online Patient-Provider Communication Into Clinical Practice: Implementation Research,COMPLETED,,INTERVENTIONAL,199.0,ACTUAL,2009-11-01,2013-12-01,Oslo University Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Access to an OPPC service,"Cancer, Injury of Liver, Diabetes",,,,,False,1491.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,199.0,5.298317366548036,1,1,0.6,True,True,0.811882256686721,1,True,0.9198661309149307,1,1,0.77485067,1
NCT03113526,Neck Drains for SLNDs,A Randomized Clinical Trial Comparing Output Volume Thresholds For Drain Removal After Selective Lateral Neck Dissections,COMPLETED,,INTERVENTIONAL,53.0,ACTUAL,2015-12-01,2017-01-11,"University of California, San Francisco",OTHER,RANDOMIZED,PARALLEL,SINGLE,PROCEDURE,remove drain,"Neck Disease, Head and Neck Cancer",,,,,False,407.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,53.0,3.9889840465642745,1,0,0.6,True,True,0.6775221658541366,1,True,0.6835686523608305,1,1,0.56444067,1
NCT03238404,Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy,The Application of Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in Enhanced Recovery After Surgery Programs for Radical Gastrectomy,COMPLETED,,INTERVENTIONAL,88.0,ACTUAL,2015-08-01,2016-12-20,JIANG Zhi-Wei,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","NAC group, Surgery alone group",Gastric Cancer,,,,,False,507.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,88.0,4.48863636973214,2,0,0.6,True,True,0.7467731376769973,1,True,0.8578026776535808,1,1,0.8378171,1
NCT04488874,Sodium Lactate and Brain Relaxation (LSD),Clinical Effectiveness of Hypertonic Sodium Lactate Infusion for Intraoperative Brain Relaxation in Patients Undergoing Scheduled Craniotomy for Supratentorial Brain Tumor Resection: Study Protocol of a Single Center Double-blind Randomized Controlled Phase II Pilot Trial,COMPLETED,PHASE3,INTERVENTIONAL,50.0,ACTUAL,2020-09-29,2023-06-30,Centre Hospitalier Universitaire de Besancon,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Sodium Lactate, Mannitol 20% Infusion","Sodium Lactate, Intracranial Hypertension, Brain Relaxation",,,,,False,1004.0,True,False,3.0,True,True,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,3,0,0.77,True,True,0.501778041739828,1,True,0.5539522733849551,1,1,0.603215,1
NCT00565448,Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents,International Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin-5-fluorouracil (TCF) vs. Cisplatin-5-fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents,COMPLETED,PHASE2,INTERVENTIONAL,75.0,ACTUAL,2007-11-01,2012-01-01,Sanofi,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","docetaxel, cisplatin, 5-fluorouracil","Nasopharyngeal Neoplasms, Carcinoma",,,,,False,1522.0,True,False,2.0,True,False,True,3,True,Medium (30-100),1,75.0,4.330733340286331,2,0,0.58,True,True,0.6733070363739986,1,True,0.8723251728356083,1,1,0.85999537,1
NCT05896566,A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer,A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,231.0,ACTUAL,2024-01-23,2025-09-18,ETOP IBCSG Partners Foundation,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Giredestrant, Triptorelin, Anastrozole",Breast Cancer,,,,,False,604.0,True,False,2.0,True,False,False,3,True,Large (100-300),1,231.0,5.44673737166631,2,1,0.58,True,True,0.6919007912118248,1,True,0.8065491177941658,1,1,0.78212035,1
NCT01646346,4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer,A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer,COMPLETED,,INTERVENTIONAL,46.0,ACTUAL,2012-01-10,2017-07-17,Yale University,OTHER,,SINGLE_GROUP,NONE,RADIATION,4D Conformal Image-Guided Partial Breast RT,Breast Cancer,,,,,False,2015.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,46.0,3.8501476017100575,0,0,0.6,True,True,0.7823066825767893,1,True,0.7465822030444857,1,1,0.64699185,1
NCT02493959,Degradation of the Anorexic Hormone Peptide YY,Degradation of the Anorexic Hormone Peptide YY,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,8.0,ACTUAL,2014-05-01,2015-07-01,Hvidovre University Hospital,OTHER,,SINGLE_GROUP,SINGLE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","PYY1-36 infusion, PYY1-36 + sitagliptin, PYY3-36 infusion, placebo",Healthy,,,,,False,426.0,True,False,0.5,False,False,False,4,True,Small (<30),0,8.0,2.19722457733622,1,0,0.57,True,False,0.22431635082201654,0,False,0.224043768591785,0,0,0.19538629,0
NCT00466531,Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2007-03-21,2026-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","therapeutic autologous lymphocytes, cyclophosphamide",Leukemia,,,,,False,7195.0,False,False,1.0,False,False,False,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.56,True,True,0.8811846236220572,1,True,0.8681767432597012,1,1,0.9300422,1
NCT00953459,Sunitinib Malate in Treating Patients With Small Cell Lung Cancer,"Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naïve (Extensive Disease) or Have a ""Sensitive"" Relapse",TERMINATED,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2009-02-01,2012-09-01,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, OTHER, RADIATION","sunitinib malate, laboratory biomarker analysis, fludeoxyglucose F 18",Lung Cancer,,,,,False,1308.0,True,False,2.0,False,False,False,3,False,Small (<30),1,9.0,2.302585092994046,1,0,0.58,False,False,0.2400198944525124,1,False,0.15854393460701804,1,0,0.16190894,1
NCT06127238,Study of ST-1898 in Advanced Renal Cell Carcinoma,A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,90.0,ESTIMATED,2023-02-07,2025-12-01,Beijing Scitech-Mq Pharmaceuticals Limited,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,ST-1898 tablets,Advanced Renal Cell Carcinoma,,,,,False,1028.0,False,False,1.0,False,False,True,1,True,Medium (30-100),0,90.0,4.51085950651685,0,0,0.56,True,True,0.8273733238493604,1,True,0.683076019464481,1,1,0.62300485,1
NCT05491616,Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study,Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,77.0,ACTUAL,2022-09-29,2026-10-01,Erasmus Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Nivolumab,Esophageal Cancer,,,,,False,1463.0,False,False,2.0,False,False,False,1,True,Medium (30-100),1,77.0,4.356708826689592,0,0,0.58,True,True,0.788658286175395,1,True,0.840828465880962,1,1,0.779419,1
NCT01205217,Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer,"Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2010-12-01,2010-12-01,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Lapatinib, Trastuzumab, Epirubicin, Cyclophosphamide, Paclitaxel","Neoplasms, Breast",,,,,False,0.0,True,False,2.0,True,False,True,5,False,,1,0.0,0.0,2,0,0.58,False,False,0.012990816902286536,1,False,0.008063711415733948,1,0,0.0018414443,1
NCT02139904,Vinorelbine in Mesothelioma,A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma,COMPLETED,PHASE2,INTERVENTIONAL,154.0,ACTUAL,2016-03-01,2021-03-17,Wales Cancer Trials Unit,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER","Vinorelbine, Active Symptom Control",Mesothelioma,,,,,False,1842.0,True,False,2.0,True,False,False,2,True,Large (100-300),1,154.0,5.043425116919247,2,1,0.58,True,True,0.6660940119642309,1,True,0.9326506369942247,1,1,0.9519886,1
NCT04388384,Real-life Pan-HER-blockade With Neratinib,"Neratinib in Patients With HER2+ Breast Cancer: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland",COMPLETED,,OBSERVATIONAL,304.0,ACTUAL,2020-07-02,2024-09-05,Pierre Fabre Pharma GmbH,INDUSTRY,,,,DRUG,Neratinib,Breast Neoplasm,,,,,False,1526.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,304.0,5.720311776607412,0,1,0.6,True,True,0.9020603128639332,1,True,0.8808961555197987,1,1,0.88209474,1
NCT00118235,"Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer","Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study",COMPLETED,PHASE2,INTERVENTIONAL,72.0,ACTUAL,2004-12-01,2011-07-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, BIOLOGICAL, OTHER","cisplatin, irinotecan hydrochloride, bevacizumab, laboratory biomarker analysis",Extensive Stage Small Cell Lung Cancer,,,,,False,2403.0,True,False,2.0,False,False,False,4,True,Medium (30-100),1,72.0,4.290459441148391,1,0,0.58,True,True,0.76739308777882,1,True,0.942186461924228,1,1,0.92136437,1
NCT04028115,Bone Healing During Ninlaro Exposure,Bone Healing During Ninlaro Exposure. An Open Label Phase 2 Single Centre Clinical Trial,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2019-10-24,2024-04-01,Thomas Lund,OTHER,,SINGLE_GROUP,NONE,DRUG,Ixazomib,Multiple Myeloma,,,,,False,1621.0,True,False,2.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.58,True,True,0.5976119461640805,1,True,0.7602157473020783,1,1,0.6985516,1
NCT02950987,Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes,Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,150.0,ESTIMATED,2012-03-01,2027-12-01,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DEVICE,Whole Body MRI,Li-Fraumeni Syndrome,,,,,False,5753.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,150.0,5.017279836814924,0,1,0.6,True,True,0.918352986184515,1,True,0.8617296299243341,1,1,0.9381625,1
NCT00003958,Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma,"Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma",COMPLETED,PHASE3,INTERVENTIONAL,702.0,ACTUAL,2002-09-01,,Children's Oncology Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, PROCEDURE, RADIATION, DRUG, BIOLOGICAL, BIOLOGICAL, OTHER","dactinomycin, vincristine sulfate, cyclophosphamide, therapeutic conventional surgery, radiation therapy, topotecan hydrochloride, filgrastim, sargramostim, laboratory biomarker analysis","Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma",,,,,False,1303.0,True,False,3.0,True,False,False,9,True,Very Large (300+),1,702.0,6.555356891810665,2,1,0.77,True,True,0.8037345092066744,1,True,0.5677597456403786,1,1,0.5227445,1
NCT03473925,Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034),A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors,COMPLETED,PHASE2,INTERVENTIONAL,107.0,ACTUAL,2018-04-10,2021-05-19,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, BIOLOGICAL","Navarixin, Pembrolizumab","Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer",,,,,False,1135.0,True,False,2.0,True,False,True,2,True,Large (100-300),1,107.0,4.68213122712422,2,1,0.58,True,True,0.543727725776378,1,True,0.6620454066027005,1,1,0.5575748,1
NCT01990209,Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),COMPLETED,PHASE2,INTERVENTIONAL,71.0,ACTUAL,2014-03-01,2021-05-01,"SCRI Development Innovations, LLC",OTHER,,SINGLE_GROUP,NONE,DRUG,Orteronel,Metastatic Breast Cancer,,,,,False,2618.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,71.0,4.276666119016055,0,0,0.58,True,True,0.8177817716392138,1,True,0.8604845003978583,1,1,0.8087074,1
NCT01891968,Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation,Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome,COMPLETED,PHASE2,INTERVENTIONAL,15.0,ACTUAL,2013-08-07,2017-01-18,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Bortezomib,Leukemia,,,,,False,1260.0,True,False,2.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.58,True,False,0.4025861573371083,0,False,0.4632098781864379,0,1,0.52678186,1
NCT00002761,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia,"CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,1996-02-01,2007-10-01,Columbia University,OTHER,,,,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","filgrastim, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, cytarabine, idarubicin, peripheral blood stem cell transplantation",Leukemia,,,,,False,4260.0,True,False,1.0,False,False,False,8,False,,1,0.0,0.0,1,0,0.56,False,False,0.047243277819018686,1,False,0.17892202674058985,1,0,0.0047744974,1
NCT02642016,A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors,"A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.",COMPLETED,PHASE1,INTERVENTIONAL,28.0,ACTUAL,2015-12-01,2019-06-04,Celldex Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,CDX-0158 (formerly known as KTN-0158),Advanced Cancer,,,,,False,1281.0,True,False,1.0,False,False,True,1,True,Small (<30),0,28.0,3.367295829986474,0,0,0.56,True,True,0.5997285868842351,1,True,0.6448409127636299,1,1,0.5643783,1
NCT00707343,[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors,Preliminary Evaluation of the Efficacy of [F-18] Fluorothymidine (FLT) to Differentiate Radiation Necrosis From Tumor Recurrence and as a Marker of Proliferation in Patients With Primary Brain Tumors,COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2007-10-31,2010-11-30,University of Utah,OTHER,,SINGLE_GROUP,NONE,RADIATION,FLT-PET Imaging,"Cancer, Brain Tumors",,,,,False,1126.0,True,False,1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.56,True,False,0.4326134232803558,0,True,0.8094314437866481,1,1,0.77684486,1
NCT05809895,Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer,"AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118) Combined With Tislelizumab (VDT482) Plus Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Chemotherapy as First-line Therapy for Participants With Advanced Triple Negative Breast Cancer (TNBC)",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2023-09-15,2029-07-18,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Ociperlimab, Tislelizumab, Paclitaxel, Nab-paclitaxel, Carboplatin, Placebo, Pembrolizumab, Gemcitabine",Triple Negative Breast Cancer,,,,,False,2133.0,True,False,2.0,True,True,True,8,False,,1,0.0,0.0,3,0,0.58,False,False,0.021414791020259213,1,False,0.052296558562015184,1,0,0.005609233,1
NCT03911999,Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients,To Investigate the Diagnostic Accuracy of Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients,COMPLETED,,OBSERVATIONAL,180.0,ACTUAL,2018-05-03,2020-12-31,Chinese University of Hong Kong,OTHER,,,,,,Prostate Cancer,,,,,False,973.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,180.0,5.198497031265826,0,1,0.6,True,True,0.8357266038141378,1,True,0.8764625454591619,1,1,0.8496678,1
NCT04111445,Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors,"First-in-human (FIH), Open-Label, Phase I (Dose Escalation) Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors",TERMINATED,PHASE1,INTERVENTIONAL,1.0,ACTUAL,2019-08-29,2021-04-27,Adagene Inc,INDUSTRY,,SEQUENTIAL,NONE,DRUG,ADG116,Solid Tumor,,,,,False,607.0,True,False,1.0,False,False,True,1,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.56,False,False,0.0661899138174625,1,False,0.06520417610780499,1,0,0.04073481,1
NCT01367457,INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus,Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus,COMPLETED,,OBSERVATIONAL,243.0,ACTUAL,2011-01-01,2015-04-01,Pfizer,INDUSTRY,,,,OTHER,Temsirolimus (Non-Interventional Study),"Carcinoma, Renal Cell, Lymphoma, Mantle-Cell",,,,,False,1551.0,True,False,-1.0,False,False,True,1,True,Large (100-300),0,243.0,5.497168225293202,0,1,0.6,True,True,0.8825480528953447,1,True,0.8081596694144095,1,1,0.7909501,1
NCT04076579,Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma,Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma,COMPLETED,PHASE2,INTERVENTIONAL,29.0,ACTUAL,2020-03-17,2024-09-26,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Olaparib, Trabectedin","Sarcoma, Sarcoma Metastatic",,,,,False,1654.0,True,False,2.0,False,False,False,2,True,Small (<30),0,29.0,3.4011973816621555,1,0,0.58,True,True,0.539637714004666,1,True,0.6722373782700352,1,1,0.600311,1
NCT05093023,ABCB1 SNPs as Predictors of PIPN,ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer,COMPLETED,,OBSERVATIONAL,92.0,ACTUAL,2018-03-01,2020-01-31,Ain Shams University,OTHER,,,,GENETIC,Real-Time PCR,"Paclitaxel Adverse Reaction, Neuropathy;Peripheral, Breast Cancer",,,,,False,701.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,92.0,4.532599493153256,0,0,0.6,True,True,0.8488755860925535,1,True,0.5949747849448837,1,1,0.6290244,1
NCT03744468,Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors,"Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,114.0,ACTUAL,2018-11-13,2025-02-06,BeiGene,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","BGB-A425, Tislelizumab, LBL-007","Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2",,,,,False,2277.0,True,False,1.0,False,False,True,3,True,Large (100-300),0,114.0,4.74493212836325,1,1,0.56,True,True,0.7284542124908665,1,True,0.7490457223064507,1,1,0.65981925,1
NCT02186509,Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2015-01-30,2018-12-31,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,,SINGLE_GROUP,NONE,"RADIATION, RADIATION, DRUG, PROCEDURE","Hyperfractionated radiation therapy, Stereotactic radiosurgery, Alisertib, Quality-of-life assessment","Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor",,,,,False,1431.0,True,False,1.0,False,False,False,4,True,Small (<30),0,17.0,2.8903717578961645,1,0,0.56,True,False,0.4184282631634638,0,False,0.40774260594340594,0,0,0.36819276,0
NCT00714376,Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients,Phase II Single Center Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients With an Early Rising PSA Following Radical Prostatectomy,TERMINATED,PHASE2,INTERVENTIONAL,6.0,ACTUAL,2008-05-01,2008-07-01,CHU de Quebec-Universite Laval,OTHER,,SINGLE_GROUP,NONE,DRUG,Docetaxel,Prostate Cancer,,,,,False,61.0,True,False,2.0,False,False,False,1,False,Small (<30),1,6.0,1.9459101490553128,0,0,0.58,False,False,0.17193721167124312,1,False,0.18325476410411345,1,0,0.4409574,1
NCT00077493,BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma,Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas,SUSPENDED,PHASE1,INTERVENTIONAL,95.0,ESTIMATED,2004-01-01,2008-10-01,MedImmune LLC,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, PROCEDURE, PROCEDURE, PROCEDURE","BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy, monoclonal antibody therapy","Leukemia, Lymphoma",,,,,False,1735.0,False,False,1.0,False,False,True,4,False,Medium (30-100),0,95.0,4.564348191467836,1,0,0.56,False,True,0.8206343022546988,0,True,0.6786186965811395,0,1,0.60236174,0
NCT01649635,Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer,"A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.",COMPLETED,PHASE4,INTERVENTIONAL,45.0,ACTUAL,2012-07-01,2016-06-01,Sanofi,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin, G-CSF (Granulocyte colony-stimulating factor)",Prostate Cancer,,,,,False,1431.0,True,False,4.0,False,False,True,4,True,Medium (30-100),1,45.0,3.828641396489095,1,0,0.7,True,True,0.525026871399125,1,True,0.8102965500710362,1,1,0.9078872,1
NCT02630043,Trial of Tolcapone With Oxaliplatin for Neuroblastoma,A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma,TERMINATED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2015-12-01,2019-07-01,Giselle Sholler,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Tolcapone, Oxaliplatin",Neuroblastoma,,,,,False,1308.0,True,False,1.0,False,False,False,2,False,Small (<30),1,5.0,1.791759469228055,1,0,0.56,False,False,0.1769187656997591,1,False,0.21017139277858796,1,0,0.17724867,1
NCT02514278,Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy,Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy,COMPLETED,PHASE3,INTERVENTIONAL,218.0,ACTUAL,2016-01-28,2024-06-30,"University Hospital, Bordeaux",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, RADIATION, PROCEDURE, PROCEDURE, DRUG","Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders, Rectal excision in bad responders, Capecitabine",Rectal Cancer,,,,,False,3076.0,True,False,3.0,True,False,False,5,True,Large (100-300),1,218.0,5.389071729816501,2,1,0.77,True,True,0.7038759302366102,1,True,0.8305476974128005,1,1,0.9233624,1
NCT00978471,Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma,Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma,COMPLETED,PHASE2,INTERVENTIONAL,44.0,ACTUAL,2009-07-01,2018-10-29,Centre Leon Berard,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Thiotepa,Osteosarcoma,,,,,False,3407.0,True,False,2.0,True,False,False,1,True,Medium (30-100),0,44.0,3.80666248977032,1,0,0.58,True,True,0.6935919659521237,1,True,0.8750354384134108,1,1,0.92370087,1
NCT06060158,Feasibility of Internet Group CBT-I for Gyn Oncology Patients,Feasibility of Internet-Delivered Group Cognitive Behavioral Therapy for Insomnia in Gynecologic Oncology Patients,COMPLETED,,INTERVENTIONAL,5.0,ACTUAL,2024-02-26,2024-12-10,"University of California, Davis",OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Cognitive Behavioral Therapy for Insomnia,Insomnia,,,,,False,288.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.6,True,False,0.2126433851473044,0,False,0.27718982964333777,0,0,0.1662328,0
NCT05274464,A Recurrence Nomogram for Hepatoid Adenocarcinoma of the Stomach,A Recurrence Nomogram to Guide Surveillance Strategies After the Resection of Hepatoid Adenocarcinoma of the Stomach: a China Hepatoid Adenocarcinoma of the Stomach Study Group Database Study,COMPLETED,,OBSERVATIONAL,261.0,ACTUAL,2004-04-01,2019-12-31,Fujian Medical University,OTHER,,,,,,Gastric Cancer,,,,,False,5752.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,261.0,5.568344503761097,0,1,0.6,True,True,0.9516183348130046,1,True,0.82493107869567,1,1,0.8641141,1
NCT00387907,Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer,"Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)",COMPLETED,PHASE2,INTERVENTIONAL,6.0,ACTUAL,2006-10-01,2008-03-01,Sanofi,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","larotaxel (XRP9881), trastuzumab","Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer",,,,,False,517.0,True,False,2.0,False,False,True,2,True,Small (<30),1,6.0,1.9459101490553128,1,0,0.58,True,False,0.15639984504052057,0,False,0.09155887609369072,0,0,0.07444626,0
NCT02297958,Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma,Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma,COMPLETED,,OBSERVATIONAL,28.0,ACTUAL,2015-01-15,2019-07-27,Rennes University Hospital,OTHER,,,,,,Ovarian Carcinoma,,,,,False,1654.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,28.0,3.367295829986474,0,0,0.6,True,True,0.6696477848565029,1,True,0.6735142560528969,1,1,0.65681607,1
NCT01147393,Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma,Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma,TERMINATED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2010-10-01,2015-07-31,Weill Medical College of Cornell University,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL","90Y-epratuzumab tetraxetan, veltuzumab",Follicular Lymphoma,,,,,False,1764.0,True,False,1.0,False,False,False,2,False,Small (<30),0,4.0,1.6094379124341005,1,0,0.56,False,False,0.1661528108906772,1,False,0.15431641424914577,1,0,0.09848697,1
NCT04275713,"Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC","Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in Locally Advanced Cervical Cancer.",COMPLETED,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2020-05-22,2024-11-08,Oslo University Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Metformin, Cisplatin",Cervical Cancer,,,,,False,1631.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,41.0,3.737669618283368,2,0,0.58,True,True,0.5342254464927998,1,True,0.6847863237215797,1,1,0.7171703,1
NCT00126555,Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer,A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin,COMPLETED,PHASE2,INTERVENTIONAL,23.0,ACTUAL,2005-03-01,2013-02-01,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, RADIATION, PROCEDURE, OTHER","Gefitinib, Radiotherapy, Conventional surgery, laboratory biomarker analysis","Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin",,,,,False,2894.0,True,False,2.0,False,False,False,4,True,Small (<30),1,23.0,3.1780538303479458,1,0,0.58,True,True,0.5267080904983112,1,True,0.6590011022536569,1,1,0.7590343,1
NCT00243113,Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx,Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness,COMPLETED,PHASE2,INTERVENTIONAL,50.0,ESTIMATED,2004-06-01,2008-11-01,Aichi Cancer Center,OTHER,,,NONE,"DRUG, RADIATION","docetaxel, radiation therapy",Head and Neck Cancer,,,,,False,1614.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.58,True,True,0.666142938750382,1,True,0.8350276952252577,1,1,0.84497714,1
NCT02300727,Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy,A Phase I/II Study to Determine the Safety and Efficacy of Curcumin in Patients With Oral Mucositis Secondary to Chemotherapy,TERMINATED,PHASE1,INTERVENTIONAL,6.0,ACTUAL,2015-02-01,2018-10-25,Amy Beres,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin",Mucositis,,,,,False,1362.0,True,False,1.0,True,False,False,3,False,Small (<30),0,6.0,1.9459101490553128,2,0,0.56,False,False,0.15443524743110015,1,False,0.2806711797264587,1,0,0.33770108,1
NCT01090128,"Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer","Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",TERMINATED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2008-09-01,2017-03-24,University of Utah,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Nanoparticle Albumin Bound Paclitaxel, doxorubicin, cyclophosphamide",Stages II-III Breast Cancer,,,,,False,3126.0,True,False,1.0,False,False,False,3,False,Small (<30),1,27.0,3.332204510175204,1,0,0.56,False,True,0.6209311581916764,0,True,0.8584035069501013,0,1,0.8653304,0
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,"Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide",TERMINATED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2010-06-01,2014-04-01,Centre Hospitalier Universitaire Vaudois,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 ""vaccine injections"" in distinct limbs",Melanoma,,,,,False,1400.0,True,False,1.0,False,False,False,3,False,Small (<30),0,16.0,2.833213344056216,1,0,0.56,False,False,0.4068187589000121,1,False,0.4796409263398808,1,1,0.5395442,0
NCT04035473,A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel,A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel,COMPLETED,PHASE1,INTERVENTIONAL,42.0,ACTUAL,2015-08-01,2019-03-27,"Athenex, Inc.",INDUSTRY,RANDOMIZED,CROSSOVER,NONE,DRUG,HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules,Solid Tumor,,,,,False,1334.0,True,False,1.0,True,False,True,1,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.56,True,True,0.6130314214668856,1,True,0.6686949283075456,1,1,0.6124355,1
NCT01833832,Surgery and Heated Chemotherapy for Adrenocortical Carcinoma,Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,11.0,ACTUAL,2013-04-12,2018-08-09,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, PROCEDURE, DRUG","Cisplatin, Cytoreductive surgery, sodium thiosulfate","Adrenocortical Carcinoma, Peritoneal Carcinomatosis",,,,,False,1945.0,True,False,2.0,False,False,False,3,True,Small (<30),1,11.0,2.4849066497880004,1,0,0.58,True,False,0.30541684385505236,0,False,0.4216735397338709,0,1,0.5858223,1
NCT01481441,Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer,Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer,TERMINATED,,INTERVENTIONAL,208.0,ACTUAL,2011-11-01,2015-11-01,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),OTHER,,SINGLE_GROUP,NONE,DRUG,SonoVue,Prostate Cancer,,,,,False,1461.0,True,False,-1.0,False,False,False,1,False,Large (100-300),0,208.0,5.342334251964811,0,1,0.6,False,True,0.8640037247459171,0,True,0.8065608980892226,0,1,0.80858713,0
NCT00324805,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE3,INTERVENTIONAL,1501.0,ACTUAL,2007-07-19,2025-01-31,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, OTHER, DRUG, OTHER, DRUG","Bevacizumab, Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium, Questionnaire Administration, Vinorelbine Tartrate","Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7",,,,,False,6406.0,True,False,3.0,True,False,False,8,True,Very Large (300+),1,1501.0,7.31455283232408,2,1,0.77,True,True,0.9457729846385635,1,True,0.9206490849896899,1,1,0.97353125,1
NCT03272971,Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors,Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors,TERMINATED,,INTERVENTIONAL,3.0,ACTUAL,2017-12-05,2019-01-30,Broncus Medical Inc,INDUSTRY,,SINGLE_GROUP,NONE,DEVICE,Radio-frequency Ablation,"Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell",,,,,False,421.0,True,False,-1.0,False,False,True,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.6,False,False,0.15136307147812106,1,False,0.15167943404816323,1,0,0.1275075,1
NCT06934070,Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection,The Predictive Value of the Albumin-Bilirubin Score and the C-Reactive Protein-Albumin-Lymphocyte Index for the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,287.0,ACTUAL,2025-04-03,2025-04-16,Qiang Xu,OTHER,,,,,,"Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) Prognosis",,,,,False,13.0,False,False,-1.0,False,False,False,0,True,Large (100-300),0,287.0,5.662960480135946,0,1,0.6,True,True,0.8668144458442323,1,True,0.9164850505529075,1,1,0.9637122,1
NCT00355355,A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC),A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC),COMPLETED,PHASE3,INTERVENTIONAL,208.0,ACTUAL,2006-07-01,2012-09-01,Light Sciences Oncology,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DEVICE, PROCEDURE, PROCEDURE","Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver, Standard Care","Carcinoma, Hepatocellular, Liver Neoplasms",,,,,False,2254.0,True,False,3.0,True,False,True,4,True,Large (100-300),0,208.0,5.342334251964811,2,1,0.77,True,True,0.6677881691733232,1,True,0.7726801085787797,1,1,0.8449956,1
NCT03672695,Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.,"An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax, a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia (AML).",COMPLETED,PHASE1,INTERVENTIONAL,37.0,ACTUAL,2018-11-28,2023-05-30,Institut de Recherches Internationales Servier,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,COMBINATION_PRODUCT,S 64315 (also referred as MIK665) and venetoclax,Acute Myeloid Leukaemia,,,,,False,1644.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.56,True,True,0.6836177147804317,1,True,0.7406774160367939,1,1,0.6617653,1
NCT01866969,Quality of Life in Caregivers of Hospitalized Older Patients With Cancer,"Physical, Emotional and Social Stressors and Their Impact on Quality of Life of Caregivers of Hospitalized Older Adults With Cancer",COMPLETED,,INTERVENTIONAL,211.0,ACTUAL,2013-06-01,2014-05-01,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"OTHER, PROCEDURE","questionnaire administration, quality-of-life assessment","Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,334.0,True,False,-1.0,False,False,False,2,True,Large (100-300),0,211.0,5.356586274672012,1,1,0.6,True,True,0.8053458364382398,1,True,0.9401083187982467,1,1,0.9579216,1
NCT07232290,Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera,"An Open Label, Randomized, Parallel Controlled, Multicenter Phase IIa Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Flonoltinib Maleate Tablets in the Treatment of Hydroxyurea or Interferon Resistant/Intolerant Polycythemia Vera",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,60.0,ESTIMATED,2025-09-23,2028-02-28,"Chengdu Zenitar Biomedical Technology Co., Ltd",INDUSTRY,RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG","Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg, Extended Phase Dose Group",Polycythemia Vera (PV),,,,,False,888.0,False,False,2.0,True,False,True,4,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.58,True,True,0.5907555843134523,1,True,0.6883137291002085,1,1,0.7819447,1
NCT00012220,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,"A Randomized Phase II Study Of Gemcitabine/Cisplatin, Gemcitabine/Docetaxel, Gemcitabine/Irinotecan, Or Fixed Dose Rate Infusion Gemcitabine In Patients With Metastic Pancreatic Cancer",COMPLETED,PHASE2,INTERVENTIONAL,259.0,ACTUAL,2001-01-01,2009-04-01,Alliance for Clinical Trials in Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","cisplatin, docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride",Pancreatic Cancer,,,,,False,3012.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,259.0,5.560681631015528,2,1,0.58,True,True,0.8018783383067966,1,True,0.9162214959073459,1,1,0.9610084,1
NCT04600206,Existential Distress in Patients with Advanced Cancer and Their Caregivers,Existential Distress in Patients with Advanced Cancer and Their Caregivers: a Longitudinal Cohort Study,COMPLETED,,OBSERVATIONAL,800.0,ACTUAL,2020-10-23,2024-12-08,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,,OTHER,Self-report questionnaires,"Neoplasms Malignant, Carcinoma, Palliative Care",,,,,False,1507.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,800.0,6.68586094706836,0,1,0.6,True,True,0.9518814244227771,1,True,0.9654695685581932,1,1,0.97750664,1
NCT01327235,Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites,A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites,COMPLETED,PHASE2,INTERVENTIONAL,336.0,ACTUAL,2011-03-01,2014-07-01,"Jiangsu Simcere Pharmaceutical Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Endostar, Cisplatin","Malignant Pleural Effusion, Malignant Ascites",,,,,False,1218.0,True,False,2.0,True,False,True,2,True,Very Large (300+),1,336.0,5.820082930352362,2,1,0.58,True,True,0.786654754185499,1,True,0.7490743159212978,1,1,0.7021529,1
NCT06728631,Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL,A Study of Candonilimab Combined With All-trans Retinoic Acid for Prevention of Oral Cancer Recurrence in Patients With High-risk Oral Precancerous Lesions.,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,22.0,ACTUAL,2020-06-30,2026-12-31,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, OTHER","Candonilimab and ATRA, other treatment or observation","Oral Cavity Cancer, Premalignant Lesion",,,,,False,2375.0,False,False,2.0,False,False,False,2,True,Small (<30),0,22.0,3.1354942159291497,1,0,0.58,True,True,0.5055571977650979,1,True,0.588825703783683,1,1,0.5772604,1
NCT00303810,"Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma",Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma,COMPLETED,,INTERVENTIONAL,567.0,ACTUAL,2001-01-01,,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION","carboplatin, cisplatin, cyclophosphamide, etoposide phosphate, high-dose chemotherapy, lomustine, methotrexate, thiotepa, vincristine sulfate, radiation therapy",Brain and Central Nervous System Tumors,,,,,False,1303.0,True,False,-1.0,False,False,False,10,True,Very Large (300+),1,567.0,6.342121418721152,1,1,0.6,True,True,0.9089539481261159,1,True,0.8033892833062494,1,1,0.627151,1
NCT01262482,Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment,"A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment",COMPLETED,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2008-10-01,2011-12-01,Grupo Espanol Multidisciplinario del Cancer Digestivo,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Oxaliplatin, Sorafenib",Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment),,,,,False,1156.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,41.0,3.737669618283368,1,0,0.58,True,True,0.5958554766378158,1,True,0.6202164734759791,1,1,0.59811574,1
NCT04165564,DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers,DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,85.0,ACTUAL,2020-08-24,2026-12-01,Boston University,OTHER,,,,"OTHER, OTHER","Institutional standard of care, Biosamples of airway and blood",Pulmonary Disease,,,,,False,2290.0,False,False,-1.0,False,False,False,2,True,Medium (30-100),0,85.0,4.454347296253507,1,0,0.6,True,True,0.8540513679575757,1,True,0.8607918971046142,1,1,0.69079554,1
NCT01486329,"VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer","VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01",COMPLETED,PHASE1,INTERVENTIONAL,72.0,ACTUAL,2011-12-01,2014-12-01,Vaximm GmbH,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"BIOLOGICAL, BIOLOGICAL","VXM01, Placebo",Stage IV Pancreatic Cancer,,,,,False,1096.0,True,False,1.0,True,True,True,2,True,Medium (30-100),0,72.0,4.290459441148391,3,0,0.56,True,True,0.7147198949803875,1,True,0.8112285819536834,1,1,0.8144388,1
NCT05236296,Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study,Pilot Study of a Novel Psychotherapeutic Intervention for Caregivers of Patients With Acute Leukemia: Emotion and Symptom-focused Engagement for Caregivers (EASE-CG),COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2022-04-12,2024-12-31,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,EASE-CG,"Leukemia, Acute",,,,,False,994.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7151833733781543,1,True,0.7841679641282445,1,1,0.7936648,1
NCT04603105,CCP Cancer UK Companion Study,Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) - a Prospective Companion Study for Patients With Cancer and COVID-19,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,9000.0,ACTUAL,2021-02-28,2025-10-31,The Clatterbridge Cancer Centre NHS Foundation Trust,OTHER,,,,,,"Cancer, Covid19",,,,,False,1706.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9108765863057354,1,True,0.9870846698976865,1,1,0.9758469,1
NCT03831243,A Trial to Improve Quality of Life With Stereotactic Body Radiotherapy for Patients With Painful Bone Metastases,"A Phase III Randomized-controlled, Single-blind Trial to Improve Quality of Life With Stereotactic Body Radiotherapy for Patients With Painful Bone Metastases",COMPLETED,,INTERVENTIONAL,126.0,ACTUAL,2019-04-09,2023-10-26,Cancer Research Antwerp,OTHER,RANDOMIZED,PARALLEL,SINGLE,"RADIATION, RADIATION","Stereotactic body radiotherapy, 3D-conformal radiotherapy","Metastasis to Bone, Radiotherapy, Neoplasm Metastasis",,,,,False,1661.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,126.0,4.844187086458591,2,1,0.6,True,True,0.697390756793648,1,True,0.7890056852848198,1,1,0.633852,1
NCT03976531,Geriatric Core Dataset (G-CODE) for Clinical Research in Elderly Cancer Patients,Multidisciplinary Development of the Geriatric Core Dataset for Clinical Research in Older Patients With Cancer: A French Initiative With International Survey,COMPLETED,,OBSERVATIONAL,42.0,ACTUAL,2015-01-01,2017-01-01,Institut Bergonié,OTHER,,,,,,Cancer,,,,,False,731.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.6,True,True,0.7185817965566584,1,True,0.7929737855740484,1,1,0.7579599,1
NCT03324945,Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients,Chemotherapy-Induced Cognitive Impairment in Patients With Ovarian Cancer: A Phase II Study of the Cognitive Effects of Platinum/Taxane-based Chemotherapy in Patients With Ovarian Cancer,COMPLETED,,INTERVENTIONAL,14.0,ACTUAL,2016-08-01,2019-04-01,Rachel Miller,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Neurocognitive assessments,Chemotherapy-induced Cognitive Impairment,,,,,False,973.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,14.0,2.70805020110221,0,0,0.6,True,False,0.45785626403563356,0,True,0.5814297174004217,1,1,0.6774549,1
NCT05024968,Sintilimab in Cancer of Unknown Primary,A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Cancer of Unknown Primary (SiARa-CUP),COMPLETED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2021-08-26,2025-04-03,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Sintilimab,Cancer of Unknown Primary Site,,,,,False,1316.0,True,False,2.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.58,True,False,0.3523931551337875,0,False,0.3161726814784604,0,0,0.25632948,0
NCT02380274,Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC),A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States,COMPLETED,,OBSERVATIONAL,1030.0,ACTUAL,2015-03-27,2021-01-14,"Astellas Pharma Global Development, Inc.",INDUSTRY,,,,,,"Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer",,,,,False,2120.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,1030.0,6.93828448401696,0,1,0.6,True,True,0.963576575908221,1,True,0.9648452713604923,1,1,0.9692727,1
NCT00102414,Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer,A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy,COMPLETED,PHASE3,INTERVENTIONAL,356.0,,1999-09-01,2004-11-01,AGO Study Group,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Gemcitabine,Ovarian Cancer,,,,,False,1888.0,True,False,3.0,True,False,False,1,True,Very Large (300+),1,356.0,5.877735781779639,1,1,0.77,True,True,0.7929690613967822,1,True,0.9146112912432965,1,1,0.9551654,1
NCT02900118,Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS),Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis,COMPLETED,,OBSERVATIONAL,28.0,ACTUAL,2012-08-01,2013-10-01,Centre Oscar Lambret,OTHER,,,,,,Breast Cancer,,,,,False,426.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,28.0,3.367295829986474,0,0,0.6,True,True,0.6108822627435172,1,True,0.7580493385486878,1,1,0.8056862,1
NCT00473590,A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER),"A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma",COMPLETED,PHASE2,INTERVENTIONAL,102.0,ACTUAL,2007-06-01,2009-11-01,"Genentech, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG, DRUG","Bevacizumab, Bortezomib, placebo",Multiple Myeloma,,,,,False,884.0,True,False,2.0,True,False,True,3,True,Large (100-300),1,102.0,4.634728988229636,2,1,0.58,True,True,0.5134048077478305,1,True,0.5849511310082685,1,1,0.71618944,1
NCT00806650,Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer,Development of a Blood Test of Anti-IMP3 Autoantibody and Serum MicroRNA Signature for the Detection of Renal Cell Carcinoma With Metastasis and Metastatic Potential,COMPLETED,,OBSERVATIONAL,155.0,ACTUAL,2008-07-01,2017-11-15,City of Hope Medical Center,OTHER,,,,"GENETIC, GENETIC, DIAGNOSTIC_TEST, OTHER, OTHER","gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method",Kidney Cancer,,,,,False,3424.0,True,False,-1.0,False,False,False,5,True,Large (100-300),0,155.0,5.049856007249537,1,1,0.6,True,True,0.8453319163325966,1,True,0.910484618252729,1,1,0.9205937,1
NCT00316030,Study of Bexarotene in Patients With Acute Myeloid Leukemia,A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia,COMPLETED,PHASE1,INTERVENTIONAL,54.0,,2004-01-01,,Abramson Cancer Center at Penn Medicine,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Bexarotene,"AML, Acute Myeloid Leukemia",,,,,False,1303.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,54.0,4.007333185232471,0,0,0.56,True,True,0.749178865387824,1,True,0.637630377410614,1,1,0.5201791,1
NCT01100437,Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients,"A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA¿",TERMINATED,PHASE4,INTERVENTIONAL,14.0,ACTUAL,2010-04-01,2011-03-01,Pfizer,INDUSTRY,RANDOMIZED,CROSSOVER,TRIPLE,"DRUG, DRUG","EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole",Chronic Pain,,,,,False,334.0,True,False,4.0,True,True,True,2,False,Small (<30),0,14.0,2.70805020110221,3,0,0.7,False,False,0.18376458868235418,1,False,0.2559961752705149,1,0,0.21276125,1
NCT06479187,PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer,PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE4,INTERVENTIONAL,20.0,ESTIMATED,2024-06-30,2027-06-20,Brigham and Women's Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DEVICE","18F-rhPSMA-7.3, PET/CT","Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",,,,,False,1085.0,False,False,4.0,False,False,False,2,True,Small (<30),0,20.0,3.044522437723423,1,0,0.7,True,False,0.32167212147114793,0,False,0.43772462503847964,0,1,0.58496684,1
NCT05721222,Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001),"Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)",TERMINATED,PHASE1,INTERVENTIONAL,42.0,ACTUAL,2023-03-15,2025-11-05,Genmab,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,GEN1160,"Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma",,,,,False,966.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.56,False,True,0.6817261726968878,0,True,0.6640949114951842,0,1,0.54503125,0
NCT00718809,Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer,Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma),TERMINATED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2008-06-01,2013-10-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,DRUG,saracatinib,"Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma, Stage IVB Thymoma",,,,,False,1948.0,True,False,2.0,False,False,False,1,False,Small (<30),0,21.0,3.091042453358316,0,0,0.58,False,True,0.5233587319632976,0,True,0.6640656995539576,0,1,0.698727,0
NCT02248805,Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,"A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma",COMPLETED,PHASE1,INTERVENTIONAL,95.0,ACTUAL,2014-10-01,2018-07-02,MacroGenics,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,MGD007,Colorectal Carcinoma,,,,,False,1370.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,95.0,4.564348191467836,0,0,0.56,True,True,0.8447405189428888,1,True,0.6494757784549023,1,1,0.5912018,1
NCT01777594,Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma,"A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma",COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2013-01-01,2015-03-01,"GenSpera, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,G-202,Advanced Adult Hepatocellular Carcinoma,,,,,False,789.0,True,False,2.0,False,False,True,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.58,True,True,0.5081959379331022,1,True,0.5046194499823983,1,1,0.52422345,1
NCT00610818,Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation,Effect of Palifermin Therapy on Benign and Malignant Skin Tumors in Patients Undergoing High-Dose Chemotherapy With Autologous Stem Cell Transplantation,TERMINATED,,OBSERVATIONAL,7.0,ACTUAL,2007-07-01,2008-01-01,McGill University Health Centre/Research Institute of the McGill University Health Centre,OTHER,,,,OTHER,Palifermin,Skin Rash,,,,,False,184.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,7.0,2.079441541679836,0,0,0.6,False,False,0.26560401283546137,1,False,0.4742997073692925,1,0,0.4855689,1
NCT01937585,Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men,"Evaluation of a Culturally Targeted, Personalized Mail-Home Brochure Directed to Partners of At-Risk Men to Facilitate Prostate Cancer Risk Assessment",COMPLETED,,INTERVENTIONAL,231.0,ACTUAL,2010-08-01,2010-11-01,Fox Chase Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Partner and CDC brochure condition, CDC brochure only condition",Prostate Cancer,,,,,False,92.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,231.0,5.44673737166631,2,1,0.6,True,True,0.7515229432658475,1,True,0.9201708299232217,1,1,0.96979797,1
NCT00146549,Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer,"A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer",COMPLETED,PHASE3,INTERVENTIONAL,250.0,,2001-08-01,2007-12-01,Dana-Farber Cancer Institute,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Trastuzumab, Vinorelbine, Paclitaxel, Docetaxel","Breast Cancer, Stage IV Breast Cancer",,,,,False,2313.0,True,False,3.0,True,False,False,4,True,Large (100-300),1,250.0,5.525452939131784,2,1,0.77,True,True,0.7022847156383125,1,True,0.8359420602858586,1,1,0.8985206,1
NCT01743950,A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,TERMINATED,PHASE2,INTERVENTIONAL,49.0,ACTUAL,2012-12-03,2024-12-24,"University of Wisconsin, Madison",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, RADIATION","Bevacizumab, PRDR",Glioma,,,,,False,4404.0,True,False,2.0,False,False,False,2,False,Medium (30-100),1,49.0,3.912023005428146,1,0,0.58,False,True,0.7773610190454744,0,True,0.9329114850417106,0,1,0.94507354,0
NCT00002773,"Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer","A CLINICAL TRIAL FOR PANCREAS CANCER USING ACTIVE INTRALYMPHATIC IMMUNOTHERAPY WITH INTERFERON-TREATED PANCREAS CANCER TISSUE CULTURE CELLS, GMCSF, AND LOW-DOSE CYCLOPHOSPHAMIDE",COMPLETED,PHASE2,INTERVENTIONAL,,,1996-05-01,2004-04-01,St. Vincent Medical Center - Los Angeles,OTHER,,,,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG","allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide",Pancreatic Cancer,,,,,False,2892.0,True,False,2.0,False,False,False,4,True,,1,,,1,0,0.58,True,True,0.7098464630295709,1,True,0.9690505107017349,1,1,0.97297084,1
NCT00188279,Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma,Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,311.0,ACTUAL,2005-06-21,2016-10-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Minimum Dose Computed Tomography (MnDCT) scan,Non-small Cell Lung Cancer,,,,,False,4120.0,True,False,2.0,False,False,False,1,True,Very Large (300+),0,311.0,5.7430031878094825,0,1,0.58,True,True,0.9187476616217667,1,True,0.8873097403198307,1,1,0.8591186,1
NCT06823687,Virtual Reality Glasses on Applied During Thyroid Fine Needle Aspiration Biopsy,"The Effect of Virtual Reality Glasses on Applied During Thyroid Fine Needle Aspiration Biopsy on Anxiety Level, Pain Intensity and Patient Satisfaction",COMPLETED,,INTERVENTIONAL,80.0,ACTUAL,2024-01-02,2024-04-30,Istanbul Sabahattin Zaim University,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,OTHER,Virtual reality glasses,Thyroid Nodule,,,,,False,119.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,80.0,4.394449154672439,0,0,0.6,True,True,0.8116047047404027,1,True,0.9419535095779724,1,1,0.9829851,1
NCT01578954,Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction,LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy,COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2012-06-28,2016-05-18,UNC Lineberger Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Lenalidomide,Acute Myeloid Leukemia,,,,,False,1420.0,True,False,1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.56,True,True,0.5211573442962028,1,True,0.5459705169852217,1,0,0.44489694,0
NCT03877029,Long-term Effects of Breast Cancer Treatment,Long-term Effects Following Treatment of Women With Screen-detected Versus Symptomatic Breast Cancer,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,4487.0,ACTUAL,2019-11-23,2025-05-01,Norwegian Institute of Public Health,OTHER_GOV,,,,,,Breast Cancer,,,,,False,1986.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,4487.0,8.409162447202533,0,1,0.6,True,True,0.9452190506449691,1,True,0.9898877734209772,1,1,0.9870487,1
NCT07250178,ONSD as an ICP Marker in vNOTES and TLH,Effect of Surgical Approach on Optic Nerve Sheath Diameter as a Surrogate Marker of Intracranial Pressure: A Comparison Between vNOTES and Total Laparoscopic Hysterectomy,COMPLETED,,INTERVENTIONAL,66.0,ACTUAL,2025-11-27,2026-01-05,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","vNOTES, TLH","Endometrial Cancer, Abnormal Uterine Bleeding, Myoma;Uterus",,,,,False,39.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,66.0,4.204692619390966,2,0,0.6,True,True,0.6651040156785251,1,True,0.9202059490394072,1,1,0.9668,1
NCT01170299,"Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer",A Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre Study,COMPLETED,,INTERVENTIONAL,177.0,ESTIMATED,2009-10-01,2014-01-01,Royal Marsden NHS Foundation Trust,OTHER,RANDOMIZED,,NONE,"DIETARY_SUPPLEMENT, OTHER, PROCEDURE, PROCEDURE, RADIATION","dietary intervention, laboratory biomarker analysis, gastrointestinal complications management/prevention, management of therapy complications, selective external radiation therapy","Anal Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastrointestinal Complications, Ovarian Cancer, Radiation Toxicity, Sarcoma",,,,,False,1553.0,True,False,-1.0,True,False,False,5,True,Large (100-300),0,177.0,5.181783550292085,2,1,0.6,True,True,0.7485101740957002,1,True,0.9051950685037196,1,1,0.86872965,1
NCT02314156,Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy,COMPLETED,PHASE2,INTERVENTIONAL,67.0,ACTUAL,2015-10-01,2021-05-01,Northwestern University,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, OTHER, DRUG, OTHER, OTHER, OTHER","Telapristone Acetate, Placebo, Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration","BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer",,,,,False,2039.0,True,False,2.0,True,True,False,6,True,Medium (30-100),0,67.0,4.219507705176107,3,0,0.58,True,True,0.6913554684749129,1,True,0.6988011975460162,1,1,0.67210984,1
NCT06019676,Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients,"Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,170.0,ACTUAL,2023-09-26,2027-04-01,Royal Marsden NHS Foundation Trust,OTHER,,,,,,Metastatic Hormone-Sensitive Prostate Cancer (mHSPC),,,,,False,1283.0,False,False,-1.0,False,False,False,0,True,Large (100-300),0,170.0,5.14166355650266,0,1,0.6,True,True,0.8368399947413289,1,True,0.9363477167752151,1,1,0.9410425,1
NCT01663753,Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy,Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy,COMPLETED,,INTERVENTIONAL,146.0,ACTUAL,2012-03-01,2018-08-01,Hospices Civils de Lyon,OTHER,,SINGLE_GROUP,NONE,DEVICE,18F-FDG-PET,Cancer of the Uterine Cervix,,,,,False,2344.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,146.0,4.990432586778736,0,1,0.6,True,True,0.8433862883771287,1,True,0.8269222893452282,1,1,0.78882635,1
NCT03045406,Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer,Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study,COMPLETED,PHASE3,INTERVENTIONAL,1170.0,ACTUAL,2017-04-13,2019-12-01,"Fadoi Foundation, Italy",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Apixaban, Dalteparin",Venous Thromboembolism,,,,,False,962.0,True,False,3.0,True,False,False,2,True,Very Large (300+),0,1170.0,7.065613363597717,2,1,0.77,True,True,0.857801187447518,1,True,0.8627895235146229,1,1,0.8262939,1
NCT02668588,Extended-release of Octreotide (LF-PB) for the Treatment of Seroma,"A Multicentre, Double Blind, Randomized Placebo Controlled Trial to Assess the Effect of LF-PB on Seroma Formation in Women With Breast Cancer Undergoing Axillary Lymph Node Dissection",COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,2015-10-22,2016-07-19,Chemi S.p.A.,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","extended release of octreotide, extended release of placebo",Seroma,,,,,False,271.0,True,False,2.0,True,True,True,2,True,Medium (30-100),0,48.0,3.8918202981106265,3,0,0.58,True,True,0.5431472803374895,1,False,0.4757928595342004,0,0,0.47854584,0
NCT01748812,Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets),Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia,TERMINATED,PHASE1,INTERVENTIONAL,1.0,ACTUAL,2012-11-16,2016-12-31,National Institute of Dental and Craniofacial Research (NIDCR),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Osteomalacia,Osteomalacia,,,,,False,1506.0,True,False,1.0,False,False,False,1,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.56,False,False,0.07873601392908393,1,False,0.1241240969053631,1,0,0.1260123,1
NCT01806649,BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy,A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2013-07-01,2016-04-30,Prince of Songkla University,OTHER,,SINGLE_GROUP,NONE,DRUG,BKM120,Esophageal Cancer,,,,,False,1034.0,True,False,2.0,False,False,False,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.58,False,False,0.18104095129670694,1,False,0.10187341885236441,1,0,0.10186145,1
NCT00033254,Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases,A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases,COMPLETED,PHASE3,INTERVENTIONAL,332.0,ACTUAL,2002-03-01,,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG, PROCEDURE","radiation therapy, thalidomide, quality-of-life assessment",Tumors Metastatic to Brain,,,,,False,1303.0,True,False,3.0,True,False,False,3,True,Very Large (300+),0,332.0,5.808142489980444,2,1,0.77,True,True,0.7228202647381362,1,True,0.7382368094387036,1,1,0.6933132,1
NCT01488513,ABC294640 in Treating Patients With Advanced Solid Tumors,"A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2011-08-01,2015-07-01,RedHill Biopharma Limited,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,sphingosine kinase-2 inhibitor ABC294640,"Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1430.0,True,False,1.0,False,False,True,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.56,True,True,0.5461570211495,1,True,0.5386634362503974,1,0,0.4081182,0
NCT05159050,Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis,Phase I Trial of Intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM) for Treatment of Peritoneal Carcinomatosis,SUSPENDED,PHASE1,INTERVENTIONAL,30.0,ESTIMATED,2022-04-26,2026-01-14,Carlos Chan,OTHER,,SINGLE_GROUP,NONE,DRUG,Paclitaxel-loaded tumor penetrating microparticles,Peritoneal Carcinomatosis,,,,,False,1359.0,False,False,1.0,False,False,False,1,False,Small (<30),1,30.0,3.4339872044851463,0,0,0.56,False,True,0.61399226994467,0,True,0.6049908882885309,0,1,0.5959219,0
NCT05082675,Stem Cell Translpantation in Multiple Myeloma,A Phase-II Study Comparing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Following Autologous Transplantation to Autologous Transplantation Alone in Multiple Myeloma,COMPLETED,PHASE2,INTERVENTIONAL,357.0,ACTUAL,2001-09-01,2012-01-01,European Society for Blood and Marrow Transplantation,NETWORK,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,HLA Matched allogeneic transplant,Multiple Myeloma,,,,,False,3774.0,True,False,2.0,False,False,False,1,True,Very Large (300+),0,357.0,5.8805329864007,0,1,0.58,True,True,0.9225290768928386,1,True,0.9011062432243122,1,1,0.8326927,1
NCT04422002,Survival Analysis of Frail Patients With Localised Colorectal Cancer,"Survival Analysis of Frail Patients With Localised Colorectal Cancer: Multicentre Observational Study, Comparing Surgical vs Palliative Treatment",COMPLETED,,OBSERVATIONAL,114.0,ACTUAL,2019-12-01,2023-12-31,Corporacion Parc Tauli,OTHER,,,,,,"Colorectal Cancer, Surgery, Frailty",,,,,False,1491.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,114.0,4.74493212836325,0,1,0.6,True,True,0.781864843136431,1,True,0.7999251159282895,1,1,0.7406594,1
NCT00022672,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,"A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE3,INTERVENTIONAL,208.0,ACTUAL,2001-01-01,2009-10-01,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","trastuzumab (Herceptin®), anastrazole (Arimidex®)",Breast Cancer,,,,,False,3195.0,True,False,3.0,True,False,True,2,True,Large (100-300),1,208.0,5.342334251964811,2,1,0.77,True,True,0.7123473450786613,1,True,0.7882881782410942,1,1,0.7969494,1
NCT00195585,Study Evaluating Isovorin in Colon Cancer,Post-Approved Phase III Study of 1-LV/5FU Therapy,COMPLETED,PHASE3,INTERVENTIONAL,650.0,,2002-10-01,2006-02-01,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Isovorin, UFT",Colon Cancer,,,,,False,1219.0,True,False,3.0,True,False,True,2,True,Very Large (300+),0,650.0,6.478509642208569,2,1,0.77,True,True,0.819111944556828,1,True,0.7816080117806508,1,1,0.8854489,1
NCT04756505,"Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial","REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2021-03-07,2022-02-16,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, RADIATION","Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy","Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic HER2 Negative Breast Adenocarcinoma, Prognostic Stage IV Breast Cancer AJCC v8",,,,,False,346.0,True,False,1.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.56,False,False,0.024416778598901942,1,False,0.0025177948768278086,1,0,0.0014793264,1
NCT03155217,Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old,Safety of Targeted Therapies in Elderly Patients (Over 5 and 75 Year-old) With Metastatic Melanoma,COMPLETED,,OBSERVATIONAL,358.0,ACTUAL,2017-05-05,2018-12-31,"University Hospital, Montpellier",OTHER,,,,,,Metastatic Melanoma,,,,,False,605.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,358.0,5.883322388488279,0,1,0.6,True,True,0.8999060102606437,1,True,0.8698325458281141,1,1,0.86140376,1
NCT02878980,An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients,An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2016-09-02,2018-12-01,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,"BEHAVIORAL, OTHER, OTHER, OTHER","Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration",Ovarian Carcinoma,,,,,False,820.0,True,False,-1.0,False,False,False,4,False,,0,0.0,0.0,1,0,0.6,False,False,0.03212322091286294,1,False,0.012360874828256666,1,0,0.002012107,1
NCT00003149,Interleukin-12 in Treating Patients With Multiple Myeloma,Phase II of Interleukin-12 for Plateau Phase Multiple Myeloma,COMPLETED,PHASE2,INTERVENTIONAL,40.0,ESTIMATED,1997-12-01,2006-09-01,Eastern Cooperative Oncology Group,NETWORK,RANDOMIZED,,,BIOLOGICAL,recombinant interleukin-12,Multiple Myeloma and Plasma Cell Neoplasm,,,,,False,3196.0,True,False,2.0,True,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.58,True,True,0.6622870394237762,1,True,0.8753637088124653,1,1,0.9136108,1
NCT00750386,Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas,Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma,COMPLETED,PHASE1,INTERVENTIONAL,50.0,ESTIMATED,2008-01-01,2011-03-01,Hellenic Oncology Research Group,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Paclitaxel, Carboplatin",Ovarian Cancer,,,,,False,1155.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.56,True,True,0.6784498976205701,1,True,0.5900376780784115,1,1,0.5952608,1
NCT07005336,A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer,"A Phase II, Randomized, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,150.0,ESTIMATED,2025-01-09,2029-01-09,"TJ Biopharma Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Uliledlimab, Sintilimab, Pemetrexed, Gemcitabine, Cisplatin Or Carboplatin",Non Small Cell Lung Cancer,,,,,False,1461.0,False,False,2.0,True,False,True,5,True,Large (100-300),1,150.0,5.017279836814924,2,1,0.58,True,True,0.6279499136937854,1,True,0.7918891835694598,1,1,0.83852077,1
NCT04673019,Nurse AMIE for Echo Show: Randomized Control Trial,Nurse AMIE for Echo Show: Randomized Control Trial,COMPLETED,,INTERVENTIONAL,42.0,ACTUAL,2021-02-02,2022-02-28,Milton S. Hershey Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Nurse AMIE (Addressing Metastatic Individuals Every day),Metastatic Breast Cancer,,,,,False,391.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,1,0,0.6,True,True,0.6215639883017955,1,True,0.8334842591946018,1,1,0.7837445,1
NCT03077191,Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience,Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy Without Boost: Results of a Homogeneous Single Institution Experience,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,410.0,ACTUAL,2016-11-01,2026-12-31,IRCCS San Raffaele,OTHER,,,,OTHER,Quality of life measurement,"Breast Cancer, Quality of Life, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Survivorship",,,,,False,3712.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,410.0,6.018593214496234,0,1,0.6,True,True,0.9497935622611231,1,True,0.8449711070036738,1,1,0.813353,1
NCT00033410,"Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",A Phase I Study Of Tirapazamine (NSC 130181) Paclitaxel And Carboplatin With Concurrent Radiation Followed By Tirapazamine/Paclitaxel/Carboplatin Consolidation For Stage III Non-Small Cell Lung Cancer,COMPLETED,PHASE1,INTERVENTIONAL,30.0,ESTIMATED,2002-03-01,,California Cancer Consortium,NETWORK,,,,"DRUG, DRUG, DRUG, RADIATION","carboplatin, paclitaxel, tirapazamine, radiation therapy",Lung Cancer,,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.56,True,True,0.5506323476887861,1,True,0.5950485485442415,1,1,0.57363886,1
NCT01691300,C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT,C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment,COMPLETED,,INTERVENTIONAL,30.0,ACTUAL,2011-05-01,2015-11-01,Chang Gung Memorial Hospital,OTHER,,SINGLE_GROUP,NONE,OTHER,ACT PET/CT,Multiple Myeloma,,,,,False,1645.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6804895368587979,1,True,0.6388527779132182,1,1,0.64965016,1
NCT03804996,Study of TG-1801 in Subjects With B-Cell Lymphoma,A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2019-03-05,2024-02-21,"TG Therapeutics, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, BIOLOGICAL","TG-1801, Ublituximab",B-Cell Lymphoma,,,,,False,1814.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.56,True,True,0.7134241455156187,1,True,0.692499162008235,1,1,0.61002284,1
NCT01687335,Impact on the Nutritional State and the Quality of Life,Conformity With European Recommendations Concerning the Nutritional Care of the Cancerous Patients Benefiting From a Treatment by Chemotherapy Impact on the Nutritional State and the Quality of Life,COMPLETED,,OBSERVATIONAL,102.0,ACTUAL,2012-06-12,2016-03-31,Assistance Publique Hopitaux De Marseille,OTHER,,,,OTHER,answering questionnare in differents time of the treatment,Cancer,,,,,False,1388.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,102.0,4.634728988229636,0,1,0.6,True,True,0.7541709940681242,1,True,0.8413576971122158,1,1,0.79062897,1
NCT00968396,Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts,Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2013-02-01,,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DRUG","Apheresis, Stem Cell Transplantation, Melphalan",Multiple Myeloma,,,,,False,1303.0,True,False,2.0,False,False,False,3,False,,0,0.0,0.0,1,0,0.58,False,False,0.02558109814543867,1,False,0.007764941025989189,1,0,0.0032573708,1
NCT02095210,HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025,"Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025",TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2011-08-01,2014-08-13,Dorte Nielsen,OTHER,,SINGLE_GROUP,NONE,OTHER,Radiolabeled [68Ga]ABY-025,HER2-positive Breast Cancer,,,,,False,1108.0,True,False,1.0,False,False,False,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.56,False,False,0.10916185761301624,1,False,0.1285429131153691,1,0,0.15698841,1
NCT02325557,ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC),A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer,COMPLETED,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2015-06-04,2020-01-22,"Advaxis, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","ADXS31-142, Pembrolizumab","Cancer, Prostate Cancer",,,,,False,1693.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.56,True,True,0.7023733627623366,1,True,0.8153698873202324,1,1,0.7732305,1
NCT01205672,Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer,Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,21.0,ACTUAL,2010-09-16,2017-05-28,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Metformin,Endometrial Cancer,,,,,False,2446.0,True,False,0.5,False,False,False,1,True,Small (<30),0,21.0,3.091042453358316,0,0,0.57,True,True,0.5985834862326549,1,True,0.6813964134253964,1,1,0.71802104,1
NCT05136521,Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions,"A Randomized, Two-way Cross-over Comparative Bioavailability Study of 300 mg Trazodone Hydrochloride Containing New Polymer vs. 300 mg Trazodone Hydrochloride Containing Contramid® Prolonged-release Tablets Under Fasting Conditions",COMPLETED,PHASE1,INTERVENTIONAL,28.0,ACTUAL,2020-02-17,2020-07-19,Aziende Chimiche Riunite Angelini Francesco S.p.A,INDUSTRY,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG","Trazodone HCl - new polymer, Trazodone HCl - Contramid®",Healthy,,,,,False,153.0,True,False,1.0,True,False,True,2,True,Small (<30),0,28.0,3.367295829986474,2,0,0.56,True,False,0.4040554873879827,0,True,0.6903452103094709,1,1,0.84071624,1
NCT03543891,Intestinal Microbiota and Thyroid Cancer,Correlation Study of Thyroid Cancer and Intestinal Microbiota,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2017-09-01,2018-04-30,First Affiliated Hospital of Harbin Medical University,OTHER,,,,OTHER,,Microbiota,,,,,False,241.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.703072891363028,1,True,0.968822554284172,1,1,0.9583843,1
NCT06638957,Impact of the COVID-19 Pandemic on Oncologic Outcomes in Colorectal Cancer,Impact of the Coronavirus Disease 2019 Pandemic on Oncologic Outcomes in Colorectal Cancer,COMPLETED,,OBSERVATIONAL,14951.0,ACTUAL,2018-01-01,2024-09-20,In Ja Park,OTHER,,,,,,"Colorectal Carcinoma, COVID 19",,,,,False,2454.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.922731960924048,1,True,0.9731885424156232,1,1,0.9787465,1
NCT06118125,Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement,Delay to Diagnosis and Management in Digestive Cancerology by the General Practitioner Within the City-hospital Network in the Context of Confinement Related to the Covid-19 Pandemic,COMPLETED,,OBSERVATIONAL,376.0,ACTUAL,2019-06-01,2022-09-01,University of Bordeaux,OTHER,,,,,,"Neoplasms, Colorectal, General Practitioner, Pandemic, COVID-19, Neoplasm, Liver, Neoplasms Pancreatic, Diagnosis, Advanced Cancer",,,,,False,1188.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,376.0,5.932245187448011,0,1,0.6,True,True,0.9137724804994956,1,True,0.9094846158308986,1,1,0.9219759,1
NCT00587236,"Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis",A Blinded Comparison of Conventional Colonoscopy to Endoscopic AFI and NBI for Dysplasia Detection in Patients With Ulcerative Colitis and Sclerosing Cholangitis or Known Colorectal Dysplasia or Cancer- A Pilot Clinical Study,COMPLETED,,OBSERVATIONAL,65.0,ACTUAL,2006-03-01,2010-08-01,Mayo Clinic,OTHER,,,,,,"Colitis, Ulcerative, Cholangitis, Sclerosing",,,,,False,1614.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,65.0,4.189654742026425,0,0,0.6,True,True,0.8287403436783154,1,True,0.7729486613163488,1,1,0.75283,1
NCT06715241,"A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS","A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,77.0,ACTUAL,2024-12-11,2030-12-31,ARCAGY/ GINECO GROUP,OTHER,RANDOMIZED,PARALLEL,NONE,"COMBINATION_PRODUCT, OTHER","combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone",LOCALLY ADVANCED CERVICAL CANCERS,,,,,False,2211.0,False,False,2.0,True,False,False,2,True,Medium (30-100),1,77.0,4.356708826689592,2,0,0.58,True,True,0.7138912084864251,1,True,0.781180185498215,1,1,0.7438229,1
NCT01141244,"Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors","A Phase 1 Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,72.0,ACTUAL,2010-06-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, OTHER","temsirolimus, temozolomide, irinotecan hydrochloride, laboratory biomarker analysis","Unspecified Childhood Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Medium (30-100),1,72.0,4.290459441148391,1,0,0.56,True,True,0.7532666038518783,1,True,0.6470598360391429,1,1,0.60287803,1
NCT01680172,Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer,Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2012-08-01,2015-02-01,Mayo Clinic,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Ketamine, Placebo","Cancer, Depression, Anxiety",,,,,False,914.0,True,False,2.0,True,True,False,2,False,Small (<30),0,5.0,1.791759469228055,3,0,0.58,False,False,0.12277548905233211,1,False,0.0696466114514241,1,0,0.057150356,1
NCT02656121,Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT,Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT,COMPLETED,PHASE2,INTERVENTIONAL,300.0,ACTUAL,2016-02-01,2018-11-01,Ain Shams University,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Vitamin D, Ovulatory Agent",PCOS,,,,,False,1004.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,300.0,5.707110264748875,3,1,0.58,True,True,0.7878385275051336,1,True,0.6960951458172373,1,1,0.8420214,1
NCT06131645,IASLC Grading System as a Predictor for EGFR-TKI Therapy,The IASLC Grading System as a Predictor for EGFR-TKI Therapy in EGFR-mutant Lung Adenocarcinoma,COMPLETED,,OBSERVATIONAL,2160.0,ACTUAL,2021-01-01,2023-07-01,Fudan University,OTHER,,,,DIAGNOSTIC_TEST,IASLC grading system,Lung Cancer,,,,,False,911.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,2160.0,7.678326356506885,0,1,0.6,True,True,0.9591618171041175,1,True,0.9535595546349122,1,1,0.98218197,1
NCT02438839,Curative Chemoradiation of Low Rectal Cancer,Curative Chemoradiation of Low Rectal Cancer. A Prospective Multicenter Observational Study,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,108.0,ACTUAL,2015-09-01,2026-12-01,Vejle Hospital,OTHER,,,,,,Rectal Cancer,,,,,False,4109.0,False,False,-1.0,False,False,False,0,True,Large (100-300),0,108.0,4.691347882229144,0,1,0.6,True,True,0.8539930724068125,1,True,0.8033630045849263,1,1,0.8162761,1
NCT01787552,A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF,"A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis",COMPLETED,PHASE1,INTERVENTIONAL,50.0,ACTUAL,2013-05-08,2018-04-10,Novartis Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","LDE225, INC424","Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera, Myeloproliferative Disorders, Bone Marrow Diseases, Hematologic Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, Hemorrhagic Disorders",,,,,False,1798.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.56,True,True,0.7127428624804,1,True,0.7029768899591476,1,1,0.61002284,1
NCT01066884,A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer,,COMPLETED,PHASE4,INTERVENTIONAL,5.0,ACTUAL,2009-04-01,2009-11-01,Hoffmann-La Roche,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,erlotinib [Tarceva],Non-Squamous Non-Small Cell Lung Cancer,,,,,False,214.0,True,False,4.0,False,False,True,1,True,Small (<30),1,5.0,1.791759469228055,0,0,0.7,True,False,0.1081582184551403,0,False,0.13396292805873944,0,0,0.22586593,0
NCT00293280,Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene,COMPLETED,PHASE2,INTERVENTIONAL,42.0,ESTIMATED,2005-07-01,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,,NONE,DRUG,lomustine,Lung Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.58,True,True,0.6638412472627037,1,True,0.7612805998810301,1,1,0.71542555,1
NCT03429673,A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients,A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer,COMPLETED,,OBSERVATIONAL,10885.0,ACTUAL,2017-12-01,2018-03-30,China-Japan Friendship Hospital,OTHER,,,,PROCEDURE,Surgeries,Non-small Cell Lung Cancer,,,,,False,119.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.877995225519466,1,True,0.9934516682256923,1,1,0.9967338,1
NCT02232152,CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients,COMPLETED,PHASE1,INTERVENTIONAL,19.0,ACTUAL,2015-01-06,2023-01-11,Wake Forest University Health Sciences,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, OTHER","6,8-bis(benzylthio)octanoic acid, fluorouracil, pharmacological study, laboratory biomarker analysis","Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer",,,,,False,2927.0,True,False,1.0,False,False,False,4,True,Small (<30),1,19.0,2.995732273553991,1,0,0.56,True,True,0.5169916446552688,1,True,0.6854133970706762,1,1,0.7528442,1
NCT00207649,Shared Decision Making: Prostate Cancer Screening,Shared Decision Making: Prostate Cancer Screening,COMPLETED,,INTERVENTIONAL,641.0,ACTUAL,2005-11-01,2011-02-01,Lisa Richarson,FED,RANDOMIZED,FACTORIAL,NONE,BEHAVIORAL,Shared decision-making for PSA screening tool,Prostate Cancer,,,,,False,1918.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,641.0,6.464588303689961,1,1,0.6,True,True,0.9289451925805479,1,True,0.945049801432771,1,1,0.962106,1
NCT00490490,Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy,"Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma",TERMINATED,PHASE2,INTERVENTIONAL,8.0,ACTUAL,2007-01-01,2013-07-01,Stanford University,OTHER,,SINGLE_GROUP,NONE,"DRUG, PROCEDURE, DRUG","Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)","Lymphoma, Non-Hodgkin",,,,,False,2373.0,True,False,2.0,False,False,False,3,False,Small (<30),0,8.0,2.19722457733622,1,0,0.58,False,False,0.2655379876223558,1,False,0.385914276749781,1,1,0.5099346,0
NCT00622349,Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer,A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer,COMPLETED,PHASE3,INTERVENTIONAL,707.0,ACTUAL,2004-02-01,2009-12-01,European Lung Cancer Working Party,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Cisplatin, Ifosfamide, Gemcitabine, Ifosfamide, Gemcitabine, Cisplatin, docetaxel","Carcinoma, Non-Small-Cell Lung",,,,,False,2130.0,True,False,3.0,True,False,False,3,True,Very Large (300+),1,707.0,6.56244409369372,2,1,0.77,True,True,0.8468209518989768,1,True,0.9425057697657719,1,1,0.9663049,1
NCT05093426,PERSONAL - Sleep In Breast Cancer,Personalised Electronic Record Supported Two-Stage Observational Study of Sleep in Patients With Breast Cancer,COMPLETED,,OBSERVATIONAL,226.0,ACTUAL,2022-01-15,2022-08-03,Closed Loop Medicine,INDUSTRY,,,,OTHER,Stage 2 Digital sleep diary app,"Insomnia, Breast Cancer",,,,,False,200.0,True,False,-1.0,False,False,True,1,True,Large (100-300),0,226.0,5.424950017481403,0,1,0.6,True,True,0.8411035518814924,1,True,0.912632897709779,1,1,0.9412933,1
NCT05603299,Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test,Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' DawnTM: A CPV® Randomized Controlled Trial,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2023-06-21,2023-12-18,"Qure Healthcare, LLC",INDUSTRY,RANDOMIZED,PARALLEL,NONE,OTHER,Educational Materials on the Dawn test,Non Small Cell Lung Cancer,,,,,False,180.0,True,False,-1.0,True,False,True,1,False,,0,0.0,0.0,1,0,0.6,False,False,0.025594664792028467,1,False,0.008768074736217766,1,0,0.0021515675,1
NCT06732401,Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer,A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR),SUSPENDED,PHASE3,INTERVENTIONAL,630.0,ESTIMATED,2025-08-07,2028-06-30,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG, PROCEDURE, BIOLOGICAL, PROCEDURE","Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test","Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8",,,,,False,1058.0,False,False,3.0,True,False,False,5,False,Very Large (300+),1,630.0,6.447305862541213,2,1,0.77,False,True,0.7964880087945871,0,True,0.6195922709176791,0,1,0.79652125,0
NCT01627808,Fluid Optimization in Liver Surgery,Study on Fluid Optimization in Liver Surgery Trough Vigileo/FloTac System Associated to Traditional Monitoring.,COMPLETED,,OBSERVATIONAL,17.0,ACTUAL,2011-09-01,2012-05-01,Catholic University of the Sacred Heart,OTHER,,,,,,Cancer of Liver,,,,,False,243.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,True,False,0.47437241057534385,0,True,0.631062549700969,1,1,0.63577425,1
NCT06164574,Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers,Distinct Survivals and Optimal Combination of Immunotherapy Plus Immunophenotype in Uncommon and 20ins EGFR-mut Lung Adenocarcinoma: a Retrospective Multi-center Study,COMPLETED,,OBSERVATIONAL,627.0,ACTUAL,2022-11-01,2023-11-29,Haiquan Chen,OTHER,,,,OTHER,Survival analysis,Lung Cancer,,,,,False,393.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,627.0,6.442540166468199,0,1,0.6,True,True,0.9300326159567687,1,True,0.9577934434211405,1,1,0.9755887,1
NCT00168740,"Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma,COMPLETED,PHASE3,INTERVENTIONAL,150.0,,1995-04-01,,Biogen,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,rituximab,Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma,,,,,False,1303.0,True,False,3.0,False,False,True,1,True,Large (100-300),1,150.0,5.017279836814924,0,1,0.77,True,True,0.6790048243999292,1,True,0.8909021967370667,1,1,0.856713,1
NCT02922764,A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer,"A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,146.0,ACTUAL,2016-11-01,2025-01-22,"Inspirna, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed","Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma",,,,,False,3004.0,True,False,1.0,False,False,True,6,True,Large (100-300),1,146.0,4.990432586778736,1,1,0.56,True,True,0.7855559339688161,1,True,0.8053809305926533,1,1,0.8534483,1
NCT03477864,Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer,"R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2018-12-24,2019-11-04,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, RADIATION, PROCEDURE, BIOLOGICAL","Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy, Anti-PD-1 Monoclonal Antibody REGN2810","Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer",,,,,False,315.0,True,False,1.0,True,False,False,4,False,,1,0.0,0.0,2,0,0.56,False,False,0.01641566822432907,1,False,0.005629333628617664,1,0,0.0013785096,1
NCT01360125,"S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy","S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML",COMPLETED,,OBSERVATIONAL,310.0,ACTUAL,2011-06-01,2015-12-01,SWOG Cancer Research Network,NETWORK,,,,"GENETIC, OTHER, OTHER","proteomic profiling, flow cytometry, laboratory biomarker analysis",Leukemia,,,,,False,1644.0,True,False,-1.0,False,False,False,3,True,Very Large (300+),0,310.0,5.739792912179234,1,1,0.6,True,True,0.8843203945047662,1,True,0.9141282368404238,1,1,0.9066252,1
NCT06147492,Urinary Retention Following taTME VS laTME Total Mesorectal Excision for Rectal Cancer,Urinary Retention Following Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer,COMPLETED,,INTERVENTIONAL,526.0,ACTUAL,2016-01-30,2023-10-30,Yanhong Deng,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, PROCEDURE","transanal total mesorectal excision, Laparoscopic Total Mesorectal Excision",Rectal Cancer,,,,,False,2830.0,True,False,-1.0,True,True,False,2,True,Very Large (300+),0,526.0,6.267200548541362,3,1,0.6,True,True,0.9261547756804788,1,True,0.8726481969621257,1,1,0.86243594,1
NCT00939380,Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial,Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial,COMPLETED,,INTERVENTIONAL,212.0,ACTUAL,2010-05-01,2015-05-01,"Rutgers, The State University of New Jersey",OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, OTHER, OTHER, OTHER","Behavioral intervention sessions, CD-ROM, DVD and pamphlet, Respite care",Childhood Cancers,,,,,False,1826.0,True,False,-1.0,True,False,False,4,True,Large (100-300),0,212.0,5.3612921657094255,2,1,0.6,True,True,0.7931674688373409,1,True,0.9138255460270797,1,1,0.9237013,1
NCT00588003,Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer,Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,45.0,ACTUAL,2004-03-01,2009-11-01,Memorial Sloan Kettering Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER","anastrozole, Placebo",Breast Cancer,,,,,False,2071.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,45.0,3.828641396489095,1,0,0.56,True,True,0.6957792504924281,1,True,0.744472915440755,1,1,0.68044776,1
NCT05523908,Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer,Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer: A Pilot Trial,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2022-02-01,2024-08-01,Anhui Provincial Hospital,OTHER_GOV,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION","High-dose hypofraction Arm, Low-dose hypofraction Arm (Standard BED)","Safety Issues, Efficacy, Self",,,,,False,912.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.585515299233302,1,True,0.7254215330028514,1,1,0.70781213,1
NCT04420754,Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer,A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,70.0,ESTIMATED,2020-09-28,2030-08-04,"AffyImmune Therapeutics, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,BIOLOGICAL,AIC100 CAR T Cells,"Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer",,,,,False,3597.0,False,False,1.0,False,False,True,1,True,Medium (30-100),0,70.0,4.262679877041316,0,0,0.56,True,True,0.8631622462330157,1,True,0.7700452925101302,1,1,0.6744147,1
NCT04452292,Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma,A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma,COMPLETED,,INTERVENTIONAL,2.0,ACTUAL,2021-09-14,2023-03-14,Charles Kunos,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma, Treatment for Small Cell Lung Cancer",Large-Cell Neuroendocrine Carcinoma,,,,,False,546.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,2.0,1.0986122886681098,1,0,0.6,True,False,0.09793442348531603,0,False,0.07926584515699293,0,0,0.0790853,0
NCT02543541,A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials,A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials,COMPLETED,,INTERVENTIONAL,132.0,ACTUAL,2015-10-25,2019-01-10,Case Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Structured palliative care, Standard supportive care",Cancer,,,,,False,1173.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,132.0,4.890349128221754,2,1,0.6,True,True,0.6857603957385413,1,True,0.8004232561259166,1,1,0.6497704,1
NCT01462149,Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer,Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,43.0,ACTUAL,2011-10-01,2016-06-01,Asan Medical Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Neoadjuvant chemotherapy, Carboplatin",Advanced Ovarian Cancer,,,,,False,1705.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,43.0,3.784189633918261,1,0,0.58,True,True,0.6346529398074494,1,True,0.8672803966879465,1,1,0.835751,1
NCT01197170,Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance,Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance,COMPLETED,PHASE1,INTERVENTIONAL,277.0,ACTUAL,2010-09-07,2021-01-13,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib","Solid Tumors, Advanced Cancer",,,,,False,3781.0,True,False,1.0,False,False,False,5,True,Large (100-300),1,277.0,5.627621113690637,1,1,0.56,True,True,0.89107346914526,1,True,0.8646703153820491,1,1,0.81121016,1
NCT03682796,Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma,"Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,32.0,ACTUAL,2018-10-15,2021-11-17,Triphase Research and Development III Corp.,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,TRPH-222,"Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular",,,,,False,1129.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,32.0,3.49650756146648,0,0,0.56,True,True,0.6252237772412611,1,False,0.49595288523433373,0,0,0.43105555,0
NCT03731988,Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis,A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis,COMPLETED,PHASE4,INTERVENTIONAL,47.0,ACTUAL,2017-02-01,2018-10-24,Dong-A University,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DEVICE, DRUG, OTHER, DEVICE","lidocaine/prilocaine (5%) application, 2940-nm Er:YAG AFL pretreatment, MAL application, Measurements of the fluorescence intensity, irradiation with red light-emitting diode lamp",Actinic Keratosis,,,,,False,630.0,True,False,4.0,True,True,False,5,True,Medium (30-100),0,47.0,3.871201010907891,3,0,0.7,True,False,0.44095972501019737,0,True,0.5951905241384954,1,1,0.69606173,1
NCT00677144,Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer,A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer,COMPLETED,PHASE2,INTERVENTIONAL,88.0,ACTUAL,2008-04-01,2012-04-01,Hallym University Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","OS (oxalipaltin+S-1), XELOX (oxalipaltin+capecitabine)",Colorectal Neoplasm,,,,,False,1461.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,88.0,4.48863636973214,2,0,0.58,True,True,0.7101789320388907,1,True,0.7041352082634432,1,1,0.75720763,1
NCT06138496,Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC,Phase II Single-arm Clinical Study of the Efficacy and Safety of Cadonilimab in Combination With Lenvatinib Neoadjuvant Therapy for Patients With High-risk Renal Carcinoma Indicating Partial Nephrectomy,COMPLETED,PHASE2,INTERVENTIONAL,39.0,ACTUAL,2023-09-01,2025-12-31,Sun Yat-sen University,OTHER,,SINGLE_GROUP,NONE,DRUG,Cadonilimab Combined With Lenvatinib,"Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy",,,,,False,852.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,39.0,3.688879454113936,0,0,0.58,True,True,0.6179676727984115,1,True,0.6235916645134361,1,1,0.745424,1
NCT01290523,Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma,Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Hepatocellular Carcinoma: A Pilot Study,TERMINATED,,INTERVENTIONAL,14.0,ACTUAL,2010-05-01,2014-05-01,"University of California, San Francisco",OTHER,,SINGLE_GROUP,NONE,DEVICE,Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere),Hepatocellular Carcinoma,,,,,False,1461.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,14.0,2.70805020110221,0,0,0.6,False,False,0.48315293890247013,1,False,0.4825245036551358,1,0,0.3900625,1
NCT02112461,Hospice and End-of-life Symptom Monitoring & Support Using an Automated System Designed for Family Caregivers,Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Symptom Care by Phone for Hospice Caregiver Support and Cancer Symptom Relief,COMPLETED,,INTERVENTIONAL,365.0,ACTUAL,2010-05-01,2017-04-01,University of Utah,OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,SCP-Hospice Alert,"Death, Cancer",,,,,False,2527.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,365.0,5.902633333401366,1,1,0.6,True,True,0.904024636702691,1,True,0.9303443211678194,1,1,0.93834615,1
NCT01815463,Non-Invasive Prediction of Colorectal Neoplasia,Non-Invasive Prediction of Colorectal Neoplasia,TERMINATED,,OBSERVATIONAL,2282.0,ACTUAL,2006-08-01,2014-08-01,Corporal Michael J. Crescenz VA Medical Center,FED,,,,,,"Colonic Polyps, Polyposis Coli, Colorectal Cancer",,,,,False,2922.0,True,False,-1.0,False,False,False,0,False,Very Large (300+),0,2282.0,7.733245646529795,0,1,0.6,False,True,0.9730036555045505,0,True,0.9063400799017194,0,1,0.8708137,0
NCT01044069,Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,93.0,ESTIMATED,2010-01-05,2026-01-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,gene-modified T cells targeted,"Leukemia, Acute Lymphoblastic Leukemia",,,,,False,5840.0,False,False,1.0,False,False,False,1,True,Medium (30-100),0,93.0,4.543294782270004,0,0,0.56,True,True,0.9310124179271293,1,True,0.7371474404299265,1,1,0.897493,1
NCT04310540,PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer,"Development and Validation of Innovative Hybrid Molecular Imaging, 68Ga-PSMA-Dual Contrast PET/MRI and 68Ga-PSMA PET/CT, to Transform the Care of Patients with Hepatocellular Carcinoma",COMPLETED,EARLY_PHASE1,INTERVENTIONAL,42.0,ACTUAL,2020-06-05,2023-11-02,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DRUG, PROCEDURE, PROCEDURE","Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography",Hepatocellular Carcinoma,,,,,False,1245.0,True,False,0.5,False,False,False,5,True,Medium (30-100),0,42.0,3.7612001156935615,1,0,0.57,True,True,0.6458953533952931,1,True,0.7326393460876014,1,1,0.78924865,1
NCT01775176,Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose,Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome: Studies in Skeletal Muscle and Adipose Tissue 'PULSE Ancillary Study',TERMINATED,,OBSERVATIONAL,17.0,ACTUAL,2012-05-01,2016-04-01,Pennington Biomedical Research Center,OTHER,,,,,,Polycystic Ovary Syndrome,,,,,False,1431.0,True,False,-1.0,False,False,False,0,False,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,False,True,0.5360983752639759,0,False,0.45710913600093867,1,0,0.22188267,1
NCT03757858,Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases,A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases,COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2018-03-01,2023-06-01,Capital Medical University,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,"DEVICE, BIOLOGICAL, DRUG, DRUG","Thermotron RF-8, Adoptive cellular Immunotherapy, Anti-PD-1 antibody, Chemotherapy","Cancer, Abdominal Cancer, Pelvic Cancer, Metastatic Cancer, Peritoneal Metastases, Liver Metastases",,,,,False,1918.0,True,False,1.0,False,False,False,4,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.56,True,True,0.6591796975165063,1,True,0.7282735392780703,1,1,0.72716665,1
NCT01613313,A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma,A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma,COMPLETED,PHASE2,INTERVENTIONAL,14.0,ACTUAL,2012-05-01,2013-10-01,Zachary Gerut,INDIV,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Collagenase Clostridium Histolyticum,Lipoma,,,,,False,518.0,True,False,2.0,False,False,False,1,True,Small (<30),0,14.0,2.70805020110221,0,0,0.58,True,False,0.34996958485834123,0,False,0.2429894188043928,0,0,0.13288377,0
NCT01377389,Ipilimumab + Androgen Depravation Therapy in Prostate Cancer,A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma,TERMINATED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2011-06-17,2017-04-07,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Ipilimumab, Leuprolide, Goserelin, Degarelix",Prostate Cancer,,,,,False,2121.0,True,False,2.0,False,False,False,4,False,Small (<30),1,30.0,3.4339872044851463,1,0,0.58,False,True,0.5552916431813648,0,True,0.8117995144964949,0,1,0.86740553,0
NCT06504524,A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US,Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in a Real-World (RW) External Control Arm of Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM) From TherapyMonitor MM Germany,COMPLETED,,OBSERVATIONAL,633.0,ACTUAL,2023-09-01,2024-05-31,Pfizer,INDUSTRY,,,,"DRUG, DRUG","Elranatamab, Standard of Care",Multiple Myeloma,,,,,False,273.0,True,False,-1.0,False,False,True,2,True,Very Large (300+),0,633.0,6.452048954437226,1,1,0.6,True,True,0.9137990669518878,1,True,0.9676335927227213,1,1,0.97382075,1
NCT02105545,Genome Sequencing of Human Cancer Tissues,Genome Sequencing of Human Cancer Tissues,COMPLETED,,INTERVENTIONAL,250.0,ESTIMATED,2015-01-01,2023-04-23,New Mexico Cancer Research Alliance,OTHER,,SINGLE_GROUP,NONE,OTHER,Cancer Treatment Options,Cancer,,,,,False,3034.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,250.0,5.525452939131784,0,1,0.6,True,True,0.9131176678538112,1,True,0.804654231490712,1,1,0.89301026,1
NCT01871155,Effect of Nutri-jelly on Quality of Life in Head and Neck Cancer Patients,Efficacy Study of Nutri-jelly Intake on Quality of Life in Head and Neck Cancer Patients Undergoing Radiotherapy,COMPLETED,,INTERVENTIONAL,64.0,ACTUAL,2012-01-01,2012-08-01,Dental Innovation Foundation Under Royal Patronage,OTHER,NON_RANDOMIZED,PARALLEL,SINGLE,DIETARY_SUPPLEMENT,Nutri-jelly,"Head and Neck Cancer, Dysphagia",,,,,False,213.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,64.0,4.174387269895637,0,0,0.6,True,True,0.7770409245694677,1,True,0.9385606040176537,1,1,0.9719704,1
NCT04610957,Effect of Adding Isoflavonoids to Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome,Effect of Adding Isoflavonoids to Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome,COMPLETED,,INTERVENTIONAL,160.0,ACTUAL,2019-01-01,2019-04-10,FAlbasri,OTHER_GOV,RANDOMIZED,PARALLEL,NONE,DRUG,Rosafem (FEMININE FORMULA),"Ovulation Induction, Polycystic Ovary Syndrome",,,,,False,99.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,160.0,5.081404364984463,1,1,0.6,True,True,0.7226950238217055,1,True,0.9412780836601614,1,1,0.9930528,1
NCT05557110,Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL,"A Multicenter, Single-arm, Open-end Study of Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Philadelphia Chromosome Negative Acute B Lymphoblastic Leukemia",COMPLETED,PHASE2,INTERVENTIONAL,35.0,ACTUAL,2022-09-08,2024-03-31,Chen Suning,OTHER,,SINGLE_GROUP,NONE,DRUG,Blinatumomab,B Acute Lymphoblastic Leukemia,,,,,False,570.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,35.0,3.58351893845611,0,0,0.58,True,True,0.5835899650324595,1,True,0.5296962183305585,1,0,0.35962164,0
NCT03500393,A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation (REM),A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation,TERMINATED,,INTERVENTIONAL,4.0,ACTUAL,2018-06-22,2021-01-23,Dartmouth-Hitchcock Medical Center,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"BEHAVIORAL, BEHAVIORAL","Remotely Supervised Exercise (REM), Unsupervised Exercise (UNSUP)",Lung Cancer,,,,,False,946.0,True,False,-1.0,True,True,False,2,False,Small (<30),0,4.0,1.6094379124341005,3,0,0.6,False,False,0.14146339518405143,1,False,0.10326159371508904,1,0,0.081150405,1
NCT02987777,Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer,Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer,COMPLETED,,OBSERVATIONAL,80.0,ACTUAL,2016-01-01,2016-08-01,Institut de Cancérologie de Lorraine,OTHER,,,,,,Endometrial Cancer,,,,,False,213.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,80.0,4.394449154672439,0,0,0.6,True,True,0.8176570338552427,1,True,0.9370565966018168,1,1,0.97955555,1
NCT05671822,Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer,A Phase Ib/II Study of SHR-A1811 Combinations in Patients With Advanced/Metastatic HER2 Expression Gastric /Gastroesophageal Junction Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,76.0,ACTUAL,2023-03-14,2026-07-30,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capecitabine, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin, SHR-A1811, SHR-1316, and 5-FU, SHR-A1811, SHR-1316, and capecitabine, SHR-1316 and SHR-A1811, SHR-A1811 and capecitabine, SHR-A1811, SHR-1316, and 5-FU, SHR-A1811and 5-FU, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin",HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma,,,,,False,1234.0,False,False,2.0,True,False,True,12,True,Medium (30-100),1,76.0,4.343805421853684,2,0,0.58,True,True,0.6206462231862302,1,True,0.6205879949157437,1,0,0.39482814,0
NCT01374789,PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer,"PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS",TERMINATED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2010-07-01,2012-03-01,WiSP Wissenschaftlicher Service Pharma GmbH,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","GemCis + Panitumumab, GemCis",Urinary Bladder Cancer,,,,,False,609.0,True,False,2.0,True,False,False,2,False,Small (<30),1,2.0,1.0986122886681098,2,0,0.58,False,False,0.05016305334969485,1,False,0.03964947169094476,1,0,0.037844997,1
NCT06561217,Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening,Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening,COMPLETED,,OBSERVATIONAL,355.0,ACTUAL,2023-08-18,2024-07-12,University of Pennsylvania,OTHER,,,,OTHER,Chart review,Cancer,,,,,False,329.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,355.0,5.87493073085203,0,1,0.6,True,True,0.8919465699861577,1,True,0.882263343369396,1,1,0.93581736,1
NCT04750109,Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers,Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid,COMPLETED,,OBSERVATIONAL,117.0,ACTUAL,2021-06-09,2024-06-28,The Christie NHS Foundation Trust,OTHER,,,,,,Cancer of Unknown Primary Site,,,,,False,1115.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,117.0,4.770684624465665,0,1,0.6,True,True,0.7728989754588925,1,True,0.8624807712655013,1,1,0.89908504,1
NCT03769558,A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur,Supplemental Data for the Juvenile Idiopathic Arthritis FDA Written Request,COMPLETED,,OBSERVATIONAL,264.0,ACTUAL,2016-07-12,2016-09-30,Bristol-Myers Squibb,INDUSTRY,,,,OTHER,Non-Interventional,Juvenile Idiopathic Arthritis,,,,,False,80.0,True,False,-1.0,False,False,True,1,True,Large (100-300),0,264.0,5.579729825986222,0,1,0.6,True,True,0.8567786905454945,1,True,0.939306112301088,1,1,0.9830602,1
NCT06916715,MR Elastography in Intracranial Lesions: Feasibility & Accuracy,Feasibility and Diagnostic Accuracy of Magnetic Resonance Elastography in Intracranial Space-Occupying Lesions,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,512.0,ACTUAL,2017-05-09,2025-12-09,Shengjing Hospital,OTHER,,,,,,Brain Neoplasms,,,,,False,3136.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,512.0,6.240275845170769,0,1,0.6,True,True,0.9536495576905742,1,True,0.8817974709268959,1,1,0.86516494,1
NCT00001698,"Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR","Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR",COMPLETED,PHASE2,INTERVENTIONAL,57.0,,1998-06-01,2004-06-01,National Cancer Institute (NCI),NIH,,,,DRUG,Ketorolac Rinse,"Leukoplakia, Periodontal Disease",,,,,False,2192.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,57.0,4.060443010546419,0,0,0.58,True,True,0.7657094918588614,1,True,0.8734886025108786,1,1,0.8097329,1
NCT00473564,Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery,Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery,COMPLETED,,INTERVENTIONAL,170.0,ACTUAL,2007-02-01,2015-12-01,University of Alabama at Birmingham,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,da Vinci® Robotic System,"Head and Neck Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Upper Aerodigestive Tract Neoplasms",,,,,False,3225.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,170.0,5.14166355650266,0,1,0.6,True,True,0.8827309217081762,1,True,0.9043140366023249,1,1,0.91892904,1
NCT00651911,Fasturtec TLS Treatment / Prophylysis,A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome,COMPLETED,PHASE4,INTERVENTIONAL,45.0,ACTUAL,2003-07-01,2004-07-01,Sanofi,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,urate oxidase,Tumor Lysis Syndrome,,,,,False,366.0,True,False,4.0,False,False,True,1,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.7,True,True,0.53893448655627,1,True,0.7046608705027068,1,1,0.7398531,1
NCT04739761,A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer,"An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,506.0,ACTUAL,2021-06-22,2026-02-03,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Trastuzumab Deruxtecan,Breast Cancer,,,,,False,1687.0,False,False,3.0,False,False,True,1,True,Very Large (300+),1,506.0,6.228511003591184,0,1,0.77,True,True,0.8752009737860885,1,True,0.9347854252521381,1,1,0.95218176,1
NCT00033748,Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer,COMPLETED,PHASE2,INTERVENTIONAL,56.0,ACTUAL,2001-12-01,2010-06-01,Alliance for Clinical Trials in Oncology,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","monoclonal antibody 11D10 anti-idiotype, monoclonal antibody 3H1 Alu Gel","Colorectal Cancer, Metastatic Cancer",,,,,False,3104.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,56.0,4.04305126783455,1,0,0.58,True,True,0.75903356827425,1,True,0.9074930244152667,1,1,0.8503623,1
NCT04718740,A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer,"A Phase I, Multi-center Study to Determine the Effect of Fluzoparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, Repaglinide and Bupropion in Patients With Recurrent Ovarian Cancer",COMPLETED,PHASE1,INTERVENTIONAL,33.0,ACTUAL,2021-06-25,2023-07-15,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,,SEQUENTIAL,NONE,DRUG,fluzoparib,Recurrent Ovarian Cancer,,,,,False,750.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,33.0,3.5263605246161616,0,0,0.56,True,True,0.6141978186824091,1,True,0.5565324932370189,1,1,0.563445,1
NCT05052359,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours,COMPLETED,,OBSERVATIONAL,37.0,ACTUAL,2018-01-01,2021-09-01,"National University Health System, Singapore",OTHER,,,,DIAGNOSTIC_TEST,Lectin-histochemistry retrospectively performed,Follicular Thyroid Cancer,,,,,False,1339.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,37.0,3.6375861597263857,0,0,0.6,True,True,0.7132214414791539,1,True,0.6793530680180331,1,1,0.6195626,1
NCT03130790,Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line),"A Two-Part Phase 2/ 3 Multicentre, Double-Blind, Randomized, Placebo Controlled Study of Varlitinib Plus mFOLFOX6 Verses Placebo Plus mFOLFOX6 In Subjects With HER1/ HER2 Co Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy",COMPLETED,PHASE2,INTERVENTIONAL,52.0,ACTUAL,2017-08-31,2019-02-22,ASLAN Pharmaceuticals,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG","Varlitinib, mFOLFOX6, Placebo, mFOLFOX6",Gastric Cancer,,,,,False,540.0,True,False,2.0,True,True,False,4,True,Medium (30-100),0,52.0,3.970291913552122,3,0,0.58,True,True,0.5674651917652944,1,False,0.3798609285666267,0,0,0.309969,0
NCT03695952,A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors,A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,100.0,ESTIMATED,2018-07-01,2026-07-30,Asan Medical Center,OTHER,,,,DRUG,Nivolumab or pembrolizumab,"Hepatocellular Carcinoma, Biliary Tract Cancer",,,,,False,2951.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),1,100.0,4.61512051684126,0,1,0.6,True,True,0.8018204685128668,1,True,0.7895793227430081,1,1,0.87505335,1
NCT00951184,Depression Screening in Patients Undergoing Radiation Therapy For Cancer,Efficiency of Screening for Depression in Cancer Patients Receiving Radiotherapy,COMPLETED,,OBSERVATIONAL,463.0,ACTUAL,2009-05-01,2014-11-01,Radiation Therapy Oncology Group,NETWORK,,,,"BEHAVIORAL, OTHER, OTHER, PROCEDURE, PROCEDURE","telephone-based intervention, screening questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care","Depression, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2010.0,True,False,-1.0,False,False,False,5,True,Very Large (300+),0,463.0,6.139884552226255,1,1,0.6,True,True,0.918193647096429,1,True,0.9337948759858371,1,1,0.9268844,1
NCT04540146,T Helper Cytokines in End Stage Colorectal Cancers,Evaluation of T Helper Cytokines in Intraabdominal Ascites in End Stage Colorectal Cancers,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2020-08-01,2020-12-15,Istanbul Training and Research Hospital,OTHER_GOV,,,,DIAGNOSTIC_TEST,Flow-Cytometric analysis,Colorectal Cancer,,,,,False,136.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.677460856740244,1,True,0.845000348934835,1,1,0.9312375,1
NCT04204473,A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation,"Phase I, Open-label, Single-arm Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of TY-9591 Tablets in Advanced NSCLC Patients With Epidermal Growth Factor Receptor( EGFR) Positive Mutation",COMPLETED,PHASE1,INTERVENTIONAL,105.0,ACTUAL,2020-05-07,2023-05-18,"TYK Medicines, Inc",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,"TY-9591(10mg,40mg) qd. po",NSCLC,,,,,False,1106.0,True,False,1.0,False,False,True,1,True,Large (100-300),0,105.0,4.663439094112067,0,1,0.56,True,True,0.7084481243085495,1,True,0.7717361177954553,1,1,0.8117804,1
NCT01205126,An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain,"A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain",COMPLETED,PHASE3,INTERVENTIONAL,260.0,ACTUAL,2009-12-01,2011-02-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG","Hydromorphone HCl, Oxycodone HCl CR, Placebo",Pain,,,,,False,427.0,True,False,3.0,True,True,True,3,True,Large (100-300),0,260.0,5.564520407322694,3,1,0.77,True,True,0.6631730250921385,1,True,0.7324760416107862,1,1,0.6715756,1
NCT02252887,"Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy","Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy",COMPLETED,PHASE2,INTERVENTIONAL,45.0,ACTUAL,2015-01-12,2025-07-24,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Gemcitabine, Trastuzumab, Pertuzumab",Metastatic HER2-Positive Breast Cancer,,,,,False,3846.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,45.0,3.828641396489095,1,0,0.58,True,True,0.7359022828730266,1,True,0.9341509327459683,1,1,0.9003875,1
NCT01645124,Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV),A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV),TERMINATED,PHASE3,INTERVENTIONAL,365.0,ACTUAL,2008-05-01,2012-07-01,Consorzio Mario Negri Sud,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE","Hydroxyurea, Phlebotomy",Polycythemia Vera,,,,,False,1522.0,True,False,3.0,True,False,False,2,False,Very Large (300+),0,365.0,5.902633333401366,2,1,0.77,False,True,0.7519091408800425,0,True,0.8557107922673921,0,1,0.8499915,0
NCT02495363,Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients,,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2015-03-01,2017-05-01,Rabin Medical Center,OTHER,,,,"PROCEDURE, DRUG","PECS Block, Bupivacaine 0.25-0.5%",Malignant Neoplasm of Breast,,,,,False,792.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.6,True,True,0.7116652427533281,1,True,0.7299667583443946,1,1,0.67466265,1
NCT00943722,A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002),"A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)",COMPLETED,PHASE3,INTERVENTIONAL,3074.0,ACTUAL,2009-08-27,2021-04-22,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,BIOLOGICAL,V503,"Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions, PAP Test Abnormalities, HPV Infections",,,,,False,4256.0,True,False,3.0,True,False,True,1,True,Very Large (300+),0,3074.0,8.031060180240619,1,1,0.77,True,True,0.9334461473434262,1,True,0.924662161351703,1,1,0.9878591,1
NCT02733445,Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib,Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI),COMPLETED,,OBSERVATIONAL,2650.0,ACTUAL,2015-12-01,2016-03-01,Bristol-Myers Squibb,INDUSTRY,,,,"DRUG, DRUG","dasatinib, nilotinib",Chronic Myeloid Leukemia (CML),,,,,False,91.0,True,False,-1.0,False,False,True,2,True,Very Large (300+),1,2650.0,7.8826922062890254,1,1,0.6,True,True,0.9363258253282136,1,True,0.9375009544631611,1,1,0.910052,1
NCT00090870,"PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer","A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma",TERMINATED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2002-04-01,2010-03-01,Medical University of South Carolina,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG","PEG-interferon alfa-2b, GM-CSF, thalidomide",Kidney Cancer,,,,,False,2891.0,True,False,2.0,False,False,False,3,False,Small (<30),0,10.0,2.3978952727983707,1,0,0.58,False,False,0.3337818018673006,1,False,0.41571711332955763,1,0,0.43702057,1
NCT02861040,Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,A Phase I Clinical Trial Evaluating the Combination of Volasertib (BI-6727) With Vincristine Sulfate Liposomal Injections (VSLI) in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-08-01,,Northwestern University,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER, DRUG, DRUG","Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome, Volasertib","Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia",,,,,False,1303.0,True,False,1.0,False,False,False,4,False,,1,0.0,0.0,1,0,0.56,False,False,0.028267177855493878,1,False,0.004397890153066289,1,0,0.0029317928,1
NCT05400291,Gag-layer in the Urothelium of the Human Upper Urinary Tract,Gag-layer in the Urothelium of the Human Upper Urinary Tract,COMPLETED,,OBSERVATIONAL,16.0,ACTUAL,2021-12-01,2022-12-31,Aarhus University Hospital,OTHER,,,,DIAGNOSTIC_TEST,Chondroitin Sulfate Staining,"Bladder Cancer, Renal Cancer",,,,,False,395.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,16.0,2.833213344056216,0,0,0.6,True,False,0.46171094097990106,0,True,0.6955695626535703,1,1,0.79286826,1
NCT00551265,"Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy","A Randomized Pilot Trial of Consolidation With an Adjuvant Ovarian Cancer Vaccine Oregovomab (Ovarex ®) With/Without Single-Dose Cyclophosphamide After a Complete Clinical Response to Second-Line Taxane/Platinum-Based Therapy to Determine Immune Response and Time to Progression in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2007-10-01,,Gynecologic Oncology Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE, BIOLOGICAL","Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab","Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer",,,,,False,1303.0,True,False,-1.0,True,False,False,3,False,,1,0.0,0.0,2,0,0.6,False,False,0.025020626335790514,1,False,0.008933019971379162,1,0,0.0029721316,1
NCT03394118,TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy,"A Phase II Study for Evaluating Anti-tumor Efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma or Pleural Effusion",COMPLETED,PHASE2,INTERVENTIONAL,63.0,ACTUAL,2017-08-11,2021-04-08,Asan Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Osimertinib,NSCLC,,,,,False,1336.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,63.0,4.158883083359672,0,0,0.58,True,True,0.7468852068673117,1,True,0.7916466668941544,1,1,0.78874046,1
NCT05188781,Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer,A Phase II Evaluation of Pembrolizumab in Combination With Anlotinib in the Treatment of Refractory or Recurrent High-Grade Serous Ovarian Cancer,COMPLETED,,OBSERVATIONAL,34.0,ACTUAL,2019-01-04,2021-08-23,The Affiliated Hospital of Qingdao University,OTHER,,,,DRUG,Pembrolizumab combined Anlotinib,High-Grade Serous Ovarian Cancer,,,,,False,962.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),1,34.0,3.555348061489413,0,0,0.6,True,True,0.6717477453334256,1,True,0.6805812375851713,1,1,0.6207158,1
NCT02910063,Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL,A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2017-01-23,2020-03-12,Amgen,INDUSTRY,,SEQUENTIAL,NONE,DRUG,Blinatumomab,B-Cell Non Hodgkin Lymphoma,,,,,False,1144.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,41.0,3.737669618283368,0,0,0.58,True,True,0.6507184598593765,1,True,0.7351125969807686,1,1,0.6917058,1
NCT03866239,"A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma","A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression",TERMINATED,PHASE1,INTERVENTIONAL,47.0,ACTUAL,2019-05-07,2024-03-13,Hoffmann-La Roche,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Obinutuzumab, Atezolizumab, Cibisatamab, Tocilizumab",Colorectal Cancer,,,,,False,1772.0,True,False,1.0,False,False,True,4,False,Medium (30-100),1,47.0,3.871201010907891,1,0,0.56,False,True,0.6833966822148477,0,True,0.7390037639469772,0,1,0.768891,0
NCT06134102,Clinical and Laboratory Characteristics of Polycythemia Vera,Clinical and Laboratory Characteristics of Polycythemia Vera,COMPLETED,,OBSERVATIONAL,1150.0,ACTUAL,2019-01-01,2023-12-31,IRCCS Azienda Ospedaliero-Universitaria di Bologna,OTHER,,,,,,Polycythemia Vera,,,,,False,1825.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1150.0,7.048386408721883,0,1,0.6,True,True,0.963201104699788,1,True,0.9715852610369045,1,1,0.97857016,1
NCT02359851,Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2015-05-01,2019-08-27,Vanderbilt-Ingram Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER","Pembrolizumab, Laboratory Biomarker Analysis","Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma",,,,,False,1579.0,True,False,2.0,False,False,False,2,False,Small (<30),1,5.0,1.791759469228055,1,0,0.58,False,False,0.16350779458474204,1,False,0.17073239484657388,1,0,0.13730203,1
NCT01087294,Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation,Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation,COMPLETED,PHASE1,INTERVENTIONAL,85.0,ACTUAL,2010-08-04,2024-04-02,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SEQUENTIAL,NONE,"PROCEDURE, BIOLOGICAL, PROCEDURE","Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis","Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell",,,,,False,4990.0,True,False,1.0,False,False,False,3,True,Medium (30-100),0,85.0,4.454347296253507,1,0,0.56,True,True,0.8912940955956651,1,True,0.7309997331395617,1,1,0.7426763,1
NCT00283101,A Safety Study in Patients With Chronic Lymphocytic Leukemia,"A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia",COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2005-07-01,2006-10-01,Seagen Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SGN-40 (anti-huCD40 mAb),"Leukemia, Lymphocytic, Chronic",,,,,False,457.0,True,False,1.0,False,False,True,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.56,True,False,0.3461698611808484,0,False,0.4487133237475338,0,0,0.48964083,0
NCT05827055,Proglumide and Chemotherapy for Metastatic Pancreatic Cancer,Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in Pancreatic Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,30.0,ESTIMATED,2024-01-31,2027-01-01,Georgetown University,OTHER,RANDOMIZED,SEQUENTIAL,TRIPLE,"DRUG, DRUG, DRUG, DRUG","Gemcitabine, Nab paclitaxel, Proglumide, Placebo",Metastatic Pancreatic Cancer,,,,,False,1066.0,False,False,2.0,True,True,False,4,True,Small (<30),1,30.0,3.4339872044851463,3,0,0.58,True,False,0.44487355510417254,0,False,0.4967663938718239,0,1,0.50235504,1
NCT04994639,Hypotension Prediction Effect on AKI,Effect of Use of Hypotension Prediction System in Prevention of Postoperative Acute Kidney Injury in Radical Cystectomy,COMPLETED,,INTERVENTIONAL,120.0,ACTUAL,2021-08-24,2023-06-27,Ewha Womans University Mokdong Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,DEVICE,BP management with HPI guidance,Bladder Cancer,,,,,False,672.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,120.0,4.795790545596741,1,1,0.6,True,True,0.6873593554164761,1,True,0.7398714500705813,1,1,0.8552079,1
NCT00378768,Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma,A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant,COMPLETED,PHASE2,INTERVENTIONAL,12.0,ESTIMATED,2005-11-01,2007-06-01,Fred Hutchinson Cancer Center,OTHER,,,NONE,BIOLOGICAL,anti-thymocyte globulin,Multiple Myeloma and Plasma Cell Neoplasm,,,,,False,577.0,True,False,2.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.58,True,False,0.3181392451673756,0,False,0.23981595980796888,0,0,0.17993316,0
NCT00666822,Compliance to a Hormone Therapy Regimen in Breast Cancer,Adherence to Endocrine Therapy in Women With Breast Cancer in Clinical Practice Settings,COMPLETED,,OBSERVATIONAL,178.0,ACTUAL,2007-12-01,2015-12-01,Case Comprehensive Cancer Center,OTHER,,,,"BEHAVIORAL, OTHER, OTHER","compliance monitoring, medical chart review, questionnaire administration",Breast Cancer,,,,,False,2922.0,True,False,-1.0,False,False,False,3,True,Large (100-300),0,178.0,5.187385805840755,1,1,0.6,True,True,0.8547250613990022,1,True,0.8448130467540547,1,1,0.8536373,1
NCT07173140,Renal Tumour Imaging Using MRI,A Two Site Pilot Study of Functional and Microstructural Imaging Using Magnetic Resonance Imaging in Patients With Renal Tumours,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,30.0,ACTUAL,2024-11-20,2025-09-30,"University College, London",OTHER,NON_RANDOMIZED,PARALLEL,NONE,DIAGNOSTIC_TEST,MRI,"Renal Cancer, MRI, Small Renal Mass, Kidney Cancers",,,,,False,314.0,False,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6175154826767346,1,True,0.8851430644429135,1,1,0.85958356,1
NCT00839982,Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS,Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML and High-Risk MDS Patients at Least 60 Years of Age,COMPLETED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2008-11-01,2012-12-01,Fred Hutchinson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","clofarabine, cytarabine","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia",,,,,False,1491.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,35.0,3.58351893845611,1,0,0.56,True,True,0.6092421651945372,1,True,0.7112243608687022,1,1,0.6490438,1
NCT00664144,Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma,"Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease",TERMINATED,PHASE2,INTERVENTIONAL,33.0,ACTUAL,2002-07-01,2005-01-01,Sanofi,INDUSTRY,NON_RANDOMIZED,,NONE,DRUG,Rasburicase (SR29142),Hyperuricemia,,,,,False,915.0,True,False,2.0,False,False,True,1,False,Medium (30-100),0,33.0,3.5263605246161616,0,0,0.58,False,True,0.5861177918275161,0,True,0.6320769661156425,0,1,0.5839322,0
NCT06270394,"FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application","Fibroblast Activation Protein PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application",COMPLETED,,INTERVENTIONAL,22.0,ACTUAL,2022-04-28,2025-05-31,The First Affiliated Hospital of Anhui Medical University,OTHER,,SINGLE_GROUP,NONE,DRUG,68Ga-Fibroblast activation protein inhibitor,"Malignant Tumors, Positron-Emission Tomography",,,,,False,1129.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.6,True,True,0.580937159025,1,True,0.5821163539014949,1,1,0.61948264,1
NCT04624958,Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL,"Zanubrutinib and Rituximab Followed by R-DHAOx (Rituximab, Dexamethasone, Cytarabine and Oxaliplatin) Regimen Then Maintenance with Zanubrutinib for Newly-Diagnosed Mantle Cell Lymphoma (MCL): a Single Arm, Open Label, Multi-center Phase II Study",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2020-12-01,2026-12-01,Sun Yat-sen University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib Maintenance","Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma",,,,,False,2191.0,False,False,2.0,False,False,False,3,True,Medium (30-100),1,42.0,3.7612001156935615,1,0,0.58,True,True,0.64754816520164,1,True,0.9419982178224195,1,1,0.92765725,1
NCT00593060,"Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer","A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer",COMPLETED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2007-11-01,2010-11-01,"Jeffrey W. Clark, MD",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Temsirolimus, Cetuximab","Colorectal Cancer, Colorectal Adenocarcinoma",,,,,False,1096.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,35.0,3.58351893845611,1,0,0.56,True,True,0.5895053228696883,1,True,0.5937896942002249,1,1,0.53009385,1
NCT03575767,Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT,Characteristics and Dynamics of TCR Repertoire in Peripheral Blood of Patients With Hematological Malignancies After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation,COMPLETED,,OBSERVATIONAL,30.0,ACTUAL,2018-05-08,2018-09-30,Affiliated Hospital to Academy of Military Medical Sciences,OTHER,,,,OTHER,Myeloablative Hematopoietic Stem Cell Transplantation,"Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Graft Vs Host Disease, Recurrence",,,,,False,145.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6091745603670774,1,True,0.8898954726300429,1,1,0.860772,1
NCT03701321,"Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma","Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2019-01-25,2020-05-28,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, BIOLOGICAL, DRUG, DRUG","Bortezomib, Daratumumab, Dexamethasone, Venetoclax","Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma",,,,,False,489.0,True,False,1.0,False,False,False,4,False,,1,0.0,0.0,1,0,0.56,False,False,0.023967702981891423,1,False,0.006703642141486856,1,0,0.0024463418,1
NCT01830426,Circulating Tumor Cells in Non-Small Cell Lung Carcinoma,Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma,COMPLETED,,OBSERVATIONAL,232.0,ACTUAL,2012-11-01,2016-01-01,Epic Sciences,INDUSTRY,,,,,,Primary Lung Cancer,,,,,False,1156.0,True,False,-1.0,False,False,True,0,True,Large (100-300),0,232.0,5.4510384535657,0,1,0.6,True,True,0.8711321810547915,1,True,0.7696008989211223,1,1,0.7717552,1
NCT05918224,Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy,"Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy for Head and Neck Tumor: A Randomized, Placebo-Controlled, Double-Blind Trial",COMPLETED,PHASE2,INTERVENTIONAL,160.0,ACTUAL,2022-01-01,2022-11-30,West China Hospital,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Streptococcus salivarius K12, Streptococcus salivarius K12 simulants",Head and Neck Squamous Cell Carcinoma,,,,,False,333.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,160.0,5.081404364984463,3,1,0.58,True,True,0.6385120620829734,1,True,0.8571002507490323,1,1,0.9614462,1
NCT02185170,DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections,Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections.,TERMINATED,,INTERVENTIONAL,5.0,ACTUAL,2014-07-01,2015-09-01,"University Hospital, Grenoble",OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, DEVICE, DEVICE","Trans-urethral resection, Use of the FEMTO-ST institute medical device, Use of the Light-CT scanner",Prostate Cancer,,,,,False,427.0,True,False,-1.0,False,False,False,3,False,Small (<30),0,5.0,1.791759469228055,1,0,0.6,False,False,0.18110763907797786,1,False,0.13073699416343124,1,0,0.116350636,1
NCT03053310,Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer,Determination of the Value of Geriatric Screening to Predict Postoperative Morbidity in an Older Head and Neck Cancer Population (GEROP),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,94.0,ESTIMATED,2017-01-25,2025-02-28,AZ Sint-Jan AV,OTHER,,,,,,Head and Neck,,,,,False,2956.0,False,False,-1.0,False,False,False,0,True,Medium (30-100),0,94.0,4.553876891600541,0,0,0.6,True,True,0.9035894954657298,1,True,0.7851299627514742,1,1,0.74079365,1
NCT00411593,Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC),Phase I-II Study of Avastin®+ Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2006-11-01,2007-05-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Bevacizumab, Bortezomib",Lung Cancer,,,,,False,181.0,True,False,1.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.56,False,False,0.02343409378773702,1,False,0.003386289028991373,1,0,0.0019638427,1
NCT02065726,Whey Protein Supplementation in Cancer Patients,"Whey Protein Supplementation in Malnourished Cancer Patients: a Randomized, Controlled Trial",COMPLETED,,INTERVENTIONAL,166.0,ACTUAL,2014-02-25,2018-06-01,Fondazione IRCCS Policlinico San Matteo di Pavia,OTHER,RANDOMIZED,PARALLEL,NONE,"DIETARY_SUPPLEMENT, OTHER","Whey protein, Nutritional counseling",Solid Tumors,,,,,False,1557.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,166.0,5.117993812416755,2,1,0.6,True,True,0.7483170687004568,1,True,0.9266329061802976,1,1,0.8943238,1
NCT03975491,The Exercise And Colorectal Cancer Treatment Trial,The Exercise And Colorectal Cancer Treatment (EXACT) Trial,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,60.0,ACTUAL,2019-08-01,2026-01-01,Pennington Biomedical Research Center,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"BEHAVIORAL, BEHAVIORAL","Moderate-Intensity Aerobic Exercise, Wait-List Control","Colon Cancer, Rectal Cancer",,,,,False,2345.0,False,False,-1.0,True,True,False,2,True,Medium (30-100),0,60.0,4.110873864173311,3,0,0.6,True,True,0.7672614573328759,1,True,0.8421590953172884,1,1,0.9248402,1
NCT03242824,The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma,MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma,COMPLETED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2017-09-29,2021-06-16,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION, PROCEDURE","Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography",Glioma,,,,,False,1356.0,True,False,2.0,False,False,False,3,True,Small (<30),0,21.0,3.091042453358316,1,0,0.58,True,False,0.4357500877816403,0,False,0.44332154480802183,0,0,0.4013486,0
NCT06503250,A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization,Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China,COMPLETED,,OBSERVATIONAL,113.0,ACTUAL,2024-07-19,2024-11-27,Hoffmann-La Roche,INDUSTRY,,,,"DRUG, DRUG, RADIATION","Atezolizumab, Bevacizumab, Transarterial Chemoembolization",Unresectable Hepatocellular Carcinoma,,,,,False,131.0,True,False,-1.0,False,False,True,3,True,Large (100-300),1,113.0,4.736198448394496,1,1,0.6,True,True,0.6697465598758198,1,True,0.9511790568626863,1,1,0.94783574,1
NCT00775502,Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma,"Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma",TERMINATED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2008-10-01,2011-10-01,"Kyowa Kirin Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,BIW-8962,Multiple Myeloma,,,,,False,1095.0,True,False,1.0,False,False,True,1,False,Small (<30),0,23.0,3.1780538303479458,0,0,0.56,False,True,0.5402700852767238,0,True,0.5913934858336116,0,1,0.6238721,0
NCT04650178,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,274.0,ESTIMATED,2020-05-26,2027-04-30,M.D. Anderson Cancer Center,OTHER,,,,"OTHER, OTHER","Quality-of-Life Assessment, Questionnaire Administration","COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Neuropathy",,,,,False,2530.0,False,False,-1.0,False,False,False,2,True,Large (100-300),0,274.0,5.616771097666572,1,1,0.6,True,True,0.893328436609474,1,True,0.8277733112056133,1,1,0.8753139,1
NCT01645930,Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma,A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma,COMPLETED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2012-12-17,2017-04-11,"Millennium Pharmaceuticals, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Ixazomib, Lenalidomide, Dexamethasone",Multiple Myeloma,,,,,False,1576.0,True,False,1.0,False,False,True,3,True,Medium (30-100),0,43.0,3.784189633918261,1,0,0.56,True,True,0.6647470961235172,1,True,0.6838748626482412,1,1,0.6696762,1
NCT02723838,Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder,A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2017-02-28,2018-02-28,Oncolytics Biotech,INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG","REOLYSIN®, Gemcitabine, Cisplatin",Muscle-invasive Transitional Cell Carcinoma of the Bladder,,,,,False,365.0,True,False,1.0,False,False,True,3,False,,1,0.0,0.0,1,0,0.56,False,False,0.023844325798650985,1,False,0.0012512581622524548,1,0,0.0017577376,1
NCT00148070,Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer,Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,45.0,ACTUAL,1999-03-01,2006-02-01,University of Michigan Rogel Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, PROCEDURE","Docetaxel, Erythromycin Breath Test (ERMBT)",Metastatic Breast Cancer,,,,,False,2529.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,45.0,3.828641396489095,1,0,0.58,True,True,0.683781458755377,1,True,0.9285231458856902,1,1,0.94844776,1
NCT00632437,Intraoperative Optical Imaging of Brain Function,Intraoperative Optical Imaging of Brain Function,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2008-02-01,2010-06-01,M.D. Anderson Cancer Center,OTHER,,,,PROCEDURE,Speckle-Contrast Imaging,Brain Tumor,,,,,False,851.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.04109799217381481,1,False,0.0034373355151794908,1,0,0.0036565303,1
NCT05259839,A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma,A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,283.0,ACTUAL,2022-10-20,2033-09-01,AbbVie,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab",Relapsed/Refractory Multiple Myeloma,,,,,False,3969.0,False,False,1.0,False,False,True,5,True,Large (100-300),1,283.0,5.648974238161206,1,1,0.56,True,True,0.896670048285056,1,True,0.8700640905781247,1,1,0.8339792,1
NCT00003614,Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer,Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,,,1999-02-04,,Eastern Cooperative Oncology Group,NETWORK,,,,"DRUG, DRUG","estramustine phosphate sodium, paclitaxel",Prostate Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,2,True,,1,,,1,0,0.58,True,True,0.6467939450242459,1,True,0.7383243821713025,1,1,0.7132991,1
NCT00956878,Cancer Pain Single Nucleotide Polymorphisms (SNPs),Storage and Analysis of Patient Blood-samples for Cancer Pain Research,COMPLETED,,OBSERVATIONAL,243.0,ACTUAL,2008-09-01,2012-12-01,Erasmus Medical Center,OTHER,,,,,,"Cancer, Pain",,,,,False,1552.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,243.0,5.497168225293202,0,1,0.6,True,True,0.8846796295389769,1,True,0.8136670317806122,1,1,0.854263,1
NCT01951534,Decisional Aid Intervention for Women Considering Breast Reconstruction,Decisional Aid Intervention for Women Considering Breast Reconstruction,COMPLETED,,INTERVENTIONAL,56.0,ACTUAL,2011-01-01,2016-06-07,"Rutgers, The State University of New Jersey",OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Breast Reconstruction Decisional Aid (BRDA), Usual Care",Breast Cancer,,,,,False,1984.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,56.0,4.04305126783455,2,0,0.6,True,True,0.7150078647667834,1,True,0.7184079609369546,1,1,0.6219891,1
NCT00392665,Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck,Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck,TERMINATED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2006-10-01,2013-12-01,Massachusetts General Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Bevacizumab, erlotinib, Sulindac",Squamous Cell Carcinoma of the Head and Neck (SCCHN),,,,,False,2618.0,True,False,2.0,True,False,False,3,False,Medium (30-100),1,36.0,3.610917912644224,2,0,0.58,False,True,0.5464168083343767,0,True,0.8190242798151794,0,1,0.8399463,0
NCT04430036,AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer,A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy,TERMINATED,PHASE2,INTERVENTIONAL,4.0,ACTUAL,2020-10-14,2022-03-14,The University of Texas Health Science Center at San Antonio,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","AGEN1884, AGEN2034, Cisplatin, Gemcitabine",Urinary Bladder Neoplasms,,,,,False,516.0,True,False,2.0,False,False,False,4,False,Small (<30),1,4.0,1.6094379124341005,1,0,0.58,False,False,0.10972322007363731,1,False,0.07035039889273702,1,0,0.06554768,1
NCT02243618,The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer,,COMPLETED,,INTERVENTIONAL,153.0,ACTUAL,2015-01-14,2016-04-14,Yonsei University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Polaprezinc, Rebamipide","Gastric Adenoma, Early Gastric Cancer",,,,,False,456.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,153.0,5.0369526024136295,2,1,0.6,True,True,0.6855473852752032,1,True,0.9367854304670706,1,1,0.95763713,1
NCT01953796,Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome,Study of Stair-step Clomiphene Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome (PCOS) Compared to Traditional Protocol.,COMPLETED,,INTERVENTIONAL,140.0,ACTUAL,2010-05-01,2011-05-01,Kufa University,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,clomiphene,Polycystic Ovary Syndrome,,,,,False,365.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,140.0,4.948759890378168,1,1,0.6,True,True,0.7067582051493864,1,True,0.8856585194689484,1,1,0.9525257,1
NCT01314677,Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation,Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2011-04-01,2012-06-01,City of Hope Medical Center,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, RADIATION","positron emission tomography/computed tomography (PET/CT), fludeoxyglucose F 18",Stage IIIA Non-small Cell Lung Cancer,,,,,False,427.0,True,False,-1.0,True,False,False,2,False,,0,0.0,0.0,2,0,0.6,False,False,0.021961813816336925,1,False,0.003609509735289086,1,0,0.002983419,1
NCT05775094,A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis,A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,10.0,ESTIMATED,2023-03-07,2027-03-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Romosozumab,"Osteoporosis, Multiple Myeloma",,,,,False,1455.0,False,False,1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.3520885696733001,0,False,0.4379902046018518,0,0,0.4199311,0
NCT00546468,Clinical Study on Laparoscopic Gastrectomy for Early Gastric Cancer (COACT_0301),Prospective Randomized Trial of Laparoscopy-assisted Distal Gastrectomy (LADG) Versus Open Distal Gastrectomy (ODG) in Patients With Early Gastric Cancer (EGC),COMPLETED,PHASE3,INTERVENTIONAL,164.0,ACTUAL,2003-06-01,2010-12-01,"National Cancer Center, Korea",OTHER_GOV,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","laparoscopy assisted distal gastrectomy, Open distal gastrectomy",Gastric Cancer,,,,,False,2740.0,True,False,3.0,True,False,False,2,True,Large (100-300),0,164.0,5.10594547390058,2,1,0.77,True,True,0.6473153052917113,1,True,0.6962670446295423,1,1,0.7547145,1
NCT02522585,p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management,Predictive Value of p16 and Ki-67 Immunohistochemical Staining and NK Cells in Expectant Management of Cervical Intraepithelial Neoplasia Grade 2,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2011-12-01,2015-12-01,Parc de Salut Mar,OTHER,,,,OTHER,Conservative management,Cervical Cancer,,,,,False,1461.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7532235380771723,1,True,0.7242310784828132,1,1,0.67082566,1
NCT02281955,De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study,De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma,COMPLETED,PHASE2,INTERVENTIONAL,115.0,ACTUAL,2014-08-01,2024-11-24,UNC Lineberger Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"RADIATION, DRUG, PROCEDURE","Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation","Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms",,,,,False,3768.0,True,False,2.0,False,False,False,3,True,Large (100-300),1,115.0,4.7535901911063645,1,1,0.58,True,True,0.7551620320492984,1,True,0.8673797030009882,1,1,0.90041536,1
NCT04846348,Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis,An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2021-07-26,2021-09-10,Joseph Butterfield,OTHER,,SINGLE_GROUP,NONE,COMBINATION_PRODUCT,"Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.",Cutaneous Mastocytoses,,,,,False,46.0,True,False,2.0,False,False,False,1,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.58,False,False,0.05142227152763397,1,False,0.1103529866293302,1,0,0.28760672,1
NCT01159301,Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia,"A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers",TERMINATED,PHASE1,INTERVENTIONAL,44.0,ACTUAL,2010-06-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, OTHER","entinostat, sorafenib tosylate, pharmacological study, laboratory biomarker analysis","Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Myeloid Leukemia, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,False,False,False,4,False,Medium (30-100),1,44.0,3.80666248977032,1,0,0.56,False,True,0.6463269915590164,0,True,0.5395194364176915,0,1,0.52021253,0
NCT05772546,Avatrombopag vs. Placebo for CIT in GI Malignancies,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,60.0,ESTIMATED,2023-11-01,2026-07-31,"Hanny Al-Samkari, MD",OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG","Avatrombopag, Matching Placebo","Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia",,,,,False,1003.0,False,False,2.0,True,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.58,True,True,0.6063660285451765,1,True,0.6657675404362473,1,1,0.71957874,1
NCT03323762,Effect of RIC on BP and Inflammatory Response in Women With Pre-eclampsia,Effect of Remote Ischemic Conditioning on Blood Pressure and Inflammatory Response in Women With Pre-eclampsia and Gestational Hypertension,COMPLETED,,INTERVENTIONAL,10.0,ACTUAL,2017-10-24,2020-08-28,University of Aarhus,OTHER,,SINGLE_GROUP,NONE,DEVICE,Remote Ischaemic Conditioning (RIC),"Pre-Eclampsia; Mild, Gestational Hypertension",,,,,False,1039.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.37934283823384923,0,True,0.5837226426067185,1,1,0.7721662,1
NCT03034252,Retrospective Evaluation of Liposarcoma,Retrospective Evaluation of Liposarcoma,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2016-01-01,2017-01-01,Technical University of Munich,OTHER,,,,PROCEDURE,Patients with Liposarcoma,"Survival , Tumor",,,,,False,366.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7084749511675842,1,True,0.9484002466078801,1,1,0.9137945,1
NCT03688204,Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer,"Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer: Impact on Risk Estimates, Management Recommendations, Clinical Outcomes, and Patient Perception",COMPLETED,,OBSERVATIONAL,118.0,ACTUAL,2018-09-21,2020-11-11,Ambry Genetics,INDUSTRY,,,,,,Breast Cancer Risk,,,,,False,782.0,True,False,-1.0,False,False,True,0,True,Large (100-300),0,118.0,4.77912349311153,0,1,0.6,True,True,0.7620775922389906,1,True,0.8562233920975452,1,1,0.85937494,1
NCT06863818,Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs,Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs (Superamento Della Resistenza Alla Neutralizzazione di EGFR Nel Trattamento Con Anticorpi Monoclonali e Nuovi Farmaci Oncologici),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,30.0,ESTIMATED,2022-10-10,2025-12-31,IRCCS Azienda Ospedaliero-Universitaria di Bologna,OTHER,,,,,,Non Small Cell Lung Cancer,,,,,False,1178.0,False,False,-1.0,False,False,False,0,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6635936651612148,1,True,0.6530535720743716,1,1,0.5749278,1
NCT01194284,Surveillance Study of Patients With Newly Diagnosed Osteosarcoma,"Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma",TERMINATED,,OBSERVATIONAL,25.0,ACTUAL,2011-12-01,2013-12-01,"Millennium Pharmaceuticals, Inc.",INDUSTRY,,,,DRUG,Mifamurtide,Osteosarcoma,,,,,False,731.0,True,False,-1.0,False,False,True,1,False,Small (<30),0,25.0,3.258096538021482,0,0,0.6,False,True,0.5929607664509733,0,True,0.7748647013438043,0,1,0.7608734,0
NCT00585312,Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP),A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis,TERMINATED,PHASE3,INTERVENTIONAL,106.0,ACTUAL,2006-09-01,2013-10-01,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Celecoxib, Placebo",Adenomatous Polyposis Coli,,,,,False,2587.0,True,False,3.0,True,True,True,2,False,Large (100-300),0,106.0,4.672828834461906,3,1,0.77,False,True,0.5649283425780217,0,True,0.6926611568947711,0,0,0.47708714,1
NCT01928576,Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.,A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.,COMPLETED,PHASE2,INTERVENTIONAL,143.0,ACTUAL,2013-11-06,2023-04-04,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Azacitidine, Entinostat, Nivolumab, CC-486 300","Non-Small Cell Lung Cancer, Epigenetic Therapy",,,,,False,3436.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,143.0,4.969813299576001,2,1,0.58,True,True,0.7124082058828419,1,True,0.8340046152923472,1,1,0.89956355,1
NCT00337272,Treating Chronic Insomnia in Breast Cancer Patients,Phase IV: Treatment of Chronic Insomnia in Patients With Breast Cancer Following Completion of Chemotherapy,TERMINATED,PHASE4,INTERVENTIONAL,16.0,ACTUAL,2006-08-01,2009-01-01,Accelerated Community Oncology Research Network,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG","Placebo, Ramelteon",Chronic Insomnia,,,,,False,884.0,True,False,4.0,True,True,False,2,False,Small (<30),0,16.0,2.833213344056216,3,0,0.7,False,False,0.22430201915651152,1,False,0.325712442364773,1,0,0.45635578,1
NCT01725490,The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study,,COMPLETED,PHASE2,INTERVENTIONAL,34.0,ACTUAL,2013-02-15,2020-08-30,Yonsei University,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","Metformin, Metformin, Placebo",Familial Adenomatous Polyposis,,,,,False,2753.0,True,False,2.0,True,True,False,3,True,Medium (30-100),0,34.0,3.555348061489413,3,0,0.58,True,True,0.5766323933747403,1,True,0.5924822471834428,1,1,0.5885539,1
NCT00538681,"Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo","Randomized, Double-Blind, Placebo Controlled, Phase 2 Study of Pemetrexed and Cisplatin Plus Enzastaurin Versus Pemetrexed and Cisplatin Plus Placebo in Chemonaive Patients With Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer",TERMINATED,PHASE2,INTERVENTIONAL,35.0,ACTUAL,2007-09-01,2008-11-01,Eli Lilly and Company,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG, DRUG","enzastaurin, pemetrexed, cisplatin, placebo",Lung Cancer,,,,,False,427.0,True,False,2.0,True,True,True,4,False,Medium (30-100),1,35.0,3.58351893845611,3,0,0.58,False,False,0.4517364225826159,1,False,0.41349142527387145,1,0,0.2707589,1
NCT02270931,A Prospective Longitudinal Breast Cancer Study,A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients With Breast Cancer,COMPLETED,,OBSERVATIONAL,130.0,ESTIMATED,2014-05-01,2021-06-30,"Fujirebio Diagnostics, Inc.",INDUSTRY,,,,DEVICE,CA 15-3 Assay,Breast Cancer,,,,,False,2617.0,True,False,-1.0,False,False,True,1,True,Large (100-300),0,130.0,4.875197323201151,0,1,0.6,True,True,0.8352976993700563,1,True,0.8052607436985071,1,1,0.67711884,1
NCT00003055,Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer,Phase II Trial of Cisplatin and Irinotecan in Patients With Advanced Esophageal Cancer,COMPLETED,PHASE2,INTERVENTIONAL,,,1997-06-01,2001-04-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,"DRUG, DRUG","cisplatin, irinotecan hydrochloride","Esophageal Cancer, Gastric Cancer",,,,,False,1400.0,True,False,2.0,False,False,False,2,True,,1,,,1,0,0.58,True,True,0.6513920392204678,1,True,0.7711236082758778,1,1,0.77457666,1
NCT04758949,FL-101 in Surgically Resectable Non-Small Cell Lung Cancer,"A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2021-08-25,2021-12-22,Flame Biosciences,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","FL-101, Nivolumab, Placebo",Non-Small Cell Lung Cancer,,,,,False,119.0,True,False,2.0,True,True,True,3,False,,1,0.0,0.0,3,0,0.58,False,False,0.01569520027417721,1,False,0.009375855503786626,1,0,0.0022722248,1
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma,TERMINATED,PHASE2,INTERVENTIONAL,234.0,ESTIMATED,2016-02-01,2020-03-01,Royal Marsden NHS Foundation Trust,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, RADIATION","Pembrolizumab, Radiotherapy",Melanoma,,,,,False,1490.0,True,False,2.0,True,False,False,2,False,Large (100-300),1,234.0,5.459585514144159,2,1,0.58,False,True,0.7361883647786006,0,True,0.8668971472851537,0,1,0.879843,0
NCT00090220,"A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)","Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study",COMPLETED,PHASE3,INTERVENTIONAL,3819.0,ACTUAL,2004-06-16,2015-11-12,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"BIOLOGICAL, BIOLOGICAL","Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo","Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18",,,,,False,4166.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,3819.0,8.24800570160062,3,1,0.77,True,True,0.9124897983284245,1,True,0.7392082600422785,1,1,0.88759273,1
NCT04081753,Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy,Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2019-12-16,2024-07-31,Augusta University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DEVICE,Remote monitoring of temperature,Acute Myeloid Leukemia (AML),,,,,False,1689.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.6,True,False,0.4562608258267654,0,True,0.5684369229790461,1,1,0.6083016,1
NCT04671485,Effectiveness of autoHYpnosis in the Prevention of Anxiety During Radiotherapy of Head and Neck Tumors (HYMACO),"Randomized, Comparative Pilot Study Evaluating the Effectiveness of autoHYpnosis by Anchoring in the Prevention of Anxiety Related to Wearing the Mask for Radiotherapy of Head and Neck Tumors",COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2020-12-16,2025-02-05,Institut de Cancérologie de Lorraine,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER, OTHER","Standard care, Autohypnosis, Musicotherapy",Head and Neck Tumors,,,,,False,1512.0,True,False,-1.0,True,False,False,3,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.6,True,True,0.705365060122385,1,True,0.7189383576998145,1,1,0.7931691,1
NCT00864227,Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604),"A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)",COMPLETED,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2008-12-01,2013-11-01,Medical College of Wisconsin,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","Hematopoietic Umbilical Cord Blood Stem Cell Transplantation, GVHD prophylaxis","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse",,,,,False,1796.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,54.0,4.007333185232471,1,0,0.58,True,True,0.6978841031150795,1,True,0.6900661495084118,1,1,0.6798338,1
NCT03638310,Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery,"Assessment of Visual Sensitivity, Psychiatric Profile and Quality of Life Following Vestibular Schwannoma Surgery in Patients Prehabituated by Chemical Vestibular Ablation",COMPLETED,,INTERVENTIONAL,37.0,ACTUAL,2016-01-01,2018-06-01,"Charles University, Czech Republic",OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","intratympanic application of gentamicin, microsurgical removal of vestibular schwannoma","Vestibular Schwannoma, Vestibular Function Disorder",,,,,False,882.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,37.0,3.6375861597263857,2,0,0.6,True,True,0.5640953549499882,1,True,0.6325569628336115,1,1,0.57588494,1
NCT06549153,ACT-Together (Acting on Cancer Testing-Together),ACT-Together (Acting on Cancer Testing-Together),ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,30.0,ACTUAL,2024-12-18,2027-12-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"OTHER, OTHER","Education Content, Focus Group",Cancer,,,,,False,1078.0,False,False,-1.0,False,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.6,True,True,0.6058291236600769,1,True,0.6946597445324193,1,1,0.6314006,1
NCT04498130,"Feasibility of a Novel, Theory Based Physical Activity Intervention Among Adult Cancer Survivors",Designing and Testing the Feasibility of a Theory-Based Intervention to Promote Physical Activity Among Cancer Survivors,COMPLETED,,INTERVENTIONAL,29.0,ACTUAL,2021-10-02,2022-12-31,University of Illinois at Urbana-Champaign,OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","12-Week Home Exercise Group, Education Comparison Group","Cancer Survivors, Exercise, Sedentary Behavior",,,,,False,455.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,29.0,3.4011973816621555,2,0,0.6,True,False,0.47873444696896494,0,True,0.7323775859352889,1,1,0.7952403,1
NCT01056523,Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia,"A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression",COMPLETED,PHASE1,INTERVENTIONAL,29.0,ACTUAL,2010-01-01,2015-01-01,Jewish General Hospital,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Ribavirin, Cytarabine arabinoside",Acute Myeloid Leukemia,,,,,False,1826.0,True,False,1.0,False,False,False,2,True,Small (<30),1,29.0,3.4011973816621555,1,0,0.56,True,True,0.5787899950386477,1,True,0.6315289834886745,1,1,0.6447718,1
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2013-12-01,2015-02-01,Bristol-Myers Squibb,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,Ipilimumab,Melanoma,,,,,False,427.0,True,False,2.0,False,False,True,1,True,Small (<30),1,20.0,3.044522437723423,0,0,0.58,True,False,0.425156622742486,0,False,0.44891079200083,0,0,0.42562297,0
NCT03598309,Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers,"Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2019-06-05,2026-05-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG, OTHER","Curcumin C3 complex®, Lovaza®, Placebo","Lung Diseases, Lung Cancer, Protection Against",,,,,False,2522.0,False,False,2.0,True,False,False,3,True,Small (<30),0,19.0,2.995732273553991,2,0,0.58,True,False,0.384883872366143,0,False,0.48482759350843735,0,0,0.49445483,0
NCT01266044,Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia,Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,435.0,ESTIMATED,2011-12-09,2026-12-31,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,SINGLE_GROUP,SINGLE,"PROCEDURE, PROCEDURE, OTHER, OTHER","Acupuncture - Group 1, Acupuncture - Group 2, Standard Care, Questionnaire",Head And Neck Cancer,,,,,False,5501.0,False,False,3.0,True,False,False,4,True,Very Large (300+),0,435.0,6.077642243349034,2,1,0.77,True,True,0.8856166087339341,1,True,0.9448030722205871,1,1,0.9850618,1
NCT01339780,Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques,,COMPLETED,,INTERVENTIONAL,53.0,ACTUAL,2011-02-01,2014-01-01,Turku University Hospital,OTHER_GOV,NON_RANDOMIZED,SINGLE_GROUP,NONE,RADIATION,"BS, SPECT/CT, PET/CT, MRI",Bone Metastases,,,,,False,1065.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,53.0,3.9889840465642745,0,0,0.6,True,True,0.7736988618145131,1,True,0.7577479132590369,1,1,0.76137865,1
NCT00726596,Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer,NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.,COMPLETED,PHASE2,INTERVENTIONAL,64.0,ACTUAL,2008-08-01,2018-01-01,"Rutgers, The State University of New Jersey",OTHER,,SINGLE_GROUP,NONE,DRUG,hydroxychloroquine,Prostate Cancer,,,,,False,3440.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,64.0,4.174387269895637,0,0,0.58,True,True,0.8270127312281226,1,True,0.8669781241140675,1,1,0.8719741,1
NCT02274012,Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment,"Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2014-05-29,2015-08-12,Columbia University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Afatinib, Paclitaxel","HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer, Esophageal Cancer",,,,,False,440.0,True,False,2.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.58,False,False,0.02130371231390543,1,False,0.004555895847302411,1,0,0.0016844526,1
NCT01601808,Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma,"A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma",COMPLETED,PHASE2,INTERVENTIONAL,142.0,ACTUAL,2011-10-10,2018-09-05,University of Liverpool,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Placebo, Caprelsa (vandetanib)",Pancreatic Cancer,,,,,False,2522.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,142.0,4.962844630259907,3,1,0.58,True,True,0.7120165232902226,1,True,0.7825422715217348,1,1,0.85354275,1
NCT00237627,Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer,A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,107.0,ACTUAL,2001-05-01,2010-01-01,UNC Lineberger Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","PS-341, Doxil, Velcade","Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,3167.0,True,False,1.0,True,False,False,3,True,Large (100-300),0,107.0,4.68213122712422,2,1,0.56,True,True,0.6807879139839065,1,True,0.7539046864652564,1,1,0.7345319,1
NCT00251797,A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors,A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors.,COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2000-03-01,2006-06-01,University of New Mexico,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Irinotecan, Thalidomide","Brain and Nervous System, Cancer",,,,,False,2283.0,True,False,1.0,False,False,False,2,True,Small (<30),1,10.0,2.3978952727983707,1,0,0.56,True,False,0.3375974449074633,0,False,0.4554502926314907,0,1,0.5031073,1
NCT02015897,Effect of Physical Therapy on Breast Cancer Related Lymphedema,"Effect of Physical Therapy on Breast Cancer Related Lymphedema; A Multicenter, Randomized, Single-blind, Equivalence Trial",COMPLETED,,INTERVENTIONAL,80.0,ACTUAL,2014-01-01,2017-09-01,Esbjerg Hospital - University Hospital of Southern Denmark,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Physical TherapyA, Physical TherapyB","Lymphoedema, Breast Cancer",,,,,False,1339.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,80.0,4.394449154672439,2,0,0.6,True,True,0.7606424327802735,1,True,0.766513196234714,1,1,0.8051268,1
NCT05269355,A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS),"A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma",TERMINATED,PHASE2,INTERVENTIONAL,359.0,ACTUAL,2022-05-23,2024-07-17,PTC Therapeutics,INDUSTRY,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, OTHER","Unesbulin, Dacarbazine, Placebo",Leiomyosarcoma,,,,,False,786.0,True,False,2.0,True,True,True,3,False,Very Large (300+),1,359.0,5.886104031450156,3,1,0.58,False,True,0.7988923500558924,0,True,0.6808442033555099,0,1,0.72941047,0
NCT07057531,Tubeless VATS for Lung Cancer Surgery,"A Prospective Randomized Controlled Study Evaluating Lung Injury, Long-term Clinical Outcomes, and Environmental Impact of Tubeless Versus Intubated Video-Assisted Thoracic Surgery for Lung Cancer Resection",COMPLETED,,INTERVENTIONAL,73.0,ACTUAL,2025-07-25,2025-12-12,The First Affiliated Hospital of Guangzhou Medical University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,PROCEDURE,Tubeless thoracic surgery,"Lung, Lung Cancer (NSCLC), VATS",,,,,False,140.0,True,False,-1.0,True,True,False,1,True,Medium (30-100),0,73.0,4.30406509320417,2,0,0.6,True,True,0.758794462782137,1,True,0.937419529912879,1,1,0.98110926,1
NCT01096732,Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS),Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period,TERMINATED,PHASE2,INTERVENTIONAL,3.0,ACTUAL,2011-02-01,2012-08-01,Lisa Bax,OTHER,,SINGLE_GROUP,NONE,DRUG,GDC-0449,Pancreatic Ductal Adenocarcinoma,,,,,False,547.0,True,False,2.0,False,False,False,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.58,False,False,0.11372642193476298,1,False,0.09119629614481306,1,0,0.064261824,1
NCT02125929,"Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms","Comparative Study of the Efficacy and Safety Outcomes of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neuroendocrine Tumors",COMPLETED,,INTERVENTIONAL,156.0,ACTUAL,2014-04-01,2014-12-01,Peking Union Medical College Hospital,OTHER,NON_RANDOMIZED,FACTORIAL,NONE,"PROCEDURE, PROCEDURE, PROCEDURE","Robotic surgery, Laparoscopic surgery, Open surgery",Pancreatic Neuroendocrine Tumors,,,,,False,244.0,True,False,-1.0,False,False,False,3,True,Large (100-300),0,156.0,5.056245805348308,1,1,0.6,True,True,0.7472652686993503,1,True,0.9668302665417096,1,1,0.9833219,1
NCT01394991,A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia,"A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia",COMPLETED,PHASE4,INTERVENTIONAL,504.0,ACTUAL,2006-01-01,2009-09-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","Epoetin alfa 450 IU/kg once a week, Epoetin alfa 150 IU/kg 3 times a week, Epoetin alfa 450 IU/kg once a week (QW), Epoetin alfa 150 IU/kg 3 times a week (TIW)","Anemia, Neoplasms",,,,,False,1339.0,True,False,4.0,True,False,True,4,True,Very Large (300+),0,504.0,6.22455842927536,2,1,0.7,True,True,0.7791692615616445,1,True,0.8740019571817536,1,1,0.9368966,1
NCT05941897,A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy,"A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,39.0,ACTUAL,2023-06-21,2027-01-01,AstraZeneca,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Ceralasertib, Durvalumab",Advanced or Metastatic NSCLC,,,,,False,1290.0,False,False,2.0,False,False,True,2,True,Medium (30-100),1,39.0,3.688879454113936,1,0,0.58,True,True,0.5899797338202591,1,True,0.6031940860010122,1,1,0.55185497,1
NCT04560439,Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors,METFIT Program - A Pilot Study Exploring the Feasibility of a Diabetes Prevention Program (DPP)-Based Lifestyle Modification Intervention to Reduce Insulin Resistance in Breast Cancer Survivors,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2022-06-15,2023-06-15,City of Hope Medical Center,OTHER,,SINGLE_GROUP,NONE,DIETARY_SUPPLEMENT,Dietary Intervention,"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8",,,,,False,365.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.037291850690733236,1,False,0.0033638806660429127,1,0,0.002720244,1
NCT00670592,Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies,"A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)",COMPLETED,PHASE1,INTERVENTIONAL,111.0,ACTUAL,2008-03-01,2013-02-01,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,HCD122,"Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma",,,,,False,1798.0,True,False,1.0,False,False,True,1,True,Large (100-300),0,111.0,4.718498871295094,0,1,0.56,True,True,0.7481266203050836,1,True,0.7094573481364218,1,1,0.6996552,1
NCT02519972,Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer,Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer,COMPLETED,,INTERVENTIONAL,1102.0,ACTUAL,2007-08-01,2011-03-01,Taichung Veterans General Hospital,OTHER,,SINGLE_GROUP,NONE,DEVICE,low dose computed tomography,Lung Cancer,,,,,False,1308.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1102.0,7.005789019253503,0,1,0.6,True,True,0.957627412624537,1,True,0.9800758126605527,1,1,0.98244214,1
NCT05886751,Randomized Trial of Trust in Online Videos About Prostate Cancer,Randomized Trial of Trust in Online Videos About Prostate Cancer,COMPLETED,,INTERVENTIONAL,3649.0,ACTUAL,2021-08-18,2022-01-07,NYU Langone Health,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER, OTHER, OTHER, OTHER, OTHER, OTHER, OTHER","Black Doctor Screening Video, White Doctor Screening Video, Black Patient Screening Video, White Patient Screening Video, Black Doctor Clinical Trials Video, White Doctor Clinical Trials Video, Black Patient Clinical Trials Video, White Patient Clinical Trials Video",Prostate Cancer,,,,,False,142.0,True,False,-1.0,True,False,False,8,True,Very Large (300+),0,3649.0,8.202482446576537,2,1,0.6,True,True,0.8832264311908156,1,True,0.9078792150501005,1,1,0.9795578,1
NCT04929808,Novel Skin Care Product for the Management of Acute Radiodermatitis,Evaluation of a Novel Skin Care Product for the Management of Acute Radiodermatitis in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2022-02-01,2023-06-13,Jessa Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Hydrating emollient for acute radiodermatitis, Standard institutional skin care","Radiodermatitis; Acute, Radiation Dermatitis",,,,,False,497.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,100.0,4.61512051684126,2,1,0.6,True,True,0.5883336335237952,1,True,0.9039339117481129,1,1,0.9279462,1
NCT04208347,Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer,"Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,580.0,ESTIMATED,2019-12-18,2027-12-01,Ruijin Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG, DRUG, DRUG","Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg",Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma,,,,,False,2905.0,False,False,2.0,True,False,False,4,True,Very Large (300+),1,580.0,6.364750756851911,2,1,0.58,True,True,0.8878726286247507,1,True,0.900996101271586,1,1,0.9212802,1
NCT01709344,Reducing Disability in Older Adult Cancer Survivors,A Phase I Randomized Controlled Trial of a Problem-solving Occupational Therapy Intervention for Older Adult Cancer Survivors,COMPLETED,,INTERVENTIONAL,73.0,ACTUAL,2013-02-01,2016-06-01,Dartmouth-Hitchcock Medical Center,OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, OTHER","PS-OT, Usual care",Cancer,,,,,False,1216.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,73.0,4.30406509320417,2,0,0.6,True,True,0.7380312995628977,1,True,0.7118166002800137,1,1,0.7467658,1
NCT04499950,Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study,A Phase II Single Arm Adaptive Weight Loss Study in Women With Early Stage Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,53.0,ACTUAL,2021-02-08,2024-01-10,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,NON_RANDOMIZED,SEQUENTIAL,SINGLE,"DRUG, BEHAVIORAL","Contrave, Behavioral Weight Loss","Breast Cancer, Overweight or Obesity",,,,,False,1066.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,53.0,3.9889840465642745,1,0,0.58,True,True,0.6605656440732639,1,True,0.6906570075556655,1,1,0.6552756,1
NCT03354390,HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma,A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2018-07-20,2026-03-03,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,cell infusion,Kidney Cancer,,,,,False,2783.0,False,False,1.0,False,False,False,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.56,True,True,0.5501786160224617,1,True,0.7461033747676145,1,1,0.6677365,1
NCT04857528,Detecting HPV DNA in Anal and Cervical Cancers,Circulating HPV DNA in Cancers of the Anus and Uterine Cervix Treated With Definitive Radiation Therapy,SUSPENDED,,OBSERVATIONAL,20.0,ESTIMATED,2020-10-06,2027-11-15,University of Chicago,OTHER,,,,"RADIATION, OTHER, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, OTHER, DIAGNOSTIC_TEST","Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test), Testing Archival Tumor Tissue, Physical Exam, Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)","Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer",,,,,False,2596.0,False,False,-1.0,False,False,False,6,False,Small (<30),0,20.0,3.044522437723423,1,0,0.6,False,True,0.560515655803464,0,True,0.5131253745501266,0,0,0.44163325,1
NCT02610140,Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM),"A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy",COMPLETED,PHASE2,INTERVENTIONAL,248.0,ACTUAL,2015-12-03,2019-09-06,Bayer,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Anetumab ravtansine (BAY94-9343), Vinorelbine",Mesothelioma,,,,,False,1373.0,True,False,2.0,True,False,True,2,True,Large (100-300),1,248.0,5.517452896464707,2,1,0.58,True,True,0.7421344844692902,1,True,0.8095689760930993,1,1,0.77215445,1
NCT04044040,Symptom Screening With Targeted Early Palliative Care (STEP) for Patients With Advanced Cancer,Symptom Screening With Targeted Early Palliative Care (STEP) for Patients With Advanced Cancer: A Pilot Trial,COMPLETED,,INTERVENTIONAL,116.0,ACTUAL,2016-09-01,2018-07-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Symptom screening with Targeted Early Palliative care (STEP),Cancer,,,,,False,668.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,116.0,4.762173934797756,0,1,0.6,True,True,0.7507230191501961,1,True,0.8649714990186308,1,1,0.87602514,1
NCT02514174,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations,COMPLETED,PHASE4,INTERVENTIONAL,25.0,ACTUAL,2015-08-18,2019-04-25,Boehringer Ingelheim,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Afatinib,"Carcinoma, Non-Small-Cell Lung, ErbB Receptors",,,,,False,1346.0,True,False,4.0,False,False,True,1,True,Small (<30),1,25.0,3.258096538021482,0,0,0.7,True,False,0.43020467020868697,0,True,0.6200511660491049,1,1,0.7086165,1
NCT04743583,Prevalence and Malignant Involvement of Calcified Intrathoracic Lymph Nodes in Patients Undergoing Endosonography,Prevalence of Intrathoracic Lymph Node Calcifications and Metastatic Involvement in Patients Undergoing Endosonography for Diagnosis and/or Mediastinal Staging of Intrathoracic Malignancy: a Cross-sectional Pilot Study,COMPLETED,,OBSERVATIONAL,362.0,ACTUAL,2021-03-20,2022-12-31,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,,DEVICE,Endosonography B-mode examination,"Lymphadenopathy, Lung Cancer, Sarcoidosis, Tuberculosis",,,,,False,651.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,362.0,5.8944028342648505,0,1,0.6,True,True,0.8998028612013467,1,True,0.8727184211215527,1,1,0.875864,1
NCT03426657,Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC,"First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)",COMPLETED,PHASE2,INTERVENTIONAL,120.0,ACTUAL,2018-09-20,2024-02-29,University of Erlangen-Nürnberg Medical School,OTHER,,SINGLE_GROUP,NONE,COMBINATION_PRODUCT,Durvalumab + Tremelimumab + RT,Locally Advanced Head and Neck Squamous Cell Carcinoma,,,,,False,1988.0,True,False,2.0,False,False,False,1,True,Large (100-300),1,120.0,4.795790545596741,0,1,0.58,True,True,0.7365057332747653,1,True,0.8348019121658357,1,1,0.8905531,1
NCT01054781,Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL),"Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)",COMPLETED,PHASE2,INTERVENTIONAL,91.0,ACTUAL,2009-01-01,,Samsung Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Rituximab,Diffuse Large B-cell Lymphoma (DLBCL),,,,,False,1303.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,91.0,4.5217885770490405,0,0,0.58,True,True,0.8109322262844303,1,True,0.67836573467463,1,1,0.568573,1
NCT01611584,A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer,A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2010-06-01,2014-07-01,Dartmouth-Hitchcock Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,ALA-induced Fluorescence,Lung Cancer in Normal and Malignant Tumors,,,,,False,1491.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.03839251891329545,1,False,0.012465263794230743,1,0,0.00265566,1
NCT01898845,A Phase I Study of LEE011 in Asian Patients,A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2013-05-01,2015-01-01,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,LEE011,Advanced Solid Tumors,,,,,False,610.0,True,False,1.0,False,False,True,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.56,True,False,0.4376142230448183,0,True,0.745501102552712,1,1,0.7221621,1
NCT03847519,Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer,"A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer",COMPLETED,PHASE1,INTERVENTIONAL,24.0,ACTUAL,2019-02-12,2022-02-22,"Advaxis, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","ADXS-503, Pembrolizumab","Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma",,,,,False,1106.0,True,False,1.0,False,False,True,2,True,Small (<30),1,24.0,3.218875824868201,1,0,0.56,True,False,0.49283592857005903,0,False,0.4491548324997385,0,0,0.3814223,0
NCT00001805,A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab,A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab,COMPLETED,PHASE2,INTERVENTIONAL,20.0,,1999-03-01,2000-06-01,National Cancer Institute (NCI),NIH,,,,DRUG,Rituximab,"Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms",,,,,False,458.0,True,False,2.0,False,False,False,1,True,Small (<30),1,20.0,3.044522437723423,0,0,0.58,True,False,0.4267341623175642,0,False,0.44583982817915,0,0,0.41315854,0
NCT06457997,A Study of PHN-010 in Patients With Advanced Solid Tumors,"First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors",TERMINATED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2024-07-01,2025-09-11,Pheon Therapeutics,INDUSTRY,,SEQUENTIAL,NONE,DRUG,PHN-010,"Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer",,,,,False,437.0,True,False,1.0,False,False,True,1,False,Small (<30),0,26.0,3.295836866004329,0,0,0.56,False,True,0.5378380027258632,0,True,0.6404705220189113,0,1,0.6517715,0
NCT04302324,"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2021-10-28,2027-12-28,Weill Medical College of Cornell University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone","Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma",,,,,False,2252.0,False,False,2.0,False,False,False,4,True,Small (<30),1,9.0,2.302585092994046,1,0,0.58,True,False,0.2735618744626921,0,False,0.37921940871824994,0,1,0.5183505,1
NCT07039383,A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients,Kymriah Real-world Effectiveness in ALL (KareALL): a Retrospective Chart Review Study of Tisagenlecleucel-treated ALL Patients,COMPLETED,,OBSERVATIONAL,79.0,ACTUAL,2023-03-01,2024-06-18,Novartis Pharmaceuticals,INDUSTRY,,,,,,Acute Lymphoblastic Leukemia,,,,,False,475.0,True,False,-1.0,False,False,True,0,True,Medium (30-100),0,79.0,4.382026634673881,0,0,0.6,True,True,0.8237650367916731,1,True,0.9099531973961272,1,1,0.87363887,1
NCT00402961,Trial of Acupuncture for Reduction of Post-Colectomy Ileus,A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus,COMPLETED,PHASE2,INTERVENTIONAL,90.0,ACTUAL,2006-10-01,2013-02-01,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"OTHER, OTHER","Acupuncture, Sham Acupuncture","Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting",,,,,False,2315.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,90.0,4.51085950651685,2,0,0.58,True,True,0.754990822712477,1,True,0.750014202453442,1,1,0.70952415,1
NCT00578461,"T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE",T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation,TERMINATED,,INTERVENTIONAL,26.0,ACTUAL,2007-10-01,2013-05-01,Baylor College of Medicine,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, RADIATION","Ara C, Mesna, Cyclophosphamide, TBI-Total Body Irradiation","Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin",,,,,False,2039.0,True,False,-1.0,False,False,False,4,False,Small (<30),1,26.0,3.295836866004329,1,0,0.6,False,True,0.601483331903221,0,True,0.726572863944464,0,1,0.66317314,0
NCT03647176,A Comparison of the Resection Rate of Cold Snare Polypectomy for Large (10-15 mm) and Small (5-9 mm) Colorectal Polyps,PLA Army General Hospital of Beijing,COMPLETED,,INTERVENTIONAL,1000.0,ACTUAL,2018-09-03,2020-02-01,Yuqi He,OTHER,NON_RANDOMIZED,PARALLEL,NONE,OTHER,Cold snare polypectomy,Adenomatous Polyps,,,,,False,516.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1000.0,6.90875477931522,0,1,0.6,True,True,0.9481528975762615,1,True,0.9875012586208952,1,1,0.9893694,1
NCT03529643,Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing RALP,Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy: Comparison of Sevoflurane-remifentanil and Sevoflurane-remifentanil-dexmedetomidine,COMPLETED,,INTERVENTIONAL,128.0,ACTUAL,2018-05-24,2018-08-22,Asan Medical Center,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, OTHER","Dexmedetomidine, Without dexmedetomidine",Prostate Cancer,,,,,False,90.0,True,False,-1.0,True,True,False,2,True,Large (100-300),0,128.0,4.859812404361672,3,1,0.6,True,True,0.6569962463146712,1,True,0.949461397794852,1,1,0.9868067,1
NCT03035331,"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2017-08-15,2022-09-10,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, BIOLOGICAL, OTHER, BIOLOGICAL, BIOLOGICAL, OTHER","Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment","Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma",,,,,False,1852.0,True,False,1.0,False,False,False,6,True,Small (<30),1,11.0,2.4849066497880004,1,0,0.56,True,False,0.3205696589596829,0,False,0.496335604247873,0,1,0.6467204,1
NCT03304054,Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG,"A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients",COMPLETED,PHASE3,INTERVENTIONAL,93.0,ACTUAL,2018-04-18,2020-03-15,"Catalyst Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Amifampridine Phosphate, Placebo Oral Tablet","Myasthenia Gravis, Generalized",,,,,False,697.0,True,False,3.0,True,True,True,2,True,Medium (30-100),0,93.0,4.543294782270004,3,0,0.77,True,True,0.6427683918443456,1,True,0.657782722126386,1,1,0.6419549,1
NCT03316794,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2018-01-04,2018-10-05,AbbVie,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SC-005,Breast Cancer,,,,,False,274.0,True,False,1.0,False,False,True,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.56,False,False,0.09339218164772708,1,False,0.07450271118535469,1,0,0.05115333,1
NCT04826575,Pre-habilitation in Lung Surgery Candidates,High Intensity Respiratory Muscle Training as a Pre-habilitation in Lung Surgery,COMPLETED,,INTERVENTIONAL,150.0,ACTUAL,2021-03-25,2024-12-31,"St. Anne's University Hospital Brno, Czech Republic",OTHER,RANDOMIZED,PARALLEL,DOUBLE,OTHER,High intensity inspiratory and expiratory muscle training,"Lung Cancer, Post-Op Complication",,,,,False,1377.0,True,False,-1.0,True,True,False,1,True,Large (100-300),0,150.0,5.017279836814924,2,1,0.6,True,True,0.7833900799971965,1,True,0.8551181103759921,1,1,0.8603013,1
NCT06339138,"Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study","Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine",ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,589.0,ACTUAL,2018-06-27,2027-01-31,Mayo Clinic,OTHER,,,,OTHER,Non-Interventional Study,"Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor, Clear Cell Renal Cell Carcinoma, Kidney Oncocytoma, Papillary Renal Cell Carcinoma, Urothelial Carcinoma",,,,,False,3140.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,589.0,6.380122536899765,0,1,0.6,True,True,0.9574123866081778,1,True,0.8865876784356539,1,1,0.8708657,1
NCT00167414,Study for Using Radiosurgery on Limited Metastases of Breast Cancer,A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer,COMPLETED,,INTERVENTIONAL,49.0,ACTUAL,2000-12-01,2016-11-01,University of Rochester,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, RADIATION","Hypofractionated Stereotactic Body Radiation Therapy, Hypofractionated Stereotactic Body Radiation Therapy","Breast Cancer, Metastatic",,,,,False,5814.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.6,True,True,0.872980123827587,1,True,0.8033944966871692,1,1,0.94473946,1
NCT03137576,Erector Spinae Plane Block Versus Paravertebral Block During Non-intubated Thoracoscopic Lung Resections.,"Pain Blocks in Awake Thoracic Surgery: A Randomized Prospective Trial to Test the Non-inferiority of Erector Spinae Plane Block (ESPB) in Comparison With Paravertebral Block During Non-intubate, Thoracoscopic Lung Resection.",TERMINATED,,INTERVENTIONAL,7.0,ACTUAL,2019-02-22,2021-11-22,IRCCS Sacro Cuore Don Calabria di Negrar,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, PROCEDURE","Paravertebral Block (PVB), Erector Spinae Plane Block (ESPB)",Lung Neoplasms,,,,,False,1004.0,True,False,-1.0,True,True,False,2,False,Small (<30),0,7.0,2.079441541679836,3,0,0.6,False,False,0.21780486788881262,1,False,0.14637928753439594,1,0,0.19557957,1
NCT01987830,Bevacizumab w / Temozolomide PET & Vascular MRI For GBM,A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI,COMPLETED,,INTERVENTIONAL,13.0,ACTUAL,2013-11-01,2019-04-01,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,"DEVICE, DEVICE","MRI-PET, TMZ-PET",Recurrent Glioblastoma,,,,,False,1977.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,13.0,2.6390573296152584,1,0,0.6,True,False,0.4395097103906404,0,True,0.5823513905007432,1,1,0.6368629,1
NCT01935973,Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,"A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973",COMPLETED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2013-09-30,2015-09-08,National Cancer Institute (NCI),NIH,RANDOMIZED,CROSSOVER,NONE,"OTHER, DRUG, DRUG","Laboratory Biomarker Analysis, Trametinib, Uprosertib","Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Cancer",,,,,False,708.0,True,False,1.0,True,False,False,3,True,Small (<30),1,26.0,3.295836866004329,2,0,0.56,True,False,0.40157334523931953,0,False,0.3370469030320842,0,0,0.410146,0
NCT01701076,"Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma","An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma",COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2012-03-01,2016-02-01,Cantonal Hospital of St. Gallen,OTHER,,SINGLE_GROUP,NONE,DRUG,Bendamustine,Multiple Myeloma,,,,,False,1432.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.58,True,True,0.7087630890517972,1,True,0.717782398838008,1,1,0.73122174,1
NCT01089413,Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART),"A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium",COMPLETED,,OBSERVATIONAL,201.0,ACTUAL,2010-01-01,2013-06-01,Hoffmann-La Roche,INDUSTRY,,,,DRUG,bevacizumab [Avastin],Colorectal Cancer,,,,,False,1247.0,True,False,-1.0,False,False,True,1,True,Large (100-300),1,201.0,5.308267697401205,0,1,0.6,True,True,0.8510593501697479,1,True,0.8827444969820563,1,1,0.8677896,1
NCT05424562,A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada,Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax (LIVEN),ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,210.0,ACTUAL,2022-09-07,2027-03-01,AbbVie,INDUSTRY,,,,,,Acute Myeloid Leukemia,,,,,False,1636.0,False,False,-1.0,False,False,True,0,True,Large (100-300),0,210.0,5.351858133476067,0,1,0.6,True,True,0.8715966288987187,1,True,0.7474300310387786,1,1,0.74076617,1
NCT00002837,High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer,"Phase I-II Study of Dose Intense Doxorubicin, Paclitaxel And Cyclophosphamide With Peripheral Blood Progenitor Cells (PBPC) And Cytokine Support In Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,1995-09-01,2002-01-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, PROCEDURE","Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel, Peripheral Blood Stem Cell Transplantation",Breast Cancer,,,,,False,2314.0,True,False,1.0,False,False,False,5,True,Small (<30),1,21.0,3.091042453358316,1,0,0.56,True,True,0.5057593122952191,1,True,0.6009197317090151,1,1,0.50050986,1
NCT01916837,Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer,Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer,COMPLETED,,OBSERVATIONAL,180.0,ACTUAL,2010-02-01,2010-12-01,Jules Bordet Institute,OTHER,,,,"OTHER, OTHER, PROCEDURE","Sampling of tumor tissue, Sampling of tumor tissue after breast cancer surgery, Sampling of tumor tissue after breast cancer surgery",Invasive Breast Cancer,,,,,False,303.0,True,False,-1.0,False,False,False,3,True,Large (100-300),0,180.0,5.198497031265826,1,1,0.6,True,True,0.7752305682324586,1,True,0.944812039738496,1,1,0.9735676,1
NCT01731886,Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma,A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma,COMPLETED,PHASE4,INTERVENTIONAL,60.0,ACTUAL,2012-09-01,2017-04-11,Columbia University,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG, DRUG, PROCEDURE, DRUG, DRUG, DRUG, DRUG","Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone, Stem cell collection, Melphalan, G-CSF, Cyclophosphamide, Mesna",Multiple Myeloma,,,,,False,1683.0,True,False,4.0,True,False,False,8,True,Medium (30-100),1,60.0,4.110873864173311,2,0,0.7,True,True,0.5051852112006683,1,True,0.681501081689548,1,1,0.82392246,1
NCT05090358,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,15.0,ACTUAL,2021-10-08,2026-10-08,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DRUG, DRUG, DRUG","Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin","Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer",,,,,False,1826.0,False,False,2.0,True,False,False,5,True,Small (<30),1,15.0,2.772588722239781,2,0,0.58,True,False,0.2839604602937763,0,False,0.3913541421124709,0,0,0.31625,0
NCT02580578,A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids,"A Multicentre Prospective Non-interventional Study Assessing the Management of Canadian Women With Uterine Fibroids, a Patient Registry",COMPLETED,,OBSERVATIONAL,1500.0,ACTUAL,2015-07-31,2020-01-31,Allergan,INDUSTRY,,,,OTHER,No Intervention,Leiomyoma,,,,,False,1645.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,1500.0,7.313886831633462,0,1,0.6,True,True,0.9642207967940095,1,True,0.9492280494685591,1,1,0.95582795,1
NCT00040846,"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial",COMPLETED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2001-11-01,2009-12-01,Fred Hutchinson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, RADIATION, PROCEDURE, PROCEDURE, DRUG, DRUG","alemtuzumab, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, mycophenolate mofetil, cyclosporine","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenström Macroglobulinemia",,,,,False,2952.0,True,False,2.0,False,False,False,7,True,Medium (30-100),0,60.0,4.110873864173311,1,0,0.58,True,True,0.7474494384467236,1,True,0.912196520781463,1,1,0.9585457,1
NCT00842348,Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour,Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour,COMPLETED,PHASE3,INTERVENTIONAL,89.0,ACTUAL,2009-02-01,2015-12-01,Ipsen,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,lanreotide (Autogel formulation),Non Functioning Entero-pancreatic Endocrine Tumour,,,,,False,2494.0,True,False,3.0,False,False,True,1,True,Medium (30-100),0,89.0,4.499809670330265,0,0,0.77,True,True,0.7938428207800274,1,True,0.7362159310025176,1,1,0.7113481,1
NCT04040699,KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor,"A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor",COMPLETED,PHASE1,INTERVENTIONAL,48.0,ACTUAL,2019-09-26,2023-12-01,Peking University,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,KN026 combined with KN046,HER2 Positive Solid Tumor,,,,,False,1527.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,48.0,3.8918202981106265,0,0,0.56,True,True,0.7345691953158008,1,True,0.7712636779300331,1,1,0.8004433,1
NCT00590213,Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX,An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients,COMPLETED,PHASE4,INTERVENTIONAL,125.0,ESTIMATED,2003-06-01,,AstraZeneca,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE, PROCEDURE","Casodex 150mg, Radiotherapy, Haematology",Prostate Cancer,,,,,False,1303.0,True,False,4.0,True,False,True,3,True,Large (100-300),0,125.0,4.836281906951478,2,1,0.7,True,False,0.4937114856627132,0,True,0.8125429249973593,1,1,0.87321675,1
NCT00669578,CC-4047 in Treating Patients With Myelofibrosis,"A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®",COMPLETED,PHASE1,INTERVENTIONAL,77.0,ACTUAL,2008-05-01,2019-12-12,Mayo Clinic,OTHER,,SINGLE_GROUP,NONE,DRUG,CC-4047,"Chronic Myeloproliferative Disorders, Secondary Myelofibrosis",,,,,False,4242.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,77.0,4.356708826689592,0,0,0.56,True,True,0.8884373056726617,1,True,0.7493669304719155,1,1,0.8043642,1
NCT05594290,Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery,Window-of-opportunity Study of Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery: the MERCURY Trial,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,36.0,ESTIMATED,2022-12-07,2026-11-01,Gruppo Oncologico del Nord-Ovest,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Retifanlimab, Cisplatin, Etoposide",Merkel Cell Carcinoma,,,,,False,1425.0,False,False,2.0,False,False,False,3,True,Medium (30-100),1,36.0,3.610917912644224,1,0,0.58,True,True,0.5714778484586834,1,True,0.7662796196960102,1,1,0.7992799,1
NCT03079427,Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma,Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis,COMPLETED,PHASE2,INTERVENTIONAL,101.0,ACTUAL,2017-05-15,2022-11-15,Asan Medical Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Gemcitabine plus cisplatin, Capecitabine","Cholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemotherapy, Capecitabine, Gemcitabine, Cisplatin",,,,,False,2010.0,True,False,2.0,True,False,False,2,True,Large (100-300),1,101.0,4.624972813284271,2,1,0.58,True,True,0.5740508268692093,1,True,0.7535802788540166,1,1,0.74054945,1
NCT03077841,Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer,Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer,SUSPENDED,PHASE2,INTERVENTIONAL,928.0,ESTIMATED,2017-03-06,2027-11-08,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, RADIATION, OTHER","Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration","Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7",,,,,False,3899.0,False,False,2.0,True,False,False,3,False,Very Large (300+),0,928.0,6.834108738813838,2,1,0.58,False,True,0.9331581288206352,0,True,0.9388609960714469,0,1,0.9688672,0
NCT04042701,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,"A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,115.0,ESTIMATED,2020-02-10,2027-03-31,Daiichi Sankyo,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Trastuzumab deruxtecan (DS-8201a), Trastuzumab deruxtecan (DS-8201a), Pembrolizumab","Breast Cancer, Non-small Cell Lung Carcinoma",,,,,False,2606.0,False,False,1.0,False,False,True,3,True,Large (100-300),1,115.0,4.7535901911063645,1,1,0.56,True,True,0.7380569627335305,1,True,0.8468752736998242,1,1,0.81276375,1
NCT03901339,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer,Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens,COMPLETED,PHASE3,INTERVENTIONAL,543.0,ACTUAL,2019-05-08,2023-10-20,Gilead Sciences,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine",Metastatic Breast Cancer,,,,,False,1626.0,True,False,3.0,True,False,True,5,True,Very Large (300+),1,543.0,6.298949246855942,2,1,0.77,True,True,0.7975263878117385,1,True,0.9103281564370362,1,1,0.9300655,1
NCT04914702,Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.,Continuous Monitoring of Vital Signs With Different Wearable Devices in Pediatric Patients Undergoing Chemotherapy for Cancer - a Comparison and Feasibility Pilot Study,COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2021-09-16,2022-03-01,"Insel Gruppe AG, University Hospital Bern",OTHER,,,,"DEVICE, DEVICE","Everion®, CORE®","Pediatric Cancer, Febrile Neutropenia, Oncology, Chemotherapy-induced Neutropenia",,,,,False,166.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,20.0,3.044522437723423,1,0,0.6,True,False,0.4550227794181051,0,True,0.6086194640704286,1,1,0.5979861,1
NCT01444924,Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery,"Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial",COMPLETED,PHASE2,INTERVENTIONAL,75.0,ACTUAL,2011-09-01,2013-03-01,"University of Wisconsin, Madison",OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Bupivicaine, Placebo","Gynecologic Cancer, Post-operative Pain",,,,,False,547.0,True,False,2.0,True,True,False,2,True,Medium (30-100),0,75.0,4.330733340286331,3,0,0.58,True,True,0.667100508950772,1,True,0.680052103077222,1,1,0.7640846,1
NCT05104567,A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203),"A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,138.0,ACTUAL,2021-12-09,2024-09-09,Sanofi,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","THOR-707, Pembrolizumab, Cetuximab","Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma",,,,,False,1005.0,True,False,2.0,False,False,True,3,True,Large (100-300),1,138.0,4.934473933130692,1,1,0.58,True,True,0.6760961604653354,1,True,0.7346730473253004,1,1,0.70475245,1
NCT01661153,An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer,A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer,COMPLETED,,OBSERVATIONAL,16.0,ACTUAL,2011-03-02,2016-09-14,Hoffmann-La Roche,INDUSTRY,,,,,,Breast Cancer,,,,,False,2023.0,True,False,-1.0,False,False,True,0,True,Small (<30),0,16.0,2.833213344056216,0,0,0.6,True,True,0.5512891047716374,1,True,0.5668217993170721,1,1,0.6459825,1
NCT02908386,ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer,"In Silico Clinical Trial on Adaptive Radiotherapy in Oropharynx Cancer, Comparing Photon & Proton Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset.",WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2015-11-01,2016-11-01,Maastricht Radiation Oncology,OTHER,,,,,,Head and Neck Neoplasms,,,,,False,366.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.03804317264753225,1,False,0.012276010762960905,1,0,0.00288228,1
NCT06758934,Comparison of Textbook Outcomes Between Laparoscopic and Open Total Gastrectomy for Gastric Cancer,Comparison of Textbook Outcomes Between Laparoscopic and Open Total Gastrectomy for Gastric Cancer,COMPLETED,,OBSERVATIONAL,94.0,ACTUAL,2024-08-01,2024-10-01,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,OTHER_GOV,,,,,,"Gastrectomy, Gastric Cancer",,,,,False,61.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,94.0,4.553876891600541,0,0,0.6,True,True,0.8368882964047285,1,True,0.8993720687560876,1,1,0.95833796,1
NCT01599949,"A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy","A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",COMPLETED,PHASE2,INTERVENTIONAL,120.0,ACTUAL,2012-08-01,2015-05-01,"Janssen Research & Development, LLC",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Ibrutinib,Mantle Cell Lymphoma,,,,,False,1003.0,True,False,2.0,False,False,True,1,True,Large (100-300),0,120.0,4.795790545596741,0,1,0.58,True,True,0.7008090135301049,1,True,0.8213470065473522,1,1,0.8200448,1
NCT03427177,Mychoice: Testing an Interactive mHealth Tool,Mychoice: Testing an Interactive mHealth Tool to Enhance Communication and Informed Decision Making About Clinical Trial Participation in Cancer Patients,COMPLETED,,INTERVENTIONAL,257.0,ACTUAL,2018-06-25,2020-02-28,Fox Chase Cancer Center,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,mychoice,"Conflict, Decisional Conflict",,,,,False,613.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,257.0,5.552959584921617,1,1,0.6,True,True,0.8212033947177052,1,True,0.8959758759269207,1,1,0.92398477,1
NCT00003462,"Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors",Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis,COMPLETED,PHASE1,INTERVENTIONAL,20.0,ESTIMATED,1998-04-01,2001-02-01,Duke University,OTHER,,,,DRUG,busulfan,Brain and Central Nervous System Tumors,,,,,False,1037.0,True,False,1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.56,True,True,0.501242583744246,1,True,0.5565313397857643,1,1,0.6147856,1
NCT01676961,Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy,Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma,TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2013-01-01,2015-11-01,NYU Langone Health,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,romiplostim,"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Thrombocytopenia",,,,,False,1034.0,True,False,2.0,False,False,False,1,False,Small (<30),0,5.0,1.791759469228055,0,0,0.58,False,False,0.18104095129670694,1,False,0.10187341885236441,1,0,0.10186145,1
NCT00082303,Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma,Music Imagery for Patients in Protected Environments,COMPLETED,PHASE1,INTERVENTIONAL,60.0,,2002-07-01,,National Center for Complementary and Integrative Health (NCCIH),NIH,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Music Imagery,"Leukemia, Lymphoma, Non-Hodgkin",,,,,False,1303.0,True,False,1.0,True,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,1,0,0.56,True,True,0.7014256854772053,1,True,0.7528544820948398,1,1,0.6860915,1
NCT01271010,A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status,"Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status",TERMINATED,PHASE4,INTERVENTIONAL,89.0,ACTUAL,2011-06-17,2016-05-04,Hoffmann-La Roche,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Cyclophosphamide, Fludarabine, Rituximab","Lymphocytic Leukemia, Chronic",,,,,False,1783.0,True,False,4.0,False,False,True,3,False,Medium (30-100),1,89.0,4.499809670330265,1,0,0.7,False,True,0.7115452056124265,0,True,0.8330865125647621,0,1,0.9201501,0
NCT02946008,Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer,A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2017-03-27,2019-07-12,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"RADIATION, PROCEDURE","Stereotactic Body Radiation Therapy, Radical Prostatectomy",Prostate Cancer,,,,,False,837.0,True,False,1.0,False,False,False,2,True,Small (<30),0,17.0,2.8903717578961645,1,0,0.56,True,False,0.3984775412805746,0,False,0.4789261707738005,0,1,0.5115297,1
NCT01834937,ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain,A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain,TERMINATED,,OBSERVATIONAL,17.0,ACTUAL,2013-06-01,2017-04-01,InSightec,INDUSTRY,,,,DEVICE,ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery),Pain Resulting From Bone Metastases,,,,,False,1400.0,True,False,-1.0,False,False,True,1,False,Small (<30),0,17.0,2.8903717578961645,0,0,0.6,False,True,0.5293846124509051,0,False,0.45481394449295287,1,0,0.34765002,1
NCT04956666,A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL),"A Multicentre, Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)",COMPLETED,PHASE2,INTERVENTIONAL,75.0,ACTUAL,2021-06-15,2023-01-23,Institut de Recherches Internationales Servier,OTHER,,SINGLE_GROUP,NONE,DRUG,Lyophilized S95014,Acute Lymphoblastic Leukemia,,,,,False,587.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,75.0,4.330733340286331,0,0,0.58,True,True,0.7568608159914127,1,True,0.7357269745045284,1,1,0.81021315,1
NCT05402618,Minimally Invasive Versus Open Surgery for PHC,Minimally Invasive Versus Open Surgery for Perihilar Cholangiocarcinoma(PHC)：A Multicenter Real-world Study,COMPLETED,,OBSERVATIONAL,783.0,ACTUAL,2018-05-01,2022-04-01,Renyi Qin,OTHER,,,,OTHER,No intervention,Perihilar Cholangiocarcinoma,,,,,False,1431.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,783.0,6.664409020350408,0,1,0.6,True,True,0.9505161600240587,1,True,0.9701325007841382,1,1,0.98019683,1
NCT06756802,Reproductive Health in Breast Cancer Survivor,Reproductive Health in Breast Cancer Survivor,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,22000.0,ESTIMATED,2024-07-11,2029-07-11,Institut Cancerologie de l'Ouest,OTHER,,,,,,Breast Cancer,,,,,False,1826.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9128833135900681,1,True,0.9916992680686387,1,1,0.9869823,1
NCT00098631,Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer,A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN),COMPLETED,PHASE2,INTERVENTIONAL,88.0,ESTIMATED,2004-10-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, OTHER","lapatinib ditosylate, laboratory biomarker analysis","Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary",,,,,False,1303.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,88.0,4.48863636973214,1,0,0.58,True,True,0.775842655721981,1,True,0.6645370029199924,1,1,0.60726506,1
NCT00541970,Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs,Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing,COMPLETED,PHASE1,INTERVENTIONAL,961.0,ACTUAL,2007-10-17,2013-03-18,GlaxoSmithKline,INDUSTRY,RANDOMIZED,PARALLEL,SINGLE,"BIOLOGICAL, DRUG","Cervarix, Placebo","Infections, Papillomavirus",,,,,False,1979.0,True,False,1.0,True,False,True,2,True,Very Large (300+),0,961.0,6.8690144506657065,2,1,0.56,True,True,0.9189070486994624,1,True,0.9184360667099607,1,1,0.9609238,1
NCT00059618,"PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer","A Phase I Study Evaluating the Safety and Tolerability of PS-341(Bortezomib)and Carboplatin in Patients With Platinum- and Taxane-Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer",COMPLETED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,2003-04-01,2007-04-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","PS-341 (Bortezomib), Carboplatin","Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer",,,,,False,1461.0,True,False,1.0,False,False,False,2,True,Small (<30),1,21.0,3.091042453358316,1,0,0.56,True,False,0.47678445307826184,0,False,0.4879851449695667,0,0,0.377568,0
NCT06540807,SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study,SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study: A Study to Investigate the Performance and Safety of the Colovac 2 Colorectal Anastomosis Protection Device,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,15.0,ESTIMATED,2024-07-31,2025-12-31,SafeHeal Inc,INDUSTRY,,SINGLE_GROUP,NONE,"DEVICE, PROCEDURE","Colovac Colorectal Anastomosis Protection Device, Stoma creation",Colorectal Cancer,,,,,False,518.0,False,False,-1.0,False,False,True,2,True,Small (<30),0,15.0,2.772588722239781,1,0,0.6,True,False,0.4008732535365933,0,True,0.5458903743401488,1,1,0.6538987,1
NCT00448279,THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.,"A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin",COMPLETED,PHASE3,INTERVENTIONAL,58.0,ACTUAL,2007-04-01,2010-09-01,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","trastuzumab, Chemotherapy",Breast Cancer,,,,,False,1249.0,True,False,3.0,True,False,True,2,True,Medium (30-100),1,58.0,4.07753744390572,2,0,0.77,True,True,0.5146452940219304,1,True,0.5018808132424118,1,1,0.5439351,1
NCT01031641,Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing,Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing,COMPLETED,,OBSERVATIONAL,1448.0,ACTUAL,2009-11-19,2020-07-16,National Cancer Institute (NCI),NIH,,,,,,"Lymphomas, Leukemias, Multiple Cancers",,,,,False,3892.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1448.0,7.278628942320682,0,1,0.6,True,True,0.9775498724111881,1,True,0.8866856830261809,1,1,0.90374804,1
NCT02177110,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT),COMPLETED,,OBSERVATIONAL,16.0,ACTUAL,2014-09-01,,Cancer Trials Ireland,NETWORK,,,,,,"Advanced Melanoma, Metastatic Melanoma",,,,,False,1303.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,16.0,2.833213344056216,0,0,0.6,True,True,0.5140050483488324,1,True,0.5095188828732657,1,1,0.65155464,1
NCT01853670,Adaptive Radiation Therapy for Head & Neck Cancer Patients,Kilovoltage Conebeam Imaging Based Adaptive Radiation Therapy for Head & Neck Patients Treated With Intensity Modulated Radiation Therapy,COMPLETED,,INTERVENTIONAL,6.0,ACTUAL,2009-08-01,2015-01-01,Beth Israel Medical Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION","concurrent chemo + IGRT, neoadjuvant chemo + IGRT",Cancer of Head and Neck,,,,,False,1979.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,6.0,1.9459101490553128,1,0,0.6,True,False,0.2694874223041435,0,False,0.3148100328654615,0,0,0.34613186,0
NCT02931890,Multicentric Randomised Trial for Resectable Gastric Cancer,A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,207.0,ESTIMATED,2017-12-21,2029-03-01,The Netherlands Cancer Institute,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, PROCEDURE, RADIATION, DRUG, DRUG","Docetaxel, Oxaliplatin, Capecitabine, gastrectomy, radiotherapy of gastric cancer, Paclitaxel, Carboplatin",Gastric Cancer,,,,,False,4088.0,False,False,2.0,True,False,False,7,True,Large (100-300),1,207.0,5.337538079701318,2,1,0.58,True,True,0.7935526052640156,1,True,0.8302016029024203,1,1,0.92066854,1
NCT01139151,4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies,Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2010-08-01,2013-11-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","3 Day Thiarabine, 5 Day Thiarabine",Leukemia,,,,,False,1188.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,31.0,3.4657359027997265,1,0,0.56,True,True,0.5702226933168798,1,True,0.5635872850321969,1,1,0.60083663,1
NCT01180335,Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer,Randomized Trial Comparing Standard Neoadjuvant Chemotherapy to Genomic Driven Chemotherapy Regimen in Patients With Breast Cancer,COMPLETED,PHASE3,INTERVENTIONAL,303.0,ACTUAL,2009-01-01,2011-12-01,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,RANDOMIZED,FACTORIAL,NONE,"DRUG, DRUG","Chemotherapy, Genomic driven chemotherapy",Breast Cancer,,,,,False,1064.0,True,False,3.0,True,False,False,2,True,Very Large (300+),0,303.0,5.717027701406222,2,1,0.77,True,True,0.6998145234163761,1,True,0.7791493167096337,1,1,0.843081,1
NCT05642962,Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC),A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2022-11-30,2025-11-30,Memorial Sloan Kettering Cancer Center,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DRUG,Pertzye,"Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma",,,,,False,1096.0,False,False,1.0,True,True,False,1,True,Small (<30),0,17.0,2.8903717578961645,2,0,0.56,True,False,0.40766673043274865,0,True,0.6547987493269516,1,1,0.6537507,1
NCT05410535,To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy,"A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer",COMPLETED,PHASE4,INTERVENTIONAL,431.0,ACTUAL,2021-09-15,2022-10-28,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, OTHER","Patients who continued UDCA 300mg medication, Patients who discontinued UDCA 300mg prescription",Gastric Cancer,,,,,False,408.0,True,False,4.0,True,False,True,2,True,Very Large (300+),0,431.0,6.068425588244111,2,1,0.7,True,True,0.7270430793239413,1,True,0.9135089916955724,1,1,0.9636188,1
NCT06042660,Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis,Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry,COMPLETED,,OBSERVATIONAL,527.0,ACTUAL,2016-02-01,2016-08-01,Polish Adult Leukemia Group,OTHER,,,,OTHER,the prevalence of comorbid conditions,Chronic Myeloid Leukemia,,,,,False,182.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,527.0,6.269096283706261,0,1,0.6,True,True,0.9177064376573845,1,True,0.9801942932876999,1,1,0.98421085,1
NCT00006482,Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix,A Phase II Evaluation Of Gemcitabine And Cisplatin In Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix,TERMINATED,PHASE2,INTERVENTIONAL,,,2000-10-01,,Gynecologic Oncology Group,NETWORK,,,,"DRUG, DRUG","cisplatin, gemcitabine hydrochloride",Cervical Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,2,False,,1,,,1,0,0.58,False,True,0.6467939450242459,0,True,0.7383243821713025,0,1,0.7132991,0
NCT07102706,Phase I Trial of GR1803 Injection in Patients With RRMM,"A Phase I Monotherapy Study Assessing the Safety and Efficacy of GR1803, a BCMA×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma",COMPLETED,PHASE1,INTERVENTIONAL,76.0,ACTUAL,2022-05-27,2025-05-20,"Genrix (Shanghai) Biopharmaceutical Co., Ltd.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,GR1803 injection,Multiple Myeloma (MM),,,,,False,1089.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,76.0,4.343805421853684,0,0,0.56,True,True,0.8029979661038946,1,True,0.6800204182941196,1,1,0.6483467,1
NCT00003323,Hormone Therapy in Treating Patients With Prostate Cancer,A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer,COMPLETED,PHASE2,INTERVENTIONAL,101.0,ACTUAL,1998-05-01,2010-03-01,Alliance for Clinical Trials in Oncology,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER","finasteride, flutamide, quality-of-life assessment","Prostate Cancer, Sexual Dysfunction and Infertility",,,,,False,4322.0,True,False,2.0,False,False,False,3,True,Large (100-300),0,101.0,4.624972813284271,1,1,0.58,True,True,0.757180044136599,1,True,0.8402404309657011,1,1,0.9471989,1
NCT01582932,Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis,"A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis",COMPLETED,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2013-04-01,2018-08-01,Mayne Pharma International Pty Ltd,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Calcipotriene 0.005% Foam,Psoriasis,,,,,False,1948.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,36.0,3.610917912644224,0,0,0.56,True,True,0.6910669574763156,1,True,0.789250672155991,1,1,0.7295879,1
NCT00171587,"Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer","A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ESTIMATED,2002-05-01,2007-03-01,Novartis,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,PTK787/ZK 222584 (vatalanib),"Tumors, Neoplasm Metastasis",,,,,False,1765.0,True,False,1.0,False,False,True,1,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.56,True,True,0.5633760692325407,1,True,0.6545196381884086,1,1,0.74895734,1
NCT02578368,Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction,Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI),COMPLETED,PHASE3,INTERVENTIONAL,183.0,ACTUAL,2016-02-01,2024-08-27,Krankenhaus Nordwest,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Trastuzumab, sodium folinate, Surgery",Gastric Cancer,,,,,False,3130.0,True,False,3.0,True,False,False,7,True,Large (100-300),1,183.0,5.214935757608986,2,1,0.77,True,True,0.6605611853402358,1,True,0.686300700247331,1,1,0.67519933,1
NCT01460693,Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia,"A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia",COMPLETED,PHASE3,INTERVENTIONAL,814.0,ACTUAL,2008-08-01,2018-03-07,Newcastle University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Imatinib, Dasatinib","Myeloid Leukemia, Chronic, Chronic Phase",,,,,False,3505.0,True,False,3.0,True,False,False,2,True,Very Large (300+),1,814.0,6.703188113240863,2,1,0.77,True,True,0.8917172902817012,1,True,0.9459641207220288,1,1,0.9609294,1
NCT01645436,Physical Activity in Pediatric Cancer (PAPEC),Physical Activity in Pediatric Cancer Patients With Solid Tumor Trial,COMPLETED,,INTERVENTIONAL,49.0,ACTUAL,2012-09-01,2015-09-01,Universidad Europea de Madrid,OTHER,RANDOMIZED,PARALLEL,SINGLE,OTHER,exercise training,Pediatric Cancer,,,,,False,1095.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,49.0,3.912023005428146,1,0,0.6,True,True,0.690764304775619,1,True,0.6703969574257934,1,1,0.6140825,1
NCT03417739,A Phase II Study of BVD-523 in Metastatic Uveal Melanoma,A Phase II Study of BVD-523 in Metastatic Uveal Melanoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,13.0,ACTUAL,2018-03-26,2025-08-31,Dana-Farber Cancer Institute,OTHER,,SINGLE_GROUP,NONE,DRUG,BVD-523,Uveal Melanoma,,,,,False,2715.0,False,False,2.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.58,True,False,0.44106087585819004,0,False,0.40787207143794374,0,0,0.30877757,0
NCT04155840,Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2020-01-31,2021-03-16,University of Washington,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, DRUG","Copanlisib, Rituximab, Bendamustine","Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",,,,,False,410.0,True,False,2.0,False,False,False,3,False,Small (<30),1,1.0,0.6931471805599453,1,0,0.58,False,False,0.043267293458169806,1,False,0.05725747986376154,1,0,0.029495941,1
NCT01763437,Intralesional Tetracycline Injection in the Treatment of Chalazia,Intralesional Tetracycline Injection in the Treatment of Chalazia,WITHDRAWN,EARLY_PHASE1,INTERVENTIONAL,0.0,ACTUAL,2014-03-01,2015-03-01,The Cleveland Clinic,OTHER,RANDOMIZED,PARALLEL,SINGLE,DRUG,Tetracycline,"Chalazia, Chalazion",,,,,False,365.0,True,False,0.5,True,False,False,1,False,,0,0.0,0.0,1,0,0.57,False,False,0.022887203396440618,1,False,0.012080751466776696,1,0,0.0026369873,1
NCT02790294,Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal,Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal Tumors - a Pilot Study,COMPLETED,,INTERVENTIONAL,8.0,ACTUAL,2016-08-31,2020-12-17,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,DEVICE,Magnetic Resonance Imaging,Spinal Tumor,,,,,False,1569.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,8.0,2.19722457733622,0,0,0.6,True,False,0.3542338115166209,0,False,0.4158966987619558,0,0,0.42493993,0
NCT01091207,Sorafenib for Imatinib/Sunitinib-failed GIST,A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib,COMPLETED,PHASE2,INTERVENTIONAL,39.0,ESTIMATED,2009-11-01,2011-08-01,Samsung Medical Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Sorafenib,Gastrointestinal Stromal Tumors,,,,,False,638.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,39.0,3.688879454113936,0,0,0.58,True,True,0.6073993245761187,1,True,0.5568086335407965,1,0,0.36135203,0
NCT00431756,Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus,Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus (Previously: Methylation in Cancer Progression of Barrett's Esophagus,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,600.0,ESTIMATED,2002-05-01,2026-06-01,Johns Hopkins University,OTHER,,,,,,"Barrett Esophagus, Esophageal Neoplasm, Gastroesophageal Reflux",,,,,False,8797.0,False,False,-1.0,False,False,False,0,True,Very Large (300+),0,600.0,6.398594934535208,0,1,0.6,True,True,0.9869308077442476,1,True,0.8255733112880758,1,1,0.86306536,1
NCT00637702,A Study of ARRY-334543 in Patients With Advanced Cancer,,COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2008-02-01,2012-10-01,"Array Biopharma, now a wholly owned subsidiary of Pfizer",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,"ARRY-334543, EGFR/ErbB2 inhibitor; oral",Advanced Cancer,,,,,False,1704.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,31.0,3.4657359027997265,0,0,0.56,True,True,0.6452797936565428,1,True,0.7535004105283193,1,1,0.7084947,1
NCT05709821,IMM60 and Pembrolizumab in Melanoma and NSCLC,IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC,TERMINATED,PHASE1,INTERVENTIONAL,1.0,ACTUAL,2023-11-15,2024-04-22,iOx Therapeutics,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","IMM60, Pembrolizumab","Non-small Cell Lung Cancer, Melanoma",,,,,False,159.0,True,False,1.0,True,False,True,2,False,Small (<30),1,1.0,0.6931471805599453,2,0,0.56,False,False,0.034675903632630976,1,False,0.05416362984465005,1,0,0.048116785,1
NCT03401034,"Influence of Lifestyle, Inflammatory Biomarkers, and Genetic Factors on Long-term Breast Cancer Prognosis","The Influence of Lifestyle and Genetic Risk Factors, Circulating Inflammatory Biomarkers and Menopausal Hormone Therapy on Long-term Prognosis After Postmenopausal Breast Cancer",COMPLETED,,OBSERVATIONAL,3813.0,ACTUAL,2002-08-01,2015-06-30,German Cancer Research Center,OTHER,,,,,,"Breast Cancer, Breast Cancer Mortality, Breast Cancer Survival, Postmenopausal Breast Cancer, Lifestyle, Genetic Factors, Inflammation, Inflammatory Biomarkers, Hormone Therapy, Phytoestrogens",,,,,False,4716.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,3813.0,8.246433786160365,0,1,0.6,True,True,0.9741655723889645,1,True,0.9639419776470874,1,1,0.9421425,1
NCT02413320,Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer,Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,101.0,ACTUAL,2015-07-01,2020-02-01,Priyanka Sharma,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Docetaxel",Triple-negative Breast Cancer,,,,,False,1676.0,True,False,2.0,True,False,False,5,True,Large (100-300),1,101.0,4.624972813284271,2,1,0.58,True,True,0.5417346377913942,1,True,0.7480411504616327,1,1,0.711284,1
NCT05363631,Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab,Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC),ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,55.0,ESTIMATED,2022-09-19,2026-12-31,Mohammed Milhem,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Selenomethionine (SLM), Axitinib, Pembrolizumab","Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic",,,,,False,1564.0,False,False,1.0,False,False,False,3,True,Medium (30-100),1,55.0,4.02535169073515,1,0,0.56,True,True,0.7131442835203311,1,True,0.7779115639737338,1,1,0.77868074,1
NCT04286984,Implementation of a Patient Blood Management Program in Gastric Cancer Surgery,Study of the Efficacy of a Patient Blood Management Program Implemented in Patients Undergoing Curative Gastric Cancer Resection,COMPLETED,,OBSERVATIONAL,1063.0,ACTUAL,2014-01-01,2018-12-31,Hospital Universitari de Bellvitge,OTHER,,,,OTHER,unified protocol of Patient Blood Management measure,"Gastric Cancer, Anemia, Iron Deficiency, Surgery--Complications, Transfusion Related Complication",,,,,False,1825.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1063.0,6.96979066990159,0,1,0.6,True,True,0.961165050218334,1,True,0.9870004055868958,1,1,0.9900086,1
NCT06989463,Complementary Behavioral Interventions To Remediate Cognitive Impairment or Emotional Distress in Cancer Survivors,Complementary Behavioral Interventions To Remediate Cognitive Impairment or Emotional Distress in Cancer Survivors: A Pilot Study,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,20.0,ACTUAL,2025-07-29,2026-11-01,St. Jude Children's Research Hospital,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER, OTHER","12 Week Exercise Intervention, Cognitive Training Intervention, Mindfulness practice intervention",Survivors of Childhood Cancer,,,,,False,460.0,False,False,-1.0,False,False,False,3,True,Small (<30),0,20.0,3.044522437723423,1,0,0.6,True,False,0.4651244898404049,0,True,0.580580133074605,1,1,0.69072455,1
NCT04925180,A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe,Study to Evaluate Physician Awareness and Knowledge of Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Monotherapies in Europe: an Observational Post-Authorisation Joint Safety Study (Safe-CAM),COMPLETED,,OBSERVATIONAL,600.0,ACTUAL,2021-10-18,2021-12-31,Bayer,INDUSTRY,,,,DRUG,"Cyproterone Acetate (Androcur, BAY94-8367)","Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer",,,,,False,74.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,600.0,6.398594934535208,0,1,0.6,True,True,0.9233246261042304,1,True,0.9725037500180079,1,1,0.9924899,1
NCT01401777,Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study,Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2014-12-01,2015-12-01,Philips Healthcare,INDUSTRY,,,,,,Kidney Tumors,,,,,False,365.0,True,False,-1.0,False,False,True,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.03803555707787671,1,False,0.012276010762960905,1,0,0.00288228,1
NCT03578224,Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer,Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,35.0,ACTUAL,2018-09-06,2022-08-25,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, DRUG","Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA), Contrast-Enhanced Ultrasound, Fine-Needle Aspiration, Sonazoid (Perflubutane)",Esophagus,,,,,False,1449.0,True,False,0.5,False,False,False,4,True,Medium (30-100),0,35.0,3.58351893845611,1,0,0.57,True,True,0.6162450918468201,1,True,0.664475835119999,1,1,0.6205766,1
NCT02123173,Hemodynamic Changes During One Lung Ventilation in Non-intubated Vedio-assisted Thoracoscopic Operations,Hemodynamic Changes and Fluid Responsiveness During One Lung Ventilation: Comparison in Non-intubated and Intubated Vedio-assisted Thoracoscopic Operations,COMPLETED,,OBSERVATIONAL,71.0,ACTUAL,2014-05-01,2014-12-01,National Taiwan University Hospital,OTHER,,,,,,Lung Neoplasms,,,,,False,214.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,71.0,4.276666119016055,0,0,0.6,True,True,0.7985239735951877,1,True,0.9503295547653049,1,1,0.9695179,1
NCT04669574,Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients,Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational Study,COMPLETED,,OBSERVATIONAL,101.0,ACTUAL,2021-06-29,2024-12-09,National Cancer Institute (NCI),NIH,,,,,,"Sleep Circadian Rhythms, Chronodisruption",,,,,False,1259.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,101.0,4.624972813284271,0,1,0.6,True,True,0.7511134151744498,1,True,0.8655073825048758,1,1,0.9014006,1
NCT00177190,In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL),In Vitro Evaluation of Immune Responses in CTCL,COMPLETED,,OBSERVATIONAL,8.0,ACTUAL,2002-06-01,2006-01-01,University of Pittsburgh,OTHER,,,,,,"Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides",,,,,False,1310.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,8.0,2.19722457733622,0,0,0.6,True,False,0.3466349656827102,0,False,0.39024096487618853,0,0,0.46783733,0
NCT02862795,Human Papillomavirus Anal Infection,Human PapillomaVirus (HPV) Anal Infection: Study of Prevalence and Risk Factors Among 1000 Patients Benefiting From a Colonoscopy,COMPLETED,,INTERVENTIONAL,500.0,ACTUAL,2012-04-01,2016-06-01,Centre Hospitalier Universitaire de Besancon,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,HPV detection in anal canal samples,HPV Infection,,,,,False,1522.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,500.0,6.2166061010848646,0,1,0.6,True,True,0.9339316040443635,1,True,0.9482357040651251,1,1,0.9049459,1
NCT03029871,Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer,Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Combination With Stereotactic Body Radiation Therapy (SBRT) in Clinical Stage 1/11A (T1A-T2B) Non-Small Cell Lung Cancer,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2017-01-13,2022-12-31,"Benjamin Movsas, M.D.",OTHER,,SEQUENTIAL,NONE,BIOLOGICAL,Ad5-yCD/mutTKSR39rep-ADP Adenovirus,Non-small Cell Lung Cancer Stage I,,,,,False,2178.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.04403376218404924,1,False,0.018548833798558942,1,0,0.003124565,1
NCT01649453,A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test,A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test,TERMINATED,,OBSERVATIONAL,19.0,ACTUAL,2012-05-01,2013-02-01,Cedar Associates LLC,OTHER,,,,DEVICE,Pathwork® Tissue of Origin Test,Neoplasm Metastasis,,,,,False,276.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,19.0,2.995732273553991,0,0,0.6,False,False,0.4994722251065998,1,True,0.710796407689384,0,1,0.5424176,0
NCT02156557,Study of KCC Peptide Application in the Colon,Phase 1B Study of KCC Peptide Application in the Colon,COMPLETED,PHASE1,INTERVENTIONAL,45.0,ACTUAL,2014-06-01,2016-08-01,Danielle Kim Turgeon,OTHER,,SINGLE_GROUP,NONE,BIOLOGICAL,Colon KCC Heptapeptide,"Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)",,,,,False,792.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.56,True,True,0.6894534096599282,1,True,0.5497004455438944,1,1,0.507214,1
NCT00005802,Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia,Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant,COMPLETED,PHASE1,INTERVENTIONAL,,,1999-06-01,2005-03-01,Fred Hutchinson Cancer Center,OTHER,,,,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION","aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy",Leukemia,,,,,False,2100.0,True,False,1.0,False,False,False,10,True,,1,,,1,0,0.56,True,True,0.6809376511147632,1,True,0.9070811507208438,1,1,0.85697144,1
NCT04833075,Real World Pharmacokinetics of Immune Checkpoint Inhibitors,Real World Pharmacokinetics of Immune Checkpoint Inhibitors,TERMINATED,,INTERVENTIONAL,19.0,ACTUAL,2021-09-15,2023-05-15,Radboud University Medical Center,OTHER,,SINGLE_GROUP,NONE,OTHER,blood sampling,Cancer,,,,,False,607.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,19.0,2.995732273553991,0,0,0.6,False,True,0.516687875873575,0,True,0.689876121070113,0,1,0.7180532,0
NCT00562523,Sorafenib/Docetaxel Dose Escalation Trial,A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2007-11-01,2009-03-01,Bayer,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,"Sorafenib (Nexavar, BAY43-9006)",Neoplasms,,,,,False,486.0,True,False,1.0,False,False,True,1,True,Small (<30),1,17.0,2.8903717578961645,0,0,0.56,True,False,0.4243546545945163,0,True,0.6297830993143336,1,1,0.6927251,1
NCT00859118,Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies,Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,30.0,ACTUAL,2009-02-01,2014-12-01,"University of Wisconsin, Madison",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","AG-013736, AG-013736",Neoplasms,,,,,False,2129.0,True,False,1.0,False,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.56,True,True,0.6093156001826416,1,True,0.7659837367088165,1,1,0.80367,1
NCT03381768,Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma,PD-L1 and PD-L2 Peptide Vaccination as Consolidation for Relapsed Follicular Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2017-12-12,2020-02-12,Lars Møller Pedersen,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","PD-L2 peptide, PD-L2 and PD-L1 peptide",Follicular Lymphoma,,,,,False,792.0,True,False,1.0,False,False,False,2,True,Small (<30),0,8.0,2.19722457733622,1,0,0.56,True,False,0.23604172521549788,0,False,0.212975380927708,0,0,0.14148566,0
NCT00599378,Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice,Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice,COMPLETED,,INTERVENTIONAL,373.0,ACTUAL,2007-09-01,2012-06-01,"Kimberly Engelman, PhD",OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Implementation Intentions-based telephone counseling,Colorectal Cancer,,,,,False,1735.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,373.0,5.924255797414532,1,1,0.6,True,True,0.890606207810469,1,True,0.9182535845862438,1,1,0.9355121,1
NCT01218243,An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia,An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia,COMPLETED,PHASE2,INTERVENTIONAL,100.0,ACTUAL,2010-09-01,2012-05-01,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DEVICE,needle,Benign Prostatic Hyperplasia (BPH),,,,,False,608.0,True,False,2.0,True,True,False,1,True,Medium (30-100),0,100.0,4.61512051684126,2,1,0.58,True,True,0.5887827766663126,1,True,0.8259601802369031,1,1,0.87996143,1
NCT06660563,A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL),A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,19.0,ACTUAL,2024-10-22,2026-09-21,"Janssen Research & Development, LLC",INDUSTRY,,SEQUENTIAL,NONE,"DRUG, DRUG","JNJ-80948543, JNJ-75348780","Lymphoma, Non-Hodgkin",,,,,False,699.0,False,False,1.0,False,False,True,2,True,Small (<30),0,19.0,2.995732273553991,1,0,0.56,True,False,0.41911864170350643,0,False,0.3703825903085008,0,0,0.3254628,0
NCT00093444,Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors,A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver,COMPLETED,PHASE1,INTERVENTIONAL,30.0,ESTIMATED,2004-09-01,2010-01-01,National Institutes of Health Clinical Center (CC),NIH,,,,"DRUG, PROCEDURE","lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation","Liver Cancer, Metastatic Cancer",,,,,False,1948.0,True,False,1.0,False,False,False,2,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.56,True,True,0.5935116570475877,1,True,0.6709172195428738,1,1,0.7575376,1
NCT02972216,Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy,A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2014-11-01,,"Yung Shin Pharm. Ind. Co., Ltd.",INDUSTRY,,,,"DRUG, DRUG, DRUG","Nolbaxol, Taxotere, cisplatin","Nonsmall Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck",,,,,False,1303.0,True,False,-1.0,False,False,True,3,True,Medium (30-100),1,40.0,3.713572066704308,1,0,0.6,True,True,0.6743689080555648,1,True,0.7975543054541094,1,1,0.87831306,1
NCT03991533,Use of Multiparametric MRI in the Management of Head and Neck Cancer: a Retrospective Analysis,Use of Multiparametric Magnetic Resonance Imaging in the Management of Head and Neck Cancer,COMPLETED,,OBSERVATIONAL,30.0,ESTIMATED,2016-11-01,2018-09-01,AZ Sint-Jan AV,OTHER,,,,OTHER,multiparametric MRI,"Head and Neck Cancer, Multiparametric MRI, Cervical Lymph Node",,,,,False,669.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.634807740727942,1,True,0.6994916522537362,1,1,0.7640172,1
NCT03283163,Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD,Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD,COMPLETED,,INTERVENTIONAL,23.0,ACTUAL,2014-08-25,2022-08-31,VA Office of Research and Development,FED,,SINGLE_GROUP,NONE,BEHAVIORAL,Exercise Testing and Training,"Chronic Musculoskeletal Pain, Posttraumatic Stress Disorder (PTSD), Mild or Moderate Traumatic Brain Injury",,,,,False,2928.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,23.0,3.1780538303479458,0,0,0.6,True,True,0.6785295743968678,1,True,0.6044204457083829,1,1,0.64501435,1
NCT05378048,Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors,"Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors: a Multicenter Open-label, Proof of Concept, Phase 2 Randomised Controlled Trial",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2022-07-04,2025-07-03,Chinese University of Hong Kong,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","PDO-guided treatment, standard of care",Organoids,,,,,False,1095.0,True,False,2.0,True,False,False,2,False,,0,0.0,0.0,2,0,0.58,False,False,0.017762862663104215,1,False,0.0020496152404173764,1,0,0.0020274904,1
NCT02117908,Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment,Application of CPAP to Reduce Complications and Improve Treatment of Radiofrequency Ablation of Lung Cancer Under Conscious Sedation. A Randomized Study,COMPLETED,,INTERVENTIONAL,47.0,ACTUAL,2014-11-01,2018-02-21,Sara Varea,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DEVICE,RESMED AUTOSET S9,"Atelectasis, Lung Cancer",,,,,False,1208.0,True,False,-1.0,True,True,False,1,True,Medium (30-100),0,47.0,3.871201010907891,2,0,0.6,True,True,0.7129493026891841,1,True,0.7104194377591847,1,1,0.76132786,1
NCT00728845,"Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer","(NJ 1508) Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study",TERMINATED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2008-06-16,2010-12-21,University of Medicine and Dentistry of New Jersey,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG","bevacizumab, carboplatin, hydroxychloroquine, paclitaxel",Lung Cancer,,,,,False,918.0,True,False,1.0,False,False,False,4,False,Small (<30),1,8.0,2.19722457733622,1,0,0.56,False,False,0.2283616245835348,1,False,0.19107026226374327,1,0,0.13189529,1
NCT01568632,Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma,"A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2012-03-01,2012-10-01,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Imetelstat,"Solid Tumors, Lymphoma",,,,,False,214.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.02969845839692837,1,False,0.007220506760226154,1,0,0.0031823644,1
NCT05697913,Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation,Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transplantation,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,66.0,ACTUAL,2014-07-01,2024-06-30,Hospital Galdakao-Usansolo,OTHER_GOV,NON_RANDOMIZED,PARALLEL,NONE,OTHER,Continued treatment adapted to the response,Multiple Myeloma,,,,,False,3652.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,66.0,4.204692619390966,0,0,0.6,True,True,0.8804005777711789,1,True,0.8823289167084957,1,1,0.8801943,1
NCT03934606,Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model,Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model: A Pilot Study of Patient Outcomes,COMPLETED,,OBSERVATIONAL,1488.0,ACTUAL,2018-01-01,2025-01-31,Abramson Cancer Center at Penn Medicine,OTHER,,,,BEHAVIORAL,Genetic testing for hereditary predisposition,"Pancreas Cancer, Prostate Cancer, Hereditary Cancer, Genetic Predisposition to Disease",,,,,False,2587.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1488.0,7.305860032684009,0,1,0.6,True,True,0.9703499109694059,1,True,0.9575772920816066,1,1,0.9703542,1
NCT06778837,Lymphedema Sensor Technology Development Study,Validation of Wearable Sensors to Monitor Tissue Hydration and Stiffness in Patients With Lymphedema,COMPLETED,,OBSERVATIONAL,30.0,ACTUAL,2025-01-27,2025-12-14,Northwestern University,OTHER,,,,DEVICE,Wearable devices to detect lymphedema,"Lymphedema Arm, Lymphedema, Cancer",,,,,False,321.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.6178595133519083,1,True,0.8851430644429135,1,1,0.85958356,1
NCT00469014,"Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.",COMPLETED,PHASE2,INTERVENTIONAL,72.0,ACTUAL,2006-09-01,2013-03-01,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, OTHER, DRUG, DRUG","Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim","Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia",,,,,False,2373.0,True,False,2.0,True,False,False,6,True,Medium (30-100),0,72.0,4.290459441148391,2,0,0.58,True,True,0.6952258999264056,1,True,0.7995047101910187,1,1,0.7829361,1
NCT00002774,Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer,COMPLETED,PHASE2,INTERVENTIONAL,63.0,ACTUAL,1996-06-01,2005-06-01,Stanford University,OTHER,RANDOMIZED,PARALLEL,,"DRUG, DRUG, DRUG, RADIATION","Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)",Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN),,,,,False,3287.0,True,False,2.0,True,False,False,4,True,Medium (30-100),1,63.0,4.158883083359672,2,0,0.58,True,True,0.7086627886186179,1,True,0.8920976331227578,1,1,0.9510323,1
NCT01664182,"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer","A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib",COMPLETED,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2012-08-01,2020-12-07,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL","Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, Sunitinib Malate, Trebananib","Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7",,,,,False,3050.0,True,False,2.0,True,False,False,5,True,Medium (30-100),1,41.0,3.737669618283368,2,0,0.58,True,True,0.5916713263190145,1,True,0.8809183796874307,1,1,0.9509387,1
NCT01318161,Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery,Epidural or Patient-controlled Analgesia for Colorectal Cancer Surgery. Long-term Outcomes.,TERMINATED,PHASE3,INTERVENTIONAL,221.0,ACTUAL,2011-03-01,2021-01-01,"Örebro University, Sweden",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Ropivacaine + opioid epidurally, Morphine","Colorectal Cancer, Pain, Other Complications",,,,,False,3594.0,True,False,3.0,True,False,False,2,False,Large (100-300),0,221.0,5.402677381872279,2,1,0.77,False,True,0.7458497760347763,0,True,0.7310480814798146,0,1,0.767157,0
NCT00424047,A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,"The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.",COMPLETED,PHASE3,INTERVENTIONAL,351.0,ACTUAL,2003-01-01,2013-11-12,Celgene,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","CC-5013 plus dexamethasone, Dexamethasone plus Placebo",Multiple Myeloma,,,,,False,3968.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,351.0,5.863631175598097,3,1,0.77,True,True,0.8467564386714624,1,True,0.8301068352517289,1,1,0.77208316,1
NCT02035345,Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,TERMINATED,PHASE4,INTERVENTIONAL,15.0,ACTUAL,2014-01-01,2016-06-01,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Carboplatin,"Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer",,,,,False,882.0,True,False,4.0,False,False,False,1,False,Small (<30),1,15.0,2.772588722239781,0,0,0.7,False,False,0.2884148683381646,1,False,0.44080418958961376,1,1,0.6656173,0
NCT01206764,A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.,"An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).",COMPLETED,PHASE4,INTERVENTIONAL,143.0,ACTUAL,2009-11-11,2017-07-01,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,RAD001,Renal Cell Carcinoma,,,,,False,2789.0,True,False,4.0,False,False,True,1,True,Large (100-300),0,143.0,4.969813299576001,0,1,0.7,True,True,0.7307579172794552,1,True,0.8813635689778636,1,1,0.9314517,1
NCT05246943,The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients,The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2022-05-25,2022-11-04,"The University of Texas Medical Branch, Galveston",OTHER,,,,DIAGNOSTIC_TEST,D-dimer and lower limb venous duplex,"Venous Thromboses, Colorectal Cancer, Diverticular Diseases, Crohn Disease, Ulcerative Colitis, Deep Vein Thrombosis",,,,,False,163.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.03581157653006252,1,False,0.010188871604872704,1,0,0.0023270305,1
NCT00535873,Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older,A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.,COMPLETED,PHASE2,INTERVENTIONAL,61.0,ACTUAL,2007-10-01,2013-02-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Lenalidomide,"Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",,,,,False,1950.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,61.0,4.127134385045092,0,0,0.58,True,True,0.769330778561045,1,True,0.8616884952624272,1,1,0.8627816,1
NCT00273208,An Intervention to Decrease Fatigue Among Breast Cancer Survivors,"Being Well, Staying Healthy: An Integrated Mind-Body Medicine Intervention to Decrease Fatigue Among Breast Cancer Survivors, PILOT STUDY",COMPLETED,,INTERVENTIONAL,25.0,,2005-09-01,2007-04-01,Mercy Medical Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,BEHAVIORAL,10 week behavioral intervention program,Fatigue After Adjuvant Breast Cancer Treatment,,,,,False,577.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.6,True,True,0.5852027019901782,1,True,0.7970901649690473,1,1,0.76685166,1
NCT06903507,Increasing Patient Comfort in Palliative Radiotherapy With a Newly Developed Mattress - A Prospective Clinical Study,The Comfort Study: Determining the Most Comfortable Radiotherapy Mattress,COMPLETED,,INTERVENTIONAL,45.0,ACTUAL,2023-08-03,2023-12-07,Erasmus Medical Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DEVICE,RT-Comfort Mattress,Neoplasms,,,,,False,126.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,45.0,3.828641396489095,0,0,0.6,True,True,0.7033012887073646,1,True,0.8528459585563833,1,1,0.9103034,1
NCT03568539,IBI308 in Subjects With Advanced/Metastatic Solid Malignancies,"An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,39.0,ACTUAL,2018-06-27,2020-12-07,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,IBI308,Advanced/Metastatic Solid Malignancies,,,,,False,894.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,39.0,3.688879454113936,0,0,0.56,True,True,0.6613530359899558,1,True,0.6179171161093494,1,1,0.6588831,1
NCT01293682,Effects of High Dose Calcitriol in Breast Cancer Patients,A Pilot Study of the Effects of High-Dose Oral Calcitriol in Breast Cancer Patients Prior to Surgery,COMPLETED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2010-11-01,2021-12-01,University of Rochester,OTHER,,SINGLE_GROUP,NONE,DRUG,Calcitriol,Breast Cancer,,,,,False,4048.0,True,False,2.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.58,True,False,0.49001256080877786,0,False,0.4109621056685362,0,1,0.5354164,1
NCT01269593,PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study,PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,INTERVENTIONAL,63.0,ACTUAL,2010-12-01,2026-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,DRUG,PET Imaging using 124 IPUH71,"Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy",,,,,False,5844.0,False,False,0.5,False,False,False,1,True,Medium (30-100),0,63.0,4.158883083359672,0,0,0.57,True,True,0.9047328246345143,1,True,0.8648375664659735,1,1,0.94421625,1
NCT05284032,A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001),A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients,TERMINATED,EARLY_PHASE1,INTERVENTIONAL,3.0,ACTUAL,2022-11-29,2024-06-11,"Firas El Chaer, MD",OTHER,,SINGLE_GROUP,NONE,DRUG,isatuximab 10 mg/kg,"Platelet Refractoriness, Hematologic Malignancy",,,,,False,560.0,True,False,0.5,False,False,False,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.57,False,False,0.13609563638395508,1,False,0.13577802408245432,1,0,0.1391085,1
NCT03238053,Laser Treatment of Genito-urinary Syndrome in Women,Laser Treatment of Genito-urinary Syndrome in Women With Breast and Endometrial Cancer and Menopausal Women,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2022-10-01,2026-12-31,Herning Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, DEVICE, DEVICE","Vaginal laser treatment, sham, laser system","Laser-Induced Scar, Breast Cancer, Endometrial Cancer, Menopause, Vaginal Atrophy, Bladder, Overactive",,,,,False,1552.0,True,False,-1.0,True,False,False,3,False,,0,0.0,0.0,2,0,0.6,False,False,0.027050439282979954,1,False,0.013461714222788588,1,0,0.002845958,1
NCT01658358,ErbB2 Positive Metastatic Breast Cancer,A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer,TERMINATED,PHASE1,INTERVENTIONAL,15.0,ESTIMATED,2012-07-01,2014-09-01,China Medical University Hospital,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Lapatinib, Lipo-Dox",Metastatic Breast Cancer,,,,,False,792.0,True,False,1.0,False,False,False,2,False,Small (<30),0,15.0,2.772588722239781,1,0,0.56,False,False,0.3661165110817256,1,True,0.5122870914093732,0,1,0.5071626,0
NCT06536244,Impact of Perioperative Anesthetic Management on Renal Cancer Progression.,Impact of Perioperative Anesthetic Management on Renal Cancer Progression.,WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2020-07-31,2028-09-01,M.D. Anderson Cancer Center,OTHER,,,,,,"Perioperative Anesthetic, Renal Cancer",,,,,False,2954.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.06346871452732286,1,False,0.06806079880803077,1,0,0.0025158585,1
NCT02000739,Genetically-informed Therapies for Patients With Metastatic Cancer,Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer,WITHDRAWN,PHASE4,INTERVENTIONAL,0.0,ACTUAL,2014-01-01,2018-01-01,Dartmouth-Hitchcock Medical Center,OTHER,,SINGLE_GROUP,NONE,GENETIC,Genetically Informed Therapy,Metastatic Cancer,,,,,False,1461.0,True,False,4.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.7,False,False,0.022316931856589575,1,False,0.020180316739728296,1,0,0.0040414636,1
NCT01287624,Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC),"A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer",COMPLETED,PHASE3,INTERVENTIONAL,240.0,ACTUAL,2011-01-01,2014-03-01,Fudan University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Gemcitabine,cisplatin, Gemcitabine, Paclitaxel",Breast Cancer,,,,,False,1155.0,True,False,3.0,True,False,False,2,True,Large (100-300),1,240.0,5.484796933490655,2,1,0.77,True,True,0.6501179150462842,1,True,0.6326143809231788,1,0,0.47801006,0
NCT03953352,Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy,Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy,WITHDRAWN,,INTERVENTIONAL,0.0,ACTUAL,2019-08-01,2021-01-01,Institut Claudius Regaud,OTHER,,SINGLE_GROUP,NONE,OTHER,Helical intensity-modulated radiotherapy (IMRT),Head and Neck Cancer,,,,,False,519.0,True,False,-1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.6,False,False,0.03845971452717212,1,False,0.0037497810042460126,1,0,0.0026482542,1
NCT07360145,Intelligent Support for Radiological Reporting of Lung Neoplasms,Intelligent Support for Radiological Reporting of Lung Neoplasms - SPOILERS Study,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,329.0,ACTUAL,2024-03-23,2026-02-15,Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria,OTHER,,,,OTHER,Collection of variables identified for the study,Pulmonary Nodules,,,,,False,694.0,False,False,-1.0,False,False,False,1,True,Very Large (300+),0,329.0,5.799092654460526,0,1,0.6,True,True,0.8927228032929567,1,True,0.8712431096934194,1,1,0.86316985,1
NCT01812161,Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome,Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome,COMPLETED,,INTERVENTIONAL,54.0,ACTUAL,2012-11-01,2017-09-01,Huazhong University of Science and Technology,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"OTHER, OTHER","acupuncture protocol 1, Acupuncture protocol 2",Polycystic Ovary Syndrome,,,,,False,1765.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,54.0,4.007333185232471,3,0,0.6,True,True,0.7235977742147148,1,True,0.7163596664392716,1,1,0.6569025,1
NCT01932073,Laser Therapy for the Management of Radiation Dermatitis,Low-Level Laser Therapy for the Management of Radiation Dermatitis: A Pilot Study in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,79.0,ACTUAL,2013-08-01,2014-07-01,Hasselt University,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DEVICE,Low-Level Laser Therapy,Radiation Dermatitis,,,,,False,334.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,79.0,4.382026634673881,0,0,0.6,True,True,0.8164087013352731,1,True,0.8901327838346432,1,1,0.9153898,1
NCT00253539,Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer,A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,3.0,ACTUAL,2002-01-01,2005-04-01,The Cleveland Clinic,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, OTHER","arzoxifene hydrochloride, tamoxifen citrate, placebo","Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)",,,,,False,1186.0,True,False,2.0,True,True,False,3,True,Small (<30),1,3.0,1.3862943611198906,3,0,0.58,True,False,0.0830852841101293,0,False,0.09852485374363228,0,0,0.14430073,0
NCT05674240,Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain,Intrathecal Targeted Drug Delivery for Cancer Associated Pain,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,30.0,ACTUAL,2022-12-06,2026-03-20,Wake Forest University Health Sciences,OTHER,,,,"DEVICE, COMBINATION_PRODUCT","Intrathecal Targeted Drug Delivery, Conservative medical management","Cancer Pain, Chronic Pain, Cancer Associated Pain, Neuropathic Pain",,,,,False,1200.0,False,False,-1.0,False,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.6,True,True,0.6118758132180071,1,True,0.723691628625682,1,1,0.7017816,1
NCT00121511,The Effect of Efudex Treatment on Photoaged Skin,The Effect of Efudex (5-fluorouracil) Treatment on Photoaged Skin,COMPLETED,,INTERVENTIONAL,21.0,ACTUAL,2005-07-01,2007-07-01,University of Michigan,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Efudex (5-fluorouracil),"Photo-aging, Keratosis",,,,,False,730.0,True,False,-1.0,False,False,False,1,True,Small (<30),1,21.0,3.091042453358316,0,0,0.6,True,True,0.5417157330881849,1,True,0.6166060206523322,1,1,0.6528991,1
NCT03335670,Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors,Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,INTERVENTIONAL,30.0,ESTIMATED,2017-11-03,2030-06-30,Yusuf Menda,OTHER,,SINGLE_GROUP,NONE,DRUG,[68Ga]Pentixafor,Neuroendocrine Tumors,,,,,False,4622.0,False,False,0.5,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.57,True,True,0.7725049822028005,1,True,0.7466473509084892,1,1,0.6253267,1
NCT02818816,Preoperative Brimonidine on IOP of Patients Undergoing RALP,"A Prospective Study to Evaluate the Effect of Preoperative Topical Brimonidine Tartrate 0.2% (Allergan, Irvine, CA) on Intraocular Pressure (IOP) of Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (RALP)",COMPLETED,PHASE4,INTERVENTIONAL,26.0,ACTUAL,2016-02-29,2017-08-07,"University Health Network, Toronto",OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, OTHER","brimonidine tartrate 0.2%, Carboxymethylcellulose Eye Drops",Prostate Cancer,,,,,False,525.0,True,False,4.0,True,False,False,2,True,Small (<30),0,26.0,3.295836866004329,2,0,0.7,True,False,0.2806847439934924,0,False,0.40819694082773955,0,0,0.3442093,0
NCT05226078,"The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients","The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,64.0,ACTUAL,2023-03-01,2026-11-30,Abramson Cancer Center at Penn Medicine,OTHER,RANDOMIZED,PARALLEL,TRIPLE,BEHAVIORAL,Cognitive Behavioral Therapy for Insomnia,"Chronic Insomnia, Cancer-related Problem/Condition, Cancer-Related Syndrome",,,,,False,1370.0,False,False,-1.0,True,True,False,1,True,Medium (30-100),0,64.0,4.174387269895637,2,0,0.6,True,True,0.779951461149846,1,True,0.6780311424667709,1,1,0.73341656,1
NCT05717998,Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy,A Pilot Study to Evaluate Early Signs of Myocardial Injury After Thoracic Radiotherapy Using Imaging and Blood-Based Biomarkers,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,28.0,ACTUAL,2021-04-02,2026-06-18,Ohio State University Comprehensive Cancer Center,OTHER,,,,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE","Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography","Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer",,,,,False,1903.0,False,False,-1.0,False,False,False,4,True,Small (<30),0,28.0,3.367295829986474,1,0,0.6,True,True,0.6197884452391839,1,True,0.7719008214397202,1,1,0.73110336,1
NCT02171741,Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors,"A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days",COMPLETED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2005-04-01,,Boehringer Ingelheim,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","BIBW 2992, Docetaxel",Neoplasms,,,,,False,1303.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,31.0,3.4657359027997265,1,0,0.56,True,True,0.5691608699804216,1,True,0.6332799643589836,1,1,0.593221,1
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,"Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma",COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2001-03-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL, OTHER","aldesleukin, gp100:209-217(210M) peptide vaccine, laboratory biomarker analysis","Recurrent Melanoma, Stage IV Melanoma",,,,,False,1303.0,True,False,2.0,False,False,False,3,True,Medium (30-100),0,50.0,3.9318256327243257,1,0,0.58,True,True,0.6533533217993597,1,True,0.7465743753664483,1,1,0.7750354,1
NCT03529422,Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN,A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,18.0,ACTUAL,2019-10-07,2026-05-06,UNC Lineberger Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","Durvalumab, Intensity Modulated Radiotherapy Treatments","Larynx, Lip, Oral Cancer, Digestive Organs--Diseases",,,,,False,2403.0,False,False,2.0,False,False,False,2,True,Small (<30),1,18.0,2.9444389791664403,1,0,0.58,True,False,0.4484419536768702,0,False,0.48790619721012446,0,0,0.38263032,0
NCT02269280,Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS),Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Dependent Versus Best Supportive Care (BSC) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Independent,COMPLETED,PHASE2,INTERVENTIONAL,185.0,ACTUAL,2014-10-13,2024-07-25,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, OTHER, DRUG","Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5",Leukemia,,,,,False,3573.0,True,False,2.0,True,False,False,4,True,Large (100-300),0,185.0,5.225746673713202,2,1,0.58,True,True,0.7719863884121542,1,True,0.8825097314102943,1,1,0.9158607,1
NCT03437837,"Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China","Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China",COMPLETED,,OBSERVATIONAL,1077.0,ACTUAL,2017-05-01,2018-09-29,Peking University First Hospital,OTHER,,,,,,"Breast Cancer, Neoadjuvant Therapy, Neoplasm Staging, Estrogen Receptor, Histological Grade, HER2, Prognosis, Predictive Value of Tests",,,,,False,516.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1077.0,6.982862751468942,0,1,0.6,True,True,0.9508783460249226,1,True,0.9729509911278342,1,1,0.967529,1
NCT03409016,Biomarkers of Immune-Related Toxicity,Identifying Biomarkers of Immune-Related Toxicity in Cancer Patients Treated With Immune Checkpoint Inhibitors; A Pilot Project,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,69.0,ESTIMATED,2018-04-18,2026-05-28,"University of Colorado, Denver",OTHER,,,,OTHER,Blood Testing,"Cancer, Metastatic Cancer",,,,,False,2962.0,False,False,-1.0,False,False,False,1,True,Medium (30-100),0,69.0,4.248495242049359,0,0,0.6,True,True,0.8697578492773665,1,True,0.8830351132918046,1,1,0.8764639,1
NCT00007982,Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer,CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ESTIMATED,1999-04-01,2008-05-01,Herbert Irving Comprehensive Cancer Center,OTHER,,,,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE","filgrastim, carmustine, cisplatin, cyclophosphamide, etoposide, thiotepa, adjuvant therapy, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation","Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma",,,,,False,3318.0,True,False,2.0,False,False,False,10,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.58,True,True,0.5861511112222466,1,True,0.8534127095449159,1,1,0.9086904,1
NCT03809000,A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery,STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,188.0,ACTUAL,2019-04-15,2029-09-15,"RTOG Foundation, Inc.",OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, DRUG, DRUG, DRUG","Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog",Prostate Cancer,,,,,False,3806.0,False,False,2.0,True,False,False,4,True,Large (100-300),1,188.0,5.241747015059643,2,1,0.58,True,True,0.7782599557732065,1,True,0.9147013504719985,1,1,0.9214528,1
NCT03770247,Intraoperative Versus CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer,Direct Intraoperative Injection Versus Percutaneous CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer ; Randomized Controlled Study,COMPLETED,,INTERVENTIONAL,76.0,ACTUAL,2018-09-01,2019-10-01,Mansoura University,OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, PROCEDURE","Intraoperative celiac plexus neurolysis, CT guided celiac plexus neurolysis","Pain, Chronic",,,,,False,395.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,76.0,4.343805421853684,3,0,0.6,True,True,0.7374377246870978,1,True,0.9341386984479669,1,1,0.95229924,1
NCT01375023,"Allogenic Haematopoietic Cell Transplantation for Patients With Refractory ""Triple Negative"" Breast Cancer","Allogenic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Refractory ""Triple Negative"" Breast Cancer",TERMINATED,PHASE2,INTERVENTIONAL,3.0,ACTUAL,2009-06-01,2013-12-01,European Institute of Oncology,OTHER,,SINGLE_GROUP,NONE,"RADIATION, BIOLOGICAL","Radiotherapy, Anti-Thymocyte Globulin",Breast Cancer,,,,,False,1644.0,True,False,2.0,False,False,False,2,False,Small (<30),0,3.0,1.3862943611198906,1,0,0.58,False,False,0.1157682555489008,1,False,0.1741463136601326,1,0,0.18573737,1
NCT00377780,"Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer","Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer",TERMINATED,PHASE2,INTERVENTIONAL,60.0,ACTUAL,2006-08-01,2015-08-01,Laurence J.C. van Warmerdam,OTHER,,SINGLE_GROUP,NONE,DRUG,"Non pegylated liposomal doxorubicin, trastuzumab, docetaxel","Breast Cancer, Neoplasm Metastasis",,,,,False,3287.0,True,False,2.0,False,False,False,1,False,Medium (30-100),1,60.0,4.110873864173311,0,0,0.58,False,True,0.808038135538039,0,True,0.9541581758783845,0,1,0.95906514,0
NCT01531608,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma Independent Of Fixed Gamma Camera Imaging,COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2011-03-01,2012-02-01,University of Virginia,OTHER,,,,,,Melanoma,,,,,False,337.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.5209668800184503,1,True,0.7073260735116703,1,1,0.63181573,1
NCT03371732,Effectiveness of Screening and Brief Interventions for Alcohol and Tobacco During Breast Cancer Treatment (ONKODETOX),"Effectiveness of Screening and Brief Interventions for Alcohol and/or Tobacco During Breast Cancer Treatment: A Phase III, Pilot Prospective Randomized Trial (ONKODETOX)",COMPLETED,,INTERVENTIONAL,104.0,ACTUAL,2016-03-01,2019-04-01,Institut Bergonié,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Motivational Intervention group, Educational advises group","Breast Cancer, Psychology, Social",,,,,False,1126.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,104.0,4.653960350157523,2,1,0.6,True,True,0.62905575392596,1,True,0.8385949568279717,1,1,0.81717813,1
NCT00859001,Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy,"A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy.",COMPLETED,PHASE2,INTERVENTIONAL,55.0,ACTUAL,,,University of Bologna,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","FM+R, Zevalin (Ibritumomab Tiuxetan)",Follicular Lymphoma,,,,,False,1303.0,True,False,2.0,False,False,False,2,True,Medium (30-100),0,55.0,4.02535169073515,1,0,0.58,True,True,0.6800011991064558,1,True,0.6819498730166397,1,1,0.5453446,1
NCT00436579,Sorafenib in Treating Patients With Advanced Solid Tumors,"A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies",TERMINATED,PHASE1,INTERVENTIONAL,110.0,ACTUAL,2007-01-01,,National Cancer Institute (NCI),NIH,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, OTHER, PROCEDURE, OTHER","sorafenib tosylate, pharmacological study, assessment of therapy complications, laboratory biomarker analysis","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,True,False,False,4,False,Large (100-300),1,110.0,4.709530201312334,2,1,0.56,False,True,0.5863550725241712,0,True,0.7167170726729921,0,1,0.66261446,0
NCT00982865,Trial of MSC1936369B in Subjects With Solid Tumors,"A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours",COMPLETED,PHASE1,INTERVENTIONAL,182.0,ACTUAL,2007-12-31,2016-04-30,"Merck KGaA, Darmstadt, Germany",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","MSC1936369B, MSC1936369B, MSC1936369B, MSC1936369B","Solid Tumors, Cancer",,,,,False,3043.0,True,False,1.0,False,False,True,4,True,Large (100-300),0,182.0,5.209486152841421,1,1,0.56,True,True,0.8312574819375961,1,True,0.7351420860239422,1,1,0.80495507,1
NCT03884868,Iconographies for Risk Communication and Reduction of Patient's Anxiety in a Colorectal Cancer Screening Program,Use of Iconographies for Risk Communication and Reduction of Patient's Anxiety During the Nurse Information Visit in the Colorectal Cancer Screening Program,COMPLETED,,INTERVENTIONAL,240.0,ACTUAL,2019-04-01,2019-12-31,Corporacion Parc Tauli,OTHER,NON_RANDOMIZED,PARALLEL,NONE,OTHER,Iconographies to communicate risks,Colo-rectal Cancer,,,,,False,274.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,240.0,5.484796933490655,0,1,0.6,True,True,0.8505880587410396,1,True,0.9457922101017582,1,1,0.955391,1
NCT04826458,Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology,Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology,COMPLETED,,INTERVENTIONAL,124.0,ACTUAL,2021-05-04,2025-11-11,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, OTHER","TreC-Onco, Paper diary","Cancer, Solid Tumor, Hematologic Malignancy, Oral Drug Administration",,,,,False,1652.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,124.0,4.8283137373023015,2,1,0.6,True,True,0.6935612311282063,1,True,0.7900569270040547,1,1,0.647202,1
NCT03319537,Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma,Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma,TERMINATED,PHASE1,INTERVENTIONAL,9.0,ACTUAL,2017-10-05,2023-06-05,Memorial Sloan Kettering Cancer Center,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","pevonedistat, Pemetrexed and cisplatin",Mesothelioma,,,,,False,2069.0,True,False,1.0,False,False,False,2,False,Small (<30),1,9.0,2.302585092994046,1,0,0.56,False,False,0.3052799275211275,1,False,0.4813964533775244,1,1,0.65105826,0
NCT01962272,The Effect of Nutritional Counseling for Cancer Patients,Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients,COMPLETED,PHASE4,INTERVENTIONAL,61.0,ACTUAL,2010-01-01,2010-09-01,University of Copenhagen,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, DIETARY_SUPPLEMENT","Weekly nutritional counseling, Forticare®.","Esophageal Cancer, Gastric Cancer, Uterine Cancer",,,,,False,243.0,True,False,4.0,True,False,False,2,True,Medium (30-100),0,61.0,4.127134385045092,2,0,0.7,True,False,0.47243937151377147,0,True,0.7504669601973848,1,1,0.882634,1
NCT03197116,Lay Tel Compliance Study,"The Effectiveness of Telephone Reminders by a Layperson on Compliance With Colorectal Cancer Screening: an Open-label, Randomized Controlled Trial",COMPLETED,,INTERVENTIONAL,500.0,ACTUAL,2017-06-15,2017-12-31,Chinese University of Hong Kong,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","Telephone reminder, No other","CRC Screening, Compliance, Patient",,,,,False,199.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,500.0,6.2166061010848646,2,1,0.6,True,True,0.8599891419159519,1,True,0.9048999753293557,1,1,0.9814372,1
NCT04507828,Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall,Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall,COMPLETED,,INTERVENTIONAL,4.0,ACTUAL,2020-10-02,2024-12-30,Indiana University,OTHER,,SINGLE_GROUP,NONE,RADIATION,Treatment Planning using the DIBH Technique,"Lung Cancer, Metastatic Cancer",,,,,False,1550.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,4.0,1.6094379124341005,0,0,0.6,True,False,0.223503690086067,0,False,0.2512742053058552,0,0,0.21269946,0
NCT04327986,Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer,A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer,TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2021-06-15,2022-02-03,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, RADIATION","M7824, M9241, SBRT","Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer",,,,,False,233.0,True,False,1.0,False,False,False,3,False,Small (<30),0,3.0,1.3862943611198906,1,0,0.56,False,False,0.10011822857081493,1,False,0.06896041598743802,1,0,0.07075518,1
NCT04568226,"The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence","The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence: a Randomized Controlled Trial",COMPLETED,,INTERVENTIONAL,177.0,ACTUAL,2021-07-21,2024-02-03,The University of Hong Kong,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"OTHER, OTHER","ConquerFear Intervention, Active control: Basic Cancer Care",Fear of Cancer Recurrence,,,,,False,927.0,True,False,-1.0,True,True,False,2,True,Large (100-300),0,177.0,5.181783550292085,3,1,0.6,True,True,0.7591470587039789,1,True,0.8524095107146222,1,1,0.7687631,1
NCT06154902,"Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel",ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,350.0,ESTIMATED,2022-07-29,2027-12-31,Bristol-Myers Squibb,INDUSTRY,,,,"DRUG, OTHER","Idecabtagene vicleucel, Not treated",Multiple Myeloma,,,,,False,1981.0,False,False,-1.0,False,False,True,2,True,Very Large (300+),0,350.0,5.860786223465865,1,1,0.6,True,True,0.9032452133809993,1,True,0.8837676645955105,1,1,0.9359747,1
NCT06630247,"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors",TERMINATED,PHASE1,INTERVENTIONAL,9.0,ACTUAL,2024-10-17,2025-05-07,Exelixis,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","XL495, ADC cytotoxic agents","Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis",,,,,False,202.0,True,False,1.0,False,False,True,2,False,Small (<30),0,9.0,2.302585092994046,1,0,0.56,False,False,0.23458988414919682,1,False,0.19987536227752037,1,0,0.15658699,1
NCT07152938,"Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West Bank","The Effect of Using Augmented Virtual Reality on Pain, Stress, Anxiety, and Self-Efficacy Among Adult Cancer Patients Undergoing Chemotherapy in the West Bank",COMPLETED,,INTERVENTIONAL,150.0,ACTUAL,2023-06-01,2023-10-30,Arab American University (Palestine),OTHER,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,AVR Group (Chemotherapy + AVR),"Cancer and Chemotherapy Related Anemia, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)",,,,,False,151.0,True,False,-1.0,True,False,False,1,True,Large (100-300),0,150.0,5.017279836814924,1,1,0.6,True,True,0.7118380365269364,1,True,0.9082288703441772,1,1,0.974497,1
NCT04736576,Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy,"Prospective, Multicenter, Observational Study to Evaluate Patient-reported Outcome and Physical Activity Using Smartphone-based Application and Wearable Device in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy",COMPLETED,,INTERVENTIONAL,99.0,ACTUAL,2021-02-24,2023-03-24,Pfizer,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DEVICE,Wearable device,Breast Cancer,,,,,False,758.0,True,False,-1.0,False,False,True,1,True,Medium (30-100),0,99.0,4.605170185988092,0,0,0.6,True,True,0.8597267907703001,1,True,0.7164716782610694,1,1,0.7506994,1
NCT04941300,ColoRectal Cancer Screening for Southern California Community Health Centers,CRC-HUB-SPOKE: A ColoRectal Cancer Screening Hub for Southern California Community Health Centers,COMPLETED,PHASE3,INTERVENTIONAL,55999.0,ACTUAL,2021-06-08,2024-08-31,"University of California, San Diego",OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Mailed FIT Outreach, Standardized navigation",Colorectal Cancer,,,,,False,1180.0,True,False,3.0,True,False,False,2,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.77,True,True,0.7149696345421428,1,True,0.8543108863368393,1,1,0.88382465,1
NCT02563080,Pancreatic Exocrine Insufficiency in Acute Pancreatitis,Development of Pancreatic Exocrine Insufficiency After Moderately Severe or Severe Acute Pancreatitis,COMPLETED,,OBSERVATIONAL,50.0,ACTUAL,2015-09-01,2022-02-01,Helsinki University Central Hospital,OTHER,,,,,,"Exocrine Pancreatic Insufficiency, Acute Pancreatitis",,,,,False,2345.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.8108310616507344,1,True,0.708767832390021,1,1,0.7270131,1
NCT01015222,"Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies","A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel + or - Methylnaltrexone in Patients With Advanced Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,122.0,ACTUAL,2009-11-01,2021-05-27,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Dasatinib, Bevacizumab, Paclitaxel",Advanced Cancer,,,,,False,4225.0,True,False,1.0,False,False,False,3,True,Large (100-300),1,122.0,4.812184355372417,1,1,0.56,True,True,0.8073518167907087,1,True,0.8694636938282099,1,1,0.87687075,1
NCT02153450,Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,A Pilot Trial of Stereotactic Body Radiation Therapy and Metformin for Borderline-Resectable and Locally-Advanced Pancreatic Adenocarcinomas,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,8.0,ACTUAL,2015-05-08,2020-06-13,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","metformin hydrochloride, stereotactic radiosurgery","Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer",,,,,False,1863.0,True,False,0.5,False,False,False,2,True,Small (<30),0,8.0,2.19722457733622,1,0,0.57,True,False,0.28893101283590283,0,False,0.4176313870680866,0,0,0.38422737,0
NCT03923504,Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx,Improving Exercise Capacity With a Tailored Physical Activity Intervention in Lymphoma and Breast Cancer Patients Undergoing Treatment,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2019-05-10,2022-04-18,Virginia Commonwealth University,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Physical Activity Intervention (PAI), Healthy Living Control","Hodgkin Lymphoma, Non-hodgkin Lymphoma, Lymphoma, Breast Cancer",,,,,False,1074.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,12.0,2.5649493574615367,2,0,0.6,True,False,0.2970115022202133,0,False,0.4120982440023821,0,0,0.357645,0
NCT00880282,Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment,A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,39.0,ACTUAL,2009-04-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, OTHER, OTHER","cixutumumab, temsirolimus, pharmacological study, laboratory biomarker analysis","Unspecified Childhood Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Medium (30-100),0,39.0,3.688879454113936,1,0,0.56,True,True,0.6236819806210215,1,True,0.6749651817670612,1,1,0.6568074,1
NCT05872503,Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy,Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy,TERMINATED,,OBSERVATIONAL,3.0,ACTUAL,2024-03-20,2024-09-10,National Cancer Institute (NCI),NIH,,,,,,"Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer, Prostatic Neoplasms",,,,,False,174.0,True,False,-1.0,False,False,False,0,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.6,False,False,0.1474382707526661,1,False,0.19898499051697374,1,0,0.26642358,1
NCT03699579,Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC,"Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan",COMPLETED,,OBSERVATIONAL,28.0,ACTUAL,2019-02-22,2019-06-23,Ipsen,INDUSTRY,,,,,,"Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma",,,,,False,121.0,True,False,-1.0,False,False,True,0,True,Small (<30),0,28.0,3.367295829986474,0,0,0.6,True,True,0.5956918020890716,1,True,0.8112139023681898,1,1,0.9254793,1
NCT00003979,CHS 828 in Treating Patients With Solid Tumors,Phase I and Pharmacokinetics Study to Determine the Safety of CHS 828 in Patients With a Solid Tumor on a Single Oral Dose Repeated Every 3 Weeks,WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,1999-04-01,,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,,,,DRUG,CHS 828,"Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1303.0,True,False,1.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.56,False,False,0.036973834170945886,1,False,0.008324861631089793,1,0,0.0023865518,1
NCT02286726,"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia",Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed AML at High Risk for Induction Mortality,COMPLETED,PHASE2,INTERVENTIONAL,56.0,ACTUAL,2015-05-04,2020-01-22,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, DRUG","Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine","Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia",,,,,False,1724.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,56.0,4.04305126783455,2,0,0.58,True,True,0.6182089396128079,1,True,0.6943739768945725,1,1,0.6773203,1
NCT02358031,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,COMPLETED,PHASE3,INTERVENTIONAL,882.0,ACTUAL,2015-03-19,2023-07-19,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL","Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Cetuximab","Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer",,,,,False,3044.0,True,False,3.0,True,False,True,5,True,Very Large (300+),1,882.0,6.78332520060396,2,1,0.77,True,True,0.880700581467447,1,True,0.9699934845794108,1,1,0.977985,1
NCT01801163,A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),A Phase Ib Study of Stereotactic Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2012-02-01,2014-10-01,Indiana University,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","Sorafenib, Stereotactic radiotherapy",Hepatocellular Carcinoma,,,,,False,973.0,True,False,1.0,False,False,False,2,False,,1,0.0,0.0,1,0,0.56,False,False,0.02751776559097147,1,False,0.005933123123123648,1,0,0.0030072953,1
NCT05712811,Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts,Cryotherapy Versus Topical Tricholoacetic Acid 90% in Treatment of Common Warts,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2022-06-01,2022-11-30,Combined Military Hospital Abbottabad,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","CRYOTHERAPY, Tricholoracetic acid",Warts,,,,,False,182.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,2,0,0.6,True,True,0.6494675235809604,1,True,0.8800806138264896,1,1,0.9572484,1
NCT05061784,Routine Transcervical Thymectomy in MEN-1 Patients,Revisiting the Evidence for Routine Transcervical Thymectomy for the Prevention of Thymic Carcinoid Tumours in MEN-1 Patients a Case Series,COMPLETED,,OBSERVATIONAL,7.0,ACTUAL,2021-07-14,2021-08-20,"National University Health System, Singapore",OTHER,,,,PROCEDURE,"Routine thymectomy, which has been performed","Multiple Endocrine Neoplasia Type 1 (MEN-1), Thymic Carcinoid",,,,,False,37.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,7.0,2.079441541679836,0,0,0.6,True,False,0.2596794370322379,0,True,0.5425818831713642,1,1,0.87118167,1
NCT05041946,"Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial","Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial",COMPLETED,PHASE3,INTERVENTIONAL,112.0,ACTUAL,2003-07-16,2021-11-19,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,SINGLE_GROUP,DOUBLE,"DRUG, OTHER","Methylphenidate, Placebo (Sugar Pill)","Fatigue, Cancer",,,,,False,6701.0,True,False,3.0,True,True,False,2,True,Large (100-300),0,112.0,4.727387818712341,3,1,0.77,True,True,0.7637969832103586,1,True,0.8206063511947076,1,1,0.8936302,1
NCT01331447,Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions,"A Pilot Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions",COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2004-05-01,2004-05-01,Roxane Laboratories,INDUSTRY,RANDOMIZED,CROSSOVER,NONE,DRUG,exemestane,Breast Cancer,,,,,False,0.0,True,False,-1.0,True,False,True,1,True,Small (<30),1,12.0,2.5649493574615367,1,0,0.6,True,False,0.28799348555593807,0,True,0.522586333813729,1,1,0.60623324,1
NCT01349569,Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission,COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2012-01-01,2016-10-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, BIOLOGICAL","Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13",Multiple Myeloma,,,,,False,1735.0,True,False,2.0,False,False,False,3,True,Small (<30),0,19.0,2.995732273553991,1,0,0.58,True,False,0.4297936347476446,0,True,0.5816611759074554,1,1,0.5776258,1
NCT00967863,Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18),Phase III Study Comparing Irradiation at a Dose of 80 Gy to Irradiation at 70 Gy in Unfavorable Prostate Cancers Associated With Prolonged Hormonal Therapy,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,500.0,ESTIMATED,2008-10-01,2026-10-01,UNICANCER,OTHER,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION","3-dimensional conformal radiation therapy, intensity-modulated radiation therapy",Prostate Cancer,,,,,False,6574.0,False,False,-1.0,True,False,False,2,True,Very Large (300+),0,500.0,6.2166061010848646,2,1,0.6,True,True,0.9585907019899909,1,True,0.9069629952263871,1,1,0.94835365,1
NCT03639935,Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,COMPLETED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2019-03-28,2024-04-30,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Rucaparib, Nivolumab",Biliary Tract Cancer,,,,,False,1860.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,32.0,3.49650756146648,1,0,0.58,True,True,0.5685781456570054,1,True,0.7325186785321125,1,1,0.776906,1
NCT04189107,"Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS","An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea",COMPLETED,PHASE3,INTERVENTIONAL,18.0,ACTUAL,2020-08-18,2022-11-09,"Rigshospitalet, Denmark",OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Dexamethasone, Placebo","Analgesia, Surgery, Cancer of Head and Neck, Oropharyngeal Cancer, Carcinoma of Unknown Primary, Pain, Postoperative, Postoperative Pain",,,,,False,813.0,True,False,3.0,True,True,False,2,True,Small (<30),0,18.0,2.9444389791664403,3,0,0.77,True,False,0.2507523749742482,0,False,0.29965020383579893,0,0,0.23933299,0
NCT02536794,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2016-01-14,2021-01-22,Northwestern University,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, OTHER, OTHER, BIOLOGICAL","Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study, Tremelimumab","Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer",,,,,False,1835.0,True,False,2.0,False,False,False,4,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.58,True,True,0.5475602403277715,1,True,0.7371304043392432,1,1,0.82040167,1
NCT00439270,Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer,Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer,COMPLETED,PHASE1,INTERVENTIONAL,49.0,ACTUAL,2007-07-01,2013-01-01,Bristol-Myers Squibb,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Dasatinib, Docetaxel",Metastatic Prostate Cancer,,,,,False,2011.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,49.0,3.912023005428146,1,0,0.56,True,True,0.7117127523383945,1,True,0.7985363276704439,1,1,0.8114546,1
NCT00492193,Early Post-Op Recovery After Partial Large Bowel Resection,"A Prospective, Observational, Multi-center Study Assessing Early Post-Operative Recovery Following Laparoscopic Partial Large Bowel Resection",COMPLETED,,OBSERVATIONAL,139.0,ACTUAL,2007-06-01,2008-05-01,University Hospitals Cleveland Medical Center,OTHER,,,,,,"Diverticulitis, Colon Polyps, Colorectal Cancer",,,,,False,335.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,139.0,4.941642422609304,0,1,0.6,True,True,0.7749934324920651,1,True,0.8705252779615748,1,1,0.79375494,1
NCT01836549,Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors,"A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma",TERMINATED,PHASE2,INTERVENTIONAL,43.0,ACTUAL,2013-03-01,2016-04-01,Pediatric Brain Tumor Consortium,NETWORK,,SINGLE_GROUP,NONE,DRUG,imetelstat sodium,"Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors",,,,,False,1127.0,True,False,2.0,False,False,False,1,False,Medium (30-100),0,43.0,3.784189633918261,0,0,0.58,False,True,0.6611466666194004,0,True,0.7394265943790156,0,1,0.7196947,0
NCT00002493,Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer,WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III,COMPLETED,PHASE3,INTERVENTIONAL,,,1992-05-01,,Gynecologic Oncology Group,NETWORK,,,,"DRUG, DRUG, RADIATION","cisplatin, doxorubicin hydrochloride, low-LET photon therapy","Endometrial Cancer, Psychosocial Effects of Cancer and Its Treatment",,,,,False,1303.0,True,False,3.0,False,False,False,3,True,,1,,,1,0,0.77,True,True,0.5556139549827526,1,True,0.8181381073472189,1,1,0.881869,1
NCT02026271,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma,"A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma",COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2015-06-01,2019-08-01,Alaunos Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG","Ad-RTS-hIL-12, veledimex","Glioblastoma Multiforme, Anaplastic Oligoastrocytoma",,,,,False,1522.0,True,False,1.0,False,False,True,2,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.56,True,True,0.649823737893084,1,True,0.6056956305583033,1,1,0.6661814,1
NCT02037542,A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer,A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer,COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2013-09-01,2016-05-01,Baptist Health South Florida,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Diet and exercise,Weight,,,,,False,973.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7338641496682157,1,True,0.8338042904918072,1,1,0.72706914,1
NCT02234297,Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery,A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2014-10-01,2016-03-01,Blaze Bioscience Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,BLZ-100,Glioma,,,,,False,517.0,True,False,1.0,False,False,True,1,True,Small (<30),0,17.0,2.8903717578961645,0,0,0.56,True,False,0.4328566779085566,0,True,0.7435325174548343,1,1,0.73901516,1
NCT01439490,FES-PET to Determine ER-expression in Epithelial Ovarian Cancer,Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,15.0,ACTUAL,2011-08-01,2014-02-01,University Medical Center Groningen,OTHER,,SINGLE_GROUP,SINGLE,OTHER,FES-PET,Epithelial Ovarian Cancer,,,,,False,915.0,True,False,2.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.58,True,False,0.3854445018980312,0,False,0.3976059733130795,0,0,0.4517518,0
NCT01484873,Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor,Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity,COMPLETED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2012-06-01,2015-03-01,Vanderbilt University Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,Exenatide,"Obesity, Overweight, Craniopharyngioma",,,,,False,1003.0,True,False,2.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.58,True,False,0.2983152045773234,0,False,0.2815638503231984,0,0,0.31432453,0
NCT03007212,Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis,,COMPLETED,PHASE4,INTERVENTIONAL,30.0,ACTUAL,2014-09-01,2015-09-01,Ain Shams University,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,transarterial chemoembolization versus the standard treatment with sorafinib,Hepatocellular Carcinoma (HCC),,,,,False,365.0,True,False,4.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.7,True,False,0.43356199243202753,0,True,0.6606256214838379,1,1,0.7625134,1
NCT06470490,Effect of Psycho-Educational Program and Relaxation Training on Resilience Among Women With Breast Cancer,"Effect of Psycho-Educational Program and Relaxation Training on Resilience, Self- Esteem and Psychological Distress Among Women With Breast Cancer",COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2024-01-07,2024-05-02,Abeer Abd Elwahed Almowafy,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,psychoeducational,Women With Breast Cancer,,,,,False,116.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,1,1,0.6,True,True,0.6191620470432764,1,True,0.9184711140247488,1,1,0.9830362,1
NCT00004003,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery,"A Study of Gemcitabine, Cisplatin, and 5-Fluorouracil in the Treatment of Advanced Pancreatic Cancer",COMPLETED,PHASE2,INTERVENTIONAL,30.0,ESTIMATED,1999-04-01,2003-08-01,Barbara Ann Karmanos Cancer Institute,OTHER,,,,"DRUG, DRUG, DRUG","cisplatin, fluorouracil, gemcitabine hydrochloride",Pancreatic Cancer,,,,,False,1583.0,True,False,2.0,False,False,False,3,True,Small (<30),1,30.0,3.4339872044851463,1,0,0.58,True,True,0.532610180019334,1,True,0.7237372262332369,1,1,0.7535707,1
NCT00086723,In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer,"Phase I/II Trial of In Vivo Angiostatin Generation With Tissue Plasminogen Activator (tPA) and Captopril in Patients With Progressive, Metastatic Cancer",COMPLETED,PHASE1,INTERVENTIONAL,,,2003-07-01,2006-01-01,Northwestern University,OTHER,,,,"BIOLOGICAL, DRUG","recombinant tissue plasminogen activator, captopril","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,915.0,True,False,1.0,False,False,False,2,True,,0,,,1,0,0.56,True,True,0.6690482702206221,1,True,0.7074442219345916,1,1,0.595682,1
NCT01576289,Analysis of Biopsies From the Upper Gastrointestinal Tract,Clinical Evaluation and Histological Analysis of Biopsies From the Upper Gastrointestinal Tract of Patients With and Without Symptoms of Reflux Disease (histoGERD Trial),COMPLETED,,OBSERVATIONAL,600.0,ESTIMATED,2011-11-01,2012-05-01,Medical University of Graz,OTHER,,,,OTHER,Histological analysis,"Gastroesophageal Reflux Disease, Gastritis",,,,,False,182.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,600.0,6.398594934535208,0,1,0.6,True,True,0.924900839538441,1,True,0.9702191949903135,1,1,0.9876736,1
NCT00486213,Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer,Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS),TERMINATED,PHASE3,INTERVENTIONAL,210.0,ACTUAL,2007-06-01,2014-08-01,"National Cancer Centre, Singapore",OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DIETARY_SUPPLEMENT, OTHER","pyridoxine hydrochloride, Placebo","Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2618.0,True,False,3.0,True,True,False,2,False,Large (100-300),0,210.0,5.351858133476067,3,1,0.77,False,True,0.7211762283245688,0,True,0.6460399962162804,0,0,0.47538158,1
NCT00169611,NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate,Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo,COMPLETED,PHASE4,INTERVENTIONAL,80.0,ESTIMATED,2004-01-01,2011-01-01,Hospices Civils de Lyon,OTHER,RANDOMIZED,CROSSOVER,DOUBLE,DRUG,methylphenidate,Neurofibromatosis Type 1,,,,,False,2557.0,True,False,4.0,True,True,False,1,True,Medium (30-100),0,80.0,4.394449154672439,2,0,0.7,True,True,0.7284924633120023,1,True,0.7266157302734669,1,1,0.7460948,1
NCT00006015,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer","Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy",TERMINATED,PHASE2,INTERVENTIONAL,26.0,ACTUAL,2000-05-01,2003-02-01,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG","trastuzumab, fluorouracil, leucovorin calcium, oxaliplatin",Colorectal Cancer,,,,,False,1006.0,True,False,2.0,False,False,False,4,False,Small (<30),1,26.0,3.295836866004329,1,0,0.58,False,False,0.4603731923544681,1,False,0.35146013513640834,1,0,0.37923604,1
NCT02067143,MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate,National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy,COMPLETED,PHASE2,INTERVENTIONAL,204.0,ACTUAL,2014-05-20,2020-12-07,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE","Prephase PDN + CY, Cycle 1 Induction, Cycle 2 Induction / Early consolidation, Cycle 3 Early consolidation, Cycle 4 Consolidation, Cycle 5 Consolidation, Cycle 6 Consolidation, Cycle 7 Consolidation, Cycle 8 Reinduction, Maintenance, Allogeneic SCT or Autologous SCT","Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo, Secondary, Low-dose Corticosteroids Pretreatment",,,,,False,2393.0,True,False,2.0,False,False,False,11,True,Large (100-300),0,204.0,5.3230099791384085,1,1,0.58,True,True,0.7817186853957787,1,True,0.7106498418490049,1,1,0.7199379,1
NCT03827850,FGFR Inhibitor in FGFR Dysregulated Cancer,A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.,TERMINATED,PHASE2,INTERVENTIONAL,22.0,ACTUAL,2019-03-25,2022-10-14,Lung Cancer Group Cologne,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,ERDAFITINIB,"Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV",,,,,False,1299.0,True,False,2.0,False,False,False,1,False,Small (<30),0,22.0,3.1354942159291497,0,0,0.58,False,True,0.5016247613209633,0,False,0.48101338699741203,1,0,0.4183712,1
NCT00038168,Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma,Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate,COMPLETED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2000-06-01,2003-01-01,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Estramustine, Taxol",Prostate Cancer,,,,,False,944.0,True,False,1.0,False,False,False,2,True,Small (<30),0,14.0,2.70805020110221,1,0,0.56,True,False,0.3572483830426949,0,False,0.422612870897446,0,0,0.4356463,0
NCT00904787,Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies,A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2009-04-01,2011-05-01,"CASI Pharmaceuticals, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,ENMD-2076,Relapsed or Refractory Hematological Malignancies,,,,,False,760.0,True,False,1.0,False,False,True,1,True,Small (<30),0,27.0,3.332204510175204,0,0,0.56,True,True,0.5641649278210108,1,True,0.5839392119575618,1,1,0.50461346,1
NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease","A Randomized Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",TERMINATED,PHASE3,INTERVENTIONAL,98.0,ACTUAL,2016-02-24,2020-03-23,Centre Hospitalier Universitaire de Besancon,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Letrozole, Anastrozole, Vinorelbine",Breast Cancer,,,,,False,1489.0,True,False,3.0,True,False,False,3,False,Medium (30-100),1,98.0,4.59511985013459,2,0,0.77,False,True,0.6527625509021812,0,True,0.6274231213770417,0,1,0.72428536,0
NCT03220100,Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL,Pilot Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL,TERMINATED,,INTERVENTIONAL,11.0,ACTUAL,2017-07-18,2018-01-29,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,OTHER,Stepped Palliative Care,Lung Cancer,,,,,False,195.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,11.0,2.4849066497880004,0,0,0.6,False,False,0.3604642385182506,1,True,0.6468291665670524,0,1,0.68556684,0
NCT00381706,Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,"Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer",COMPLETED,PHASE2,INTERVENTIONAL,245.0,ACTUAL,2006-09-15,2014-10-15,Alliance for Clinical Trials in Oncology,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG","cetuximab, ECF, IC, FOLFOX",Esophageal Cancer,,,,,False,2952.0,True,False,2.0,True,False,False,4,True,Large (100-300),1,245.0,5.5053315359323625,2,1,0.58,True,True,0.7913614943191358,1,True,0.9105983365717087,1,1,0.95210546,1
NCT03229122,Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA,Japan CHARLOTTE: Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA,COMPLETED,,OBSERVATIONAL,446.0,ESTIMATED,2016-12-26,2018-07-06,AstraZeneca,INDUSTRY,,,,,,Ovarian Cancer,,,,,False,557.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,446.0,6.102558594613569,0,1,0.6,True,True,0.9148987326528956,1,True,0.9600776539464794,1,1,0.9612269,1
NCT02312401,Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy,Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,120.0,ACTUAL,2014-12-01,2026-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DEVICE, DEVICE, PROCEDURE","multi-parametric MRI(MP-MRI), dynamic contrast-enhanced MRI (DCE), biopsy",Prostate Cancer,,,,,False,4383.0,False,False,2.0,False,False,False,3,True,Large (100-300),0,120.0,4.795790545596741,1,1,0.58,True,True,0.7901567946419152,1,True,0.8278360874656369,1,1,0.9031254,1
NCT02252484,Energy Balance for Prostate Cancer Survivorship,Energy Balance for Prostate Cancer Survivorship,COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2014-10-01,2016-06-01,"Jill Hamilton-Reeves, PhD RD LD",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Weight Loss Program, Standard of Care",Prostate Cancer,,,,,False,609.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,20.0,3.044522437723423,1,0,0.6,True,False,0.47796433954361534,0,True,0.5763580797383842,1,1,0.61700475,1
NCT00014170,Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma),COMPLETED,PHASE2,INTERVENTIONAL,92.0,ACTUAL,2001-03-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, OTHER, OTHER, OTHER, PROCEDURE","gefitinib, pharmacological study, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment","Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma",,,,,False,1303.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,92.0,4.532599493153256,1,0,0.58,True,True,0.7680913492586673,1,True,0.7331234512992133,1,1,0.6822309,1
NCT01022515,Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma,Clinical Application of New Pheochromocytoma Markers: INSERM Pilot Study of the Specificity of Elevated Plasma EM66 Concentrations in Patients With Pheochromocytoma or Paraganglioma Compared to Patients With Essential Hypertension,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2008-11-01,2013-12-01,"University Hospital, Rouen",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","plasma EM66 & CgA levels assessment, usual follow up with regular EM66 & Cga levels assessment","Pheochromocytoma, Paraganglioma, Essential Hypertension",,,,,False,1856.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,60.0,4.110873864173311,1,0,0.6,True,True,0.7883580964193166,1,True,0.8454193498912823,1,1,0.829808,1
NCT01667198,Randomized Study of Train the Colonoscopy Leaders Course Versus Audit and Feedback on Colonoscopy Quality Indicators,Quality Improvement in Screening Colonoscopy - a Randomized Trial of Tailored Training Intervention Versus Simple Feedback on the Quality Indicators.,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2012-07-01,2012-12-01,Maria Sklodowska-Curie National Research Institute of Oncology,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, BEHAVIORAL","Train the leaders course, Audit and feedback",Colorectal Cancer,,,,,False,153.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,40.0,3.713572066704308,2,0,0.6,True,True,0.546736637513969,1,True,0.903020189367244,1,1,0.90156347,1
NCT03608878,Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype,"Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype",TERMINATED,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2019-04-26,2019-12-31,Chang Gung Memorial Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, PROCEDURE","adagloxad simolenin/OBI-821, TACE",Hepatocellular Carcinoma,,,,,False,249.0,True,False,2.0,True,False,False,2,False,Small (<30),0,5.0,1.791759469228055,2,0,0.58,False,False,0.09701365517383531,1,False,0.05357666577555878,1,0,0.033907402,1
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,"Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-Α2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study",COMPLETED,PHASE1,INTERVENTIONAL,30.0,ACTUAL,2013-05-21,2017-02-27,Diwakar Davar,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI",Melanoma,,,,,False,1378.0,True,False,1.0,True,False,False,2,True,Small (<30),1,30.0,3.4339872044851463,2,0,0.56,True,False,0.477492171413712,0,True,0.615995162713432,1,1,0.6688136,1
NCT04089449,"A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas","A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas",COMPLETED,PHASE1,INTERVENTIONAL,86.0,ACTUAL,2019-11-06,2023-03-28,Prelude Therapeutics,INDUSTRY,,SEQUENTIAL,NONE,DRUG,PRT811,"Advanced Solid Tumor, Recurrent Glioma",,,,,False,1238.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,86.0,4.465908118654584,0,0,0.56,True,True,0.8269210152479065,1,True,0.691950579611045,1,1,0.69542277,1
NCT00660218,"A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",COMPLETED,PHASE1,INTERVENTIONAL,53.0,ACTUAL,2008-03-01,2017-04-01,State University of New York - Upstate Medical University,OTHER,,SINGLE_GROUP,NONE,"DRUG, BIOLOGICAL, RADIATION","paclitaxel poliglumex, cetuximab, radiation therapy (IMRT or 3D-CRT)","Carcinoma, Squamous Cell",,,,,False,3318.0,True,False,1.0,False,False,False,3,True,Medium (30-100),1,53.0,3.9889840465642745,1,0,0.56,True,True,0.7750602278089892,1,True,0.8426667564856974,1,1,0.8885713,1
NCT01418118,Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery,An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study,COMPLETED,PHASE4,INTERVENTIONAL,25.0,ACTUAL,2008-10-01,2010-02-01,Oxford University Hospitals NHS Trust,OTHER,RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Epinephrine, Norepinephrine, Dobutamine, Dopexamine","Oral Cancer, Head and Neck Cancer, Free Flap, Hypotension",,,,,False,488.0,True,False,4.0,True,False,False,4,True,Small (<30),0,25.0,3.258096538021482,2,0,0.7,True,False,0.26298186532221746,0,False,0.40465473649074035,0,0,0.3349034,0
NCT04407611,Scalable Communication Modalities for Returning Genetic Research Results,Testing Scalable Communication Modalities for Returning Breast Cancer Genetic Research Results to African American Women,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,932.0,ACTUAL,2023-03-06,2026-03-01,Boston University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, BEHAVIORAL","Online modality, Genetic counselor follow-up","Hereditary Breast and Ovarian Cancer, Lynch Syndrome",,,,,False,1091.0,False,False,-1.0,True,False,False,2,True,Very Large (300+),0,932.0,6.838405200847344,2,1,0.6,True,True,0.9191048353563036,1,True,0.8485008424219719,1,1,0.82334214,1
NCT00849251,"Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma","Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)",TERMINATED,PHASE1,INTERVENTIONAL,31.0,ACTUAL,2008-11-01,2015-06-01,University of Washington,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, bortezomib, dexamethasone","Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma",,,,,False,2403.0,True,False,1.0,False,False,False,4,False,Medium (30-100),1,31.0,3.4657359027997265,1,0,0.56,False,True,0.6145124877724102,0,True,0.7716122795635946,0,1,0.83481795,0
NCT00236002,Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L ),"A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer",TERMINATED,PHASE3,INTERVENTIONAL,182.0,ACTUAL,2005-07-01,2009-08-01,Canadian Urology Research Consortium,OTHER,RANDOMIZED,PARALLEL,DOUBLE,DRUG,Alendronate,Osteoporosis,,,,,False,1492.0,True,False,3.0,True,True,False,1,False,Large (100-300),0,182.0,5.209486152841421,2,1,0.77,False,True,0.6866777799427771,0,True,0.6932989158264949,0,1,0.77502507,0
NCT00899951,Studying Fentanyl in Patients With Cancer,Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients,TERMINATED,,OBSERVATIONAL,2.0,ACTUAL,2007-10-01,2009-07-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,,,"DRUG, OTHER","fentanyl citrate, pharmacological study","Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,639.0,True,False,-1.0,False,False,False,2,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.6,False,False,0.09965767038862837,1,False,0.07888240253905793,1,0,0.047491368,1
NCT01132573,"Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia","A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults With Relapsed and Refractory Disease",COMPLETED,PHASE1,INTERVENTIONAL,27.0,ACTUAL,2010-04-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, OTHER","entinostat, clofarabine, pharmacological study, laboratory biomarker analysis","Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia",,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Small (<30),0,27.0,3.332204510175204,1,0,0.56,True,True,0.530424135145335,1,False,0.49136546714045015,0,1,0.5449715,1
NCT00095017,Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083),"A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2004-11-01,,Organon and Co,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,DRUG,"MK0663, etoricoxib / Duration of Treatment: 4 weeks",Bone Neoplasms,,,,,False,1303.0,True,False,2.0,True,True,True,1,False,,0,0.0,0.0,2,0,0.58,False,False,0.02570126701001277,1,False,0.006990865629676689,1,0,0.0030945542,1
NCT02546986,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,"A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer",COMPLETED,PHASE2,INTERVENTIONAL,100.0,ACTUAL,2015-10-09,2025-07-07,Celgene,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","CC-486, Pembrolizumab, Placebo","Carcinoma, Non-Small-Cell Lung",,,,,False,3559.0,True,False,2.0,True,True,True,3,True,Medium (30-100),1,100.0,4.61512051684126,3,1,0.58,True,True,0.671748738905868,1,True,0.8380545594665189,1,1,0.9228136,1
NCT01067274,ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML),"A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)",WITHDRAWN,PHASE3,INTERVENTIONAL,0.0,ACTUAL,2010-04-01,,Acute Leukemia French Association,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Vesanoid (ATRA), AZACITIDINE (VIDAZA), CYTARABINE",Acute Myeloid Leukemia,,,,,False,1303.0,True,False,3.0,True,False,False,3,False,,1,0.0,0.0,2,0,0.77,False,False,0.012379027186337014,1,False,0.004536780799456383,1,0,0.0025718685,1
NCT05090215,Supervised Exercise for Post-surgery Colorectal Cancer Patients,A Randomised Controlled Trial to Assess the Efficacy of a Postoperative Supervised Exercise Programme in Patients Who Have Undergone Elective Curative Surgery for Colorectal Cancer.,COMPLETED,,INTERVENTIONAL,21.0,ACTUAL,2022-05-13,2024-01-27,University of Nottingham,OTHER,RANDOMIZED,PARALLEL,SINGLE,"BEHAVIORAL, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, BEHAVIORAL","Aerobic and resistance training 12 week exercise programme, Venous blood sampling, Muscle Ultrasound, Cardiopulmonary exercise testing (CPET), Quality of life questionnaire completion","Colorectal Cancer, Colorectal Neoplasms",,,,,False,624.0,True,False,-1.0,True,False,False,5,True,Small (<30),0,21.0,3.091042453358316,2,0,0.6,True,False,0.3902471529683255,0,False,0.49905921568279266,0,0,0.41290295,0
NCT02780128,Next Generation Personalized Neuroblastoma Therapy,Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial),TERMINATED,PHASE1,INTERVENTIONAL,66.0,ACTUAL,2016-07-01,2022-08-01,Yael P Mosse,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, GENETIC, PROCEDURE, PROCEDURE, OTHER, OTHER, OTHER, OTHER, BEHAVIORAL, OTHER, OTHER, DRUG, DRUG","Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib","Neuroblastoma, Cancer",,,,,False,2222.0,True,False,1.0,False,False,False,13,False,Medium (30-100),1,66.0,4.204692619390966,1,0,0.56,False,True,0.7373662375244876,0,True,0.8812173551596513,0,1,0.77697057,0
NCT03212404,Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers,"A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,272.0,ACTUAL,2017-09-20,2025-12-01,"Checkpoint Therapeutics, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,CK-301 (cosibelimab),"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Classical Hodgkin Lymphoma, Cutaneous Squamous Cell Carcinoma, Non Hodgkin Lymphoma, Endometrial Cancer",,,,,False,2994.0,False,False,1.0,False,False,True,1,True,Large (100-300),0,272.0,5.60947179518496,0,1,0.56,True,True,0.9019460043645586,1,True,0.8002947386718908,1,1,0.870639,1
NCT03647163,Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors,Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,33.0,ACTUAL,2019-04-09,2025-09-30,"Vyriad, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab","Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)",,,,,False,2366.0,False,False,1.0,False,False,True,3,True,Medium (30-100),1,33.0,3.5263605246161616,1,0,0.56,True,True,0.6328174059034598,1,True,0.764230798662212,1,1,0.84835786,1
NCT06876584,The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy,The CT-based Deep Learning Model Outperforms Traditional Anatomical Classification Models in Preoperatively Predicting Complications and Risk Grade in Partial Nephrectomy,COMPLETED,,OBSERVATIONAL,1474.0,ACTUAL,2024-06-01,2025-02-28,Du Lingzhi,OTHER,,,,,,"Renal Cell Carcinoma (RCC), Renal Cyst",,,,,False,272.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1474.0,7.29641326877392,0,1,0.6,True,True,0.9536782086977317,1,True,0.9716043469491774,1,1,0.97150695,1
NCT03514654,MIAMI Safe Surgery for Multiple Breast Cancers,Can Patients With Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? A Randomised Controlled Feasibility Study.,COMPLETED,,INTERVENTIONAL,4.0,ACTUAL,2017-11-01,2020-10-31,"University College, London",OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","Mastectomy, Therapeutic Mammoplasty","Breast Cancer, Unilateral",,,,,False,1095.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,4.0,1.6094379124341005,2,0,0.6,True,False,0.1303089865727179,0,False,0.07603574639985883,0,0,0.042033855,0
NCT07022652,Influence of Hospital Volume on Mortality and Length of Hospital Stay After Oesophageal Cancer Resection in Switzerland,Influence of Hospital Volume on Mortality and Length of Hospital Stay After Oesophageal Cancer Resection in Switzerland: A Retrospective National Registry Study,COMPLETED,,OBSERVATIONAL,2880.0,ACTUAL,2013-01-01,2025-05-15,Cantonal Hospital of St. Gallen,OTHER,,,,PROCEDURE,Esophageal cancer resection,Esophageal Cancer,,,,,False,4517.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,2880.0,7.965892735084528,0,1,0.6,True,True,0.9781864562453382,1,True,0.966674567568474,1,1,0.89425516,1
NCT04220307,A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma,"A Single-arm, Open-label, Multicenter, Phase II Study of AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy",COMPLETED,PHASE2,INTERVENTIONAL,34.0,ACTUAL,2020-04-26,2023-03-09,Akeso,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,AK104,Nasopharyngeal Carcinoma,,,,,False,1047.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,34.0,3.555348061489413,0,0,0.58,True,True,0.6002610393562741,1,True,0.6238892425531861,1,1,0.5959165,1
NCT05867615,Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:,Radiometabolic Therapy (RMT) With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: a Basket Trial,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,83.0,ACTUAL,2023-05-25,2028-12-01,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,OTHER,,SINGLE_GROUP,NONE,DRUG,[177Lu]Lu-PSMA I&T,Cancer,,,,,False,2017.0,False,False,2.0,False,False,False,1,True,Medium (30-100),0,83.0,4.430816798843313,0,0,0.58,True,True,0.823178756861215,1,True,0.8109128175081796,1,1,0.7432469,1
NCT02612740,Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal,Deproteinized Bovine Bone for the Treatment of Alveolar Bone Critical Size Defect in Humans: A Randomized Clinical Pilot Study,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2010-04-01,2016-10-01,"University of Padova, School of Dental Medicine",OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DEVICE","Deproteinized bovine bone, granules of deproteinized bovine bone (Bio-Oss)",Maxillary Cyst,,,,,False,2375.0,True,False,2.0,True,False,False,2,True,Small (<30),0,20.0,3.044522437723423,2,0,0.58,True,False,0.39505074616842395,0,False,0.48989840979151894,0,0,0.4031036,0
NCT02982694,"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer",A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature,TERMINATED,PHASE2,INTERVENTIONAL,46.0,ACTUAL,2017-11-24,2020-11-27,Vall d'Hebron Institute of Oncology,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Atezolizumab, Bevacizumab","MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC",,,,,False,1099.0,True,False,2.0,False,False,False,2,False,Medium (30-100),1,46.0,3.8501476017100575,1,0,0.58,False,True,0.6216480019892018,0,True,0.6264919087815383,0,1,0.53175604,0
NCT00191373,A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease,Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,66.0,,2002-03-01,2007-07-01,Eli Lilly and Company,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Gemcitabine, Trastuzumab","Breast Neoplasms, Cancer of the Breast, Breast Cancer",,,,,False,1948.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,66.0,4.204692619390966,1,0,0.58,True,True,0.7407020485280126,1,True,0.7519753612025013,1,1,0.8309413,1
NCT03961919,Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant,Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),COMPLETED,PHASE2,INTERVENTIONAL,15.0,ACTUAL,2009-02-10,2021-12-31,Ciceri Fabio,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, PROCEDURE","Fludarabine, ARA-C, Treosulfan, Peripheral Blood Stem Cell Transplant","Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy",,,,,False,4707.0,True,False,2.0,False,False,False,4,True,Small (<30),0,15.0,2.772588722239781,1,0,0.58,True,True,0.5183520299966508,1,True,0.5407384815896444,1,1,0.69574195,1
NCT00002526,Chemotherapy in Treating Patients With Advanced Sarcoma,Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,1993-01-01,1995-09-01,Swiss Cancer Institute,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG","filgrastim, doxorubicin hydrochloride, ifosfamide","Ovarian Cancer, Sarcoma",,,,,False,973.0,True,False,2.0,False,False,False,3,True,Small (<30),1,20.0,3.044522437723423,1,0,0.58,True,False,0.3972990473784155,0,False,0.38165583218932675,0,0,0.45204383,0
NCT02593591,Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.,Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.,COMPLETED,,OBSERVATIONAL,40.0,ACTUAL,2015-11-06,2018-07-31,Samsung Medical Center,OTHER,,,,,,Colorectal Cancer,,,,,False,998.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7195126173333095,1,True,0.7893810000159021,1,1,0.7974162,1
NCT00330759,Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.",COMPLETED,PHASE3,INTERVENTIONAL,1779.0,ACTUAL,2006-06-01,2011-10-01,Amgen,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"BIOLOGICAL, DRUG","Denosumab, Zoledronic Acid",Bone Metastases,,,,,False,1948.0,True,False,3.0,True,True,True,2,True,Very Large (300+),0,1779.0,7.484368643286131,3,1,0.77,True,True,0.9031506337799707,1,True,0.658872924800764,1,1,0.7423372,1
NCT01445522,ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer,A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas,COMPLETED,PHASE1,INTERVENTIONAL,35.0,ACTUAL,2008-12-03,2012-07-03,National Cancer Institute (NCI),NIH,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","ABT-888, Cyclophosphamide","Neoplasms, Lymphoma",,,,,False,1308.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,35.0,3.58351893845611,1,0,0.56,True,True,0.6001384523956822,1,True,0.6656961449054444,1,1,0.6705649,1
NCT04504825,A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES),"A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,125.0,ACTUAL,2020-08-25,2027-10-22,"Alexion Pharmaceuticals, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, OTHER, DRUG","CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen",AL Amyloidosis,,,,,False,2614.0,False,False,3.0,True,True,True,3,True,Large (100-300),1,125.0,4.836281906951478,3,1,0.77,True,True,0.5952851699431088,1,True,0.7016099067476347,1,1,0.68826014,1
NCT02350673,A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors,"A Phase 1b, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v), That Targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an Antibody That Targets Programmed Death-Ligand 1 (PD-L1), Administered Intravenously, in Patients With Locally Advanced and/or Metastatic Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,70.0,ACTUAL,2015-06-29,2019-12-16,Hoffmann-La Roche,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","Atezolizumab, Cergutuzumab Amunaleukin",Solid Tumors,,,,,False,1631.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,70.0,4.262679877041316,1,0,0.56,True,True,0.7678434739665226,1,True,0.7744671260567102,1,1,0.70897704,1
NCT01700647,Breath Testing in Early and Late Larynx Cancer,Breath Testing in Laryngeal Cancer- Comparing in Situ Cancer and Advanced Cancer,COMPLETED,,OBSERVATIONAL,30.0,ACTUAL,2012-10-01,2014-10-01,Royal Brisbane and Women's Hospital,OTHER_GOV,,,,"OTHER, OTHER","Breath test- sampling using ENose, Laryngoscopy and bronchoscopy",Larynx Cancer,,,,,False,730.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.6,True,True,0.5884080031771327,1,True,0.7023578621483823,1,1,0.7046208,1
NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,7.0,ACTUAL,2016-02-23,2021-10-27,H. Lee Moffitt Cancer Center and Research Institute,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Tamoxifen, Ribociclib, Goserelin","Breast Cancer, Breast Cancer - Female, Breast Cancer - Male",,,,,False,2073.0,True,False,1.0,False,False,False,3,True,Small (<30),1,7.0,2.079441541679836,1,0,0.56,True,False,0.25255998307444943,0,False,0.4583020155637269,0,1,0.5299667,1
NCT02873533,Modification of the Quality of Life Based on Objective Geriatric Tests,Pilot Project - Prospective Longitudinal Cohort of Patients Over 70 Years With Malignant Solid Tumors: Modification of Quality of Life Based on Objective Geriatric Tests,COMPLETED,,INTERVENTIONAL,76.0,ACTUAL,2013-03-01,2019-04-01,Centre Antoine Lacassagne,OTHER,,SINGLE_GROUP,NONE,OTHER,geriatric care and longitudinal follow up,"Cancer, Elderly Patients",,,,,False,2222.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,76.0,4.343805421853684,0,0,0.6,True,True,0.8635445510749187,1,True,0.8732506421549046,1,1,0.69584984,1
NCT01751919,A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I),"A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400 mg (1 Tablet) and Glivec Film-coated Tablet 100 mg (4 Tablets) After Oral Administration in Healthy Male Subjects (Phase I)",COMPLETED,PHASE1,INTERVENTIONAL,37.0,ACTUAL,2012-05-01,2012-08-01,"Dong-A ST Co., Ltd.",INDUSTRY,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG","Imatinib mesylate tablet 400 mg, 1 Tablet, Glivec film-coated tablet 100 mg, 4 Tablets","Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor",,,,,False,92.0,True,False,1.0,True,False,True,2,True,Medium (30-100),1,37.0,3.6375861597263857,2,0,0.56,True,False,0.46530840691215064,0,True,0.6359254024309667,1,1,0.62649196,1
NCT02774538,Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort,Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort of Women Infected With Cervical HPV,COMPLETED,,INTERVENTIONAL,165.0,ACTUAL,2016-05-11,2022-04-01,Institut de Cancérologie de Lorraine,OTHER,,SINGLE_GROUP,NONE,OTHER,Agreement between oral and cervical HPV infection,Human Papillomavirus-Related Cervical Carcinoma,,,,,False,2151.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,165.0,5.111987788356544,0,1,0.6,True,True,0.8538920697863779,1,True,0.9004587309560922,1,1,0.9182743,1
NCT01578356,Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery,Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2009-01-01,2012-10-31,"University Hospital, Ghent",OTHER,,,,,,Prostate Cancer,,,,,False,1399.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7546364602172835,1,True,0.8276618221886045,1,1,0.82397926,1
NCT00984997,Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors,Phase II Study of Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors,COMPLETED,PHASE2,INTERVENTIONAL,38.0,ACTUAL,1993-10-01,2015-06-01,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, RADIATION, DRUG, DRUG, RADIATION","Surgery, Chest Irradiation, Cisplatin, Etoposide, Prophylactic Cranial Irradiation",Lung Cancer,,,,,False,7913.0,True,False,2.0,False,False,False,5,True,Medium (30-100),1,38.0,3.6635616461296463,1,0,0.58,True,True,0.8393729656744888,1,True,0.913058499722268,1,1,0.96018577,1
NCT02784028,Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer,"Phase I Study Assessing Safety of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer",COMPLETED,,INTERVENTIONAL,18.0,ACTUAL,2014-12-01,2017-12-08,Institut du Cancer de Montpellier - Val d'Aurelle,OTHER,,SINGLE_GROUP,NONE,OTHER,SGM-101,Peritoneal Carcinomatosis,,,,,False,1103.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,18.0,2.9444389791664403,0,0,0.6,True,True,0.5285815251988991,1,True,0.6339950305813062,1,1,0.6376048,1
NCT00843531,RAD001 and Erlotinib in Patients With Neuroendocrine Tumors,A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors,TERMINATED,PHASE2,INTERVENTIONAL,17.0,ACTUAL,2009-06-25,2016-08-20,"University of California, San Francisco",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","RAD001, erlotinib",Neuroendocrine Tumors,,,,,False,2613.0,True,False,2.0,False,False,False,2,False,Small (<30),1,17.0,2.8903717578961645,1,0,0.58,False,False,0.4447636126618683,1,True,0.5180281993849054,0,0,0.4243405,1
NCT02826889,Assessing the Diagnostic Accuracy of Corrected Flow Time (FTc) and Pleth Variability Index (PVI) as Predictors of Fluid Responsiveness in Patients in the Prone Position Using the Jackson Table,,COMPLETED,,INTERVENTIONAL,58.0,ACTUAL,2016-05-24,2017-07-27,Yonsei University,OTHER,,SINGLE_GROUP,NONE,"DEVICE, DEVICE","Philips Intelivue MP70 monitor, Pleth Variability Index (PVI)","Elective Posterior Lumbar Spinal Fusion for Spinal Stenosis, Spondylolisthesis, Spinal Fractures, Scoliosis or Tumors",,,,,False,429.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,58.0,4.07753744390572,1,0,0.6,True,True,0.7276537194777639,1,True,0.8950635434087866,1,1,0.9369258,1
NCT00724568,"Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma","A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma",COMPLETED,PHASE1,INTERVENTIONAL,74.0,ACTUAL,2008-05-01,2014-09-03,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Lenalidomide, Bortezomib, Dexamethasone, Doxil",Multiple Myeloma,,,,,False,2316.0,True,False,1.0,False,False,False,4,True,Medium (30-100),0,74.0,4.31748811353631,1,0,0.56,True,True,0.7995713547186843,1,True,0.8172580682089199,1,1,0.69401675,1
NCT05103826,A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,A Phase I Study to Evaluate Safety 、Tolerability 、 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2021-10-25,2023-06-15,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SHR6390、Famitinib,ER+ / HER2- Advanced Breast Cancer,,,,,False,598.0,True,False,1.0,False,False,True,1,False,Small (<30),0,3.0,1.3862943611198906,0,0,0.56,False,False,0.13110505529183086,1,False,0.11606318826721372,1,0,0.069766276,1
NCT02997189,Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss,"A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer",TERMINATED,PHASE2,INTERVENTIONAL,12.0,ACTUAL,2016-11-15,2017-09-26,"Otonomy, Inc.",INDUSTRY,RANDOMIZED,PARALLEL,SINGLE,DRUG,OTO-104,Cisplatin Induced Hearing Loss,,,,,False,315.0,True,False,2.0,True,False,True,1,False,Small (<30),0,12.0,2.5649493574615367,1,0,0.58,False,False,0.23742855644303792,1,False,0.266163601593359,1,0,0.12927549,1
NCT01709539,"Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden","Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden",COMPLETED,,INTERVENTIONAL,388.0,ACTUAL,2012-10-01,2021-12-01,Region Skane,OTHER,NON_RANDOMIZED,PARALLEL,NONE,PROCEDURE,Diagnostiskt Centrum,Cancer,,,,,False,3348.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,388.0,5.963579343618446,0,1,0.6,True,True,0.9435836917036791,1,True,0.8968237814462396,1,1,0.82816815,1
NCT01536392,"Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation","Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation",COMPLETED,PHASE3,INTERVENTIONAL,76.0,ACTUAL,2012-03-01,2019-10-03,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, BEHAVIORAL, BEHAVIORAL","Granisetron, Ondansetron, Questionnaires, Study Drug Diary",Cancer of the Cervix,,,,,False,2772.0,True,False,3.0,True,False,False,4,True,Medium (30-100),0,76.0,4.343805421853684,2,0,0.77,True,True,0.6555945640918515,1,True,0.6999948222702238,1,1,0.6271163,1
NCT04631445,Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer,Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer,COMPLETED,,INTERVENTIONAL,32.0,ACTUAL,2020-12-02,2025-02-01,Translational Drug Development,OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,Ketogenic Diet,Metastatic Pancreatic Ductal Adenocarcinoma,,,,,False,1522.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,32.0,3.49650756146648,1,0,0.6,True,True,0.6100959743250114,1,True,0.6941697846303615,1,1,0.553072,1
NCT02165852,Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal Injection,A Prospective Comparative Study of Papillectomy,COMPLETED,PHASE3,INTERVENTIONAL,50.0,ACTUAL,2014-01-01,2015-10-01,Soon Chun Hyang University,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Papillectomy without injection, Papillectomy with injection",Ampulla of Vater Adenoma,,,,,False,638.0,True,False,3.0,True,False,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,2,0,0.77,True,False,0.45137656934718745,0,False,0.45341678855410833,0,0,0.36920494,0
NCT05395052,FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors,"A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,INTERVENTIONAL,5.0,ACTUAL,2022-05-31,2023-08-11,Fate Therapeutics,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, DRUG","FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab, IL-2","Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer",,,,,False,437.0,True,False,1.0,False,False,True,12,False,Small (<30),1,5.0,1.791759469228055,1,0,0.56,False,False,0.12743506054364542,1,False,0.1110339773920714,1,0,0.06203178,1
NCT03651037,Physical Activity Platform to Improve Bone Health in Cancer Survivors,Physical Activity Platform to Improve Bone Health in Cancer Survivors,COMPLETED,,INTERVENTIONAL,134.0,ACTUAL,2019-01-21,2020-03-01,Thrivors Inc,INDUSTRY,RANDOMIZED,PARALLEL,NONE,BEHAVIORAL,Thrivors+BH,"Breast Cancer, Physical Activity, Bone Health",,,,,False,405.0,True,False,-1.0,True,False,True,1,True,Large (100-300),0,134.0,4.90527477843843,1,1,0.6,True,True,0.6992889753131863,1,True,0.8068232276345023,1,1,0.84213686,1
NCT00019123,Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma,A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA,COMPLETED,PHASE2,INTERVENTIONAL,,,1996-04-01,2004-04-01,National Cancer Institute (NCI),NIH,,,,DRUG,thalidomide,Sarcoma,,,,,False,2922.0,True,False,2.0,False,False,False,1,True,,0,,,0,0,0.58,True,True,0.7646584674751425,1,True,0.9588514444988613,1,1,0.9533256,1
NCT05646797,A Study of ASP2074 in Adults With Solid Tumors,A Phase 1/1b Study of ASP2074 in Participants With Metastatic or Locally Advanced Solid Tumors,TERMINATED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2023-02-28,2024-10-17,"Astellas Pharma Global Development, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,DRUG,ASP2074,Advanced Solid Tumors,,,,,False,597.0,True,False,1.0,False,False,True,1,False,Small (<30),0,23.0,3.1780538303479458,0,0,0.56,False,True,0.5144426585539971,0,True,0.5321420846308034,0,0,0.45955294,1
NCT01426880,Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,595.0,ACTUAL,2011-08-01,2013-08-01,GBG Forschungs GmbH,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Carboplatin, background treatment","Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer",,,,,False,731.0,True,False,2.0,True,False,False,2,True,Very Large (300+),1,595.0,6.39024066706535,2,1,0.58,True,True,0.842501351331766,1,True,0.7233258675032848,1,1,0.58314466,1
NCT03342937,KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer,"A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.",COMPLETED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2018-01-11,2023-02-06,Duke University,OTHER,,SINGLE_GROUP,NONE,DRUG,Oxaliplatin+Capecitabine+Pembrolizumab,"Gastric Cancer, Esophagus Cancer",,,,,False,1852.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,36.0,3.610917912644224,0,0,0.58,True,True,0.646907901493382,1,True,0.8090888917673068,1,1,0.8510057,1
NCT04303091,The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients,Assessing the Feasibility and Benefits of a Physical Activity Intervention for Advanced Multiple Myeloma Patients,COMPLETED,,INTERVENTIONAL,19.0,ACTUAL,2018-03-02,2018-12-20,Dr. Nicole Culos-Reed,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Physical Activity for Advanced Cancer Treatment (PAACT),"Multiple Myeloma, Hematologic Neoplasms, Advanced Cancer",,,,,False,293.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.6,True,True,0.5003567308205473,1,True,0.708453470640999,1,1,0.65919316,1
NCT04396860,Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma,A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,159.0,ACTUAL,2020-09-01,2026-09-11,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, BIOLOGICAL, BIOLOGICAL, DEVICE, OTHER, OTHER, RADIATION, DRUG","Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide","Gliosarcoma, MGMT-Unmethylated Glioblastoma",,,,,False,2201.0,False,False,2.0,True,False,False,8,True,Large (100-300),1,159.0,5.075173815233827,2,1,0.58,True,True,0.6624001062694164,1,True,0.7633382661496482,1,1,0.83730626,1
NCT02416570,Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?,Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2015-04-01,2015-10-01,University of Nottingham,OTHER,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG","Clarithromycin, Placebo","Cachexia, Lung Cancer",,,,,False,183.0,True,False,2.0,True,True,False,2,False,Small (<30),0,1.0,0.6931471805599453,3,0,0.58,False,False,0.03494193793033749,1,False,0.06212831817071373,1,0,0.08038649,1
NCT04253262,A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer,A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,13.0,ACTUAL,2020-04-03,2027-01-01,Brown University,OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","Rucaparib, Copanlisib",Metastatic Castration-resistant Prostate Cancer,,,,,False,2464.0,False,False,1.0,False,False,False,2,True,Small (<30),0,13.0,2.6390573296152584,1,0,0.56,True,False,0.41437496780815375,0,False,0.4332070291473593,0,0,0.4362621,0
NCT01596751,Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,COMPLETED,PHASE1,INTERVENTIONAL,67.0,ACTUAL,2012-07-12,2019-07-05,"Hope Rugo, MD",OTHER,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","PLX3397, Eribulin",Metastatic Breast Cancer,,,,,False,2549.0,True,False,1.0,False,False,False,2,True,Medium (30-100),0,67.0,4.219507705176107,1,0,0.56,True,True,0.7973785175312766,1,True,0.8008600316953316,1,1,0.81498784,1
NCT02518061,11C-Methionine PET as Prognostic Marker of Gliomas,Role of 11C-Methionine PET for the Prognostic and Molecular Characterization of Gliomas Candidate to Surgery.,COMPLETED,,OBSERVATIONAL,145.0,ACTUAL,2015-07-01,2018-12-31,Istituto Clinico Humanitas,OTHER,,,,OTHER,No intervention,Glioma,,,,,False,1279.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,145.0,4.983606621708336,0,1,0.6,True,True,0.8107831671162367,1,True,0.8703749841695487,1,1,0.8482224,1
NCT03995875,Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC,Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC.,COMPLETED,,OBSERVATIONAL,529.0,ACTUAL,2019-07-25,2024-01-11,AstraZeneca,INDUSTRY,,,,,,"Carcinoma, Non-Small-Cell Lung",,,,,False,1631.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,529.0,6.272877006546167,0,1,0.6,True,True,0.9391545909811273,1,True,0.9204806624964101,1,1,0.82205635,1
NCT00350233,MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors,MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors,COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2006-05-01,2010-02-01,InSightec,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DEVICE,ExAblate 2000,Bone Metastases,,,,,False,1372.0,True,False,1.0,False,False,True,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.3481581536777017,0,False,0.39561963251977716,0,0,0.36804035,0
NCT03992352,Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704),"Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)",COMPLETED,,OBSERVATIONAL,1229.0,ACTUAL,2019-07-19,2023-05-30,Center for International Blood and Marrow Transplant Research,NETWORK,,,,DIAGNOSTIC_TEST,Age 60+ with planned HCT for Hematologic Malignancy,Hematologic Malignancy,,,,,False,1411.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,1229.0,7.114769448366463,0,1,0.6,True,True,0.960260060541048,1,True,0.9759380878760291,1,1,0.98516965,1
NCT02137096,Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma,"High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma",TERMINATED,PHASE3,INTERVENTIONAL,1.0,ACTUAL,2014-06-01,2017-05-09,University of Florida,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, PROCEDURE","Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation",Recurrent Nasopharynx Carcinoma,,,,,False,1073.0,True,False,3.0,False,False,False,4,False,Small (<30),1,1.0,0.6931471805599453,1,0,0.77,False,False,0.034232745942638844,1,False,0.13255624498550345,1,0,0.21428101,1
NCT01355302,E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer",TERMINATED,PHASE1,INTERVENTIONAL,7.0,ACTUAL,2011-11-01,2013-07-01,Eisai Inc.,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","E7050, cisplatin, capecitabine","Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer",,,,,False,608.0,True,False,1.0,True,False,True,3,False,Small (<30),1,7.0,2.079441541679836,2,0,0.56,False,False,0.14933000202804486,1,False,0.12419961543178705,1,0,0.086678624,1
NCT03618667,GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification,A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification,COMPLETED,PHASE2,INTERVENTIONAL,13.0,ACTUAL,2018-01-22,2022-04-28,Samsung Medical Center,OTHER,,SINGLE_GROUP,NONE,DRUG,GC1118,"Glioblastoma, Adult, EGFR Amplification",,,,,False,1557.0,True,False,2.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.58,True,False,0.38275769528086306,0,False,0.4202106307088098,0,1,0.5981324,1
NCT03330028,Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology,A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology,COMPLETED,PHASE1,INTERVENTIONAL,29.0,ACTUAL,2017-10-27,2023-04-18,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Dexamethasone, Diphenhydramine, Famotidine, Mitomycin C, Cisplatin, Paclitaxel",Diseases of Oesophagus Stomach and Duodenum,,,,,False,1999.0,True,False,1.0,False,False,False,6,True,Small (<30),1,29.0,3.4011973816621555,1,0,0.56,True,True,0.5675188121994869,1,True,0.7368773309437242,1,1,0.79492354,1
NCT00461149,Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly,Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly,COMPLETED,PHASE4,INTERVENTIONAL,50.0,,1995-01-01,2006-12-01,Federico II University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Octreotide-LAR,Acromegaly,,,,,False,4352.0,True,False,4.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.7,True,True,0.7494407560014443,1,True,0.8905034129731585,1,1,0.9576449,1
NCT04020679,The Goals of Care Initiative,A Hybrid Implementation-effectiveness Stepped Wedge Cluster Randomised Controlled Trial to Determine the Effectiveness of the Goals of Care Initiative,TERMINATED,,INTERVENTIONAL,220.0,ACTUAL,2019-06-11,2021-01-11,The Christie NHS Foundation Trust,OTHER,RANDOMIZED,SEQUENTIAL,SINGLE,BEHAVIORAL,Goals of Care Initiative,"Decision-Making Oncology, Chemotherapy Effect",,,,,False,580.0,True,False,-1.0,True,False,False,1,False,Large (100-300),0,220.0,5.3981627015177525,1,1,0.6,False,True,0.7973402961486629,0,True,0.8946306441363125,0,1,0.87963045,0
NCT00376519,Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases,Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells,TERMINATED,PHASE1,INTERVENTIONAL,3.0,ACTUAL,2007-05-01,2008-03-01,"Masonic Cancer Center, University of Minnesota",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE, RADIATION","cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation","Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis",,,,,False,305.0,True,False,1.0,False,False,False,7,False,Small (<30),1,3.0,1.3862943611198906,1,0,0.56,False,False,0.09184857098341964,1,False,0.059280679349682945,1,0,0.038502894,1
NCT00003707,Combination Chemotherapy in Treating Patients With Advanced Cancer,"A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer",COMPLETED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,1998-10-01,2002-11-01,The University of Texas Health Science Center at San Antonio,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","gemcitabine hydrochloride, tipifarnib","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,1492.0,True,False,1.0,False,False,False,2,True,Small (<30),1,22.0,3.1354942159291497,1,0,0.56,True,False,0.4903981869549237,0,True,0.5030244322948166,1,0,0.44182286,0
NCT02084134,Peri-Operative Steroid Management in Patients,The Use of Perioperative Steroids in Patients Undergoing Transsphenoidal Resection of Pituitary Tumors or Cysts,COMPLETED,,INTERVENTIONAL,43.0,ACTUAL,2012-03-01,2016-12-31,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,SINGLE,"DRUG, DRUG","hydrocortisone, dexamethasone","Pituitary Adenoma, Pituitary Diseases",,,,,False,1766.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,43.0,3.784189633918261,2,0,0.6,True,True,0.645365209965264,1,True,0.6710045776808901,1,1,0.6527365,1
NCT03872206,Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression,"A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy",COMPLETED,PHASE1,INTERVENTIONAL,95.0,ACTUAL,2019-04-16,2023-01-04,"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target",Advanced Cancers Associated With Mesothelin Expression,,,,,False,1359.0,True,False,1.0,False,False,True,3,True,Medium (30-100),0,95.0,4.564348191467836,1,0,0.56,True,True,0.8119784958416958,1,True,0.6889912236224124,1,1,0.6757292,1
NCT00960960,"A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer","A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer",COMPLETED,PHASE1,INTERVENTIONAL,71.0,ACTUAL,2009-08-01,2015-12-01,"Genentech, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Bevacizumab, Pictilisib, Letrozole, Paclitaxel, Trastuzumab",Breast Cancer,,,,,False,2313.0,True,False,1.0,False,False,True,5,True,Medium (30-100),1,71.0,4.276666119016055,1,0,0.56,True,True,0.7843634059629621,1,True,0.9007614353861755,1,1,0.863407,1
NCT05607602,Are Uterine Fibroids Pro-thrombotic?,Does the Presence of Uterine Fibroids Cause Changes in the Blood That Increase the Risk of Clots?,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,105.0,ESTIMATED,2022-10-17,2024-12-31,King's College Hospital NHS Trust,OTHER,,,,OTHER,Comparison of blood samples between the two groups,"Leiomyoma, Uterine, Thrombosis",,,,,False,806.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,105.0,4.663439094112067,0,1,0.6,True,True,0.7368254386580544,1,True,0.9073057536658786,1,1,0.8773832,1
NCT04718402,A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma,"A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric Carcinoma",TERMINATED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,2021-03-30,2022-05-30,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,"Mitoxantrone Hydrochloride Liposome, intravenous injection",Advanced Gastric Carcinoma,,,,,False,426.0,True,False,1.0,False,False,True,1,False,Small (<30),0,21.0,3.091042453358316,0,0,0.56,False,False,0.48204232049670087,1,True,0.5733038195974032,0,1,0.71075946,0
NCT01240408,E7080 Food Effect Study in Healthy Subjects,E7080 Food Effect Study in Healthy Subjects,COMPLETED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2010-07-01,,Eisai Inc.,INDUSTRY,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG","HOPE, HOPE",Cancer,,,,,False,1303.0,True,False,1.0,True,False,True,2,True,Small (<30),0,16.0,2.833213344056216,2,0,0.56,True,False,0.3259047462122196,0,True,0.5897682254240435,1,1,0.5794319,1
NCT00185081,Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging,Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-targeting Method and an In-Labeled Peptide,COMPLETED,PHASE1,INTERVENTIONAL,42.0,ESTIMATED,2005-07-01,2008-12-01,Radboud University Medical Center,OTHER,NON_RANDOMIZED,CROSSOVER,NONE,DRUG,Indium labeled IMP-205xm734,Colonic Neoplasms,,,,,False,1249.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.56,True,True,0.6943665871802239,1,True,0.7066778742154068,1,1,0.7516445,1
NCT02351765,ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers,"A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers",COMPLETED,PHASE1,INTERVENTIONAL,21.0,ACTUAL,2016-01-01,2019-03-01,The Christie NHS Foundation Trust,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Acelarin, Cisplatin","Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer",,,,,False,1155.0,True,False,1.0,False,False,False,2,True,Small (<30),1,21.0,3.091042453358316,1,0,0.56,True,False,0.46092647384852325,0,True,0.5198055270105726,1,0,0.42374536,0
NCT03998033,Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma,"An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose (""RP2D"") in Adults With Advanced Hepatocellular Carcinoma (""HCC"")",TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2019-05-30,2020-12-31,Eureka Therapeutics Inc.,INDUSTRY,,SEQUENTIAL,NONE,BIOLOGICAL,ET140202 autologous T cell product,"Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer",,,,,False,581.0,True,False,1.0,False,False,True,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.56,False,False,0.09894432054671422,1,False,0.07507012995594266,1,0,0.050258752,1
NCT00005957,Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer,A Phase III Study of Regional Radiation Therapy in Early Breast Cancer,COMPLETED,,INTERVENTIONAL,1832.0,ACTUAL,2000-03-09,2017-04-19,NCIC Clinical Trials Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION","Standard Breast Irradiation, Breast Radiation plus Regional Radiation",Breast Cancer,,,,,False,6250.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,1832.0,7.513709247839705,2,1,0.6,True,True,0.9763370147470497,1,True,0.8812959511623393,1,1,0.93154454,1
NCT02337205,"Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis","A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis",COMPLETED,PHASE1,INTERVENTIONAL,29.0,ACTUAL,2014-12-01,2016-03-01,"Athenex, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,KX2-391 Ointment,Actinic Keratosis,,,,,False,456.0,True,False,1.0,False,False,True,1,True,Small (<30),0,29.0,3.4011973816621555,0,0,0.56,True,True,0.5668856120314665,1,True,0.6385026201283183,1,1,0.60926145,1
NCT01234012,Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1,A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1,COMPLETED,PHASE1,INTERVENTIONAL,23.0,ACTUAL,2011-05-01,2014-03-01,"ImmunoFrontier, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,IMF-001,Solid Tumor,,,,,False,1035.0,True,False,1.0,False,False,True,1,True,Small (<30),0,23.0,3.1780538303479458,0,0,0.56,True,True,0.5371670295696945,1,True,0.5982404634895103,1,1,0.649687,1
NCT00774046,High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML,High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia,COMPLETED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2002-12-01,2011-03-01,University of Chicago,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Ara-C, Mitoxantrone, Etoposide","Myelodysplastic Syndrome, Acute Myeloid Leukemia",,,,,False,3012.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,32.0,3.49650756146648,1,0,0.58,True,True,0.6213509078777445,1,True,0.8584203447801724,1,1,0.89598244,1
NCT04621955,Observational Study of Home Administration of Carfilzomib,"Observational Study of Home Administration of Carfilzomib: Feasibility, Quality of Life and Description of the Process With Related Health-care Economics",WITHDRAWN,,OBSERVATIONAL,0.0,ACTUAL,2017-06-01,2018-11-01,Universitaire Ziekenhuizen KU Leuven,OTHER,,,,,,"Multiple Myeloma, Hematologic Diseases",,,,,False,518.0,True,False,-1.0,False,False,False,0,False,,0,0.0,0.0,0,0,0.6,False,False,0.03921791983581276,1,False,0.015272100828682132,1,0,0.002355986,1
NCT00265070,Trial of Iressa in Prostate Cancer Patients,"An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy",COMPLETED,PHASE2,INTERVENTIONAL,80.0,ACTUAL,2003-01-01,2011-08-01,AstraZeneca,INDUSTRY,RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Gefitinib,Prostate Cancer,,,,,False,3134.0,True,False,2.0,True,False,True,1,True,Medium (30-100),1,80.0,4.394449154672439,1,0,0.58,True,True,0.7948180379525414,1,True,0.8734736234270364,1,1,0.86140037,1
NCT02965144,Long Term Survivors of High-grade Glioma and Their Caregivers,Long-term Survivors of High-grade Glioma,COMPLETED,,OBSERVATIONAL,13.0,ACTUAL,2016-12-01,2017-09-01,"Rigshospitalet, Denmark",OTHER,,,,OTHER,no treatment,"Quality of Life, Brain Diseases, Depression, Physical Impairment",,,,,False,274.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.6,True,False,0.4038681532575951,0,True,0.6145175517841512,1,1,0.53150594,1
NCT00589472,Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer,Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET),COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2007-11-01,2010-06-01,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, DRUG, PROCEDURE, DRUG","Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat","Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer",,,,,False,943.0,True,False,2.0,False,False,False,6,True,Small (<30),1,19.0,2.995732273553991,1,0,0.58,True,False,0.3688049840268329,0,False,0.3394528044398715,0,0,0.34630892,0
NCT00532064,Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy,Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers,TERMINATED,,OBSERVATIONAL,55.0,ACTUAL,2007-09-12,2018-05-02,M.D. Anderson Cancer Center,OTHER,,,,"PROCEDURE, OTHER","Biospecimen Collection, Questionnaire Administration",Malignant Neoplasm,,,,,False,3885.0,True,False,-1.0,False,False,False,2,False,Medium (30-100),0,55.0,4.02535169073515,1,0,0.6,False,True,0.8384369044513263,0,True,0.8538396677353297,0,1,0.76680124,0
NCT00193232,Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer,A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer,COMPLETED,PHASE2,INTERVENTIONAL,50.0,,2004-05-01,2007-02-01,"SCRI Development Innovations, LLC",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","Docetaxel, Bortezomib",Prostate Cancer,,,,,False,1006.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.58,True,True,0.6374364798498563,1,True,0.6870698123757388,1,1,0.7349047,1
NCT01837563,Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer,Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer,TERMINATED,,OBSERVATIONAL,36.0,ACTUAL,2006-09-01,2015-09-01,Dartmouth-Hitchcock Medical Center,OTHER,,,,,,Locally Advanced Breast Cancer,,,,,False,3287.0,True,False,-1.0,False,False,False,0,False,Medium (30-100),0,36.0,3.610917912644224,0,0,0.6,False,True,0.787247520443359,0,True,0.5919659724722348,0,1,0.65168446,0
NCT04973631,The Effects of Sex and Age Differences on Gastric Cancer : a Retrospective Study,The Effects of Sex and Age Differences on Gastric Cancer in Terms of Incidence of Histologic Subtypes and Survival Rate: a Retrospective Study,COMPLETED,,OBSERVATIONAL,14900.0,ACTUAL,2003-05-01,2022-01-01,Seoul National University Bundang Hospital,OTHER,,,,GENETIC,"Sex, Age","Sex, Age, Gastric Cancer",,,,,False,6820.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9666953619414728,1,True,0.9741821089183389,1,1,0.98203385,1
NCT00472420,A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.,An Open-label Study of the Effect of the Addition of MabThera to Standard Chemotherapy on Clinical Response in Patients With Previously Untreated Mantle Cell Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,2007-06-27,2011-05-25,Hoffmann-La Roche,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","rituximab [MabThera/Rituxan], First line chemotherapy",Mantle Cell Lymphoma,,,,,False,1428.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,48.0,3.8918202981106265,1,0,0.58,True,True,0.6478183072709335,1,True,0.8102625353834878,1,1,0.74191153,1
NCT02662166,MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer,Magnetic Resonance Imaging of Bladder Cancer,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2014-07-01,2020-05-01,Turku University Hospital,OTHER_GOV,,SINGLE_GROUP,NONE,DEVICE,MR imaging,Bladder Cancer,,,,,False,2131.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,50.0,3.9318256327243257,0,0,0.6,True,True,0.8006500842055492,1,True,0.7177985406463412,1,1,0.66307765,1
NCT02143869,Evolution of Corporeal Composition in the PeriOperative Period,Perioperative Body Composition Changes in Patients Undergoing Gastrointestinal or Lung Cancer Surgery,COMPLETED,,OBSERVATIONAL,374.0,ACTUAL,2013-12-01,2019-09-01,Hôpital Européen Marseille,OTHER,,,,DEVICE,Bioelectrical Impedance Analysis,"Gastrointestinal Cancer (Esophagus, Gastric, Pancreatic, Hepatic, Colorectal and Anal), Lung Cancer",,,,,False,2100.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,374.0,5.926926025970411,0,1,0.6,True,True,0.9258909387512276,1,True,0.9114510075463084,1,1,0.93527025,1
NCT02295839,Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy,"Feasibility, Acceptability, and Effectiveness of a Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy for Acute Lymphoblastic Leukemia",COMPLETED,,INTERVENTIONAL,20.0,ACTUAL,2011-05-01,2014-08-01,The Hospital for Sick Children,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Sleep Hygiene and Relaxation Education,"Sleep, Fatigue, Acute Lymphoblastic Leukemia",,,,,False,1188.0,True,False,-1.0,True,False,False,1,True,Small (<30),0,20.0,3.044522437723423,1,0,0.6,True,False,0.47266245781294597,0,False,0.4414802635211069,0,0,0.40801218,0
NCT01498640,Retreatment of Recurrent Dupuytren's Contractures,"Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe",COMPLETED,PHASE4,INTERVENTIONAL,52.0,ACTUAL,2012-03-01,2013-10-01,Endo Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,BIOLOGICAL,Collagenase clostridium histolyticum,Dupuytren's Disease,,,,,False,579.0,True,False,4.0,False,False,True,1,True,Medium (30-100),0,52.0,3.970291913552122,0,0,0.7,True,True,0.5869406780350316,1,True,0.7938941957496521,1,1,0.8827741,1
NCT01170650,Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED),A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer,TERMINATED,PHASE3,INTERVENTIONAL,441.0,ACTUAL,2011-04-22,2015-09-08,Endocyte,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG, DRUG","EC145, Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®), placebo, EC20",Ovarian Cancer,,,,,False,1600.0,True,False,3.0,True,True,True,4,False,Very Large (300+),1,441.0,6.091309882077698,3,1,0.77,False,True,0.7931653355238288,0,True,0.739636273309034,0,1,0.7505157,0
NCT04427527,Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia,Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS),COMPLETED,,INTERVENTIONAL,5413.0,ACTUAL,2020-08-19,2025-03-31,University of Kentucky,OTHER,RANDOMIZED,FACTORIAL,TRIPLE,BEHAVIORAL,Multi-level intervention to increase CRC screening,Colorectal Cancer,,,,,False,1685.0,True,False,-1.0,True,True,False,1,True,Very Large (300+),0,5413.0,8.596743470174246,2,1,0.6,True,True,0.900974610775474,1,True,0.9077972518086159,1,1,0.9474218,1
NCT04044937,Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms,Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm,COMPLETED,PHASE2,INTERVENTIONAL,143.0,ACTUAL,2018-10-29,2024-03-31,Thomas Hope,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE","F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)","Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma",,,,,False,1980.0,True,False,2.0,False,False,False,2,True,Large (100-300),0,143.0,4.969813299576001,1,1,0.58,True,True,0.7356260972704732,1,True,0.7472620759649768,1,1,0.7598776,1
NCT06083662,Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers,"Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, an Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab Biosimilar (Herzuma®) in Patients with HER2 Mutated Advanced Solid Cancers",COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2021-06-15,2024-12-30,Korea University Guro Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Neratinib Maleate,"Metastatic Cancer, HER2 Gene Mutation",,,,,False,1294.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.58,True,True,0.6634231318491645,1,True,0.7612805998810301,1,1,0.72272384,1
NCT00272987,"ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib","A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer",TERMINATED,PHASE3,INTERVENTIONAL,63.0,ACTUAL,2005-12-13,2019-10-21,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG","lapatinib, paclitaxel, trastuzumab","Neoplasms, Breast",,,,,False,5060.0,True,False,3.0,False,False,True,3,False,Medium (30-100),1,63.0,4.158883083359672,1,0,0.77,False,True,0.7802805780470864,0,True,0.8499957177056967,0,1,0.91540086,0
NCT05586100,"Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study","Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,52.0,ESTIMATED,2022-10-13,2026-04-28,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,OTHER,,SINGLE_GROUP,NONE,DRUG,Toripalimab+cetuximab,Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma,,,,,False,1293.0,False,False,2.0,False,False,False,1,True,Medium (30-100),1,52.0,3.970291913552122,0,0,0.58,True,True,0.7053954085433588,1,True,0.7185928957392673,1,1,0.65220296,1
NCT01210378,Nitroglycerin in Non-small Cell Lung Cancer,Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial,TERMINATED,PHASE2,INTERVENTIONAL,47.0,ACTUAL,2011-12-01,2017-03-01,Maastricht Radiation Oncology,OTHER,,SINGLE_GROUP,NONE,DRUG,Nitroglycerin patch,Non Small Cell Lung Cancer (NSCLC),,,,,False,1917.0,True,False,2.0,False,False,False,1,False,Medium (30-100),0,47.0,3.871201010907891,0,0,0.58,False,True,0.7162061583746109,0,True,0.8513034847449442,0,1,0.8353628,0
NCT02785939,Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer,A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study),COMPLETED,PHASE2,INTERVENTIONAL,53.0,ACTUAL,2014-09-01,2019-06-01,SWOG Cancer Research Network,NETWORK,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER, DRUG","Docetaxel, Laboratory Biomarker Analysis, Palbociclib","CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7",,,,,False,1734.0,True,False,2.0,False,False,False,3,True,Medium (30-100),1,53.0,3.9889840465642745,1,0,0.58,True,True,0.6804965968604076,1,True,0.9066693432318556,1,1,0.9086186,1
NCT04937335,Craniopharyngioma With Tumoral Hemorrhage,Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage,COMPLETED,,OBSERVATIONAL,185.0,ACTUAL,2013-01-01,2021-02-01,Tongji Hospital,OTHER,,,,OTHER,intratumoral hemorrhage,"Craniopharyngioma, Apoplexy",,,,,False,2953.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,185.0,5.225746673713202,0,1,0.6,True,True,0.8854658553438539,1,True,0.8650237394297565,1,1,0.9071497,1
NCT02422615,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,"A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment",COMPLETED,PHASE3,INTERVENTIONAL,726.0,ACTUAL,2015-06-09,2023-01-11,Novartis Pharmaceuticals,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","Ribociclib, Fulvestrant, Placebo",Advanced Breast Cancer,,,,,False,2773.0,True,False,3.0,True,True,True,3,True,Very Large (300+),1,726.0,6.588926477533519,3,1,0.77,True,True,0.8794987713460269,1,True,0.8766562514461653,1,1,0.90000266,1
NCT04997850,The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma,The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib +Programmed Cell Death Protein 1 (PD-1) Antibody in the Conversion-resection of Advanced Unresectable Hepatocellular Carcinoma:a Multicenter Prospective Cohort Study,COMPLETED,PHASE1,INTERVENTIONAL,142.0,ACTUAL,2020-10-01,2024-01-31,Xinrui Zhu，MD,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, PROCEDURE","lenvatinib + sindilimab/carrelizumab, TACE","Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade",,,,,False,1217.0,True,False,1.0,False,False,False,2,True,Large (100-300),1,142.0,4.962844630259907,1,1,0.56,True,True,0.7272361958667815,1,True,0.6796299989323703,1,1,0.60702944,1
NCT03314805,PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,COMPLETED,PHASE2,INTERVENTIONAL,67.0,ACTUAL,2018-03-01,2021-08-27,PhytoHealth Corporation,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, PROCEDURE","Astragalus polysaccharides 500 mg, Placebo, EC Chemotherapy","Cancer-related Fatigue, Neutropenia, Malignant",,,,,False,1275.0,True,False,2.0,True,True,True,3,True,Medium (30-100),0,67.0,4.219507705176107,3,0,0.58,True,True,0.6701844043170392,1,True,0.7742038870518664,1,1,0.7831491,1
NCT05178043,GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma,A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination With Nivolumab as a Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,5.0,ACTUAL,2021-08-01,2025-12-01,"Suzhou Kintor Pharmaceutical Inc,",INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Nivolumab, GT90001","Hepatocellular Carcinoma, HCC",,,,,False,1583.0,False,False,2.0,False,False,True,2,True,Small (<30),1,5.0,1.791759469228055,1,0,0.58,True,False,0.1636216867465839,0,False,0.17073239484657388,0,0,0.13730203,0
NCT04264962,Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter,Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,300.0,ACTUAL,2017-01-01,2021-02-28,Beijing Ditan Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, OTHER","Yang Yin Fu Zheng Jie Du therapy, Routine medical care",Hepatocellular Carcinoma,,,,,False,1519.0,True,False,0.5,True,False,False,2,True,Large (100-300),0,300.0,5.707110264748875,2,1,0.57,True,True,0.816901761894737,1,True,0.8882556590170849,1,1,0.9228748,1
NCT05940740,Investigation of the Effect of Training on the Side Effects of Chemotherapy Given Via the Mobile Health Application on the Quality of Life in Colorectal Cancer Patients,Investigation of the Effect of Training on the Side Effects of Chemotherapy Given Via the Mobile Health Application on the Quality of Life in Colorectal Cancer Patients,COMPLETED,,INTERVENTIONAL,70.0,ACTUAL,2023-03-01,2025-01-14,NESLISAH YASAR KARTAL,OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,Colorectal-Mobile application,"Colorectal Cancer, Mobile Phone Use, Nurse's Role",,,,,False,685.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,70.0,4.262679877041316,1,0,0.6,True,True,0.7483644728684476,1,True,0.8497156950388952,1,1,0.842784,1
NCT00005878,Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus,Chemoprevention for Barrett's Esophagus Trial (CBET),COMPLETED,PHASE2,INTERVENTIONAL,,,2000-07-01,2005-09-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,RANDOMIZED,,DOUBLE,DRUG,celecoxib,Esophageal Cancer,,,,,False,1888.0,True,False,2.0,True,True,False,1,True,,0,,,2,0,0.58,True,True,0.6768386998543634,1,True,0.6704776714626901,1,1,0.72534037,1
NCT01186601,Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer,Open-label Study for an Exploration of Tumor Accumulation of the 18F Labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 0.1 mg Total Quantity) in Patients With Prostate Cancer or Other Malignant Tumors,COMPLETED,PHASE1,INTERVENTIONAL,30.0,ACTUAL,2010-12-01,2011-10-01,Life Molecular Imaging SA,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,PET tracer (BAY94-9392),Neoplasms,,,,,False,304.0,True,False,1.0,False,False,True,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.56,True,True,0.5677861787961123,1,True,0.6639236451535772,1,1,0.66069573,1
NCT04455737,Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision,Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision,COMPLETED,,OBSERVATIONAL,189.0,ACTUAL,2013-10-01,2020-06-01,Walter Brunner,OTHER,,,,OTHER,injection of indigo carmine,Rectal Neoplasms,,,,,False,2435.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,189.0,5.247024072160486,0,1,0.6,True,True,0.8763592338027423,1,True,0.8367178008405847,1,1,0.84576356,1
NCT00889798,Tumor Registry of Lymphatic Neoplasia,"Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.",COMPLETED,,OBSERVATIONAL,3795.0,ACTUAL,2009-04-01,2019-08-31,iOMEDICO AG,INDUSTRY,,,,,,"Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)",,,,,False,3804.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,3795.0,8.241703159729818,0,1,0.6,True,True,0.9690922544406391,1,True,0.964052880473298,1,1,0.9559555,1
NCT03017313,To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients,A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.,COMPLETED,,OBSERVATIONAL,510.0,ACTUAL,2017-07-13,2021-06-14,Ipsen,INDUSTRY,,,,DRUG,LHRH analogues,Prostate Cancer,,,,,False,1432.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,510.0,6.236369590203704,0,1,0.6,True,True,0.9337515689643873,1,True,0.9679592562689492,1,1,0.93403965,1
NCT02627144,Bevacizumab in Metastatic Renal Cancer,AVASTIN® First Line in Metastatic Renal Cancer,COMPLETED,,OBSERVATIONAL,365.0,ACTUAL,2008-01-01,2014-09-01,Hoffmann-La Roche,INDUSTRY,,,,"DRUG, DRUG","Bevacizumab, Interferon alpha-2a",Renal Cell Cancer,,,,,False,2435.0,True,False,-1.0,False,False,True,2,True,Very Large (300+),1,365.0,5.902633333401366,1,1,0.6,True,True,0.9119044730909004,1,True,0.8851407568339266,1,1,0.9583983,1
NCT01743131,Abatacept as GVHD Prophylaxis Phase 2,Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial,COMPLETED,PHASE2,INTERVENTIONAL,186.0,ACTUAL,2013-02-01,2024-03-30,Boston Children's Hospital,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG","Abatacept, placebo","Graft vs Host Disease, Malignancy",,,,,False,4075.0,True,False,2.0,True,True,False,2,True,Large (100-300),0,186.0,5.231108616854587,3,1,0.58,True,True,0.8170390140449891,1,True,0.8709654605273599,1,1,0.88724434,1
NCT01603979,"A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors","A Phase 1 Open-label, Multiple Dose, Dose Escalation Study of Monoclonal Antibody AV-203 Administered in Subjects With Metastatic or Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,24.0,ACTUAL,2012-05-01,2014-12-01,"AVEO Pharmaceuticals, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,AV-203,Solid Tumors,,,,,False,944.0,True,False,1.0,False,False,True,1,True,Small (<30),0,24.0,3.218875824868201,0,0,0.56,True,True,0.5434146640682819,1,True,0.6364469747424786,1,1,0.6631606,1
NCT04020978,Parametric PET of Genitourinary Cancer,Pilot Study Using Parametric PET to Assess Early Treatment Response to Targeted Therapy for Genitourinary Cancer (GUC),COMPLETED,,INTERVENTIONAL,11.0,ACTUAL,2019-07-16,2023-12-15,"University of California, Davis",OTHER,,SINGLE_GROUP,NONE,DIAGNOSTIC_TEST,Parametric PET/CT,Genitourinary Cancer,,,,,False,1613.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,11.0,2.4849066497880004,0,0,0.6,True,False,0.4308860585677929,0,True,0.5327025779956297,1,1,0.58919543,1
NCT01939028,Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery,Sentinel Lymph Node Mapping for Endometrial Cancer,TERMINATED,,INTERVENTIONAL,58.0,ACTUAL,2013-07-01,2016-10-01,Case Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, DRUG, DRUG, PROCEDURE, PROCEDURE","lymph node mapping, sentinel lymph node biopsy, isosulfan blue, indocyanine green solution, therapeutic conventional surgery, lymphadenectomy","Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma",,,,,False,1188.0,True,False,-1.0,False,False,False,6,False,Medium (30-100),0,58.0,4.07753744390572,1,0,0.6,False,True,0.742429717725475,0,True,0.7614001013416424,0,1,0.8811972,0
NCT00359086,Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma,A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma,COMPLETED,PHASE2,INTERVENTIONAL,74.0,ACTUAL,2006-08-01,2012-01-01,Mirati Therapeutics Inc.,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,MGCD0103,Lymphoma,,,,,False,1979.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,74.0,4.31748811353631,0,0,0.58,True,True,0.8039761220796616,1,True,0.8104321526309164,1,1,0.74918616,1
NCT01502280,Fluorescence-guided Surgery for Low- and High-grade Gliomas,Barrow 5-ALA Intraoperative Confocal Evaluation Trial,COMPLETED,PHASE3,INTERVENTIONAL,127.0,ACTUAL,2010-11-01,2018-06-01,"St. Joseph's Hospital and Medical Center, Phoenix",OTHER,RANDOMIZED,SINGLE_GROUP,SINGLE,"DRUG, DRUG","5-Aminolevulinic acid (ALA), Placebo - ascorbic acid",Glioma,,,,,False,2769.0,True,False,3.0,True,False,False,2,True,Large (100-300),0,127.0,4.852030263919617,2,1,0.77,True,True,0.5882951426597688,1,True,0.7189931155301565,1,1,0.63330823,1
NCT04510935,Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro,Effects of Serum From Hepatocellular Carcinoma Surgery Patients Under Different Anesthetic Methods on Hepatic Cancer Cell Function in Vitro,COMPLETED,,INTERVENTIONAL,35.0,ACTUAL,2020-08-20,2020-12-28,RenJi Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","general anesthesia, local anesthesia",Hepatocellular Carcinoma,,,,,False,130.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,35.0,3.58351893845611,2,0,0.6,True,True,0.5108201281352236,1,True,0.7600931166532799,1,1,0.8437782,1
NCT02773004,"Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer","Prospective Multicenter Study Assessing EndoPredict® (EP) Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments",COMPLETED,,INTERVENTIONAL,203.0,ACTUAL,2016-09-01,2017-12-01,UNICANCER,OTHER,,SINGLE_GROUP,NONE,OTHER,EPClin genomic test,Breast Cancer,,,,,False,456.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,203.0,5.318119993844216,0,1,0.6,True,True,0.8342699242555037,1,True,0.8848590341679501,1,1,0.88874716,1
NCT00393068,"Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer",A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer,COMPLETED,PHASE2,INTERVENTIONAL,62.0,ACTUAL,2007-02-01,2011-08-01,"SCRI Development Innovations, LLC",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE","Erlotinib, Bevacizumab, Paclitaxel, Carboplatin, 5-FU, Radiation therapy, Surgery",Esophageal Cancer,,,,,False,1642.0,True,False,2.0,False,False,False,7,True,Medium (30-100),1,62.0,4.143134726391533,1,0,0.58,True,True,0.6938747074461323,1,True,0.8818908113022128,1,1,0.9237602,1
NCT00130533,Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients,"Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Capecitabine Following Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Patients",COMPLETED,PHASE3,INTERVENTIONAL,876.0,ACTUAL,2006-01-01,2017-02-17,Spanish Breast Cancer Research Group,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Capecitabine,Breast Cancer,,,,,False,4065.0,True,False,3.0,True,False,False,1,True,Very Large (300+),1,876.0,6.776506992372183,1,1,0.77,True,True,0.9225393548498331,1,True,0.9537158374599719,1,1,0.9817664,1
NCT00193245,Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer,A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer,COMPLETED,PHASE2,INTERVENTIONAL,80.0,,2000-11-01,2009-01-01,"SCRI Development Innovations, LLC",OTHER,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG","Topotecan, Docetaxel",Lung Cancer,,,,,False,2983.0,True,False,2.0,True,False,False,2,True,Medium (30-100),1,80.0,4.394449154672439,2,0,0.58,True,True,0.752982827169569,1,True,0.8622208256283919,1,1,0.9049626,1
NCT06800677,Methylated Biomarkers Predictive of Endometrial Cancer Risk,Methylated Biomarkers Predictive of Endometrial Cancer Risk,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,200.0,ESTIMATED,2024-07-31,2026-12-01,University of Manchester,OTHER,,,,PROCEDURE,Hysterectomy,Endometrial Cancer,,,,,False,853.0,False,False,-1.0,False,False,False,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8434797194536546,1,True,0.8658754742350611,1,1,0.93207544,1
NCT00584753,Molecular Imaging of Breast Cancer With Breast PET/CT,Molecular Imaging of Breast Cancer With Breast PET/CT,TERMINATED,PHASE1,INTERVENTIONAL,4.0,ACTUAL,2007-04-01,2011-07-01,"University of California, Davis",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION, RADIATION","Positron emission tomography and computed tomography, Positron emission tomography and computed tomography, Positron emission tomography and computed tomography",Breast Cancer,,,,,False,1552.0,True,False,1.0,False,False,False,3,False,Small (<30),0,4.0,1.6094379124341005,1,0,0.56,False,False,0.1573892712242323,1,False,0.14223436070722867,1,0,0.10493909,1
NCT00003354,Conventional Surgery Compared With Laparoscopic-Assisted Surgery in Treating Patients With Colorectal Cancer,Conventional Versus Laparoscopic-Assisted Surgery in Colorectal Cancer,COMPLETED,PHASE3,INTERVENTIONAL,1200.0,ESTIMATED,1996-07-01,2009-12-01,Medical Research Council,OTHER_GOV,RANDOMIZED,,,"PROCEDURE, PROCEDURE","conventional surgery, laparoscopic surgery",Colorectal Cancer,,,,,False,4901.0,True,False,3.0,True,False,False,2,True,Very Large (300+),0,1200.0,7.090909822079984,2,1,0.77,True,True,0.9325901817078065,1,True,0.9555375359729922,1,1,0.9688779,1
NCT00578162,A Study of Survivorship Service Capacities Among Health Care Agencies in New York City,A Study of Survivorship Service Capacities Among Health Care Agencies in New York City,COMPLETED,,OBSERVATIONAL,,,2005-04-01,2009-04-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,BEHAVIORAL,we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER,All Cancers,,,,,False,1461.0,True,False,-1.0,False,False,False,1,True,,0,,,0,0,0.6,True,True,0.7737892455011589,1,True,0.6986838651233533,1,1,0.6585942,1
NCT00495144,"A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors","A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,129.0,ACTUAL,2007-06-01,2012-06-01,Threshold Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,TH-302,"Tumors, Hypoxia",,,,,False,1827.0,True,False,1.0,False,False,True,1,True,Large (100-300),0,129.0,4.867534450455582,0,1,0.56,True,True,0.7768354963538475,1,True,0.7286975137550914,1,1,0.67752755,1
NCT02451865,"Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer","A Phase IB Dose Escalation and Expansion Trial of MEK 162 With Docetaxel in Previously Treated Stage IV, Non-small Cell Lung Cancer (NSCLC)",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2016-06-01,2019-06-01,Jonsson Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER","Binimetinib, Docetaxel, Laboratory Biomarker Analysis","Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer",,,,,False,1095.0,True,False,1.0,False,False,False,3,False,,1,0.0,0.0,1,0,0.56,False,False,0.02764841925654424,1,False,0.004365810266406106,1,0,0.0037689984,1
NCT04680455,Strength Training for Men Living With Obesity,Potential Benefits of Strength Training for Men Living With Obesity,COMPLETED,,INTERVENTIONAL,60.0,ACTUAL,2020-09-22,2022-01-05,University of New Brunswick,OTHER,RANDOMIZED,PARALLEL,NONE,OTHER,Online home-based strength training,Obesity,,,,,False,470.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,60.0,4.110873864173311,1,0,0.6,True,True,0.7078248493193774,1,True,0.882912447612849,1,1,0.9067888,1
NCT03748901,PD-L1 Expression in Japanese Renal Cell Carcinoma Patients,A Retrospective Multicenter Analysis of PD-L1 Expression in Japanese Renal Cell Carcinoma Patients,COMPLETED,,OBSERVATIONAL,830.0,ACTUAL,2018-12-16,2021-07-21,Chugai Pharmaceutical,INDUSTRY,,,,,,Renal Cell Carcinoma,,,,,False,948.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,830.0,6.7226297948554485,0,1,0.6,True,True,0.9484245326956983,1,True,0.9541943702252614,1,1,0.9325775,1
NCT00311896,Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT),"Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)",TERMINATED,PHASE3,INTERVENTIONAL,402.0,ACTUAL,2005-07-01,2010-12-01,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","Bemiparin, Placebo","Cancer, Thrombosis",,,,,False,1979.0,True,False,3.0,True,True,False,2,False,Very Large (300+),0,402.0,5.998936561946683,3,1,0.77,False,True,0.8043754685976203,0,True,0.7658956285265996,0,1,0.79352725,0
NCT05215470,CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy,CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,100.0,ESTIMATED,2022-01-18,2026-11-30,Hospital das Clínicas de Ribeirão Preto,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Nivolumab, Ipilimumab",Renal Cancer Metastatic,,,,,False,1777.0,False,False,2.0,False,False,False,2,True,Medium (30-100),1,100.0,4.61512051684126,1,1,0.58,True,True,0.6432897186414915,1,True,0.6868322731903578,1,1,0.8270941,1
NCT01313039,Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,4.0,ACTUAL,2011-02-01,2014-04-01,University of Miami,OTHER,,SINGLE_GROUP,NONE,DRUG,AZ6244,Breast Cancer,,,,,False,1155.0,True,False,0.5,False,False,False,1,True,Small (<30),0,4.0,1.6094379124341005,0,0,0.57,True,False,0.1853287000148264,0,False,0.20352688378369888,0,0,0.26115942,0
NCT03763565,Effectiveness of HPV Vaccine in Thai Adult Women,Effectiveness of HPV Vaccine Among Women Age Equal or More Than 20 Years,COMPLETED,,OBSERVATIONAL,993.0,ACTUAL,2018-11-01,2019-07-01,Mahidol University,OTHER,,,,"BIOLOGICAL, OTHER","Bivalent or Quadrivalent HPV vaccines, Control group","Uterine Cervical Dysplasia, Papillomavirus Vaccines",,,,,False,242.0,True,False,-1.0,False,False,False,2,True,Very Large (300+),0,993.0,6.901737206656574,1,1,0.6,True,True,0.9332285875533738,1,True,0.9827488114959031,1,1,0.98672026,1
NCT05379972,Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers,Study of Induction SBRT and Olaparib Followed by Combination Pembrolizumab/Olaparib in Gastric and Gastroesophageal Junction (GEJ) Cancers,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2023-01-12,2028-12-01,"University of Colorado, Denver",OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, RADIATION","Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy","Gastric Cancer, GastroEsophageal Cancer",,,,,False,2150.0,False,False,2.0,False,False,False,3,True,Small (<30),1,9.0,2.302585092994046,1,0,0.58,True,False,0.27342105659405963,0,False,0.41439859512380756,0,1,0.80230415,1
NCT03280849,Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery,Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery,COMPLETED,,INTERVENTIONAL,1.0,ACTUAL,2015-01-01,2017-02-01,University of Guadalajara,OTHER,,SINGLE_GROUP,NONE,OTHER,Implant of bilaminar chitosan scaffold,Csf Leakage,,,,,False,762.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,1.0,0.6931471805599453,0,0,0.6,True,False,0.08238487063520088,0,False,0.12344420277260117,0,0,0.07539324,0
NCT01454089,A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer,"A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma",COMPLETED,PHASE2,INTERVENTIONAL,183.0,ACTUAL,2011-10-01,2014-11-01,Achieve Life Sciences,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","OGX-427 600 mg, OGX-427 1000 mg, Placebo, Gemcitabine, Cisplatin, Carboplatin","Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms",,,,,False,1127.0,True,False,2.0,True,True,True,6,True,Large (100-300),1,183.0,5.214935757608986,3,1,0.58,True,True,0.6806108899299722,1,True,0.5499984982458807,1,1,0.6270592,1
NCT03896412,Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma,Detection of Circulating Tumor DNA by a Personalized Molecular Tool During Treatment of Locally Advanced Operable Head and Neck Squamous Cell Carcinoma,COMPLETED,,INTERVENTIONAL,40.0,ACTUAL,2019-01-21,2023-01-09,Centre Henri Becquerel,OTHER,,SINGLE_GROUP,NONE,OTHER,Detecton of circulating tumor DNA,Head and Neck Squamous Cell Carcinoma,,,,,False,1449.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,40.0,3.713572066704308,0,0,0.6,True,True,0.7340731841162813,1,True,0.7382065688520797,1,1,0.6381758,1
NCT06022887,Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer,Feasibility and Acceptability of a Remote Time-Restricted Eating and Mindfulness-Based Stress Reduction Intervention to Reduce Risk Factors Associated With Early-Onset Colorectal Cancer Development Among Young Adults,COMPLETED,,INTERVENTIONAL,43.0,ACTUAL,2023-10-18,2024-07-24,Lisa Tussing-Humphreys,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","TRE, MBSR","Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological",,,,,False,280.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,43.0,3.784189633918261,2,0,0.6,True,True,0.5718646522992878,1,True,0.7854876652527915,1,1,0.66622055,1
NCT00310024,Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma,A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma,COMPLETED,PHASE1,INTERVENTIONAL,40.0,ACTUAL,2005-11-01,,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, OTHER","bortezomib, vorinostat, laboratory biomarker analysis, pharmacological study","Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma",,,,,False,1303.0,True,False,1.0,False,False,False,4,True,Medium (30-100),0,40.0,3.713572066704308,1,0,0.56,True,True,0.6298673056088404,1,True,0.6817288473194125,1,1,0.6961706,1
NCT06802523,"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia",A Phase I Study of Lintuzumab-Ac-225 in Combination With Venetoclax and ASTX-727 in Adults With Newly Diagnosed AML,SUSPENDED,PHASE1,INTERVENTIONAL,53.0,ESTIMATED,2026-04-21,2028-12-31,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"RADIATION, PROCEDURE, PROCEDURE, PROCEDURE, DRUG, DRUG","Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax",Acute Myeloid Leukemia,,,,,False,985.0,False,False,1.0,True,False,False,6,False,Medium (30-100),0,53.0,3.9889840465642745,2,0,0.56,False,True,0.5910498795430538,0,True,0.677435169131267,0,1,0.7056631,0
NCT00953446,Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma,Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma,TERMINATED,,INTERVENTIONAL,2.0,ACTUAL,2010-06-15,2011-09-13,Beth Israel Deaconess Medical Center,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging,Renal Cell Carcinoma,,,,,False,455.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.6,False,False,0.1159737910223727,1,False,0.10198575476361416,1,0,0.057655863,1
NCT00262782,"Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia",Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia,COMPLETED,PHASE3,INTERVENTIONAL,877.0,ACTUAL,1997-04-01,2010-06-01,German CLL Study Group,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,Fludarabine,Chronic Lymphocytic Leukemia,,,,,False,4809.0,True,False,3.0,True,False,False,1,True,Very Large (300+),0,877.0,6.777646593635117,1,1,0.77,True,True,0.9346937810613449,1,True,0.9685585076303913,1,1,0.98159677,1
NCT06416696,Toripalimab for High-risk Locally Advanced Cervical Cancer,Toripalimab Combined With Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk Locally Advanced Cervical Cancer: the Phase II Single-arm TorCH -CC Study,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,57.0,ESTIMATED,2024-01-09,2026-12-01,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",OTHER,,SINGLE_GROUP,NONE,DRUG,Toripalimab,Cervical Cancers,,,,,False,1057.0,False,False,2.0,False,False,False,1,True,Medium (30-100),0,57.0,4.060443010546419,0,0,0.58,True,True,0.720717994776496,1,True,0.7824248738955083,1,1,0.7775828,1
NCT02539719,Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer,A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer,TERMINATED,PHASE1,INTERVENTIONAL,74.0,ACTUAL,2015-08-01,2019-01-02,Stemcentrx,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","SC-003, SC-003 in combination with ABBV-181",Ovarian Cancer,,,,,False,1250.0,True,False,1.0,False,False,True,2,False,Medium (30-100),0,74.0,4.31748811353631,1,0,0.56,False,True,0.7690227655818603,0,True,0.6826568187081962,0,1,0.7071377,0
NCT01631357,Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer,Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer,COMPLETED,PHASE2,INTERVENTIONAL,96.0,ACTUAL,2014-12-01,2018-12-01,Tianjin Medical University Cancer Institute and Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG","CIK cell, Gemcitabine Injection, Cisplatin injection","Non-small Cell Lung Cancer, Squamous Cell Carcinoma",,,,,False,1461.0,True,False,2.0,True,False,False,3,True,Medium (30-100),1,96.0,4.574710978503383,2,0,0.58,True,True,0.7241780029590802,1,True,0.8155405960244789,1,1,0.83329374,1
NCT03208790,Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.,Clinical And Immunohistochemical Evaluation Of The Cancer Chemopreventive Effect Of Thymoquinone Compared To A Placebo On Oral Potentially Malignant Lesions Among An Egyptian Population : A Randomized Clinical Trial,COMPLETED,PHASE2,INTERVENTIONAL,48.0,ACTUAL,2017-09-30,2020-03-12,Cairo University,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, DRUG","Nigella sativa buccal tablets 10mg, Nigella sativa buccal tablets 5mg, Placebo buccal tablets",Premalignant Lesion,,,,,False,894.0,True,False,2.0,True,True,False,3,True,Medium (30-100),0,48.0,3.8918202981106265,3,0,0.58,True,True,0.5700752555386914,1,True,0.5266252462413523,1,0,0.46460846,0
NCT05753254,"Effect on Markers of Cardiovascular, Reproductive and Cancer Risk From Firefighting Training","Effect on Markers of Cardiovascular, Reproductive and Cancer Risk From Firefighting Activities - a Study Under Different Training Methods",COMPLETED,,INTERVENTIONAL,35.0,ACTUAL,2023-03-10,2024-07-05,"National Research Centre for the Working Environment, Denmark",OTHER_GOV,RANDOMIZED,CROSSOVER,SINGLE,"OTHER, OTHER, OTHER","Firefighting training exercises with no fire, Firefighting training exercises under wood fire, Firefighting training exercises under gas fire","Reactive Hyperemia, Micro RNA, Heart Rate Variability, DNA Strand Breaks, Oxidative Stress, Heat Stress",,,,,False,483.0,True,False,-1.0,True,False,False,3,True,Medium (30-100),0,35.0,3.58351893845611,2,0,0.6,True,True,0.5240399177043055,1,True,0.6501164098178106,1,1,0.64324087,1
NCT04653389,Perioperative Therapy for Hepatocellular Carcinoma,Perioperative Multidisciplinary Therapy for Technically Resectable Hepatocellular Carcinoma With Vein Thrombosis: An Exploratory Clinical Trail,TERMINATED,PHASE2,INTERVENTIONAL,10.0,ACTUAL,2020-12-26,2021-12-01,Zhejiang University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, RADIATION","Sintilimab Injection, TACE, Radiotherapy",Hepatocellular Carcinoma,,,,,False,340.0,True,False,2.0,False,False,False,3,False,Small (<30),0,10.0,2.3978952727983707,1,0,0.58,False,False,0.22757739259661852,1,False,0.22268870544806402,1,0,0.0802835,1
NCT02280954,Indocyanine Green for Solid Tumors,A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green,COMPLETED,PHASE1,INTERVENTIONAL,48.0,ACTUAL,2013-11-01,2017-02-01,University of Pennsylvania,OTHER,,SINGLE_GROUP,NONE,DRUG,Indocyanine Green (ICG),"Solid Tumor, Neoplasms",,,,,False,1188.0,True,False,1.0,False,False,False,1,True,Medium (30-100),0,48.0,3.8918202981106265,0,0,0.56,True,True,0.720587497774625,1,True,0.7094461430377375,1,1,0.7736471,1
NCT03910296,Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain,Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain,COMPLETED,,OBSERVATIONAL,10.0,ACTUAL,2019-02-20,2021-07-30,Dana-Farber Cancer Institute,OTHER,,,,BEHAVIORAL,Acceptance & Commitment Therapy,Cancer,,,,,False,891.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.6,True,False,0.37211826876239046,0,True,0.5845349291730535,1,1,0.7946569,1
NCT04626843,Intermittent Fasting and CLL/SLL,Feasibility Study of Intermittent Fasting in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients at BC Cancer- Victoria,COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2021-02-03,2022-12-31,Eleah Stringer,OTHER,,SINGLE_GROUP,NONE,OTHER,Intermittent fast,"Neoplasms, Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic, Intermittent Fasting, Diet Habit, Inflammation",,,,,False,696.0,True,False,1.0,False,False,False,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.56,True,False,0.41079314825544955,0,True,0.7358349739430896,1,1,0.57656604,1
NCT05582031,Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers,"An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2023-04-30,2025-04-30,Translational Research in Oncology,OTHER,,SINGLE_GROUP,NONE,COMBINATION_PRODUCT,Regorafenib in combination with Tislelizumab,"Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma, Small Cell Lung Carcinoma, Castrate Resistant Prostate Cancer, Neuroendocrine Carcinoma of Prostate, Gastroenteropancreatic Neuroendocrine Neoplasm",,,,,False,731.0,True,False,2.0,False,False,False,1,False,,1,0.0,0.0,0,0,0.58,False,False,0.027690846193668416,1,False,0.00918213295295527,1,0,0.0025680976,1
NCT06517485,First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b,"A Phase 1b/2, First-in-Human, Dose Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b",COMPLETED,PHASE1,INTERVENTIONAL,142.0,ACTUAL,2019-07-30,2022-08-03,Mersana Therapeutics,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,upifitamab rilsodotin,"Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma",,,,,False,1100.0,True,False,1.0,False,False,True,1,True,Large (100-300),0,142.0,4.962844630259907,0,1,0.56,True,True,0.76723535152752,1,True,0.7475544263317367,1,1,0.71503884,1
NCT04848909,Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy,Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer: A Treatment Feasibility and Outcomes Multicenter Study,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,30.0,ESTIMATED,2021-06-03,2034-12-01,Sunnybrook Health Sciences Centre,OTHER,,SINGLE_GROUP,NONE,RADIATION,stereotactic body radiotherapy (SBRT),Prostate Cancer,,,,,False,4929.0,False,False,-1.0,False,False,False,1,True,Small (<30),0,30.0,3.4339872044851463,0,0,0.6,True,True,0.8083749486239512,1,True,0.6337938112182914,1,1,0.5451885,1
NCT00847691,GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .,GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .,COMPLETED,,OBSERVATIONAL,350.0,ACTUAL,2009-03-01,2012-07-01,Centre Hospitalier Universitaire de Nice,OTHER,,,,,,Sarcoma,,,,,False,1218.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,350.0,5.860786223465865,0,1,0.6,True,True,0.9091866672614173,1,True,0.8995952678111739,1,1,0.9348872,1
NCT04083599,GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors,"A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,350.0,ACTUAL,2019-09-17,2026-11-01,Genmab,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel","Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)",,,,,False,2602.0,False,False,1.0,False,False,True,9,True,Very Large (300+),1,350.0,5.860786223465865,1,1,0.56,True,True,0.8794301391266679,1,True,0.8139158638075504,1,1,0.8407698,1
NCT02754011,Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative,"Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes",COMPLETED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2017-02-02,2022-12-23,UNICANCER,OTHER,,SINGLE_GROUP,NONE,DRUG,Combination of ribociclib + capecitabine,Breast Cancer,,,,,False,2150.0,True,False,1.0,False,False,False,1,True,Small (<30),1,18.0,2.9444389791664403,0,0,0.56,True,True,0.5249732235835577,1,True,0.599772485093939,1,1,0.74555296,1
NCT00375180,Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients,"Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients Prior to, on Completion of and Six Weeks After Oncology Treatment",COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2006-11-01,2012-01-01,AHS Cancer Control Alberta,OTHER,,,,,,Head and Neck Cancer,,,,,False,1887.0,True,False,-1.0,False,False,False,0,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.772952311034544,1,True,0.7377064773834856,1,1,0.8195437,1
NCT02226497,Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy,Integrating a Telemonitoring Device Into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study,TERMINATED,,INTERVENTIONAL,24.0,ACTUAL,2015-01-09,2018-08-30,Fred Hutchinson Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"DEVICE, OTHER, OTHER, PROCEDURE","Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care","Acute Myeloid Leukemia, Myelodysplastic Syndrome",,,,,False,1329.0,True,False,-1.0,True,False,False,4,False,Small (<30),0,24.0,3.218875824868201,2,0,0.6,False,False,0.46483886686190296,1,True,0.5589914314082496,0,0,0.48930877,1
NCT02229266,Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML,Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With Haploidentical Natural Killer Cells in High-risk Acute Myeloid Leukemia,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2015-09-01,2017-04-22,Technische Universität Dresden,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG","NK cells, Cytarabine",Acute Myeloid Leukemia,,,,,False,599.0,True,False,2.0,True,False,False,2,False,Small (<30),1,1.0,0.6931471805599453,2,0,0.58,False,False,0.03272830681717833,1,False,0.04170501940480018,1,0,0.03575572,1
NCT02682082,EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer,A Randomize Double-Blind Control Trial Study Comparing Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis W/Wo Bupivacaine In Patient Being Treated Palliatively For Pancreatic Cancer,TERMINATED,,INTERVENTIONAL,22.0,ACTUAL,2016-05-27,2019-06-14,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,RANDOMIZED,PARALLEL,DOUBLE,"PROCEDURE, DRUG","Endoscopic ultrasound-guided celiax plexus neurolysis, Bupivacaine",Pancreatic Cancer,,,,,False,1113.0,True,False,-1.0,True,True,False,2,False,Small (<30),0,22.0,3.1354942159291497,3,0,0.6,False,False,0.47281965775690826,1,True,0.5817252765743977,0,1,0.70752966,0
NCT05403723,Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC,"A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer",SUSPENDED,PHASE1,INTERVENTIONAL,50.0,ESTIMATED,2025-12-31,2027-08-01,Taofeek Owonikoko,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, DEVICE","Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy",Extensive-stage Small-cell Lung Cancer,,,,,False,578.0,False,False,1.0,False,False,False,5,False,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.56,False,True,0.6376119552078716,0,True,0.5976610750460183,0,1,0.59499717,0
NCT00201682,Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,Phase I/II Study of Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,COMPLETED,PHASE1,INTERVENTIONAL,36.0,ACTUAL,2002-10-01,2009-08-01,John Byrd,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Etanercept, Rituximab","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",,,,,False,2496.0,True,False,1.0,False,False,False,2,True,Medium (30-100),1,36.0,3.610917912644224,1,0,0.56,True,True,0.6643389908744218,1,True,0.8519621420136034,1,1,0.8877408,1
NCT04289077,Quality of Life of Patients With Desmoid-type Fibromatosis,The Evaluation of Health-related Quality of Life Issues Experienced by Patients With Desmoid-type Fibromatosis,COMPLETED,,OBSERVATIONAL,156.0,ACTUAL,2020-08-06,2021-02-01,Erasmus Medical Center,OTHER,,,,OTHER,Questionnaires,"Desmoid Tumor, Desmoid-type Fibromatosis",,,,,False,179.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,156.0,5.056245805348308,0,1,0.6,True,True,0.7857132675943492,1,True,0.9548530796382849,1,1,0.9871377,1
NCT00218179,Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1,"Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial",COMPLETED,,OBSERVATIONAL,200.0,ACTUAL,2005-09-01,2007-12-01,University of Minnesota,OTHER,,,,OTHER,Non-intervention,"Tobacco Use Disorder, Lung Cancer",,,,,False,821.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,200.0,5.303304908059076,0,1,0.6,True,True,0.8425984675634279,1,True,0.8633352526933762,1,1,0.8304583,1
NCT00256789,Once Weekly Radiation for Lung Cancer With Chemotherapy,Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study,COMPLETED,,INTERVENTIONAL,26.0,ACTUAL,2002-09-01,2004-12-01,Clinical Oncology Research Associates,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, DRUG","Radiation, Chemotherapy","Carcinoma, Non-Small-Cell Lung",,,,,False,822.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,26.0,3.295836866004329,1,0,0.6,True,True,0.5566735562587561,1,True,0.6814408037310328,1,1,0.62769926,1
NCT00765973,"Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors","A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2008-11-10,2010-06-30,"Spectrum Pharmaceuticals, Inc",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Topotecan Liposomes Injection (TLI), Topotecan Liposomes Injection (TLI)","Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors",,,,,False,597.0,True,False,1.0,False,False,True,2,True,Small (<30),1,14.0,2.70805020110221,1,0,0.56,True,False,0.33452053376647417,0,False,0.43173621017203667,0,1,0.5172867,1
NCT00148876,TBP Study With Capecitabine Plus Minus Trastuzumab,A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab,COMPLETED,PHASE3,INTERVENTIONAL,482.0,ESTIMATED,2003-09-01,2011-01-01,GBG Forschungs GmbH,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Capecitabine, Trastuzumab",Breast Cancer,,,,,False,2679.0,True,False,3.0,True,False,False,2,True,Very Large (300+),1,482.0,6.180016653652572,2,1,0.77,True,True,0.8259094290696916,1,True,0.9444045828162944,1,1,0.94881725,1
NCT02812589,Diffusion Tensor Breast MRI (DTI),Improving the Specificity of Breast MRI Through Diffusion Tensor Breast MRI (DTI),COMPLETED,,INTERVENTIONAL,267.0,ACTUAL,2016-04-01,2020-04-01,"University Health Network, Toronto",OTHER,,SINGLE_GROUP,NONE,OTHER,Diffusion tensor imaging (DTI) in Breast MRI,Breast Cancer,,,,,False,1461.0,True,False,-1.0,False,False,False,1,True,Large (100-300),0,267.0,5.5909869805108565,0,1,0.6,True,True,0.8896113051492235,1,True,0.8519228661137628,1,1,0.80049735,1
NCT02678442,Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle,Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling,COMPLETED,,INTERVENTIONAL,50.0,ACTUAL,2016-05-16,2018-11-10,Mayo Clinic,OTHER,RANDOMIZED,CROSSOVER,SINGLE,"DEVICE, DEVICE","Fine Needle Biopsy (FNB), Fine Needle Aspiration (FNA)",Pancreatic Cancer,,,,,False,908.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,50.0,3.9318256327243257,2,0,0.6,True,True,0.6405291043132446,1,True,0.5891383075536241,1,1,0.6315826,1
NCT05887531,Abdominopelvic Cancer Prehabilitation,Effectiveness of a Prehabilitation Consultation in Self-care and Physical Exercise in Patients Diagnosed With Abdominopelvic Cancer,COMPLETED,,INTERVENTIONAL,66.0,ACTUAL,2023-06-01,2024-10-10,Universitat Jaume I,OTHER,,SINGLE_GROUP,NONE,OTHER,Prehabilitation,"Prehabilitation, Cancer of Colon, Cancer of Rectum, Cancer, Ovarian",,,,,False,497.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,66.0,4.204692619390966,0,0,0.6,True,True,0.7924263558168433,1,True,0.9066334789158386,1,1,0.9052263,1
NCT00480363,QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression,"QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression",COMPLETED,PHASE3,INTERVENTIONAL,120.0,ACTUAL,2007-05-01,2013-07-01,PETHEMA Foundation,OTHER,RANDOMIZED,PARALLEL,NONE,PROCEDURE,Maintenance with lower doses of lenalidomide and dexamethasone,Multiple Myeloma,,,,,False,2253.0,True,False,3.0,True,False,False,1,True,Large (100-300),0,120.0,4.795790545596741,1,1,0.77,True,True,0.5987500047020138,1,True,0.7264204318877687,1,1,0.5907589,1
NCT04587830,ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme,Phase 1-2 Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (GBM),ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,100.0,ACTUAL,2020-09-14,2027-05-30,Polaris Group,INDUSTRY,RANDOMIZED,PARALLEL,QUADRUPLE,"DRUG, DRUG, DRUG","ADI-PEG 20, Temozolomide, Placebo",Glioblastoma Multiforme (GBM),,,,,False,2449.0,False,False,2.0,True,True,True,3,True,Medium (30-100),1,100.0,4.61512051684126,3,1,0.58,True,True,0.618949757938762,1,True,0.7865531686475329,1,1,0.9176351,1
NCT00161226,"A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35","A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35",TERMINATED,,OBSERVATIONAL,44.0,ESTIMATED,2004-02-01,2006-06-01,University of Medicine and Dentistry of New Jersey,OTHER,,,,DEVICE,Levonorgestrel intrauterine system,Endometrial Cancer,,,,,False,851.0,True,False,-1.0,False,False,False,1,False,Medium (30-100),0,44.0,3.80666248977032,0,0,0.6,False,True,0.7291832555202968,0,True,0.7644661403018369,0,1,0.78745306,0
NCT05634785,CD30 CAR for CD30+ NSGCT,Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT),COMPLETED,PHASE2,INTERVENTIONAL,2.0,ACTUAL,2022-12-09,2025-12-18,UNC Lineberger Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG","ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine","Germ Cell Tumor, Nonseminomatous Germ Cell Tumor",,,,,False,1105.0,True,False,2.0,False,False,False,3,True,Small (<30),0,2.0,1.0986122886681098,1,0,0.58,True,False,0.07726700713580603,0,False,0.14151260482308617,0,0,0.17228733,0
NCT01812746,"A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer","An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer",COMPLETED,PHASE2,INTERVENTIONAL,42.0,ACTUAL,2013-04-01,2016-04-01,BIND Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,BIND-014,"CRPC, Prostate Cancer",,,,,False,1096.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,42.0,3.7612001156935615,0,0,0.58,True,True,0.6541607093459845,1,True,0.7495275601145459,1,1,0.7476842,1
NCT01243073,Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera,"A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy",COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2010-12-01,2015-04-01,Geron Corporation,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,Imetelstat,"Essential Thrombocythemia, Polycythemia Vera",,,,,False,1582.0,True,False,2.0,False,False,True,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.58,True,False,0.4917514109683607,0,True,0.5825511256500785,1,1,0.54216886,1
NCT04845035,Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2024-01-01,2029-01-01,University of Michigan Rogel Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine",Acute Lymphoblastic Leukemia,,,,,False,1827.0,True,False,2.0,False,False,False,4,False,,1,0.0,0.0,1,0,0.58,False,False,0.027127165173664234,1,False,0.026832328039285994,1,0,0.0036553543,1
NCT05875935,Assessment of Awake Surgery With Electrocorticographic Recordings in the Management of Gliomas and Correlation With Imaging Data (ECoG),Assessment of Awake Surgery With Electrocorticographic Recordings in the Management of Gliomas and Correlation With Imaging Data,TERMINATED,,INTERVENTIONAL,1.0,ACTUAL,2021-12-17,2022-05-31,Ramsay Générale de Santé,OTHER,,SINGLE_GROUP,NONE,PROCEDURE,ECoG : electrocorticography,"Electrocorticography, Karnofski Index, Glioma",,,,,False,165.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,1.0,0.6931471805599453,0,0,0.6,False,False,0.07346632072535254,1,False,0.14923914355359189,1,0,0.11624132,1
NCT01339039,Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,TERMINATED,PHASE1,INTERVENTIONAL,26.0,ACTUAL,2011-12-01,2017-04-08,"Patrick Y. Wen, MD",OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG, PROCEDURE","Plerixafor, Plerixafor, Bevacizumab, Plerixafor, Surgery","High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)",,,,,False,1955.0,True,False,1.0,False,False,False,5,False,Small (<30),1,26.0,3.295836866004329,1,0,0.56,False,True,0.5422832138010708,0,True,0.626927917880568,0,1,0.6011854,0
NCT03516994,Reducing Disparities in the Quality of Advance Care Planning for Older Adults,REducing Disparities in the QUALity of Palliative Care for Older African Americans Through Improved Advance Care Planning (EQUAL ACP),COMPLETED,,INTERVENTIONAL,790.0,ACTUAL,2018-08-01,2024-04-15,Duke University,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Respecting Choices First Steps, Five Wishes Form","Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications",,,,,False,2084.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,790.0,6.673297967767654,2,1,0.6,True,True,0.9268140043787036,1,True,0.935490694741621,1,1,0.9534917,1
NCT03742596,Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients,Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy on the Immune System Among Colorectal Cancer Patients,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2018-11-07,2022-12-30,King Hussein Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,QUADRUPLE,"DIETARY_SUPPLEMENT, DRUG","Probiotic Formula Capsule, Control",Colorectal Cancer,,,,,False,1514.0,True,False,2.0,False,True,False,2,False,,0,0.0,0.0,2,0,0.58,False,False,0.03078365250454017,1,False,0.01364314770821299,1,0,0.0036558963,1
NCT00567580,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy,ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,1792.0,ACTUAL,2008-02-01,,Radiation Therapy Oncology Group,NETWORK,RANDOMIZED,PARALLEL,NONE,"RADIATION, RADIATION, DRUG, DRUG","PBRT, PLNRT, AA, LHRH agonist",Prostate Cancer,,,,,False,1303.0,False,False,3.0,True,False,False,4,True,Very Large (300+),0,1792.0,7.491645473605133,2,1,0.77,True,True,0.873450069148127,1,True,0.8536965972888187,1,1,0.9040941,1
NCT02048488,"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",COMPLETED,PHASE1,INTERVENTIONAL,72.0,ACTUAL,2012-10-01,2018-06-01,"Tesaro, Inc.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,TSR-011,"Solid Tumors, Lymphomas",,,,,False,2069.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,72.0,4.290459441148391,0,0,0.56,True,True,0.8253522934046151,1,True,0.6266841836112226,1,1,0.5264263,1
NCT06103214,The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery,The Effects of Two Hemodilution Methods on Vascular Endothelial Function in Patients Undergoing Primary Debulking Gynaecological Surgery,COMPLETED,,INTERVENTIONAL,144.0,ACTUAL,2017-01-01,2023-01-31,Zhejiang Cancer Hospital,OTHER,RANDOMIZED,PARALLEL,SINGLE,"OTHER, OTHER","acute normovolemic hemodilution (ANH), acute hypervolemic hemodilution (AHH)",Ovarian Neoplasm Epithelial,,,,,False,2221.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,144.0,4.976733742420574,2,1,0.6,True,True,0.7476359563659575,1,True,0.8095062328222435,1,1,0.76914066,1
NCT00002445,"Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients",A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma,COMPLETED,PHASE3,INTERVENTIONAL,200.0,,,,Cytran,INDUSTRY,,,DOUBLE,DRUG,IM862,"Sarcoma, Kaposi, HIV Infections",,,,,False,1303.0,True,False,3.0,False,True,True,1,True,Large (100-300),0,200.0,5.303304908059076,1,1,0.77,True,True,0.7662892134602775,1,True,0.74222176336635,1,1,0.7408269,1
NCT05521087,A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias,"A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations",WITHDRAWN,PHASE1,INTERVENTIONAL,0.0,ACTUAL,2025-12-26,2030-01-29,"Janssen Research & Development, LLC",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","JNJ-75276617, Fludarabine, Cytarabine, Intrathecal Chemotherapy, Dexamethasone, Vincristine, Pegaspargase","Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage",,,,,False,1495.0,True,False,1.0,False,False,True,7,False,,1,0.0,0.0,1,0,0.56,False,False,0.027679888710000176,1,False,0.012294245430292228,1,0,0.0031873188,1
NCT04116073,INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer,A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer,COMPLETED,PHASE2,INTERVENTIONAL,25.0,ACTUAL,2020-04-09,2024-12-03,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,,SINGLE_GROUP,NONE,DRUG,INCMGA00012 (PD-1 antibody),"Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic",,,,,False,1699.0,True,False,2.0,False,False,False,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.58,True,True,0.5553164005736186,1,True,0.6248706558203017,1,1,0.63721144,1
NCT00983619,A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies,"A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,136.0,ACTUAL,2010-04-16,2019-03-21,MedImmune LLC,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","MEDI-551, Rituximab","B-cell Malignancies, Cancer",,,,,False,3261.0,True,False,1.0,False,False,True,2,True,Large (100-300),1,136.0,4.919980925828125,1,1,0.56,True,True,0.7961850122275215,1,True,0.8159489439225613,1,1,0.7844101,1
NCT07319689,Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients,Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients,COMPLETED,,OBSERVATIONAL,100.0,ACTUAL,2022-01-01,2025-12-18,Tanta University,OTHER,,,,OTHER,Data collection,"Predictor, Myasthenia Gravis, Thoracoscopic Thymectomy, Thymomatous, Non-Thymomatous",,,,,False,1447.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,100.0,4.61512051684126,0,1,0.6,True,True,0.7526815525018893,1,True,0.7248430401411313,1,1,0.6734136,1
NCT00900055,"Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma",Dysregulation of Hematopoiesis in Fanconi Anemia,COMPLETED,,OBSERVATIONAL,213.0,ACTUAL,1975-06-01,2016-08-23,OHSU Knight Cancer Institute,OTHER,,,,"GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, OTHER, OTHER, OTHER","microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique","Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms",,,,,False,15059.0,True,False,-1.0,False,False,False,9,True,Large (100-300),0,213.0,5.365976015021851,1,1,0.6,True,True,0.9872586297208957,1,True,0.8386776931900763,1,1,0.88986653,1
NCT03763266,Low Residue Diet During 3 Days vs 1 Day Prior Colonoscopy,Low Residue Diet 3 Days Versus 1 Day as Preparation for Colonoscopy: a Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,858.0,ACTUAL,2018-12-06,2020-01-20,Parc Taulí Hospital Universitari,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"OTHER, OTHER","1 day low residue diet, 3 day low residue diet","Colonoscopy, Colon Adenoma, Colorectal Neoplasms, Inflammatory Bowel Diseases, Colon Disease",,,,,False,410.0,True,False,-1.0,True,True,False,2,True,Very Large (300+),0,858.0,6.755768921984255,3,1,0.6,True,True,0.9142871035721277,1,True,0.9266100370522337,1,1,0.9496141,1
NCT02833610,A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency,"A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency",COMPLETED,PHASE2,INTERVENTIONAL,55.0,ESTIMATED,2016-08-01,2023-03-20,Massachusetts General Hospital,OTHER,,SINGLE_GROUP,NONE,DRUG,Denosumab Q4W,Multiple Myeloma,,,,,False,2422.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,55.0,4.02535169073515,0,0,0.58,True,True,0.7676105702438387,1,True,0.9179552515480858,1,1,0.84917426,1
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1),COMPLETED,PHASE1,INTERVENTIONAL,47.0,ACTUAL,2017-04-10,2020-03-19,Regeneron Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,REGN2810,Melanoma,,,,,False,1074.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,47.0,3.871201010907891,0,0,0.56,True,True,0.71129219940888,1,True,0.6072175152428262,1,1,0.59903014,1
NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma,WITHDRAWN,EARLY_PHASE1,INTERVENTIONAL,0.0,ACTUAL,2008-11-01,,Northwestern University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION","Rituximab, Cytarabine, Methotrexate, Motexafin gadolinium, Procarbazine hydrochloride, Vincristine sulfate, Radiation therapy","Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity",,,,,False,1303.0,True,False,0.5,False,False,False,7,False,,1,0.0,0.0,1,0,0.57,False,False,0.02797935147926684,1,False,0.023294469364608182,1,0,0.0035476426,1
NCT02943733,Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs,Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors,TERMINATED,PHASE1,INTERVENTIONAL,18.0,ACTUAL,2017-08-22,2022-01-31,"University of Wisconsin, Madison",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","TAS-102, Temozolomide, Filgrastim, Pegfilgrastim","Neuroendocrine Tumors, Neoplasms, Cancer, Tumors",,,,,False,1623.0,True,False,1.0,False,False,False,4,False,Small (<30),1,18.0,2.9444389791664403,1,0,0.56,False,False,0.43562258429934436,1,False,0.45805278800379823,1,0,0.3653822,1
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,Endogenous Heat-shock Vaccines for Melanoma A Feasibility Study,COMPLETED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2005-11-25,2018-05-24,Mayo Clinic,OTHER,RANDOMIZED,,,"BIOLOGICAL, OTHER, OTHER, OTHER, OTHER, PROCEDURE, PROCEDURE, PROCEDURE","sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation",Melanoma (Skin),,,,,False,4563.0,True,False,1.0,True,False,False,8,True,Small (<30),0,11.0,2.4849066497880004,2,0,0.56,True,False,0.36593772038821354,0,False,0.4687619218204494,0,1,0.7521196,1
NCT01078974,"Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia","Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia",TERMINATED,PHASE1,INTERVENTIONAL,7.0,ACTUAL,2010-05-01,2016-03-01,"Steven P. Treon, MD, PhD",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","pomalidomide, dexamethasone, rituximab",Waldenstrom's Macroglobulinemia,,,,,False,2131.0,True,False,1.0,False,False,False,3,False,Small (<30),1,7.0,2.079441541679836,1,0,0.56,False,False,0.25484544784567226,1,False,0.47202275611512495,1,1,0.6045413,0
NCT05161325,A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan,An Observational Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan,ACTIVE_NOT_RECRUITING,,OBSERVATIONAL,525.0,ACTUAL,2020-12-15,2026-06-01,Bristol-Myers Squibb,INDUSTRY,,,,,,Non-Small Cell Lung Cancer,,,,,False,1994.0,False,False,-1.0,False,False,True,0,True,Very Large (300+),0,525.0,6.26530121273771,0,1,0.6,True,True,0.9430112853843593,1,True,0.9359907244920045,1,1,0.9127091,1
NCT02973217,Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer,"Prospective, Open, Non Comparative Trial to Evaluate Safety and Feasibility of Immunostimulating Interstitial Laser Thermotherapy (imILT) in Stage III Pancreatic Carcinoma",COMPLETED,,INTERVENTIONAL,5.0,ACTUAL,2016-10-01,2019-07-22,Clinical Laserthermia Systems AB,INDUSTRY,,SINGLE_GROUP,NONE,DEVICE,Immunostimulating Interstitial Laser Thermotherapy,Neoplasms Pancreatic,,,,,False,1024.0,True,False,-1.0,False,False,True,1,True,Small (<30),0,5.0,1.791759469228055,0,0,0.6,True,False,0.2394150519187994,0,False,0.31872202394633414,0,0,0.41023844,0
NCT00315731,"A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma","A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,15.0,ACTUAL,2003-03-31,2013-06-30,GlaxoSmithKline,INDUSTRY,,SINGLE_GROUP,NONE,BIOLOGICAL,Follicular Lymphoma,"Lymphoma, Follicular",,,,,False,3744.0,True,False,1.0,False,False,True,1,True,Small (<30),0,15.0,2.772588722239781,0,0,0.56,True,True,0.5679910499189182,1,True,0.7650116569167738,1,1,0.7793174,1
NCT00954525,Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer,"Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer",COMPLETED,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2009-07-01,2011-12-01,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,,SINGLE_GROUP,NONE,"DRUG, DIETARY_SUPPLEMENT","Gemcitabine and Erlotinib, Intravenous Vitamin C",Metastatic Pancreatic Cancer,,,,,False,883.0,True,False,1.0,False,False,False,2,True,Small (<30),1,14.0,2.70805020110221,1,0,0.56,True,False,0.3478989501793487,0,False,0.4777244173715821,0,1,0.5181034,1
NCT00342446,A Follow-up Study of Women Evaluated and Treated for Infertility,Follow-Up Study of Women Evaluated and Treated for Infertility,COMPLETED,,OBSERVATIONAL,12193.0,ACTUAL,1995-10-01,2023-01-11,National Cancer Institute (NCI),NIH,,,,,,"Ovarian Cancer, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Colorectal Cancer, Melanoma",,,,,False,9964.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.9827583021405095,1,True,0.9403859858824475,1,1,0.95945007,1
NCT05984199,Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant,Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation,TERMINATED,PHASE1,INTERVENTIONAL,38.0,ACTUAL,2023-12-11,2025-05-28,Vor Biopharma,INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,BIOLOGICAL,VCAR33,"Leukemia, Myeloid, Acute",,,,,False,534.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.56,False,True,0.6381355418909307,0,True,0.5172454949367771,0,0,0.3656762,1
NCT01876238,Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer,Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer,COMPLETED,,INTERVENTIONAL,29.0,ACTUAL,2013-05-01,2015-06-01,Case Comprehensive Cancer Center,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","T-PAT, Surveys","Advanced Breast Cancer, Stage 4 Breast Cancer, Recurrent Breast Cancer",,,,,False,761.0,True,False,-1.0,True,False,False,2,True,Small (<30),0,29.0,3.4011973816621555,2,0,0.6,True,False,0.494642923118354,0,True,0.6490823476002044,1,1,0.6382473,1
NCT01030302,A Retreatment Study With Bortezomib for Multiple Myeloma,"An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma",COMPLETED,,OBSERVATIONAL,56.0,ACTUAL,2008-11-01,2010-09-01,"Janssen Korea, Ltd., Korea",INDUSTRY,,,,DRUG,bortezomib,Multiple Myeloma,,,,,False,669.0,True,False,-1.0,False,False,True,1,True,Medium (30-100),0,56.0,4.04305126783455,0,0,0.6,True,True,0.7692936047991524,1,True,0.7163943416476758,1,1,0.7692983,1
NCT05968846,Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load,"Repeat PET/CT Imaging of Patients With Systemic Amyloidosis Using Amyloid Reactive Peptide 124I-AT-01 (124I-p5+14, Iodine-124I-evuzamitide) to Measure Changes in Organ-specific Amyloid Load",COMPLETED,PHASE2,INTERVENTIONAL,19.0,ACTUAL,2022-12-07,2023-09-01,University of Tennessee Graduate School of Medicine,OTHER,,SINGLE_GROUP,NONE,DRUG,Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01),Systemic Amyloidosis,,,,,False,268.0,True,False,2.0,False,False,False,1,True,Small (<30),0,19.0,2.995732273553991,0,0,0.58,True,False,0.411134128515442,0,False,0.4776485129721742,0,0,0.3947098,0
NCT03217539,The Swedish Two-County Trial of Mammography Screening,The Two-County Swedish Mammography Screening Trial,COMPLETED,,INTERVENTIONAL,133065.0,ACTUAL,1977-07-07,2015-12-31,"Dalarna County Council, Sweden",OTHER,RANDOMIZED,PARALLEL,NONE,DIAGNOSTIC_TEST,Imaging,Breast Neoplasm Female,,,,,False,14056.0,True,False,-1.0,True,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,1,1,0.6,True,True,0.9892726164254172,1,True,0.9443023444513546,1,1,0.98244196,1
NCT03547453,Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome,Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome,COMPLETED,,OBSERVATIONAL,240.0,ACTUAL,2018-06-04,2022-12-31,Cornell University,OTHER,,,,,,"Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity",,,,,False,1671.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,240.0,5.484796933490655,0,1,0.6,True,True,0.8859963623251664,1,True,0.8041585644454193,1,1,0.80304235,1
NCT02324543,Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer,Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer,COMPLETED,PHASE1,INTERVENTIONAL,47.0,ACTUAL,2015-02-01,2020-02-01,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Gemcitabine, Taxotere, Xeloda, Cisplatin, Irinotecan",Metastatic Pancreatic Adenocarcinoma,,,,,False,1826.0,True,False,1.0,False,False,False,5,True,Medium (30-100),1,47.0,3.871201010907891,1,0,0.56,True,True,0.681385183905016,1,True,0.7433591066674891,1,1,0.6941374,1
NCT02865135,"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients",COMPLETED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2017-03-30,2023-02-06,Dana-Farber Cancer Institute,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG","DPX-E7 vaccine, Cyclophosphamide","Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus",,,,,False,2139.0,True,False,1.0,False,False,False,2,True,Small (<30),1,11.0,2.4849066497880004,1,0,0.56,True,False,0.35220811439009225,0,False,0.4506772947865541,0,1,0.59080595,1
NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,COMPLETED,PHASE3,INTERVENTIONAL,646.0,ACTUAL,2004-12-01,2014-06-01,"Janssen Research & Development, LLC",INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Bortezomib (VELCADE), Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)",Multiple Myeloma,,,,,False,3469.0,True,False,3.0,True,False,True,3,True,Very Large (300+),1,646.0,6.472346294500901,2,1,0.77,True,True,0.8727400034191127,1,True,0.9577131271498903,1,1,0.9644161,1
NCT01267357,P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer,"Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance",COMPLETED,,OBSERVATIONAL,62.0,ACTUAL,2010-07-01,,Rambam Health Care Campus,OTHER,,,,OTHER,no intervention,Serous Papillary Endometrial Cancer,,,,,False,1303.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,62.0,4.143134726391533,0,0,0.6,True,True,0.8088129140587159,1,True,0.8839154137619128,1,1,0.86688834,1
NCT03452982,Sentinel Lymph Node in Early Ovarian Cancer,Sentinel Lymph Node in Early Ovarian Cancer,COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2018-03-23,2019-08-21,Instituto de Investigacion Sanitaria La Fe,OTHER,,SINGLE_GROUP,NONE,OTHER,sentinel node technique,Ovarian Cancer,,,,,False,516.0,True,False,2.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.58,True,False,0.4366295553144997,0,False,0.430615506655208,0,0,0.376953,0
NCT03187210,Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas,"Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study",SUSPENDED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2018-09-01,2025-04-30,"Insel Gruppe AG, University Hospital Bern",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Brentuximab Vedotin, BeEAM Regimen",Lymphoma,,,,,False,2433.0,False,False,1.0,True,False,False,2,False,Small (<30),0,20.0,3.044522437723423,2,0,0.56,False,False,0.43470824701888083,1,True,0.6166192409977393,0,1,0.57984424,0
NCT01637766,Intra-arterial Chemotherapy for Spinal Metastases,Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2012-04-01,2018-12-01,Weill Medical College of Cornell University,OTHER,,SINGLE_GROUP,NONE,DRUG,Melphalan (intra-arterial infusion),"Spinal Diseases, Spinal Metastases, Spinal Tumors",,,,,False,2435.0,True,False,1.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.56,True,False,0.444169159709236,0,False,0.45634673815725696,0,0,0.4237799,0
NCT00559611,Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC),Prospective Comparison of Endobronchial Ultrasound Needle Biopsy Versus Mediastinoscopy for Staging of Mediastinal Nodes in Patients With Clinical Stage IIIA Non-Small Cell Lung Cancer (NSCLC),COMPLETED,,INTERVENTIONAL,53.0,ACTUAL,2007-10-19,2018-03-22,M.D. Anderson Cancer Center,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE","Endobronchial Ultrasound, Mediastinoscopy",Lung Cancer,,,,,False,3807.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,53.0,3.9889840465642745,1,0,0.6,True,True,0.8308654233861907,1,True,0.8110092098676173,1,1,0.7598688,1
NCT00002480,Radiation Therapy in Treating Patients With Prostate Cancer,Phase I Study of 3-Dimensional Conformal Radiotherapy in Patients With Locally Advanced (Stage T2c and T3) Adenocarcinoma of the Prostate,COMPLETED,PHASE1,INTERVENTIONAL,,,1991-02-01,2005-08-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,RADIATION,radiation therapy,Prostate Cancer,,,,,False,5295.0,True,False,1.0,False,False,False,1,True,,0,,,0,0,0.56,True,True,0.8610035920718846,1,True,0.8159633471210183,1,1,0.9194594,1
NCT05393258,Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas,A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy,ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,13.0,ACTUAL,2022-06-28,2026-05-27,Washington University School of Medicine,OTHER,,SINGLE_GROUP,NONE,RADIATION,temporally-modulated pulsed radiotherapy (TMPRT),"Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant",,,,,False,1429.0,False,False,-1.0,False,False,False,1,True,Small (<30),0,13.0,2.6390573296152584,0,0,0.6,True,False,0.46281978584199235,0,False,0.49056325678348417,0,0,0.40148434,0
NCT00776945,Feasibility and Functionality of fPAM Imaging in Melanoma,Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma,TERMINATED,,OBSERVATIONAL,2.0,ACTUAL,2009-01-01,2014-12-01,Washington University School of Medicine,OTHER,,,,,,Melanoma,,,,,False,2160.0,True,False,-1.0,False,False,False,0,False,Small (<30),0,2.0,1.0986122886681098,0,0,0.6,False,False,0.16033197779037134,1,False,0.2678104604940438,1,0,0.384188,1
NCT06180226,Evaluation of Brain Functional Changes With 18F-FDG PET and Cognitive Processes After Brain Radiotherapy for Cavernous Sinus Meningiomas and Non-secreting ACTH Adenomas,Evaluation of Brain Functional Changes With 18F-FDG PET and Cognitive Processes After Brain Radiotherapy for Cavernous Sinus Meningiomas and Non-secreting ACTH Adenomas,COMPLETED,,OBSERVATIONAL,20.0,ACTUAL,2008-04-21,2014-12-11,IRCCS San Raffaele,OTHER,,,,DIAGNOSTIC_TEST,PET CT with 18 FDG .,Meningioma,,,,,False,2425.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.6,True,True,0.6219774258453239,1,True,0.5418142349395358,1,1,0.6135912,1
NCT00508274,Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China,An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer,TERMINATED,PHASE3,INTERVENTIONAL,52.0,ACTUAL,2007-07-18,2020-07-01,Novartis Pharmaceuticals,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","lapatinib, capecitabine","Neoplasms, Breast",,,,,False,4732.0,True,False,3.0,False,False,True,2,False,Medium (30-100),1,52.0,3.970291913552122,1,0,0.77,False,True,0.7348876088147852,0,True,0.8596100194303683,0,1,0.8254342,0
NCT01006304,An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model,"A Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Effects of JNJ-39439335 (a TRPV1 Antagonist) in Healthy Male Adult Subjects on the Paradoxical Pain Induced by a Thermal Grill",COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2009-06-01,2010-06-01,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,RANDOMIZED,CROSSOVER,TRIPLE,DRUG,"JNJ-39439335, Placebo",Pain,,,,,False,365.0,True,False,1.0,True,True,True,1,True,Small (<30),0,12.0,2.5649493574615367,2,0,0.56,True,False,0.2933892026294709,0,False,0.3860833328991987,0,0,0.3109625,0
NCT00003992,Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2,Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer,COMPLETED,PHASE2,INTERVENTIONAL,200.0,ACTUAL,1999-08-01,2009-03-01,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG","trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate",Breast Cancer,,,,,False,3500.0,True,False,2.0,True,False,False,5,True,Large (100-300),1,200.0,5.303304908059076,2,1,0.58,True,True,0.7741236175875464,1,True,0.8992102576314963,1,1,0.92145574,1
NCT00592371,Head and Neck Cancer Screening and Serum Repository,Head and Neck Cancer Screening and Serum Repository,COMPLETED,,OBSERVATIONAL,300.0,ACTUAL,2006-03-01,2012-09-01,University of Arkansas,OTHER,,,,,,Head and Neck Squamous Cell Cancer,,,,,False,2376.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,300.0,5.707110264748875,0,1,0.6,True,True,0.9172554305979518,1,True,0.9017495113278801,1,1,0.9103547,1
NCT03799523,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,COMPLETED,,INTERVENTIONAL,75.0,ACTUAL,2019-01-16,2024-02-22,The University of Texas Health Science Center at San Antonio,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER","Temporary skin markings, Surface imaging",Breast Cancer,,,,,False,1863.0,True,False,-1.0,False,False,False,2,True,Medium (30-100),0,75.0,4.330733340286331,1,0,0.6,True,True,0.8246829042521459,1,True,0.7710941170392165,1,1,0.6827015,1
NCT04626479,Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A),A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants,ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,400.0,ESTIMATED,2020-12-16,2026-05-31,Merck Sharp & Dohme LLC,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, BIOLOGICAL, DRUG","Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab","Carcinoma, Renal Cell",,,,,False,1992.0,False,False,1.0,True,False,True,6,True,Very Large (300+),1,400.0,5.993961427306569,2,1,0.56,True,True,0.8440093802582236,1,True,0.9078353326483192,1,1,0.9589814,1
NCT04693546,Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening,Subject Enrollment and Specimen Collection Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for Colorectal Cancer Screening,SUSPENDED,,OBSERVATIONAL,12000.0,ESTIMATED,2026-03-01,2028-03-01,Metabiomics Corp,INDUSTRY,,,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","LifeKit Prevent Colorectal Neoplasia Test, FIT Test","Colorectal Cancer, Colorectal Adenoma",,,,,False,731.0,False,False,-1.0,False,False,True,2,False,Very Large (300+),0,5757.019999999997,8.658348944594362,1,1,0.6,False,True,0.8690681258797438,0,True,0.9220230010765675,0,1,0.94391674,0
NCT01753297,A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.,"A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients",COMPLETED,PHASE4,INTERVENTIONAL,226.0,ACTUAL,2012-12-11,2019-09-09,Ipsen,INDUSTRY,RANDOMIZED,PARALLEL,NONE,DRUG,Triptorelin 11.25 mg,Prostate Cancer,,,,,False,2463.0,True,False,4.0,True,False,True,1,True,Large (100-300),0,226.0,5.424950017481403,1,1,0.7,True,True,0.7370141065790821,1,True,0.7955344811039577,1,1,0.89762163,1
NCT04047004,Adjuvant PIPAC in Gastric Cancer Patients,Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study),COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2020-03-11,2022-10-01,Michael Bau Mortensen,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Doxorubicin, Cisplatin","Gastric Adenocarcinoma, Gastric Cancer",,,,,False,934.0,True,False,1.0,False,False,False,2,True,Small (<30),1,20.0,3.044522437723423,1,0,0.56,True,False,0.43710085512224756,0,True,0.5567803040727363,1,1,0.5055066,1
NCT03444207,Effect of Endurance and Endurance-Strength Training on Inflammatory Markers in Women With Abdominal Obesity,Effect of Endurance and Endurance-Strength Training on Inflammatory Markers in Women With Abdominal Obesity,COMPLETED,,INTERVENTIONAL,38.0,ACTUAL,2012-12-06,2017-12-30,Poznan University of Medical Sciences,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Endurance training, Endurance-strength training",Obesity,,,,,False,1850.0,True,False,-1.0,True,False,False,2,True,Medium (30-100),0,38.0,3.6635616461296463,2,0,0.6,True,True,0.6194241024119553,1,True,0.6661840772659713,1,1,0.5861676,1
NCT00962312,Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer,A Phase II Study of Lapatinib and Capecitabine in the Treatment of Metastatic Pancreatic Cancer.,COMPLETED,PHASE2,INTERVENTIONAL,9.0,ACTUAL,2009-01-01,,Cancer Trials Ireland,NETWORK,,SINGLE_GROUP,NONE,"DRUG, DRUG","capecitabine, lapatinib ditosylate",Pancreatic Cancer,,,,,False,1303.0,True,False,2.0,False,False,False,2,True,Small (<30),1,9.0,2.302585092994046,1,0,0.58,True,False,0.24359100619290608,0,False,0.14674521178719088,0,0,0.10822973,0
NCT00693927,Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC),Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial,COMPLETED,PHASE2,INTERVENTIONAL,54.0,ACTUAL,2002-03-01,2008-05-01,University of Liege,OTHER,RANDOMIZED,PARALLEL,NONE,"PROCEDURE, PROCEDURE","Unmanipulated PBSC after nonmyeloablative conditioning, CD8-depleted PBSC after nonmyeloablative conditioning",Hematologic Malignancies,,,,,False,2253.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,54.0,4.007333185232471,2,0,0.58,True,True,0.6416164240243761,1,True,0.6973022764620151,1,0,0.48078954,0
NCT03319940,"Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)","A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,269.0,ACTUAL,2017-12-26,2027-12-31,Amgen,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Tarlatamab, Pembrolizumab, CRS Mitigation Strategies",Small Cell Lung Carcinoma,,,,,False,3657.0,False,False,1.0,False,False,True,3,True,Large (100-300),1,269.0,5.598421958998375,1,1,0.56,True,True,0.8898960995962482,1,True,0.8104699065970712,1,1,0.83251727,1
NCT00960752,Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,COMPLETED,PHASE2,INTERVENTIONAL,47.0,ACTUAL,2010-05-20,2020-07-20,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,FACTORIAL,NONE,"DRUG, DRUG, DRUG","gp100, R848 gel, MAGE-3",Melanoma,,,,,False,3714.0,True,False,2.0,True,False,False,3,True,Medium (30-100),0,47.0,3.871201010907891,2,0,0.58,True,True,0.6728313892798966,1,True,0.8695689015899495,1,1,0.8590159,1
NCT02948478,Economic and Social Disparities and Breast Cancer,"Breast Cancer and Precariousness: Influence of Socio-demographic Inequalities in Cancer Stage at Diagnosis, Treatment Management and Rehabilitation in the Ile de France Area",COMPLETED,,OBSERVATIONAL,936.0,ACTUAL,2016-12-01,2021-02-23,Assistance Publique - Hôpitaux de Paris,OTHER,,,,"OTHER, OTHER","Exposed, Non exposed",Breast Cancer,,,,,False,1545.0,True,False,-1.0,False,False,False,2,True,Very Large (300+),0,936.0,6.842683282238422,1,1,0.6,True,True,0.9467004672504195,1,True,0.921211110287555,1,1,0.9300201,1
NCT03067792,FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer,,COMPLETED,PHASE3,INTERVENTIONAL,52.0,ACTUAL,2014-12-01,2016-10-17,Yonsei University,OTHER,RANDOMIZED,PARALLEL,,"DRUG, DRUG","5-fluorouracil, irinotecan and leucovorin, docetaxel and cisplatin",Inoperable Gastric Cancer,,,,,False,686.0,True,False,3.0,True,False,False,2,True,Medium (30-100),1,52.0,3.970291913552122,2,0,0.77,True,False,0.4569935531367703,0,False,0.3734182294744804,0,0,0.28186074,0
NCT06673901,Biomechanical Changes in Females with Poly Cystic Ovarian Syndrome,Biomechanical Changes in Females with Poly Cystic Ovarian Syndrome,COMPLETED,,OBSERVATIONAL,95.0,ACTUAL,2023-04-03,2024-09-03,Cairo University,OTHER,,,,DEVICE,Measurments,"Poly Cystic Ovarian Syndrome, Polycystic Ovary Syndrome (PCOS)",,,,,False,519.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,95.0,4.564348191467836,0,0,0.6,True,True,0.8482489345367438,1,True,0.7507474450355693,1,1,0.8250189,1
NCT04741503,Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool,Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool,COMPLETED,,INTERVENTIONAL,1277.0,ACTUAL,2021-04-19,2021-08-30,Washington University School of Medicine,OTHER,RANDOMIZED,PARALLEL,NONE,"OTHER, OTHER","Breast Cancer Screening Decision Support Tool, National Cancer Institute Breast Cancer Screening PDQ","Breast Cancer Screening, Oncology, Preventative Medicine, Mammography",,,,,False,133.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,1277.0,7.15305163493748,2,1,0.6,True,True,0.9148774181647599,1,True,0.9269868955664435,1,1,0.9874434,1
NCT01167374,Carbon Ion Radiotherapy for Hepatocellular Carcinoma,Phase I Study Evaluating the Treatment of Patients With Hepatocellular Carcinoma (HCC) With Carbon Ion Radiotherapy,TERMINATED,,INTERVENTIONAL,21.0,ACTUAL,2011-08-01,2022-08-01,University Hospital Heidelberg,OTHER,,SINGLE_GROUP,NONE,RADIATION,Carbon Ion Radiotherapy,Hepatocellular Carcinoma,,,,,False,4018.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,21.0,3.091042453358316,0,0,0.6,False,True,0.7067833242520736,0,True,0.5764384182753345,0,1,0.53471226,0
NCT01161550,Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML,Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML,COMPLETED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2010-11-01,2012-08-01,Washington University School of Medicine,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine, All-Trans Retinoic Acid (ATRA), Midostaurin","Leukemia, Myeloid, Acute",,,,,False,639.0,True,False,1.0,False,False,False,5,True,Small (<30),1,11.0,2.4849066497880004,1,0,0.56,True,False,0.27228025956798374,0,False,0.36062861428486365,0,0,0.34696192,0
NCT05166148,Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients,Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2021-11-22,2022-04-28,Institut de cancérologie Strasbourg Europe,OTHER,,SINGLE_GROUP,NONE,"OTHER, OTHER, OTHER","Session (a), Session (b), Session (c)",Breast Cancer,,,,,False,157.0,True,False,-1.0,False,False,False,3,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.6,True,False,0.326739674977479,0,True,0.5300867464376242,1,0,0.38701338,0
NCT01305044,The HEALS Project - Health Education and Active Living for Surviving Seniors,Biobehavioral Effects of Tai Chi Chih Among Elderly Female Cancer Survivors,COMPLETED,PHASE2,INTERVENTIONAL,63.0,ACTUAL,2009-12-01,2011-11-01,University of Utah,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Tai Chi Chih, Health Education Classes","Cancer Survivorship, Safety and Efficacy, Quality of Life",,,,,False,700.0,True,False,2.0,True,False,False,2,True,Medium (30-100),0,63.0,4.158883083359672,2,0,0.58,True,True,0.6034350077582672,1,True,0.7218393642906683,1,1,0.79304844,1
NCT03677362,Weight Loss Intervention in Women With PCOS,Weight Loss Intervention in Women With PCOS,COMPLETED,,INTERVENTIONAL,12.0,ACTUAL,2018-09-10,2020-02-22,University of Kansas Medical Center,OTHER,,SINGLE_GROUP,NONE,BEHAVIORAL,Weight loss intervention,"Polycystic Ovary Syndrome, Overweight and Obesity",,,,,False,530.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,12.0,2.5649493574615367,0,0,0.6,True,False,0.39732702886267957,0,True,0.5313740471160893,1,0,0.45025513,0
NCT04681768,Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients,Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden,COMPLETED,,OBSERVATIONAL,95.0,ACTUAL,2020-12-22,2025-04-01,Technical University of Munich,OTHER,,,,DRUG,Abemaciclib,Breast Cancer/ Metastatic Breast Cancer,,,,,False,1561.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),1,95.0,4.564348191467836,0,0,0.6,True,True,0.8709660682350141,1,True,0.6940796273116433,1,1,0.6241724,1
NCT02973113,"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE),COMPLETED,PHASE1,INTERVENTIONAL,8.0,ACTUAL,2016-02-16,2020-07-11,Baylor College of Medicine,OTHER,,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","EBVST Cells, Nivolumab","NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD, Hodgkin Lymphoma, EBV Related Non-Hodgkin's Lymphoma, EBV Related Hodgkin's Lymphoma",,,,,False,1607.0,True,False,1.0,False,False,False,2,True,Small (<30),1,8.0,2.19722457733622,1,0,0.56,True,False,0.26247334585339854,0,False,0.41700728118369684,0,1,0.52113414,1
NCT03637868,Eribulin in Brain Metastases From HER2-negative Breast Cancer,A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes,WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2019-02-26,2020-04-14,Institut Paoli-Calmettes,OTHER,,SINGLE_GROUP,NONE,DRUG,Eribulin,Metastatic Breast Cancer,,,,,False,413.0,True,False,2.0,False,False,False,1,False,,0,0.0,0.0,0,0,0.58,False,False,0.026688052554047662,1,False,0.00637878469690907,1,0,0.0024581382,1
NCT01696968,Screening for Lung Cancer in Older Patients (PLCO Screening Trial),"Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial",ACTIVE_NOT_RECRUITING,,INTERVENTIONAL,154901.0,ACTUAL,1993-11-16,2026-03-25,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,SINGLE,"OTHER, PROCEDURE","Screening Questionnaire Administration, X-Ray Imaging",Lung Carcinoma,,,,,False,11817.0,False,False,-1.0,True,False,False,2,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.6,True,True,0.979163374717848,1,True,0.8988796568267469,1,1,0.9673788,1
NCT03020238,Impact of Nerve-sparing Radical Hysterectomy on Patients' Urinary Dynamics,Impact of Nerve-sparing Radical Hysterectomy on Patients' Urinary Dynamics: a Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,120.0,ACTUAL,2013-01-01,2017-01-01,Peking Union Medical College Hospital,OTHER,RANDOMIZED,FACTORIAL,NONE,"PROCEDURE, PROCEDURE","BiClamp group, water jet group","Cervical Cancer, Urinary Retention",,,,,False,1461.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,120.0,4.795790545596741,2,1,0.6,True,True,0.677826967171775,1,True,0.8215334403558571,1,1,0.7342335,1
NCT05105841,Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),A Phase 2 Study of the Safety and Efficacy of Venetoclax in Combination With Obinutuzumab or Ibrutinib in Japanese Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),COMPLETED,PHASE2,INTERVENTIONAL,20.0,ACTUAL,2021-11-08,2025-10-09,AbbVie,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","Venetoclax, Ibrutinib, Obinutuzumab","Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)",,,,,False,1431.0,True,False,2.0,True,False,True,3,True,Small (<30),1,20.0,3.044522437723423,2,0,0.58,True,False,0.3381880622724721,0,False,0.3448825789401097,0,0,0.3931232,0
NCT00079105,A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years,"A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years; Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma",COMPLETED,PHASE2,INTERVENTIONAL,175.0,ACTUAL,2004-01-01,2010-12-01,Newcastle-upon-Tyne Hospitals NHS Trust,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","bleomycin sulfate, cyclophosphamide, etoposide, mitoxantrone hydrochloride, prednisolone, procarbazine hydrochloride, vinblastine sulfate",Lymphoma,,,,,False,2526.0,True,False,2.0,True,False,False,7,True,Large (100-300),1,175.0,5.170483995038151,2,1,0.58,True,True,0.7020694135465207,1,True,0.7770090386528952,1,1,0.8113497,1
NCT07150104,"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM","A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 7 - Belantamab Mafodotin, Nirogacestat, Pomalidomide, and Dexamethasone in Combination",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,14.0,ACTUAL,2022-08-31,2027-03-11,GlaxoSmithKline,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Belantamab mafodotin, Nirogacestat, Pomalidomide, Dexamethasone",Multiple Myeloma,,,,,False,1653.0,False,False,1.0,False,False,True,4,True,Small (<30),0,14.0,2.70805020110221,1,0,0.56,True,False,0.3820609883835031,0,False,0.4115396047517308,0,0,0.36916998,0
NCT04609319,Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review,ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review,COMPLETED,,OBSERVATIONAL,307.0,ACTUAL,2021-06-11,2024-05-28,Pfizer,INDUSTRY,,,,DRUG,Dacomitinib,Lung Cancer,,,,,False,1082.0,True,False,-1.0,False,False,True,1,True,Very Large (300+),0,307.0,5.730099782973574,0,1,0.6,True,True,0.894437589705494,1,True,0.9228379345143535,1,1,0.93211687,1
NCT01877109,Samsung Medical Center-Lymphoma Cohort Study-II,Prospective Observation Cohort Study of Malignant Lymphoma Patients,COMPLETED,,OBSERVATIONAL,1358.0,ACTUAL,2012-02-01,2017-02-28,Samsung Medical Center,OTHER,,,,,,Lymphoma,,,,,False,1854.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,1358.0,7.214504414151143,0,1,0.6,True,True,0.965501683363265,1,True,0.9651876717086058,1,1,0.9717985,1
NCT00502177,Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin,Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin,COMPLETED,,OBSERVATIONAL,48.0,ACTUAL,2007-06-19,2018-08-29,M.D. Anderson Cancer Center,OTHER,,,,BEHAVIORAL,Questionnaire,Peritoneal Neoplasms,,,,,False,4089.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,48.0,3.8918202981106265,0,0,0.6,True,True,0.8526126670380351,1,True,0.7892754008205918,1,1,0.77881235,1
NCT04609137,Early Drain Removal Versus Standard Drain Management After Distal Pancreatectomy (Early-Dist),EARLY-DIST - Early Drain Removal Versus Standard Drain Management After Distal Pancreatectomy: a Randomized Controlled Trial,COMPLETED,,INTERVENTIONAL,150.0,ACTUAL,2020-10-13,2023-10-30,IRCCS San Raffaele,OTHER,RANDOMIZED,PARALLEL,SINGLE,"PROCEDURE, PROCEDURE","Early drain removal, Standard drain removal","Pancreas Disease, Complication,Postoperative, PROMs, Pancreatic Fistula",,,,,False,1112.0,True,False,-1.0,True,False,False,2,True,Large (100-300),0,150.0,5.017279836814924,2,1,0.6,True,True,0.7101524686544275,1,True,0.8498033856049833,1,1,0.762094,1
NCT00305643,Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer,A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer,TERMINATED,PHASE3,INTERVENTIONAL,11.0,ACTUAL,2006-02-01,2008-10-01,M.D. Anderson Cancer Center,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DRUG, DRUG, PROCEDURE, DRUG","Capecitabine, Celecoxib, Radiation Therapy, Placebo","Breast Cancer, Colorectal Cancer, Pain",,,,,False,973.0,True,False,3.0,True,True,False,4,False,Small (<30),1,11.0,2.4849066497880004,3,0,0.77,False,False,0.16390748244351966,1,False,0.16868433343380265,1,0,0.1298946,1
NCT04655157,Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma,A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma),TERMINATED,PHASE1,INTERVENTIONAL,2.0,ACTUAL,2021-05-28,2022-09-20,"Jason J. Luke, MD",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG","encorafenib, nivolumab, ipilimumab, binimetinib",Melanoma,,,,,False,480.0,True,False,1.0,True,False,False,4,False,Small (<30),1,2.0,1.0986122886681098,2,0,0.56,False,False,0.05429465806904999,1,False,0.04775400241845953,1,0,0.042065654,1
NCT02093403,Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia,COMPLETED,PHASE1,INTERVENTIONAL,25.0,ACTUAL,2014-03-01,2016-11-26,Bhavana Bhatnagar,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, OTHER, OTHER","decitabine, selinexor, pharmacological study, laboratory biomarker analysis","Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia",,,,,False,1001.0,True,False,1.0,False,False,False,4,True,Small (<30),0,25.0,3.258096538021482,1,0,0.56,True,False,0.4947642396429538,0,False,0.37276839391411554,0,0,0.36819857,0
NCT04488003,Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations,"A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations",TERMINATED,PHASE2,INTERVENTIONAL,104.0,ACTUAL,2021-01-07,2023-05-23,"BioMed Valley Discoveries, Inc",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, DRUG","Ulixertinib, Physician's Choice","Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation, MEK Alteration, MAP2K1 Gene Mutation, MAP2K1 Gene Alteration, MAP2K2 Gene Mutation, MAP2K2 Gene Alteration",,,,,False,866.0,True,False,2.0,False,False,True,2,False,Large (100-300),0,104.0,4.653960350157523,1,1,0.58,False,True,0.6150334568096716,0,True,0.6958632186030118,0,1,0.7595861,0
NCT00520637,"A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)","A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)",COMPLETED,PHASE1,INTERVENTIONAL,34.0,,2007-05-01,,"Enzon Pharmaceuticals, Inc.",INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,EZN-2208,"Advanced Solid Tumors, Lymphoma",,,,,False,1303.0,True,False,1.0,False,False,True,1,True,Medium (30-100),0,34.0,3.555348061489413,0,0,0.56,True,True,0.6482199501539601,1,True,0.5572779687093125,1,1,0.5021874,1
NCT05246462,The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients,"The Effect of Logotherapy on Traumatic Stress Symptom, Post-Traumatic Growth, Finding Meaning in Life, and Spiritual Well-Being in Gynecological Cancer Patients: A Randomized Control Study",COMPLETED,,INTERVENTIONAL,68.0,ACTUAL,2019-03-25,2019-12-15,Akdeniz University,OTHER,RANDOMIZED,PARALLEL,SINGLE,OTHER,Logotherapy,"Cancer of Ovary, Endometrium Cancer, Cervix Cancer",,,,,False,265.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,68.0,4.23410650459726,1,0,0.6,True,True,0.7255958233095527,1,True,0.9130114295154779,1,1,0.8941492,1
NCT00101998,Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects",COMPLETED,PHASE2,INTERVENTIONAL,233.0,ACTUAL,2003-10-01,2006-05-01,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG","alvimopan, placebo","Constipation, Bowel Dysfunction",,,,,False,943.0,True,False,2.0,True,True,True,2,True,Large (100-300),0,233.0,5.455321115357702,3,1,0.58,True,True,0.7431947313938487,1,True,0.6690889872361839,1,1,0.51684374,1
NCT00694759,Cortisol Regulation in Polycystic Ovary Syndrome (PCOS),Cortisol Regulation in Polycystic Ovary Syndrome,COMPLETED,,INTERVENTIONAL,37.0,ACTUAL,2006-10-01,2011-07-01,Oregon Health and Science University,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG","pioglitazone, metformin, placebo",Polycystic Ovary Syndrome,,,,,False,1734.0,True,False,-1.0,True,False,False,3,True,Medium (30-100),0,37.0,3.6375861597263857,2,0,0.6,True,True,0.6021898303188116,1,True,0.6264192357513714,1,1,0.5279347,1
NCT06195085,CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors,Long-term Outcomes of CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors,COMPLETED,,OBSERVATIONAL,38.0,ACTUAL,2013-07-01,2023-07-01,Peking University Third Hospital,OTHER,,,,RADIATION,CT-guided radioactive iodine-125 seed implantation,"Brachytherapy, Desmoid Tumor, Radioactive Iodine-125 Seed Implantation",,,,,False,3652.0,True,False,-1.0,False,False,False,1,True,Medium (30-100),0,38.0,3.6635616461296463,0,0,0.6,True,True,0.8053864602250635,1,True,0.7087988989942695,1,1,0.76840514,1
NCT02057874,3-Tesla MRI Response to TACE in HCC (Liver Cancer),Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC),TERMINATED,,INTERVENTIONAL,2.0,ACTUAL,2014-02-01,2015-12-04,Vanderbilt-Ingram Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DEVICE, DRUG","3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)","Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Stage A Adult Primary Liver Cancer (BCLC), Stage B Adult Primary Liver Cancer (BCLC)",,,,,False,671.0,True,False,-1.0,False,False,False,2,False,Small (<30),0,2.0,1.0986122886681098,1,0,0.6,False,False,0.10025682384819642,1,False,0.08184441483561165,1,0,0.07320826,1
NCT07355946,The Effect of Nurse-Led Coaching Program on Self-Care Agency and Quality of Life in Reconstructed Breast Cancer Patients,The Effect of Nurse-Led Coaching Program on Self-Care Agency and Quality of Life in Reconstructed Breast Cancer Patients,COMPLETED,,INTERVENTIONAL,58.0,ACTUAL,2025-02-24,2025-12-01,Gazi University,OTHER,RANDOMIZED,PARALLEL,SINGLE,BEHAVIORAL,Nurse-led Coaching Program,Breast Reconstruction,,,,,False,280.0,True,False,-1.0,True,False,False,1,True,Medium (30-100),0,58.0,4.07753744390572,1,0,0.6,True,True,0.6921053927849223,1,True,0.8673813542785793,1,1,0.8614707,1
NCT02948335,Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital,Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital,COMPLETED,,OBSERVATIONAL,22.0,ACTUAL,2017-02-23,2018-02-19,St. Jude Children's Research Hospital,OTHER,,,,,,Infection,,,,,False,361.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,22.0,3.1354942159291497,0,0,0.6,True,True,0.5466900003908085,1,True,0.6756249626113637,1,1,0.57882774,1
NCT06777290,"Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma","Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma",COMPLETED,,OBSERVATIONAL,14.0,ACTUAL,2021-01-01,2022-12-31,"Charles University, Czech Republic",OTHER,,,,,,"Lymphoma, Diffuse Large B-Cell",,,,,False,729.0,True,False,-1.0,False,False,False,0,True,Small (<30),0,14.0,2.70805020110221,0,0,0.6,True,False,0.45035474520400054,0,True,0.5044648077517756,1,0,0.45750886,0
NCT01324596,A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib,A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib,COMPLETED,PHASE3,INTERVENTIONAL,1132.0,ACTUAL,2011-04-01,2015-06-01,University Hospital Southampton NHS Foundation Trust,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Intravenous, Bortezomib","Lymphoma, Large B-Cell, Diffuse",,,,,False,1522.0,True,False,3.0,True,False,False,2,True,Very Large (300+),0,1132.0,7.032624261028007,2,1,0.77,True,True,0.8698548197638851,1,True,0.8746685806513824,1,1,0.9270492,1
NCT03310892,Tailored Messaging for CRC Screening,Patient-directed Messaging to Increase Colorectal Cancer Screening,COMPLETED,,INTERVENTIONAL,600.0,ACTUAL,2017-10-09,2023-10-01,University of Pennsylvania,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL","Generic message, Tailored message",Colorectal Cancer,,,,,False,2183.0,True,False,-1.0,True,False,False,2,True,Very Large (300+),0,600.0,6.398594934535208,2,1,0.6,True,True,0.9144445374346902,1,True,0.9244005599797714,1,1,0.95223594,1
NCT05617040,Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer,"A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer",TERMINATED,PHASE1,INTERVENTIONAL,22.0,ACTUAL,2023-01-30,2025-02-05,Barinthus Biotherapeutics,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"BIOLOGICAL, BIOLOGICAL","ChAdOx1-PCAQ, MVA-PCAQ",Prostate Cancer,,,,,False,737.0,True,False,1.0,False,False,True,2,False,Small (<30),0,22.0,3.1354942159291497,1,0,0.56,False,False,0.45827806097765933,1,False,0.4874572277082905,1,0,0.46033788,1
NCT03161431,SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,"A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab",ACTIVE_NOT_RECRUITING,PHASE1,INTERVENTIONAL,77.0,ESTIMATED,2019-06-12,2027-06-01,"Syntrix Biosystems, Inc.",INDUSTRY,NON_RANDOMIZED,SEQUENTIAL,NONE,"DRUG, BIOLOGICAL","SX-682, Pembrolizumab","Melanoma Stage III, Melanoma Stage IV",,,,,False,2911.0,False,False,1.0,False,False,True,2,True,Medium (30-100),1,77.0,4.356708826689592,1,0,0.56,True,True,0.8265541969963495,1,True,0.8335988277522133,1,1,0.8486163,1
NCT03197467,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN],COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2018-06-18,2023-05-05,AIO-Studien-gGmbH,OTHER,,SINGLE_GROUP,NONE,DRUG,Pembrolizumab,Non-small Cell Lung Cancer (NSCLC),,,,,False,1782.0,True,False,2.0,False,False,False,1,True,Small (<30),1,30.0,3.4339872044851463,0,0,0.58,True,True,0.5988718597782441,1,True,0.7129819009007702,1,1,0.8308385,1
NCT02974725,A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma,"A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma",TERMINATED,PHASE1,INTERVENTIONAL,241.0,ACTUAL,2017-02-24,2024-04-24,Novartis Pharmaceuticals,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","LXH254, LTT462, Trametinib, Ribociclib","Non-Small Cell Lung Cancer, Melanoma",,,,,False,2616.0,True,False,1.0,False,False,True,4,False,Large (100-300),1,241.0,5.488937726156687,1,1,0.56,False,True,0.8518223596963926,0,True,0.7819602784259723,0,1,0.7553619,0
NCT00919659,Parenteral Nutrition Support for Patients With Pancreatic Cancer,Parenteral Nutrition Support for Patients With Pancreatic Cancer. A Phase II Study.,COMPLETED,PHASE2,INTERVENTIONAL,32.0,ACTUAL,2002-01-01,2004-05-01,CONKO-Studiengruppe,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DIETARY_SUPPLEMENT,parenteral nutrition,"Cancer Cachexia, Pancreatic Cancer",,,,,False,851.0,True,False,2.0,False,False,False,1,True,Medium (30-100),0,32.0,3.49650756146648,0,0,0.58,True,True,0.5750610862729038,1,True,0.6142237257134183,1,1,0.67213887,1
NCT00025337,Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated,"Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer",COMPLETED,PHASE3,INTERVENTIONAL,880.0,ACTUAL,2001-09-01,,National Cancer Institute (NCI),NIH,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, DRUG, DRUG, DRUG","bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil","Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer",,,,,False,1303.0,True,False,3.0,True,False,False,4,True,Very Large (300+),1,880.0,6.78105762593618,2,1,0.77,True,True,0.8396930804452675,1,True,0.7555899111432374,1,1,0.83978635,1
NCT05788484,A Study of CDX-585 in Patients With Advanced Malignancies,A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,20.0,ACTUAL,2023-05-11,2025-05-21,Celldex Therapeutics,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,CDX-585,"Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors",,,,,False,741.0,True,False,1.0,False,False,True,1,True,Small (<30),0,20.0,3.044522437723423,0,0,0.56,True,False,0.4858455593710986,0,True,0.5731993363027219,1,1,0.6262441,1
NCT04245085,"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance",COMPLETED,PHASE2,INTERVENTIONAL,95.0,ACTUAL,2020-09-29,2024-07-22,ETOP IBCSG Partners Foundation,NETWORK,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG","Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel, Pemetrexed",EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC,,,,,False,1392.0,True,False,2.0,True,False,False,5,True,Medium (30-100),1,95.0,4.564348191467836,2,0,0.58,True,True,0.7107692319861361,1,True,0.687037435950581,1,1,0.54119045,1
NCT06400225,Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L),"MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations",ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,35.0,ESTIMATED,2019-07-24,2026-12-31,National Cancer Institute (NCI),NIH,,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, DRUG","Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Ulixertinib","Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma",,,,,False,2717.0,False,False,2.0,False,False,False,7,True,Medium (30-100),0,35.0,3.58351893845611,1,0,0.58,True,True,0.6162253517545516,1,True,0.8728449588614875,1,1,0.94627255,1
NCT00045448,Combination Chemotherapy in Treating Patients With Advanced Solid Tumors,Single Center Open-Label Non-Comparative Phase I Dose Finding Study Of Weekly Flavopiridol In Combination With Weekly Docetaxel In Patients With Advanced Solid Tumors,COMPLETED,PHASE1,INTERVENTIONAL,,,2002-04-01,2009-12-01,Memorial Sloan Kettering Cancer Center,OTHER,,,,"DRUG, DRUG","alvocidib, docetaxel","Unspecified Adult Solid Tumor, Protocol Specific",,,,,False,2801.0,True,False,1.0,False,False,False,2,True,,1,,,1,0,0.56,True,True,0.7442413350464037,1,True,0.89889906437946,1,1,0.9351794,1
NCT03942263,A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation,KLIO - Non-interventional Multicenter Prospective and Retrospective Study to Describe Treatment Patterns and Disease Control in Patients With Classical Hodgkin's Lymphoma (cHL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) in Routine Clinical Practice in the Russian Federation,COMPLETED,,OBSERVATIONAL,2000.0,ACTUAL,2019-05-31,2022-12-08,Takeda,INDUSTRY,,,,,,"Hodgkin Disease, Lymphoma, Large-cell, Anaplastic",,,,,False,1287.0,True,False,-1.0,False,False,True,0,True,Very Large (300+),0,2000.0,7.601402334583733,0,1,0.6,True,True,0.9631736837066177,1,True,0.9501394912238627,1,1,0.9431959,1
NCT04869462,DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy),"Prospective, Monocentric, Single Arm, Observational PMCF - Study on the Performance and Safety of Double-Shank Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)",COMPLETED,,OBSERVATIONAL,67.0,ACTUAL,2021-05-27,2022-01-29,Aesculap AG,INDUSTRY,,,,,,"Prostate Cancer, Kidney Cancer, Congenital Abnormality of Kidney, Nephrolithiasis, Kidney Tuberculosis, Nephritis, Kidney Injury, Hydronephrosis",,,,,False,247.0,True,False,-1.0,False,False,True,0,True,Medium (30-100),0,67.0,4.219507705176107,0,0,0.6,True,True,0.7898024419749136,1,True,0.9543676097655402,1,1,0.9498237,1
NCT02861417,"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant",Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,204.0,ACTUAL,2016-08-05,2026-08-31,M.D. Anderson Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"PROCEDURE, DRUG, DRUG, DRUG, DRUG, OTHER, DRUG, OTHER, DRUG, DRUG","Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa","Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma",,,,,False,3678.0,False,False,2.0,False,False,False,10,True,Large (100-300),1,204.0,5.3230099791384085,1,1,0.58,True,True,0.8227946672739299,1,True,0.7560289456192092,1,1,0.78198683,1
NCT00756834,Case Collection Study for Collecting Images for the Development and Validation of Computer Aided Detection Software,"A Multi-center, Controlled, Consecutive Collection of Screening or Diagnostic Full Field Digital Mammography Images Acquired on the Mammomat Novation DR System for Development and Validation of Computer Aided Detection (CAD) Software",TERMINATED,,OBSERVATIONAL,135.0,ACTUAL,2006-11-01,2020-08-01,Siemens Medical Solutions,INDUSTRY,,,,DEVICE,Screening,Breast Cancer,,,,,False,5022.0,True,False,-1.0,False,False,True,1,False,Large (100-300),0,135.0,4.912654885736052,0,1,0.6,False,True,0.8968090013878031,0,True,0.8007976355894033,0,0,0.49585786,1
NCT00644124,Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma,"A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,25.0,ACTUAL,2008-03-01,2011-10-01,Sanofi,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,aflibercept,"Lymphoma, Non-Hodgkin",,,,,False,1309.0,True,False,1.0,False,False,True,1,True,Small (<30),0,25.0,3.258096538021482,0,0,0.56,True,True,0.5725838781343046,1,True,0.6105844091871163,1,1,0.63226026,1
NCT00148109,Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas,Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas,COMPLETED,PHASE2,INTERVENTIONAL,36.0,ACTUAL,2005-06-01,2009-12-01,University of Michigan Rogel Cancer Center,OTHER,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","Cetuximab, Cetuximab",Sarcoma,,,,,False,1644.0,True,False,2.0,False,False,False,2,True,Medium (30-100),1,36.0,3.610917912644224,1,0,0.58,True,True,0.5875825755885079,1,True,0.7741963329173492,1,1,0.7764209,1
NCT04205812,"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)",ACTIVE_NOT_RECRUITING,PHASE3,INTERVENTIONAL,583.0,ACTUAL,2020-09-11,2026-08-28,Incyte Corporation,INDUSTRY,RANDOMIZED,PARALLEL,DOUBLE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel","Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer",,,,,False,2177.0,False,False,3.0,True,True,True,7,True,Very Large (300+),1,583.0,6.369900982828227,3,1,0.77,True,True,0.8354822805757047,1,True,0.9094888347999128,1,1,0.91202766,1
NCT03212937,"Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma","A Phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export / SINE™ Compound and Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",COMPLETED,PHASE1,INTERVENTIONAL,11.0,ACTUAL,2016-07-01,2020-11-01,"National Cancer Centre, Singapore",OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Selinexor, ICE Chemotherapy",Peripheral T-cell Lymphoma,,,,,False,1584.0,True,False,1.0,False,False,False,2,True,Small (<30),0,11.0,2.4849066497880004,1,0,0.56,True,False,0.3325691051637337,0,False,0.43350609344851365,0,0,0.498836,0
NCT04329819,Satisfaction and QUality of Life After Breast REconstruction,Evaluation of the Satisfaction and the Quality of Life of Patients After Breast Reconstruction as Part of Breast Cancer. Comparison of Several Technics.,COMPLETED,,OBSERVATIONAL,300.0,ACTUAL,2019-09-03,2019-11-25,Institut Cancerologie de l'Ouest,OTHER,,,,,,"Mammaplasty, Breast Neoplasm Female",,,,,False,83.0,True,False,-1.0,False,False,False,0,True,Large (100-300),0,300.0,5.707110264748875,0,1,0.6,True,True,0.873073394310937,1,True,0.920270021505864,1,1,0.97348714,1
NCT06187350,The Use of AI to Safely Reduce the Workload in Breast Cancer Screening With Mammography in Region Östergötland,The Use of Artificial Intelligence (AI) to Safely Reduce the Workload in Breast Cancer Screening With Mammography in Region Östergötland,COMPLETED,,OBSERVATIONAL,60000.0,ACTUAL,2023-08-01,2025-03-20,"Ostergotland County Council, Sweden",OTHER,,,,DEVICE,AI cancer detection system,"Artificial Intelligence, Breast Diseases, Neoplasms, Breast Neoplasms",,,,,False,597.0,True,False,-1.0,False,False,False,1,True,Very Large (300+),0,5757.019999999997,8.658348944594362,0,1,0.6,True,True,0.88825723420905,1,True,0.9917534839548914,1,1,0.99311477,1
NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,"Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study",COMPLETED,PHASE2,INTERVENTIONAL,50.0,ACTUAL,2016-12-01,2019-06-28,Hutchison Medipharma Limited,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Fruquintinib, Gefitinib",NSCLC,,,,,False,939.0,True,False,2.0,False,False,True,2,True,Medium (30-100),1,50.0,3.9318256327243257,1,0,0.58,True,True,0.6342077352313539,1,True,0.6685564294445147,1,1,0.5846609,1
NCT03363217,Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.,A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,114.0,ACTUAL,2018-08-16,2027-03-01,St. Justine's Hospital,OTHER,NON_RANDOMIZED,PARALLEL,NONE,DRUG,Trametinib,"Low-grade Glioma, Plexiform Neurofibroma, Central Nervous System Glioma",,,,,False,3119.0,False,False,2.0,False,False,False,1,True,Large (100-300),1,114.0,4.74493212836325,0,1,0.58,True,True,0.7704930662777661,1,True,0.7928546109992195,1,1,0.83232397,1
NCT00724737,Presurgical Planning With Functional MRI (fMRI) Mapping of Motor Cortex in Patients With Cerebral Tumors,Presurgical Planning With Motion Corrected fMRI Mapping of Motor Cortex in Patients With Cerebral Tumors,COMPLETED,,INTERVENTIONAL,23.0,ACTUAL,2006-07-01,2013-12-01,University of Michigan,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,"PROCEDURE, PROCEDURE","Presurgical MRI, functional MRI (fMRI) of the brain",Brain Tumors,,,,,False,2710.0,True,False,-1.0,False,False,False,2,True,Small (<30),0,23.0,3.1780538303479458,1,0,0.6,True,True,0.6209181443146684,1,True,0.6894602906737696,1,1,0.758359,1
NCT01573247,Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia,"A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)",TERMINATED,PHASE1,INTERVENTIONAL,25.0,ACTUAL,2011-12-01,2016-03-01,Akinion Pharmaceuticals AB,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,AKN-028,Acute Myeloid Leukemia,,,,,False,1552.0,True,False,1.0,False,False,True,1,False,Small (<30),0,25.0,3.258096538021482,0,0,0.56,False,True,0.5849127868196023,0,True,0.5675393651564371,0,1,0.5601174,0
NCT03806218,Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC,Radiofrequency Ablation Using Internally Cooled Wet Electrodes in Bipolar Mode for the Treatment of Recurrent Hepatocellular Carcinoma After Locoregional Treatment: A Randomized Prospective Comparative Study,COMPLETED,,INTERVENTIONAL,77.0,ACTUAL,2015-05-16,2019-02-12,Seoul National University Hospital,OTHER,RANDOMIZED,PARALLEL,TRIPLE,"DEVICE, DEVICE, DEVICE, DEVICE","Bipolar RFA, SM-RFA, Twin internally cooled-wet electrodes, Separable clustered electrodes",Hepatocellular Carcinoma,,,,,False,1368.0,True,False,-1.0,True,True,False,4,True,Medium (30-100),0,77.0,4.356708826689592,3,0,0.6,True,True,0.7698907113410418,1,True,0.8051861676374434,1,1,0.8671066,1
NCT02941601,A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),"A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)",WITHDRAWN,PHASE2,INTERVENTIONAL,0.0,ACTUAL,2016-11-01,2019-02-01,Eli Lilly and Company,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG","Necitumumab, Gemcitabine, Carboplatin","Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer",,,,,False,822.0,True,False,2.0,False,False,True,3,False,,1,0.0,0.0,1,0,0.58,False,False,0.022568833391985232,1,False,0.009086283193802053,1,0,0.0022793044,1
NCT00486473,Multihance Versus Magnevist in Breast MRI,"Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast",COMPLETED,PHASE3,INTERVENTIONAL,130.0,ESTIMATED,2007-07-01,2009-12-01,"Bracco Diagnostics, Inc",INDUSTRY,RANDOMIZED,CROSSOVER,TRIPLE,"DRUG, DRUG","Multihance, Magnevist",Breast Cancer,,,,,False,884.0,True,False,3.0,True,True,True,2,True,Large (100-300),0,130.0,4.875197323201151,3,1,0.77,True,True,0.5285385189129824,1,True,0.6096833863369345,1,1,0.69627047,1
NCT00240071,Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.,The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial,COMPLETED,PHASE2,INTERVENTIONAL,30.0,ACTUAL,2005-10-01,2011-04-01,University of Alabama at Birmingham,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Avastin, Hormonal therapy",Metastatic Breast Cancer,,,,,False,2008.0,True,False,2.0,False,False,False,2,True,Small (<30),0,30.0,3.4339872044851463,1,0,0.58,True,True,0.5665677831448569,1,True,0.7188300562477746,1,1,0.771235,1
NCT02122770,"Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors","A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,INTERVENTIONAL,51.0,ACTUAL,2014-04-01,2017-06-05,"Millennium Pharmaceuticals, Inc.",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel",Advanced Solid Tumors,,,,,False,1161.0,True,False,1.0,False,False,True,6,True,Medium (30-100),1,51.0,3.951243718581428,1,0,0.56,True,True,0.6651873469467313,1,True,0.6064797359212128,1,1,0.5721967,1
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma,COMPLETED,PHASE1,INTERVENTIONAL,16.0,ACTUAL,2008-12-01,2018-01-17,Jonsson Comprehensive Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","sunitinib malate, temozolomide",Metastatic Melanoma,,,,,False,3334.0,True,False,1.0,False,False,False,2,True,Small (<30),1,16.0,2.833213344056216,1,0,0.56,True,True,0.5044059673049011,1,True,0.6152159657788332,1,1,0.7474802,1
NCT00982540,Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients,Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index,TERMINATED,,INTERVENTIONAL,28.0,ACTUAL,2010-02-01,2013-12-01,Universidade Federal do Rio de Janeiro,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,caspofungin as preemptive antifungal therapy,"Invasive Fungal Infections, Invasive Aspergillosis, Invasive Fusariosis",,,,,False,1399.0,True,False,-1.0,False,False,False,1,False,Small (<30),0,28.0,3.367295829986474,0,0,0.6,False,True,0.6531700014145119,0,True,0.687660574424643,0,1,0.64352655,0
NCT00246090,"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine","A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease",COMPLETED,PHASE2,INTERVENTIONAL,298.0,ACTUAL,2005-10-01,2007-09-01,Eisai Inc.,INDUSTRY,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,E7389,Breast Cancer,,,,,False,700.0,True,False,2.0,False,False,True,1,True,Large (100-300),0,298.0,5.700443573390687,0,1,0.58,True,True,0.8421967074877343,1,True,0.888097406889189,1,1,0.93419224,1
NCT01969669,A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199,A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199,COMPLETED,PHASE1,INTERVENTIONAL,12.0,ACTUAL,2013-12-01,2014-09-01,AbbVie,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","ABT-199, Ketoconazole",Non-Hodgkin's Lymphoma,,,,,False,274.0,True,False,1.0,False,False,True,2,True,Small (<30),0,12.0,2.5649493574615367,1,0,0.56,True,False,0.2927201759919477,0,False,0.3363801936207115,0,0,0.274091,0
NCT03843775,A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers,A Phase I/II Study of Binimetinib With Encorafenib in Patients With Non-V600 Activating BRAF Mutant Advanced Malignancies,COMPLETED,PHASE1,INTERVENTIONAL,17.0,ACTUAL,2019-02-14,2023-09-02,Memorial Sloan Kettering Cancer Center,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG","Binimetinib, Encorafenib",Advanced BRAF Mutant Cancers,,,,,False,1661.0,True,False,1.0,False,False,False,2,True,Small (<30),1,17.0,2.8903717578961645,1,0,0.56,True,False,0.4332538278062347,0,True,0.5171490955685358,1,0,0.4907069,0
NCT04300244,Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma,Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study),ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,118.0,ESTIMATED,2020-05-04,2027-03-15,Åslaug Helland,OTHER,RANDOMIZED,PARALLEL,NONE,"BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","UV1 vaccine + leukine, ipilimumab, nivolumab","Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural",,,,,False,2506.0,False,False,2.0,True,False,False,3,True,Large (100-300),1,118.0,4.77912349311153,2,1,0.58,True,True,0.6317944475368049,1,True,0.8712650234437764,1,1,0.942013,1
NCT01304303,Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination,,COMPLETED,PHASE1,INTERVENTIONAL,57.0,ACTUAL,2011-10-01,2016-10-01,Sun Pharma Advanced Research Company Limited,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","SPARC1023 I, SPARC1023 II",Solid Tumor in Advanced Stage,,,,,False,1827.0,True,False,1.0,True,False,True,2,True,Medium (30-100),0,57.0,4.060443010546419,2,0,0.56,True,True,0.6685199758155675,1,True,0.661323941382375,1,0,0.48482126,0
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,"Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma",TERMINATED,PHASE1,INTERVENTIONAL,9.0,ACTUAL,2006-12-01,2008-09-01,Michael Weichenthal,OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","PTK787/ZK 222584, Dacarbazine",Melanoma,,,,,False,640.0,True,False,1.0,True,False,False,2,False,Small (<30),1,9.0,2.302585092994046,2,0,0.56,False,False,0.18699613571144139,1,False,0.13579985290107746,1,0,0.124280594,1
NCT01856803,Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis,Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies,COMPLETED,PHASE4,INTERVENTIONAL,300.0,ACTUAL,2013-10-01,2019-06-01,Peking University People's Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,DRUG,anti thymoglobulin,"Leukemia, GVHD, ATG, Transplantation",,,,,False,2069.0,True,False,4.0,True,False,False,1,True,Large (100-300),0,300.0,5.707110264748875,1,1,0.7,True,True,0.7710565675479201,1,True,0.9282055924175991,1,1,0.94634306,1
NCT02015806,Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices,Assessing the Impact of Low-Touch Devices on Medication Adherence,COMPLETED,,INTERVENTIONAL,53480.0,ACTUAL,2014-03-01,2015-02-01,Brigham and Women's Hospital,OTHER,RANDOMIZED,PARALLEL,NONE,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","RxTimerCap, Take-N-Slide, Pillbox","Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy",,,,,False,337.0,True,False,-1.0,True,False,False,3,True,Very Large (300+),0,5757.019999999997,8.658348944594362,2,1,0.6,True,True,0.8084949257909567,1,True,0.9422102531687923,1,1,0.9827375,1
NCT00759226,"Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer","An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer",COMPLETED,PHASE2,INTERVENTIONAL,92.0,ACTUAL,2002-07-01,2007-08-01,CONKO-Studiengruppe,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, DRUG","Gemcitabine, Cisplatin, 5-FU, Folinic Acid",Esophageal Cancer,,,,,False,1857.0,True,False,2.0,False,False,False,4,True,Medium (30-100),1,92.0,4.532599493153256,1,0,0.58,True,True,0.7913995900999296,1,True,0.8843140601193659,1,1,0.8930671,1
NCT02194166,A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration,"An Open-Label, Randomized, Cross-Over, Multicenter, Phase IIIb Study, to Assess Patients' Tolerability of Trastuzumab Administrated Subcutaneously (SC) Either Via a Single Use Injection Device (SID) or Via Vial for Manual Administration (SC Vial) in Patients With HER2-Positive Early Breast Cancer (eBC)",COMPLETED,PHASE3,INTERVENTIONAL,90.0,ACTUAL,2014-07-18,2018-07-12,Hoffmann-La Roche,INDUSTRY,RANDOMIZED,CROSSOVER,NONE,"DRUG, DRUG, DRUG","Trastuzumab, Paclitaxel, Docetaxel",Breast Cancer,,,,,False,1455.0,True,False,3.0,True,False,True,3,True,Medium (30-100),1,90.0,4.51085950651685,2,0,0.77,True,True,0.6310132958867158,1,True,0.5890284041256275,1,1,0.6563103,1
NCT03546582,SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma,KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,INTERVENTIONAL,86.0,ACTUAL,2018-11-14,2029-07-01,"RTOG Foundation, Inc.",OTHER,RANDOMIZED,PARALLEL,NONE,"DRUG, RADIATION","Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT)",Head and Neck Squamous Cell Carcinoma (HNSCC),,,,,False,3882.0,False,False,2.0,True,False,False,2,True,Medium (30-100),1,86.0,4.465908118654584,2,0,0.58,True,True,0.7984120065245618,1,True,0.8647026045795608,1,1,0.8395265,1
NCT02963493,A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma,"A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody",COMPLETED,PHASE2,INTERVENTIONAL,157.0,ACTUAL,2016-12-28,2021-11-16,Oncopeptides AB,INDUSTRY,,SINGLE_GROUP,NONE,"DRUG, DRUG","Melphalan flufenamide (Melflufen), Dexamethasone",Multiple Myeloma,,,,,False,1784.0,True,False,2.0,False,False,True,2,True,Large (100-300),0,157.0,5.062595033026967,1,1,0.58,True,True,0.7457299937936138,1,True,0.842843603926065,1,1,0.9372048,1
NCT02681549,Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC),A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases,COMPLETED,PHASE2,INTERVENTIONAL,41.0,ACTUAL,2016-05-01,2025-03-31,Yale University,OTHER,NON_RANDOMIZED,SINGLE_GROUP,NONE,DRUG,Pembrolizumab plus Bevacizumab,"Melanoma, Non-small Cell Lung Cancer, Brain Metastasis",,,,,False,3256.0,True,False,2.0,False,False,False,1,True,Medium (30-100),1,41.0,3.737669618283368,0,0,0.58,True,True,0.7375902178688611,1,True,0.9530994595678125,1,1,0.9629276,1
NCT06129422,"Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer","A Phase I Trial to Assess Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and Positron Emission Tomography (PET) Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer Histologically Positive for MUC5AC",COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2023-10-31,2025-10-07,"Nihon Medi-Physics Co., Ltd.",INDUSTRY,,SINGLE_GROUP,NONE,DRUG,NMK89,Pancreatic Cancer,,,,,False,707.0,True,False,1.0,False,False,True,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.31744375218366516,0,False,0.3648450956666977,0,0,0.23759933,0
NCT04960462,Case Report of Nerve Root Sleeve Reinforcement and Reconstruction and Sacral Canal Plasty for the Treatment of Sacral Canal,Case Report of Nerve Root Sleeve Reinforcement and Reconstruction and Sacral Canal Plasty for the Treatment of Sacral Canal,COMPLETED,,OBSERVATIONAL,24.0,ACTUAL,2017-08-01,2018-04-30,Peking University Third Hospital,OTHER,,,,PROCEDURE,nerve root sleeve reinforcement,Tarlov Cysts,,,,,False,272.0,True,False,-1.0,False,False,False,1,True,Small (<30),0,24.0,3.218875824868201,0,0,0.6,True,True,0.5593073274366004,1,True,0.8687408792654112,1,1,0.85068274,1
NCT03454620,"A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy",Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor,COMPLETED,PHASE1,INTERVENTIONAL,53.0,ACTUAL,2018-04-02,2022-01-10,Green Cross Corporation,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG","irinotecan, FOLFIRI","Metastatic Colorectal Cancer, Solid Tumor",,,,,False,1379.0,True,False,1.0,False,False,True,2,True,Medium (30-100),1,53.0,3.9889840465642745,1,0,0.56,True,True,0.7014232855993231,1,True,0.7133750253097072,1,1,0.612718,1
NCT00398281,Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer,Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride,COMPLETED,PHASE3,INTERVENTIONAL,450.0,ESTIMATED,2006-11-01,2012-09-01,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,RANDOMIZED,,DOUBLE,"DRUG, OTHER","dutasteride, placebo",Prostate Cancer,,,,,False,2131.0,True,False,3.0,True,True,False,2,True,Very Large (300+),0,450.0,6.111467339502679,3,1,0.77,True,True,0.8235746170527017,1,True,0.7814411373284592,1,1,0.8707836,1
NCT00813943,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]",COMPLETED,PHASE2,INTERVENTIONAL,265.0,ACTUAL,2009-03-01,2013-08-01,EMD Serono,INDUSTRY,RANDOMIZED,PARALLEL,NONE,"DRUG, DRUG, DRUG, RADIATION","Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy",Glioblastoma,,,,,False,1614.0,True,False,2.0,True,False,True,4,True,Large (100-300),1,265.0,5.583496308781699,2,1,0.58,True,True,0.7555814904585492,1,True,0.8426151212005863,1,1,0.90984124,1
NCT04454489,Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition,Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer,COMPLETED,PHASE2,INTERVENTIONAL,21.0,ACTUAL,2021-02-25,2025-04-30,Wake Forest University Health Sciences,OTHER,,SINGLE_GROUP,NONE,"DRUG, RADIATION","Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy","Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck",,,,,False,1525.0,True,False,2.0,False,False,False,2,True,Small (<30),1,21.0,3.091042453358316,1,0,0.58,True,False,0.442504952024585,0,False,0.497348027698361,0,1,0.5085544,1
NCT05463276,The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study,The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study,COMPLETED,,OBSERVATIONAL,690.0,ACTUAL,2022-02-28,2022-05-01,Sindh Institute of Urology and Transplantation,OTHER,,,,,,"Breast Cancer, Breast Neoplasms, Breast Cancer Invasive, Breast Cancer Stage, Breast Cancer Metastatic",,,,,False,62.0,True,False,-1.0,False,False,False,0,True,Very Large (300+),0,690.0,6.53813982376767,0,1,0.6,True,True,0.931299784297457,1,True,0.9406146062303817,1,1,0.9627906,1
NCT00239135,Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel,"An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks",COMPLETED,PHASE2,INTERVENTIONAL,34.0,,2005-09-01,2005-12-01,Peplin,INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,PEP005,Keratosis,,,,,False,91.0,True,False,2.0,False,False,True,1,True,Medium (30-100),0,34.0,3.555348061489413,0,0,0.58,True,True,0.5517121951245706,1,True,0.6178715113984324,1,1,0.84305805,1
NCT01635712,Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies,"A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies",COMPLETED,PHASE1,INTERVENTIONAL,10.0,ACTUAL,2014-02-01,2017-02-01,Esanex Inc.,INDUSTRY,,SINGLE_GROUP,NONE,DRUG,SNX-5422,Cancer,,,,,False,1096.0,True,False,1.0,False,False,True,1,True,Small (<30),0,10.0,2.3978952727983707,0,0,0.56,True,False,0.33523852856821856,0,False,0.4709555044266675,0,1,0.52120036,1
NCT02323113,"Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)","An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",TERMINATED,PHASE1,INTERVENTIONAL,43.0,ACTUAL,2015-03-09,2018-08-15,"Calithera Biosciences, Inc",INDUSTRY,NON_RANDOMIZED,PARALLEL,NONE,DRUG,TAK-659,Acute Myelogenous Leukemia,,,,,False,1255.0,True,False,1.0,False,False,True,1,False,Medium (30-100),0,43.0,3.784189633918261,0,0,0.56,False,True,0.6998198497760848,0,True,0.7039331990441688,0,1,0.7516445,0
NCT02326285,Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB,Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.,TERMINATED,PHASE2,INTERVENTIONAL,1.0,ACTUAL,2015-11-01,2018-01-01,AIO-Studien-gGmbH,OTHER,,SINGLE_GROUP,NONE,"DRUG, DRUG, DRUG, PROCEDURE","Gefitinib, docetaxel, cisplatin, Surgery","Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation, NSCLC",,,,,False,792.0,True,False,2.0,False,False,False,4,False,Small (<30),1,1.0,0.6931471805599453,1,0,0.58,False,False,0.045775716684782426,1,False,0.09482175510413786,1,0,0.06826611,1
NCT01479907,Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer,Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer,COMPLETED,,INTERVENTIONAL,100.0,ACTUAL,2010-11-01,2015-09-01,University of Athens,OTHER,RANDOMIZED,SINGLE_GROUP,QUADRUPLE,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Synbiotics, Placebo",Colorectal Neoplasms,,,,,False,1765.0,True,False,-1.0,True,True,False,2,True,Medium (30-100),0,100.0,4.61512051684126,3,1,0.6,True,True,0.6785305247749056,1,True,0.8471684375038574,1,1,0.7991184,1
NCT01050439,Unrelated Donor Transplant for Malignant and Non-Malignant Disorders,Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders,TERMINATED,PHASE2,INTERVENTIONAL,22.0,ACTUAL,2002-11-01,2011-04-01,Columbia University,OTHER,,SINGLE_GROUP,NONE,"PROCEDURE, OTHER","UDAlloSCT, Therapy","Leukemia, Lymphoma, Bone Marrow Failure Syndromes, Immunodeficiencies, Histiocytosis",,,,,False,3073.0,True,False,2.0,False,False,False,2,False,Small (<30),0,22.0,3.1354942159291497,1,0,0.58,False,True,0.5417765760221159,0,True,0.6702641740279671,0,1,0.72336847,0
